<SEC-DOCUMENT>0001680367-22-000005.txt : 20220315
<SEC-HEADER>0001680367-22-000005.hdr.sgml : 20220315
<ACCEPTANCE-DATETIME>20220315060231
ACCESSION NUMBER:		0001680367-22-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220315
DATE AS OF CHANGE:		20220315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39593
		FILM NUMBER:		22738847

	BUSINESS ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-900-4690

	MAIL ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sttk-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:cbc5e4f4-a5cf-4cd7-9e77-2f3acab88ac0,g:c886f0b9-fa14-42f2-91e7-6b4a395bcd32,d:92757ae30a234940aa4371e66352259c--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sttk="http://www.shattucklabs.com/20211231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sttk-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF8zLTEtMS0xLTA_469d06e3-2bc5-4ed8-ba57-237abd82d33b">0001680367</ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF80LTEtMS0xLTA_58f9f2a0-98e3-4400-ab71-7b6303a384b5">false</ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF81LTEtMS0xLTA_c0ea591e-b557-48a1-9e30-736d236b33c1">2021</ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF82LTEtMS0xLTA_10580521-eae6-429f-b27f-74a7e0572e38">FY</ix:nonNumeric><ix:nonNumeric contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0wLTEtMS0w_31f163b6-9c40-4353-9e20-429d03b53ecd">http://fasb.org/us-gaap/2021-01-31#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0wLTEtMS0w_5cd945f9-9202-4d21-9fbf-20327c19355b">http://fasb.org/us-gaap/2021-01-31#LicenseMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sttk-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i37b06acb50a449ef9343f66141212130_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id391983719f643a293d7ebe4bde080c8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9e4df91ba02947e29a776bfdd375a444_I20220301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d907eb546d4b419a06e844b32e0c37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6085e2e606c14212b39aba95286e4bee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa3d82eadadb40ab92d3249bab64bf52_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2ca173e0004d11919d92632a37774d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e12961d654945e09068f8b39b05845b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dae071f8e3d4bec9f3b7ed2455cd014_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9145f0685d40abb21ee4ec19d9937f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e6543ccfb74775ac5df4a5733524f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24b53685d3540c7a804b8f394e399a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108a91c3f6de49d7ad25831cb4cbbac8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46bf273b1e0431682728738c320b383_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d28057558bb4a0295c8315232a69252_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82048836e6fa4e5aa557a2623e6ff0f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3683f766ae45e09c86c03f022c9e01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eaebef00de14f10b1d30533510da470_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d204922a202445caae9e3f732504db5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic115a1576f394c55b1a7bb9b66af7321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11f7173c81c46b2b06d4f80310b846d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic14f82c5bd594e0c86f407f962585613_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac2c9de295f4a84843194e8e6f933cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb89c4e37124b489c0152e257cc9e7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafbad4a0cb66454aa263e9cc4b0b02cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae4c24644ef446b38a0bc1bd5b7b9dad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7b805cabed4fef89935fc4a01cc352_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da23b727bc545ce8a8626f9c21738f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2978472561c24d05b2c48b66c0b36df6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f0d368be5c4c9cbee436c3481aa483_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8eeb11b3ac40f1b3c9e84a79462ae7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie30e987b03ab4ec59ff05cf3acc5e3a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55c9db39c55b45f684b6bf134143d66a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c736cc6e69478988dbcd443d316c34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314de4ca010e41458b9633658578103b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if34e74c583cf482a8c7f8c3fdc28de97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83035001040e4d90ac2aa8830614906e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cbb284a8c1342259be91fd8741fe70a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f3fa86426e412a8755fb1b72e9c76a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a6c00e553649a9a7fd199a899a8098_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef03e1dffea436194212535f30c3f7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcfc895622274a9fa067f83a85414b73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc6f8f8312648d79a5c147096aa6201_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e8869244b74fc28985b69bc05e3793_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id283059be4d44a2e824a82620e3e234d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524cc2fcaa1e4182b2577f5ace25f6fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0256d931b38f4e8ebd1fafc29f3baef9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2830e52a30463b83b72e983bfd983c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c95f2381594579b82d242587361ef8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i199bf9783e444bf89f2a5c5f09e19ee1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8507d1aa293d4d058b8d4ea3b458979e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4739b7937ffb414cba8e7cf3495311be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b4d224548b44d2b88ff83fa65e5ba7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34cfe1bf8a0f4d1e8923ff1731e97dc4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022cbf9c4d41418ca5d4cc35b286630f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b150d14a3340bdbbda062f1916514e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7705c519eda74dc58737c23718104aaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia854a6038a4a4bb088d1e1adb51da387_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef12007a5ff492690c14861cd4a497c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc2651a89a543bbaf7e68cc3e676d0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c94c0bd8ebb4b1bb951ba7df8bdb437_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide31a45817b8402c950886d450a9c631_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4178f0dec2b24b44bad57c8e7393db7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e6a315dca248c9aa85cda7c35059e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2329b727b8467788e859b46061df44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd9021bd3124402f8714a57978b7021a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b6ab46fb514d5d8d7aa64487be02ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c436ab0261649adb338c58e3639b366_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94f371b06b64697b125dc4b3ab1f16a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fa63cc109d410793fee3147230e084_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1717f2eaa0f544379a47d6697e8ce5e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfaa1273d97b46978197a4b2f339b0ec_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa51a2a2b1c84fdfa550195209974723_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8842228fdf1940c7b1002d140baf64ed_I20201014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-14</xbrli:startDate><xbrli:endDate>2020-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7daecd893b478db292941cdfb8d361_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6c1f46b13448baa40f5da3fc4f9b3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913ac2af34fd4ec98af9b2bb3e0c81da_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285a21f9461d4185ba105fc77795dd4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1cbb318d64475ea98211bc07f51f73_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81735796faf4a8a9e36cbc592eb5f3d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978d55b8117440bcb06be5d1eba9a7db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a0ec0b83ac44b2a0e7939e7f49c2e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd78bd931e046948447da6b4292615e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d2b249a41e4985a2641c447e8e27d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1853d269d625472aa52bdf974466c9d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ef9bb233dc4b89a2c5f083ab045bbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb12636928d4d21b00a09885bc9f550_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592680b58da94f418a342d39beb4d6a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1394695528d34d00a6380d9c1031687d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b14739a6c64b198bf3d0441927bd8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e068c367ec34e2ab303dcd0a6d4da40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4714dd5ac54741bc7b7aa1ad1ce320_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68499c9c9c54c7ca37c93a1819e89f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sttk:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i92757ae30a234940aa4371e66352259c_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTU5_ba93af6e-610a-4e5f-9e03-27b6f6464c79">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YTc1NWZlYTY0NmMwNGY4Zjg4ZWJiMjAxODllMGIwOTYvdGFibGVyYW5nZTphNzU1ZmVhNjQ2YzA0ZjhmODhlYmIyMDE4OWUwYjA5Nl8wLTAtMS0xLTA_c8c1ba07-ea03-4c83-b418-25ba8f5e3518">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8xMzA_cbe30ab4-e7c0-4250-a74c-54efbf8245f8"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8xMzA_11d8685c-3083-4d78-9c2b-235d51e34733">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZWViYTY1YzgwNzBhNDlkMGI4YjM5ZjEyZTBmNjM1NTEvdGFibGVyYW5nZTplZWJhNjVjODA3MGE0OWQwYjhiMzlmMTJlMGY2MzU1MV8wLTAtMS0xLTA_dfba2f95-2e86-4542-b286-9aa969a17373">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from         to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTY3_0d2e5577-b94d-4d6e-b04e-89f321f0df37">001-39593</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTYz_6dbe7a68-eaca-46ba-86cf-3fd24a715bd2">Shattuck Labs, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YmZkODE1N2YyODcyNDU5ZGEyZTdmMjExNDdiZTVhYzAvdGFibGVyYW5nZTpiZmQ4MTU3ZjI4NzI0NTlkYTJlN2YyMTE0N2JlNWFjMF8wLTAtMS0xLTA_041c1bb2-1ec4-42f5-b7bc-bbcab743613a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YmZkODE1N2YyODcyNDU5ZGEyZTdmMjExNDdiZTVhYzAvdGFibGVyYW5nZTpiZmQ4MTU3ZjI4NzI0NTlkYTJlN2YyMTE0N2JlNWFjMF8wLTItMS0xLTA_0824393b-6d9d-498e-a66f-909201da85e1">81-2575858</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDIw_c1105c09-a962-44d5-958c-11f8a7344867">500 W. 5th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDIy_8f278b0d-1438-4da1-8591-2d2308a38db4">Suite 1200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDI0_0027e5c3-49b5-43cd-84fe-194d155ee86c">Austin</ix:nonNumeric>, <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDI1_d442ed42-85c5-40e8-a22c-e7099c03d94a">TX</ix:nonNumeric> <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDI3_ebb72a50-abf4-4850-b9cf-8fddb46f3a41">78701</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDM0_7a5532a9-3164-48d5-81a6-a7257cabfbe8">512</ix:nonNumeric>) <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDM4_97dead23-71a9-46fd-94d7-df7723e7098a">900-4690</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Former name, former address and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.380%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZjgzM2E0NzA5MDNhNGU2MWE4ZDVkZDVhMjYyZDRmYjMvdGFibGVyYW5nZTpmODMzYTQ3MDkwM2E0ZTYxYThkNWRkNWEyNjJkNGZiM18xLTAtMS0xLTA_6f6bc9b9-1836-4d9d-8826-9ac99223f093">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZjgzM2E0NzA5MDNhNGU2MWE4ZDVkZDVhMjYyZDRmYjMvdGFibGVyYW5nZTpmODMzYTQ3MDkwM2E0ZTYxYThkNWRkNWEyNjJkNGZiM18xLTEtMS0xLTA_740e5f99-4e8f-4837-8076-886ce356708b">STTK</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZjgzM2E0NzA5MDNhNGU2MWE4ZDVkZDVhMjYyZDRmYjMvdGFibGVyYW5nZTpmODMzYTQ3MDkwM2E0ZTYxYThkNWRkNWEyNjJkNGZiM18xLTItMS0xLTA_eb2ee0b7-b7f6-4747-9e87-b03715fb9d0a">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTYx_1561d737-ebae-4448-a95a-b5ec73783ea8">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTYy_caf168a8-052e-420a-a2ca-bd8377f515d1">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDQw_20c3361a-4e06-4504-9012-2e168656de06">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTY5_17f6f0cc-f646-40b0-a9f8-3e77b00e9366">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YjljNDgyYzYzMWNkNDIxZTk2NzU0Mzg4MjMzZWMwNDYvdGFibGVyYW5nZTpiOWM0ODJjNjMxY2Q0MjFlOTY3NTQzODgyMzNlYzA0Nl8xLTAtMS0xLTA_fcf8adc6-926a-4f69-a782-af7468d2c88b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YjljNDgyYzYzMWNkNDIxZTk2NzU0Mzg4MjMzZWMwNDYvdGFibGVyYW5nZTpiOWM0ODJjNjMxY2Q0MjFlOTY3NTQzODgyMzNlYzA0Nl8xLTQtMS0xLTA_dfb0cd09-ef46-46da-9c51-d309b818b67d">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YjljNDgyYzYzMWNkNDIxZTk2NzU0Mzg4MjMzZWMwNDYvdGFibGVyYW5nZTpiOWM0ODJjNjMxY2Q0MjFlOTY3NTQzODgyMzNlYzA0Nl8yLTQtMS0xLTA_5e2d81fc-1ed1-413c-a898-4491f4fa10d3">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTcw_34b1c567-7839-422f-add4-ed022540c752">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTY2_f1641144-e787-43c9-ad8c-9010a1789da8">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTcx_518e7333-ddcd-4e6f-978f-2dc244e4bc82">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="id391983719f643a293d7ebe4bde080c8_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDYx_bb8d3d21-6ded-43f8-9a3f-58bd0152e48c">690,080,047</ix:nonFraction>, based on the closing price on The Nasdaq Global Select Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March 1, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i9e4df91ba02947e29a776bfdd375a444_I20220301" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8xMDk5NTExNjMyNDg3_8834322b-2c23-4f86-bc69-ee09991bb070">42,363,901</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5NjA3_5e113a75-c352-4618-a6a3-6da34eac8212" escape="true"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2022, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></div></ix:nonNumeric><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_13">Part I.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_19">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_22">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_25">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_31">50</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_34">Part II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_34">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_37">Market for Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_37">s Common Equity, Related Stockholder Matters and Issue Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_37">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_40">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_43">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_46">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_46">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_46">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_49">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_49">Audited Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_49">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_109">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_109">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_109">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_112">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_112">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_115">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_115">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_551">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_551">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_118">Part III.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_121">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_121">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_124">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_124">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_124">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_127">Item 12. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_127">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_127">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_130">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_130">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_130">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_133">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_133">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_136">Part IV.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_136">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_139">Item 15.</a> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_139">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_139">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_142">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_142">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_142">84</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_145">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_145">85</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred to under the sections entitled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and &#8220;Business&#8221; are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts, and reflect our current views with respect to future events. Given the significant uncertainties, you should not place undue reliance on these forward-looking statements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this Annual Report on Form 10-K. Such risks, uncertainties and other factors include, among others, the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and our research and development programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional qualified professionals; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the commercialization of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the pricing, coverage, and reimbursement of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the implementation of our business model, strategic plans for our business, and product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platforms, including our ARC and GADLEN product candidates and other product candidates, including the defense of such intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding the market opportunity for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">developments relating to our competitors and our industry, including competing product candidates and therapies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the recent and ongoing COVID-19 pandemic and associated public health guidance measures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other factors that may cause our actual results to differ materially from the forward-looking statements expressed or implied in this Annual Report on Form 10-K, including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of these risks and uncertainties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the risks, uncertainties, and other factors referred to above and elsewhere in this Annual Report on Form 10-K may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements contained in this Annual Report on Form 10-K speak only as of the date hereof and not of any future date, and we expressly disclaim any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, unless the context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Shattuck Labs,&#8221; &#8220;Shattuck,&#8221; or the &#8220;company&#8221; refer to Shattuck Labs, Inc. Additionally, references to our &#8220;Board&#8221; refer to the board of directors of Shattuck Labs, Inc.</span></div><div id="i92757ae30a234940aa4371e66352259c_16"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that are not achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling CD40 activation with CD47 inhibition differentiates SL-172154 from all other clinical-stage CD47/SIRP&#945; inhibitors in development, and in our published preclinical studies, SL-172154 resulted in superior antitumor immunity as compared to certain CD47/SIRP&#945; inhibitors. We are pursuing a broad clinical development strategy in both hematologic and solid tumors, with multiple ongoing clinical trials. SL-172154 is in an ongoing Phase 1 clinical trial for the treatment of patients with ovarian cancer. In addition to our clin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ical trials in solid tumors, we are also evaluating SL-172154 in an ongoing Phase 1 clinical trial for the treatment of patients with certa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in hematologic malignancies, including acute myeloid leukemia, or AML, and higher-risk myelodysplastic syndromes, or HR-MDS. We believe our clinical development plan will provide both first-in-class and best-in-class development opportunities for SL-172154.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, SL-279252, is designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 costimulatory receptor and is in an ongoing Phase 1 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, at the 36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> annual meeting of the Society for Immunotherapy of Cancer, or the SITC Meeting, we announced initial clinical data from our ongoing Phase 1 clinical trials for SL-172154 in ovarian cancer and for SL-279252 in advanced solid tumors and lymphoma. We believe that these data generated in human cancer patients have demonstrated that the unique protein engineering and physical properties of the ARC platform have led to a differentiated profile in terms of safety and on-target immune activation as compared to monoclonal or bispecific antibodies. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical-stage ARC product candidates, we possess a deep pipeline of preclinical immuno-oncology candidates. As an example, SL-9258, an ARC in preclinical development, is designed to inhibit the TIGIT/PVR checkpoint interaction while simultaneously activating HVEM and LT&#946; costimulatory receptors. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our expertise in dual-sided fusion proteins has led to the development of a second novel platform technology. We call this our gamma delta T cell engager, or GADLEN, platform. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to nominate a third clinical product candidate from our preclinical pipeline in 2022. Longer-term, we are pursuing additional disease areas, including autoimmune diseases, where our dual-sided fusion protein platforms may provide advantages over current treatment modalities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling the costimulatory effect of CD40 activation with CD47 inhibition differentiates SL-172154 from other CD47/SIRP&#945; inhibitors in clinical development. In clinical studies, we believe that SL-172154 has further differentiated from other CD47/SIRP&#945; inhibitors both in terms of safety and tolerability, and has demonstrated evidence of potent CD40 activation in human cancer patients.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducting a Phase 1 clinical trial evaluating SL-172154 in patients with platinum-resistant ovarian cancer. In November 2021, at the SITC Meeting, we a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nnounced initial data from 15 patients in the first four dose-escalation cohorts from the monotherapy dose-escalation portion of this trial. These data demonstrated that SL-172154 was well tolerated through 3 mg/kg, with no treatment-related grade 3 or greater adverse events. Near-complete target occupancy on leukocytes was observed for both CD47 and CD40 at 3 mg/kg. We also observed pharmacodynamic activity, including dose-dependent margination of CD40 expressing leukocytes from the peripheral blood and dose-dependent increases in cytokines, such as IL-12, that are associated with antitumor immunity. Monotherapy dose escalation is ongoing. We plan to initiate combination clinical trials in parallel due to the observation of monotherapy immunologic activity across the current dose range. We plan to initiate a Phase 1B clinical trial evaluating SL-172154 in combination with liposomal doxorubicin in patients with platinum-resistant ovarian </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancer in 2022. We expect to announce additional data from the ongoing Phase 1A monotherapy dose-escalation trial and initial data from the Phase 1B combination trial in the first half of 2023. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted a Phase 1 clinical trial in patients with cutaneous squamous cell carcinoma, or CSCC, or head and neck squamous cell carcinoma, or HNSCC, to evaluate the intratumoral administration of SL-172154. We expect to announce data from this trial in the first half of 2022. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to evaluating SL-172154 in solid tumors, we have expanded our evaluation of SL-172154 to include hematologic malignancies. We are conducting a Phase 1A/B clinical trial in patients with AML and HR-MDS, wherein patients will be enrolled into either a monotherapy Phase 1A or combination Phase 1B cohort in a staggered parallel design. In AML, we intend to study SL-172154 in combination with azacitidine and venetoclax. In HR-MDS and TP53 mutant AML, we intend to study SL-172154 in combination with azacitidine. We expect to announce initial data from this Phase 1A/B trial in the first half of 2023.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also intend to continue to assess other drug combination opportunities for SL-172154 in ovarian cancer and other solid tumors, as well as hematologic malignancies.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, SL-279252, is designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. We are evaluating SL-279252 in a Phase 1 clinical trial in patients with advanced solid tumors. In November 2021, at the SITC Meeting, we announced initial data from 43 patients from the first ten dose levels of this clinical trial. These data demonstrated initial monotherapy antitumor activity in patients who previously failed checkpoint inhibitors, at doses of 1 mg/kg or greater. Data through 6 mg/kg demonstrated that SL-279252 was well tolerated, and we observed pharmacodynamic activity, including dose-dependent margination of OX40+ lymphocytes from the peripheral blood. We are currently dosing at 12 mg/kg and plan to continue dose escalation to 24 mg/kg. We expect to announce additional data from this clinical trial in the second half of 2022. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our proprietary ARC and GADLEN platforms to discover and develop dual-sided, bi-functional fusion protein product candidates. We own, or have exclusively licensed, the intellectual property rights to our product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table highlights our clinical-stage product candidates:</span></div><div style="margin-top:6pt;text-align:center"><img src="sttk-20211231_g1.jpg" alt="sttk-20211231_g1.jpg" style="height:216px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical-stage ARC product candidates, we possess a deep pipeline of preclinical immuno-oncology candidates. As an example, SL-9258 is designed to inhibit the interaction between TIGIT and its known ligands, including PVR, PVRL2, PVRL3, and NECTIN-4, while simultaneously activating HVEM and LT&#946; receptors with two preformed LIGHT trimers. With the addition of HVEM and LT&#946; receptor activation, we believe this compound is a highly differentiated TIGIT inhibitor. Utilizing a proprietary animal model of PD-1 acquired resistance, SL-9258 demonstrated differentiation from antibody-mediated TIGIT blockade in its ability to overcome checkpoint inhibitor acquired resistance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table highlights the preclinical programs from which we may select our next clinical candidates:</span></div><div style="margin-top:6pt;text-align:center"><img src="sttk-20211231_g2.jpg" alt="sttk-20211231_g2.jpg" style="height:239px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ARC Platform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary ARC platform has the potential to create therapeutics that can dramatically change the way we treat cancer and other diseases. We developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions. Compounds developed from our ARC platform simultaneously block immune checkpoint receptors and activate costimulatory molecules in the tumor necrosis factor, or TNF, superfamily.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional domains of ARC compounds are derived from native human proteins, rather than antibody binding domains. This enables the rapid generation of new constructs, given that the starting template for distinct ARC compounds is the human genome. Therefore, an ARC compound can be taken from the conception stage to a manufactured purified protein in approximately six weeks, whereas it can take approximately six months to reach the same stage for an antibody therapeutic candidate. This rapid reduction in discovery processing time, has allowed us to generate more than 400 unique, dual-sided fusion proteins.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Structure of an ARC Compound </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary ARC platform is designed to overcome the limitations of existing bivalent antibodies. ARC compounds consolidate checkpoint blockade and immune costimulation within a single therapeutic. Additionally, ARC compounds possess a structure that matches the native structure of the target receptors and colocalizes both mechanisms of activity within the immune synapse to promote a coordinated immune response. We designed the ARC platform as a modular scaffold wherein three principal components are fused together, comprising a human Type 1 extracellular domain protein, an optimized, proprietary Fc domain, and a human Type 2 extracellular domain protein. As shown in Figure 1 below, one end of the ARC compound consists of a checkpoint receptor domain and the opposite end consists of a TNF ligand domain, connected by an optimized, proprietary scaffold such as an Fc domain. We designed ARC compounds to self-assemble into a hexameric structure, as shown in Figure 1 below, comprising six distinct checkpoint receptor domains and six distinct TNF ligand domains, which importantly form two trimerized costimulatory ligand domains.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1&#8212;Structural Properties of ARC Compounds</span></div><div style="text-align:center;text-indent:27pt"><img src="sttk-20211231_g3.jpg" alt="sttk-20211231_g3.jpg" style="height:344px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unique dual-sided structure of our ARC compounds allows us to simultaneously and effectively target a wide array of pathways for the creation of a deep and differentiated product pipeline. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal domains. Initially, our efforts are concentrated on three broad target families: immune checkpoints, TNF superfamily costimulatory receptors, and cytokines.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the following features represent the key advantages offered by compounds developed with the ARC platform:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Matching native structure of TNF receptors </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Target specificity, high affinity, and high avidity </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Replacing tumor immune evasion with potent immune stimulation </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Versatility </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Speed from concept to compound to clinic </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Accelerated lead selection process </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these collective advantages create the potential for the capital-efficient identification and pursuit of differentiated product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many TNF receptor agonist antibodies have been developed and tested in human clinical trials, most have been discontinued prior to pivotal studies due to toxicity. As shown in Panel A of Figure 2 below, activation of TNF receptors, such as CD40, and downstream signaling requires the assembly of three receptor molecules, or trimerization. As shown in Panel B of Figure 2 below, there is a structural mismatch between bivalent antibody therapeutics and trimeric TNF receptors. Traditional bivalent antibodies can only bind to two TNF receptors and are thus unable to individually trimerize a TNF receptor, leading to weak signaling of TNF pathways. For TNF receptor agonist antibodies to trimerize a TNF receptor, multiple antibodies must be cross-linked through Fc receptors located on accessory cells. This mechanism becomes less effective at increasing antibody doses due to saturation of TNF receptors and Fc receptors independently of each other. Consequently, there is no free Fc receptor available to cross-link the TNF receptor bound antibody. This effect manifests in clinical trials as an atypical dose-response relationship, known as a &#8220;bell-shaped&#8221; dose-response curve, wherein any signs of immune activation initially increase with dose but then subsequently decrease at higher doses. As shown in Panel C of Figure 2, ARCs are designed to self-assemble into two sets of TNF trimers, which induces trimerization of TNF receptor targets and drives a costimulatory signal.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2&#8212;Antibody Therapies Lead to Inefficient TNF Pathway Activation</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g4.jpg" alt="sttk-20211231_g4.jpg" style="height:265px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Versatility of the Platform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The modularity of our dual-sided fusion protein platforms, including our ARC platform, facilitates a vast repertoire of potential dual-sided fusion proteins that can be synthesized and developed. In the human genome, there are more than 1,400 Type 1 membrane proteins, which are characterized by an extracellular amino terminal domain, and more than 450 Type 2 membrane proteins, which are characterized by an extracellular carboxy terminal domain. ARC compounds are assembled from any combination of Type 1 and Type 2 membrane proteins and, therefore, have significant diversity, with more than 630,000 possible combinations. Within this vast set of possible combinations, we have chosen to focus initially on three classes of targets that have already shown significant clinical relevance for the treatment of cancer comprising immune checkpoints, the TNF superfamily, and cytokines. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal targets within a single therapeutic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become the world leader in the discovery, development, and commercialization of dual-sided, bi-functional fusion proteins for the treatment of cancer and autoimmune diseases. We plan to achieve this by utilizing our proprietary ARC and GADLEN platforms to create novel therapeutics to treat patients who lack effective treatment options. Key elements of our strategy include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Rapidly advancing our clinical-stage ARC product candidates, SL-172154 and SL-279252, through clinical development and marketing approval</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Leveraging our ARC and GADLEN platforms to rapidly advance additional product candidates into clinical development </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Continuing to augment our fusion protein manufacturing capabilities </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Collaborating with leading biopharmaceutical companies </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Building on our culture of R&amp;D excellence and continuing to out-innovate ourselves</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Deepening our intellectual property portfolio to continue to protect our platform technologies and product candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ARC Product Candidates </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SL-172154: A Dual CD47/SIRP&#945; Blocking and CD40-Activating ARC Compound </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data to Date </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, at the SITC Meeting, we presented data from the dose-escalation portion of our ongoing Phase 1A trial of SL-172154 as monotherapy in heavily pretreated platinum-resistant ovarian cancer patients. As of a September 15, 2021 data cutoff, we had enrolled a total of 15 patients across four dose levels ranging from 0.1 mg/kg to 3 mg/kg. Dose escalation was conducted according to the Modified Toxicity Probability Interval-2 trial design. Patients received SL-172154 on either a weekly schedule or, after doses on day one, day eight, and day 15, a bi-weekly schedule. The patients treated as of September 15, 2021 were heavily pretreated with a median of five prior lines of systemic therapies. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SL-172154 has been generally well tolerated. Specifically, we did not observe dose-limiting hemolytic anemia, thrombocytopenia or other cytopenias (toxicities which have limited the development of some CD47 inhibitors) through the 3 mg/kg dose level. We believe that SL-172154 may have a differentiated safety profile, which may be due to the lack of an Fc gamma receptor binding Fc domain.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have observed high levels of target occupancy of SL-172154 on both CD47 and CD40 through 3 mg/kg. As shown in Figure 3, we observed preferential binding of SL-172154 to CD47+ leukocytes compared to red blood cells. Binding to leukocytes approached near-full CD47 target occupancy at doses of 1 mg/kg or greater. </span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3&#8212;CD47 Targets Occupancy of SL-172154 on White Blood Cells and Red Blood Cells</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g5.jpg" alt="sttk-20211231_g5.jpg" style="height:217px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also observed unique pharmacodynamic effects consistent with on-target CD40 activation. Immediately post-infusion of SL-172154, a rapid, dose-dependent margination of CD40+ B cells and monocytes from the circulation was observed, as shown in Panel A and Panel B of Figure 4. We also observed an increase in B cell activation markers CD86 and CD95 following each infusion of SL-172154, as shown in Panel C of Figure 4. Additionally, increases in on-target cytokines such as IL-12, CCL2, CCL3, CCL4 and CCL22 have been observed following each infusion of SL-172154. No evidence of a bell-shaped dose response curve was observed through 3 mg/kg, a dose at which high levels of CD40 target occupancy were observed. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Figure 4&#8212;CD40 Activation of SL-172154 with Dose-Dependent Margination and Activation B Cells</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g6.jpg" alt="sttk-20211231_g6.jpg" style="height:211px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In paired biopsies collected from our ongoing clinical trials, we have observed increases in CD68+ macrophages as well as both CD40 and MHC Class II activation markers in the tumor microenvironment, consistent with induction of an innate immune response. Additionally, we have seen an increase in PD-L1 expression by the combined positive score, suggesting that the increase in tumor-infiltrating CD8+ T cells induced a local interferon response. We have also observed increases in Ki67+ CD8 T cells and the Granzyme B+ CD8 T cells. These findings are consistent with the postulated mechanism of action of SL-172154: simultaneous CD47 inhibition and CD40 activation bridging an innate to adaptive immune response. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 7, 2021, 14 of the 15 patients treated with SL-172154 in platinum-resistant ovarian cancer had a post-baseline scan at eight weeks and were evaluable for efficacy. Four patients had stable disease as best response including one patient with stable disease of 16 weeks or greater at 0.3 mg/kg and nine had progressive disease. We are continuing monotherapy dose escalation at the next dose level of 10 mg/kg.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Strategy</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that SL-172154 is a highly differentiated CD47 inhibitor with potential for both best-in-class and first-in-class development opportunities. We are conducting Phase 1 clinical trials evaluating the administration of SL-172154 in both solid tumors and hematologic malignancies. As a class, CD47 inhibitors are being developed in combination with other agents that potentiate phagocytosis and initiate an immune response, such as chemotherapy, ADCP-competent antibodies, antibody drug conjugates, and others.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ovarian Cancer</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ovarian cancer expresses the highest levels of CD47 of any solid tumor and is a tumor type with a significant infiltration of macrophages, which express CD40. We believe this makes ovarian cancer particularly well-suited to the investigation of SL-172154. We are conducting a Phase 1 clinical trial of SL-172154 administered intravenously in patients with advanced ovarian, fallopian tube, and primary peritoneal cancers, collectively referred to as ovarian cancer. Patients that are eligible for this trial have relapsed after standard-of-care therapies and are ineligible for further platinum-based therapies. The primary objective of this trial is to assess the safety and tolerability of SL-172154. The secondary objectives include evaluation of the pharmacokinetic and pharmacodynamic profiles and the antitumor activity of SL-172154.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ongoing Phase 1A monotherapy dose-escalation trial, three or more patients will be enrolled through each of the dose levels until a maximum tolerated dose or maximum administered dose is defined. In parallel, we plan to evaluate SL-172154 in a Phase 1B combination dose-escalation and dose-expansion trial in platinum-resistant ovarian cancer in combination with liposomal doxorubicin. Liposomal doxorubicin is a standard-of-care chemotherapy for this patient population. According to the literature and our internally generated data, liposomal doxorubicin upregulates calreticulin, an endogenous &#8220;eat me&#8221; signal, on the surface of tumor cells. We believe that liposomal doxorubicin is an attractive combination partner due to the observed upregulation of calreticulin, which led to potentiation of SL-172154-mediated ovarian cancer cell phagocytosis in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Furthermore, because the overall response rate of this patient population to liposomal doxorubicin is approximately 10%, there is significant opportunity for improved response rates in combination with SL-172154, wherein we believe the contribution of SL-172154 will be discernible. We are evaluating additional combination opportunities in ovarian cancer.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce additional data from the ongoing Phase 1A monotherapy dose-escalation trial and initial data from the Phase 1B combination trial in the first half of 2023.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cutaneous Squamous Cell Carcinoma and Head and Neck Squamous Cell Carcinoma</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a Phase 1 trial of SL-172154 administered intratumorally in patients with locally advanced or metastatic CSCC and HNSCC not amenable to further treatment with surgery, radiation, or standard systemic therapies. The primary objective of this trial was to assess the safety and tolerability of SL-172154. The secondary objectives included evaluation of the pharmacokinetic and pharmacodynamic profiles and the antitumor activity of SL-172154.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the totality of the safety and biomarker data collected to date in our ongoing Phase 1A clinical trial in ovarian cancer patients, we have decided to focus development of SL-172154 as an intravenously administered product candidate. Thus, as of February 24 2022, we ceased enrollment and are in the process of closing this trial. In addition, we experienced enrollment and operational challenges associated with intratumoral administration trials (which have been exacerbated by the COVID-19 pandemic), further supporting the decision to pursue a registrational strategy via intravenous administration. Overall, SL-172514 was well tolerated in this trial; we did not observe dose-limiting toxicities and did not reach a maximum tolerated dose. We expect to announce data from this trial in the first half of 2022. We may continue further development in HNSCC and/or CSCC in an intravenous administration trial of SL-172154 following selection of a recommended Phase 2 dose in our ovarian cancer trial.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a Phase 1A/B clinical trial for SL-172154 in patients with AML and HR-MDS. This ongoing Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, antitumor activity, and pharmacodynamic effects of SL-172154, as both monotherapy and in combination. In AML, we plan to evaluate SL-172154 in combination with both azacitidine and venetoclax. In both HR-MDS and TP53 mutant AML, we plan to evaluate SL-172154 in combination with azacitidine.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated the monotherapy Phase 1A dose escalation portion of this trial. We plan to conduct the Phase 1B dose escalation portion of this trial of SL-172154 in combination with azacitidine in a parallel staggered manner. Monotherapy dose-escalation and initial dose-escalation combination cohorts are anticipated to be in a heavily pretreated, predominantly refractory patient population. Once a recommended dose and schedule have been determined in combination with azacitidine, we plan to enroll patients in expansion cohorts in combination with azacitidine, with or without venetoclax, depending on the indication. As a class, CD47 inhibitors have demonstrated clinical activity in both AML and HR-MDS. We see an opportunity for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SL-172154 to continue to differentiate from other compounds in the field due to the combined effects of CD47 blockade and CD40 costimulation. Specifically, we believe that our preclinical and initial clinical data from our ongoing Phase 1A clinical trial in ovarian cancer indicate that SL-172154 may differentiate from other CD47/SIRP&#945; inhibitors in one or more of the following ways:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Improved overall response rate due to CD40-mediated activation of both innate and adaptive immunity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Improved response durability due to enhanced CD40-mediated activation of adaptive immunity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Differentiated safety profile due to the absence of dose-limiting anemia or thrombocytopenia</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce initial combination data from this trial in the first half of 2023.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have experienced delays in our clinical trials of SL-172154 because of the ongoing COVID-19 pandemic. In particular, we have experienced: delays with certain third-party vendors supporting this trial, including third-party manufacturers; difficulty procuring sufficient quantities of raw materials required for our manufacturing processes; delays as a result of some patients choosing to forego one or more doses in our clinical trials; and staffing shortages at many clinical trial sites. We expect to continue to experience some or all of these delays in the future. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Experience </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, simultaneously inhibits CD47 and activates the CD40 receptor. The pairing of a CD40 agonist domain to a CD47 inhibitory domain was selected based on prior publications which demonstrated that tumor rejection in the setting of CD47 inhibition was dependent upon a T cell mediated adaptive immune response. Agents which only block the interaction between CD47 and SIRP&#945; do not directly activate T cell mediated adaptive immunity, but instead function to enable macrophage mediated phagocytosis of tumor cells. Antigen presenting cells, including macrophages, express CD40. Stimulation of CD40 on antigen presenting cells is known to improve the efficiency of antigen presentation and activation of T cell mediated adaptive immunity, including antitumor immunity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have conducted extensive preclinical studies of SL-172154 that have demonstrated the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Specific binding to CD47 and CD40 with high picomolar affinity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">A significant increase in macrophage-mediated phagocytosis of tumor cells</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Durable receptor occupancy to CD47 expressing cells</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Dose-dependent CD40-mediated pharmacodynamic activity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The activation of antigen presenting cells by a CD40-induced type I interferon response</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Dose-dependent increases in multiple anti-cancer cytokines in both non-human primates and by human lymphocytes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Dose-dependent activation of a CD8+ T cell response, which was responsible for tumor cell killing</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Superior tumor rejection as compared to CD47 inhibitory antibodies, CD40 agonist antibodies, or the combination thereof, in mouse tumor models</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taken together, we believe these data demonstrate the potential ability of SL-172154 to activate and bridge the adaptive and innate immune responses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed standard </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tumor cell phagocytosis assays to demonstrate whether SL-172154 enhanced macrophage-mediated phagocytosis of various tumor cell lines, both alone and in combination with tumor-targeted ADCP-competent antibodies. As shown in Figure 5 below, consistent with the mechanism of action of CD47 blocking agents, SL-172154 significantly enhanced the ability of macrophages to phagocytose tumor cells in the presence of tumor-targeted ADCP-competent antibodies. Additionally, SL-172154 potentiated macrophage-mediated phagocytosis of tumor cells that expressed calreticulin, a well-established &#8220;eat me&#8221; signal expressed on the surface of cells marked for phagocytosis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 5&#8212;Tumor Phagocytosis Activity of SIRP&#945;-Fc-CD40L with or without ADCP-competent Antibodies</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g7.jpg" alt="sttk-20211231_g7.jpg" style="height:299px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:6pt;text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human monocyte derived macrophages were co-cultured with HCC1954, A431, HCC827, or Caov-3 cells in the presence of an IgG negative control, SL-172154, an ADCP-competent tumor-targeted antibody, including Trastuzumab or Cetuximab, or the combination of SL-172154 and the ADCP-competent tumor-targeted antibody. After two hours, the proportion of tumor cells phagocytosed by human macrophages was determined and reported as the phagocytosis index.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted dose-range finding and repeat dose toxicity studies in nonhuman primates, or NHP, to evaluate the safety and pharmacologic effects of SL-172154. In these studies, SL-172154 was administered as five once-weekly doses across a dose range of 0.1 mg/kg to 40 mg/kg, followed by a recovery period. Data from these studies indicated that SL-172154 induced a potent immune response in NHP. Figure 6 below shows dose-dependent saturation of CD47+ red blood cells, which was durable for greater than seven days. In addition, SL-172154 bound CD40-expressing B cells in the peripheral blood and stimulated a dose-dependent migration of lymphocytes from the peripheral blood within 24 hours of treatment. We believe these data are supportive of either a once weekly or every other week dosing schedule. Histology samples demonstrated that the post-dose decreases in peripheral blood lymphocytes were accompanied by accumulation of proliferating lymphocytes in lymph nodes, spleen and bone marrow. Whereas other CD47-targeted agents are administered at super-saturating doses, which we believe is intended to establish a concentration gradient that facilitates passive diffusion into tissues, we believe these data suggest that SL-172154 may be actively transported into tissues via CD40 binding, which may lead to a unique dosing profile in humans. Administration of SL-172154 was also associated with dose-dependent post-treatment increases in multiple serum cytokines, such as CCL2. Overall, SL-172154 was well tolerated; however, at the higher dose levels, we observed toxicities that were consistent with cytokine release syndrome in the setting of an anti-drug antibody response, which is expected in NHP because SL-172154 is a human protein construct. No evidence of anemia was observed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 6&#8212;CD47 Receptor Occupancy following SL-172154 Infusion</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g8.jpg" alt="sttk-20211231_g8.jpg" style="height:282px;margin-bottom:5pt;vertical-align:text-bottom;width:425px"/></div><div style="margin-top:6pt;text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cynomolgus monkeys were treated on Day 1 and 8 with 0.1 mg/kg, 1 mg/kg, 10 mg/kg, and 40 mg/kg of SL-172154 or a vehicle control. Receptor occupancy was evaluated at the indicated time points by flow cytometry. SL-172154 occupancy on red blood cell CD47 is plotted as the proportion of total CD47 expression minus the proportion of CD47 detected using an antibody that is prevented from binding when CD47 is occupied by SL-172154.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SL-279252: A Dual PD-1 Blocking and OX40-Activating ARC Compound</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, SL-279252, is a dual-sided, bi-functional fusion protein that both inhibits the PD-/PD-L1 interaction and activates the OX40 costimulatory receptor. We are evaluating SL-279252 in an ongoing Phase 1 dose-escalation clinical trial in patients with advanced solid tumors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data Observed to Date </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, at the SITC Meeting, we presented data from the dose-escalation portion of our ongoing Phase 1 clinical trial as monotherapy in late-stage solid tumor cancer patients. As of June 11, 2021 we had enrolled a total of 43 patients from the first ten dose levels, ranging from 0.0001 mg/kg to 6 mg/kg. Dose escalation was conducted according to the keyboard design. Patients received SL-279252 on either a weekly or bi-weekly basis with a 28-day cycle. The patients treated as of June 11, 2021, were heavily pretreated with a median of three prior lines of systemic therapies and 58% were checkpoint inhibitor experienced. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of our latest safety data cutoff date of January 19, 2022, SL-279252 has been observed to be well tolerated and has demonstrated monotherapy antitumor activity in some PD-1 inhibitor experienced patients during dose escalation at doses of 1 mg/kg and higher. Dose escalation is continuing in a primarily PD-1/L1 inhibitor experienced patient population. Treatment-related adverse events, including immune-related events, have been reported in some patients. To date, we have observed no Grade 4 or Grade 5 adverse events, and we have not observed any dose-limiting toxicities. A maximum tolerated dose has not been reached.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 11, 2021, preliminary pharmacodynamic activity has been evaluated in patients treated across a dose range of 0.0001 mg/kg to 6 mg/kg. Increases in the number of proliferating CD8+ central memory and effector memory T cells were observed in the peripheral blood of some patients at higher peak SL-279252 concentrations corresponding to doses of 1.0 mg/kg or greater. Post-dose receptor occupancy on OX40+ lymphocytes was observed in a dose-dependent fashion, and the total number of OX40+ cells in the blood declined rapidly post-infusion of SL-279252. We believe the post-infusion decreases in OX40+ lymphocytes provides evidence of on-target activation. In NHP, similar post-infusion decreases in lymphocytes were associated with migration of lymphocytes into tissues. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 11, 2021, preliminary pharmacokinetic activity has been evaluated across a dose range of 0.0001 to 6 mg/kg. A linear increase in SL-279252 Cmax and AUC was observed up to 3.0 mg/kg, while a greater than proportional increase in AUC was observed at 6.0 mg/kg, suggesting potential target saturation at 6 mg/kg. Within subject exposure was similar on Days 1, 15 and 29, indicating no accumulation or time-dependent changes in pharmacokinetics on either schedule. The preliminary half-life is approximately 23 hours.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 20, 2021, the best response to therapy has been one confirmed partial response, or PR, in a patient with ocular melanoma who remained on treatment for greater than one year. This patient was heavily pretreated, with four prior systemic regimens and had progressed on prior PD-1 and CTLA-4 checkpoint inhibitor therapies. In addition, stable disease, or SD, was seen in an additional 12 patients. In five of these patients, SD was sustained for greater than 24 weeks. One unconfirmed PR was observed in a patient with mucosal melanoma of the vulvar who had also progressed on prior PD-1 and CTLA-4 checkpoint inhibitor therapies. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Strategy </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently dosing at 12 mg/kg and plan to continue dose escalation to 24 mg/kg in our Phase 1 trial of SL-279252 in patients with advanced solid tumors and we are primarily selecting for patients with PD-L1 expressing tumors. The primary objective of the Phase 1 trial is to assess the safety and tolerability of SL-279252. The secondary objectives include evaluation of the pharmacokinetic and pharmacodynamic profiles as well as the antitumor activity of SL-279252. We are evaluating antitumor response according to immune Response Evaluation Criteria in Solid Tumors or Response Evaluation Criteria in Lymphoma 2017. These are standard, widely-accepted criteria to evaluate tumor response in oncology clinical trials. We expect to provide additional data from the dose-escalation portion of this Phase 1 trial in the second half of 2022.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the way that the PD-1 inhibitor landscape has evolved, the development path for SL-279252 is first in PD-1 relapsed and refractory patients. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have experienced delays in our clinical trial of SL-279252 because of the ongoing COVID-19 pandemic. In particular, we have experienced: delays with certain third-party vendors supporting this trial, including third-party manufacturers; difficulty procuring sufficient quantities of raw materials required for our manufacturing processes; delays as a result of some patients choosing to forego one or more doses in our clinical trials; and staffing shortages at many clinical trial sites. We expect to continue to experience some or all of these delays in the future. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our GADLEN Platform </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expertise in engineering dual-sided, bi-functional fusion proteins has enabled the development of our GADLEN platform to leverage gamma delta T cells for the treatment of cancer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The therapeutic utilization of gamma delta T cells represents a novel approach for the treatment of cancer. This approach may be particularly beneficial in targeting tumors that are not addressable by alpha beta T cells. Additionally, as immunotherapies that stimulate alpha beta T cell-dependent immune response are increasingly utilized across cancer treatment paradigms, we expect the proportion of patients who will become refractory to alpha beta T cell-mediated therapies will also increase over time, creating an opportunity for therapeutics which harness the antitumor activity of gamma delta T cells.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of T cells in the human body bear an alpha beta T cell receptor, which recognizes tumor antigens presented on major histocompatibility complex, or MHC, molecules. Some cancer cells reduce the expression of MHC molecules or tumor antigens, rendering those cancer cells invisible to most alpha beta T cells. The predominant gamma delta T cell population in the peripheral blood expresses the V gamma 9 / V delta 2 T cell receptor and is activated by a heterodimer consisting of butyrophilin 2A1 and butyrophilin 3A1. Thus, therapeutics which are designed to display a heterodimer of butyrophilin 2A1 and 3A1 may provide a means of modulating gamma delta T cells in vivo. We have leveraged our expertise in engineering dual sided bi-functional fusion proteins to develop a suite of heterodimerized butyrophilin proteins connected to antigen-targeted single chain antibody fragments.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GADLEN compounds are comprised of two distinct fusion protein chains, and an engineered Fc linker domain that facilitates heterodimerization between the two chains. As shown in the left panel of Figure 7 below, the assembled GADLEN compound contains the extracellular domains of heterodimerized butyrophilin proteins on one side and is linked to tumor antigen specific single chain antibody fragments on the opposite side. The gamma delta T cell receptors recognize and are activated by specific butyrophilin protein heterodimers. Thus, the GADLEN construct is designed to facilitate targeting of specific gamma delta T cells to tumor cells expressing a defined antigen, as shown in the right panel of Figure 7 below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 7&#8212;GADLEN Platform Overview</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g9.jpg" alt="sttk-20211231_g9.jpg" style="height:173px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To demonstrate the feasibility of the GADLEN approach, a murine GADLEN construct was developed incorporating a butyrophilin 1, or BTNL1, and butyrophilin 6, or BTNL 6, heterodimer and an scFv domain targeting the CD19 antigen. In both mice and humans, gamma delta T cells represent approximately 2% to 5% of the total T cell population, as shown in Figure 10 in a murine model. We treated mice on Days 0, 3, and 6 with the murine GADLEN, mBTNL1/6-Fc-CD19scFv. We observed dose-dependent expansion of the endogenous gamma delta T cell compartment to approximately 12% of all T cells 24 hours after the second treatment. Concurrent with expansion, mBTNL1/6-Fc-CD19scFv also caused activation of murine gamma delta T cells, as demonstrated by upregulation of the CD69 activation marker, shown in Figure 10. Murine B cells express CD19, and therefore were a potential target of gamma delta T cells following treatment with mBTNL1/6-Fc-CD19scFv. Accordingly, we observed depletion of the endogenous B cell compartment concurrent with gamma delta T cell expansion and activation following treatment with mBTNL1/6-Fc-CD19scFv, as shown in Figure 8. Importantly, when mice with established CD19+ tumors were treated with mBTNL1/6-Fc-CD19scFv, dose-dependent reduction in tumor growth and rejection was observed. We believe these studies indicate that GADLEN compounds enable therapeutic modulation of gamma delta T cells in vivo, and that GADLEN compounds may be designed to activate tissue-restricted populations of endogenous gamma delta T cells to target specific tumor antigens in both solid and liquid tumors.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 8&#8212;Dose Dependent Gamma T Cell Expansion, Activation, and Killing Activity Following Administration of the GADLEN Compound mBTNL1/6-Fc-CD19scFv</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20211231_g10.jpg" alt="sttk-20211231_g10.jpg" style="height:125px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To characterize the types of gamma delta T cell subsets that reside within different tumor types, we performed single cell RNA sequencing of patient tumor tissues, including multiple colorectal, melanoma, and non-small cell lung cancer patient tumors to identify the prevalent gamma delta T cell subsets in each tumor type. As a result of this analysis, we have advanced a number of preclinical GADLEN candidates comprised of butyrophilin heterodimers and tumor antigen specific targeting domains for a number of antigens with therapeutic relevance for both hematologic and solid tumors. Our preclinical findings with these GADLEN compounds have also revealed that gamma delta T cells, like alpha beta T cells, require costimulation through either costimulatory or natural cytoxicity receptors (NCR) for efficient T cell receptor activation. The data generated to date suggest these signals can be provided by the tumor cells that express costimulatory ligands and stress ligands that enable efficient activation of gamma delta T cell receptors via GADLEN compounds.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In alignment with our strategy to leverage our expertise to build and expand novel platforms beyond our ARC platform, where dual-sided fusion proteins may provide advantages over existing therapeutic antibodies, we continue to invest in and advance our GADLEN platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement with Takeda </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2017, we entered into a Collaboration Agreement with Millennium Pharmaceuticals, Inc., or Takeda, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd., or the Collaboration Agreement. The Collaboration Agreement was subsequently amended in April 2018, October 2018 and March 2020. The Collaboration Agreement was </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mutually terminated pursuant to the termination agreement, or the Termination Agreement, dated November 8, 2021. Under the terms of the Termination Agreement, we are not required to satisfy any remaining performance obligations, we will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. The remaining deferred revenue was recognized as revenue in the fourth quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heat License Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into an Exclusive License Agreement, or the Heat License Agreement, with Heat Biologics Inc., or Heat. The Heat License Agreement was subsequently amended in November 2016, December 2016, and March 2017. Pursuant to the Heat License Agreement, Heat granted to us (1) a worldwide, sublicensable exclusive license to research, develop, manufacture, and commercialize products under three provisional patent applications, including all patents issuing from such applications, or the Fusion Protein Patent Rights, and (2) a worldwide, sublicensable nonexclusive license to research, develop, manufacture, and commercialize certain know-how owned and controlled by Heat related to the Fusion Protein Patent Rights.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Heat License Agreement, Heat was required to conduct certain research and development services under a mutually-agreed upon research and development plan and Heat was eligible to receive financial support from us for these efforts. Effective March 2017, Heat completed all research and development services under the Heat License Agreement and assigned to us three patent applications and all data derived from the research and development activities, referred to collectively as the Research Services Inventions. Pursuant to the terms of the Heat License Agreement, we are obligated to use commercially reasonable efforts to diligently research and develop at least one product covered by the Fusion Protein Patent Rights, including the obligation to file an Investigational New Drug, or IND, application for such product. Our development efforts to date, including the development of SL-279252 and certain other ARC compounds, satisfy these obligations. In addition, we are to provide annual reports to Heat on or before the anniversary of the effective date of the Heat License Agreement to inform Heat of our progress.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless sooner terminated or extended, the term of the Heat License Agreement continues until the later of (1) 20 years following the effective date, and (2) the expiration of the last-to-expire royalty term. Either party may terminate the agreement due to a material breach by the other party (subject to a 90-day cure period) or if the other party files for bankruptcy. In the event we terminate the Heat License Agreement due to a material breach by Heat, Heat must assign to us all right, title, and interest in the patent rights licensed under the Heat License Agreement.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an upfront payment of $50,000, which we made in 2016, the Heat License Agreement requires us to make further payments to Heat in the future of up to $20.6 million in the aggregate for the achievement of specified development, regulatory, and commercial sale milestones for certain licensed products. We are also required to pay Heat a percentage of certain upfront fees or other non-royalty payments that are not tied to milestone events which we receive in connection with certain sublicenses of the Fusion Protein Patent Rights. We are also required to pay Heat a royalty on all worldwide net sales by us, our affiliates, and sublicenses of certain licensed products in the low single digits. Royalties are payable, on a product-by-product and country-by-country basis, commencing on the first commercial sale of such product and continuing until the last-to-expire valid patent claim to the licensed patent rights that cover such product in that country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By working with third-party vendors to conduct activities in compliance with current Good Manufacturing Practices, or cGMP, we have invested significant resources to identify and scale up a suitable manufacturing process for ARC compounds, including SL-172154 and SL-279252. Currently, ARC compounds are produced by mammalian cell lines commonly used in the manufacture of monoclonal antibodies, including Chinese hamster ovary, or CHO, cells. Both SL-172154 and SL-279252 have achieved cell culture titer greater than two grams per liter, and another ARC compound has achieved titers exceeding seven grams per liter. Purification of ARC compounds initially utilizes affinity chromatography directed to the Fc domain for capture, and subsequent chromatography steps are designed to remove process-related impurities including CHO derived DNA and proteins. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have manufactured bulk drug substance, or BDS, for our product candidates utilizing the services of one third-party contract manufacturer, KBI Biopharma, Inc., or KBI, with whom we maintain a master service agreement, pursuant to which we may manufacture BDS through KBI on a per project basis. We may terminate the master services agreement at any time for convenience in accordance with the terms of the agreement. Either KBI or we may also terminate the master services agreement with respect to an uncured breach by the other party in accordance with the terms of the agreement. These agreements include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the complexity of manufacturing our dual-sided, bi-functional fusion proteins, our increased need for manufacturing driven by multiple clinical trial programs, and the challenges faced by biologics manufacturing facilities during </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the COVID-19 pandemic, we are actively working to make arrangements to procure redundant supply, including engaging with additional third-party manufacturers to identify suitable additional suppliers and building out a facility to support internal process development activities and cGMP manufacturing. We have recently entered into a master service agreement with Abzena Plc, pursuant to which we may manufacture BDS on a per project basis.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote significant resources to process development and optimization of the manufacture of our product candidates. To our knowledge, no other company has successfully scaled up commercial manufacturing of dual-sided, bi-functional fusion proteins. Due to the novelty of our product candidates, we may face challenges in developing large-scale manufacturing processes. Moreover, the nature of biologic medicines could create challenges for the stability of the drug substance. While these and other challenges may result in timeline delays and higher costs, we believe that we will have sufficient BDS to support our current clinical trial programs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are manufactured from a master cell bank of that protein&#8217;s production cell line. We have or intend to have one master cell bank for each product candidate that was or will be produced and tested in accordance with cGMP and applicable regulations. Each master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in product development. It is possible that we could lose multiple cell banks from multiple locations and have our manufacturing severely impacted by the need to replace the cell banks. However, we believe we have adequate backup should any particular cell bank be lost in a catastrophic event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing, and commercialization of cancer therapies. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the segments of the pharmaceutical, biotechnology, and other related markets that develop cancer therapies. There are many other companies that have commercialized or are developing cancer therapies, including large pharmaceutical and biotechnology companies, such as AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech and Gilead.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition from pharmaceutical and biotechnology companies that target specific tumor-associated antigens using immune cells or other cytotoxic modalities. These generally include immune cell redirecting therapeutics (e.g., T cell engagers), adoptive cellular therapies (e.g., CAR-Ts), antibody drug conjugates, targeted radiopharmaceuticals, targeted immunotoxin, and targeted cancer vaccines.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our lead product candidate, SL-172154, we are aware of other competing clinical-stage therapeutics that target the CD47 pathway or the CD40 pathway, which include, but are not limited to magrolimab, ALX148, TTI-621, TTI-622, DSP107, and APX005M.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our second lead product candidate, SL-279252, we are aware of other competing clinical-stage therapeutics, that target the PD-1 pathway or the OX40 pathway, which include, but are not limited to PF-04518600, BMS-986178, INBRX-106, pembrolizumab, nivolumab, avelumab, and atezolizumab.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and manufacturing capacity and enrolling subjects for our clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companion diagnostics, if required, the level of biosimilar or generic competition, and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance our proprietary technology, inventions, and improvements that we consider commercially important to the development of our business, including by seeking, maintaining, and defending U.S. and foreign patent rights, including patents covering our platform technologies, product candidates, and methods of using the same, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, and continuing technological innovation to develop, strengthen and maintain our proprietary position in our field. Additionally, we intend to rely on regulatory protection afforded through data exclusivity and market exclusivity, among others, as well as patent term extensions, where available.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future commercial success depends, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business, including our platform technologies and product candidates, defend and enforce our intellectual property rights, in particular our patents rights, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biotechnology companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing, or those we will file or license from others, will grant us patents in any particular jurisdiction or whether the claims of any granted patents will provide sufficient proprietary protection from competitors.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the coverage claimed in a patent application may be significantly reduced before a patent is granted, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. See &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property and Information Technology&#8221; for a more comprehensive description of risks related to our intellectual property.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any individual patent, the term depends on the applicable law in the country in which the patent is granted. In most countries where we have filed patent applications or in-licensed patents and patent applications, patents have a term of 20 years from the application filing date or earliest claimed nonprovisional priority date. In the United States, the patent term is 20 years from the application filing date or earliest claimed nonprovisional priority date, but may be shortened if a patent is terminally disclaimed over another patent that expires earlier. The term of a U.S. patent may also be lengthened by a Patent Term Adjustment in order to address administrative delays by the U.S. Patent and Trademark Office in granting a patent.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the term of a patent that covers an FDA-approved drug or biologic may be eligible for Patent Term Extension in order to restore the period of a patent term lost during the premarket FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a Patent Term Extension of up to five years beyond the natural expiration of the patent (but the total patent term, including the extension period, must not exceed 14 years following FDA approval). The term extension period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office reviews and approves the application for any Patent Term Extension in consultation with the FDA. In the future, we may decide to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant biologics license application.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property related to our most advanced programs is summarized below.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally file patent applications directed to our key technologies and programs in an effort to secure our intellectual property positions. As of February 1, 2022, we own or exclusively license (i) more than 15 patents and more than 15 pending non-provisional patent applications in the United States and (ii) 3 patents and more than 120 pending patent applications in jurisdictions outside of the United States. We also own additional pending provisional patent applications in the United States and pending international patent applications </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed under the Patent Cooperation Treaty, or PCT. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office and other patent offices may be significantly revised before issuance, if granted at all.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SL-172154 Product Candidate</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2022, we own or exclusively license (i) 2 patents and 5 pending non-provisional patent applications in the United States and (ii) 3 patents and more than 35 pending patent applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan) that relate to SL-172154.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These patents and applications originate from several different patent families.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in a family generally directed to compositions and methods of treating cancer are expected to expire in the United States in 2036, without taking potential patent term extension or patent term adjustment into account.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in other families, generally directed to methods of treating cancer with various combination agents, are expected to expire in the United States in 2038 and 2039, depending on the family and without taking potential term extension or patent term adjustment into account.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of individual patents granted in jurisdictions outside of the United States depends on the legal term for patents in those jurisdictions.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SL-279252 Product Candidate</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2022, we own or exclusively license (i) 2 patents and 1 pending non-provisional patent application in the United States (ii) 3 patents and more than 35 pending patent applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan) that relate to SL-279252.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These patents and applications originate from two different patent families.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in a family generally directed to compositions and methods of treating cancer are expected to expire in the United States in 2036, without taking potential patent term extension or patent term adjustment into account.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in another family, generally directed to methods of treating cancer with various combination agents, are expected to expire in the United States in 2039, without taking potential patent term extension or patent term adjustment into account.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of individual patents granted in jurisdictions outside of the United States depends on the legal term for patents in those jurisdictions.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARC Platform </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2022, we own or exclusively license (i) more than 15 patents and 15 pending non-provisional patent applications in the United States and (ii) 3 patents and more than 100 pending patent applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan) that relate to the ARC platform. As of February 1, 2022, these include patents and/or patent applications related to SL&#8209;172154 and SL-279252 (described above) and other ARC compounds combining TIM3, PD&#8209;1, SIRP&#945;, TIGIT, CSF1R, VSIG8, or FLT3L with OX40, CD40L, 4-1BBL, or LIGHT.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These patents and applications originate from several different patent families.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in families generally directed to compositions and methods of treating cancer are expected to expire in the United States in 2036, 2038, 2039, and 2040, depending on the family and without taking potential patent term extension or patent term adjustment into account.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in other families, generally directed to methods of treating cancer with various combination agents, are expected to expire in the United States in 2038, 2039, and 2040, depending on the family and without taking potential patent term extension or patent term adjustment into account. The terms of individual patents granted in jurisdictions outside of the United States depends on the legal term for patents in those jurisdictions.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GADLEN Platform </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2022, we (i) own 2 patents and 1 pending non-provisional patent application in the United States and (ii) more than 10 pending patent applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan) that relate to the GADLEN platform.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These patents and applications originate from a family generally directed to compositions and methods of treating cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents granted in this family are expected to expire in the United States in 2040, without taking potential patent term extension or adjustment into account.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademark Protection</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2022, we own a registered trademark and an allowed application for &#8220;ARC&#8221; and an allowed application for &#8220;GADLEN&#8221; with the U.S. Patent and Trademark Office. We plan to register trademarks in connection with our biological products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed Intellectual Property from Heat Biologics, Inc.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into an exclusive license agreement with Heat, pursuant to which we received an exclusive (as to the patent rights), non-transferable, sublicensable, worldwide, royalty-bearing, non-field restricted license to certain patent rights and know-how, including rights related to the ARC platform. We paid Heat an initial license fee of $50,000, and we are obligated to pay Heat fees upon receipt of certain sublicensing income, achievement of certain milestones, and royalties upon sales of commercial products. The Heat license provides us rights in the patent family including PCT/US16/54598.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2022, that family includes (i) 10 patents and 3 pending non-provisional patent applications in the United States, and (ii) 2 patents and more than 25 pending applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan). We control prosecution, maintenance, and enforcement of this family of patents and patent applications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Biologics Regulation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and other federal, state, local, and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">approval by an independent IRB or ethics committee at each clinical site before the trial is commenced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacture of the proposed biologic candidate in accordance with cGMPs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA Submission and Review </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan, or PSP, within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the FDA established a new regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (i) the drug qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of breakthrough therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through: the submission of clinical evidence, preclinical studies, clinical trials, patient registries or other sources of real world evidence such as electronic health records; the collection of larger confirmatory datasets; or post-approval monitoring of all patients treated with the therapy prior to approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation, breakthrough therapy designation, priority review and RMAT designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In May 2018, the Right to Try Act established a new regulatory pathway to increase access to unapproved, investigational treatments for patients diagnosed with life-threatening diseases or conditions who have exhausted approved treatment options and who are unable to participate in a clinical trial. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">fines, warning letters or holds on post-approval clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Diagnostic Tests</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates may require use of a diagnostic to identify appropriate patient populations for our product candidates. These diagnostics, often referred to as companion diagnostics, are medical devices, often in vitro devices, which provide information that is essential for the safe and effective use of a corresponding drug. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion diagnostic developed for our drug candidates will utilize the PMA pathway.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. FDA review of an initial PMA may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;In Vitro Companion Diagnostic Devices.&#8221; According to the guidance, for novel drugs such as our drug candidates, a companion diagnostic device and its corresponding drug should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Reference Product Exclusivity </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. As of March 2020, certain products previously approved as drugs under the FDCA, such as insulin and human growth hormone,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are now deemed to be biologics under the PHSA, which means they may face competition through the biosimilars pathway and are not be eligible for the twelve-year period of exclusivity granted to new BLAs. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute, or AKS; the federal False Claims Act, or FCA; HIPAA and similar foreign, federal and state fraud, abuse and transparency laws.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCA imposes mandatory treble damages and per-violation civil penalties up to approximately $23,000.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such reporting obligations will be expanded to include payments and other transfers of value provided in 2021 to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by HITECH, and their respective implementing regulations imposes privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, state laws govern the privacy and security of personal information, including health-related information, in certain circumstances. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the CCPA, which went into effect on January 1, 2020, creates new data privacy obligations for covered companies and provides new privacy rights to California residents.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act, or the ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the Tax Act was enacted, which, among other things, removes penalties for not complying with the ACA&#8217;s requirement to carry health insurance, known as the &#8220;individual mandate,&#8221; effective January 1, 2019. Since the enactment of the Tax Act, there have been additional amendments to certain provisions of the ACA. In December 2019, the U.S. District Court for the Fifth Circuit upheld a ruling by a Texas U.S. District Court Judge that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. The Supreme Court heard the case but overturned the decision on the basis that the plaintiffs lacked standing and did not address the constitutionality.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supreme Court&#8217;s decision left open the opportunity for additional challenges to the ACA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through December 31, 2020, unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021. In October 2020, the FDA issued guidance describing procedures for manufacturers to facilitate the importation of FDA-approved biologics manufactured abroad and originally intended for sale in a foreign country into the United States. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Biden administration has stayed the effective dates of some last-minute drug price regulations issued by the Trump administration, Congress and the Biden administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Government Regulation Outside of the United States</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation in the European Union</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Data Laws</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data and other personal information in the European Union is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679, or the GDPR, which came into force in May 2018, and related implementing laws in individual EU Member States. Under the GDPR, personal data can only be transferred to countries outside the EU Member States and the three additional European Economic Area, or EEA, countries (Norway, Iceland and Liechtenstein) that have adopted a national law implementing the GDPR if such cross-border transfers comply with specific conditions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes a number of strict obligations and restrictions on the ability to collect, analyze and transfer personal data of individuals within the EU and in the EEA, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to (i) the consent of the individuals to whom the personal data relates, (ii) the information provided to such individuals prior to processing their personal data, (iii) data processing obligations to the national data protection authorities and (iv) the security and confidentiality of the personal data. EU Member States may also impose additional requirements. The GDPR increased responsibility and liability in relation to personal data that we process. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance (up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater); other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers; and civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and at the national level in individual EU Member States concerning implementation and compliance practices are regularly updated or otherwise revised.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there is a growing trend towards required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation, European Medical Agency, or the EMA, disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the EU Clinical Trials Regulation and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the EU to the United Kingdom, or UK, personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level. Such adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force (June 2025). Following the UK's withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the GDPR as incorporated into UK national law). Penalties under this regime are up to the greater of &#163;17.5 million or 4% of global turnover.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug and Biologic Development Process</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of clinical trials is currently governed by the EU Clinical Trials Directive 2001/20/EC, or Clinical Trials Directive, and will be replaced by the EU Clinical Trials Regulation (EU) No. 536/2014, or Clinical Trials Regulation, once the latter comes into effect. The Clinical Trials Regulation introduces a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. It entered into force on January 31, 2022.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current regime, which will expire after a transition period of three years (as outlined below in more detail), before a clinical trial can be initiated, it must be approved in each EU Member State where there is a site at which the trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority, or NCA, and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State where they occur.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A more unified procedure will apply under the new Clinical Trials Regulation. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU Member State proposed by the applicant) will take the lead in validating and evaluating the application consult and coordinate with the other concerned Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned Member States. However, a concerned EU Member State may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial form being conducted in such Member State. The Clinical Trials Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. After several postponements of the effective date of the Clinical Trials Regulation, or CTR, due to technical difficulties with the underlying IT systems, the &#8220;go live&#8221; date of these systems and, accordingly, the coming into force of the regulation, occurred on January 31, 2022. The CTR foresees a three-year transition period. Member States will work in CTIS immediately after the system has gone live. For one year, until January 31, 2023, clinical trial sponsors can still choose whether to submit an initial clinical trial application in line with the current system (Clinical Trials Directive) or via CTIS. After January 31, 2023, submission of initial clinical trial applications via CTIS becomes mandatory and by January 31, 2025, all ongoing trials approved under the current Clinical Trials Directive will be governed by the new Clinical Trials Regulation and have to be transitioned to CTIS.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both the current regime and the new Clinical Trials Regulation, national laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good Clinical Practice, or GCP, and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use, or CHMP, on the recommendation of the Scientific Advice Working Party, or SAWP. A fee is incurred with each scientific advice procedure, but is significantly reduced for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Marketing Authorization</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, medicinal products, including advanced therapy medicinal products, or ATMPs, are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. We anticipate that our gene therapy development products will be regulated as ATMPs in the European Union under the EU Regulation (EC) No 1394/2007 on advanced therapy medicinal products, or ATMP Regulation. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a marketing authorization application; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA, after completion of all required clinical testing, medicinal products may only be placed on the market after a related Marketing Authorization, or MA, has been granted. MAs can be obtained through, amongst others, a centralized procedure, which is compulsory for certain medicinal products such as ATMPs. The centralized procedure provides for the grant of a single MA by the European Commission, or EC, that is valid for all 27 EU Member States and, after respective national implementing decisions, in the three additional EEA Member States (Iceland, Norway, and Liechtenstein). The centralized procedure is compulsory for certain medicinal products, including medicinal products derived from biotechnological processes, orphan medicinal products, ATMPs and products with a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. It is optional for medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004, that constitute significant therapeutic, scientific or technical innovations, or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level. The timeframe for the evaluation of an application under the centralized procedure is 210 days, excluding clock stops. Typically, the overall process takes a year or more unless the application is eligible for an accelerated assessment. Applications may be eligible for accelerated assessment if the CHMP decides the product is of major interest for public health and therapeutic innovation. On request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. However, the EC has final authority for granting the MA within 67 days after receipt of the CHMP opinion.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized marketing authorization procedure permits companies to file identical applications for a marketing authorization to the competent authorities in several EU Member States simultaneously for a pharmaceutical product that has not yet been authorized in any EU Member State. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a marketing authorization for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health related to authorization of the product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these circumstances the matter is submitted to the Heads of Medicines Agencies, or CMDh, for review.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new marketing authorization applications must include a Risk Management Plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports, or PSURs, are routinely available to third parties requesting access, subject to limited redactions.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the holder of a marketing authorization for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MAs have an initial duration of five years. The authorization may subsequently be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance unless the EC or the national competent authority grants only a five-year </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">renewal on justified grounds relating to pharmacovigilance. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data and Market Exclusivity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, it may be possible to obtain a period of market and/or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a marketing authorization) and prohibiting another applicant from relying on the marketing authorization holder&#8217;s pharmacological, toxicological and clinical data in support of another marketing authorization for the purposes of submitting an application, obtaining MA or placing the product on the market. New chemical entities, or NCE, approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data exclusivity period begins on the date of the product&#8217;s first marketing authorization in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the marketing authorization holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first marketing authorization in the EU of the innovator product), or three years later (or a total of 11 years after the first marketing authorization in the EU of the innovator product) if the marketing authorization holder obtains marketing authorization for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full marketing authorization application with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Designation and Exclusivity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of (i) a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics, or SmPC, addressing the pediatric population and completed in accordance with a fully compliant PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Development</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee, or PDCO. Companies must conduct pediatric clinical trials in compliance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA. The marketing authorization application for the product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a marketing-authorization holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRIME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Designation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Regulation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of a marketing authorization for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of PSURs in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase IV safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the marketing authorization holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products in the European Union is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice, or GMP. These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Regulations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the European Union. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Legislation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Markets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK formally left the EU on January 31, 2020 and the transition period, during which EU laws continued to apply to the UK, expired on December 31, 2020. This means EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. Following the end of the transition period, the EU and the UK concluded the TCA, which applied provisionally from January 1, 2021 and entered into force on May 1, 2021.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCA includes provisions affecting the life sciences sector (including on customs and tariffs) but areas for further discussion between the EU and the UK remain. Some specific provisions concerning pharmaceuticals are in place, including the mutual recognition of Good Manufacturing Practice, or GMP, and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2021, the EU laws which have been transposed into UK law through secondary legislation continue to be applicable in the UK as &#8220;retained EU law.&#8221; As there is no general power to amend these regulations, the UK government has enacted the Medicines and Medical Devices Act 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the act is to enable the existing regulatory frameworks in relation to human medicines, clinical trials of human medicines, veterinary medicines and medical devices to be updated. The powers under the act may only be exercised in relation to specified matters and must safeguard public health.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified provisions of the Medicines and Medical Devices Act 2021 entered into force on February 11, 2021. The remaining provisions came into effect within two months of February 11, 2021 or will otherwise come into effect as stipulated in subsequent statutory instruments. The Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002, or the UK Regulations, which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which, since May 26, 2021, now applies in all EU Member States. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK&#8217;s Medicines and Healthcare products Regulatory Agency, or MHRA, conducted a comprehensive consultation between September and November 2021 on proposals to develop a new UK regime for medical devices in the UK. The proposals include more closely aligning definitions for medical devices and in vitro medical devices with internationally recognized definitions and changing the classification of medical devices according to levels or risk. The proposals are intended to improve patient and public safety and increase the appeal of the UK market. The new regime is planned to come into force on July 1, 2023, which will align with the date from which the UK is due to stop accepting CE marked medical devices and require UK Conformity Assessed marking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is envisaged that, in Northern Ireland, the amended regime could run in parallel with any existing or future EU rules in accordance with the Protocol on Ireland and Northern Ireland.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shattuck Employees</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Shattuck employed 85 full-time employees at two locations in the United States, including Austin, TX and Durham, NC. During 2021, we expanded our capabilities across the two sites by hiring 37 new employees. These employees were hired to support our clinical development, preclinical research and development, and efforts associated with operating as a public company.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to hire additional employees in 2022 and beyond with a focus on increasing expertise and bandwidth in preclinical and clinical research and development and in-house process development and manufacturing, as well as expanding our in-house general and administrative functions. The Company continually evaluates business needs and opportunities, with a hiring philosophy that balances in-house expertise with outsourced services. Currently, we outsource clinical trial work to clinical research organizations and drug manufacturing to contract manufacturers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines. Pharmaceutical companies compete for a limited number of highly qualified applicants to fill specialized positions. To attract these applicants to the Company, Shattuck offers a total rewards package consisting of a base salary and cash target bonus targeting the 25th to 75th percentile of market based on geography, a comprehensive benefit package and equity compensation for full-time employees. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our management team has the experience necessary to effectively execute our strategy and advance our product and technology leadership. A large majority of Shattuck&#8217;s employees have obtained advanced degrees in their professions. Shattuck supports our employees&#8217; further development with individualized development plans, mentoring, coaching, group training and conference attendance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the years ended December 31, 2021 and 2020 were $56.6 million and $37.5 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in May 2016. Our corporate offices are located at 500 W. 5th Street, Suite 1200, Austin, Texas 78701 and 21 Alexandria Way, Suite 200, Durham, North Carolina 27709 and our telephone number is (512) 900-4690. Our website address is www.shattucklabs.com. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is for convenience only and the information on the referenced website does not constitute a part of nor is incorporated by reference into this report.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, including our annual reports on Form 10-K, our quarterly reports on Form 10-Q and our current reports on Form 8-K, and amendments to those reports, are accessible through our website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. These SEC reports can be accessed through the &#8220;Investors&#8221; section of our website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report on Form 10-K before making an investment decision. The occurrence of any of the following risks could materially and adversely affect our business, financial condition, reputation, or results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment. It is not possible to predict or identify all such risks; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Key Risk Factors</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are an early clinical-stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. Additional funding may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs, our efforts to access manufacturing capacity and our commercialization efforts. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Public health crises such as pandemics or other events could materially and adversely affect our business operations, workforce, product development activities, research and development activities, preclinical and clinical trials, and financial condition. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Our ARC and GADLEN platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. We may not be successful in our efforts to use and expand our technology platforms to develop and commercialize our product candidates, or may experience significant delays in doing so. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical drug development is a lengthy and expensive process with uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially and adversely affected. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed. We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We rely on third parties to manufacture biological materials and our product candidates. The manufacture of our product candidates is complex. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We rely on patents and other intellectual property rights to protect our technology, including product candidates from our ARC and GADLEN platforms, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early clinical-stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant operating losses since inception. For the years ended December&#160;31, 2021 and 2020, we reported a net loss of $45.0 million and $36.6 million, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $117.1 million. We expect to continue to incur significant operating losses for the foreseeable future. To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. We may never succeed in these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2016, we have devoted a significant portion of our resources to developing our product candidates, our other research and development efforts, building our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. While we are conducting Phase 1 clinical trials for SL-172154 and SL-279252, we have not completed a clinical trial for any product candidate. We have not yet demonstrated our ability to successfully complete product development activities, complete clinical trials (including Phase 3 or other pivotal clinical trials), obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. Additional funding may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs and other operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current business plans, we estimate that our existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect, requiring us to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may materially and adversely affect the development of our product candidates. Our ability to raise additional funds will depend on financial, economic, and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us or at all. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights as holders of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take certain actions, which could materially and adversely impact our ability to conduct our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or other events could materially and adversely affect our business operations, workforce, product development activities, research and development activities, preclinical and clinical trials, and financial condition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our program timelines may continue to be negatively affected by the COVID-19 pandemic, which could materially and adversely affect our business, financial condition, and results of operations. We have experienced delays in our clinical trials of SL-172154 and SL-279252 as a result of the ongoing pandemic, including delays with certain third-party </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vendors supporting these trials. In addition, we have experienced and may in the future experience additional disruptions, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays or difficulties in manufacturing sufficient quantities of materials of our product candidates for preclinical studies and clinical trials, including difficulty reserving manufacturing capacity with our third-party vendors and obtaining sufficient quantities of raw materials required for our manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increased rates of patients either declining to enroll in our clinical trials, missing treatments, or withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interruption of key clinical trial activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, due to public health guidance measures, we may need to implement policies that could negatively impact productivity, or disrupt, delay, or otherwise materially and adversely impact our business. For example, we have in the past and may again in the future implement work-from-home requirements, and if our personnel are required to work from home, some of our research activities that require our personnel to be in our laboratories may be delayed. The COVID-19 pandemic may also result in the loss of some of our employees and key personnel, either temporarily or permanently, which could negatively impact our operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar public health emergency is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our research, our clinical trials, healthcare systems, or the global economy as a whole. Specifically, biologics manufacturing resources are being diverted to assist with COVID-19 vaccine production, which may result in delays in the manufacture of our product candidates. In addition, hospitals, healthcare workers, and other medical care resources are being diverted to treat COVID-19 patients and administer COVID-19 vaccines, which may result in further delays to the progress of our clinical trials. We do not yet know the full impact that the COVID-19 pandemic may have on our business. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ARC and GADLEN platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. We may not be successful in our efforts to use and expand our technology platforms to develop and commercialize our current and future product candidates, or may experience significant delays in doing so. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our proprietary ARC and GADLEN platforms to build a pipeline of product candidates and progress these product candidates through preclinical and clinical development. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers and other indications, we have not received regulatory approval for any of our product candidates. The scientific research that forms the basis of our efforts to develop product candidates with our proprietary platforms is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our platforms is both preliminary and limited. Given the novelty of our technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. To our knowledge, our dual-sided fusion protein product candidates have not previously been tested in humans and may have properties that negatively impact safety or efficacy, such as greater immunogenicity when compared to existing therapeutics. Moreover, our product candidates may have unexpected biological interactions when administered in vivo. For example, it may be necessary to either implement a loading dose strategy or delay enrollment of patients recently treated with anti-PD-1 antibodies to mitigate interactions between anti-PD-1 antibodies and SL-279252. Finally, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates will depend on several factors, including the successful and timely completion of clinical trials and preclinical studies, successful patient enrollment in clinical trials, receipt of regulatory approvals and marketing authorizations, commercially viable manufacturing processes, and our ability to demonstrate the safety and efficacy of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a marketable product, which could result in significant harm to our financial position and materially and adversely affect our share price. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel. We expect to continue to expand our capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continued contributions of our key management, scientific, and technical personnel, many of whom have been instrumental for us and have substantial experience with our product candidates and related technologies. Although we have employment agreements with certain of our key employees, including our Chief Executive Officer, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience continued growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, business development, manufacturing, regulatory affairs, quality assurance, human resources, legal, accounting and finance and, ultimately, sales and marketing. The competition for qualified personnel in the biotechnology and pharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly-skilled scientific, technical, and managerial employees. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems, and expand our facilities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations systems and facilities. These activities may lead to significant costs and may divert our management and other resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a small company with limited resources, our business prospects are uncertain and our stock price is volatile. For some or all of the foregoing reasons, we may not be able to recruit all of the management, technical and other personnel that we require or we may be unable to retain all of our existing personnel. In such event, we may be required to limit our growth and expansion efforts and our business and financial results may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Clinical Testing of Our Product Candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our investigational drug products are safe and effective for use in each targeted indication. Clinical testing is expensive and takes many years to complete, and its outcome is inherently uncertain. The process of obtaining regulatory approval is expensive, often taking many years following the commencement of clinical trials, and can vary substantially based upon the type, complexity, and novelty of the product candidates involved, as well as the target indications, patient population, and regulatory agency. As mentioned herein, our product candidates and technology platforms are novel and entail significant complexity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials that we conduct may not demonstrate the efficacy and safety that is necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials could limit the prospects for regulatory approval of that product candidate or other product candidates in any indications. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we are able to submit our product candidates for approval. Moreover, results that are acceptable to support approval in one jurisdiction may be deemed inadequate to support regulatory approval in other jurisdictions. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate in a manner that does not meet our expectations, which limitations may reduce its commercial potential. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, topline or preliminary data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. The interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. As a result, interim, topline or preliminary data should be viewed with caution until the final data are available. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim, topline or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Material differences between interim, topline or preliminary data and final data could significantly harm our business prospects. Further, disclosure of interim, topline or preliminary data by us or by our competitors could impact our ability to enroll our clinical trials and influence industry expectations, which could result in volatility in the price of our common stock and affect our ability to raise additional capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is a lengthy and expensive process with uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. The design of a clinical trial can determine whether its results will support approval of a product candidate, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, the results of our preclinical animal studies, including our non-human primate studies, may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, all of our trials, including our ongoing Phase 1 trial evaluating SL-279252 and Phase 1 trials evaluating SL-172154, are open-label trials in which both the patient and investigator know whether the patient is receiving the investigational product candidate or an existing approved therapy. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect, as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be materially and adversely affected, and we may incur significant additional costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. While we believe that the targeted nature of our dual-sided fusion proteins may carry a lower risk of overstimulating the immune system and causing a cytokine storm (a side effect associated with certain other antibody therapies), we do not have enough clinical data and experience with these molecules in humans to fully anticipate side effects. Accordingly, we may experience unexpected side effects and/or higher levels of known side effects in clinical trials, such as cytokine storms associated with certain immunotherapies or red blood cell lysis associated with some CD47 targeting therapies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our clinical trials could be suspended or terminated and the FDA or comparable foreign authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business and financial condition significantly. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. Trials have been and may continue to be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, fewer than expected patients who meet enrollment eligibility criteria, patient withdrawal, or adverse events. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials compete with other clinical trials that are in the same therapeutic areas as our product candidates and/or that seek to enroll the same specific patient populations as our clinical trials, which reduces the number and types of patients available to us. Moreover, enrolling patients in clinical trials for cancer therapies is challenging, as cancer patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care therapy, such as PD-1 checkpoint inhibitors, (and thus do not enroll in clinical trials) are believed to have tumor types that may have responded well to our product candidates. This may limit the number of eligible patients able to enroll in our clinical trials and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these patients may have either compromised immune function from prior administration of chemotherapy or an enhanced immune response from the prior administration of checkpoint inhibitors. Either of these prior treatment regimens may render our therapies less effective in clinical trials. We have sought and may continue to seek to mitigate these effects in the future through modification of enrollment eligibility criteria, including patients with tumor types that are not typically responsive to anti-PD-1 antibodies, or pursuing combination regimens early in clinical development to enable access to anti-PD-1 na&#239;ve patients. Additionally, patients who have failed approved therapies will typically have more advanced cancer and a poorer long-term prognosis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to adequately enroll our clinical trial sites in the United States, Canada, and Europe, we may in the future use clinical trial sites in other parts of the world. It may be more difficult to control international clinical trials and the results may be less reliable. In addition, if the international clinical trial was conducted in a country with lower quality healthcare than in developed countries, the patients may experience side effects not experienced by patients in developed countries.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Regulatory Environment </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis, if at all, our business will be substantially harmed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to our product candidates are subject to extensive regulation. Obtaining approval of a BLA can be a lengthy, expensive, and uncertain process, and as a company we have no experience with the preparation of a BLA submission or any other application for marketing approval. This lengthy approval process may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. See &#8220;Business&#8212;Government Regulation&#8212;BLA Submission and Review.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies could negatively affect the review of our regulatory submissions, which could negatively impact our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve regulatory submissions can be affected by a variety of factors, including disruptions caused by government shutdowns and public health crises. Such disruptions could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. To the extent the activities of animal rights groups are successful, our research and development activities may be interrupted, delayed, or become more expensive. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with healthcare professionals, principal investigators, consultants, vendors, customers, and third-party payors are subject to applicable healthcare laws, which could expose us to penalties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. See &#8220;Business&#8212;Government Regulation&#8212;Other Healthcare Laws and Compliance Requirements.&#8221; for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming, may require significant personnel resources and may impair our business even if we are successful in defending against such claims. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners, suppliers, and vendors acting for us or on our behalf may engage in misconduct or other improper activities, including noncompliance with applicable laws and regulations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of conduct, but it is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is highly dependent on our ability to expeditiously discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and market them successfully. With the proliferation of new oncology drugs and immuno-therapies, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological innovation, we may be unable to compete effectively. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized by line of therapy (first, second, third, fourth, etc.), and the FDA often initially approves new therapies only for use in a particular line or lines of therapy. For example, we may initially seek approval of our product candidates as a third line therapy for patients who have failed other approved treatments. We may subsequently seek approval as a second and first line therapy. There is no guarantee that our product candidates, even if initially approved, would be subsequently approved as a second or first line therapy. Because the potentially addressable patient target population for our product candidates may be limited to patients who are ineligible for or have failed prior treatments, even if we obtain significant market share for our product candidates, we may never achieve profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval may face competition sooner than anticipated. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity under the BPCIA. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. See &#8220;Business&#8212;Government Regulation&#8212;Biosimilars and Reference Product Exclusivity.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture our product candidates and other biological materials. The manufacture of our product candidates is complex. Our third-party manufacturers may encounter difficulties in production, which could delay or entirely halt their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls that are in compliance with current Good Manufacturing Practices, or cGMP. We do not currently own or operate any GMP manufacturing facilities, nor do we have any in-house GMP manufacturing capabilities. We rely on third-party contract manufacturers to produce sufficient quantities of materials required for the manufacture, transport, and storage of our product candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of product candidate or we may be delayed in doing so. Such failure or substantial delay could materially and adversely harm our business.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a single-source supplier for bulk drug substances, or BDS. The loss of our current supplier or its failure to supply us with BDS on a timely basis could cause our inability to develop and manufacture our product candidates, which could materially and adversely affect our business. We are working toward the successful manufacture of satisfactory, validated BDS with additional suppliers. The process for identifying additional BDS suppliers and successfully manufacturing BDS with those suppliers is lengthy and expensive, and there can be no assurance that any additional suppliers will be able to successfully produce satisfactory BDS. If we are not able to successfully manufacture BDS with additional suppliers, our existing supplier may need to increase manufacturing capacity to meet anticipated demand, which could involve significant challenges.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a third-party manufacturer to provide our BDS, there can be no assurance that our supply of BDS will not be limited or interrupted, have satisfactory quality or product characteristics, or continue to be available at acceptable prices. There can also be no assurance that our supplier will continue to meet regulatory requirements for cGMP manufacturing. As is common in our industry, we have experienced enrollment delays in our clinical trials as a result of delays in receipt of BDS. We have limited control over the process or timing of the acquisition or manufacture of materials by our supplier, and cannot ensure that it will deliver to us the BDS we order on time, or at all. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the process of manufacturing our product candidates has been negatively impacted by equipment failure, or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes, which we have experienced, results in reduced production yields and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, this could lead to withdrawal of our products from the market, and such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our process development efforts, we also may make changes to our manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. We are investing in an in-house process development pilot plant to reduce our reliance on third parties for process development efforts. This undertaking is costly, and we have no guarantee that these efforts </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will result in useful changes to our manufacturing processes. Any changes to our manufacturing processes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMPs and similar foreign standards relating to methods, facilities, and controls used in the manufacturing, processing, packing, storage, and distribution of the product, which are intended to ensure that biological products are safe and that they consistently meet applicable requirements and specifications. We are dependent on third parties for all of these activities, and we have limited ability to prevent or control the risk that such activities will not be in compliance with cGMP. In addition, the storage and distribution of our product candidates for use in clinical trials is subject to extensive regulation by the FDA and other regulatory authorities. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in our clinical trials and development efforts, or a delay in or failure to obtain regulatory approval of any of our product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical manufacturers are also subject to extensive oversight by the FDA and comparable regulatory authorities in other jurisdictions, which include periodic unannounced and announced inspections by the FDA to assess compliance with cGMP requirements. If an FDA inspection of a manufacturer&#8217;s facilities reveals conditions that the FDA determines not to comply with applicable regulatory requirements, the FDA may issue observations through a Notice of Inspectional Observations, commonly referred to as a &#8220;Form FDA 483&#8221; report. If observations in the Form FDA 483 report are not addressed in a timely manner and to the FDA&#8217;s satisfaction, the FDA may issue a Warning Letter or proceed directly to other forms of enforcement action. Any failure by one of our contract manufacturers to comply with cGMP or to provide adequate and timely corrective actions in response to deficiencies identified in a regulatory inspection could result in further enforcement action that could lead to a shortage of products and harm our business. The failure of a manufacturer to address any concerns raised by the FDA or foreign regulators could also lead to plant shutdown or the delay or withholding of product approval by the FDA in additional indications, or by foreign regulators in any indication. Moreover, if the FDA determines that our third-party manufacturers are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance. Certain countries may impose additional requirements on the manufacturing of drug products or drug substances, and on manufacturers, as part of the regulatory approval process for products in such countries. The failure by our third-party manufacturers to satisfy such requirements could impact our ability to obtain or maintain approval of our products in such countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely, and expect to continue to rely, on third parties to conduct preclinical studies, nonclinical studies, and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied, and plan to continue to rely, upon third parties, including independent clinical investigators and third-party CROs, to conduct certain preclinical studies, nonclinical studies, and clinical trials and to monitor, record, and manage data for our ongoing preclinical, nonclinical, and clinical programs. We rely on these parties for execution of certain preclinical studies and clinical trials, and control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies, nonclinical studies and clinical trials and the management of data developed through these preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. If we or any of these third parties fail to comply with applicable good laboratory practice, or GLP, or good clinical practice, or GCP, regulations, such data may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or nonclinical studies, or clinical trials before approving our marketing applications. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, that they devote to our product candidates and clinical trials. There is a limited number of third-party service providers that specialize in or have the expertise required to achieve our business objectives. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or to do so in a timely manner or on commercially reasonable terms. If the third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical, nonclinical, or clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical studies, nonclinical studies, or clinical trials may be extended, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of any existing or future collaborative or licensing arrangement, and if we fail to enter into new strategic relationships our business, financial condition, commercialization prospects, and results of operations may be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may decide in the future to enter into, collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of certain of our product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue, or specific net income that justifies such transaction. We may not be able to control the amount and timing of resources that is required of us to complete our development obligations or that the collaboration partner devotes to the product development or marketing programs. We also may not be able to ensure that our collaboration partner adequately protects and does not misuse our intellectual property. We and our collaboration partner may disagree regarding the research plan or the development plan for product candidates on which we are collaborating and disputes could arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources. If our strategic collaborations do not result in the successful development and commercialization of product candidates or if one of our collaborators fails to act under the collaboration agreement or terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. In November 2021, we and Takeda mutually agreed to terminate, pursuant to a Termination Agreement, our collaboration agreement for SL-279252 and SL-115154, originally executed in 2017. Under the terms of the Termination Agreement, we are not required to satisfy any remaining performance obligations, we will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. In addition, if a collaboration is terminated, it may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate such products or business into our existing operations and company culture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply difficulties, our business may be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work closely with our suppliers to ensure the continuity of supply of raw and intermediate materials but cannot guarantee these efforts will always be successful. As has been commonly experienced during the COVID-19 pandemic, we have experienced raw and intermediate materials supply shortages, which has contributed to manufacturing delays and impacted the progress of our clinical trials. Further, while efforts are made to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier, and there can be no assurance that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our product candidates in a timely or cost-effective manner and could delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property and Information Technology </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and other intellectual property rights to protect our technology, including product candidates from our ARC and GADLEN platforms, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prosecution, enforcement, defense, and maintenance of intellectual property rights is often challenging, costly, and uncertain. Contributors to these challenges and uncertainty include the early stage of our products and our intellectual property portfolio development; the unpredictability of what patent claim scope will ultimately be issued to protect our products and how the law will change or develop as to scope, length and enforcement of patent protection; the competitive and crowded immune-oncology space; complicated and unforgiving procedural, documentary and fee requirements of U.S. and foreign patent offices; lack of perfect visibility into what our competitors are doing and the patent claim scope they are obtaining; lack of perfect ability to determine what prior art may exist; and the expense and time consuming nature of patent portfolio development across relevant jurisdictions. For at least these reasons, the issuance, scope, validity, enforceability, and commercial value of our current or future patent rights are highly uncertain. We cannot be sure that patent coverage will issue, or will be maintained, to protect our products, in some or all relevant jurisdictions. We cannot be sure that we will not encounter freedom-to-operate challenges in the development and commercialization of our product candidates. We cannot be sure our trademarks and trade names are sufficient to build name recognition in our markets of interest. We cannot be sure our measures to protect our trade secrets will be sufficient. Failure to protect or enforce these rights adequately could harm our ability to develop and market our product candidates and could impair our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Others may challenge our patents or other intellectual property as invalid or unenforceable. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Even if patents do successfully issue and even if such patents cover our product candidates and extend for a commercially relevant time, third parties may initiate invalidity, non-infringement, opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification, or derivation actions in court or before patent offices, or similar proceedings challenging the validity, inventorship, ownership, enforceability, or scope of such patents, which may result in the patent claims being narrowed, invalidated, or held unenforceable or circumvented. Such challenges and potential negative results could materially and adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention, such as where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Additionally, some countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties; and some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Additionally, our competitors or other third parties may be able to evade our patent rights by developing new fusion proteins, antibodies, biosimilar antibodies, or alternative technologies or products in a non-infringing manner. These risks may impact our ability to enjoy the protection we obtain, and may materially and adversely impact our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture, market, and sell our product candidates without infringing or otherwise violating the intellectual property and other proprietary rights of third parties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may accuse us of infringing their intellectual property. Contested proceedings are lengthy, time consuming, and costly, and we cannot guarantee that our operations and activities do not, or will not in the future, infringe existing or future patents. We also cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to our product candidates or necessary for the commercialization of our product candidates in any jurisdiction. Furthermore, we may be subject to third-party claims asserting that our employees, consultants, contractors, collaborators, or advisors have misappropriated or wrongfully used or disseminated their intellectual property, or claiming ownership of what we regard as our own intellectual property. These and related risks to defending against third-party claims may materially and adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit, or otherwise interfere with our ability to make, use, and sell our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. As such, there may be applications of third parties now pending or recently revived patents of which we are unaware. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current technology, including our platform technologies, product candidates and their respective methods of use, manufacture, and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely in part on in-licensed patents and other intellectual property rights to develop and commercialize our product candidates. We may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our methods or product candidates or elements thereof, our manufacture or uses relevant to our development plans, our product candidates or other attributes of our product candidates, or our ARC or GADLEN platform. In such cases, we may not be in a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, which can be expensive and time-consuming, or we may have to enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms, if at all.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. For example, we are aware of a patent that may impact our competitive position with respect to SL-172154. The patent lists claims that generally relate to methods of using fusion proteins to treat certain types of cancers. While we believe that the claims may not be valid and that they may be reasonably challenged for validity, there can be no assurance that any such challenge would be successful, in which case we may be required to obtain a license in order to commercialize our product candidate, if approved. The targets of our product candidates have also been the subject of research by many companies that have filed patent applications or have patents related to such targets and therapeutics methods related to those targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise with our licensors of patents and other intellectual property rights. We may yet need to obtain licenses from others for continued development and commercialization of our product candidates, and we may be unable to secure those licenses on commercially reasonable terms or at all. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use, or sell our product candidates, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain, or use these proprietary rights. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all licenses impose obligations upon us that must be met to maintain the license. If we are unable to meet these obligations, we may be required to pay damages and our licensors may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we and/or our licensors must cooperate in order to enforce such patents against third parties, and such cooperation may not be provided. We also may rely on our licensors to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property rights we license from them and may have limited control over these activities or any other intellectual property rights that may be related to our in-licensed intellectual property rights. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors may independently develop substantially equivalent trade secrets, proprietary information, or know-how and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how. Under certain circumstances, and to make it more likely that we have our freedom to operate, we may also decide to publish some know-how to make it difficult for others to obtain patent rights covering such know-how, at the risk of potentially exposing our trade secrets to our competitors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties and if we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell any future products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot determine currently the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are of national or regional effect. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents throughout the world, as appropriate, the process of obtaining patents is time-consuming, expensive, and sometimes unpredictable in other countries. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all markets. We have not, and will not, file for patent protection in all national and regional jurisdictions where such protection may be available. Filing, prosecuting, and defending patents on all of our research programs and product candidates in all countries throughout the world would be prohibitively expensive, and, therefore, the scope and strength of our intellectual property rights will vary from jurisdiction to jurisdiction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">others may be able to make product candidates similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the patents of third parties may have a material and adverse effect on our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating, or otherwise violating our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we cannot predict the degree and range of protection any issued patents will afford us against competitors, whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications, or whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may not develop additional technologies that are patentable.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret and proprietary know-how, which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets and/or confidential know-how can be difficult to protect or maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, we generally require our employees, consultants, contractors, collaborators, advisors, and other third parties to enter into confidentiality agreements with us. Despite these efforts, any of these parties may unintentionally or willfully breach the agreements and disclose our confidential information, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is also expensive, time-consuming, and unpredictable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. The laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, some courts inside and outside the United States are less willing or are unwilling to protect trade secrets or other proprietary information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any sort of contested proceeding related to intellectual property, offensive or defensive, may cause us to incur significant expenses and would be likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities, and may impact our reputation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a material and adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Infringement or related suits against us by others could result in damages awards against us or injunction or other equitable relief precluding continued commercialization of our products. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents within prescribed time limits. If we fail to maintain the patents and patent applications covering our product candidates or if we otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would have a material and adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, store, and transmit large amounts of confidential information in digital form. Despite the implementation of security measures, our information technology systems and data and those of our current or future CROs or other contractors and consultants are vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. While we continue to make investments to improve the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Although to our knowledge we have not experienced any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations or subject us to litigation or regulatory actions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taken by governmental authorities. See Part I, Item 1. &#8220;Business&#8212;Government Regulation&#8212;Data Privacy and Security.&#8221; Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our business, prospects, operating results, share price, stockholder value, and financial condition. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be highly volatile and may fluctuate significantly as a result of a variety of factors, some of which are related in complex ways and many of which are beyond our control, including the factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Stock Market, or Nasdaq, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. In addition, broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Securities class action litigation is often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. We are the subject of putative securities class action cases against the Company and certain of our officers and directors, alleging that defendants made false or misleading statements. This type of litigation, and others like it, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results, or financial condition. See the discussion of Legal Proceedings in Part I, Item 3 of this Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 41.6% of our outstanding voting stock. Therefore, these stockholders have the ability to influence us through this ownership position and may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part upon research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, result in more litigation, and divert management&#8217;s attention. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to certain reporting requirements, listing requirements, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. As a result, management&#8217;s attention may be diverted from other business concerns, which could materially and adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By disclosing information in this and in future filings required of a public company, our business and financial condition will become more visible, which has resulted in and may in future result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business. See the discussion of Legal Proceedings in Part I, Item 3 of this Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class-action litigation filed against us could harm our business, and insurance coverage may not be sufficient to cover all related costs and damages.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face the threat of legal claims and regulatory matters involving various aspects of our business. Given the volatility of the trading price of our common stock, and the increase in shareholder litigation generally, we face a risk of lawsuits alleging violations of the securities laws. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against the Company and certain of our officers and directors, in each case alleging that defendants made false or misleading statements regarding our collaboration agreement with Takeda. The plaintiffs in both lawsuits seek a ruling that the case may proceed as a class action, and seeks unspecified damages, and attorneys&#8217; fees, expert fees and costs. Similar class-action lawsuits may be filed in future. We and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against the claims asserted in these lawsuits. However, litigation is inherently uncertain, and adverse rulings may occur, including awards of monetary damages, that may have a material adverse impact on our business. These lawsuits may also divert management&#8217;s attention and resources, and may require us to incur substantial costs, some of which will not be covered by insurance. See the discussion of Legal Proceedings in Part I, Item 3 of this Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to report upon the effectiveness of our internal control over financial reporting. To comply with the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended, or the Exchange Act, we have implemented and will continue to implement additional financial and management controls, reporting systems and procedures and we have hired and will continue to hire additional accounting and finance staff. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our amended and restated bylaws each contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. As a Delaware corporation, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two-thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction) is the exclusive forum for certain actions. It also provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act. These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disputes, which may discourage lawsuits. There is uncertainty as to whether a court would enforce such provisions. If a court were to find these types of provisions to be inapplicable or unenforceable, and if a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could materially and adversely affect our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had U.S. federal and state net operating loss, or NOL, carryforwards of $97.4 million and $0.2 million, respectively, which may be available to offset future taxable income. As of December 31, 2021, we also had gross federal tax credits of $7.6 million, which may be used to offset future tax liabilities. These NOLs and tax credit carryforwards will begin to expire in 2036. Use of our NOL carryforwards and tax credit carryforwards depends on many factors, including having current or future taxable income, which cannot be assured.</span></div><div id="i92757ae30a234940aa4371e66352259c_22"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i92757ae30a234940aa4371e66352259c_25"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:3pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Austin, Texas where we currently occupy approximately 8,000 square feet of office space under a lease that expires on September 30, 2026. We use this facility for administrative purposes.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease approximately 32,200 square feet of office and laboratory space in Durham, North Carolina under a lease that expires on December 31, 2028. We use this facility for research and development purposes.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these spaces to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.</span></div><div id="i92757ae30a234940aa4371e66352259c_28"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of our officers and directors. In each complaint, the plaintiff cites the volatility in our common stock and alleges that the defendants made or are responsible for false or misleading statements regarding our collaboration agreement with Takeda. The plaintiffs in both lawsuits seek a ruling that the case may proceed as a class action, and seek unspecified damages and attorneys&#8217; fees, expert fees and costs. We and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against these lawsuits.</span></div><div id="i92757ae30a234940aa4371e66352259c_31"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II.</span></div><div id="i92757ae30a234940aa4371e66352259c_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issue Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;STTK&#8221;. At March 1, 2022, there were approximately 36 stockholders of record of our common stock and the closing price of our common stock was $5.01 per share. Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has never paid dividends on its Common Stock and does not anticipate that it will do so in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Initial Public Offering of Common Stock</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in our intended use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on October 13, 2020.</span></div><div id="i92757ae30a234940aa4371e66352259c_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div id="i92757ae30a234940aa4371e66352259c_43"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes appearing in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that are not achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling CD40 activation with CD47 inhibition differentiates SL-172154 from all other clinical-stage CD47/SIRP&#945; inhibitors in development, and in our published preclinical studies, SL-172154 resulted in superior antitumor immunity as compared to certain CD47/SIRP&#945; inhibitors. We are pursuing a broad clinical development strategy in both hematologic and solid tumors, with multiple ongoing clinical trials. SL-172154 is in an ongoing Phase 1 clinical trial for the treatment of patients with ovarian cancer. In addition to our clin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ical trials in solid tumors, we are also evaluating SL-172154 in an ongoing Phase 1 clinical trial for the treatment of patients with certa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in hematologic malignancies, including acute myeloid leukemia, or AML, and higher-risk myelodysplastic syndromes, or HR-MDS. We believe our clinical development plan will provide both first-in-class and best-in-class development opportunities for SL-172154.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, SL-279252, is designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 costimulatory receptor and is in an ongoing Phase 1 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, at the 36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> annual meeting of the Society for Immunotherapy of Cancer, or the SITC Meeting, we announced initial clinical data from our ongoing Phase 1 clinical trials for SL-172154 in ovarian cancer and for SL-279252 in advanced solid tumors and lymphoma. We believe that these data generated in human cancer patients have demonstrated that the unique protein engineering and physical properties of the ARC platform have led to a differentiated profile in terms of safety and on-target immune activation as compared to monoclonal or bispecific antibodies. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical-stage ARC product candidates, we possess a deep pipeline of preclinical immuno-oncology candidates. As an example, SL-9258, an ARC in preclinical development, is designed to inhibit the TIGIT/PVR checkpoint interaction while simultaneously activating HVEM and LT&#946; costimulatory receptors. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our expertise in dual-sided fusion proteins has led to the development of a second novel platform technology. We call this our gamma delta T cell engager, or GADLEN, platform. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to nominate a third clinical product candidate from our preclinical pipeline in 2022. Longer-term, we are pursuing additional disease areas, including autoimmune diseases, where our dual-sided fusion protein platforms may provide advantages over current treatment modalities.</span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2016, we have devoted substantially all of our resources to developing and perfecting our intellectual property rights, conducting research and development activities, including undertaking nonclinical studies of our product candidates, conducting clinical trials of our most advanced product candidates, manufacturing our product candidates, organizing and staffing our company, business planning, and raising capital. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have funded our operations as of the filing date of this Annual Report on Form 10-K through the net proceeds from our initial public offering of approximately $213.5 million, the sale of redeemable convertible preferred stock for approximately $152.9&#160;million, the issuance of convertible notes for approximately $10.5&#160;million and payments received pursuant to our collaboration agreement with Takeda for approximately $82.0&#160;million. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, our net loss was $45.0 million and $36.6 million, respectively. We have not been profitable since inception, and as of December&#160;31, 2021, we had an accumulated deficit of $117.1 million&#160;and $268.8 million in cash and cash equivalents and short-term investments. We expect to continue to incur significant expenses and increasing operating losses in the near term. We expect our expenses will increase substantially in connection with our ongoing activities, as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to advance the nonclinical and clinical development of our clinical-stage product candidates, SL-172154 and SL-279252; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">initiate nonclinical studies and clinical trials for additional product candidates that we may identify in the future; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacture sufficient quantities of bulk drug substance and drug product to support our ongoing and planned nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue our process development efforts for our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expand our operational, financial, and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increase personnel and infrastructure to support our clinical development, research and manufacturing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">build out and expand our in-house process development and manufacturing capabilities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to develop, perfect, and defend our intellectual property portfolio; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant product revenue unless and until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, which we expect will take several years. We expect to spend a significant amount in development and marketing costs prior to such time. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our nonclinical and clinical trials. We may elect to discontinue, delay, or modify nonclinical and clinical trials of our product candidates. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time as we can generate significant product revenue, if ever, we expect to continue to seek private or public equity and debt financing to meet our capital requirements. There can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates. In addition, we may not be profitable even if we commercialize any of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty as to the future effects of the ongoing COVID-19 pandemic, which may, among other things, materially impact our business, including our ongoing and planned clinical trials. We have experienced, and expect to continue to experience, delays in our SL-172154 and SL-279252 clinical trials as a result of the ongoing pandemic. Our manufacturing operations have been impacted by the ongoing pandemic, including delays with our third-party manufacturer and difficulties in obtaining raw materials needed to manufacture material for our clinical trials. Additionally, we have experienced, and expect to continue to experience, delays in enrolling patients, missed treatments for enrolled patients, and performance delays from certain third-party vendors supporting the SL-172154 and SL-279252 clinical trials, although the significance of any future delays is difficult to predict.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, due to public health guidance measures, we have in the past implemented, and may in the future implement, a work-from-home policy for our employees, excluding those necessary to maintain minimum basic operations, which may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. For example, some of our research activities that require our personnel to be in our laboratories may be delayed. We may also experience delays or disruptions to our operations if and when our employees need to take time off work due to illness or other COVID-19-related impacts to our workforce. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the impact of the COVID-19 pandemic and work-from-home policies and other operational limitations mandated by federal, state and local governments as a result of the pandemic, certain of our research and development activities, including the conduct of nonclinical studies, have been delayed and may be further delayed and other aspects of our business, such as the conduct of various corporate functions and the ability of our Board and management to provide oversight and guidance may be adversely impacted until such operational limitations are lifted. The COVID-19 pandemic or local outbreaks associated with the COVID-19 pandemic could result in difficulty manufacturing our product candidates, securing clinical trial site locations, contract research organizations, or CROs; and/or trial monitors and other critical vendors and consultants supporting our clinical trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact our ability to enroll patients or to complete all scheduled physician visits for currently enrolled patients. These situations, or others associated with COVID-19 pandemic, could cause delays in our clinical trial plans and could increase expected costs, all of which could have a material adverse effect on our business and its financial condition. At the current time, we are unable to quantify the potential effects of the COVID-19 pandemic on our future operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2017, we entered into a Collaboration Agreement with Millennium Pharmaceuticals, Inc., or Takeda, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd., or the Collaboration Agreement. The Collaboration Agreement was mutually terminated pursuant to the termination agreement, or the Termination Agreement, dated November 8, 2021. Under the terms of the Termination Agreement, we are not required to satisfy any remaining performance obligations, we will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. The remaining deferred revenue was recognized as revenue in the fourth quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operation </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue - Related Party</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale, and we have not generated any revenue from commercial product sales. Our total revenue to date has been generated solely from our Collaboration Agreement with Takeda, which was terminated in November 2021. We expect that any collaboration revenue we may generate from any future collaboration partners will fluctuate from period to period.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received cash of $3.6 million and $14.0 million for the years ended December&#160;31, 2021 and 2020, respectively, from Takeda under the Collaboration Agreement. We have recognized total aggregate revenue of $82.0 million through December&#160;31, 2021 under the Collaboration Agreement. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expense </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. These expenses include: </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenses incurred to conduct our clinical trials and nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs of manufacturing clinical trial and nonclinical study materials, including the costs of raw materials required for manufacturing; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">process development activities to optimize manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">employee-related expenses, including salaries, benefits, and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">fees paid to third parties who assist with research and development activities; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenses relating to regulatory activities, including filing fees paid to regulatory agencies; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">laboratory materials and supplies used to support our research activities; and </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">allocated expenses for facility-related costs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by product candidate: </span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:75.207%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SL-172154</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SL-279252</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other pipeline candidates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal costs, including personnel related benefits, facilities, and depreciation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, including increased demand for clinical trial material. We expect our research and development expenses to increase significantly over the next several years as we conduct additional nonclinical studies and clinical trials, including later-stage clinical trials, for our current and future product candidates and pursue regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting the necessary nonclinical and clinical research to obtain regulatory approval is costly and time consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the safety and efficacy of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">early clinical data for our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">investment in our clinical programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing capability; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">commercial viability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never succeed in achieving regulatory approval for any of our product candidates due to the uncertainties discussed above. We are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if ever. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, and stock-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation, and maintenance, not otherwise included in research and development expense, as well as legal fees related to intellectual property and corporate matters and fees for accounting and tax services. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense will increase in the future to support our growing research and development activities and as a result of the increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers, and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the Securities and Exchange Commission, or SEC, insurance, and investor relations costs. If any of our current or future product candidates obtains regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash, cash equivalents and short-term investments, which consists of amounts held in a money market fund and at various times in short-term government and corporate obligations. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recorded any income tax benefits for the net operating losses, or NOLs, we have incurred or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more likely than not that all of our NOLs and tax credits will not be realized. Our NOLs and tax credit carryforwards will begin to expire in 2036. We have recorded a full valuation allowance against our deferred tax assets at each balance sheet date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the years ended December&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:54.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,931)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,338)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,974)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,371)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue - Related Party</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue increased by $20.1 million, or 202.2%, to $30.0 million for the year ended December&#160;31, 2021 from $9.9 million for the year ended December&#160;31, 2020. The Collaboration Agreement with Takeda was mutually terminated pursuant to the Termination Agreement and all remaining deferred revenue under the Collaboration Agreement was recognized in the fourth quarter of 2021. The increase was primarily attributable to the recognition of the remainder of the deferred revenue associated with the Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $19.1 million, or 50.9%, to $56.6 million for the year ended December&#160;31, 2021 from $37.5 million for the year ended December&#160;31, 2020. The increase was primarily attributable to an increase of $6.4&#160;million in personnel costs as a result of an increase in headcount to expand our manufacturing and clinical development capabilities, an increase of $5.8&#160;million in manufacturing and clinical costs, an increase of $3.1 million in assay development and nonclinical pipeline costs and an increase of $2.0 million in laboratory and facilities related costs. The remaining $1.8 million increase primarily resulted from an increase in depreciation and outside service fees.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $9.3 million, or 99.6%, to $18.7 million for the year ended December&#160;31, 2021 from $9.4 million for the year ended December&#160;31, 2020. The increase was primarily due to a $5.0&#160;million increase in personnel-related costs driven by higher employee headcount needed to support our growing research and development activities, and a $3.3 million increase for costs associated with being a public company.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $0.1 million to $0.6 million for the year ended December&#160;31, 2021 from $0.5 million for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our primary sources of liquidity have been generated by sales of our preferred stock and common stock, including our initial public offering, or IPO, and through our Collaboration Agreement with Takeda.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had an accumulated deficit of $117.1 million and $268.8 million of cash and cash equivalents and short-term investments.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources and Funding Requirements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash and cash equivalents and short-term investments are to fund our operations, which consist primarily of research and development expenditures related to our programs, product development costs, research expenses, administrative support, capital expenditures related to bringing in-house certain process development and manufacturing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capabilities and working capital requirements. We anticipate incurring additional net losses and negative cash flows from operations in the near future until such time, if ever, that we can generate significant sales of our product candidates currently in development. Our future funding requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the scope, timing, progress, and results of discovery, nonclinical development, laboratory testing, and clinical trials for our product candidates; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of process development and scale-up of a commercially ready manufacturing process to support registrational clinical trials;</span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs of preparing, filing and prosecuting patent applications, maintaining, and enforcing our intellectual property rights and defending other intellectual property-related claims; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs and fees associated with the discovery, acquisition, or in-license of additional product candidates or technologies; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing, distribution, and storage capabilities, for any of our product candidates for which we receive marketing approval; and </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we obtain regulatory approval to market our product candidates, if ever, we cannot generate revenues from sales of our products. Even if we are able to sell our products, we may not generate a sufficient amount of product revenues to finance our cash requirements. Accordingly, it will be necessary for us to seek to raise additional capital through equity offerings and/or debt financings or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of our development programs or patent portfolios. There can be no assurance that such funding may be available to us on acceptable terms, or at all. The issuance of equity securities may result in dilution to stockholders and the issuance of debt securities may have rights, preferences and privileges senior to those of our common stock and the terms of any such debt securities could impose significant restrictions on our operations. The failure to raise funds as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. Additionally, if additional funding is not secured when required, we may need to delay or curtail our operations until such funding is received, which would have a material and adverse impact on our business prospects and results of operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents and short-term investments as of December 31, 2021 are sufficient to fund projected operations into the second half of 2024.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,885&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash used in operating activities was $57.1 million and primarily reflected our net loss of $45.0 million, offset primarily by noncash charges of $6.8 million in stock-based compensation and depreciation, $3.0 million in net amortization of premium on short-term investments and a $22.0 million net change in our operating assets and liabilities. We expect our operating activities expenses to increase as we continue to conduct our clinical trials and nonclinical studies, incur costs of manufacturing clinical trial and nonclinical study materials and continue process development activities to optimize our manufacturing processes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, net cash used in operating activities was $33.7 million and primarily reflected our net loss of $36.6 million, offset primarily by noncash charges of $1.9 million in stock-based compensation and depreciation and a $1.1 million net change in our operating assets and liabilities.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash used in investing activities was $10.4 million of which $204.1 million was used to purchase short-term investments, $201.6 million was received from the sale of short-term investments and $7.9 million was used to purchase property and equipment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, net cash used in investing activities was $146.3 million of which $183.2 million was used to purchase short-term investments, $37.6 million was received from the sale of short-term investments and $0.7 million&#160;was used to purchase property and equipment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash provided by financing activities was $1.9 million and was from the exercise of stock options and ESPP purchases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, net cash provided by financing activities was $330.9 million and was primarily from the sale of our Series B and B-1 redeemable convertible preferred stock and proceeds from our initial public offering. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations and commitments at December&#160;31, 2021: </span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less&#160;than</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1 year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1 to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3&#160;years </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3 to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5&#160;years </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">More&#160;than</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5 years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum, or variable price provisions, and the approximate timing of the actions under the contracts. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation are not included in the preceding tables as the amount and timing of such payments are not known. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not included any potential contingent payments upon the achievement by us of specified regulatory and commercial events, as applicable, or patent prosecution or royalty payments we may be required to make under the Heat License Agreement (as defined below). We have excluded these potential payments in the preceding tables because the timing and likelihood of these contingent payments are not currently known and would be difficult to predict or estimate. Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which we cannot reasonably predict future payment. Our contractual obligations result primarily from obligations for various contract manufacturing organizations, or CMO, and clinical research organizations, or CROs, which include potential payments we may be required to make under its agreements. The contracts also contain variable costs and milestones that are hard to predict. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Also, those agreements are cancellable upon written notice by us and, therefore, not long-term liabilities. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heat License Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into an Exclusive License Agreement, or the Heat License Agreement, with Heat Biologics Inc., or Heat. The Heat License Agreement was subsequently amended in November 2016, December 2016, and March 2017. Pursuant to the Heat License Agreement, Heat granted to us a worldwide, sublicensable exclusive license to research, develop, manufacture, and commercialize products under three provisional patent applications, including all patents issuing from such applications, or the Fusion Protein Patent Rights and a worldwide, sublicensable nonexclusive license to research, develop, manufacture, and commercialize certain know-how owned and controlled by Heat related to the Fusion Protein Patent Rights. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Heat License Agreement, Heat was required to conduct certain research and development services under a mutually-agreed upon research and development plan and Heat was eligible to receive financial support from us for these efforts. Effective March 2017, Heat completed all research and development services under the Heat License Agreement and assigned to us three patent applications and all data derived from the research and development activities, referred to collectively as the Research Services Inventions. Pursuant to the terms of the Heat License Agreement, we are obligated to use </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercially reasonable efforts to diligently research and develop at least one product covered by the Fusion Protein Patent Rights, including the obligation to file an IND application for such product. Our development efforts, including the development of SL-279252 and certain other ARC compounds, to date satisfy these obligations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless sooner terminated or extended, the term of the Heat License Agreement continues until the later of 20 years following the effective date and the expiration of the last-to-expire royalty term. Either party may terminate the agreement due to a material breach by the other party (subject to a 90-day cure period) or if the other party files for bankruptcy. In the event we terminate the Heat License Agreement due to a material breach by Heat, Heat must assign to us all right, title, and interest in the patent rights licensed under the Heat License Agreement. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an upfront payment of $50,000, which we made in 2016, the Heat License Agreement requires us to make further payments to Heat in the future of up to $20.6 million in the aggregate, for the achievement of specified development, regulatory, and commercial sale milestones for certain licensed products. We are also required to pay Heat a percentage of certain upfront fees or other non-royalty payments not tied to milestone events that we receive in connection with certain sublicenses of the Fusion Protein Patent Rights. We will be required to pay Heat a royalty on all worldwide net sales by us, our affiliates, and sublicenses of certain licensed products in the low single digits. Royalties are payable, on a product-by-product and country-by-country basis, commencing on the first commercial sale of such product and continuing until the last-to-expire valid patent claim to the licensed patent rights that cover such product in that country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, the accrual for research and development expenses, and the valuation of stock-based awards. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note&#160;2 to our financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our financial statements. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and may continue to enter into collaboration agreements with other companies. Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering and patent committees. We evaluate the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, we consider the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, we develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines, and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we conclude that a contract should be accounted for as a combined performance obligation and recognized over time, we then determine the period over which revenue should be recognized and the method by which to measure revenue. We generally recognize revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize collaboration revenue when our customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for such arrangements, we perform the following five steps: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only apply the five-step model to contracts when we determine that it is probable we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the arrangement consist of a license to our intellectual property and research, development and manufacturing services. We may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, we estimate the probability and extent of consideration we expect to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. We then consider any constraints on the variable consideration and include in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then allocate the transaction price to each performance obligation based on the relative standalone selling price and recognize revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in our balance sheet.&#160;Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as noncurrent liabilities. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue expenses for manufacturing, process development, nonclinical studies and clinical trial activities performed by vendors based upon estimates of the proportion of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our prepaid and accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure compensation expense for all share-based awards based on the estimated fair value of the share-based awards on the grant date. We use the Black-Scholes option pricing model to value our stock option awards. We recognize </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model requires the use of subjective assumptions that include the expected stock price volatility and, for options granted prior to our IPO, the fair value of the underlying common stock on the date of grant. See Note&#160;9 to our audited financial statements included elsewhere in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted during the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our financial statements found elsewhere in this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company as defined in the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards and delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation exemptions to the requirements for (1)&#160;providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act and (2)&#160;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a)&#160;the last day of the fiscal year (i)&#160;following the fifth anniversary of the completion of our initial public offering, (ii)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined under the Exchange Act. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div id="i92757ae30a234940aa4371e66352259c_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Audited Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_52">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_52">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_55">Balance Sheets as of December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_55">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_58">Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_58">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_61">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_61"> (Deficit)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_61"> for the Years Ended December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_61">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_64">Statements of Cash Flows for the Years Ended December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_64">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_67">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i92757ae30a234940aa4371e66352259c_67">67</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc.:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Shattuck Labs, Inc. (the Company) as of December&#160;31, 2021 and 2020, the related statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181Mi9mcmFnOjUwYWYyZTBkMTdjMTRlMzlhMjM2MTU3YWMxMmEyMDM0L3RleHRyZWdpb246NTBhZjJlMGQxN2MxNGUzOWEyMzYxNTdhYzEyYTIwMzRfMzI5ODUzNDg4NTY4Nw_9ffd6168-8a06-47d7-a07a-3fc16677f792">KPMG LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181Mi9mcmFnOjUwYWYyZTBkMTdjMTRlMzlhMjM2MTU3YWMxMmEyMDM0L3RleHRyZWdpb246NTBhZjJlMGQxN2MxNGUzOWEyMzYxNTdhYzEyYTIwMzRfMzI5ODUzNDg4NTY5NA_2cef5c04-9e72-4795-931b-1861abfb03c9">Austin, Texas</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 15, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNC0xLTEtMS0w_69dcf049-2f54-4d59-8a3b-cda3bce37ab7">92,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNC0zLTEtMS0w_b928c8a4-eb56-4104-b9b9-04b7272c4d4d">157,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNS0xLTEtMS0w_8ecf89b9-7c14-4ee4-b66a-903b11360e9f">176,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNS0zLTEtMS0w_39a9c20e-2653-4e5e-b10a-f6afd7122af7">177,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNi0xLTEtMS0w_574245fc-e845-4819-98c4-246baa71cfdd">19,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNi0zLTEtMS0w_8fc0d8fb-bbac-4124-8267-83cada4ec227">10,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNy0xLTEtMS0w_ba87d4c8-d5d5-4137-b871-16dd97cdaa28">288,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNy0zLTEtMS0w_f1e60539-a07d-43f7-8194-2ef43d2f1896">345,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOC0xLTEtMS0w_82235092-81c2-493a-98ba-6af67cd408d8">9,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOC0zLTEtMS0w_b546e533-2d22-4c8d-ba71-4ab1377e5181">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOS0xLTEtMS0w_70f4503e-bd5a-41f4-9a79-4810a3656bd6">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOS0zLTEtMS0w_68eb386a-ba70-4cf0-9e07-315f4a7d83f2">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTAtMS0xLTEtMA_3111e5f7-05ed-4f16-a575-a0d06d178e35">298,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTAtMy0xLTEtMA_996501d4-5a3e-4cf2-ae63-45d22686b7ad">348,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTQtMS0xLTEtMA_8d926b57-2a77-45fa-8d8d-bb49319b533d">10,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTQtMy0xLTEtMA_44ecd80f-de28-4378-934b-43285bc05e25">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTUtMS0xLTEtMA_2928ffc6-7b2f-453f-96e5-347b9ea55807">14,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTUtMy0xLTEtMA_9b39f3ca-6186-48b2-b252-6844a68f735d">7,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTYtMS0xLTEtMA_bd6da7c6-9c40-4b27-9ee4-f2cde5c44480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTYtMy0xLTEtMA_ef24076e-3d5b-4f7e-9d24-e946bc2f8f97">7,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTctMS0xLTEtMA_da4c2ea7-448b-4a04-9e16-24ad6fd9d33f">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTctMy0xLTEtMA_57b0e94d-0d5b-4f93-bedf-e1d87e560d14">16,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredRentCreditNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMS0xLTEtMTkxNjI_860becf9-077a-42fb-b12e-c2c9c61cc5cc">2,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMy0xLTEtMTkxNjI_dce19839-88e8-4879-be87-eb7496627de0">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - related party, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMS0xLTEtMA_c0df00bd-31fe-47bd-bda7-c2c83e0b09dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMy0xLTEtMA_6a6c44c3-db32-4b47-b8a0-8acd6fdcfb4a">21,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjAtMS0xLTEtMA_32b005f1-534e-4c99-b741-48a728f90968">26,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjAtMy0xLTEtMA_e40e899c-5bec-454f-9be4-8459e8e9569f">39,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjEtMS0xLTEtMA_ef396d3a-7a0a-4999-a229-94df70b8ebd3"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjEtMy0xLTEtMA_ed4b5143-425f-49c8-a6e3-dc11f7c35034"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzE5_6bd5adce-8352-4bc0-80e1-617d812f148c"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzE5_d31e9b06-59ff-4136-80a4-8b9295f29f02">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzMz_36fdacee-8d65-4c65-81b8-4c19d3afb10f"><ix:nonFraction unitRef="shares" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzMz_4f786e65-4843-472b-9f11-a844de765590">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzU1_3e7ce2b5-2d05-4872-b7cf-3661f5c0dd80"><ix:nonFraction unitRef="shares" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzU1_4531bcc4-ebe2-4731-bab9-6f68ba6dadba">42,338,898</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzYy_7f121abf-883b-45f5-a5b5-f017131f53d4">41,779,183</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3Xzkw_cdb101dd-c95c-430b-99b8-b76fdc9c117e">41,767,431</ix:nonFraction> shares outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMS0xLTEtMA_d2cdd3f0-4a04-4d3a-a4d8-3d799e6eb588">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMy0xLTEtMA_6e81f1e8-2f3d-4a6a-9e25-95b069ff5174">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjgtMS0xLTEtMA_e7442bde-30e1-4e6f-b077-13bf45492442">389,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjgtMy0xLTEtMA_941220ac-28e3-4313-ad3a-c21a8c431604">382,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjktMS0xLTEtMA_2d7ad700-500c-476d-869c-b1a677eba9e6">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjktMy0xLTEtMA_760c48ba-a286-4756-a91e-daf961577a1c">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzAtMS0xLTEtMA_b32a2e6c-3f29-47c9-96fe-964e10df8ae6">117,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzAtMy0xLTEtMA_c00a53c3-c65e-48ca-bc06-34b9fbdee36e">72,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzEtMS0xLTEtMA_3f5e39c4-d2b0-4cb2-8d9b-92561b7d9e8b">271,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzEtMy0xLTEtMA_2585d2cc-cfb9-4f1a-a7bc-e2dffb3a7837">309,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzItMS0xLTEtMA_1a5e1c52-ebc7-4896-afe7-cf306ac3f3bc">298,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzItMy0xLTEtMA_8d330048-80eb-4c72-ad51-1a5893af6e86">348,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0wLTEtMS0w_31f163b6-9c40-4353-9e20-429d03b53ecd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0wLTEtMS0w_5cd945f9-9202-4d21-9fbf-20327c19355b">Collaboration revenue - related party</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0xLTEtMS0w_6334f400-355f-41c1-970e-fde6bd98fcb1">30,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0zLTEtMS0w_5219352e-0d33-4fa8-9ef2-fefa53fc365c">9,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNC0xLTEtMS0w_51fb20fb-c4ea-408d-9951-52cd369480d7">56,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNC0zLTEtMS0w_7ed45eb0-e2cf-4cf1-93cc-82a5592fbddc">37,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNS0xLTEtMS0w_13ed277f-36e0-4c1f-a3a7-62972577330f">18,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNS0zLTEtMS0w_173824dc-54de-49ed-b4c4-00d69dba5b80">9,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNi0xLTEtMS0w_f72a4da4-60ab-43cd-98af-efc90226333e">75,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNi0zLTEtMS0w_06f6bda6-1b40-48f8-a698-51107817b04c">46,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNy0xLTEtMS0w_bfc88656-6413-4c2f-9fb1-400f8f6c1862">45,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNy0zLTEtMS0w_492e59d9-1cf9-4f48-8631-c624059964b7">36,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTAtMS0xLTEtMA_a4480e91-6b85-4162-b1f5-dcc8978421d8">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTAtMy0xLTEtMA_fa5e8210-38db-4728-94b1-6952a1b88172">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTEtMS0xLTEtMA_e1ac12c5-13fa-48ea-8b7b-3e1800cb5162">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTEtMy0xLTEtMA_71500d6a-1b73-4e2e-8a39-85861018cd8c">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTItMS0xLTEtMA_fdebaef1-a7a3-4c89-8a71-778a2eca9ed6">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTItMy0xLTEtMA_28dd22ef-4173-457a-9ab2-f60e525cbf87">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTMtMS0xLTEtMA_e8f83c0c-225f-47d4-af2d-bef88df99469">44,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTMtMy0xLTEtMA_1535b785-780a-4928-85bb-4748ece86a01">36,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTUtMS0xLTEtMA_96d219ff-f9f8-494f-9fb7-090707dab276">497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTUtMy0xLTEtMA_ecdf179e-f0d5-4c16-ab01-80ee561e5296">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTYtMS0xLTEtMA_13b5e598-c28c-476b-810b-e01d006543f6">45,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTYtMy0xLTEtMA_31710516-db22-4dff-9075-9f3abd875587">36,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMS0xLTEtMA_559d0646-72e1-4647-b4a3-64f5d574be23"><ix:nonFraction unitRef="usdPerShare" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMS0xLTEtMA_e66ccd2d-836f-4bdd-9455-86650c98cbe1">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMy0xLTEtMA_57dd03f5-fe58-48b7-987f-18bd4f49b05f"><ix:nonFraction unitRef="usdPerShare" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMy0xLTEtMA_fa33af83-54dd-4b8e-a3e8-639ec7937888">2.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMS0xLTEtMA_d500af2d-15d0-4418-88c4-8574d5a1d2b2"><ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMS0xLTEtMA_db9fd0ff-3cf2-40f9-870a-0d27622093e2">42,032,384</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMy0xLTEtMA_a0b9d30b-a05a-416b-9b72-3385a5cdc9f4"><ix:nonFraction unitRef="shares" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMy0xLTEtMA_a55a0e7c-d1be-480c-911c-42ca15b6731b">15,506,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.593%"><tr><td style="width:1.0%"></td><td style="width:17.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.703%"></td><td style="width:0.1%"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Redeemable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Convertible</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Preferred Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series B</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Redeemable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Convertible</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Preferred Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series B-1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Redeemable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Convertible</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Preferred Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93d907eb546d4b419a06e844b32e0c37_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xLTEtMS0w_24f00559-419b-4e59-a3e7-8823c6f07f52">1,093,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d907eb546d4b419a06e844b32e0c37_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0zLTEtMS0w_720923af-c297-4de9-a1ce-67b350c4cb8e">49,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6085e2e606c14212b39aba95286e4bee_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC01LTEtMS0w_0719a3eb-1211-40f8-b790-2227d7c639a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6085e2e606c14212b39aba95286e4bee_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC03LTEtMS0w_0157da03-a7c1-4d03-b7b3-4236973775b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa3d82eadadb40ab92d3249bab64bf52_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC05LTEtMS0w_2f01c2cc-f3bd-40c0-8aeb-aec7e8e86af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3d82eadadb40ab92d3249bab64bf52_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xMS0xLTEtMA_4b4f8bfe-807a-4bfe-a207-612613d19987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b2ca173e0004d11919d92632a37774d_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xNC0xLTEtMA_b91fd403-b82a-4cf0-b4c2-159b068bb921">7,600,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2ca173e0004d11919d92632a37774d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xNi0xLTEtMA_00845c5b-b064-43af-9e08-e3cb1faf044f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e12961d654945e09068f8b39b05845b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xOC0xLTEtMA_849cca49-5d7c-4e73-abb3-3c1c3183ec97">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dae071f8e3d4bec9f3b7ed2455cd014_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0yMC0xLTEtMA_bfaa9eff-e044-4fe4-bd1e-33f28a803f51">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief9145f0685d40abb21ee4ec19d9937f_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0yMi0xLTEtMA_4ee1e3f9-84c2-432f-9a52-a7cdfe4cc224">35,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2e6543ccfb74775ac5df4a5733524f6_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0yNC0xLTEtMA_10b5e161-32a4-41f4-acab-671c911635bb">34,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales of Series B Redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="INF" name="sttk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOS01LTEtMS0w_178e6d9a-3898-4a01-8e90-00829dc52ad2">550,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOS03LTEtMS0w_e23878ca-1595-4a52-b725-0882947bc2a4">34,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales of Series B-1 Redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="INF" name="sttk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTAtOS0xLTEtMA_00d0f36a-e0f8-417c-816c-11ae4be6c4d9">1,319,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTAtMTEtMS0xLTA_f4f19192-d6e6-464f-88cc-cc793b7a6b51">82,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series A redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231" decimals="INF" name="sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMS0xLTEtMA_cc7295ef-90f9-4e49-b178-0d86d0bea1aa">1,093,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231" decimals="-3" name="sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMy0xLTEtMA_efc04e16-525b-44bf-ae70-7df3f6e7e3d7">49,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia24b53685d3540c7a804b8f394e399a6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMTQtMS0xLTA_4c188480-e3ec-4b23-9473-a6be87d40a5b">7,487,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24b53685d3540c7a804b8f394e399a6_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMTYtMS0xLTA_3bcd12eb-df50-49cf-8db7-7441874a5de9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i108a91c3f6de49d7ad25831cb4cbbac8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMTgtMS0xLTA_9b23ae5b-fb53-40c9-b27f-7796ef496d2a">49,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMjQtMS0xLTA_9f019cc4-74c2-4729-b44f-f6465f986e0f">49,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series B redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="INF" name="sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItNS0xLTEtMA_bb003238-0146-473b-91a9-0749cbf5ea23">550,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="-3" name="sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItNy0xLTEtMA_7a218e8f-6995-4d15-a8bb-01cc74048b95">34,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia46bf273b1e0431682728738c320b383_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMTQtMS0xLTA_cab7c44a-3d16-4560-9e28-04b1ccf8538c">3,771,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46bf273b1e0431682728738c320b383_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMTYtMS0xLTA_7cfe0fd9-7dc5-4d1a-8250-66f670b44062">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d28057558bb4a0295c8315232a69252_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMTgtMS0xLTA_7adb40e9-6cd4-45a3-83fa-caae7777ccdb">34,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMjQtMS0xLTA_c34b90b4-2e48-4762-a2ba-663c196909a0">34,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series B-1 redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="INF" name="sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtOS0xLTEtMA_d1dd4134-0a8e-43af-8866-44367c130991">1,319,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="-3" name="sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTEtMS0xLTA_1c70a286-2b50-49f9-8635-a0396bc69399">82,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82048836e6fa4e5aa557a2623e6ff0f7_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTQtMS0xLTA_d7a43666-d68c-4e5c-860e-ead7fffacaf3">9,041,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82048836e6fa4e5aa557a2623e6ff0f7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTYtMS0xLTA_7c37340c-e155-47b8-ae55-c484e8f686a1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3683f766ae45e09c86c03f022c9e01_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTgtMS0xLTA_56a552c0-5a1e-4c27-8b8a-278c6a221dc4">82,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMjQtMS0xLTA_8e7b3570-271b-4c79-a229-cefb5cac93ad">82,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon initial public offering, net of issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMTQtMS0xLTA_9942518f-f2ab-480f-bac8-2c6827e665d6">13,664,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMTYtMS0xLTA_264f4ec1-10fa-4a97-b9b8-8d2fddce4460">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMTgtMS0xLTA_04a69ea4-1803-455a-aeec-36ade46d37c3">213,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMjQtMS0xLTA_367337ea-5318-4d3e-8075-5f32fb43ad80">213,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTQtMS0xLTA_a3e83f6d-23c6-442a-a44f-0253a0a110f9">181,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTYtMS0xLTA_f1e0cedc-df00-4084-ab3c-12bf6a9993c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTgtMS0xLTA_2a659859-3d66-4f87-b27d-0732937d8fb3">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMjQtMS0xLTA_3aeb89af-532e-4d6f-a3ab-2c489837222a">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of common stock previously subject to vesting requirements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTYtMTQtMS0xLTA_a7671d50-3991-4110-9fee-887d3068c9fe">20,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMTgtMS0xLTA_63fcfa75-61b4-4e19-bd6c-88888342f588">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMjQtMS0xLTA_fa3ffefe-2c4a-46d7-8f9e-f727b1e9d57a">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eaebef00de14f10b1d30533510da470_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjAtMS0xLTA_1f0ceee1-8d2d-4958-a31b-90872b9cfc31">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjQtMS0xLTA_4a5ef4cd-3f1c-4c6f-904c-a715fcaec894">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d204922a202445caae9e3f732504db5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjItMS0xLTA_03d56b8f-0758-42ff-8de6-ecc2af550e19">36,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjQtMS0xLTA_3850e2f0-ebcf-4f3f-ae81-58933fdfbc16">36,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic115a1576f394c55b1a7bb9b66af7321_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMS0xLTEtMA_11543442-09cd-4a9a-b252-a810d3b6563f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic115a1576f394c55b1a7bb9b66af7321_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMy0xLTEtMA_0ffb58af-cf23-438d-b61b-18ea7334781b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if11f7173c81c46b2b06d4f80310b846d_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNS0xLTEtMA_a8d5485e-8361-4d00-a1c3-447ba04df780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11f7173c81c46b2b06d4f80310b846d_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNy0xLTEtMA_29a69e37-a423-4701-8996-4efd4180f916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic14f82c5bd594e0c86f407f962585613_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtOS0xLTEtMA_f7d11694-bfed-45b4-85d3-b7a3a4f59dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14f82c5bd594e0c86f407f962585613_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTEtMS0xLTA_9735de96-963e-4e04-8cbe-92af1c6a397a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaac2c9de295f4a84843194e8e6f933cf_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTQtMS0xLTA_fa0b9499-965f-42d8-8d33-d7b2147b66b8">41,767,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac2c9de295f4a84843194e8e6f933cf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTYtMS0xLTA_c047df41-0ee5-4949-94ae-7a828e4c0152">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb89c4e37124b489c0152e257cc9e7a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTgtMS0xLTA_a86bc432-2cd6-42e1-a890-43a5f7c0892e">382,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafbad4a0cb66454aa263e9cc4b0b02cd_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjAtMS0xLTA_fa900999-36f9-42d0-9bb0-cf329b7e27de">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae4c24644ef446b38a0bc1bd5b7b9dad_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjItMS0xLTA_49b3e027-c436-46d2-a540-91c92c882570">72,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjQtMS0xLTA_b5c95e80-2cfe-4b85-9cf3-465ff6e589b2">309,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP purchases</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b7b805cabed4fef89935fc4a01cc352_D20210101-20211231" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTQtMS0xLTM5Mg_d33902cf-e600-48e5-84a9-f979aee74737">559,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da23b727bc545ce8a8626f9c21738f4_D20210101-20211231" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTgtMS0xLTM5Mg_e26fbc47-4bff-45c2-8c9b-1151c12257cc">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMjQtMS0xLTM5Mg_997cf9b1-312d-4d95-9cc4-6cdf9d3acaa9">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of common stock previously subject to vesting requirements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b7b805cabed4fef89935fc4a01cc352_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTYtMTQtMS0xLTM5Mg_ef7f605a-ff53-41d7-b8f1-c0fb8652ddec">11,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da23b727bc545ce8a8626f9c21738f4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMTgtMS0xLTM5Mg_7a361fc1-4d4e-463a-8f2b-3d1c682d2be8">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMjQtMS0xLTM5Mg_c6089c91-a927-4108-8b0f-9fcb3c8d6909">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2978472561c24d05b2c48b66c0b36df6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjAtMS0xLTM5Mg_c0480fc1-3043-45f6-a991-4ebead44e322">497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjQtMS0xLTM5Mg_7f673a8e-72f5-49b5-83f3-52fa0d07388d">497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3f0d368be5c4c9cbee436c3481aa483_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjItMS0xLTM5Mg_e2a93420-88c8-4303-a01c-2f3e160cdb8c">44,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjQtMS0xLTM5Mg_739cc5b7-1a44-475d-9171-02b0ab3f929b">44,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8eeb11b3ac40f1b3c9e84a79462ae7_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMS0xLTEtNDEw_1ca1401d-a3fc-4a2f-b565-1fec94b71ddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8eeb11b3ac40f1b3c9e84a79462ae7_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMy0xLTEtNDEw_1bcf410f-d748-4b10-832b-7206d432600f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie30e987b03ab4ec59ff05cf3acc5e3a1_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNS0xLTEtNDEw_c02c5bde-8e8e-448f-a7de-95d6fd5853c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30e987b03ab4ec59ff05cf3acc5e3a1_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNy0xLTEtNDEw_58477a6d-e125-4d50-aeb9-42bfcd702bfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55c9db39c55b45f684b6bf134143d66a_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtOS0xLTEtNDEw_6e3874f9-f1ae-4284-aad0-188eb694a457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c9db39c55b45f684b6bf134143d66a_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTEtMS0xLTQxMA_85bd89d9-2f4f-41f6-8975-1ee19ac65879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7c736cc6e69478988dbcd443d316c34_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTQtMS0xLTQxMw_561ec897-c5c2-4bc6-9179-7a6c28054df8">42,338,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c736cc6e69478988dbcd443d316c34_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTYtMS0xLTQxMw_2ca0ef0e-7f12-4423-a8ee-a7c7084685f9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314de4ca010e41458b9633658578103b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTgtMS0xLTQxMw_61521477-330e-474a-a952-995e866381bd">389,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34e74c583cf482a8c7f8c3fdc28de97_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjAtMS0xLTQxMw_52ff3bd4-5dd6-46d1-b69d-f28a1cf991f6">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83035001040e4d90ac2aa8830614906e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjItMS0xLTQxMw_36defe3a-041f-4829-a485-d6128a700dfc">117,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjQtMS0xLTQxMw_78aedc74-f18e-496d-8b49-afc577eeb929">271,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMy0xLTEtMS0w_e8f83c0c-225f-47d4-af2d-bef88df99469">44,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMy0zLTEtMS0w_5e5b23c7-e38e-4df3-aa17-93b8a2706dcd">36,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0xLTEtMS0xNDA0Mw_7ab8833d-49b0-4e17-894b-72187ccba9dd">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0zLTEtMS0xNDA0Mw_fc50d7dd-9f1c-4035-912e-3d83df7a2a33">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0xLTEtMS0w_137273e7-82ff-45a0-8241-e117a59e5f1d">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0zLTEtMS0w_7ebf123c-e469-4e02-ac2d-e83816b0ceab">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amortization of premium on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOC0xLTEtMS0yMTI2Nw_00668d1a-6b9a-48c6-88ff-04e5d34525c2">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOC0zLTEtMS0yMTI3MQ_28a7740e-b74b-46e6-bf67-409f4a2d0cfb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOS0xLTEtMS0w_394a9368-d8a5-4e62-8ec4-9182ce661236">9,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOS0zLTEtMS0w_947b8964-1e12-418b-bc72-3af26c5efb16">6,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTAtMS0xLTEtMA_d8b83636-03f4-4210-b337-fff9d2794ead">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTAtMy0xLTEtMA_f5da0d61-785c-47bc-a296-7c21806674c6">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTEtMS0xLTEtMA_e42bb22e-af32-4fbd-8b1e-fb7cfce5fa32">7,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTEtMy0xLTEtMA_837b70f8-0b9b-45ed-8191-f242e497ca45">1,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTItMS0xLTEtMA_b651e5c4-12ac-4d25-aacc-199c26858cc7">6,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTItMy0xLTEtMA_21337310-0f4b-47fb-8d8b-bb4b5c85f199">3,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTMtMS0xLTEtMA_66cdaf78-44c4-4e87-a3f6-792c5d97141b">29,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTMtMy0xLTEtMA_864c4448-6bc6-43b5-ab34-6b2a4c4f5dc3">6,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="sttk:IncreaseDecreaseInDeferredRentCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTQtMS0xLTEtMA_1dfcce5b-c7d6-4dd9-93f8-cc2a415598ae">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="sttk:IncreaseDecreaseInDeferredRentCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTQtMy0xLTEtMA_bb40e0e2-8bce-42dd-b15a-92f404237ac4">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTUtMS0xLTEtMA_ad155b69-969c-4de6-8af1-32fd1d34cdb6">57,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTUtMy0xLTEtMA_cf83235a-5cbe-45a8-bad1-f5aab29cd7ca">33,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTgtMS0xLTEtMA_6f41de69-e9fc-447a-b655-8f636e445b78">7,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTgtMy0xLTEtMA_c4d10997-80a4-4d1d-822f-d154e9619f72">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale and maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTktMS0xLTEtMA_46904d4e-0abc-4230-848c-3db886ed13a2">201,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTktMy0xLTEtMA_8afbc39e-bba3-4778-9e79-8957c61325a2">37,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjAtMS0xLTEtMA_bb056427-e5ea-4380-a439-d146af707bcf">204,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjAtMy0xLTEtMA_a1b08050-e37c-4304-9fcc-e7a4a2aef87d">183,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjEtMS0xLTEtMA_6ec918a5-aabb-4a1e-99a4-cf3144c46565">10,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjEtMy0xLTEtMA_b907b219-a794-41f7-81fa-97cbc48dfe87">146,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercises of stock options and ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMS0xLTEtMTg1MzE_5a145144-58af-4609-a5e9-6342fb31fe51">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMy0xLTEtMTg1MzE_6f8c3583-9864-4aa6-99d2-192d6acf2724">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the initial public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMS0xLTEtMA_51b74531-96d5-46d7-a830-30897ada839e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMy0xLTEtMA_402b4fe2-a4e3-4ddc-9eec-8b4adaff2c39">232,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs of the initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cbb284a8c1342259be91fd8741fe70a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjUtMS0xLTEtMA_14d7ed93-030d-4c45-b499-426f06275cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0f3fa86426e412a8755fb1b72e9c76a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjUtMy0xLTEtMA_51f71dfa-72cb-4c5a-8be4-50d188ffc0cc">18,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Series B-1 redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a6c00e553649a9a7fd199a899a8098_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjYtMS0xLTEtMA_66bbf33a-fe6d-420b-b4c6-1bd53304f8af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjYtMy0xLTEtMA_923c3c1f-0826-4330-9f70-a8df366aa598">83,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs of Series B-1 redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a6c00e553649a9a7fd199a899a8098_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjctMS0xLTEtMA_6ff292c0-46f4-425b-9df8-94bc705bde57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjctMy0xLTEtMA_8d0187f4-760a-4e79-a251-4ff72b001b1d">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Series B redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef03e1dffea436194212535f30c3f7d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjgtMS0xLTEtMA_1d1efb76-3526-471b-b520-3682aea0a568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjgtMy0xLTEtMA_91fdfdfe-7162-439c-a4d9-630ea932fee2">34,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs of Series B redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef03e1dffea436194212535f30c3f7d_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjktMS0xLTEtMA_b874dc2f-8009-4691-bb6f-2c42111543ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjktMy0xLTEtMA_26a035b3-0326-4a2e-be95-388e9ceea5d5">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzEtMS0xLTEtMA_2a623548-b7de-465b-800f-12dcc1baceea">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzEtMy0xLTEtMA_9b1967c4-0aa2-4001-87bb-84b1cb24c7a3">330,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzItMS0xLTEtMA_ab890c77-6f59-42e8-832f-862903e169d3">65,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzItMy0xLTEtMA_2570b95f-7aad-40bb-8005-0d953da76cd9">150,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzQtMS0xLTEtMA_c0b72bac-73dc-4549-a59f-86c6a8c37873">157,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e6543ccfb74775ac5df4a5733524f6_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzQtMy0xLTEtMA_78bc92d4-302b-4aa6-ad17-cc64f7666517">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzUtMS0xLTEtMA_c6d85e43-194e-4276-9c7c-204aae9a0dd8">92,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzUtMy0xLTEtMA_2a3c5119-d1ed-49dd-a136-0f850618729e">157,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosures of non-cash financial activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzgtMS0xLTEtMA_db6518f0-8f7a-4845-be69-fcc46d6bf437">497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzgtMy0xLTEtMA_9607979b-3c36-4fdf-98ae-ea994aecc413">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid amounts related to purchase of property and equipment </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzktMS0xLTEtMA_113127ba-0407-412a-81cf-5b84ccd637d1">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzktMy0xLTEtMA_bb0be8a8-01ea-403f-af7b-f07155486d12">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_67"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div id="i92757ae30a234940aa4371e66352259c_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183MC9mcmFnOjNjYjFmN2FhMDhmNDQ3YmNiMjJhZDJkOWY2YWIzMzhiL3RleHRyZWdpb246M2NiMWY3YWEwOGY0NDdiY2IyMmFkMmQ5ZjZhYjMzOGJfNTQwMg_d4f28e63-7387-48a2-8be5-ad71a81c8072" continuedAt="i0b6a64ee370a48bfb17d3bd39ec908e9" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="i0b6a64ee370a48bfb17d3bd39ec908e9"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has two clinical-stage product candidates, SL-172154 and SL-279252, and has several compounds in preclinical development.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183MC9mcmFnOjNjYjFmN2FhMDhmNDQ3YmNiMjJhZDJkOWY2YWIzMzhiL3RleHRyZWdpb246M2NiMWY3YWEwOGY0NDdiY2IyMmFkMmQ5ZjZhYjMzOGJfMjQzNg_4e69aec3-51aa-45ed-97a7-96c864a556bf">117.1</ix:nonFraction> million as of December&#160;31, 2021. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183MC9mcmFnOjNjYjFmN2FhMDhmNDQ3YmNiMjJhZDJkOWY2YWIzMzhiL3RleHRyZWdpb246M2NiMWY3YWEwOGY0NDdiY2IyMmFkMmQ5ZjZhYjMzOGJfMzI5MQ_f19c98ae-23d2-4ac5-89e9-90bf3f131b35">268.8</ix:nonFraction> million as of December&#160;31, 2021, are sufficient to fund projected operations of the Company for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and in which the Company&#8217;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While the Company has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company&#8217;s continuity plans will be successful. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has already experienced disruptions to its business such as work-from-home orders for offices and similar disruptions have occurred for its partners. Specifically, the outbreak has caused disruptions in its ability to manufacture clinical trial materials, including the acquisition of raw materials needed for such manufacturing, enrollment and treatment of patients in clinical trials in process, and slowdowns and shutdowns of the laboratories and other service providers that are being relied upon in the development of the Company&#8217;s product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic or any other health epidemic may impact the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to mitigate its impact, among others. Accordingly, the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s business, results of operations and financial condition.</span></div></ix:continuation><div id="i92757ae30a234940aa4371e66352259c_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTU_f4f2f601-28db-4162-bea2-8decc2b3d5d1" continuedAt="i1be9af1582a440e38e0745d31b9d07e0" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i1be9af1582a440e38e0745d31b9d07e0" continuedAt="i2c2d4ad1ad9d4b4ea94dacb8b56b8c0d"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDc_4dc1d227-c60f-4dd3-a16f-4456da7ac322" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTk_827fa348-a4df-4325-8930-09df77e0d8f5" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates. A change in the Company&#8217;s estimates occurred in the second quarter of 2021, which impacted the Company&#8217;s revenue recognition and related balance sheet accounts.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="i2c2d4ad1ad9d4b4ea94dacb8b56b8c0d" continuedAt="i7a236463343845e7a2210d049d91f79c"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDE_03c82b81-0c38-4fdd-a486-9d63fcaee0ff" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDg_1bf2266b-9508-4cbf-b593-a801015fbce7" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), which was mutually terminated pursuant to the termination agreement, dated November 8, 2021. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on one third-party contract manufacturing organization (&#8220;CMO&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on three contract research organizations (&#8220;CROs&#8221;) and a limited number of third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTI_86ac3392-9486-48a7-adab-03f951844479" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $<ix:nonFraction unitRef="usd" contextRef="ifcfc895622274a9fa067f83a85414b73_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTY3Nw_fb69d4d1-0669-4e4c-9e41-0b7ee959c78f">14.6</ix:nonFraction> million held in operating accounts and $<ix:nonFraction unitRef="usd" contextRef="i2bc6f8f8312648d79a5c147096aa6201_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTY2OQ_6e476c56-9387-406d-9db2-873584eaccfb">77.7</ix:nonFraction> million held in money market funds as of December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib7e8869244b74fc28985b69bc05e3793_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTY5Mg_0b8a4731-bbb0-4536-ba4c-25fce0ec6e6d">2.7</ix:nonFraction> million held in operating accounts, $<ix:nonFraction unitRef="usd" contextRef="id283059be4d44a2e824a82620e3e234d_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTcwMA_08d669c7-5629-40d4-b7b4-8c501aab4d67">80.2</ix:nonFraction> million held in money market funds and $<ix:nonFraction unitRef="usd" contextRef="i524cc2fcaa1e4182b2577f5ace25f6fd_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTcwOA_c3a54394-fa30-497a-938c-6467955c0ed3">75.0</ix:nonFraction> million held in government obligations as of December&#160;31, 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODc_cba0ee45-9ade-43c8-8404-17c8206db87a" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of highly-rated U.S. Treasury securities with maturities of more than three months but less than one year at the date of purchase. The Company classifies its short-term investments at the time of purchase as available-for-sale securities. Available-for-sale securities are carried at fair value. Credit impairments for available-for-sale debt securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2021, there were no impairments related to credit losses of short-term investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="i7a236463343845e7a2210d049d91f79c" continuedAt="i17ed40917eff44c8a14816e652af83eb"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDI_e049259d-c241-4091-a011-82e5cd663965" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded against gross proceeds.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDU_79340142-682b-45fa-993c-7306233ccbac" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of stockholders&#8217; equity on the balance sheet because the shares contain liquidation features that are not solely within the Company&#8217;s control. Upon the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in the fourth quarter of 2020, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into common stock.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="sttk:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODk_c0822559-ac37-489b-a2f8-23c736038973" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTQ_c150ceb8-2572-47af-b84d-fc38c21ccc91" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTY_5087c067-5eb3-4829-b8b4-da25650999a9" escape="true"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0256d931b38f4e8ebd1fafc29f3baef9_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMC0xLTEtMS0w_3a14cac1-3d7d-4e89-be05-36841cf29fa9">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d2830e52a30463b83b72e983bfd983c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMS0xLTEtMS0wL3RleHRyZWdpb246MGVjNjc3MTRmYjA2NDE0Y2E4YjY1ZDI4NTE3YmQzNDNfNA_76fd80f1-ca89-4746-a7b7-eb3ec43d687f">5</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="i82c95f2381594579b82d242587361ef8_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMS0xLTEtMS0wL3RleHRyZWdpb246MGVjNjc3MTRmYjA2NDE0Y2E4YjY1ZDI4NTE3YmQzNDNfMTA_de776b0a-2b7d-422a-89b7-cef0147d8f69">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i199bf9783e444bf89f2a5c5f09e19ee1_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMi0xLTEtMS0w_44ff88d0-e72d-4559-bbe5-fda077ed5b6a">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or <ix:nonNumeric contextRef="i8507d1aa293d4d058b8d4ea3b458979e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMy0xLTEtMS0wL3RleHRyZWdpb246OGUwMTUwYTU1ZTZiNDNjM2E2OTI1ZDI4ZjBhNTA3MTlfMjk_4c45fcfb-d741-4110-8f80-f2d9f99ecb69">15</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTM_999d3735-966f-4431-9b6f-d2dd260d6a6d" continuedAt="iaeab5cb6fbac43f0af94444deab316aa" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaeab5cb6fbac43f0af94444deab316aa">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfODczNQ_4dd85978-8bd2-4b9f-bf0a-1bd2ce158600"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfODczNQ_f2744070-aa96-4a26-b3c8-1bd5508bda68">no</ix:nonFraction></ix:nonFraction> impairments of long-lived assets for the years ended December&#160;31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODY_7b95fd31-81a7-4816-898c-eb7559990f9a" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Rent</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense on a straight-line basis over the term of the leases and, accordingly records the difference between cash payments and the recognition of rent expense as a deferred rent asset or liability. Incentives granted under the Company&#8217;s leases, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDY_e0db53b3-05be-444f-8f1e-95deb52edda2" continuedAt="i0fa906caf6c344e9bd27e33d5d174d13" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="i17ed40917eff44c8a14816e652af83eb" continuedAt="ia6af8eb1230e4e3b8a14db1185eb06ef"><ix:continuation id="i0fa906caf6c344e9bd27e33d5d174d13" continuedAt="i983d3e1b0061474ca493bf5e951faa86"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract which would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="ia6af8eb1230e4e3b8a14db1185eb06ef" continuedAt="ia20d1fd187c84597901cd9a40fee7213"><ix:continuation id="i983d3e1b0061474ca493bf5e951faa86" continuedAt="ib82136e0034445ce80a354aea505edac"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><ix:continuation id="ib82136e0034445ce80a354aea505edac" continuedAt="ia0fc76cbbbb944c8987836ad0e88da2b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0fc76cbbbb944c8987836ad0e88da2b"> and will recognize the payments received from these agreements as revenue when the related costs are incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTc_ee9d1792-bf52-4ce8-a744-f0f8489d4a88" continuedAt="ifeb380939bec485694413b949eeb8584" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifeb380939bec485694413b949eeb8584">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgements and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="ia20d1fd187c84597901cd9a40fee7213" continuedAt="i64a0e5c1d17a4ee6bac35cd395cbc6dd"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTA_38e33a5e-28c1-43f7-8f59-d8b843b1580a" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee Board members as compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company adjusts expense for forfeitures in the periods they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDA_e2148f46-9a6c-4ec3-9c53-f327b9ff58d9" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTg_5b52598e-6879-4d4f-a2d6-0c768bf15c58" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible notes, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTE_1d1e3b22-3dae-46a4-b347-72f2da7e1169" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4739b7937ffb414cba8e7cf3495311be_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfMy0xLTEtMS0w_a3bcf090-17ce-4696-b963-504823276105">2,448,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b4d224548b44d2b88ff83fa65e5ba7_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfMy0zLTEtMS0w_25b93ee8-c40b-4a51-b555-82c51e1b3f00">2,742,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34cfe1bf8a0f4d1e8923ff1731e97dc4_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNC0xLTEtMS0w_49d3783c-0954-471d-8385-deb8436ea164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i022cbf9c4d41418ca5d4cc35b286630f_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNC0zLTEtMS0w_56bae901-2ac6-4425-9c96-f29e179e0043">11,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNS0xLTEtMS0w_f5ff233f-8b80-4a0b-8495-d6bf9978408b">2,448,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNS0zLTEtMS0w_c6037922-21d1-481b-876d-493359006947">2,753,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDM_f308255f-64ed-4eb0-a2ac-992fdf89528f" continuedAt="i3baf1fda95f44398ba0b591e92a4cec3" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3baf1fda95f44398ba0b591e92a4cec3">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on short-term investments.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODg_c3ff5092-0feb-40c4-aa0e-c5dfaee908ef" continuedAt="i07b41c9808404d45afc5861b7efb3358" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes: Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU removes certain exceptions to the general principles in ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year, with early adoption permitted. The Company adopted this pronouncement effective January 1, 2021 and it did not have a material impact on the financial statements or related disclosures.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements (not yet adopted) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i64a0e5c1d17a4ee6bac35cd395cbc6dd"><ix:continuation id="i07b41c9808404d45afc5861b7efb3358">transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The FASB deferred the effective date of this ASU until the annual periods beginning after December 15, 2021. The Company expects that the most significant effects of adopting this standard will primarily relate to (a) the recognition of right of use assets and lease liabilities on the balance sheet in relation to its existing operating lease agreements in Austin, Texas and Durham, North Carolina; and (b) providing significant new disclosures about leasing activities. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.</ix:continuation></ix:continuation> </span></div><div id="i92757ae30a234940aa4371e66352259c_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RleHRyZWdpb246YTg5ZjUwYzBhNDU5NGE0ZDgxZGQ3MDY1NGI3NzE4ZTNfNTMw_00e7f47e-04e9-410f-9ce1-e2ac9a987e80" continuedAt="id3af26afcd484868977f2b08a6109c03" escape="true">Short-Term Investments</ix:nonNumeric></span></div><ix:continuation id="id3af26afcd484868977f2b08a6109c03"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RleHRyZWdpb246YTg5ZjUwYzBhNDU5NGE0ZDgxZGQ3MDY1NGI3NzE4ZTNfNTMx_e465872c-5f06-4b98-bc6d-cae0eb728b31" escape="true"><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available for sale short-term investments by major security type (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b150d14a3340bdbbda062f1916514e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfMy0xLTEtMS0w_7c70e10e-c0df-4c0b-a293-08be2b0039b8">177,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6b150d14a3340bdbbda062f1916514e_I20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfMy0zLTEtMS0w_7246b850-bc10-44f7-9335-0027170241f5">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b150d14a3340bdbbda062f1916514e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfMy01LTEtMS0w_36eeb373-9905-4354-8a69-96f8d3442164">176,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfNC0xLTEtMS0w_f430a8ed-0ccb-4c28-8c0f-9903cdfc910e">177,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfNC0zLTEtMS0w_6c685db5-55ae-4a31-983d-1486a680a9ca">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfNC01LTEtMS0w_b857bf9f-cd5a-4a18-a68f-913476fc5cf1">176,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7705c519eda74dc58737c23718104aaf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNC0xLTEtMS0w_bb1b49bb-2c50-4008-aeef-8187bf2b2f80">177,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7705c519eda74dc58737c23718104aaf_I20201231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNC0zLTEtMS0w_7f88005a-2fb1-412b-9b5c-664bccc85caf">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7705c519eda74dc58737c23718104aaf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNC01LTEtMS0w_f63a56b6-01de-446a-9d54-a414472ee3c9">177,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNS0xLTEtMS0w_f2c9d595-a12c-43c9-b228-018ecb988f28">177,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNS0zLTEtMS0w_52ef4f88-09b7-4790-b44a-7968d7345df3">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNS01LTEtMS0w_807490f5-e551-41d2-be40-0eb2e6611e93">177,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have an average maturity of <ix:nonNumeric contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RleHRyZWdpb246YTg5ZjUwYzBhNDU5NGE0ZDgxZGQ3MDY1NGI3NzE4ZTNfNTIy_17d1ed9e-3fc0-43f1-afe9-079d53a2d904">0.43</ix:nonNumeric> years as of December&#160;31, 2021.</span></div></ix:continuation><div id="i92757ae30a234940aa4371e66352259c_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMjIw_69304edb-4b66-43d6-b83f-8eb723d0006b" continuedAt="i0544e4031c0943c6a346f0cb88fa08be" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i0544e4031c0943c6a346f0cb88fa08be"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMjIx_13a08d8e-63e5-4128-9c31-2989ea6d6de7" escape="true"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia854a6038a4a4bb088d1e1adb51da387_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMi0xLTEtMS0w_ed8d4139-d043-4203-86ae-67f982f9bde4">5,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef12007a5ff492690c14861cd4a497c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMi0zLTEtMS0w_a953acaa-f818-461c-a53b-69fe02fb817b">2,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc2651a89a543bbaf7e68cc3e676d0e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMy0xLTEtMS0w_fb392de4-eff1-413d-8961-560571217865">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c94c0bd8ebb4b1bb951ba7df8bdb437_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMy0zLTEtMS0w_225e361e-6b69-4883-bb9a-db5f050ae7e6">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide31a45817b8402c950886d450a9c631_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNC0xLTEtMS0w_60fcb472-cfda-4655-a668-4be7b5c05d8e">2,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4178f0dec2b24b44bad57c8e7393db7c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNC0zLTEtMS0w_cd9072f2-1fac-44c8-9ea8-293e54a7426e">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e6a315dca248c9aa85cda7c35059e5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNS0xLTEtMS0w_2089ce27-cdc9-438f-98d6-3ffabbdb3ec7">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2329b727b8467788e859b46061df44_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNS0zLTEtMS0w_e3f7d1f5-1168-4306-94df-1ac1c146a0b7">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9021bd3124402f8714a57978b7021a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNi0xLTEtMS0w_727b17b4-ba74-4d31-8ac0-cc2a3e17b0ae">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b6ab46fb514d5d8d7aa64487be02ee_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNi0zLTEtMS0w_3a2a0ce2-d4c9-4751-ad99-7be2c6e9c5dc">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNy0xLTEtMS0w_81f0a0b1-b641-41ec-9b73-f0798cde5329">12,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNy0zLTEtMS0w_2e5ea52c-70f5-4f1b-b8fe-5d96b464bf6f">4,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOC0xLTEtMS0w_3aec434e-49cb-498f-8060-ed01ef34c8af">2,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOC0zLTEtMS0w_90f033ce-7e93-4b07-b6c3-843750f98145">1,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOS0xLTEtMS0w_958c647d-d938-4996-acbf-964a8422bac6">9,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOS0zLTEtMS0w_00c8b2dc-ede6-4603-8f98-afa540d6637c">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMTgx_0866fca9-e3be-4642-8de1-98f180b69b61">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMTk2_02eed971-7d72-4639-98e5-a319f3ff22cc">0.6</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i92757ae30a234940aa4371e66352259c_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RleHRyZWdpb246NTg4OTUyNGU3ODFlNGY3M2FjZjMyMjMzODg3NjQ1NDdfOTU_6b3eec56-79b1-4808-8e39-9ec66875e81b" continuedAt="if4a3035ecbda4b2a99d6857c6bb558a3" escape="true">Accrued Expenses</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if4a3035ecbda4b2a99d6857c6bb558a3" continuedAt="iafdffb1839e04f2391a69bb64ec59d0e"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RleHRyZWdpb246NTg4OTUyNGU3ODFlNGY3M2FjZjMyMjMzODg3NjQ1NDdfOTY_69b29494-f992-4840-8d34-b26548006d3d" continuedAt="ia16f4bd96aaf4d0397101b0c02f5faa2" escape="true">Accrued expenses consisted of the following (amounts in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="iafdffb1839e04f2391a69bb64ec59d0e"><ix:continuation id="ia16f4bd96aaf4d0397101b0c02f5faa2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="sttk:AccruedResearchAndDevelopmentContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMi0xLTEtMS0w_2ad8cc00-3e15-496a-a450-60e2b93c89fa">10,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="sttk:AccruedResearchAndDevelopmentContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMi0zLTEtMS0w_e3c39835-bd83-46df-a07f-082bc2872c6b">5,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMy0xLTEtMS0w_9152b531-f6f0-4a32-8c00-b47d7824753f">3,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMy0zLTEtMS0w_66862890-b5aa-4d17-b9e0-4022087dcf6a">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNC0xLTEtMS0w_ab002828-a7ad-4669-a42b-12480011c662">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNC0zLTEtMS0w_aaca37ad-1a65-44be-b181-4ff29456a3d8">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNS0xLTEtMS0w_1150d837-243c-4bd9-981b-5555881b1370">14,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNS0zLTEtMS0w_b2131a50-c5e8-4a44-94f6-648cdcb196a3">7,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i92757ae30a234940aa4371e66352259c_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjUxMQ_6fd3074d-45fd-4cb0-b2a0-67695a9f28bb" continuedAt="i11deacea2a854a9c8250e7d49f9bbc5b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i11deacea2a854a9c8250e7d49f9bbc5b" continuedAt="ib994a96fd7fc4e02bce339ef63020b56"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjUxMA_9644f087-1ed8-400c-b7c3-8e433280b790" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future minimum payments, by year and in aggregate, under non-cancelable operating leases consist of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMC0xLTEtMS0w_afc463c9-5515-4227-85b8-bf1b5dc15c8b">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMS0xLTEtMS0w_4d93c2d6-647c-44e2-ba91-fea11b36cd42">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMi0xLTEtMS0w_fff34cba-ac92-41d7-8dca-6b0c802a4149">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMy0xLTEtMS0w_e8a3f530-0ea8-41c6-b5c6-f9ec72a76b5a">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfNC0xLTEtMS0w_de24485f-d480-496b-9cb8-b3a63e883fc6">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfNS0xLTEtMS0w_779a8247-4914-4724-ad6e-c825e00b3501">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfNi0xLTEtMS0w_6cd84a25-d557-4a45-9d6c-087347bf600a">7,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized rent expense of $<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasesRentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjQ1_26413a32-8282-4392-899b-1aa6e2244ff4">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasesRentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjUy_16a9216e-ca38-49d2-987a-0195e4852ad2">0.4</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heat License Agreement</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a license agreement with Heat Biologics Inc. (&#8220;Heat&#8221;), the Company is required to make payments of up to $<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-5" name="sttk:LicenseAgreementRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfNDQ3_55c51611-2d67-4c53-ade1-bfe54f2c6ad1">20.6</ix:nonFraction>&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products.&#160;The Company is required to pay Heat a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents.&#160;The Company is also required to pay Heat a royalty on all of its worldwide net sales, those of its affiliates and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the payments aforementioned given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company&#8217;s officers and directors. In each complaint, the plaintiff cites the volatility in the Company&#8217;s common stock and alleges that the defendants made or are responsible for false or misleading statements regarding the Company&#8217;s collaboration agreement with Takeda. The plaintiffs in both lawsuits seek a ruling that the case may proceed as a class action, and seeks unspecified damages and attorneys&#8217; fees, expert fees and costs. The Company and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against these lawsuits.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib994a96fd7fc4e02bce339ef63020b56">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</ix:continuation> </span></div><div id="i92757ae30a234940aa4371e66352259c_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:PreferredStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfNjAy_1735ba4a-57c3-46f1-bbbc-d2212e4eccf6" continuedAt="i11383190ad9f41df877e8eaf78f65805" escape="true">Preferred Stock</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i11383190ad9f41df877e8eaf78f65805" continuedAt="ie227befe7c704911814842381fe26a7e">During the year ended December 31, 2020, the Company entered into various stock purchase agreements with new and existing investors pursuant to which the Company sold an aggregate <ix:nonFraction unitRef="shares" contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMTg5_39e02c77-e66d-457f-bede-537256546385">550,571</ix:nonFraction> shares of Series B redeemable convertible </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie227befe7c704911814842381fe26a7e" continuedAt="i3670d1e663394a4e8b33f7ff24791a1c">preferred stock and <ix:nonFraction unitRef="shares" contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMjY3_fc23fda1-ff1f-4411-adce-942a37d0d3b5">1,319,964</ix:nonFraction> shares of Series B-1 redeemable convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="if11f7173c81c46b2b06d4f80310b846d_I20201231" decimals="5" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMzQ4_0b92c03e-5ef7-4c17-8c10-fc04e740114d"><ix:nonFraction unitRef="usdPerShare" contextRef="ic14f82c5bd594e0c86f407f962585613_I20201231" decimals="5" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMzQ4_707c316e-796b-46da-813c-2faa9714c192">62.88051</ix:nonFraction></ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1c436ab0261649adb338c58e3639b366_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMzgx_410d5b80-86dd-40d2-9803-daa8675f968c">117.0</ix:nonFraction> million.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3670d1e663394a4e8b33f7ff24791a1c">The Company&#8217;s Series A, Series B and Series B-1 redeemable convertible preferred stock converted into common stock upon the completion of the Company&#8217;s IPO in 2020 and the rights, preferences, and terms are no longer applicable</ix:continuation>.</span></div><div id="i92757ae30a234940aa4371e66352259c_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfMjQwMQ_454e3c54-4f0e-4ebe-84b3-f0518d3815af" continuedAt="i6ba3c6eb1dbc4f9b952c610dc806efb7" escape="true">Collaboration Agreement - Related Party</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ba3c6eb1dbc4f9b952c610dc806efb7">The Company recognized revenue for the allocated up-front payments using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company used actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. In August 2017, the Company entered into a Collaboration Agreement with Takeda related to the development of certain ARC molecules, as amended in April 2018, October 2018 and March 2020 (the &#8220;Collaboration Agreement&#8221;). The Collaboration Agreement was mutually terminated pursuant to a termination agreement dated November 8, 2021 (the &#8220;Termination Agreement&#8221;). Under the terms of the Termination Agreement, the Company is not required to satisfy any remaining performance obligations, the Company will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. The remaining deferred revenue was recognized as revenue in the fourth quarter of 2021. The Company received cash of $<ix:nonFraction unitRef="usd" contextRef="i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfODM0_66a2bc1f-dc61-4d16-897b-0945de90f02a">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia94f371b06b64697b125dc4b3ab1f16a_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfODQx_1ec4797e-8445-40aa-a772-dceef84407cb">14.0</ix:nonFraction> million in the years ended December 31, 2021 and 2020, respectively, and recognized total revenue of $<ix:nonFraction unitRef="usd" contextRef="i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfOTQ1_6ba98a27-073d-4148-84f5-454b0edaad82">82.0</ix:nonFraction> million through December&#160;31, 2021 under the Collaboration Agreement.</ix:continuation></span></div><div id="i92757ae30a234940aa4371e66352259c_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNA_f8ca83db-1eac-42f7-a78d-847b68bb8946" continuedAt="i2ffd3af8611b42aebad3a6903bacf50b" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i2ffd3af8611b42aebad3a6903bacf50b" continuedAt="i947f8d228b9e4efca917f12782f2c80f"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to <ix:nonFraction unitRef="number" contextRef="i83fa63cc109d410793fee3147230e084_I20200930" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTAyOA_198c385d-e15e-4290-8e28-184958dcc123">4</ix:nonFraction>% of the Company&#8217;s outstanding common shares on December 31st of the preceding calendar year. The Board of Directors may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i1717f2eaa0f544379a47d6697e8ce5e2_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzOTAyMw_4733cdd1-2839-440c-a48b-24b6d2e02e82">3,912,408</ix:nonFraction> shares available for future grants under the 2020 Plan and on January 1, 2022, the share reserve automatically increased by <ix:nonFraction unitRef="shares" contextRef="ibfaa1273d97b46978197a4b2f339b0ec_D20220101-20220101" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzI5ODUzNDg5NDEwOA_2c049f7b-6287-44cd-8ce8-8f4efa412bd4">1,693,555</ix:nonFraction> shares. The 2020 Plan permits the granting of options and restricted stock. The terms of the agreements under the 2020 Plan are determined by the Company&#8217;s Board of Directors. The Company&#8217;s awards vest based on the terms in the agreements and generally vest over <ix:nonNumeric contextRef="ifa51a2a2b1c84fdfa550195209974723_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNjcw_b1d8dfc0-aabf-4666-8dc6-52eef85bcb23">four years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="ifa51a2a2b1c84fdfa550195209974723_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNjky_b6673646-e545-453d-a413-cd3ba71bd898">10</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) became effective in connection with the Company&#8217;s IPO. A total of <ix:nonFraction unitRef="shares" contextRef="i8842228fdf1940c7b1002d140baf64ed_I20201014" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA1OA_99c718c7-1182-41bd-b775-0c7b0e3b47c0">395,795</ix:nonFraction> shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at <ix:nonFraction unitRef="number" contextRef="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA3MA_998788b3-5aba-4671-9643-f2aad9e344e5">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing <ix:nonFraction unitRef="number" contextRef="i8842228fdf1940c7b1002d140baf64ed_I20201014" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA5MQ_da0571d0-c283-4bcd-a454-b9e257a3d845">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction unitRef="usd" contextRef="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014" decimals="-3" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA3NQ_afdb0bc3-9ad1-438d-a821-6f7a7771bcf0">25,000</ix:nonFraction> of stock during any calendar year or more than <ix:nonFraction unitRef="shares" contextRef="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA5Ng_1c280f2c-ba22-4b8c-8275-4e16c4c9fe48">600</ix:nonFraction> shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for <ix:nonNumeric contextRef="ibd7daecd893b478db292941cdfb8d361_D20210101-20210101" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTE1MA_d620ef57-f234-4776-9ae8-19cf1f0a99be">ten years</ix:nonNumeric>, commencing on January 1, 2021, in an amount equal to <ix:nonFraction unitRef="number" contextRef="i8842228fdf1940c7b1002d140baf64ed_I20201014" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA4Nw_c7e947d1-d9bb-4bbd-b43f-6bf028714cd6">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. As of December&#160;31, 2021 there were <ix:nonFraction unitRef="shares" contextRef="iaf6c1f46b13448baa40f5da3fc4f9b3a_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzOTQ2NA_e97b563c-485e-47e3-9c52-be4df20d50d6">393,689</ix:nonFraction> shares available for future purchases and on January 1, 2022, the share reserve automatically increased by <ix:nonFraction unitRef="shares" contextRef="i913ac2af34fd4ec98af9b2bb3e0c81da_D20220101-20220101" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzI5ODUzNDg5NDExOQ_5a98449f-06e2-46f3-9843-54ee5a207433">423,388</ix:nonFraction> shares. Under the 2020 ESPP, the Company issued <ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTExOA_43efc6ee-f8df-47b2-bc35-e7104d3df6d9">2,106</ix:nonFraction> shares of common stock for aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTEwNA_29462bb4-0ef8-476f-98f1-b7b91ed4367e">0.1</ix:nonFraction>&#160;million during the year ended December&#160;31, 2021. There were <ix:nonFraction unitRef="shares" contextRef="i285a21f9461d4185ba105fc77795dd4e_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTEyNw_f99ca7df-19ac-4a95-acf3-a27a5f17e4a9">no</ix:nonFraction> shares of common stock issued during the year ended December 31, 2020.</span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNQ_623d2835-049d-4a5c-bf9a-a84b86293c2a" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1cbb318d64475ea98211bc07f51f73_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMi0xLTEtMS0w_7ab4cf12-0e19-4870-98dc-b43031ecb1a0">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81735796faf4a8a9e36cbc592eb5f3d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMi0zLTEtMS0w_82df9ce3-1f79-413d-befd-2db64fcfd508">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978d55b8117440bcb06be5d1eba9a7db_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMy0xLTEtMS0w_e5426298-1a10-4f68-8fae-47cab65129da">3,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a0ec0b83ac44b2a0e7939e7f49c2e8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMy0zLTEtMS0w_f90c9577-b374-4a61-805f-efcbb3f9abd9">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfNC0xLTEtMS0w_68134111-aef3-430b-89be-29ae1c7275c5">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfNC0zLTEtMS0w_a577cde6-8a04-4872-bc6b-fb7619e4914b">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="i947f8d228b9e4efca917f12782f2c80f" continuedAt="i8845286a1c87470c99cdc6fe54afd7d5"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNg_7bb24ac8-b18c-4393-8656-d272a75ee421" escape="true"><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan and the 2016 Stock Incentive Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMS0xLTEtMS0w_d1942458-2879-441c-9e27-ba9577c5fedf">2,742,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMS0zLTEtMS0w_2a9af510-19fd-4885-b897-cd627c5af17e">7.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMS01LTEtMS0w_303c082d-17e3-454e-bdf5-09e9a72ce66b">8.82</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMi0xLTEtMS0w_109468c5-7368-4aa5-99ae-95845664823c">325,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMi0zLTEtMS0w_24b4482e-04c1-4a20-bf91-3cd3226f628d">23.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMy0xLTEtMS0w_e7b50c8f-419c-4847-b3b6-e780560acb7c">557,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMy0zLTEtMS0w_12f5b4bb-8cf1-4a1e-b38e-b505f8b53db1">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNC0xLTEtMS0w_f1045c1f-5a79-48bc-921b-60677aa880e5">61,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNC0zLTEtMS0w_9e20c7e1-e3f3-4389-adcd-669ef39cc3ee">12.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNS0xLTEtMS0w_db3ac5fa-8286-47db-82f2-32c65945c534">2,448,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNS0zLTEtMS0w_cbe3b997-63b6-42db-b2d7-cb90b90e9fdc">10.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNS01LTEtMS0w_e6306c6d-b0ea-4a8d-af61-b1d4cd396859">8.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNi0xLTEtMS0w_06b82025-00d8-4d31-8a03-9794317a08f2">2,418,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNi0zLTEtMS0w_25930cae-4522-488b-8d19-423341bf7644">10.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNi01LTEtMS0w_0b26da85-d6e1-48fc-869c-60b8e83af190">8.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNy0xLTEtMS0w_4ea51021-5a44-4d67-918d-bb8cdd3eba9f">1,259,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNy0zLTEtMS0w_39b2e20c-2651-45e8-8105-82a2b7633400">6.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNy01LTEtMS0w_125b5230-23d3-44fe-9702-13956f585a8d">7.55</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the years ended December&#160;31, 2021 and 2020 had weighted-average grant-date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5NA_f64f5b24-6e8b-41db-ad3f-88187121736e">16.38</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzMTc1Mw_5bcad1af-a1ae-4788-9fc7-977851423a7a">8.93</ix:nonFraction> per share, respectively. As of December&#160;31, 2021, the unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTE3OA_1b2df4e4-4318-4f10-bce8-d42e4aa81c72">11.4</ix:nonFraction> million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="i6dd78bd931e046948447da6b4292615e_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTI2Mg_718bdedf-28d9-47d9-8dcb-8b99c80fba06">2.48</ix:nonNumeric> years. The aggregate intrinsic value of options exercised as of December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTM0NQ_29dfe12f-e6a4-420a-bb3a-c0bb32959d2c">10.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzMTc1OA_975099db-bc9d-4aa3-82a3-24054caa6611">49.7</ix:nonFraction> million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTQ1Mg_4f4736e3-d5f7-4494-bf54-18f15ff6ba1e"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTQ1Mg_fad1eec9-83ac-4b59-b40c-88f2fc0a3c55">5.9</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i6dd78bd931e046948447da6b4292615e_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMjYzOQ_82f77bb5-c190-44f3-bc8f-e6eb7fb4d654">0</ix:nonFraction>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, its Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNw_ce253642-ce14-4bf4-98d0-67efce8855b1" continuedAt="ifcb859032baf44c28b0cd62881517304" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options granted under the Company&#8217;s 2020 Plan were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"></td><td style="width:43.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMi0xLTEtMS0w_cc595adf-00e4-4e2f-8082-b4129e54a005">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMi0zLTEtMS0w_808f38db-3998-48da-9925-ec79ec5fefc2">5.94</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMy0xLTEtMS0w_1daad8e4-c4cf-4407-bb54-167d484467c1">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMy0zLTEtMS0w_d896405b-1e57-4669-9a1f-c3ac19f9f302">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNC0xLTEtMS0w_e8e3bb8b-a1a9-4ccd-8a71-e1ecab9c0e41">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNC0zLTEtMS0w_972b4836-a182-4583-b93d-28ae27cc354b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNS0xLTEtMS0w_c74172c6-d3db-40bf-b9d1-5d2f54f9ecc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNS0zLTEtMS0w_7f733cfc-ca68-4d26-b47a-6294416bd6ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted shares are considered the issuance of share-based payments as opposed to the sale of stock and as such, the Company has recognized compensation expense for these awards based on the fair value of the award on the date of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="i8845286a1c87470c99cdc6fe54afd7d5"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzMw_d3716628-3760-4580-8193-a9f2cb46b146" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to these shares:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76d2b249a41e4985a2641c447e8e27d7_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjg0OTk2MmVkYzA2YjQ4MGRiNDZlMTFkYmIxNzdkOTcxL3RhYmxlcmFuZ2U6ODQ5OTYyZWRjMDZiNDgwZGI0NmUxMWRiYjE3N2Q5NzFfMS0xLTEtMS0w_bf522af5-7dd8-4f47-bb51-dfc3fdd21bc3">11,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1853d269d625472aa52bdf974466c9d8_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjg0OTk2MmVkYzA2YjQ4MGRiNDZlMTFkYmIxNzdkOTcxL3RhYmxlcmFuZ2U6ODQ5OTYyZWRjMDZiNDgwZGI0NmUxMWRiYjE3N2Q5NzFfMi0xLTEtMS0w_dfe6bd1e-c764-4fc5-898b-413f9b405e95">11,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43ef9bb233dc4b89a2c5f083ab045bbf_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjg0OTk2MmVkYzA2YjQ4MGRiNDZlMTFkYmIxNzdkOTcxL3RhYmxlcmFuZ2U6ODQ5OTYyZWRjMDZiNDgwZGI0NmUxMWRiYjE3N2Q5NzFfMy0xLTEtMS0w_eecf3e38-4c21-44b3-b08b-6d83186e1a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="ifcb859032baf44c28b0cd62881517304"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued under the Company&#8217;s 2020 ESPP were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"></td><td style="width:43.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMi0xLTEtMS0yMDM3OA_9bb090ea-5a13-4697-9e61-9988845d7ec8">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMi0zLTEtMS0yMDM4Mg_4419fbaa-80ce-44cf-9715-de1f825449df">0.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMy0xLTEtMS0yMDM3OA_d3dbdc17-039b-457a-8716-783be73cac99">81.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMy0zLTEtMS0yMDM4Mg_6b63a96a-1510-4a49-b583-ccc18eb60e00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNC0xLTEtMS0yMDM3OA_f3d08896-36fc-4421-8d32-da7a485e6db6">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNC0zLTEtMS0yMDM4Mg_0774495e-ee8a-4a41-b701-89dde307308d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNS0xLTEtMS0yMDM3OA_1d61d9c9-c51a-4d73-bdbd-96f9f0a49710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNS0zLTEtMS0yMDM4Mg_8ba96cd8-f12f-4456-96c9-6e8baaa26758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="i92757ae30a234940aa4371e66352259c_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjc5OQ_77d5d709-96e7-42c0-ae9a-beada8adb744" continuedAt="i3f19a45e705c42fbb6ee0ebf780cd9e8" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24pt"><ix:continuation id="i3f19a45e705c42fbb6ee0ebf780cd9e8" continuedAt="ide0d232393e1441a988e60da84916af3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded no federal provision for income taxes as of December&#160;31, 2021 and 2020 due to reported net losses since inception. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjgwMA_eb6b5ca6-f587-4c75-a7f1-e1f5d1467bde" continuedAt="i4292c574a27244b0bebf129a9270e988" escape="true">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows for the years ended December&#160;31, 2021 and 2020 (amounts in thousands):</ix:nonNumeric></span><ix:continuation id="i4292c574a27244b0bebf129a9270e988"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMi0xLTEtMS0w_5895adb5-1d52-4b4e-aa6e-920b3c9ad53a">9,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMi0zLTEtMS0w_aaa7ed02-8a9d-41fe-b79d-0be4021d84ee">7,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNC0xLTEtMS0w_a1531a08-c9ae-4419-8487-626ccb7b2995">13,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNC0zLTEtMS0w_0b4295d3-4285-44e1-8f06-8582d4b5cd05">8,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNS0xLTEtMS0w_dffd62cf-f9ee-484f-9cab-90b26858548e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" sign="-" name="sttk:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNS0zLTEtMS0w_b8b89229-f448-4272-9860-a606b348d87c">745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNi0xLTEtMS0w_790fbd8a-0e0a-4da8-9e30-35bcaa294e9b">3,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNi0zLTEtMS0w_a4cc159f-30c7-4251-9f39-0525a90ae34f">1,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNy0xLTEtMS0w_33a89de0-9034-4665-bca9-cb8d9e7d8744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNy0zLTEtMS0w_a8364266-d535-44e8-aab3-4cd137660db3">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0xLTEtMS0yMDc0NA_a491d661-62ea-4e13-ae8e-18817fb63a74">1,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0zLTEtMS0yMDczOA_77f6d7f8-1ef0-4f6b-8300-3b124848ddef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0xLTEtMS0yMDc0NA_88581f59-f9d8-42ba-89bd-0170b6b44981">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0zLTEtMS0yMDczOA_2d86dce4-0b0e-4d1c-99cd-d8db55d1c6e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0xLTEtMS0w_68bc1544-bef8-48b0-b80b-3f92263c1266">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0zLTEtMS0w_223f6a1d-62b2-41d4-8654-e0e48c05c55b">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0xLTEtMS0w_9f24706e-3c55-49b9-9591-108b04192c34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0zLTEtMS0w_140edf0b-b55f-44d4-b2a5-655c82420cd3">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMTAtMS0xLTEtMA_b46a7575-ce1b-499e-bf76-aed63684ec34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMTAtMy0xLTEtMA_f914249e-e226-4c03-9217-96b6637773dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="ide0d232393e1441a988e60da84916af3"><div style="margin-top:6pt;text-indent:27pt"><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjgwMQ_ee26788b-5333-43e2-83ca-657139be9006" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are as follows (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMy0xLTEtMS0w_5f848a78-0f08-48dc-8a22-cacc2f466e9d">20,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMy0zLTEtMS0w_f58a90ae-86b7-418f-810a-652c4954b63b">9,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNC0xLTEtMS0w_fb8858f1-8776-4564-a7bc-2d94644cef08">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNC0zLTEtMS0w_4ea23b5f-e908-4ade-80a3-874db2455b1a">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNS0xLTEtMS0w_59b2e81b-f26a-49cb-b6df-bf310d461cf1">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNS0zLTEtMS0w_720288e3-3bc6-47bd-ac4d-f15ee6754463">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNi0xLTEtMS0w_10ac4e28-900e-498f-921c-66dfbe310ff0">6,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNi0zLTEtMS0w_2cda3a25-6e34-4725-88dd-d432b2a8d912">3,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNy0xLTEtMS0w_f71de687-5099-4e6f-8075-efa113b86e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNy0zLTEtMS0w_f1ad8e67-96e3-4731-a937-7999f20b99a5">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOC0xLTEtMS0w_32f99dc2-967c-4600-841a-c6df17eef71b">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOC0zLTEtMS0w_a1cd9d88-9cf1-4d1a-8164-856dcb59a65b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOS0xLTEtMS0w_87c775f7-ce9e-49b7-ab91-3bbf9e5dfec1">31,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOS0zLTEtMS0w_68beb275-1ae5-43ec-bd8e-b8f8f5b6ab7a">17,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTAtMS0xLTEtMA_e3bf9c0c-822b-4596-a9db-47d5458428f0">30,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTAtMy0xLTEtMA_053eb2ef-17ce-4b98-9d50-449912506866">17,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTEtMS0xLTEtMA_78dd4297-0a4c-4522-9969-b8b6ce2cfa02">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTEtMy0xLTEtMA_62203f8e-2d61-48ac-a153-e71e358c3fa4">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTMtMS0xLTEtMA_2cfe9611-1411-4066-9908-f6ba6094ba4a">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTMtMy0xLTEtMA_5565ffd6-4853-462c-bb67-e736f34f6e79">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTQtMS0xLTEtMA_9d21785b-714f-42cf-8b7c-b92d22a00cf1">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTQtMy0xLTEtMA_74127211-8072-4cb3-9e5b-18bd48883ad0">378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTUtMS0xLTEtMA_b568da48-99e4-46f2-a015-7453e8001e33">1,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTUtMy0xLTEtMA_f6f83f2f-e37b-4e21-bbac-5b86330a81dc">499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTYtMS0xLTEtMA_796f4e92-def1-40af-821e-93356b54027b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTYtMy0xLTEtMA_45676308-f326-44f9-9c21-620fe92771ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfNzQ5_21dce1ea-b499-44b1-80e3-c117325ba8a4">13.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfNzU2_22c1c2ec-8a0a-4096-8996-9b884406df8d">8.7</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively, primarily due to continuing loss from operations, general business credit carryforwards, and accrued expenses.</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had gross U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="idfb12636928d4d21b00a09885bc9f550_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTAwNw_e20f39dd-b101-4cfe-a129-e2f98a271210">97.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i592680b58da94f418a342d39beb4d6a9_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTAxNA_0885bb2c-0859-410b-b5b3-49b06fe6f297">47.1</ix:nonFraction> million, respectively. Additionally, as of December 31, 2021 and 2020, the Company had capital loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i1394695528d34d00a6380d9c1031687d_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTA5OTUxMTYzMTU4OQ_0454f1a5-5f3b-4214-ad71-352bcb632dd4">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56b14739a6c64b198bf3d0441927bd8c_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTA5OTUxMTYzMTU5Ng_626cf9fe-7869-4604-b69e-80ddb96f89c5">0.1</ix:nonFraction> million, respectively. As of December&#160;31, 2021 and 2020, the Company had gross state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i3e068c367ec34e2ab303dcd0a6d4da40_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTExNA_b0169653-8bcd-4408-a606-ef0b36be1a59">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e4714dd5ac54741bc7b7aa1ad1ce320_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTA5OTUxMTYzMDYzNw_e6ece89b-a775-4f9a-8715-edae1484acf5">0.2</ix:nonFraction> million, respectively. As of December&#160;31, 2021 and 2020, the Company had gross U.S. tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="idfb12636928d4d21b00a09885bc9f550_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTE5Mg_ebfe3f5d-650e-4e67-8453-ce53ad0ce357">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i592680b58da94f418a342d39beb4d6a9_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTE5OQ_aa06b8bc-8353-4f9e-9095-63f8e96310fc">4.5</ix:nonFraction> million, respectively. The NOL, capital loss, and tax credit carryforwards will begin to expire in 2036, if not utilized. The NOL, capital loss, and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or credit carryforwards are utilized.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2019 financial statements were filed, the Company completed a Section 382 study from formation through October 14, 2020. Although an ownership change occurred during 2020, no deferred tax assets were impacted by the limitation. </span></div><ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjgwMg_a00381f1-781c-4662-803d-f44f762444d1" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of our liability for unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:65.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMi0xLTEtMS0w_25189aee-dc22-404d-a510-dca8bf200910">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e6543ccfb74775ac5df4a5733524f6_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMi0zLTEtMS0w_745a4072-35b5-4586-be98-800923647a14">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMy0xLTEtMS0w_1273daee-d359-46bd-8a75-ee541b7395d5">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMy0zLTEtMS0w_8475bf9d-8b5c-4ed4-9bea-ed3ebca209aa">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNC0xLTEtMS0yMDg2Nw_99f7660f-726a-47d7-b324-c6ac5daa9acb">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNC0zLTEtMS0yMDg3OQ_0e102bfe-a916-4934-811f-4d7df9f8d35a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNS0xLTEtMS0w_d3318950-d2f5-414c-b2c2-6bf858259d8b">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNS0zLTEtMS0w_88db76b9-5798-405b-b5ce-32d53efb193c">783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s gross unrecognized tax benefits, if recognized, would affect its effective tax rate. The Company does not expect unrecognized tax benefits to decrease within the next twelve months due to the lapse of statute limitations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December 31, 2021, the Company has not accrued any interest or penalties related to unrecognized tax benefits.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2018, 2019, and 2020 tax years. There are currently no federal or state income tax audits in progress.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_103"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMDMvZnJhZzoyZmY0ZjFmZTFmOWI0ZWFmYWQ4ZDZhNTVlY2FkNzAyMS90ZXh0cmVnaW9uOjJmZjRmMWZlMWY5YjRlYWZhZDhkNmE1NWVjYWQ3MDIxXzkxMg_b16b3f11-fd6d-4e7d-872c-116714aec1cc" continuedAt="i6382cce336fd4995b0fe78f2afe0beae" escape="true">Related Party</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6382cce336fd4995b0fe78f2afe0beae">As of December 31, 2020, Takeda held an approximate <ix:nonFraction unitRef="number" contextRef="ic68499c9c9c54c7ca37c93a1819e89f8_I20201231" decimals="3" name="sttk:ShareholderOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMDMvZnJhZzoyZmY0ZjFmZTFmOWI0ZWFmYWQ4ZDZhNTVlY2FkNzAyMS90ZXh0cmVnaW9uOjJmZjRmMWZlMWY5YjRlYWZhZDhkNmE1NWVjYWQ3MDIxXzU0OTc1NTgxNDIzNzg_6ee82e6d-bbc8-4ae1-a1e8-b23b85e4699f">5.0</ix:nonFraction>% ownership interest in the Company&#8217;s outstanding shares. Considering the resignation of the Takeda director and percent ownership of the Company&#8217;s common stock as of December 31, 2020, the Company no longer considers Takeda a related party.</ix:continuation></span></div><div id="i92757ae30a234940aa4371e66352259c_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMDYvZnJhZzo2OTY5NjdmNTk1YTU0MjhjODEwZDhkMTI5NjQ0YmQ5Zi90ZXh0cmVnaW9uOjY5Njk2N2Y1OTVhNTQyOGM4MTBkOGQxMjk2NDRiZDlmXzU5NA_b22d6e61-a105-4509-9fd1-19b2567c3f95" continuedAt="i78b4062165124c2c9d73899a4752786b" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i78b4062165124c2c9d73899a4752786b">None.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79   </span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i92757ae30a234940aa4371e66352259c_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of December&#160;31, 2021, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of Registered Public Accounting Firm </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm. For as long as we remain an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, we intend to take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during fourth quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i92757ae30a234940aa4371e66352259c_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i92757ae30a234940aa4371e66352259c_551"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i92757ae30a234940aa4371e66352259c_118"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III.</span></div><div id="i92757ae30a234940aa4371e66352259c_121"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, including under the heading &#8220;Directors, Executive Officers, and Corporate Governance.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar functions. A copy of the code is available on our website located at&#8239;ir.shattucklabs.com, under &#8220;Governance.&#8221;&#8239;We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days following the date of the amendment or waiver. </span></div><div id="i92757ae30a234940aa4371e66352259c_124"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, including under the headings &#8220;Executive Compensation&#8221; and &#8220;Directors, Executive Officers and Corporate Governance.&#8221;</span></div><div id="i92757ae30a234940aa4371e66352259c_127"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, including under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive Compensation-Securities Authorized for Issuance Under Equity Compensation Plans.&#8221;</span></div><div id="i92757ae30a234940aa4371e66352259c_130"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, including under the headings &#8220;Directors, Executive Officers and Corporate Governance&#8221; and &#8220;Certain Relationships and Related Party Transactions.&#8221;</span></div><div id="i92757ae30a234940aa4371e66352259c_133"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, including under the heading &#8220;Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm.&#8221; Our independent registered public accounting firm is KPMG LLP, Austin, TX PCAOB ID:<ix:nonNumeric contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMzMvZnJhZzpkZDgzOWZjN2MwYTc0MzNlYmUwNDA1NTE5MjA3ZjQ2MS90ZXh0cmVnaW9uOmRkODM5ZmM3YzBhNzQzM2ViZTA0MDU1MTkyMDdmNDYxXzEwOTk1MTE2MzQxNTU_72c3db57-e321-47a1-9568-59a9d49d31dd">185</ix:nonNumeric>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV.</span></div><div id="i92757ae30a234940aa4371e66352259c_139"></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Financial Statements.</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Consolidated Financial Statements at Part II, Item 8 &#8220;Financial Statements &#8211; Audited Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No financial statement schedules are provided because the information called for is not required or is shown in the financial statements or the notes thereto.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Exhibits.</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K:</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description of Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex31.htm">Amended and Restated Certificate of Incorporation of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex32.htm">Amended and Restated Bylaws of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">Form of common stock certificate of the Company (incorporated by reference from Exhibit 4.1 of the Company&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, dated as of June 12, 2020, by and among Shattuck Labs, Inc. and certain of its stockholders (incorporated by reference from Exhibit 4.2 of the Company&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/a43-descriptionofsecurities.htm">Description of Securities</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/a43-descriptionofsecurities.htm"> (incorporated by reference from Exhibit 4.3 of the Company&#8217;s Annual Report on Form 10-K filed on March 16, 2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex101.htm">Form of Indemnification Agreement for directors and executive officers (incorporated by reference from Exhibit 10.1 of the Company&#8217;s Amendment No. 1 to Registration Statement on Form S-1 filed on October 5, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex104.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Taylor Schreiber (incorporated by reference from Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex105.htm">Amendment No. 1 to Employment Agreement, dated March 27, 2020, by and between Shattuck Labs, Inc. and Taylor Schreiber (incorporated by reference from Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment2totaylorschreibe.htm">Amendment No. 2 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Taylor Schreiber (incorporated by reference from Exhibit 10.6 of Shattuck&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex106.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Arundathy Nirmalini Pandite (incorporated by reference from Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1tolinipanditeemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Arundathy Nirmalini Pandite</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1tolinipanditeemp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1tolinipanditeemp.htm">(incorporated by reference from Exhibit 10.8 of Shattuck&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex107.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Erin Ator Thomson (incorporated by reference from Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1toerinthomsonemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Erin Ator Thomson</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1toerinthomsonemp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1toerinthomsonemp.htm">(incorporated by reference from Exhibit 10.10 of Shattuck&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex108.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Andrew R. Neill (incorporated by reference from Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1toandrewneillemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Andrew R. Neill</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1toandrewneillemp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1toandrewneillemp.htm">(incorporated by reference from Exhibit 10.12 of Shattuck&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/casideyoungemploymentagree.htm">Employment Agreement, dated December 9, 2019, by and between Shattuck Labs, Inc. and Casi DeYoung</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/casideyoungemploymentagree.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/casideyoungemploymentagree.htm">(incorporated by reference from Exhibit 10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/casideyoungemploymentagree.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/casideyoungemploymentagree.htm"> of Shattuck&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1tocasideyoungemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Casi DeYoung</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1tocasideyoungemp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/amendment1tocasideyoungemp.htm">(incorporated by reference from Exhibit 10.14 of Shattuck&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.15+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex109.htm">2020 Equity Incentive Plan (incorporated by reference from Exhibit 10.9 of the Company&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.16+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1010.htm">2020 Employee Stock Purchase Plan (incorporated by reference from Exhibit 10.10 of the Company&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.17+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1011.htm">Non-Employee Director Compensation Policy (incorporated by reference from Exhibit 10.11 of the Company&#8217;s Amendment No. 1 to Registration Statement on Form S-1 filed on October 5, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex1012.htm">Exclusive License Agreement, dated June 3, 2016, by and between Shattuck Labs, Inc. and Heat Biologics, Inc., as amended (incorporated by reference from Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex1013.htm">Lease Agreement, dated April 17, 2018, between Shattuck Labs, Inc. and Parmer RTP, LLC, as amended (incorporated by reference from Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001680367/000168036721000008/officeleaseagreement-shatt.htm">Lease Agreement, dated January 8, 2021, between Shattuck Labs, Inc. and International Bank of Commerce, Laredo, Texas.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.22&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex1014.htm">Master Services Agreement, dated March 31, 2017, between Shattuck Labs, Inc. and KBI Biopharma, Inc. (incorporated by reference from Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000057/terminationagreement-ex101.htm">Takeda Termination Agreement (incorporated by reference from Exhibit 10.1 of Shattuck&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2022 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ye2021consent.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sub-certxsection302xceo202.htm">Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sub-certxsection302xarn202.htm">Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sub-certxsection906ofthesa.htm">Certification of the principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Definition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, formatted in Inline XBRL (included in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">__________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*            Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+            Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;            Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#            The certifications on Exhibit 32 hereto are deemed not &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div id="i92757ae30a234940aa4371e66352259c_142"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i92757ae30a234940aa4371e66352259c_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, on this 15th day of March 2022.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shattuck Labs, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 15, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dr. Taylor Schreiber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Taylor Schreiber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 15, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Andrew R. Neill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew R. Neill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates set forth opposite their names.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.348%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Taylor Schreiber</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Taylor Schreiber</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Andrew R. Neill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Andrew R. Neill</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial and accounting officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. George Golumbeski</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;George Golumbeski</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Helen M. Boudreau</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Helen M. Boudreau</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Neil Gibson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Neil Gibson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Carrie Brownstein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Carrie Brownstein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michael Lee</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Lee</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Tyler Brous</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tyler Brous</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ye2021consent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i96a7ebaa774344b39365fd31f365b0b4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statement (Nos. 333-249555 and 333-254340) on Form S-8 of our report dated March 15, 2022, with respect to the balance sheets of Shattuck Labs, Inc. as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes, which report appears in the December 31, 2021 annual report on Form 10-K of Shattuck Labs, Inc.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austin, Texas</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 15, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sub-certxsection302xceo202.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i69263686dc6846428c2c1fc14de0a407_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:194%">Exhibit 31.1</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Taylor Schreiber, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Annual Report on Form&#160;10-K of Shattuck Labs, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 15, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Dr.&#160;Taylor Schreiber</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%">Chief Executive Officer</font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sub-certxsection302xarn202.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i932ae4e3b1a2439e883c4c65073f49ef_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:194%">Exhibit 31.2</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Andrew R. Neill, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:3.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Annual Report on Form&#160;10-K of Shattuck Labs, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:62.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.729%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 15, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Andrew R. Neill</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:121%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">(principal financial and accounting officer)</font></div></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1#
<SEQUENCE>5
<FILENAME>sub-certxsection906ofthesa.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i830fe7bd4217423daccdf0dcbe0faf88_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:194%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Shattuck Labs, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:35.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.162%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 15, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chief Executive Officer</font></div><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">(principal executive officer)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 15, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Financial Officer</font></div><div style="margin-top:2.65pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">(principal financial and accounting officer)</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Note&#58; A signed original of this written statement required by &#167;906 has been provided to Shattuck Labs, Inc. and will be retained by Shattuck Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sttk-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cbc5e4f4-a5cf-4cd7-9e77-2f3acab88ac0,g:c886f0b9-fa14-42f2-91e7-6b4a395bcd32-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sttk="http://www.shattucklabs.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.shattucklabs.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://www.shattucklabs.com/role/COVER">
        <link:definition>0001001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.shattucklabs.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETS" roleURI="http://www.shattucklabs.com/role/BALANCESHEETS">
        <link:definition>1001003 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETSParenthetical" roleURI="http://www.shattucklabs.com/role/BALANCESHEETSParenthetical">
        <link:definition>1002004 - Statement - BALANCE SHEETS - Parenthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004006 - Statement - STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCASHFLOWS" roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS">
        <link:definition>1005007 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestments" roleURI="http://www.shattucklabs.com/role/ShortTermInvestments">
        <link:definition>2109103 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsTables" roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsTables">
        <link:definition>2310302 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails">
        <link:definition>2411405 - Disclosure - Short-Term Investments - Schedule of available for sale short-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsNarrativeDetails" roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsNarrativeDetails">
        <link:definition>2412406 - Disclosure - Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.shattucklabs.com/role/PropertyandEquipment">
        <link:definition>2113104 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentTables">
        <link:definition>2314303 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofpropertyandequipmentDetails" roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails">
        <link:definition>2415407 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2416408 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.shattucklabs.com/role/AccruedExpenses">
        <link:definition>2117105 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.shattucklabs.com/role/AccruedExpensesTables">
        <link:definition>2318304 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofaccruedexpensesDetails" roleURI="http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails">
        <link:definition>2419409 - Disclosure - Accrued Expenses - Schedule of accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesTables">
        <link:definition>2321305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails">
        <link:definition>2422410 - Disclosure - Commitments and Contingencies - Schedule of minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStock" roleURI="http://www.shattucklabs.com/role/PreferredStock">
        <link:definition>2124107 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStockDetails" roleURI="http://www.shattucklabs.com/role/PreferredStockDetails">
        <link:definition>2425412 - Disclosure - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementRelatedParty" roleURI="http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty">
        <link:definition>2126108 - Disclosure - Collaboration Agreement - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementRelatedPartyDetails" roleURI="http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails">
        <link:definition>2427413 - Disclosure - Collaboration Agreement - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.shattucklabs.com/role/StockBasedCompensation">
        <link:definition>2128109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationTables">
        <link:definition>2329306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2430414 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails">
        <link:definition>2431415 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofoptionactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails">
        <link:definition>2432416 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails">
        <link:definition>2433417 - Disclosure - Stock-Based Compensation - Schedule of 2020 Plan valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails">
        <link:definition>2434418 - Disclosure - Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofrestrictedstockactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails">
        <link:definition>2435419 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.shattucklabs.com/role/IncomeTaxes">
        <link:definition>2136110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.shattucklabs.com/role/IncomeTaxesTables">
        <link:definition>2337307 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails">
        <link:definition>2438420 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails">
        <link:definition>2439421 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2440422 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails">
        <link:definition>2441423 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParty" roleURI="http://www.shattucklabs.com/role/RelatedParty">
        <link:definition>2142111 - Disclosure - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDetails" roleURI="http://www.shattucklabs.com/role/RelatedPartyDetails">
        <link:definition>2443424 - Disclosure - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.shattucklabs.com/role/SubsequentEvents">
        <link:definition>2144112 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_ShareholderOwnershipPercentage" abstract="false" name="ShareholderOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sttk_AccruedResearchAndDevelopmentContractCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentContractCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_LicenseAgreementRoyaltyPaymentsMaximum" abstract="false" name="LicenseAgreementRoyaltyPaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" abstract="false" name="TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_OperatingAccountMember" abstract="true" name="OperatingAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_IncreaseDecreaseInDeferredRentCredits" abstract="false" name="IncreaseDecreaseInDeferredRentCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sttk_SeriesB1PreferredStockMember" abstract="true" name="SeriesB1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>sttk-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cbc5e4f4-a5cf-4cd7-9e77-2f3acab88ac0,g:c886f0b9-fa14-42f2-91e7-6b4a395bcd32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="simple" xlink:href="sttk-20211231.xsd#BALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2cfc8cb3-3afd-4107-bf49-fba916db75b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_97136832-04c2-4f26-bb71-a2a900a08c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cfc8cb3-3afd-4107-bf49-fba916db75b4" xlink:to="loc_us-gaap_LiabilitiesCurrent_97136832-04c2-4f26-bb71-a2a900a08c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_00483c65-7d6e-4234-8d41-fe6980a40089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cfc8cb3-3afd-4107-bf49-fba916db75b4" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_00483c65-7d6e-4234-8d41-fe6980a40089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_50635328-ad42-4348-a171-121c7168b44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cfc8cb3-3afd-4107-bf49-fba916db75b4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_50635328-ad42-4348-a171-121c7168b44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7858db41-3e52-4e62-94fc-238fb1f2a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b2ce1c8b-b7b7-4067-9765-99fbb9f09137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7858db41-3e52-4e62-94fc-238fb1f2a77d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b2ce1c8b-b7b7-4067-9765-99fbb9f09137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b97a4aa-c435-4ea1-b5c5-f3485ce6651f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7858db41-3e52-4e62-94fc-238fb1f2a77d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b97a4aa-c435-4ea1-b5c5-f3485ce6651f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d82e6abc-a6e0-4a82-adfa-ff6ecca62547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7858db41-3e52-4e62-94fc-238fb1f2a77d" xlink:to="loc_us-gaap_AssetsCurrent_d82e6abc-a6e0-4a82-adfa-ff6ecca62547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d235c7c1-c7ed-408c-bda8-399cd347cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_773e3291-5e45-4b36-bfb5-d14d9cf47f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d235c7c1-c7ed-408c-bda8-399cd347cff5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_773e3291-5e45-4b36-bfb5-d14d9cf47f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5d33c908-7e5f-435c-ac0b-c63109e556b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d235c7c1-c7ed-408c-bda8-399cd347cff5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5d33c908-7e5f-435c-ac0b-c63109e556b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_10def179-2a7d-4ef0-a162-1c047e50ce0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d235c7c1-c7ed-408c-bda8-399cd347cff5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_10def179-2a7d-4ef0-a162-1c047e50ce0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cd78822d-37d2-44bd-8857-3380faea7f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d235c7c1-c7ed-408c-bda8-399cd347cff5" xlink:to="loc_us-gaap_CommonStockValue_cd78822d-37d2-44bd-8857-3380faea7f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_01db675d-8338-4718-9d41-ae6128bfc979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_364ce0e8-5d2a-414b-adbd-198f153ea435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_01db675d-8338-4718-9d41-ae6128bfc979" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_364ce0e8-5d2a-414b-adbd-198f153ea435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_539ed42a-500f-41c6-9687-6e0dd20031f6" xlink:href="sttk-20211231.xsd#sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_01db675d-8338-4718-9d41-ae6128bfc979" xlink:to="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_539ed42a-500f-41c6-9687-6e0dd20031f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ed6bdec6-2d15-41c5-8e1c-899e5f0ef0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_01db675d-8338-4718-9d41-ae6128bfc979" xlink:to="loc_us-gaap_AccountsPayableCurrent_ed6bdec6-2d15-41c5-8e1c-899e5f0ef0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f735f8b-d379-47b1-96c7-070be5657127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cfc12f66-72ac-49ed-a5ce-21934f547cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f735f8b-d379-47b1-96c7-070be5657127" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cfc12f66-72ac-49ed-a5ce-21934f547cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a3adbd37-115c-4c39-96a0-d5a9fc41c0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f735f8b-d379-47b1-96c7-070be5657127" xlink:to="loc_us-gaap_Liabilities_a3adbd37-115c-4c39-96a0-d5a9fc41c0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c356806-594b-4fc8-8d47-63d9ebf31d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f735f8b-d379-47b1-96c7-070be5657127" xlink:to="loc_us-gaap_StockholdersEquity_2c356806-594b-4fc8-8d47-63d9ebf31d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2d2aa878-68bb-4716-a586-5b169eb08437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_042a8e1a-36e6-422e-8c13-f9a0654339f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d2aa878-68bb-4716-a586-5b169eb08437" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_042a8e1a-36e6-422e-8c13-f9a0654339f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_388bf9eb-e862-4a5b-aa00-6a9dcc6fa014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d2aa878-68bb-4716-a586-5b169eb08437" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_388bf9eb-e862-4a5b-aa00-6a9dcc6fa014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6650d087-3930-4bcd-8873-f6a7a5f3d900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d2aa878-68bb-4716-a586-5b169eb08437" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6650d087-3930-4bcd-8873-f6a7a5f3d900" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0e25ae6c-644d-4993-a46c-da3760a5e297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_033503ea-3738-46c8-9f5f-860d3364f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0e25ae6c-644d-4993-a46c-da3760a5e297" xlink:to="loc_us-gaap_OperatingExpenses_033503ea-3738-46c8-9f5f-860d3364f6e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f337017-6a69-4bec-803e-9003e434ca9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0e25ae6c-644d-4993-a46c-da3760a5e297" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f337017-6a69-4bec-803e-9003e434ca9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f0243634-f5e5-4ae3-9c2a-4f5d1179cceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_88f423b9-d556-40af-a074-a67d4545504f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f0243634-f5e5-4ae3-9c2a-4f5d1179cceb" xlink:to="loc_us-gaap_InvestmentIncomeInterest_88f423b9-d556-40af-a074-a67d4545504f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c5b9a5ee-fa7e-4249-a184-8bbd132c5b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f0243634-f5e5-4ae3-9c2a-4f5d1179cceb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c5b9a5ee-fa7e-4249-a184-8bbd132c5b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7535438e-179a-4336-88e7-4e0986372ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3056d0ae-c6ac-41cd-9508-cfc8b12d7521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7535438e-179a-4336-88e7-4e0986372ef6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3056d0ae-c6ac-41cd-9508-cfc8b12d7521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_086d9e08-942b-4522-9118-8b99dbbddbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7535438e-179a-4336-88e7-4e0986372ef6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_086d9e08-942b-4522-9118-8b99dbbddbc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d081e57-c98f-4900-9026-33d0be258bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de376255-305c-43ba-8ec7-bf97da8a9219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d081e57-c98f-4900-9026-33d0be258bce" xlink:to="loc_us-gaap_NetIncomeLoss_de376255-305c-43ba-8ec7-bf97da8a9219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_643c597e-d772-4cff-83f6-7992bdc7513e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d081e57-c98f-4900-9026-33d0be258bce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_643c597e-d772-4cff-83f6-7992bdc7513e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4eb4d67c-aa82-4790-8c16-434fe350328b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_588161e8-a1cf-4322-9474-1912a9f1cdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4eb4d67c-aa82-4790-8c16-434fe350328b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_588161e8-a1cf-4322-9474-1912a9f1cdbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b190bb6-aec9-4d2f-9738-503ab8c14a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4eb4d67c-aa82-4790-8c16-434fe350328b" xlink:to="loc_us-gaap_OperatingIncomeLoss_2b190bb6-aec9-4d2f-9738-503ab8c14a3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_47ec8d1d-7cab-4c1e-9f0f-43952105d68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_591e9caa-d0a4-482c-90d6-0ba23f38ce35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_47ec8d1d-7cab-4c1e-9f0f-43952105d68e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_591e9caa-d0a4-482c-90d6-0ba23f38ce35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9a20d1e1-a60b-492a-9f65-46f3d9e3c9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_47ec8d1d-7cab-4c1e-9f0f-43952105d68e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9a20d1e1-a60b-492a-9f65-46f3d9e3c9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d4b199ef-64c3-4188-b3e5-dafe9ba9302f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_47ec8d1d-7cab-4c1e-9f0f-43952105d68e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d4b199ef-64c3-4188-b3e5-dafe9ba9302f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9f00b52b-783d-4a2e-a89f-ade39f1bf116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_ShareBasedCompensation_9f00b52b-783d-4a2e-a89f-ade39f1bf116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_92b63ba1-df05-4f41-afab-162e5532bc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_Depreciation_92b63ba1-df05-4f41-afab-162e5532bc1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ec649801-83d1-4ef0-8787-cad6411143de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ec649801-83d1-4ef0-8787-cad6411143de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a32c481-5c44-4fba-a402-b5e28a0c3245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a32c481-5c44-4fba-a402-b5e28a0c3245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInDeferredRentCredits_b1370e2f-2b1d-40a6-8652-10ee58a80885" xlink:href="sttk-20211231.xsd#sttk_IncreaseDecreaseInDeferredRentCredits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_sttk_IncreaseDecreaseInDeferredRentCredits_b1370e2f-2b1d-40a6-8652-10ee58a80885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e17fd126-1a34-43f2-b1c0-e95891e34c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e17fd126-1a34-43f2-b1c0-e95891e34c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8480229b-e22b-4d40-a022-1750dbce0c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_NetIncomeLoss_8480229b-e22b-4d40-a022-1750dbce0c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_418191cf-3dc5-48a2-bc8b-be5932a8b876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_418191cf-3dc5-48a2-bc8b-be5932a8b876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75e5b72c-920c-4afe-ad6f-2d26a43dc7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75e5b72c-920c-4afe-ad6f-2d26a43dc7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_15a609a4-3151-4628-999c-1d9b08bb1a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c487591-5d5b-48e7-b882-097204f05fba" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_15a609a4-3151-4628-999c-1d9b08bb1a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d5bdd8f-c1c8-433f-a982-1e5bfb634504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_a701d057-2439-407f-a176-ffadb527e117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d5bdd8f-c1c8-433f-a982-1e5bfb634504" xlink:to="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_a701d057-2439-407f-a176-ffadb527e117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_493f54ca-cade-42eb-82f1-143662080814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d5bdd8f-c1c8-433f-a982-1e5bfb634504" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_493f54ca-cade-42eb-82f1-143662080814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4fd0908f-fca2-47a2-a008-997a8c022017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d5bdd8f-c1c8-433f-a982-1e5bfb634504" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4fd0908f-fca2-47a2-a008-997a8c022017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_3a3c2548-911b-4ba7-b3ee-b6c9e9c7ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d5bdd8f-c1c8-433f-a982-1e5bfb634504" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_3a3c2548-911b-4ba7-b3ee-b6c9e9c7ac12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f457e0cc-0312-4e89-84a3-a4745957b9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72674e38-2ed3-4dd2-9633-5853a231be59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f457e0cc-0312-4e89-84a3-a4745957b9cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72674e38-2ed3-4dd2-9633-5853a231be59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1cb4424d-e551-4fcd-9e39-e5676ace4058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f457e0cc-0312-4e89-84a3-a4745957b9cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1cb4424d-e551-4fcd-9e39-e5676ace4058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa5462dd-f2f5-4d0c-8ed1-7aeea6762a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f457e0cc-0312-4e89-84a3-a4745957b9cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa5462dd-f2f5-4d0c-8ed1-7aeea6762a26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aebed144-5451-4fb5-9a4a-6069d42df7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e35ed2af-625d-4d05-98f0-f9a1a2f3fc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aebed144-5451-4fb5-9a4a-6069d42df7a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e35ed2af-625d-4d05-98f0-f9a1a2f3fc2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_6a356a45-7816-4c47-979c-c46788de4d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aebed144-5451-4fb5-9a4a-6069d42df7a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_6a356a45-7816-4c47-979c-c46788de4d3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#PropertyandEquipmentScheduleofpropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fae79765-f78b-4403-8293-45cc2d8bc62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7d3c3f9-50d2-4bf7-b24f-636d1dd6fa06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fae79765-f78b-4403-8293-45cc2d8bc62c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7d3c3f9-50d2-4bf7-b24f-636d1dd6fa06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_707e746f-c17e-4d3e-97b6-c65c754b6506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fae79765-f78b-4403-8293-45cc2d8bc62c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_707e746f-c17e-4d3e-97b6-c65c754b6506" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#AccruedExpensesScheduleofaccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_f86a6383-d222-4e44-8413-274edeb48b3a" xlink:href="sttk-20211231.xsd#sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_83b781bc-8826-49df-aee4-75d861e75e19" xlink:href="sttk-20211231.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_f86a6383-d222-4e44-8413-274edeb48b3a" xlink:to="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_83b781bc-8826-49df-aee4-75d861e75e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7ccdd09e-3c63-457a-aa12-02adcb17f431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_f86a6383-d222-4e44-8413-274edeb48b3a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7ccdd09e-3c63-457a-aa12-02adcb17f431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1836e564-d050-4cf9-a4ea-aba0670a8043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_f86a6383-d222-4e44-8413-274edeb48b3a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1836e564-d050-4cf9-a4ea-aba0670a8043" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_61cf00f1-b4df-4973-a0be-59feaf464e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_61cf00f1-b4df-4973-a0be-59feaf464e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c3748143-2492-40e2-82ff-3fe4eb972ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c3748143-2492-40e2-82ff-3fe4eb972ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9e24f9fa-c080-41e8-9cca-69b0429cd5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9e24f9fa-c080-41e8-9cca-69b0429cd5b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1f4ac0a1-5d0d-4e55-9d8e-453047283c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1f4ac0a1-5d0d-4e55-9d8e-453047283c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1238cf9a-d9b7-4555-90e4-f4dcf316e822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1238cf9a-d9b7-4555-90e4-f4dcf316e822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_74bbced1-06f4-4b6e-a357-a272d94fa903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_76455a24-caba-460b-9cc2-2361b7eacfa5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_74bbced1-06f4-4b6e-a357-a272d94fa903" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5016d418-e69c-4c3c-b0d5-b94708544ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5016d418-e69c-4c3c-b0d5-b94708544ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_7d4ddd77-2366-47fd-8d9c-bb471eea57bc" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_7d4ddd77-2366-47fd-8d9c-bb471eea57bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_9f7b90f3-6c21-4bc0-a5bc-86d426e47323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_9f7b90f3-6c21-4bc0-a5bc-86d426e47323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_c7e544b9-f86c-499a-8db8-11b80a49fb3a" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_c7e544b9-f86c-499a-8db8-11b80a49fb3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_18618d9f-65cb-4e9a-8b65-83ded40add4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_18618d9f-65cb-4e9a-8b65-83ded40add4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8a2536da-8040-4881-b1a6-ebc986ab70f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8a2536da-8040-4881-b1a6-ebc986ab70f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_715e25e8-8f8c-4af9-b15c-cada94a22e63" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_715e25e8-8f8c-4af9-b15c-cada94a22e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d9cab43c-a016-4b60-aeac-836d831bee99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d9cab43c-a016-4b60-aeac-836d831bee99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3f99efd3-d69d-42d7-8304-1b04eaab2da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_30900d4c-ee7d-43a2-a5bd-aea162e63843" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3f99efd3-d69d-42d7-8304-1b04eaab2da2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4ab1e5a9-f8b1-48ef-9724-39777225e2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e083d4c0-c717-4ec8-a1af-d4fc1597495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4ab1e5a9-f8b1-48ef-9724-39777225e2df" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e083d4c0-c717-4ec8-a1af-d4fc1597495c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0050c208-1dac-4fd5-b6b9-ebf0325ef85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4ab1e5a9-f8b1-48ef-9724-39777225e2df" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0050c208-1dac-4fd5-b6b9-ebf0325ef85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fe26790d-ec7c-4b44-840a-774d1b7dc5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_71f750f5-e254-41ca-b4a0-0069507f561d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fe26790d-ec7c-4b44-840a-774d1b7dc5f2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_71f750f5-e254-41ca-b4a0-0069507f561d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f8193b83-2b46-4352-8d9e-06eab96ba650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fe26790d-ec7c-4b44-840a-774d1b7dc5f2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f8193b83-2b46-4352-8d9e-06eab96ba650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b1878a7c-8f53-490c-8c48-d810e861e711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_8293e8c1-3041-4428-b913-aabb1bd4f6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b1878a7c-8f53-490c-8c48-d810e861e711" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_8293e8c1-3041-4428-b913-aabb1bd4f6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e99489dc-c534-48c3-9142-04c4f2ae8d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b1878a7c-8f53-490c-8c48-d810e861e711" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e99489dc-c534-48c3-9142-04c4f2ae8d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9864c740-8f54-44ef-aaf3-ec74c150d944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9864c740-8f54-44ef-aaf3-ec74c150d944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2071c3d4-6523-4db1-920e-8b6395cf3868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2071c3d4-6523-4db1-920e-8b6395cf3868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_402f2bd4-8207-40c4-9add-8f252b004b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_402f2bd4-8207-40c4-9add-8f252b004b3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_99eb4fce-1010-412b-adfd-9b7d09acb900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_99eb4fce-1010-412b-adfd-9b7d09acb900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_418d2f03-ea6f-4056-8db6-2bc3cb484d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_418d2f03-ea6f-4056-8db6-2bc3cb484d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8ce5b28d-fe0e-4095-a8a9-116f653a673d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1769ef23-9d4f-4517-8517-d9353f673dce" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8ce5b28d-fe0e-4095-a8a9-116f653a673d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>sttk-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cbc5e4f4-a5cf-4cd7-9e77-2f3acab88ac0,g:c886f0b9-fa14-42f2-91e7-6b4a395bcd32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="ib69aee3838fe4399953927474b15a8ad_STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ba4648bf-1050-4749-99bb-8433d8ecc252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ba4648bf-1050-4749-99bb-8433d8ecc252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0bae7067-c59e-43e0-bc6b-e62cde0fb2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0bae7067-c59e-43e0-bc6b-e62cde0fb2bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_42f9461c-3ff9-4b52-968b-2d30bd5f0824" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_42f9461c-3ff9-4b52-968b-2d30bd5f0824" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_8c7f440a-3882-4bd5-8ce7-81528fee592d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_8c7f440a-3882-4bd5-8ce7-81528fee592d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_77059a5a-2a61-4e38-a780-f3dd7b5d47f9" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_77059a5a-2a61-4e38-a780-f3dd7b5d47f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_7d33892a-e5d2-4304-a045-e5fac8488c58" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_7d33892a-e5d2-4304-a045-e5fac8488c58" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_8c98a71a-3b62-4b20-83f9-633d2483c9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0751e12a-e000-49b9-ac18-7c1c74279b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_314e8b35-f71f-40c5-bf2d-f254ba81dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_SharesOutstanding_314e8b35-f71f-40c5-bf2d-f254ba81dd4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6186481f-6931-4f41-aca8-b19b45fadff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockholdersEquity_6186481f-6931-4f41-aca8-b19b45fadff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0f4531b6-e693-4ea6-82c3-ad8fec6e3365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0f4531b6-e693-4ea6-82c3-ad8fec6e3365" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8e815f5-cf87-40aa-8d91-b896037a6e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8e815f5-cf87-40aa-8d91-b896037a6e1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_05cafcab-6a20-4369-b485-d4d5b403dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_05cafcab-6a20-4369-b485-d4d5b403dc85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_af2d025b-bb7b-474f-82c0-a48b79fa99db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_af2d025b-bb7b-474f-82c0-a48b79fa99db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c95988de-6681-4b6d-8d1b-008b3ff07b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c95988de-6681-4b6d-8d1b-008b3ff07b50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f32ad2cf-0ecd-4099-ba42-864c585a4f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f32ad2cf-0ecd-4099-ba42-864c585a4f32" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5f48f726-ba39-4df1-9591-2190ae757fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5f48f726-ba39-4df1-9591-2190ae757fe7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07d7a5b-4322-4176-a1f0-fdbf0148380b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07d7a5b-4322-4176-a1f0-fdbf0148380b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e5628606-75de-48c7-a743-4759517b2cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e5628606-75de-48c7-a743-4759517b2cee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8adfbcf2-b07c-410c-b54c-61eeca75eb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_NetIncomeLoss_8adfbcf2-b07c-410c-b54c-61eeca75eb0a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_520de38a-c115-4609-81f1-35618e74697b" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_520de38a-c115-4609-81f1-35618e74697b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_985e8f43-7f42-4b25-8749-515954536df6" xlink:href="sttk-20211231.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_985e8f43-7f42-4b25-8749-515954536df6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_77c75848-8408-4868-a2ea-de21f10ebf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c2fc93b-aaee-4c84-a2d4-1f2d0c052a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:to="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e8090fad-67b9-4ea5-92bd-33efd5dc2330_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:to="loc_us-gaap_ClassOfStockDomain_e8090fad-67b9-4ea5-92bd-33efd5dc2330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:to="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7203fbb0-4d78-4af3-90fa-21dca29ed398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7203fbb0-4d78-4af3-90fa-21dca29ed398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8f3c7644-a8ff-4966-8500-2bb382218bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8f3c7644-a8ff-4966-8500-2bb382218bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember_ee32d982-99aa-438b-8799-24b4f99de164" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:to="loc_sttk_SeriesB1PreferredStockMember_ee32d982-99aa-438b-8799-24b4f99de164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9fb7fc97-13d3-499c-8ac3-1e63947c56c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:to="loc_us-gaap_EquityComponentDomain_9fb7fc97-13d3-499c-8ac3-1e63947c56c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:to="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ca7aa13-abd8-4ed3-9c31-8a81fd7c50b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_CommonStockMember_8ca7aa13-abd8-4ed3-9c31-8a81fd7c50b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_144222c1-b053-4857-9196-807d2e986968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_144222c1-b053-4857-9196-807d2e986968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70cfbaa0-eb42-4365-afd4-494a36a28166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70cfbaa0-eb42-4365-afd4-494a36a28166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b9d03b22-17da-4112-af80-aac1a3afed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_RetainedEarningsMember_b9d03b22-17da-4112-af80-aac1a3afed9a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended" id="i13409c26af47412e8d7585c7fd6ae395_STATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_395ce1a1-b28b-45cc-ba70-f6ded3183776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:to="loc_us-gaap_NetIncomeLoss_395ce1a1-b28b-45cc-ba70-f6ded3183776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5612d245-3b8a-49a8-a1e1-19d89e308cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_ShareBasedCompensation_5612d245-3b8a-49a8-a1e1-19d89e308cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_65be597f-dc39-4aa0-a680-3d89c4682cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_Depreciation_65be597f-dc39-4aa0-a680-3d89c4682cc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_afd8602e-739e-4809-8485-fe5a2991cdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_afd8602e-739e-4809-8485-fe5a2991cdb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2baaa5f9-601d-4cb0-8d12-9491868e16a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2baaa5f9-601d-4cb0-8d12-9491868e16a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9759e51a-b4ad-42cd-87ab-134b6a8dd4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9759e51a-b4ad-42cd-87ab-134b6a8dd4b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_06ac39ac-96e2-47fb-85de-c822c421c752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_06ac39ac-96e2-47fb-85de-c822c421c752" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_346cc38f-1d1a-40de-b337-36f7050cb268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_346cc38f-1d1a-40de-b337-36f7050cb268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdf0391b-6060-452b-81fd-80d39aaeaf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdf0391b-6060-452b-81fd-80d39aaeaf40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInDeferredRentCredits_3f68a1de-6439-4357-bc46-03e3314b1d9d" xlink:href="sttk-20211231.xsd#sttk_IncreaseDecreaseInDeferredRentCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_sttk_IncreaseDecreaseInDeferredRentCredits_3f68a1de-6439-4357-bc46-03e3314b1d9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e860031-d6c4-4de7-b708-4506b59cfa77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e860031-d6c4-4de7-b708-4506b59cfa77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_439afa9d-62ab-4344-a8be-adc8e4807a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_439afa9d-62ab-4344-a8be-adc8e4807a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2c3c5619-6f20-497c-9982-c83059db8970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2c3c5619-6f20-497c-9982-c83059db8970" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12bdd92f-7844-4cd5-afcd-ee7972a3aa32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12bdd92f-7844-4cd5-afcd-ee7972a3aa32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2df654f4-e5f5-4304-8b96-0728aa6b2457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2df654f4-e5f5-4304-8b96-0728aa6b2457" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0715d2cc-7d4a-4f7e-8830-bc0745557244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0715d2cc-7d4a-4f7e-8830-bc0745557244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_de1f4d72-4d30-4bc9-be81-7a8dfb571f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_de1f4d72-4d30-4bc9-be81-7a8dfb571f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_692b1e58-a124-419c-bebc-e2249c267295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_692b1e58-a124-419c-bebc-e2249c267295" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_50ec696f-6f57-4c5b-9078-9c7e00119885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_50ec696f-6f57-4c5b-9078-9c7e00119885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f17f6-edb1-42c1-8ac6-013a08a990d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f17f6-edb1-42c1-8ac6-013a08a990d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0f9852a-b35d-4a73-a6a8-60219c858f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0f9852a-b35d-4a73-a6a8-60219c858f4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4cb6eda-3fa2-49e6-aab6-e7aff2b414f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4cb6eda-3fa2-49e6-aab6-e7aff2b414f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0a08a65-7fb4-4cbf-8e42-942fddd5b949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_67e3b997-4e6b-471a-8e08-567492211fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_67e3b997-4e6b-471a-8e08-567492211fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0a82e599-f91e-4751-be23-8fd306e6dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0a82e599-f91e-4751-be23-8fd306e6dc3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_43fbd3f0-32a5-416c-adff-08f5a45fb1ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:to="loc_us-gaap_ClassOfStockDomain_43fbd3f0-32a5-416c-adff-08f5a45fb1ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:to="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember_fe3e3372-12ea-4554-8ff4-731db58d3f71" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:to="loc_sttk_SeriesB1PreferredStockMember_fe3e3372-12ea-4554-8ff4-731db58d3f71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_cce82373-daf2-4041-b662-96eb64e357d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_cce82373-daf2-4041-b662-96eb64e357d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9f87337-b387-40f3-ae46-23447c783c0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9f87337-b387-40f3-ae46-23447c783c0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7725b8f-3e7c-4d2a-9c07-f3eae326b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7725b8f-3e7c-4d2a-9c07-f3eae326b42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c986117f-860f-4963-8ed5-2b3a8b869095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7725b8f-3e7c-4d2a-9c07-f3eae326b42c" xlink:to="loc_us-gaap_IPOMember_c986117f-860f-4963-8ed5-2b3a8b869095" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ieccfdbdf3f3e400da2c7536a2381bbac_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_30cc5120-36bf-4cf9-817f-0b88dbd8a5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4bd6d950-21bb-42a5-bca7-d5e2a5443cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_30cc5120-36bf-4cf9-817f-0b88dbd8a5cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4bd6d950-21bb-42a5-bca7-d5e2a5443cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_30cc5120-36bf-4cf9-817f-0b88dbd8a5cf" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a8871a-a5b1-46ee-85b3-5f556dc9ac70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a8871a-a5b1-46ee-85b3-5f556dc9ac70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_b287d59c-389c-413c-8cfc-15acc49995b1" xlink:href="sttk-20211231.xsd#sttk_OperatingAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:to="loc_sttk_OperatingAccountMember_b287d59c-389c-413c-8cfc-15acc49995b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_26028a96-0836-4849-851e-196e006df0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_26028a96-0836-4849-851e-196e006df0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_05f83803-c085-4285-8391-a87c17acbb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_05f83803-c085-4285-8391-a87c17acbb26" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="extended" id="i14ae19fa3c2842fe8694cd70ab1ebe42_BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dd9abe69-5e52-428b-8841-8d9b3ee79964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302711a2-6525-402c-826c-28bde762529c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dd9abe69-5e52-428b-8841-8d9b3ee79964" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302711a2-6525-402c-826c-28bde762529c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dd9abe69-5e52-428b-8841-8d9b3ee79964" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9011670-7b2f-49d0-b073-34f361bec1e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9011670-7b2f-49d0-b073-34f361bec1e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_cdcb9a29-0993-476d-ae88-f8b16d370db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_us-gaap_OfficeEquipmentMember_cdcb9a29-0993-476d-ae88-f8b16d370db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_948ac67a-67f6-4d46-b52f-c8b09377c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_948ac67a-67f6-4d46-b52f-c8b09377c26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_f09da99f-28da-45f9-96b5-52b3dedb4694" xlink:href="sttk-20211231.xsd#sttk_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_sttk_LabEquipmentMember_f09da99f-28da-45f9-96b5-52b3dedb4694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_749c4176-2778-4c10-b140-115630a16639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_749c4176-2778-4c10-b140-115630a16639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:to="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82dfda42-fb1b-4bd6-81ec-2c0d7180293d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:to="loc_srt_RangeMember_82dfda42-fb1b-4bd6-81ec-2c0d7180293d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:to="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4169460-56c2-4a32-b593-9b648090b5e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:to="loc_srt_MinimumMember_e4169460-56c2-4a32-b593-9b648090b5e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d45cd078-5cbe-4a05-a300-6e31e90967e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:to="loc_srt_MaximumMember_d45cd078-5cbe-4a05-a300-6e31e90967e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended" id="i8cbdb087ee6c4e35bee26f7a4287f6bf_BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38359475-1008-43ef-ba83-5a7da6c2432e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3209dfa-f2e8-4589-bc67-5efeaeef39bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38359475-1008-43ef-ba83-5a7da6c2432e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3209dfa-f2e8-4589-bc67-5efeaeef39bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38359475-1008-43ef-ba83-5a7da6c2432e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b58f3c8-5c14-4822-b887-f1b8beab2ee2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b58f3c8-5c14-4822-b887-f1b8beab2ee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28b5ed64-6083-498f-8bcc-ec5dcc67379e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28b5ed64-6083-498f-8bcc-ec5dcc67379e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e68b6397-4331-4ba3-a7a6-ff937efad9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:to="loc_us-gaap_RestrictedStockMember_e68b6397-4331-4ba3-a7a6-ff937efad9fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" xlink:type="extended" id="i937f582deebd4d18a911ef8e2be8a661_ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd75fb9b-2fc8-4e4d-ad17-86263301ece5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd75fb9b-2fc8-4e4d-ad17-86263301ece5" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6678474-8766-4614-bbe1-9a7f2df048e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6678474-8766-4614-bbe1-9a7f2df048e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_436007d8-98ad-4b9e-941f-3b5eccd37685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_436007d8-98ad-4b9e-941f-3b5eccd37685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65c0217f-139e-41eb-b004-66dba3426f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65c0217f-139e-41eb-b004-66dba3426f96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd75fb9b-2fc8-4e4d-ad17-86263301ece5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b941a6e-4877-4aa0-924f-4d9d57d1620b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b941a6e-4877-4aa0-924f-4d9d57d1620b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_48a44069-3899-461f-8fe9-602ad0283afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b941a6e-4877-4aa0-924f-4d9d57d1620b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_48a44069-3899-461f-8fe9-602ad0283afb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#PropertyandEquipmentScheduleofpropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="extended" id="i0bb740a083454bb4bf6d78d180ebcf1b_PropertyandEquipmentScheduleofpropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f2e00e61-1ea1-4d84-83fd-4cb57a02e687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f2e00e61-1ea1-4d84-83fd-4cb57a02e687" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a08b89b7-eefa-431f-bedc-a4de8b738395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a08b89b7-eefa-431f-bedc-a4de8b738395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_faa87d70-e475-4ae9-b85b-d2ce9efddd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_faa87d70-e475-4ae9-b85b-d2ce9efddd56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_253f2af6-674a-4c52-81f8-dafac4f01899_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_253f2af6-674a-4c52-81f8-dafac4f01899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_c720ce9f-5fad-46ba-8bad-ee790572e941" xlink:href="sttk-20211231.xsd#sttk_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_sttk_LabEquipmentMember_c720ce9f-5fad-46ba-8bad-ee790572e941" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c52f10c2-45f9-4680-8d44-94d37d3dbae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c52f10c2-45f9-4680-8d44-94d37d3dbae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_819d3390-ec12-4bc1-8b43-1d0b39f2b55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_ConstructionInProgressMember_819d3390-ec12-4bc1-8b43-1d0b39f2b55c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d7b8dce9-0e1d-4495-8bb9-a43c55d30be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d7b8dce9-0e1d-4495-8bb9-a43c55d30be9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_6b329631-3f84-4d01-afd9-c4c6759e13c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_OfficeEquipmentMember_6b329631-3f84-4d01-afd9-c4c6759e13c7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#PreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/PreferredStockDetails" xlink:type="extended" id="i77674fd023814cc3abc98575f2c94bea_PreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ee46246-faa4-4611-ac57-6d98173287e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ee46246-faa4-4611-ac57-6d98173287e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2fa7b7bc-b105-4a92-b915-4466a2c67c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2fa7b7bc-b105-4a92-b915-4466a2c67c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fb6c3af-e934-4c03-b03a-a2e962f8f5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fb6c3af-e934-4c03-b03a-a2e962f8f5a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c734d14-c4a2-48e8-8bc9-6f58baef495e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:to="loc_us-gaap_ClassOfStockDomain_6c734d14-c4a2-48e8-8bc9-6f58baef495e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_62d81aa6-6615-4f3d-b1f4-d5b1b0549f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:to="loc_us-gaap_ClassOfStockDomain_62d81aa6-6615-4f3d-b1f4-d5b1b0549f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_62d81aa6-6615-4f3d-b1f4-d5b1b0549f7d" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_98932372-809d-485a-aadd-74c4e2117d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_98932372-809d-485a-aadd-74c4e2117d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember_9c67135a-728a-4006-a8cc-9b2bf9a21d89" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:to="loc_sttk_SeriesB1PreferredStockMember_9c67135a-728a-4006-a8cc-9b2bf9a21d89" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#CollaborationAgreementRelatedPartyDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails" xlink:type="extended" id="i746ef66d5ebd46419aaeeaafe223c013_CollaborationAgreementRelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_53271698-a659-41ee-a572-a2e8705f7a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:to="loc_us-gaap_ProceedsFromCollaborators_53271698-a659-41ee-a572-a2e8705f7a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45a663e2-24d4-4384-a9c8-87c36c3b6c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45a663e2-24d4-4384-a9c8-87c36c3b6c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d37cc23-accb-438e-adfe-bdb96fb506a3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d37cc23-accb-438e-adfe-bdb96fb506a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d9b0bb-ad7b-4fa0-af1b-665619f1af13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d9b0bb-ad7b-4fa0-af1b-665619f1af13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TakedaMember_57ab3a0a-6747-4291-9c74-04e91f899850" xlink:href="sttk-20211231.xsd#sttk_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d9b0bb-ad7b-4fa0-af1b-665619f1af13" xlink:to="loc_sttk_TakedaMember_57ab3a0a-6747-4291-9c74-04e91f899850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:to="loc_us-gaap_RelatedPartyDomain_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_29a1dec3-2ed9-497b-8ad3-3820e3609cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:to="loc_us-gaap_RelatedPartyDomain_29a1dec3-2ed9-497b-8ad3-3820e3609cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_e1e49224-592b-49c6-a4d5-9768a944c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_29a1dec3-2ed9-497b-8ad3-3820e3609cb8" xlink:to="loc_us-gaap_InvestorMember_e1e49224-592b-49c6-a4d5-9768a944c4d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b06cae69-6c29-47e5-b772-bf3293ac015d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b06cae69-6c29-47e5-b772-bf3293ac015d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3489ff2-472f-45bf-810e-c68bf7994527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3489ff2-472f-45bf-810e-c68bf7994527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c4259a4a-aff7-4ae4-b558-ea4a099547a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3489ff2-472f-45bf-810e-c68bf7994527" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c4259a4a-aff7-4ae4-b558-ea4a099547a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i426c53a79b524de6b995b20e409c820e_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_3fe4496c-dae8-41a5-bdd2-6017917dce51" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_3fe4496c-dae8-41a5-bdd2-6017917dce51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5581cbc-eabf-466c-9d06-3227c3a1eef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5581cbc-eabf-466c-9d06-3227c3a1eef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_9fc0f52e-91cc-40a4-8244-4410ea55e548" xlink:href="sttk-20211231.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_9fc0f52e-91cc-40a4-8244-4410ea55e548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f861c5f-d0a5-4307-ab15-5eaedc42fc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f861c5f-d0a5-4307-ab15-5eaedc42fc82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_833100cd-fe8e-4cae-8e07-479b81b38d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_833100cd-fe8e-4cae-8e07-479b81b38d90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e462d755-498a-40f7-9392-5f0bbe2d6b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e462d755-498a-40f7-9392-5f0bbe2d6b98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3e63ba00-7319-4e6c-873d-616ac71370c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3e63ba00-7319-4e6c-873d-616ac71370c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_3dd6bfec-0436-4a9b-b49f-c946c13abd1b" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_3dd6bfec-0436-4a9b-b49f-c946c13abd1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_49a08b27-aaa3-4ccc-ae17-df19a4f08064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_49a08b27-aaa3-4ccc-ae17-df19a4f08064" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_7378b2f5-1fb6-4d46-bd99-f21944578bc6" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_7378b2f5-1fb6-4d46-bd99-f21944578bc6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d613edac-62c3-46c9-a4c5-1f108c268917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d613edac-62c3-46c9-a4c5-1f108c268917" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_cabdfa5b-3805-41d7-9902-315720a1d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ProceedsFromStockPlans_cabdfa5b-3805-41d7-9902-315720a1d0c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1b94670-470a-4986-9369-ef615d53727d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1b94670-470a-4986-9369-ef615d53727d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f8f2c39-9275-44d7-a1b0-df3e1d0de048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f8f2c39-9275-44d7-a1b0-df3e1d0de048" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63eb346a-3876-41d7-ae7c-c4e3ae098ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63eb346a-3876-41d7-ae7c-c4e3ae098ebc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6a40475a-7ac5-408f-97f2-f69630d9cf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6a40475a-7ac5-408f-97f2-f69630d9cf65" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_10159f25-5198-4c28-9b26-264ca37cbcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_10159f25-5198-4c28-9b26-264ca37cbcd0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5fba0fda-3665-414c-8d5b-fe83578f76c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5fba0fda-3665-414c-8d5b-fe83578f76c9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_980f0b7b-cfb4-4e14-ac81-d7299ee740f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_980f0b7b-cfb4-4e14-ac81-d7299ee740f0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4756875-479b-4d82-80ce-fe127c8ba6d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:to="loc_us-gaap_PlanNameDomain_f4756875-479b-4d82-80ce-fe127c8ba6d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:to="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_a903f244-587a-4138-99c1-fe4f2b803f51" xlink:href="sttk-20211231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:to="loc_sttk_A2020StockIncentivePlanMember_a903f244-587a-4138-99c1-fe4f2b803f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_e215e395-ddbd-4d84-b2e4-62cf1c4815ca" xlink:href="sttk-20211231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_e215e395-ddbd-4d84-b2e4-62cf1c4815ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3342f31-c814-4e25-9e4e-cc3a91a4aa47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3342f31-c814-4e25-9e4e-cc3a91a4aa47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1915d27f-54e2-4d02-af8b-3e092974f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1915d27f-54e2-4d02-af8b-3e092974f0f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa97dd09-13c7-4f70-af70-f7fe4339a920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1915d27f-54e2-4d02-af8b-3e092974f0f6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa97dd09-13c7-4f70-af70-f7fe4339a920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3a27e861-fae2-4458-a735-6eabcca6acd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3a27e861-fae2-4458-a735-6eabcca6acd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e409b04-cde3-4cd3-9a1b-7f97927f58e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e409b04-cde3-4cd3-9a1b-7f97927f58e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8931fb16-2859-4758-89b5-a7667f7440e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6e409b04-cde3-4cd3-9a1b-7f97927f58e0" xlink:to="loc_us-gaap_SubsequentEventMember_8931fb16-2859-4758-89b5-a7667f7440e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended" id="i1a1417d9913745918431765644f531b0_StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14a110cd-c971-42b1-a6dd-144b1a639ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f11b538-a851-4cb9-bc5c-215befa4adeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14a110cd-c971-42b1-a6dd-144b1a639ffb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f11b538-a851-4cb9-bc5c-215befa4adeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14a110cd-c971-42b1-a6dd-144b1a639ffb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51ac6dbb-4691-453b-b95a-fa7689cc5e94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51ac6dbb-4691-453b-b95a-fa7689cc5e94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3fcaeaa0-5fad-4317-b15e-0af337607b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3fcaeaa0-5fad-4317-b15e-0af337607b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_06636ecb-87cd-4b29-bac1-6b794104277a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_06636ecb-87cd-4b29-bac1-6b794104277a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails" xlink:type="extended" id="i2c1812ff3929466a9448d676973bd945_StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a04db77-d86d-43ce-928a-617dcd41ead2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a04db77-d86d-43ce-928a-617dcd41ead2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_53202eb3-8935-42e5-8e85-e9710b6b6878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_53202eb3-8935-42e5-8e85-e9710b6b6878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d64200bb-3974-4781-8b86-eaacc92fb991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d64200bb-3974-4781-8b86-eaacc92fb991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd681eb4-2a95-48ad-8d78-4c358f551599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd681eb4-2a95-48ad-8d78-4c358f551599" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:to="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae109c33-8e42-41f1-b9a6-659c6d7c4509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae109c33-8e42-41f1-b9a6-659c6d7c4509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0118be4f-bef7-483d-8fc5-be0f7cc15cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae109c33-8e42-41f1-b9a6-659c6d7c4509" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0118be4f-bef7-483d-8fc5-be0f7cc15cf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:to="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_419c7010-00b9-4307-8f3d-57a4dd156aeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:to="loc_us-gaap_PlanNameDomain_419c7010-00b9-4307-8f3d-57a4dd156aeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c6cc9948-3e36-4b4a-8b7f-252abd3fe953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:to="loc_us-gaap_PlanNameDomain_c6cc9948-3e36-4b4a-8b7f-252abd3fe953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_51a48d8f-e816-497f-be8a-ad2230cf7247" xlink:href="sttk-20211231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c6cc9948-3e36-4b4a-8b7f-252abd3fe953" xlink:to="loc_sttk_A2020StockIncentivePlanMember_51a48d8f-e816-497f-be8a-ad2230cf7247" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="extended" id="iaee1539c5a8644ff93a75c2a0148af4f_StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5442d332-7dcb-4e81-bfb8-97365e8dd549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5442d332-7dcb-4e81-bfb8-97365e8dd549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_89e9f471-2e60-4b14-be0a-e46ae216c972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_89e9f471-2e60-4b14-be0a-e46ae216c972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbccfbc7-a80c-4fa8-9deb-af76d0a7829c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbccfbc7-a80c-4fa8-9deb-af76d0a7829c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71f98c72-8987-4773-8ff8-4bc52da1f4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71f98c72-8987-4773-8ff8-4bc52da1f4e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:to="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_529d8718-666b-4a4c-9296-2b9bea0154e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_529d8718-666b-4a4c-9296-2b9bea0154e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1131190-4d4b-44bf-9f63-5ccea2eaab95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1131190-4d4b-44bf-9f63-5ccea2eaab95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fd36b3be-e61e-44b4-8235-09e8932e4188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1131190-4d4b-44bf-9f63-5ccea2eaab95" xlink:to="loc_us-gaap_EmployeeStockMember_fd36b3be-e61e-44b4-8235-09e8932e4188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:to="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c8310652-6420-4aa3-bb73-c3ca05853706_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:to="loc_us-gaap_PlanNameDomain_c8310652-6420-4aa3-bb73-c3ca05853706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8eeaf02-bdfb-4573-8c31-c1a2f0ac8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:to="loc_us-gaap_PlanNameDomain_a8eeaf02-bdfb-4573-8c31-c1a2f0ac8d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_40d4b98a-628e-4294-9c54-eb9aa2538faa" xlink:href="sttk-20211231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a8eeaf02-bdfb-4573-8c31-c1a2f0ac8d89" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_40d4b98a-628e-4294-9c54-eb9aa2538faa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleofrestrictedstockactivityDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="extended" id="icb538af027164ae7be428fbeb0131284_StockBasedCompensationScheduleofrestrictedstockactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fadf5ac-2990-4fec-bcd6-2d2a1a8e4ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fadf5ac-2990-4fec-bcd6-2d2a1a8e4ab1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_985ffb4f-361f-4957-8bd0-afac9f7a63bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_985ffb4f-361f-4957-8bd0-afac9f7a63bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a30282f5-9a71-4e5a-b5cf-f8069f1fd072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a30282f5-9a71-4e5a-b5cf-f8069f1fd072" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93c68ad3-da7c-4398-97ed-b72865592b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fadf5ac-2990-4fec-bcd6-2d2a1a8e4ab1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:to="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc2b72b-bccb-42d5-80a5-8edead1a9653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc2b72b-bccb-42d5-80a5-8edead1a9653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_eae79850-5199-428e-8f35-7c66423e6f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc2b72b-bccb-42d5-80a5-8edead1a9653" xlink:to="loc_us-gaap_RestrictedStockMember_eae79850-5199-428e-8f35-7c66423e6f18" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ie89cddd8c9e945b4a8c90f0291678827_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8fc53f19-e337-4d9e-9def-d5796e80a447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8fc53f19-e337-4d9e-9def-d5796e80a447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0fd4c7e6-973b-4d4c-b766-ffd765f645aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0fd4c7e6-973b-4d4c-b766-ffd765f645aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ba170761-7619-484e-a5fc-aff89e90483c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ba170761-7619-484e-a5fc-aff89e90483c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0cad989f-b60d-4957-8f57-de0af7b309e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0cad989f-b60d-4957-8f57-de0af7b309e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e6b96a82-113c-4d3e-a591-0c9aa286a2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:to="loc_us-gaap_DomesticCountryMember_e6b96a82-113c-4d3e-a591-0c9aa286a2f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c585c8c3-974a-450b-a895-572c07c6a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c585c8c3-974a-450b-a895-572c07c6a0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_adfc3f59-1b87-4105-bbac-39397b4bacaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_adfc3f59-1b87-4105-bbac-39397b4bacaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f143bc18-b8ec-4b1e-b813-f91bbc975505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f143bc18-b8ec-4b1e-b813-f91bbc975505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_1c50ff45-e24e-4bd0-b356-ec70103325fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f143bc18-b8ec-4b1e-b813-f91bbc975505" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_1c50ff45-e24e-4bd0-b356-ec70103325fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/RelatedPartyDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#RelatedPartyDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/RelatedPartyDetails" xlink:type="extended" id="i55ed1a9ec25b4238b825fe71500654c0_RelatedPartyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9da2ee84-1a42-48a3-a932-9a3565837539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareholderOwnershipPercentage_f1a8eced-1f6c-481e-8a22-c18eaf75f780" xlink:href="sttk-20211231.xsd#sttk_ShareholderOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9da2ee84-1a42-48a3-a932-9a3565837539" xlink:to="loc_sttk_ShareholderOwnershipPercentage_f1a8eced-1f6c-481e-8a22-c18eaf75f780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9da2ee84-1a42-48a3-a932-9a3565837539" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:to="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_58d5fc39-2879-410b-b75f-bc29818f333d_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:to="loc_dei_EntityDomain_58d5fc39-2879-410b-b75f-bc29818f333d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7965dd4b-8795-4690-9a00-f1a0559732de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:to="loc_dei_EntityDomain_7965dd4b-8795-4690-9a00-f1a0559732de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TakedaMember_c2672f90-60f6-44e4-bec1-1daa463e0668" xlink:href="sttk-20211231.xsd#sttk_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7965dd4b-8795-4690-9a00-f1a0559732de" xlink:to="loc_sttk_TakedaMember_c2672f90-60f6-44e4-bec1-1daa463e0668" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>sttk-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cbc5e4f4-a5cf-4cd7-9e77-2f3acab88ac0,g:c886f0b9-fa14-42f2-91e7-6b4a395bcd32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ce326c7d-d7e5-4c13-9a0b-a46a7c07a196_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2730dd6e-2180-4b84-9efb-fb18205261aa_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash financial activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7f83a75e-7e97-446f-a33f-ccba12901662_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1e41f3b2-15bb-455a-8b1e-c77da82a21cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock previously subject to vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0410edd-053c-4e34-809d-63b81d0af6d0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0de8ffd0-a694-48e1-b7f2-686edf850a4b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2a121b16-0c49-4cb3-9228-99e6fef50dfc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9764c639-53f0-4e08-ade5-70e3dabe3033_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_af20bd0a-8ba3-4ca2-88b3-36094a8cbe98_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repurchase of) Redeemable Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:to="lab_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5670606a-668f-4ba1-88cd-bbc08733f04e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d5be4e4f-4a98-46ac-a040-9d239fab7ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c8ae6809-cad8-4168-b007-760ec96ab8a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_02acc335-bcff-41c1-b68f-ba75bb7785a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_83c0dfe6-1784-4994-86f9-359555dec503_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_a0be3083-aee9-4761-957d-2a5f37ce442b_terseLabel_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:href="sttk-20211231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ca959c6d-50bb-4bd2-a304-08c65460052e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dd77cd2f-9c99-4eba-8153-73d0a5bc6b53_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_f48ac014-b889-41da-a85b-96a6df638239_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee during any one purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_01a6fb8d-c2ff-4539-8fc1-1caaf6d75b65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_42fe6c71-aea4-4e6b-905f-2f3a23984987_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_6edb6587-8ece-4df6-945c-9764a6e2bd31_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f4b39000-b317-43b0-810a-4ed13c2b06f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3952affe-2a52-47ad-a11e-f2c303432089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_241f650a-c587-431a-9ba1-3b6871b0f99c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_66a1df0d-c008-428e-bd71-4e293aaa86fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_263be5d4-dae2-4542-9020-d406506b6637_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_034cea7b-bc48-4918-8618-76ba77b4082c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f25049c8-ca7d-45ee-8084-0cd31ed35026_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1fcedf53-a344-477b-8af7-933a430a6bb1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e1b27773-10e3-4c3c-9b1d-aca45be878c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0feb997f-05f1-4cd3-8be5-4794178fddd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of available for sale short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5b35d90e-3fbd-4268-b941-2f3555e1b2f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_f6396fda-aff4-43e8-bc95-783e37fa8cd0_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and ESPP purchases (in shares)</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_14bc91dd-e290-49aa-9b5d-e0e217557b99_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b501fc55-8c6d-4151-9c68-9fc4a7c44591_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0b0e4ca-6806-4993-9796-33fdf6378229_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_32d37c8b-f90e-472f-9d73-74d19c552723_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_b5513f76-78d7-4f6f-807f-925f977f0e45_terseLabel_en-US" xlink:label="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment depreciation periods</link:label>
    <link:label id="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:href="sttk-20211231.xsd#sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9cdc9d81-0a43-4fab-8b9d-54d5dbd9a5f1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2609c548-cd65-44b6-9a0a-cab535bddf34_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11841bfd-4189-4dfa-8abe-984f439e95c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_17b9fa03-6fd4-44e5-83cf-311632618f05_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5ccea984-88cb-46b5-aeb9-21e8e9aa9ada_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_05dc2825-ce28-4400-8a76-3cb1453e2c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_15886df7-59a2-4b20-8fb0-8ae6f873dca5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3950720f-e984-42da-a885-6c4eebb8873e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_166221f5-8a50-4e86-bc0a-236a21eef4f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7d71587b-d620-4a73-8d1f-62b5de4e4014_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4d117dfa-2263-4773-aaa7-a693d4c284e4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options and ESPP purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_067e1d67-b160-42cc-b0d9-d69122e4b3a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5f698719-9d6f-481a-9a87-b6d33fcffba9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_21dc9499-7523-4390-b829-e75f9a1118f2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_31313e0a-1818-453a-95b9-c9c2a2678e58_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_fd97cc47-d219-440a-a3a3-2a19ceeeb711_negatedTerseLabel_en-US" xlink:label="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_label_en-US" xlink:label="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities Into Common Stock</link:label>
    <link:label id="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_documentation_en-US" xlink:label="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities Into Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" xlink:to="lab_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_81b0dcfb-5697-446a-8461-11b959abbbac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_17676be2-9acb-48a7-848c-f49aa339bbfa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_93607f59-9776-4541-8ba8-f8e6c33bb6ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c35774bc-d565-4fbc-8618-2d3ff65a4935_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_650d9e15-bb8b-44d7-96f0-0f98b944766f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dfccae58-e5cc-47f5-9a88-afa3f57f7d47_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_67422bca-fd3f-442a-b0eb-a5ffcdd7e40e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid amounts related to purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e43d66af-9346-4906-88e2-3e468cf00147_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7b530a17-1892-4441-9b2f-be65e869db11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution limit in percentage of employee's eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e1547e18-3722-49c6-83c7-dfa96acc5ca8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_c5223634-6797-4f94-a56a-48dbcd12b3cc_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cfd66d5f-1bc7-48f0-93d5-c3f325483982_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_463e1c18-9cba-4f29-a695-a7fc9db8bb98_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8ae2ce14-84bb-4027-accc-4021ac68bbba_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f9a6a426-36b4-45e8-a1c1-dcf3bca87c04_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_aaabaa75-278a-4994-8c52-5a31fb0902ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_5800a621-40f7-4f36-991d-16f11c24ba4f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1ba865dc-709a-4967-a7e5-9c23098f9ce8_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e96cf97e-0970-4b40-a136-b07c7b18b8db_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_31cd3347-dad2-48bf-8964-56113d737520_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_94479bb5-4747-41bc-b9f6-07661662637e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_21df5eca-95a7-40e7-9258-af806604e7a6_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ae8d3eb9-e14e-490d-b618-3c4cd57b8123_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8f601f0-8c5d-4feb-8ce3-04ef861ca891_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_19d61297-78cf-4f2d-be98-8be250d0881e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_610b2a30-471b-47da-b3b2-31b7a5ce3ee7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_45174495-be81-4fa1-87e0-7e6c15518995_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_TakedaMember_9e2d1cd5-4f9e-4213-9fcc-649b514f56c2_terseLabel_en-US" xlink:label="lab_sttk_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_sttk_TakedaMember_label_en-US" xlink:label="lab_sttk_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_sttk_TakedaMember_documentation_en-US" xlink:label="lab_sttk_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TakedaMember" xlink:href="sttk-20211231.xsd#sttk_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_TakedaMember" xlink:to="lab_sttk_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_15a71611-999c-46ac-83f2-d1123a69860a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7cdb4281-b4a0-4746-98e8-321c23e02f3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_ec006ebf-b7fb-48b9-940a-cd4d2b6faa9a_terseLabel_en-US" xlink:label="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of redeemable convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_804f58fe-fbeb-4fce-b556-9af4bcfbdf97_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_66bbb359-8557-4b89-bf3a-eba7a5c1146c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fee0b69c-e03e-47c3-8ec4-7b5a9f4ee728_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b9faa1c4-3cdd-478c-a832-75e5453d6ea2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ed2752fa-73df-4d87-a64b-3240b54a0c73_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9c6801ef-4f99-4230-ae3e-4303d0524ab3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d9d75c0c-88f7-42bd-a1c3-ea728ca7e50f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the initial public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a2c1432d-8c6a-4e47-9659-547f21663930_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_63005abf-b4d3-4352-bcfe-54c60d03f18c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ac11e542-55c2-43b6-a64c-7122d2168eb9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_69583d52-e462-41a5-9eaf-2bd370c569df_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ae331a33-f677-4c98-927e-4bafa2746a9a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d7c219c2-de67-4c30-b2a0-a33bd7e5a889_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_60e342fc-2abd-4e24-8a21-0d290a587e2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_143bac60-1675-412b-ac0b-669f00840ea5_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3b747857-2aa2-4cf2-8005-395c534124ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5cdf91ac-856a-44df-8a3b-652f75b27d10_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d33091dd-3e82-4002-a588-33bd43a73d05_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f9324cad-02ac-4448-8899-737156bb2900_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a36680c8-4e68-44ad-b790-ad60d0d1a2ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f050b2a7-f867-40cd-9854-0630a9005c97_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_5cf05dc8-9494-4a44-acf5-6f32b44b342b_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Obligations</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_577732e4-e7ab-41aa-99df-83d10a99d9c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ce3cf005-e4e6-408f-aa55-b801044f36b0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_65c82137-471f-4e35-98a6-190400ca12b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8c9796ee-b8ff-4fad-820a-28d232901fa7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d19a5038-66c4-4402-bb09-8b52b6fdef83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c9774759-5d84-4b99-b2dd-d0b6e4857287_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_47a3757c-3bb3-4534-bb3a-69b9e34911dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_98b45a77-6f91-4c96-826f-ca57638b640b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1579a08a-b4c6-44f4-be05-df1af9e13bcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e7dea273-1529-47e1-a1c7-d2e2ac0a0e05_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fb72fab4-0900-4994-a3a6-e3e72ada1d90_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_78f558da-eb4c-49bf-93b2-c6951144fb0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.0001 par value: 300,000,000 shares authorized, 42,338,898 shares issued and outstanding at December&#160;31, 2021 and 41,779,183 shares issued and 41,767,431 shares outstanding at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_adddee1c-5da9-45ae-aaa8-f8a4a73d1ad9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_91cd939b-5a7c-4e5d-855c-b68314079915_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_26dec908-8228-4f92-b95d-84fcec08a7e5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d4e9382e-4093-4885-ab82-a6fc85073aaa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_245b14bf-f97c-4758-bdf2-82f90f43a5dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9e9312f8-5b85-408d-98e0-dc1ba80f82d1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_8c88e17c-8a44-4d3c-994b-f1a48b501286_terseLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_66fdf106-af9e-4f78-9176-7a4d83169065_totalLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities And Employee-Related Liabilities, Current</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities And Employee-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:href="sttk-20211231.xsd#sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3f44a928-b2dd-468e-810a-205ed0de37ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_c848abba-98b3-4d67-ac97-f7c5dfadafd4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_d6a924e1-37d1-4417-87c6-4dc6f8e8f21a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_29d3e98c-6820-4a7c-8ac9-4a400e3990e2_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e11f4b64-af9d-4a38-ac39-f02fb58084bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1ce04f2e-3bac-4d33-aade-4479b2f6579b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5c019e6a-be5c-44a3-b25d-09fa22aed18c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6a409baf-d06f-4737-8894-6ce74e4527d8_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_c51a212b-0671-4a2f-9a28-bdf3a4d49df5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_77aea553-188b-46c0-b181-74de14fca85b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e9d86310-14be-4088-8d55-be9773c823d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a3158660-e1d9-4a4b-9178-a36eba9a74e8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_fb684c53-916f-4af1-8e47-e091dea97100_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b7dfbb3c-25d4-45bf-aa18-7fdca466c9f9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_34355caa-c7f8-43e2-8e14-01a850e35441_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7b97d5a2-4ca6-4411-89bb-a272063c4efa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_68def24f-a36c-495e-9e48-198bc6570edb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_52edf9db-9652-4508-9378-a3337c9da1ce_negatedTerseLabel_en-US" xlink:label="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_label_en-US" xlink:label="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities Into Common Stock</link:label>
    <link:label id="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_documentation_en-US" xlink:label="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities Into Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" xlink:to="lab_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_81b02650-52bc-4545-89a1-79011a1b7b1d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_51532df1-0f21-45e1-ab44-8ed339117b97_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1aaa11ee-8e42-4b91-b9bf-051fd0007bc2_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_65e8a671-d964-4988-8aa3-99abd4208d20_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_5fdfbfaa-563c-44a7-b788-71203767c3f3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_25c021a5-ddca-46e2-9147-045a0a6d976f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue - related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e5f85b4a-5bc1-40de-bfb7-3eaae59a4a13_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_46f07568-282c-4451-a227-87e9e7d7833b_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fd083119-cbc8-4e39-801e-744b8d507ad6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bf1c1922-6515-443b-898d-6e3c9b5f9b6c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_14337b7a-b8b4-488a-8e34-ddda5186ef9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f7740883-7bd0-4baa-b961-e7ffd8e7fbc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6399d95c-bee4-4ebc-a4d4-e74218e91978_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_28640d00-5397-4509-bb81-79c445868a14_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a001b9ee-db11-4294-b8c6-cc745c17870e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe661dc2-9f51-41ee-aba3-f12a184d46c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_d1ad722c-afc0-4488-bc1f-9ffeb705a7a5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9b614056-2dc2-41f2-a53d-26bab985f7a1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement - Related Party</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_87bd2868-e4c6-42f7-9236-83006ee868ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_22f876ca-0044-4454-b356-24d40e62187f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0d27ddd-1caf-4f51-b6a8-c1258fc5f1a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0f1936d4-84af-4aab-a218-1b380fb8e5be_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bbf37238-426e-4f89-a6b7-34a2e5318adc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a95d56d6-fce9-46cb-bf10-4263c766bc20_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8079a57e-a042-460d-b891-cef1e02f8336_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_faa48fb9-0a4f-476b-88b6-baeed6954ab6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ed428fc-d7c2-4e45-8165-3bf30faf5864_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_329e41c1-e2f8-4701-bf6d-49a5d8570797_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b0aa43d-2227-45fb-b2e8-38fc0abe98a9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_3ba72a55-e5be-4ce4-9355-1dbd172cf54b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c595141f-f43f-4f03-9d68-07d7a57ec1a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_b0bb3631-200c-4738-a73f-b8028ab6d96a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Intangible Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_IncreaseDecreaseInDeferredRentCredits_6b1245db-c37b-4b0c-ac77-b0a31ad88028_negatedTerseLabel_en-US" xlink:label="lab_sttk_IncreaseDecreaseInDeferredRentCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_sttk_IncreaseDecreaseInDeferredRentCredits_label_en-US" xlink:label="lab_sttk_IncreaseDecreaseInDeferredRentCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Rent Credits</link:label>
    <link:label id="lab_sttk_IncreaseDecreaseInDeferredRentCredits_documentation_en-US" xlink:label="lab_sttk_IncreaseDecreaseInDeferredRentCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Rent Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInDeferredRentCredits" xlink:href="sttk-20211231.xsd#sttk_IncreaseDecreaseInDeferredRentCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_IncreaseDecreaseInDeferredRentCredits" xlink:to="lab_sttk_IncreaseDecreaseInDeferredRentCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5da8f6f6-4df9-46bb-bf8a-fb6de217d1a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_32d9551c-c11f-4950-8a80-db1b86c3a29d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_100e399f-b2a3-47b3-9e41-77703beaf73b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_d5e4e50a-de1c-401b-873d-0bb023a22086_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_94df13ff-652b-4260-98ce-818fae4e1409_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_43136e89-8d6c-4601-8aa5-af6cb4ab8ba9_terseLabel_en-US" xlink:label="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_label_en-US" xlink:label="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Policy Text Block]</link:label>
    <link:label id="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="sttk-20211231.xsd#sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4b6bdcc6-c498-4cd0-a331-4a08f6ffe6ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4e3643ab-b1e2-431b-ada3-9b1803dae814_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_da923243-7d48-41ac-bf63-da0507e5274d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51556754-d268-44a9-b196-56e0e1e019d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4b5c0587-4793-47d7-bd7e-c64e0e8eb4ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a8e73140-0ea4-417a-ab38-9619a6bc9565_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f5945cb5-3782-4eea-b55a-c8257a7eaf7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_eff5c087-3e16-4a02-85cb-a55ea37a1db9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_fe0b3f49-06cd-44e4-a7c9-614271832f55_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8384fb2a-6281-4adb-8f34-35fbc703ed90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c4c616f7-a304-4e6d-b585-bb2a089c6aed_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_34134cb7-2000-4efe-bb55-3d22a1aa1958_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f2858199-83dd-4865-a72c-eac841ce4b9c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_d1b3b53d-0d43-4ac7-a79c-afed6f745be4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_e98d5827-4204-4a1d-a84e-5cee8f7c22ac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment depreciation and amortization periods</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_86b06017-fc2e-4c74-9f81-a92b93a8bef5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b94ea867-3a7c-4e4f-8c7f-c1437b00a0c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OperatingAccountMember_251a4d93-3142-4885-a4af-f23c94585b54_terseLabel_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_label_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account [Member]</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_documentation_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember" xlink:href="sttk-20211231.xsd#sttk_OperatingAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OperatingAccountMember" xlink:to="lab_sttk_OperatingAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_afc88594-3c3d-4179-9ebc-cd8923d83375_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_5319ba49-5020-45ec-aecb-d7ed27c3d188_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized, percentage of capital stock outstanding</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ebe9e933-9d28-4750-8b61-82de13839745_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ff26492e-c074-4e6f-b397-384fb91e6d7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_e379595f-b8f5-44cb-aa79-c6a2f63e7ea4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cea29e95-ed40-4e3f-9243-17d4ee3dfea2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ef06d047-7b25-4a32-b051-a73e2e7bcdf1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_85d25d68-d838-433d-bddb-03cc2bee455e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_11681c71-e565-4bf5-9af2-7f6c04220ad6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4f7d2305-20d7-4cb5-9ef0-c777741e5d4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4ac47bcb-13e3-4129-bb30-0314329dc3a1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a7d22255-4d7e-49e3-ae66-0823bf915986_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_53d5120f-5744-4c08-bc2d-a279b09c2593_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0781c101-f540-4b0d-9938-d100bca631e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_21d8554c-46f3-4e73-87b3-d6f1a41d04e5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0dfb19c1-cf97-40da-8b0f-0727f6cea082_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2acc906c-62ea-42e6-a9c2-fd57521ea35d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56045111-cd39-44a5-b5eb-7b9fd4f01da2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_53a9cea0-b453-419b-84b6-aac13e7b5e4d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_92a3826f-b287-4e16-9674-bb051a8d84f3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5b2f613c-ee6f-4dfd-90ac-247362c90117_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bb6c1cff-bf39-4534-80ee-00c69de0945e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_48cb2f10-32f5-4b72-8afd-bfd9f8d16be1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3591259e-9f79-49d1-ac91-9aab94e4ffbf_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_dbfd9aab-a739-470d-bae6-240ec9504545_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cb56ea0e-365b-4727-ae4a-e955eebcb0de_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8f66f279-643c-432f-ab45-52b166ac6b08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c0bc2173-f040-4209-9627-2e047e189a02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_28ca9da7-d4be-48f3-8950-94100a5cd582_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2540ee86-6cf5-41f2-9588-02c74f603a99_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_261c10e2-ab6c-41ac-baed-f969b4e97f59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_56c74e2b-cb51-4d8e-b1a5-9c39c48fd371_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_6961ab57-9f85-4120-93ff-d84a581e94b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_4bd981e7-3cfb-43cd-a1c1-448ab0ad8e59_terseLabel_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and ESPP purchases</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_label_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_documentation_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:href="sttk-20211231.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:to="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c4bfac21-70fc-475f-9c8d-90c36cd5ee13_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_640aa9d1-567e-41af-a030-ca7713fa93a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6f8995c6-a64c-448c-8d8f-29aea7228ab8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_73adbf85-eca0-4a59-9ae4-5d118d1d97ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_3ce508c6-83f5-4202-9b79-a4e349596ad5_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_15ebaa81-3b38-486d-8107-be4457f8e7c4_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_282e1a47-91c8-473c-b2cb-7cddf0cb9a30_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareholderOwnershipPercentage_6c2e0d2b-91be-4041-8308-655be20d7227_terseLabel_en-US" xlink:label="lab_sttk_ShareholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder ownership percentage</link:label>
    <link:label id="lab_sttk_ShareholderOwnershipPercentage_label_en-US" xlink:label="lab_sttk_ShareholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Ownership Percentage</link:label>
    <link:label id="lab_sttk_ShareholderOwnershipPercentage_documentation_en-US" xlink:label="lab_sttk_ShareholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareholderOwnershipPercentage" xlink:href="sttk-20211231.xsd#sttk_ShareholderOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareholderOwnershipPercentage" xlink:to="lab_sttk_ShareholderOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c05b4ab6-9d06-432d-a83f-794c0011c62e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_75096c78-d21a-4b11-9568-179577af7497_terseLabel_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_label_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_documentation_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:to="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_352c831f-7e86-4252-a318-ab9a6dadaf8f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_c88cab43-e97b-4fad-a518-ccd10a989d07_terseLabel_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember" xlink:href="sttk-20211231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020StockIncentivePlanMember" xlink:to="lab_sttk_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9dc4061f-f114-4559-a9da-1c4948289fe6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock in percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dbc31be6-4c40-4bfb-b9de-c5edc2968b73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3e1cac1a-d28c-45bf-9850-16a43747d6bf_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1cc92872-c199-4a44-8ea1-cb08d147bae8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - related party, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_fd600abd-6b3b-4991-8800-ac9d56a14181_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_22024a79-69be-4560-9503-c48247b6ab59_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_63be04e8-7816-4906-9050-66903c81aa78_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c9b10248-4f73-4fa2-802d-e114309265b6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a9999b3f-8251-417a-a62c-3b9541df0d92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2d37b37f-5ee6-4aa8-b9e7-cfe47d9d99a3_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40f55f26-434c-4a5c-bb2d-c4a7df52f9b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_89db8d77-1574-4fdd-8617-2b045189d55d_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8a1c0777-d26a-4873-8b49-e07280a0e857_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_f9663f71-16b0-4e92-8f22-0e07f2253045_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, average maturity term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5d9820e2-bae0-49fa-9dd8-d477166557c9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_abbe1d9a-5b5f-4575-b813-e744b040390f_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4ba6360c-9b35-4712-8189-3e783028393b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_26c572eb-4c9c-462c-973f-827b2a4bb18d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_914f6d8c-f8c8-4ea5-a061-0dfd7fea88c9_terseLabel_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, maximum payment</link:label>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_label_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payments, Maximum</link:label>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_documentation_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:href="sttk-20211231.xsd#sttk_LicenseAgreementRoyaltyPaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:to="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_568b9bd4-7023-447e-bf8c-f795e1fb7c31_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_592f9896-9781-4fc6-8cfb-f264124d0ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_LabEquipmentMember_262133b8-b4fe-4479-b53d-d7d2910c8dbf_terseLabel_en-US" xlink:label="lab_sttk_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_sttk_LabEquipmentMember_label_en-US" xlink:label="lab_sttk_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_sttk_LabEquipmentMember_documentation_en-US" xlink:label="lab_sttk_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember" xlink:href="sttk-20211231.xsd#sttk_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_LabEquipmentMember" xlink:to="lab_sttk_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45c46d32-aefd-4eab-a713-38737849be1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_88c2264c-9250-4459-a64b-0aedb4182d93_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, annual increase in number of shares authorized, term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0bd835c-cd2c-47df-9bc8-ba9725e43886_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1cba25f4-712f-4017-96b9-c6443563237a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7dc6d816-b94f-4658-a293-3cc6f8e45441_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e5084369-7873-46ad-8671-afbda05fba51_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_468ee941-de7f-45a4-abdc-e9a2cf082afd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_73e9f809-75ce-487a-ac26-320d133166bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_c3c67f86-1a43-4914-b209-2f6a9d643660_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_67884e0c-d30a-4f67-becb-7d411f656d46_terseLabel_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision adjustments</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_label_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision Adjustment</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_documentation_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" xlink:to="lab_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d66dc98e-0a94-4e3f-bb9f-9c2ebef6178f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_898accf1-e43a-49e3-8042-9203f3cb61cd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AuditorInformationAbstract_label_en-US" xlink:label="lab_sttk_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_sttk_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_sttk_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AuditorInformationAbstract" xlink:href="sttk-20211231.xsd#sttk_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AuditorInformationAbstract" xlink:to="lab_sttk_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4893c124-cbdc-4944-bb5c-88011793791d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_91875e3a-f7b2-4651-a67c-088e432ef996_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of preferred stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5bb09379-3655-4165-8f06-9d1192b2fb74_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_43ec544b-4c47-4122-aeb4-6e25495d6fe1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_ebd7ac3a-ebaa-4117-9f66-b01250ccf8ca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb65d5ba-a60c-470f-bbbd-f9a12a4c695b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_891b60e0-d27e-4ea6-9618-3e11329fbd09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_849ccead-dc90-4e38-8cbf-2e74e3dced39_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7255471e-b359-41ae-9dde-c61c2e57341c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9ef13d11-31a5-4fb4-890a-f8206183626f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income tax reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SeriesB1PreferredStockMember_7253bc01-9a74-4bda-af5b-e3010e539d0d_terseLabel_en-US" xlink:label="lab_sttk_SeriesB1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B-1 Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_sttk_SeriesB1PreferredStockMember_label_en-US" xlink:label="lab_sttk_SeriesB1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_sttk_SeriesB1PreferredStockMember_documentation_en-US" xlink:label="lab_sttk_SeriesB1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B-1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SeriesB1PreferredStockMember" xlink:to="lab_sttk_SeriesB1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fa03e983-babd-4b93-8de8-0bd1256326ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b461e9c2-0418-494e-b5eb-ebcf278d6ea8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4ea243a-ec08-4b39-ad6e-dc69453a4231_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_13c54679-8d6a-486e-a547-c22ec7e1ad5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a058d6ec-c4e5-4a01-951c-9a5742970a03_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e6427653-0b88-4a62-b361-41ae68cf0ca4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_56f9db36-43a7-4e74-9a1d-7dc91c0960f8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2c981d71-d3a1-4522-8833-21618d076a8a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec258395-ff2a-450c-953a-5dabc94cedf5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e9a6c5e0-f970-466c-9899-c06d2bd493ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_c2b3d763-8fbd-4fdc-8b13-69c23297522c_terseLabel_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:href="sttk-20211231.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_838ec695-f0cc-416b-ba55-448392f7f278_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments of long-lived assets</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0ca4d98b-e4ea-4f3c-98b8-37de18fed5f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8980f6d5-a172-4523-8aa9-b7abf1edc9f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_22b3f6b4-9ec9-4382-bb77-25b39987f31c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_84dc6090-b9fd-4adf-a0cb-5791f42432e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6b199ced-06db-4165-b229-e6628fbe3e00_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7e8b31a9-b6eb-4be6-ae71-86d51856500f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_40cb476d-7080-4137-a3d2-04cf8a39a0b5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from operations</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2560e4fb-a639-42b2-bf5e-2ca47094b9a2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_e1926629-0d75-4d03-a389-5e550b23bb9d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_8bcdd91f-f3a0-4cd2-9add-bec53849a71b_terseLabel_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_label_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences, Amount</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_documentation_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" xlink:to="lab_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9b84c0f6-4792-489d-8ea9-3e8cc1b3aee0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_16ac9d74-9652-49b4-ba75-cf30a388b925_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_ce88ba4d-2926-4786-beb8-fbf6855c39d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum rental payments for operating leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a468ceb8-a4bd-4251-b412-b62ebfedeb83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4d39f40c-9890-44d7-a24e-cdd87d65cb39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3100f3e-b133-4afb-8acc-cd05b42f5c9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_faff2e51-1071-4a8e-aa83-5540175fa329_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_b8829dfb-6154-4c90-8992-1f51f5e470e0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_2529d849-46b0-4de8-b13f-b6d10f64d888_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ea24e05f-4815-4fe7-a2c0-a2203145c13f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_11a580dd-393e-44b8-bcf5-ad3b01daf2d3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0b508834-ae72-4c07-9d02-b383ebc55fab_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1712f09a-0a0d-4cad-b04d-7467af31d958_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_805a9df4-b687-44b0-ab43-5827f67d73e8_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2c1fb3f7-3841-4d9a-b1f2-4f4904d14cd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of premium on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c9fda3f2-cdcb-445d-81cd-b125702a8be5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_895bb193-6bac-4516-96c1-a96b8b19eccd_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares per employee during any calendar year</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_e1c0b8cb-f570-49b3-aa88-8c7d4acec302_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c915cd08-ae4b-4514-b42a-c180f0c4d885_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f78de03f-9450-40be-9f73-9e3845ab3da3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_24b192b4-6894-43ee-8e84-917f65679a8c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e0867fac-b485-4e23-a7db-ceaec322a92f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7e390f1d-8b30-4ab0-9088-19ef229bf71a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2f3016c6-6fae-41fb-b79c-cb698a2f65bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a8bdb23d-c59d-47e6-915d-048da0b75356_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e19d912f-0ed6-4c7e-aee3-0795f04bcdc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_6dfbbaab-7f2d-468b-b225-b94a65c9a673_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bed58f3e-427f-4ebd-b5ab-d778ef77ccdd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_97511dbe-ae29-47a9-a408-05b88926af59_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a31cbf40-723f-4b09-abfa-09dd0e5fcd1c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8db48221-9b86-43d2-95f3-dd0b33b952c4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70e07b24-e307-4b86-940d-b63149cc7ebd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_78ffaff3-2778-45a1-aee3-7311ffc3704b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4ceeb3d9-7bc5-4751-a1f6-8489a5028cb2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_6a75c8f6-6c4e-4cbc-a63a-1ba1d6a7aa29_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5ebd945c-5678-4c67-ae64-c50889b7d0f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1de99815-9f4a-4fc3-9ac4-97e2a14be185_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_afaaa070-28f0-4db6-b970-0b69463a0cc0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_bf22662d-0c67-4386-80c2-1492a9edc022_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8d59f56a-cbf8-42fb-83aa-3c995bd48112_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_614b14ca-d0ba-4586-9917-693d29df7909_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_08bb484c-5ef2-4287-bb48-9ee4dbfd019c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aa6944a2-8e02-4120-8219-f26e78c85703_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8435554d-a438-4281-b9fe-72d50e6ce03f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_44a4c33b-2c12-4e18-9bf8-e1ffffd18b62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fdc862ac-291b-4dec-ada9-5219d4896f88_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operations:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_986895fc-63cf-443f-be61-c2e8bdd819e3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5db588be-b182-495f-9de4-fd12b961aacc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8cef1916-a31a-4135-b323-d6f379df83fe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term - years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4f73ae25-4bc8-4862-a3f5-746a28d643b4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_23dde4fd-c3c7-40d6-aaf4-30515080b8c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b8f2305b-1f20-4c4f-8095-7a9132e9ebfa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_449dff57-4803-4616-85b7-4cac7eba8990_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c5d1cd81-1708-4512-8bfb-04cf4a59ddc5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_076b5f62-62b0-40ad-b71e-b9df8f97530e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_07886e4f-585b-462c-bd0e-491adc448c19_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d4edb321-57b7-42d8-bb2b-a0bab88daf76_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_17f2b061-2247-4839-8222-e231e977b06a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements (not yet adopted)</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_770f0723-d4d2-4187-89f7-bfc5c36dea54_terseLabel_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development contract costs</link:label>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_label_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Contract Costs, Current</link:label>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Contract Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:href="sttk-20211231.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:to="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_ac0c1620-a9fe-45ed-854e-6871dc500c3e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0771de9c-7779-4077-9b69-c0081d9aa6da_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_235d8a33-d4d3-49ab-961c-edb3a761e234_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit computed at federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_eac9ff8f-699f-479b-912c-92fd12470686_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_4e6d74cf-4690-4653-99dc-e4061ff1a7e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_51338cf9-a084-4978-856f-be2d0b204b71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_a1cf957c-ba55-45b2-9b75-be32cd9439fb_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80afe880-f533-4fee-aef7-90810b49f444_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4b47e5b7-143e-4c4d-ac25-53290392fbd5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0a536e8a-ddc4-4e2a-adfc-43bc216919e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2ffd3cbe-e6ab-4154-963c-4ca443bc2be9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_030507bd-fb87-4af6-9130-f84bc975eec2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax position</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6abe1c5b-3d5a-42d6-adfc-56f3f357463d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>sttk-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cbc5e4f4-a5cf-4cd7-9e77-2f3acab88ac0,g:c886f0b9-fa14-42f2-91e7-6b4a395bcd32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/COVER" xlink:type="simple" xlink:href="sttk-20211231.xsd#COVER"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6e1076f8-443a-46dd-8d87-d6ebbdc7cdc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentType_6e1076f8-443a-46dd-8d87-d6ebbdc7cdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_24901a20-e32c-4c54-98c8-8e60a585a27a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentAnnualReport_24901a20-e32c-4c54-98c8-8e60a585a27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_95617b16-8766-4f99-8b7d-65ba929cc954" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentPeriodEndDate_95617b16-8766-4f99-8b7d-65ba929cc954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d8a2a3ce-c953-4442-b0d9-5d1f43459279" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_CurrentFiscalYearEndDate_d8a2a3ce-c953-4442-b0d9-5d1f43459279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_86a9c582-68ba-4028-9632-41192f76625d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentTransitionReport_86a9c582-68ba-4028-9632-41192f76625d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8cf3c2c8-94ab-4a77-8fd6-949d33ac4656" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityFileNumber_8cf3c2c8-94ab-4a77-8fd6-949d33ac4656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7513563c-82a8-4236-8381-4b8fc9f5ff5d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityRegistrantName_7513563c-82a8-4236-8381-4b8fc9f5ff5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d109ac2e-089b-4699-ac20-03a7212a5250" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d109ac2e-089b-4699-ac20-03a7212a5250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_07d381cd-8850-4c58-b6af-a8928745f64f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityTaxIdentificationNumber_07d381cd-8850-4c58-b6af-a8928745f64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e0099fd9-002d-4ccb-977c-956dae321138" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityAddressAddressLine1_e0099fd9-002d-4ccb-977c-956dae321138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6b03c9c3-8bed-41a5-a31e-81b09a87c079" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityAddressAddressLine2_6b03c9c3-8bed-41a5-a31e-81b09a87c079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_17c7db55-cd74-4c82-a3e9-e927c2ef6a0b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityAddressCityOrTown_17c7db55-cd74-4c82-a3e9-e927c2ef6a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ba9b6ccd-9fba-45cb-aef0-5387ebe2e7db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityAddressStateOrProvince_ba9b6ccd-9fba-45cb-aef0-5387ebe2e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5a1c853b-da82-464e-b7a8-ff3db39a943a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityAddressPostalZipCode_5a1c853b-da82-464e-b7a8-ff3db39a943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a06e00e2-cbfe-4687-b54a-38b2de702093" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_CityAreaCode_a06e00e2-cbfe-4687-b54a-38b2de702093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ca127b62-c325-4c06-98b7-9ccc32c87686" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_LocalPhoneNumber_ca127b62-c325-4c06-98b7-9ccc32c87686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a78a06c-1209-48f1-8779-f0696d048c87" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_Security12bTitle_4a78a06c-1209-48f1-8779-f0696d048c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c5c60157-6f1f-492b-a808-18a2c75d6343" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_TradingSymbol_c5c60157-6f1f-492b-a808-18a2c75d6343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0747d0d4-a8be-418e-b779-251c9b63a718" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_SecurityExchangeName_0747d0d4-a8be-418e-b779-251c9b63a718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eac3be3c-8164-4742-9d22-aef25eb67363" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eac3be3c-8164-4742-9d22-aef25eb67363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_30280c05-dbc3-4c65-b7e9-173ff721d1a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityVoluntaryFilers_30280c05-dbc3-4c65-b7e9-173ff721d1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_35f89531-b820-46a5-82cb-ddc4a059c32b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityCurrentReportingStatus_35f89531-b820-46a5-82cb-ddc4a059c32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e29d7c5e-0e6f-4150-b739-b6a2931a02a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityInteractiveDataCurrent_e29d7c5e-0e6f-4150-b739-b6a2931a02a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f810eb65-8183-41e2-a697-dde0913ed9f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityFilerCategory_f810eb65-8183-41e2-a697-dde0913ed9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_461cfa4c-f241-4e03-810e-44ef1f920abc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntitySmallBusiness_461cfa4c-f241-4e03-810e-44ef1f920abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6afc0cbd-8f60-4120-a5bc-98e766adee32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityEmergingGrowthCompany_6afc0cbd-8f60-4120-a5bc-98e766adee32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_a7e25526-fa12-4602-9d89-c8b7817db6da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityExTransitionPeriod_a7e25526-fa12-4602-9d89-c8b7817db6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1e6c363d-3abd-47dd-97e1-152e0d17affc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1e6c363d-3abd-47dd-97e1-152e0d17affc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c8b2f1bd-1adc-419f-8715-6da8c66b73c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityShellCompany_c8b2f1bd-1adc-419f-8715-6da8c66b73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c0417521-bc60-4c93-b3df-cfaaffafdb82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityPublicFloat_c0417521-bc60-4c93-b3df-cfaaffafdb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_74cf7954-319c-4cd8-977f-aff28b5bd989" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_74cf7954-319c-4cd8-977f-aff28b5bd989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da5dede7-13bb-4065-b480-dd0c529e4f07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da5dede7-13bb-4065-b480-dd0c529e4f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4a14f86b-34f5-4a53-b4b7-c5211234a330" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_EntityCentralIndexKey_4a14f86b-34f5-4a53-b4b7-c5211234a330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2579c2b4-4d1f-4d83-9632-bee2da77a196" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_AmendmentFlag_2579c2b4-4d1f-4d83-9632-bee2da77a196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8f4eafc6-1ed6-483e-ac90-d4ca90942b5a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentFiscalYearFocus_8f4eafc6-1ed6-483e-ac90-d4ca90942b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_35d5ddbc-bd13-420a-9ba6-3705518ad0c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee5afdf5-d620-42a2-b4a9-6efdc9c0292e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_35d5ddbc-bd13-420a-9ba6-3705518ad0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AuditInformation" xlink:type="simple" xlink:href="sttk-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AuditorInformationAbstract_94b2acd7-de6e-49f4-b898-fd6f446c68f9" xlink:href="sttk-20211231.xsd#sttk_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_2ed47359-a1d6-44ea-925a-a7e55a4c5bfd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_AuditorInformationAbstract_94b2acd7-de6e-49f4-b898-fd6f446c68f9" xlink:to="loc_dei_AuditorName_2ed47359-a1d6-44ea-925a-a7e55a4c5bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a8528a0e-5977-49e5-b754-610a8a9d088a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_AuditorInformationAbstract_94b2acd7-de6e-49f4-b898-fd6f446c68f9" xlink:to="loc_dei_AuditorFirmId_a8528a0e-5977-49e5-b754-610a8a9d088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b87beac7-e7ca-4718-a3bf-66528bb04c0c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_AuditorInformationAbstract_94b2acd7-de6e-49f4-b898-fd6f446c68f9" xlink:to="loc_dei_AuditorLocation_b87beac7-e7ca-4718-a3bf-66528bb04c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="simple" xlink:href="sttk-20211231.xsd#BALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12311472-dc9a-46b6-92ae-d2da1d25d6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4fb4630c-c973-4e2e-985a-d9e818b6a868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12311472-dc9a-46b6-92ae-d2da1d25d6fc" xlink:to="loc_us-gaap_AssetsAbstract_4fb4630c-c973-4e2e-985a-d9e818b6a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3e8ed000-3324-4900-982a-f260719aa07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4fb4630c-c973-4e2e-985a-d9e818b6a868" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3e8ed000-3324-4900-982a-f260719aa07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b79c489-3df9-42cf-b698-8538a15bc19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3e8ed000-3324-4900-982a-f260719aa07b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b79c489-3df9-42cf-b698-8538a15bc19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f86b2506-019a-463b-a9c5-b4da6615f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3e8ed000-3324-4900-982a-f260719aa07b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f86b2506-019a-463b-a9c5-b4da6615f5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_daa3cef9-2827-4495-b313-77a3653168bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3e8ed000-3324-4900-982a-f260719aa07b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_daa3cef9-2827-4495-b313-77a3653168bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77739a3f-f9ce-4397-bca8-4bd4f624d68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3e8ed000-3324-4900-982a-f260719aa07b" xlink:to="loc_us-gaap_AssetsCurrent_77739a3f-f9ce-4397-bca8-4bd4f624d68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9118ccfc-ce97-488c-9ae0-2875f935b794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12311472-dc9a-46b6-92ae-d2da1d25d6fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9118ccfc-ce97-488c-9ae0-2875f935b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_02307eaf-ad24-40fa-a3cb-929c8e28877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12311472-dc9a-46b6-92ae-d2da1d25d6fc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_02307eaf-ad24-40fa-a3cb-929c8e28877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8e363b9c-c184-4dde-9161-5ef566624634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12311472-dc9a-46b6-92ae-d2da1d25d6fc" xlink:to="loc_us-gaap_Assets_8e363b9c-c184-4dde-9161-5ef566624634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12311472-dc9a-46b6-92ae-d2da1d25d6fc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0551555e-ace6-4901-8bae-40aaa48dcd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0551555e-ace6-4901-8bae-40aaa48dcd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_225e7ade-18a2-4864-ba37-f2474cfc98af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0551555e-ace6-4901-8bae-40aaa48dcd70" xlink:to="loc_us-gaap_AccountsPayableCurrent_225e7ade-18a2-4864-ba37-f2474cfc98af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_2a49a435-b619-42f3-944b-d596a833c471" xlink:href="sttk-20211231.xsd#sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0551555e-ace6-4901-8bae-40aaa48dcd70" xlink:to="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_2a49a435-b619-42f3-944b-d596a833c471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1c8bd538-6ffa-406d-b465-030aa6ea019f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0551555e-ace6-4901-8bae-40aaa48dcd70" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1c8bd538-6ffa-406d-b465-030aa6ea019f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3d3fd17c-dc11-4d73-9d67-ccd3b8f9588d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0551555e-ace6-4901-8bae-40aaa48dcd70" xlink:to="loc_us-gaap_LiabilitiesCurrent_3d3fd17c-dc11-4d73-9d67-ccd3b8f9588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_041ce3c8-1495-4f98-8ea2-1b15521217d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_041ce3c8-1495-4f98-8ea2-1b15521217d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_aa834cfe-1b71-4ad3-bbf5-1fac38fe903a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_aa834cfe-1b71-4ad3-bbf5-1fac38fe903a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_64ea3da8-781d-4b36-bd11-7e5f1fea9098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_Liabilities_64ea3da8-781d-4b36-bd11-7e5f1fea9098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_03871f8a-ff99-450a-8aa7-a4fb0f6632c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_CommitmentsAndContingencies_03871f8a-ff99-450a-8aa7-a4fb0f6632c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_22d2e8f4-d179-46d2-8d75-f71b70a7348b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:to="loc_us-gaap_CommonStockValue_22d2e8f4-d179-46d2-8d75-f71b70a7348b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d4b8a618-6128-48f8-95de-e8217de2f7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d4b8a618-6128-48f8-95de-e8217de2f7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59c9ef03-c104-457c-b786-ebff3b422f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59c9ef03-c104-457c-b786-ebff3b422f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3ffcc425-e969-480c-b1f9-248e1333c5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3ffcc425-e969-480c-b1f9-248e1333c5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e519d38-1357-4294-aa8d-6951842b09be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_85f91b44-60c0-41ff-8813-fd44c35046fe" xlink:to="loc_us-gaap_StockholdersEquity_1e519d38-1357-4294-aa8d-6951842b09be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1590b5e6-35ed-44d1-9775-019955df4619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07a5abe7-36ce-4f49-a0af-ecfb29f35392" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1590b5e6-35ed-44d1-9775-019955df4619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sttk-20211231.xsd#BALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_00c51cb7-50f0-4b6b-b088-59d630c1a704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b67c4dc9-90f1-4bb1-98bf-613c8e961478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00c51cb7-50f0-4b6b-b088-59d630c1a704" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b67c4dc9-90f1-4bb1-98bf-613c8e961478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c39b4d15-9423-4a41-bc87-500b650c00d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00c51cb7-50f0-4b6b-b088-59d630c1a704" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c39b4d15-9423-4a41-bc87-500b650c00d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_83eaa144-c06e-4eb4-aa8c-c06720e96d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00c51cb7-50f0-4b6b-b088-59d630c1a704" xlink:to="loc_us-gaap_CommonStockSharesIssued_83eaa144-c06e-4eb4-aa8c-c06720e96d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d646782b-e686-467e-9c56-6369c8bf071b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00c51cb7-50f0-4b6b-b088-59d630c1a704" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d646782b-e686-467e-9c56-6369c8bf071b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_fef70104-8b71-46a4-8664-83f0da21c970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_fef70104-8b71-46a4-8664-83f0da21c970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d248646-c01c-4722-9fe4-bab35fb0c999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d248646-c01c-4722-9fe4-bab35fb0c999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b16284f7-7cec-4bd3-b99b-c77a67ef9f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b16284f7-7cec-4bd3-b99b-c77a67ef9f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d9036a8f-4329-404f-b01d-7744d5a0a630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b16284f7-7cec-4bd3-b99b-c77a67ef9f7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d9036a8f-4329-404f-b01d-7744d5a0a630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6ee729f4-f6b3-4ca9-bce6-548e67d5a0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b16284f7-7cec-4bd3-b99b-c77a67ef9f7c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6ee729f4-f6b3-4ca9-bce6-548e67d5a0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5b5d01da-b869-466c-85d9-ca4f584455cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b16284f7-7cec-4bd3-b99b-c77a67ef9f7c" xlink:to="loc_us-gaap_OperatingExpenses_5b5d01da-b869-466c-85d9-ca4f584455cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ad2c47f5-a107-4bad-9c69-f6f87cb36a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_OperatingIncomeLoss_ad2c47f5-a107-4bad-9c69-f6f87cb36a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a8ee48f-5d2c-4c29-96b6-1b473688bccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a8ee48f-5d2c-4c29-96b6-1b473688bccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_726bf433-32c3-4bd2-895a-e03bcb2f0518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a8ee48f-5d2c-4c29-96b6-1b473688bccb" xlink:to="loc_us-gaap_InvestmentIncomeInterest_726bf433-32c3-4bd2-895a-e03bcb2f0518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d3436147-3492-444d-a7e8-c39fd7834c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a8ee48f-5d2c-4c29-96b6-1b473688bccb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d3436147-3492-444d-a7e8-c39fd7834c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e5185e88-3863-4c55-b021-37a98d3695d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a8ee48f-5d2c-4c29-96b6-1b473688bccb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e5185e88-3863-4c55-b021-37a98d3695d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4911205e-5c9d-4d7c-96a5-ea84e06d534a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_NetIncomeLoss_4911205e-5c9d-4d7c-96a5-ea84e06d534a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fdc19c9-46ba-40ac-87e5-8743e6de3c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fdc19c9-46ba-40ac-87e5-8743e6de3c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c98b8059-618c-4bd1-b9fa-f9d53f9c5835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c98b8059-618c-4bd1-b9fa-f9d53f9c5835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_26bf9ddc-68e1-4e59-aaae-ec895adceaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_EarningsPerShareBasic_26bf9ddc-68e1-4e59-aaae-ec895adceaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5bfb28db-8c0c-4bf3-8e2e-bd41cdb4178f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5bfb28db-8c0c-4bf3-8e2e-bd41cdb4178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f357be0-bc72-4548-8c7a-c9d25709958b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f357be0-bc72-4548-8c7a-c9d25709958b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d0ceeeb-535f-454c-a213-375167a50ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71bcd685-221b-4634-a75e-a3b94bec460b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d0ceeeb-535f-454c-a213-375167a50ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_34c8222b-df1f-4bb7-8a9c-e5e93bfe1508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_34c8222b-df1f-4bb7-8a9c-e5e93bfe1508" xlink:to="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e8090fad-67b9-4ea5-92bd-33efd5dc2330" xlink:to="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7203fbb0-4d78-4af3-90fa-21dca29ed398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7203fbb0-4d78-4af3-90fa-21dca29ed398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8f3c7644-a8ff-4966-8500-2bb382218bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8f3c7644-a8ff-4966-8500-2bb382218bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember_ee32d982-99aa-438b-8799-24b4f99de164" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_077b067c-94af-499a-bc23-753393919c49" xlink:to="loc_sttk_SeriesB1PreferredStockMember_ee32d982-99aa-438b-8799-24b4f99de164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9fb7fc97-13d3-499c-8ac3-1e63947c56c7" xlink:to="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ca7aa13-abd8-4ed3-9c31-8a81fd7c50b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_CommonStockMember_8ca7aa13-abd8-4ed3-9c31-8a81fd7c50b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_144222c1-b053-4857-9196-807d2e986968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_144222c1-b053-4857-9196-807d2e986968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70cfbaa0-eb42-4365-afd4-494a36a28166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70cfbaa0-eb42-4365-afd4-494a36a28166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b9d03b22-17da-4112-af80-aac1a3afed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b2958fc8-a415-4d91-8903-e5926c802c2d" xlink:to="loc_us-gaap_RetainedEarningsMember_b9d03b22-17da-4112-af80-aac1a3afed9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86fe8e45-e63c-4417-9a3e-366b25405867" xlink:to="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ba4648bf-1050-4749-99bb-8433d8ecc252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ba4648bf-1050-4749-99bb-8433d8ecc252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0bae7067-c59e-43e0-bc6b-e62cde0fb2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0bae7067-c59e-43e0-bc6b-e62cde0fb2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_42f9461c-3ff9-4b52-968b-2d30bd5f0824" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_42f9461c-3ff9-4b52-968b-2d30bd5f0824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_8c7f440a-3882-4bd5-8ce7-81528fee592d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_8c7f440a-3882-4bd5-8ce7-81528fee592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_77059a5a-2a61-4e38-a780-f3dd7b5d47f9" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock_77059a5a-2a61-4e38-a780-f3dd7b5d47f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_7d33892a-e5d2-4304-a045-e5fac8488c58" xlink:href="sttk-20211231.xsd#sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock_7d33892a-e5d2-4304-a045-e5fac8488c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_8c98a71a-3b62-4b20-83f9-633d2483c9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_8c98a71a-3b62-4b20-83f9-633d2483c9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0751e12a-e000-49b9-ac18-7c1c74279b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d9f37e88-1b2e-454f-9487-608c84008f9d" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0751e12a-e000-49b9-ac18-7c1c74279b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc78aaec-f4b5-4b40-886a-1f2e6221103f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_314e8b35-f71f-40c5-bf2d-f254ba81dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_SharesOutstanding_314e8b35-f71f-40c5-bf2d-f254ba81dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6186481f-6931-4f41-aca8-b19b45fadff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockholdersEquity_6186481f-6931-4f41-aca8-b19b45fadff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0f4531b6-e693-4ea6-82c3-ad8fec6e3365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0f4531b6-e693-4ea6-82c3-ad8fec6e3365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8e815f5-cf87-40aa-8d91-b896037a6e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8e815f5-cf87-40aa-8d91-b896037a6e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_05cafcab-6a20-4369-b485-d4d5b403dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_05cafcab-6a20-4369-b485-d4d5b403dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_af2d025b-bb7b-474f-82c0-a48b79fa99db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_af2d025b-bb7b-474f-82c0-a48b79fa99db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c95988de-6681-4b6d-8d1b-008b3ff07b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c95988de-6681-4b6d-8d1b-008b3ff07b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f32ad2cf-0ecd-4099-ba42-864c585a4f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f32ad2cf-0ecd-4099-ba42-864c585a4f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5f48f726-ba39-4df1-9591-2190ae757fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5f48f726-ba39-4df1-9591-2190ae757fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07d7a5b-4322-4176-a1f0-fdbf0148380b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d07d7a5b-4322-4176-a1f0-fdbf0148380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e5628606-75de-48c7-a743-4759517b2cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e5628606-75de-48c7-a743-4759517b2cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8adfbcf2-b07c-410c-b54c-61eeca75eb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_NetIncomeLoss_8adfbcf2-b07c-410c-b54c-61eeca75eb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_520de38a-c115-4609-81f1-35618e74697b" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_520de38a-c115-4609-81f1-35618e74697b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_985e8f43-7f42-4b25-8749-515954536df6" xlink:href="sttk-20211231.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_985e8f43-7f42-4b25-8749-515954536df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_77c75848-8408-4868-a2ea-de21f10ebf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_SharesOutstanding_77c75848-8408-4868-a2ea-de21f10ebf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c2fc93b-aaee-4c84-a2d4-1f2d0c052a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cf596b-7478-4100-94fd-2592553b531e" xlink:to="loc_us-gaap_StockholdersEquity_4c2fc93b-aaee-4c84-a2d4-1f2d0c052a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20211231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7c1e9951-e779-4d06-ab7e-d3f79a767e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7c1e9951-e779-4d06-ab7e-d3f79a767e7a" xlink:to="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43fbd3f0-32a5-416c-adff-08f5a45fb1ca" xlink:to="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember_fe3e3372-12ea-4554-8ff4-731db58d3f71" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:to="loc_sttk_SeriesB1PreferredStockMember_fe3e3372-12ea-4554-8ff4-731db58d3f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_cce82373-daf2-4041-b662-96eb64e357d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35a90188-9999-4d49-8140-0947fd7b258d" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_cce82373-daf2-4041-b662-96eb64e357d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7725b8f-3e7c-4d2a-9c07-f3eae326b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f9f87337-b387-40f3-ae46-23447c783c0b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7725b8f-3e7c-4d2a-9c07-f3eae326b42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c986117f-860f-4963-8ed5-2b3a8b869095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7725b8f-3e7c-4d2a-9c07-f3eae326b42c" xlink:to="loc_us-gaap_IPOMember_c986117f-860f-4963-8ed5-2b3a8b869095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d74d665b-755b-4238-8d29-31d87ea6f4c2" xlink:to="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_395ce1a1-b28b-45cc-ba70-f6ded3183776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:to="loc_us-gaap_NetIncomeLoss_395ce1a1-b28b-45cc-ba70-f6ded3183776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33fb35ce-8629-494a-ad96-73f5548ec294" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5612d245-3b8a-49a8-a1e1-19d89e308cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_ShareBasedCompensation_5612d245-3b8a-49a8-a1e1-19d89e308cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_65be597f-dc39-4aa0-a680-3d89c4682cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_Depreciation_65be597f-dc39-4aa0-a680-3d89c4682cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_afd8602e-739e-4809-8485-fe5a2991cdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_afd8602e-739e-4809-8485-fe5a2991cdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c61c744-3c61-4b5d-9ba8-bc6e073fadff" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2baaa5f9-601d-4cb0-8d12-9491868e16a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2baaa5f9-601d-4cb0-8d12-9491868e16a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9759e51a-b4ad-42cd-87ab-134b6a8dd4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9759e51a-b4ad-42cd-87ab-134b6a8dd4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_06ac39ac-96e2-47fb-85de-c822c421c752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_06ac39ac-96e2-47fb-85de-c822c421c752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_346cc38f-1d1a-40de-b337-36f7050cb268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_346cc38f-1d1a-40de-b337-36f7050cb268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdf0391b-6060-452b-81fd-80d39aaeaf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdf0391b-6060-452b-81fd-80d39aaeaf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInDeferredRentCredits_3f68a1de-6439-4357-bc46-03e3314b1d9d" xlink:href="sttk-20211231.xsd#sttk_IncreaseDecreaseInDeferredRentCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_sttk_IncreaseDecreaseInDeferredRentCredits_3f68a1de-6439-4357-bc46-03e3314b1d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e860031-d6c4-4de7-b708-4506b59cfa77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c74df0b2-28ff-488d-847c-217d7b94ed6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e860031-d6c4-4de7-b708-4506b59cfa77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_439afa9d-62ab-4344-a8be-adc8e4807a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_439afa9d-62ab-4344-a8be-adc8e4807a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2c3c5619-6f20-497c-9982-c83059db8970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2c3c5619-6f20-497c-9982-c83059db8970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12bdd92f-7844-4cd5-afcd-ee7972a3aa32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12bdd92f-7844-4cd5-afcd-ee7972a3aa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2df654f4-e5f5-4304-8b96-0728aa6b2457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28db9624-2103-4799-a038-526ea1688e96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2df654f4-e5f5-4304-8b96-0728aa6b2457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0715d2cc-7d4a-4f7e-8830-bc0745557244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0715d2cc-7d4a-4f7e-8830-bc0745557244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_de1f4d72-4d30-4bc9-be81-7a8dfb571f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_de1f4d72-4d30-4bc9-be81-7a8dfb571f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_692b1e58-a124-419c-bebc-e2249c267295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_692b1e58-a124-419c-bebc-e2249c267295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_50ec696f-6f57-4c5b-9078-9c7e00119885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_50ec696f-6f57-4c5b-9078-9c7e00119885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f17f6-edb1-42c1-8ac6-013a08a990d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5cd5b924-5993-4ce2-8358-caba00bf3c3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f17f6-edb1-42c1-8ac6-013a08a990d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0f9852a-b35d-4a73-a6a8-60219c858f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0f9852a-b35d-4a73-a6a8-60219c858f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4cb6eda-3fa2-49e6-aab6-e7aff2b414f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4cb6eda-3fa2-49e6-aab6-e7aff2b414f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0a08a65-7fb4-4cbf-8e42-942fddd5b949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0a08a65-7fb4-4cbf-8e42-942fddd5b949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef608ba2-d03b-4f98-a061-fc03efdd44b7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_67e3b997-4e6b-471a-8e08-567492211fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_67e3b997-4e6b-471a-8e08-567492211fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0a82e599-f91e-4751-be23-8fd306e6dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83be20c3-936d-42c4-8272-482d5e733b6b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0a82e599-f91e-4751-be23-8fd306e6dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="sttk-20211231.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d974ce6-4787-485c-a363-9d03462e32fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_bbe2fb25-d343-4921-9771-1df19f5c0a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d974ce6-4787-485c-a363-9d03462e32fc" xlink:to="loc_us-gaap_NatureOfOperations_bbe2fb25-d343-4921-9771-1df19f5c0a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65cf3e10-18c7-4c8a-afa5-045a360f7c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b452a5dd-cab2-411a-b99a-a44d9a8d195a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65cf3e10-18c7-4c8a-afa5-045a360f7c55" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b452a5dd-cab2-411a-b99a-a44d9a8d195a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_80b3c634-7279-4883-8b91-6b43c7f39e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65cf3e10-18c7-4c8a-afa5-045a360f7c55" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_80b3c634-7279-4883-8b91-6b43c7f39e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91ab9879-7faa-429d-8d2c-6e3a1879bca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_152613c4-ee4b-41c0-991d-0bba1ac3d068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91ab9879-7faa-429d-8d2c-6e3a1879bca6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_152613c4-ee4b-41c0-991d-0bba1ac3d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_69d6af58-d8b4-45f5-9dc3-ce58c22ca60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_69d6af58-d8b4-45f5-9dc3-ce58c22ca60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_051140e9-f061-4c3b-8655-d651c708e270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_UseOfEstimates_051140e9-f061-4c3b-8655-d651c708e270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8f3ab347-1c0b-4376-9f8c-8031ed614a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8f3ab347-1c0b-4376-9f8c-8031ed614a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2069185b-5062-4a64-b403-a7ab94b64d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2069185b-5062-4a64-b403-a7ab94b64d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_edd9b0b3-ecde-43dd-a96e-422f25d1f97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_edd9b0b3-ecde-43dd-a96e-422f25d1f97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_445917e0-ba73-45e4-8467-71b99f9e0cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_445917e0-ba73-45e4-8467-71b99f9e0cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_59af154d-0d94-45e5-a195-e4f0886bea78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_59af154d-0d94-45e5-a195-e4f0886bea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_f1ea0ebb-3333-4baa-a8c0-2d513513e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_f1ea0ebb-3333-4baa-a8c0-2d513513e4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_d7d6a68e-3343-4675-80f7-89c9b60dd74a" xlink:href="sttk-20211231.xsd#sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_d7d6a68e-3343-4675-80f7-89c9b60dd74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7822a703-fa15-49c0-af99-7ec888a67ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7822a703-fa15-49c0-af99-7ec888a67ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_88ac61bd-445a-45db-90ad-6ffc51367d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_88ac61bd-445a-45db-90ad-6ffc51367d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_600e2945-441d-48a4-9e05-42817635df75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_600e2945-441d-48a4-9e05-42817635df75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1f9874f5-c04c-4b47-b0a0-836157b2010f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1f9874f5-c04c-4b47-b0a0-836157b2010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_df0633f5-86df-438d-929d-cc57c7bee604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_df0633f5-86df-438d-929d-cc57c7bee604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_82f05c3e-1c6b-48ac-8365-f1004ba9f814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_82f05c3e-1c6b-48ac-8365-f1004ba9f814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_db9878aa-caac-4f4c-903f-7afe6a66639f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_db9878aa-caac-4f4c-903f-7afe6a66639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5eb774c5-66b7-49c6-9d49-4151a56ba4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5eb774c5-66b7-49c6-9d49-4151a56ba4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_77d4b7fd-e143-40a0-ab9c-55eee0555f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_77d4b7fd-e143-40a0-ab9c-55eee0555f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cc9968fa-9c3f-4942-85b8-d5311361ad90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d154f67d-183e-4c21-a3fa-ea9dd16e94ea" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cc9968fa-9c3f-4942-85b8-d5311361ad90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77fd483d-f9ba-4431-b61b-f8d5424039ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_dca20ee6-0c31-4e98-af20-831b1eb51999" xlink:href="sttk-20211231.xsd#sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77fd483d-f9ba-4431-b61b-f8d5424039ca" xlink:to="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_dca20ee6-0c31-4e98-af20-831b1eb51999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_41708fe8-2157-4ce4-bc47-5fbd6c80a222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77fd483d-f9ba-4431-b61b-f8d5424039ca" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_41708fe8-2157-4ce4-bc47-5fbd6c80a222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b1900e6-9524-4d7b-841e-85f90143f176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_d2dae44e-25e8-426e-834f-ba9b74909942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b1900e6-9524-4d7b-841e-85f90143f176" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_d2dae44e-25e8-426e-834f-ba9b74909942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b1900e6-9524-4d7b-841e-85f90143f176" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_06a8871a-a5b1-46ee-85b3-5f556dc9ac70" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_b287d59c-389c-413c-8cfc-15acc49995b1" xlink:href="sttk-20211231.xsd#sttk_OperatingAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:to="loc_sttk_OperatingAccountMember_b287d59c-389c-413c-8cfc-15acc49995b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_26028a96-0836-4849-851e-196e006df0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_26028a96-0836-4849-851e-196e006df0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_05f83803-c085-4285-8391-a87c17acbb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05c33dec-cc3e-4029-8bd4-f6c420e20f7a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_05f83803-c085-4285-8391-a87c17acbb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_30cc5120-36bf-4cf9-817f-0b88dbd8a5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6ebb9285-cdad-4863-91b6-1285d42300ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_30cc5120-36bf-4cf9-817f-0b88dbd8a5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4bd6d950-21bb-42a5-bca7-d5e2a5443cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_30cc5120-36bf-4cf9-817f-0b88dbd8a5cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4bd6d950-21bb-42a5-bca7-d5e2a5443cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfdf417-4212-4f3b-90ac-0172ad1ad3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acfdf417-4212-4f3b-90ac-0172ad1ad3b2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9011670-7b2f-49d0-b073-34f361bec1e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_cdcb9a29-0993-476d-ae88-f8b16d370db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_us-gaap_OfficeEquipmentMember_cdcb9a29-0993-476d-ae88-f8b16d370db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_948ac67a-67f6-4d46-b52f-c8b09377c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_948ac67a-67f6-4d46-b52f-c8b09377c26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_f09da99f-28da-45f9-96b5-52b3dedb4694" xlink:href="sttk-20211231.xsd#sttk_LabEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_sttk_LabEquipmentMember_f09da99f-28da-45f9-96b5-52b3dedb4694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_749c4176-2778-4c10-b140-115630a16639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c51abb4b-4aa0-43d7-8bcc-c1d30635abe6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_749c4176-2778-4c10-b140-115630a16639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:to="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82dfda42-fb1b-4bd6-81ec-2c0d7180293d" xlink:to="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4169460-56c2-4a32-b593-9b648090b5e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:to="loc_srt_MinimumMember_e4169460-56c2-4a32-b593-9b648090b5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d45cd078-5cbe-4a05-a300-6e31e90967e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9a97642-7377-439b-85aa-5a5743663dfa" xlink:to="loc_srt_MaximumMember_d45cd078-5cbe-4a05-a300-6e31e90967e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dd9abe69-5e52-428b-8841-8d9b3ee79964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d471c243-ab1a-4da2-804b-a52b29bd698f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dd9abe69-5e52-428b-8841-8d9b3ee79964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302711a2-6525-402c-826c-28bde762529c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dd9abe69-5e52-428b-8841-8d9b3ee79964" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302711a2-6525-402c-826c-28bde762529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c251136-f00a-492d-a8e8-c206a8a40f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c251136-f00a-492d-a8e8-c206a8a40f41" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b58f3c8-5c14-4822-b887-f1b8beab2ee2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28b5ed64-6083-498f-8bcc-ec5dcc67379e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28b5ed64-6083-498f-8bcc-ec5dcc67379e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e68b6397-4331-4ba3-a7a6-ff937efad9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ed3837d-2a92-4147-8dec-21137305a9ad" xlink:to="loc_us-gaap_RestrictedStockMember_e68b6397-4331-4ba3-a7a6-ff937efad9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38359475-1008-43ef-ba83-5a7da6c2432e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f77ac847-55a3-41ff-a5b2-9a5559dff37b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38359475-1008-43ef-ba83-5a7da6c2432e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3209dfa-f2e8-4589-bc67-5efeaeef39bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38359475-1008-43ef-ba83-5a7da6c2432e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3209dfa-f2e8-4589-bc67-5efeaeef39bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/ShortTermInvestments" xlink:type="simple" xlink:href="sttk-20211231.xsd#ShortTermInvestments"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/ShortTermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_069b7368-18fc-4761-8014-06df1ccdc8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6465d4be-f584-45dc-8d96-90a54fd112d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_069b7368-18fc-4761-8014-06df1ccdc8ce" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6465d4be-f584-45dc-8d96-90a54fd112d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#ShortTermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/ShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7425c784-c606-4cdf-9868-40fa91c82322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7d69b7d1-6ec5-47d1-a716-0807a7296b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7425c784-c606-4cdf-9868-40fa91c82322" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7d69b7d1-6ec5-47d1-a716-0807a7296b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d2b72bd-ebfe-4b05-b45c-ed2872312ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d2b72bd-ebfe-4b05-b45c-ed2872312ce1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b941a6e-4877-4aa0-924f-4d9d57d1620b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37e7b01d-dc8b-4eb6-a238-b09cfa936ffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b941a6e-4877-4aa0-924f-4d9d57d1620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_48a44069-3899-461f-8fe9-602ad0283afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b941a6e-4877-4aa0-924f-4d9d57d1620b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_48a44069-3899-461f-8fe9-602ad0283afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd75fb9b-2fc8-4e4d-ad17-86263301ece5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6ad14cf9-dc51-431d-9b99-8ce72c3a9657" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd75fb9b-2fc8-4e4d-ad17-86263301ece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd75fb9b-2fc8-4e4d-ad17-86263301ece5" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6678474-8766-4614-bbe1-9a7f2df048e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6678474-8766-4614-bbe1-9a7f2df048e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_436007d8-98ad-4b9e-941f-3b5eccd37685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_436007d8-98ad-4b9e-941f-3b5eccd37685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65c0217f-139e-41eb-b004-66dba3426f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_88769bee-a856-4f3d-a5f0-18ba85e4bb4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65c0217f-139e-41eb-b004-66dba3426f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#ShortTermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e47f6b53-8703-4bd0-9efb-3111d3ba6f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_8d02b402-73ae-4ce5-8866-506e404fa5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e47f6b53-8703-4bd0-9efb-3111d3ba6f64" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_8d02b402-73ae-4ce5-8866-506e404fa5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="sttk-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6e8f75a1-c7ee-4d6d-9e39-a018003540c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_f031278c-b301-4443-9d55-5bc3ebe783d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6e8f75a1-c7ee-4d6d-9e39-a018003540c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_f031278c-b301-4443-9d55-5bc3ebe783d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3d506872-b33c-4ae4-89e7-4a9226e6f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_cf5a372b-21e1-4bf6-ad09-8732a59d02a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3d506872-b33c-4ae4-89e7-4a9226e6f8a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_cf5a372b-21e1-4bf6-ad09-8732a59d02a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#PropertyandEquipmentScheduleofpropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_02c218c3-adb3-4b3c-a94d-50e9eeb525ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_02c218c3-adb3-4b3c-a94d-50e9eeb525ca" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_253f2af6-674a-4c52-81f8-dafac4f01899" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_c720ce9f-5fad-46ba-8bad-ee790572e941" xlink:href="sttk-20211231.xsd#sttk_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_sttk_LabEquipmentMember_c720ce9f-5fad-46ba-8bad-ee790572e941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c52f10c2-45f9-4680-8d44-94d37d3dbae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c52f10c2-45f9-4680-8d44-94d37d3dbae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_819d3390-ec12-4bc1-8b43-1d0b39f2b55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_ConstructionInProgressMember_819d3390-ec12-4bc1-8b43-1d0b39f2b55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d7b8dce9-0e1d-4495-8bb9-a43c55d30be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d7b8dce9-0e1d-4495-8bb9-a43c55d30be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_6b329631-3f84-4d01-afd9-c4c6759e13c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf397d12-417d-4ba2-8d55-98b2ee5cc63b" xlink:to="loc_us-gaap_OfficeEquipmentMember_6b329631-3f84-4d01-afd9-c4c6759e13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a091c10a-3920-4254-b550-f74425dd1950" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f2e00e61-1ea1-4d84-83fd-4cb57a02e687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f2e00e61-1ea1-4d84-83fd-4cb57a02e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a08b89b7-eefa-431f-bedc-a4de8b738395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a08b89b7-eefa-431f-bedc-a4de8b738395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_faa87d70-e475-4ae9-b85b-d2ce9efddd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55affa18-041b-415e-b600-58d4caf4916c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_faa87d70-e475-4ae9-b85b-d2ce9efddd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_76a830fe-1db3-4ade-b3e3-17796c91f3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_74ca3b15-da8f-4e0b-9b83-e67faa9af8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_76a830fe-1db3-4ade-b3e3-17796c91f3c5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_74ca3b15-da8f-4e0b-9b83-e67faa9af8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpenses" xlink:type="simple" xlink:href="sttk-20211231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_92bf184a-47c8-40e4-894e-ef117f551ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2dde8d89-d855-44fc-877c-00944e33991a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_92bf184a-47c8-40e4-894e-ef117f551ffe" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2dde8d89-d855-44fc-877c-00944e33991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4fb9186f-8c04-4af9-b788-297b9d96a07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b4da5ccc-cdcf-4524-9519-9cedffd580bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4fb9186f-8c04-4af9-b788-297b9d96a07d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b4da5ccc-cdcf-4524-9519-9cedffd580bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#AccruedExpensesScheduleofaccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_611bb4a0-601f-4d20-896e-6a65372bca89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_de65a31f-e31e-435b-940a-c28eb4ae2291" xlink:href="sttk-20211231.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_611bb4a0-601f-4d20-896e-6a65372bca89" xlink:to="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_de65a31f-e31e-435b-940a-c28eb4ae2291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b526a47f-02b1-400a-9a6e-15bfdec06095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_611bb4a0-601f-4d20-896e-6a65372bca89" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b526a47f-02b1-400a-9a6e-15bfdec06095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7030c986-c790-4957-a30a-fa8cbd7051c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_611bb4a0-601f-4d20-896e-6a65372bca89" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7030c986-c790-4957-a30a-fa8cbd7051c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_13661fdb-d7e5-4d52-9ff9-0554cc619728" xlink:href="sttk-20211231.xsd#sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_611bb4a0-601f-4d20-896e-6a65372bca89" xlink:to="loc_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_13661fdb-d7e5-4d52-9ff9-0554cc619728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sttk-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7b5aae3-0247-48c8-8f06-bd0581e0e8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eff1e1fa-16ac-4604-8d57-4831f4d7397b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7b5aae3-0247-48c8-8f06-bd0581e0e8a9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eff1e1fa-16ac-4604-8d57-4831f4d7397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7a84cd4-bd90-4f69-8e69-fca04338a47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_64247011-b871-437a-b6b2-2a236608caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7a84cd4-bd90-4f69-8e69-fca04338a47b" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_64247011-b871-437a-b6b2-2a236608caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_66ae1ea0-9e46-4ef9-b421-2c1f80498bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_66ae1ea0-9e46-4ef9-b421-2c1f80498bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_152db5f2-f2ad-4d23-82e7-bbd4b87472ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_152db5f2-f2ad-4d23-82e7-bbd4b87472ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0e612f7d-e529-430a-aaf7-e03996e865a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0e612f7d-e529-430a-aaf7-e03996e865a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_35b3fc26-3ef7-43a4-82d7-3b54689e9c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_35b3fc26-3ef7-43a4-82d7-3b54689e9c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_539053eb-3792-472b-ad73-c636ab1c6b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_539053eb-3792-472b-ad73-c636ab1c6b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0e192ff6-36cd-48ab-bc64-cf8d64b50372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0e192ff6-36cd-48ab-bc64-cf8d64b50372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0b4571ce-72d2-47ca-a21b-703b42baf750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f714c02b-54ba-4cb4-9a1e-79593de19a30" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0b4571ce-72d2-47ca-a21b-703b42baf750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b2c908b-b62f-4ffe-9139-69d451284e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_b7e0095b-c314-46e5-a133-4358271e9edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b2c908b-b62f-4ffe-9139-69d451284e90" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_b7e0095b-c314-46e5-a133-4358271e9edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum_e879f772-b6f9-4f96-bc28-a1516ca4d13c" xlink:href="sttk-20211231.xsd#sttk_LicenseAgreementRoyaltyPaymentsMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b2c908b-b62f-4ffe-9139-69d451284e90" xlink:to="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum_e879f772-b6f9-4f96-bc28-a1516ca4d13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PreferredStock" xlink:type="simple" xlink:href="sttk-20211231.xsd#PreferredStock"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_7d15502a-11e5-45a0-b4f1-6736ffea8edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_3323fa21-2bd5-46cd-bd60-15f58b73fd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_7d15502a-11e5-45a0-b4f1-6736ffea8edf" xlink:to="loc_us-gaap_PreferredStockTextBlock_3323fa21-2bd5-46cd-bd60-15f58b73fd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#PreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_ef1a052c-8b03-427b-905a-fd92e3965502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_ef1a052c-8b03-427b-905a-fd92e3965502" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_62d81aa6-6615-4f3d-b1f4-d5b1b0549f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c734d14-c4a2-48e8-8bc9-6f58baef495e" xlink:to="loc_us-gaap_ClassOfStockDomain_62d81aa6-6615-4f3d-b1f4-d5b1b0549f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_62d81aa6-6615-4f3d-b1f4-d5b1b0549f7d" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_98932372-809d-485a-aadd-74c4e2117d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_98932372-809d-485a-aadd-74c4e2117d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SeriesB1PreferredStockMember_9c67135a-728a-4006-a8cc-9b2bf9a21d89" xlink:href="sttk-20211231.xsd#sttk_SeriesB1PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_16cb1a82-8718-4878-9e59-83ce9cd42759" xlink:to="loc_sttk_SeriesB1PreferredStockMember_9c67135a-728a-4006-a8cc-9b2bf9a21d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_d7888ec4-a3f2-4ed7-957a-21cd2d5436e9" xlink:to="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ee46246-faa4-4611-ac57-6d98173287e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ee46246-faa4-4611-ac57-6d98173287e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2fa7b7bc-b105-4a92-b915-4466a2c67c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2fa7b7bc-b105-4a92-b915-4466a2c67c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fb6c3af-e934-4c03-b03a-a2e962f8f5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_14fe25d6-66be-4a58-b2a8-1754d1a50646" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fb6c3af-e934-4c03-b03a-a2e962f8f5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty" xlink:type="simple" xlink:href="sttk-20211231.xsd#CollaborationAgreementRelatedParty"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6d9e606e-c87e-44b2-9bb3-2fb8708d29a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0a0bb91a-3ff3-431e-ba3e-8bf8cec8814d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6d9e606e-c87e-44b2-9bb3-2fb8708d29a4" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0a0bb91a-3ff3-431e-ba3e-8bf8cec8814d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#CollaborationAgreementRelatedPartyDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0cee4ca5-c5f6-4973-a3af-37571fc80f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0cee4ca5-c5f6-4973-a3af-37571fc80f78" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d9b0bb-ad7b-4fa0-af1b-665619f1af13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6d37cc23-accb-438e-adfe-bdb96fb506a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d9b0bb-ad7b-4fa0-af1b-665619f1af13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TakedaMember_57ab3a0a-6747-4291-9c74-04e91f899850" xlink:href="sttk-20211231.xsd#sttk_TakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2d9b0bb-ad7b-4fa0-af1b-665619f1af13" xlink:to="loc_sttk_TakedaMember_57ab3a0a-6747-4291-9c74-04e91f899850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_29a1dec3-2ed9-497b-8ad3-3820e3609cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd32dafb-f9ca-4eb0-b67a-5c6f27cec683" xlink:to="loc_us-gaap_RelatedPartyDomain_29a1dec3-2ed9-497b-8ad3-3820e3609cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_e1e49224-592b-49c6-a4d5-9768a944c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_29a1dec3-2ed9-497b-8ad3-3820e3609cb8" xlink:to="loc_us-gaap_InvestorMember_e1e49224-592b-49c6-a4d5-9768a944c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3489ff2-472f-45bf-810e-c68bf7994527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b06cae69-6c29-47e5-b772-bf3293ac015d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3489ff2-472f-45bf-810e-c68bf7994527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c4259a4a-aff7-4ae4-b558-ea4a099547a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3489ff2-472f-45bf-810e-c68bf7994527" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c4259a4a-aff7-4ae4-b558-ea4a099547a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b0c2921d-a0a2-4320-9035-c122fc01a8a2" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_53271698-a659-41ee-a572-a2e8705f7a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:to="loc_us-gaap_ProceedsFromCollaborators_53271698-a659-41ee-a572-a2e8705f7a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45a663e2-24d4-4384-a9c8-87c36c3b6c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1a159838-f559-495b-9571-ea19196f61bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45a663e2-24d4-4384-a9c8-87c36c3b6c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62c1b626-ce0b-4454-bf0e-21d9d0088aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7fbe3984-d845-4cb6-bbcb-2db75cb729b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62c1b626-ce0b-4454-bf0e-21d9d0088aa2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7fbe3984-d845-4cb6-bbcb-2db75cb729b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf2c6b6f-0e6c-4d2b-bdf9-b3df40092382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d9d893c-0a4f-48ac-b620-3dd5e4379447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf2c6b6f-0e6c-4d2b-bdf9-b3df40092382" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d9d893c-0a4f-48ac-b620-3dd5e4379447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00b88d09-c3f5-4847-8018-b6414773dc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf2c6b6f-0e6c-4d2b-bdf9-b3df40092382" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00b88d09-c3f5-4847-8018-b6414773dc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e69f6cb4-8484-4618-9491-b46f9714f8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf2c6b6f-0e6c-4d2b-bdf9-b3df40092382" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e69f6cb4-8484-4618-9491-b46f9714f8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_d65ff7d0-9da1-4dff-ae29-9c0a02864e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf2c6b6f-0e6c-4d2b-bdf9-b3df40092382" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_d65ff7d0-9da1-4dff-ae29-9c0a02864e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9b2d580-0eb9-4835-8d29-483fb665ef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9b2d580-0eb9-4835-8d29-483fb665ef62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f4756875-479b-4d82-80ce-fe127c8ba6d3" xlink:to="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_a903f244-587a-4138-99c1-fe4f2b803f51" xlink:href="sttk-20211231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:to="loc_sttk_A2020StockIncentivePlanMember_a903f244-587a-4138-99c1-fe4f2b803f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_e215e395-ddbd-4d84-b2e4-62cf1c4815ca" xlink:href="sttk-20211231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33e1443b-4360-423a-bd77-6877c01e047a" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_e215e395-ddbd-4d84-b2e4-62cf1c4815ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1915d27f-54e2-4d02-af8b-3e092974f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a3342f31-c814-4e25-9e4e-cc3a91a4aa47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1915d27f-54e2-4d02-af8b-3e092974f0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa97dd09-13c7-4f70-af70-f7fe4339a920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1915d27f-54e2-4d02-af8b-3e092974f0f6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa97dd09-13c7-4f70-af70-f7fe4339a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e409b04-cde3-4cd3-9a1b-7f97927f58e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3a27e861-fae2-4458-a735-6eabcca6acd5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e409b04-cde3-4cd3-9a1b-7f97927f58e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8931fb16-2859-4758-89b5-a7667f7440e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6e409b04-cde3-4cd3-9a1b-7f97927f58e0" xlink:to="loc_us-gaap_SubsequentEventMember_8931fb16-2859-4758-89b5-a7667f7440e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30f39af7-4805-4319-813b-9db37cf0c974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_3fe4496c-dae8-41a5-bdd2-6017917dce51" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_3fe4496c-dae8-41a5-bdd2-6017917dce51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5581cbc-eabf-466c-9d06-3227c3a1eef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5581cbc-eabf-466c-9d06-3227c3a1eef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_9fc0f52e-91cc-40a4-8244-4410ea55e548" xlink:href="sttk-20211231.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_9fc0f52e-91cc-40a4-8244-4410ea55e548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f861c5f-d0a5-4307-ab15-5eaedc42fc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f861c5f-d0a5-4307-ab15-5eaedc42fc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_833100cd-fe8e-4cae-8e07-479b81b38d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_833100cd-fe8e-4cae-8e07-479b81b38d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e462d755-498a-40f7-9392-5f0bbe2d6b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e462d755-498a-40f7-9392-5f0bbe2d6b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3e63ba00-7319-4e6c-873d-616ac71370c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3e63ba00-7319-4e6c-873d-616ac71370c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_3dd6bfec-0436-4a9b-b49f-c946c13abd1b" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_3dd6bfec-0436-4a9b-b49f-c946c13abd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_49a08b27-aaa3-4ccc-ae17-df19a4f08064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_49a08b27-aaa3-4ccc-ae17-df19a4f08064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_7378b2f5-1fb6-4d46-bd99-f21944578bc6" xlink:href="sttk-20211231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_7378b2f5-1fb6-4d46-bd99-f21944578bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d613edac-62c3-46c9-a4c5-1f108c268917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d613edac-62c3-46c9-a4c5-1f108c268917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_cabdfa5b-3805-41d7-9902-315720a1d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ProceedsFromStockPlans_cabdfa5b-3805-41d7-9902-315720a1d0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1b94670-470a-4986-9369-ef615d53727d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1b94670-470a-4986-9369-ef615d53727d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f8f2c39-9275-44d7-a1b0-df3e1d0de048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f8f2c39-9275-44d7-a1b0-df3e1d0de048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63eb346a-3876-41d7-ae7c-c4e3ae098ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63eb346a-3876-41d7-ae7c-c4e3ae098ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6a40475a-7ac5-408f-97f2-f69630d9cf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6a40475a-7ac5-408f-97f2-f69630d9cf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_10159f25-5198-4c28-9b26-264ca37cbcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_10159f25-5198-4c28-9b26-264ca37cbcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5fba0fda-3665-414c-8d5b-fe83578f76c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5fba0fda-3665-414c-8d5b-fe83578f76c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_980f0b7b-cfb4-4e14-ac81-d7299ee740f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c629d40a-9c33-49ca-b5b8-dca87f1c7f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_980f0b7b-cfb4-4e14-ac81-d7299ee740f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b8d0cf9-b368-4d96-a0cd-ad9935b10207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b8d0cf9-b368-4d96-a0cd-ad9935b10207" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51ac6dbb-4691-453b-b95a-fa7689cc5e94" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3fcaeaa0-5fad-4317-b15e-0af337607b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3fcaeaa0-5fad-4317-b15e-0af337607b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_06636ecb-87cd-4b29-bac1-6b794104277a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d832093-535c-4671-bdf6-a0e97b42a6f3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_06636ecb-87cd-4b29-bac1-6b794104277a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14a110cd-c971-42b1-a6dd-144b1a639ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e71eb281-fa23-4468-a7e5-fcb9396d4821" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14a110cd-c971-42b1-a6dd-144b1a639ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f11b538-a851-4cb9-bc5c-215befa4adeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14a110cd-c971-42b1-a6dd-144b1a639ffb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f11b538-a851-4cb9-bc5c-215befa4adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleofoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f30619ae-98a1-4cc3-9d4e-568214d6b487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f30619ae-98a1-4cc3-9d4e-568214d6b487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3afff725-543a-4016-9c6d-868a013582e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3afff725-543a-4016-9c6d-868a013582e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b3706d2e-da1b-4707-8174-b7b4c6c342dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b3706d2e-da1b-4707-8174-b7b4c6c342dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f6e6102a-4841-458d-9302-df9bedb7d531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f6e6102a-4841-458d-9302-df9bedb7d531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0746c743-a060-43ef-80f0-240204b9b04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5046cda8-a38e-497d-ad87-fbdd536559d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0746c743-a060-43ef-80f0-240204b9b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6c50e145-1443-4126-923d-efa2ac349a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6c50e145-1443-4126-923d-efa2ac349a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c65a7165-a6f1-4f51-a570-062a17e348cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c65a7165-a6f1-4f51-a570-062a17e348cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66bc1a58-fbe7-4115-9b7a-54cca7c23afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66bc1a58-fbe7-4115-9b7a-54cca7c23afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c24e5d8d-fc33-4564-81ab-c59140400e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c24e5d8d-fc33-4564-81ab-c59140400e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18fdc6a7-9ddc-43a0-b4da-5bfe65f6f83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18fdc6a7-9ddc-43a0-b4da-5bfe65f6f83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3e1c07d-862a-4b45-8e74-bfc2776690af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3e1c07d-862a-4b45-8e74-bfc2776690af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ef654368-d4d9-4a6c-8cdf-097e985a00d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b1c3000-68cb-44d4-ac6b-e617bcea0002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ef654368-d4d9-4a6c-8cdf-097e985a00d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_069ba1e0-0125-45a8-9cae-c23cbc63f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_069ba1e0-0125-45a8-9cae-c23cbc63f4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ef2e9088-e46d-4372-9e56-1183f11da978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ef2e9088-e46d-4372-9e56-1183f11da978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f9c05982-1901-4aea-9b11-ac56c232dedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ba5cfc0-5e6d-4c93-afc2-f5dab1b30eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f9c05982-1901-4aea-9b11-ac56c232dedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0bae5f13-7237-4b89-96e7-c8ec7004de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f9c05982-1901-4aea-9b11-ac56c232dedf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0bae5f13-7237-4b89-96e7-c8ec7004de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_05028351-afaf-47c3-817e-2a297c9b5061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f9c05982-1901-4aea-9b11-ac56c232dedf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_05028351-afaf-47c3-817e-2a297c9b5061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c38bab43-bf0d-4712-bbb0-ffe21129963e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f9c05982-1901-4aea-9b11-ac56c232dedf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c38bab43-bf0d-4712-bbb0-ffe21129963e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d71765d5-44fa-4859-8f41-55919240f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d71765d5-44fa-4859-8f41-55919240f9fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:to="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae109c33-8e42-41f1-b9a6-659c6d7c4509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc09858a-388d-4e5e-9aa7-c9cdbd8ca45c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae109c33-8e42-41f1-b9a6-659c6d7c4509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0118be4f-bef7-483d-8fc5-be0f7cc15cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae109c33-8e42-41f1-b9a6-659c6d7c4509" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0118be4f-bef7-483d-8fc5-be0f7cc15cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:to="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c6cc9948-3e36-4b4a-8b7f-252abd3fe953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_419c7010-00b9-4307-8f3d-57a4dd156aeb" xlink:to="loc_us-gaap_PlanNameDomain_c6cc9948-3e36-4b4a-8b7f-252abd3fe953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_51a48d8f-e816-497f-be8a-ad2230cf7247" xlink:href="sttk-20211231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c6cc9948-3e36-4b4a-8b7f-252abd3fe953" xlink:to="loc_sttk_A2020StockIncentivePlanMember_51a48d8f-e816-497f-be8a-ad2230cf7247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f37d050-3f5b-405c-980a-ca4df311fef7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a04db77-d86d-43ce-928a-617dcd41ead2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a04db77-d86d-43ce-928a-617dcd41ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_53202eb3-8935-42e5-8e85-e9710b6b6878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_53202eb3-8935-42e5-8e85-e9710b6b6878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d64200bb-3974-4781-8b86-eaacc92fb991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d64200bb-3974-4781-8b86-eaacc92fb991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd681eb4-2a95-48ad-8d78-4c358f551599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f670dbc2-4665-44bc-bb04-6f63e5ff1df8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd681eb4-2a95-48ad-8d78-4c358f551599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96322978-f1ce-4ee6-a4de-7f799c9efbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96322978-f1ce-4ee6-a4de-7f799c9efbfc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:to="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1131190-4d4b-44bf-9f63-5ccea2eaab95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_529d8718-666b-4a4c-9296-2b9bea0154e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1131190-4d4b-44bf-9f63-5ccea2eaab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fd36b3be-e61e-44b4-8235-09e8932e4188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1131190-4d4b-44bf-9f63-5ccea2eaab95" xlink:to="loc_us-gaap_EmployeeStockMember_fd36b3be-e61e-44b4-8235-09e8932e4188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:to="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8eeaf02-bdfb-4573-8c31-c1a2f0ac8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c8310652-6420-4aa3-bb73-c3ca05853706" xlink:to="loc_us-gaap_PlanNameDomain_a8eeaf02-bdfb-4573-8c31-c1a2f0ac8d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_40d4b98a-628e-4294-9c54-eb9aa2538faa" xlink:href="sttk-20211231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a8eeaf02-bdfb-4573-8c31-c1a2f0ac8d89" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_40d4b98a-628e-4294-9c54-eb9aa2538faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0055c608-c568-42d9-b063-809b880486d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5442d332-7dcb-4e81-bfb8-97365e8dd549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5442d332-7dcb-4e81-bfb8-97365e8dd549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_89e9f471-2e60-4b14-be0a-e46ae216c972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_89e9f471-2e60-4b14-be0a-e46ae216c972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbccfbc7-a80c-4fa8-9deb-af76d0a7829c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbccfbc7-a80c-4fa8-9deb-af76d0a7829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71f98c72-8987-4773-8ff8-4bc52da1f4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0131b2b8-98c2-428c-82b0-64ed093c73c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71f98c72-8987-4773-8ff8-4bc52da1f4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#StockBasedCompensationScheduleofrestrictedstockactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca9ce045-7f63-423f-b321-6fd5c977d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca9ce045-7f63-423f-b321-6fd5c977d1fa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:to="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc2b72b-bccb-42d5-80a5-8edead1a9653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_24d0d9e2-3f22-4cee-8b77-cb76f0adfc5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc2b72b-bccb-42d5-80a5-8edead1a9653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_eae79850-5199-428e-8f35-7c66423e6f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc2b72b-bccb-42d5-80a5-8edead1a9653" xlink:to="loc_us-gaap_RestrictedStockMember_eae79850-5199-428e-8f35-7c66423e6f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fadf5ac-2990-4fec-bcd6-2d2a1a8e4ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d434d3d-e635-400e-a7f0-089feb15f3f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fadf5ac-2990-4fec-bcd6-2d2a1a8e4ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fadf5ac-2990-4fec-bcd6-2d2a1a8e4ab1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_985ffb4f-361f-4957-8bd0-afac9f7a63bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_985ffb4f-361f-4957-8bd0-afac9f7a63bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a30282f5-9a71-4e5a-b5cf-f8069f1fd072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a30282f5-9a71-4e5a-b5cf-f8069f1fd072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93c68ad3-da7c-4398-97ed-b72865592b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6a4ffb99-d9d9-4184-9e9a-292fdc1a0ae3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93c68ad3-da7c-4398-97ed-b72865592b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8342b687-7ead-4794-b9fb-8e6238f679fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_67c53f55-fc7d-40c4-98d1-49ae03c9ca29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8342b687-7ead-4794-b9fb-8e6238f679fb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_67c53f55-fc7d-40c4-98d1-49ae03c9ca29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_20734a28-bc4d-4de4-8ec1-e1fb4c7fb4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b24a9013-1797-4ac0-8ada-fd59db799384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_20734a28-bc4d-4de4-8ec1-e1fb4c7fb4ed" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b24a9013-1797-4ac0-8ada-fd59db799384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_86d42f49-f5fd-4add-b048-04622358809b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_20734a28-bc4d-4de4-8ec1-e1fb4c7fb4ed" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_86d42f49-f5fd-4add-b048-04622358809b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_864968fc-8a05-43b3-9572-3b703e901c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_20734a28-bc4d-4de4-8ec1-e1fb4c7fb4ed" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_864968fc-8a05-43b3-9572-3b703e901c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6f48c017-5c71-4e75-9604-8321abab0ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6f48c017-5c71-4e75-9604-8321abab0ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7359690c-1529-4b6f-bf86-ea23bc9a6786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7359690c-1529-4b6f-bf86-ea23bc9a6786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_c8faae7a-f835-4495-884f-d406661bf1bc" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment_c8faae7a-f835-4495-884f-d406661bf1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_6f63e796-9325-4846-9d17-d81c3378e613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_6f63e796-9325-4846-9d17-d81c3378e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_cf1b1fbe-5147-46d3-ac3f-64b7c84e24d5" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount_cf1b1fbe-5147-46d3-ac3f-64b7c84e24d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2714a9f0-22f6-4ed7-8531-befddc58b059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2714a9f0-22f6-4ed7-8531-befddc58b059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_352d45aa-c87a-4072-bb9b-536e38af762f" xlink:href="sttk-20211231.xsd#sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_352d45aa-c87a-4072-bb9b-536e38af762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_feebbe62-2656-47fc-80f5-311ca9c11a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_feebbe62-2656-47fc-80f5-311ca9c11a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_75ca971d-5d43-4ab4-b0cb-1ed7f5610d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_75ca971d-5d43-4ab4-b0cb-1ed7f5610d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bfa66e15-01d2-49ee-af01-1f3248cb9032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e58954d9-43d1-4cad-8dd7-da071a2ff1c1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bfa66e15-01d2-49ee-af01-1f3248cb9032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6693f450-78a1-4595-99fe-5d1ced6ab1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6693f450-78a1-4595-99fe-5d1ced6ab1fa" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_477548d8-6477-4df3-a7f7-5fcb587209b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_477548d8-6477-4df3-a7f7-5fcb587209b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e68ec82e-004c-4378-b689-872a79667732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e68ec82e-004c-4378-b689-872a79667732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3653551c-daf8-4372-9a25-0383c3dec43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3653551c-daf8-4372-9a25-0383c3dec43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_251a2e8c-44d7-4da2-87d3-8dc289dae1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_251a2e8c-44d7-4da2-87d3-8dc289dae1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5d36b96c-d532-4d5a-a6a0-66043ddfee6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5d36b96c-d532-4d5a-a6a0-66043ddfee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0f0a4202-2450-45d8-9115-0f65f0724c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0f0a4202-2450-45d8-9115-0f65f0724c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e7c76449-45e9-411e-9b41-cccf30b13ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e7c76449-45e9-411e-9b41-cccf30b13ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4048b0ba-dbfb-4a45-bbd7-c415cbdd58c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4048b0ba-dbfb-4a45-bbd7-c415cbdd58c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_045d76d5-b150-4338-9bfa-dfd35ae56bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b68ebcd8-ffa5-46dc-9e2d-10a667c7c619" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_045d76d5-b150-4338-9bfa-dfd35ae56bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5d2d7d3-65d5-4a89-a128-3ced90aeffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6693f450-78a1-4595-99fe-5d1ced6ab1fa" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5d2d7d3-65d5-4a89-a128-3ced90aeffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c0d91e86-86b3-49d7-8953-f8017c5f3d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5d2d7d3-65d5-4a89-a128-3ced90aeffe9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c0d91e86-86b3-49d7-8953-f8017c5f3d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_0f58f13d-d0b9-48b5-b66e-fc423f2de2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5d2d7d3-65d5-4a89-a128-3ced90aeffe9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_0f58f13d-d0b9-48b5-b66e-fc423f2de2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2eeec3a4-abb4-450f-9fcf-f7ec2516b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5d2d7d3-65d5-4a89-a128-3ced90aeffe9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2eeec3a4-abb4-450f-9fcf-f7ec2516b0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a26d77c1-8377-4b7b-b9e2-fb8397ce18e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5d2d7d3-65d5-4a89-a128-3ced90aeffe9" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a26d77c1-8377-4b7b-b9e2-fb8397ce18e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9e6c3240-7738-4231-992a-ebdf2125aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9e6c3240-7738-4231-992a-ebdf2125aed4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0cad989f-b60d-4957-8f57-de0af7b309e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e6b96a82-113c-4d3e-a591-0c9aa286a2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:to="loc_us-gaap_DomesticCountryMember_e6b96a82-113c-4d3e-a591-0c9aa286a2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c585c8c3-974a-450b-a895-572c07c6a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1b91474-f5ea-47ae-a389-ba4f0791bcfd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c585c8c3-974a-450b-a895-572c07c6a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f143bc18-b8ec-4b1e-b813-f91bbc975505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_adfc3f59-1b87-4105-bbac-39397b4bacaa" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f143bc18-b8ec-4b1e-b813-f91bbc975505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_1c50ff45-e24e-4bd0-b356-ec70103325fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f143bc18-b8ec-4b1e-b813-f91bbc975505" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_1c50ff45-e24e-4bd0-b356-ec70103325fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a2220f99-5fcf-4879-80eb-01974a0c7fee" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8fc53f19-e337-4d9e-9def-d5796e80a447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8fc53f19-e337-4d9e-9def-d5796e80a447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0fd4c7e6-973b-4d4c-b766-ffd765f645aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0fd4c7e6-973b-4d4c-b766-ffd765f645aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ba170761-7619-484e-a5fc-aff89e90483c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1c20f741-e22e-4e25-ab3b-6f482fd289bb" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ba170761-7619-484e-a5fc-aff89e90483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a23527c-edb3-4852-a428-3035c4658351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e1aaaf5-4307-4e03-9e6b-c7b0d06c4222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a23527c-edb3-4852-a428-3035c4658351" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e1aaaf5-4307-4e03-9e6b-c7b0d06c4222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cc8b5cad-65d0-4bd4-9ff7-0178faf0fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e1aaaf5-4307-4e03-9e6b-c7b0d06c4222" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cc8b5cad-65d0-4bd4-9ff7-0178faf0fbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_20d48a04-0004-4714-9aff-269f6794c637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e1aaaf5-4307-4e03-9e6b-c7b0d06c4222" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_20d48a04-0004-4714-9aff-269f6794c637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b1b38723-373c-4b51-941b-0a656b9193c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e1aaaf5-4307-4e03-9e6b-c7b0d06c4222" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b1b38723-373c-4b51-941b-0a656b9193c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3042d470-c48a-458e-a557-046eb69db298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e1aaaf5-4307-4e03-9e6b-c7b0d06c4222" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3042d470-c48a-458e-a557-046eb69db298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/RelatedParty" xlink:type="simple" xlink:href="sttk-20211231.xsd#RelatedParty"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/RelatedParty" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c0982171-6067-44af-9ff4-1ee5447e106e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f11fface-f145-44e7-9c09-d18a86070681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c0982171-6067-44af-9ff4-1ee5447e106e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f11fface-f145-44e7-9c09-d18a86070681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/RelatedPartyDetails" xlink:type="simple" xlink:href="sttk-20211231.xsd#RelatedPartyDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/RelatedPartyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a27d1bbb-6646-4030-9abd-957a652d65ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a27d1bbb-6646-4030-9abd-957a652d65ec" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:to="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7965dd4b-8795-4690-9a00-f1a0559732de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_58d5fc39-2879-410b-b75f-bc29818f333d" xlink:to="loc_dei_EntityDomain_7965dd4b-8795-4690-9a00-f1a0559732de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_TakedaMember_c2672f90-60f6-44e4-bec1-1daa463e0668" xlink:href="sttk-20211231.xsd#sttk_TakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7965dd4b-8795-4690-9a00-f1a0559732de" xlink:to="loc_sttk_TakedaMember_c2672f90-60f6-44e4-bec1-1daa463e0668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9da2ee84-1a42-48a3-a932-9a3565837539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a11f4d7-5969-4733-a2b4-b54eebc6a78c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9da2ee84-1a42-48a3-a932-9a3565837539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareholderOwnershipPercentage_f1a8eced-1f6c-481e-8a22-c18eaf75f780" xlink:href="sttk-20211231.xsd#sttk_ShareholderOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9da2ee84-1a42-48a3-a932-9a3565837539" xlink:to="loc_sttk_ShareholderOwnershipPercentage_f1a8eced-1f6c-481e-8a22-c18eaf75f780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sttk-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_7cdd5d8b-3da8-488d-8357-6c1ddbd7d159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_83980e58-4830-4d2e-8666-3605e2750d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_7cdd5d8b-3da8-488d-8357-6c1ddbd7d159" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_83980e58-4830-4d2e-8666-3605e2750d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>sttk-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M0W5N;FEN9VAA;0    60 P "    %   $*R0!  "    %   $,"2D0 "
M S@W  "2D@ "     S@W  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               R,#(R.C S.C$Q(# X.C$R.C4T #(P
M,C(Z,#,Z,3$@,#@Z,3(Z-30   !- &D 8P!H &$ 90!L "  0P!U &X ;@!I
M &X 9P!H &$ ;0   /_A"R5H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M #P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q
M8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(R
M+3 S+3$Q5# X.C$R.C4T+C@W,#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S
M8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F
M-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R
M/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y-:6-H865L($-U;FYI;F=H
M86T\+W)D9CIL:3X\+W)D9CI397$^#0H)"0D\+V1C.F-R96%T;W(^/"]R9&8Z
M1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO>#IX;7!M971A/@T*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04&!00'
M!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL
M*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@!FP34
M P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*"__$
M +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$
M P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "
M$0,1 #\ ^D:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***BN(&GC"K/)#@YS&0"?S!H EHJC_ &=)_P!!&[_[Z7_XFC^SI/\
MH(W?_?2__$T 7J*H_P!G2?\ 01N_^^E_^)H_LZ3_ *"-W_WTO_Q- %ZBJ/\
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M3_V=)_T$;O\ [Z7_ .)H O451_LZ3_H(W?\ WTO_ ,31_9TG_01N_P#OI?\
MXF@"]15'^SI/^@C=_P#?2_\ Q-']G2?]!&[_ .^E_P#B: +U%4?[.D_Z"-W_
M -]+_P#$T?V=)_T$;O\ [Z7_ .)H O451_LZ3_H(W?\ WTO_ ,31_9TG_01N
M_P#OI?\ XF@"]15'^SI/^@C=_P#?2_\ Q-']G2?]!&[_ .^E_P#B: +U%4?[
M.D_Z"-W_ -]+_P#$T?V=)_T$;O\ [Z7_ .)H O451_LZ3_H(W?\ WTO_ ,31
M_9TG_01N_P#OI?\ XF@"]15'^SI/^@C=_P#?2_\ Q-']G2?]!&[_ .^E_P#B
M: +U%4?[.D_Z"-W_ -]+_P#$T?V=)_T$;O\ [Z7_ .)H O451_LZ3_H(W?\
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M2_\ Q-']G2?]!&[_ .^E_P#B: +U%4?[.D_Z"-W_ -]+_P#$T?V=)_T$;O\
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M1_LZ3_H(W?\ WTO_ ,31_9TG_01N_P#OI?\ XF@"]15'^SI/^@C=_P#?2_\
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MT?V=)_T$;O\ [Z7_ .)H O451_LZ3_H(W?\ WTO_ ,31_9TG_01N_P#OI?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117F/Q
M;\6^)-)NK'2_!$R1:A':W&K7A,2R9MH%_P!7M8'[[$#(YXX- 'IU%>3?$OXC
MZOI&A>#]=\'?Z3;ZG-]HGME16-Q;B+S60$C(.T'I@Y'X5?\ "OB:_P#'?BOQ
M;;:?X@NK72K8:;/ILMI#!OC2:V\QQ^\C<')/.X$C&!B@#TJBO#(?%_BV']F^
M\\=/XGNY]79&6-9+6U$4)6\\K<JK""24&/F)')X'&.WAOM<\7^+_ !'8Z=KM
MQH5CH<B6D1M+>"1[B9HU=GD\U'^5=P 5<9Y)/0  [RBO.=9\0^(=(\<:?H\N
MIQS*?#UW=SM%:K&LL\97;( =Q7K]W<17->#_ !WJ^HR>"6M/%W_"17^K'&L:
M5LM3]CC\LEI/W,:O'M; PY.=V.M 'M=%>26_Q!UQ_B\-]S'_ ,(=-J<GA^-#
M&N1>)$'#[\;CE]R8SCCIGII>*9O$%G\4O"^C6/BW4[:QU[[<\T:6]FQ@\F-7
M18RT!.,L0=VXX[T >DT5Y++XEU1OB?XGT2^\2^(K:RTN*Q^R+I&C)=LQDA+2
M&0K:RX)(!&=HY; P.-*:^US4?BW;^&;;Q-J=CIZ>&8]0+QVML)IIO/,9=_,@
M.TE<94*H!'0=* /2**Y/X<^(=0U_P[<IK3))J6E:A<:9=3QIL6X>%]OF!<G;
MN&"1TSG'&*ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_4M4E1S_P"I:@"I1110 444
M4 %%%% !7C4^DW_C#XZ^*=(G\5^)-*LK"UM988=*U%H%!:-<_*01[\ <FO9:
M\NU'PAX^T[XHZWXH\'3>&V@U2&"$QZJTY91&BCI&N!R#W/% &1IWC?5OAYJ7
MBWP[K%W=>)5TA8)M*EN9!]HE\]PJPR2'[Q#2+\Q[ \8PH[0^(/$?AW6]$M/%
M;Z7>6^LR_95FTZWD@-M<;"X4AW?S%.T@-\I&.G/&#;?"74-5TWQ#>^+=8A/B
M377B?[38Q$PV'DN&B6-6P6 *KG."<8ZY8[I\/^(_$6N:'>>*UTNSM]&E^U+#
MIUQ)/]IN-A4,2\:>6J[B0OS$YZ\<@'&:1\:=8NO"OBF[O["Q74M.9/[,BB1P
MER))F@3(+DDB1><$<&M;_A9FNW'PC\/ZUIUA93^)->G6WM;78_D;M[;B1NW8
M"(3][KCZ5FZ=\&-3@U3PW=7=Y9%-/N+J2^2.1R)E:9IK< %1G:YR<XQVS5SP
M[\*]?LO^$5AU+6HK*'P[83I%+IK+)(;F60Y;$T)39Y9QG&[)/2@#7N_B-<2>
M O"?B'2H;9CKFH6=K.D@++&)6*R!<$<JP(!.>G(K";XR7L6H>.]-N+2UCO-"
M6XDTIRC^7<K"/F5_FY890G:1D-T&.;,/PPUVVT2+1TU"TN+2S\41:O:R3.1)
M]G#;W1@L84/N+$ #;SVZ55\1_!J^U[0/$D0N[2#4[W6IM1TVX61P(XY45'CD
M(7(#*&! R/N]>E &SXF^(EWI"^%83=:9I)URU::74-2A=[:)Q&C"/"NNW<7^
M\S8 '?-=YIC7KZ7;-JRVRWIC'GBU=FBWXYV%@#CTR*Y;6O#6JWOAG3M$;3-!
MUJPCLU@N[749)(OWBH%$D<JH^,<_P!NA#"M/P+X<E\(^!M+T*XN1=2V<.UY1
MG!)8L0,\[1G SV H Z"BBB@ HHHH **** )(/]<M6ZJ0?ZY:MT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5P_P 0_'$OA&_\/V:W-EIL
M.K7,D,NJ:C \L%J%3*AE5TY9BHR6  #$]*[BN<\8Z5J6LV<-G:Z9HFKZ=+N6
M]L-69X_,&/D9)%5PI##."A]05(Y .<\;>*/&/A7X7GQ0)O#[7=G;QM=6T=O-
M<0SNTBJ&BE\Q"JX8'!5O3)ZUI>+?$6O>$/!?G/)I^J:]>7D5EIZ1VDD$,DLK
M!55D,KMP-S$AAT[5@S_"S4E_9]G\!V=W:_;YAN5Y'?R(B;@2E%;!8JHRH)&3
MC) S@;_B_P ':GXI\7>'[J/4_P"SM-T@RW!>W*M.UP0%0A9(WCPHW<GGYN!W
MH IV7Q,W?".U\67=B)-0D*VLEA$^P&\\WR3'D[BJ[\GG)"\\]]W2X_&D.I6O
M]M7.@WME)$WVK[);36TD$F 5V;GD$JDY!SY9'!Y^[7)6GPIU!=)\5:)=:SNL
M=2U*/5=,OBJM<0W/RO(TB*B)CS$!"KP03]TFI3X(U_6?B-H'B;6=,\-Z7)IF
M^2ZN-.DDGN+V0Q^6H+-$F$ S@$L1@"@"IX,^(]_XG$+7WBWPCIUS)?26XTA[
M9C<L%E*  FZ!W, ,?(>O0UVGC?Q._A/PY]MMK47=Y/<16=G;L^U9)I7"(&/8
M9.3["N?\#:#XQ\&Z&NC'3M#O(!=S3&Y&K3(VV25G^Y]F(R W3=SCJ*Z#QMX8
M;Q9X=^Q077V.[@N(KNTN"F\1S1.'4E>,C(P?8T 9D?B+Q!H7B[1]&\5MIM[#
MK:NEM=:=;R6_D3QH79'5Y'W*RCY6!!!4@KSD5?AWX@\6>,M!M=>O+[1K>TEN
M)HWLXM,E\S;'*R<2FXP"=N<[#UZ59C\.^(->\8:/K/BH:;90:&LCVUIIUQ)<
M?:)Y$*-([O&FU57[J@')8DG@ P?#?X:V/@_0[4ZIIFD3:]#-.YU*WMU:3$DC
MD 2LH?[C;3^(Z4 7/B!XEU;P\?#UOH?V-9]8U>+3WEO('E6)75SN"JZ$D%1W
MK!UOXAZ]X9LO%ECJ<6G7.KZ+I\>I6=Q#!)'!<PN=OS1EV92KJ1PYR"#QS6]\
M0/#6K>(3X>N-#^QM/H^KQ:@\5Y.\2RJBN-H94<@DL.U86N_#W7/$UEXKOM1?
M3K75]9TZ/3;.WAN))(+>)#NRTA12Q9V)X08  YY- $UCXQU;4M#O[C1?%OA'
M7=2ATV2ZBTVQMFWAPH(#8NG.W)"G@<L.13H/B1=ZLG@!-#AM6N/$X,]VLBLX
M@@CCW3;2",,&(4$Y&>QKI= ;Q/"MM::QI6DV]K#"$,]KJDLSD@8'R-;H.?\
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MD<5UE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.6O_ #+[G_\ )&_-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\
M?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4
MZ/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$
MT?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_
M .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^
M$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_
ME?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\
M\D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY
M:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/
M_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _
M3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-
M'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)
M_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A
M*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y
M$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D
M'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,O
MN?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K
M7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?
M]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/
M_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$
MG_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;
M_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1
M,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?
MWK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?
M_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6
MO_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_
M .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\
M\_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\
M"4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK_P"1,C_A*='_ .?I
MO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-0_E?WK_Y$R/^$IT?
M_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\ ,ON?_P D'-0_E?WK
M_P"1,C_A*='_ .?IO^_$G_Q-'_"4Z/\ \_3?]^)/_B:UZ*.6O_,ON?\ \D'-
M0_E?WK_Y$R/^$IT?_GZ;_OQ)_P#$T?\ "4Z/_P _3?\ ?B3_ .)K7HHY:_\
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M$J6 4MU+8P2>=J^JT4 <#_R&_C[_ 'X/#6B_]\7%T_\ \;B_6N^HHH ****
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MAT?6[2+PU*OD:18KJVM)Y2OYT!E1!&"0=IVB1N,' %;7B/Q1J%MX[T&STN]
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M/R\8&  *W?#&B_\ "-^$]*T7[1]I_L^TBMO.V;/,V*%W;<G&<=,F@#4HHHH
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M *!]Y_WPO^-7J* */]I-_P! ^\_[X7_&C^TF_P"@?>?]\+_C5ZB@"C_:3?\
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M[X'^-'VF7_GPNO\ O@?XUKT4 9'VF7_GPNO^^!_C1]IE_P"?"Z_[X'^-:]%
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M7_&C^TF_Z!]Y_P!\+_C5ZB@"C_:3?] ^\_[X7_&KB-OC5BK+N .UNH]C3J*
M"BBB@ HHHH XK6-5U75OB5%X2TK4I=(MK;3?[2N[RWBCDFD+2&-(E\U615X9
MF.TDX4#'-4?$NI^)/"P\(V<NNK?27_B*.SN+C[''&TULRN=CCE=W RR!,XX
MK>UKPK<W/BBV\2:!J,6G:M%:M92M<VIN(9[<MO"L@="&5^0P88RP(.>,S6_
MNLZYINB_:O$\<NIZ5JJZFMS-IJF)BH8"(1(Z$(-W=V;CDG/ !+\0->U+1-0\
M(QZ7<^0FHZ]#9W0\M6\R%D<E?F!QRHY&#[UY=)\8O$MIIOCZROKORKVTN;I]
M!O3!'@I#,$>'&W:Q4%3R"2&8D\"O4]5\':OXADT277=:LGET?5H]10V>FO"L
MBHK#RR&F?!);.[/X=ZYO7O@;9:_X,U/1+G5=MS=:U-JUM>BUR;8RL"T>W?\
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M4_YW^'^0>UA_S[7_ )-_F9']J:K_ -"_/_X$Q?\ Q5']J:K_ -"_/_X$Q?\
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M?\^U_P"3?YF1_:FJ_P#0OS_^!,7_ ,51_:FJ_P#0OS_^!,7_ ,56O11[*?\
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M  (B_P :/[;U'_H S_\ @1%_C5RBCV4_YW^'^0>UA_S[7_DW^93_ +;U'_H
MS_\ @1%_C1_;>H_] &?_ ,"(O\:N44>RG_._P_R#VL/^?:_\F_S*?]MZC_T
M9_\ P(B_QH_MO4?^@#/_ .!$7^-7**/93_G?X?Y![6'_ #[7_DW^93_MO4?^
M@#/_ .!$7^-']MZC_P! &?\ \"(O\:N44>RG_._P_P @]K#_ )]K_P F_P R
MG_;>H_\ 0!G_ / B+_&C^V]1_P"@#/\ ^!$7^-7**/93_G?X?Y![6'_/M?\
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M_@3%_P#%5JQ$&%""6&T8)ZFG4>RG_._P_P @]K#_ )]K_P F_P S(_M35?\
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M%BC1N3Z?>/YUSG_'I_I=[^]NY/ECC7^'_9'^/^2?\>G^EWO[V[D^6.-?X?\
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MZ?>/YUSG_'I_I=[^]NY/ECC7^'_9'^/^2?\ 'I_I=[^]NY/ECC7^'_9'^/\
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MQZ?Z7>_O;N3Y8XU_A_V1_C_DG_'I_I=[^]NY/ECC7^'_ &1_C_DGUS$?SO\
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M\3DQ683KQY4K+^OP"BBBO1/-"H[@!K=P4,@(^Z#C-25'<$"W?<648Y*=1]*
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M 4444 %%%% !4<_^I:I*CG_U+4 5**** "BBB@ HHHH **** "BBB@ HHHH
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M H^;J?\ SZV__?X__$T>;J?_ #ZV_P#W^/\ \35ZB@"CYNI_\^MO_P!_C_\
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M4_\ GUM_^_Q_^)J]10!1\W4_^?6W_P"_Q_\ B:/-U/\ Y];?_O\ '_XFKU%
M%'S=3_Y];?\ [_'_ .)H\W4_^?6W_P"_Q_\ B:O44 4?-U/_ )];?_O\?_B:
M/-U/_GUM_P#O\?\ XFKU% %'S=3_ .?6W_[_ !_^)H\W4_\ GUM_^_Q_^)J]
M10!F2SZF)8AY=NF2?E\TG?\ ^.U+YNI_\^MO_P!_C_\ $U9EW>=%M$9&3DMU
M'TJ6@"CYNI_\^MO_ -_C_P#$T>;J?_/K;_\ ?X__ !-7J* */FZG_P ^MO\
M]_C_ /$T>;J?_/K;_P#?X_\ Q-7J* */FZG_ ,^MO_W^/_Q-'FZG_P ^MO\
M]_C_ /$U>HH H^;J?_/K;_\ ?X__ !-'FZG_ ,^MO_W^/_Q-7J* */FZG_SZ
MV_\ W^/_ ,33)IM36%CY-O'@?>\TG'_CM:-,FSY+;0I.. _3\: *:3:F8U/V
M>W;@?-YQY]_NTOFZG_SZV_\ W^/_ ,35R//EKD ' R%Z4Z@"CYNI_P#/K;_]
M_C_\31YNI_\ /K;_ /?X_P#Q-7J* */FZG_SZV__ '^/_P 31YNI_P#/K;_]
M_C_\35ZB@"CYNI_\^MO_ -_C_P#$T>;J?_/K;_\ ?X__ !-7J* */FZG_P ^
MMO\ ]_C_ /$T>;J?_/K;_P#?X_\ Q-7J* */FZG_ ,^MO_W^/_Q-103ZFQD_
M=V\F'(_UI&WV^[6G44&[]YN$8^<XV=Q[^] %;S=3_P"?6W_[_'_XFCS=3_Y]
M;?\ [_'_ .)J]10!1\W4_P#GUM_^_P ?_B:/-U/_ )];?_O\?_B:O44 4?-U
M/_GUM_\ O\?_ (FCS=3_ .?6W_[_ !_^)J]10!1\W4_^?6W_ ._Q_P#B:/-U
M/_GUM_\ O\?_ (FKU% %'S=3_P"?6W_[_'_XFCS=3_Y];?\ [_'_ .)J]10!
M1\W4_P#GUM_^_P ?_B:/-U/_ )];?_O\?_B:O44 4?-U/_GUM_\ O\?_ (FC
MS=3_ .?6W_[_ !_^)K#7XD^&6B,YN;Y+19#$U[)I5TEJA#["6G:,1A0P(+%L
M#'6NJH H^;J?_/K;_P#?X_\ Q-'FZG_SZV__ '^/_P 35ZB@"CYNI_\ /K;_
M /?X_P#Q-'FZG_SZV_\ W^/_ ,35R218HGDD.$12S''0"N9LOB'H.I003V$>
MM7$%R%:&9- OC&ZMT8/Y.,'/7.* -KS=3_Y];?\ [_'_ .)H\W4_^?6W_P"_
MQ_\ B:O44 4?-U/_ )];?_O\?_B:/-U/_GUM_P#O\?\ XFKU4]-U:RU>.X?3
MYO.6VN9+64[&7;+&VUUY S@]QQZ4 -\W4_\ GUM_^_Q_^)H\W4_^?6W_ ._Q
M_P#B:GNKZUL?)^V7$<)N)5AA#M@R2'HJCN>"<#L">@-+;74=TLAB651'(T3>
M;"\>2IP2-P&1Z,,@]B: *_FZG_SZV_\ W^/_ ,31YNI_\^MO_P!_C_\ $U>H
MH H^;J?_ #ZV_P#W^/\ \31YNI_\^MO_ -_C_P#$U>HH H^;J?\ SZV__?X_
M_$T>;J?_ #ZV_P#W^/\ \35ZB@"CYNI_\^MO_P!_C_\ $U<0L8U,@"O@;@#D
M TZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&IZYIVC[/[1
MNEA,GW1M+$_@ :4ZWIPAM)OM*F.]<1P,JD[V/0<#C\<8K%URV:X\46KZ5?0P
MZK%"<P7*'9+%GGG'U! YQZ8K"@GAGT_0A#:+:&+6%CDC1RR[\J2023QSZUY5
M3&5(5)1TMT_#S\]M+>9ZU+!TYTXRUOU_'R\M];^1Z+45U=0V5K)<W4@BAB7<
M[GL/\]J;>W7V*SDN/(FN-F/W<";G;G' [US?B&*#6_#4^HSV][;M;1OY<%RO
ME_-Q\Y7O['W-=M>M[.+Y=9)7.*A1]I)<VD6[&Q>>(M+L+6VN+NZ\N*Z7?"WE
ML=PP#G ''!'6FP>)]'N;.>ZBO5,%OCS'9&7&>@P1R>.@JH=2.D_#^WO%QOCL
MH@F?[Q50/U-5X]*TK2_",;:VGF*I%S,Q)#/*?H>3SC'2N9UZW-[K5N6[O?3M
MK?O?ILCI5"CR^\G?FLK-:]]+=K==V;>F:S8:Q&[Z;<K,(SAQ@J5]." ?Q]CZ
M5):ZC:7MQ<P6LPDDM6V3  _*WIGH>AZ5S^D:9/JTNI:K?K)9?VDBQQ)$V'6,
M#J3ZD ?K5;0(H]-F\3QVF(([<_NR<D( K8/<G]31'$U?<YDK.^NVUVM.E[=6
M$L+2]_E;NK:;[M)Z];7Z(V[7Q3HU[?)9VMYYD[DJJ>4XR1[D8[5=N-3L[6^M
M[.><+<7.?*CP26Q].GXUQFDW]WX<ATE6U"&^TZZ63]U'%@Q@')920&/)/7W&
M.]9D>LV=SXHL-7N;G$CSN98]K$01@ 1KTY/7)'K7-_:,HP7/;F;7E9.WF[[_
M / T.G^S8RF^2_*D[=;M7\E;;_@ZGJ%1S_ZEJDJ.?_4M7M'B%2BBB@ K+U+Q
M1H&C7D=GJ^N:;87,BAT@NKN.)V4D@$*Q!()!&?8UJ5YZ^E^(+#6/$%YX970_
M$NDZG-+)>6-U.T-PLRQK&8!* Z,/D(VN%QG!/>@#NY;VUANDMIKF&.>1&D2)
MY &9%QN8#J0-PR>V1ZUD6_COPC>745M:>*=%GGF<1Q11:C$S2,3@* &R22<
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ML#V S^O^2#5M1LXS/>:A=23RG"0K,V![ 9_7_)I_\>G^EWO[V[D^6.-?X?\
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M'1T=2&1AV92"/6L^V\&:':VNH0+:RS?VE$8+N:ZNI9YI8RNW899&+A<$X ;
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M=GL../K_ )(NDZC;JUY=:?=3W+#"HD+'9[#CCZ_Y/J%%']E0_F?]=0_M:?\
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M>>6U5?.D01M\BN<[/FVDL 3@$#!.X</-<RV?AOX23V]C<7\B&+;;6S1B1_\
MB72#@R,J^_+#I^%>J7EJE]8SVDI81SQM&Q4\@,,''OS6/'X/L([?PW"LUSM\
M.;?LA++E\0-"-_R\_*Q/&.?RH Y6XOKO6OBUHL5YH=YI!_L7444:C]GE63<]
MN/NQ2OD#N"1G/UQ)XG\,>$=#T.WG\363:\+>PBTK3=-GC64NZ@@+;QX^663C
M<PZ"-3E0I-=C<:%;7/B:QUV1YA=6-M-;1HI&PK*4+$C&<_NUQR.IZUE:MX(&
MI^+$\0PZ_JMA>QV_V>)8%MI$B7.6*"6%]I;^(@@G !X H Y?2/#TNK:]I/A[
MX@1QZTVE^&H)9([O$T<ER\C(\AW?>=1& '//S$Y^8U%I=KX?G\!V>M>.@VJ6
MVEO=:=;6EZHN4F*73Q1LL3 F29E15!Y)R<=23V5_X/\ MTEG=+KNJ6NJ6L#6
MYU*W\A9IXV()5U,1C(R 1A 01QC)SGS_  TL/M6D3:9J^J:9_8]NT%I'!Y$J
MH6.6EQ-%)^\;H7ZXSZG(!CV7AS3+#X=Z1??$S,MOI4$S#3K]A<PQ^;)F)60@
MF6:.,K$O4_,P&2V:Z+X<V-]IW@FVAU"&6U#2S2VME,Q9[.V:1FA@8GND95<=
ML;>@J/4_ 3:M<Z5=7GB?66NM*+M!-LM#N=C]]D,!3>H^56"@@9[DD]%IEG/8
M60@NM2NM2D#$_:+I8E<^V(D1<#Z4 6Z*** "BBB@ HHHH **** "BBB@ HHH
MH Y/X@ZC]FT6.R5]KW;X;V1>3^N*P[#4]+TSQC9/I%R);2:%+><[&3#8V@\C
MU"G\ZZR^\-1ZEXBAU&]F6:"%-BVCQ94]>2<\\G/3L*9K/A#3]3LA#:0V]A*K
MAA-#;KGZ<8KQ:^&Q-2K*M%+1JW?3YVUN]SW,/B<+3I1HR;U3OVU^5W:RV,3Q
M-)?1?$+3WTF%)[L6G[N.0X4_ZS/<=L]ZJ6\NH>*_%%O;ZO\ 9K*2P;>T2J5=
ML$$@9)ST]>G-=4WA]Y/$5AJ\MYODM+?R63RL>8<,"V<\?>Z<]*;K7AD:GJ=M
MJ-I=?8KN _ZP1[MX'3(R/_U4IX2M)RGK9RORW6JT_'Y]!T\91BHPTNHVYK/1
MZ_A\NIDQQ0W/Q5NEO55Q';@P*XR,[5Z?FQKH[FPTJ758+FZC@^VKS$S-ACCT
M'?'Z52USPM!K4D5P)WM;V(8$\0Z_AG^M5=-\%K;:I'?ZGJ,^HS1$&,R C!'0
M\DDXK>-.K3G*'LU).5[W7Y;W1SRJ4:D(S]HXM1M:SZ>>UF=/1117J'E!1110
M 4444 %%%% !1110 4444 %%%% !1110 5'/_J6J2HY_]2U %2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 4>:3^X*"3L7!
M(_2EVZI_STM/^_;?XTZ#_7+5N@"EMU3_ )Z6G_?MO\:-NJ?\]+3_ +]M_C5V
MB@"EMU3_ )Z6G_?MO\:-NJ?\]+3_ +]M_C5VB@"EMU3_ )Z6G_?MO\:-NJ?\
M]+3_ +]M_C5VB@"EMU3_ )Z6G_?MO\:-NJ?\]+3_ +]M_C5VB@"EMU3_ )Z6
MG_?MO\:-NJ?\]+3_ +]M_C5VB@"EMU3_ )Z6G_?MO\:-NJ?\]+3_ +]M_C5V
MB@"EMU3_ )Z6G_?MO\:-NJ?\]+3_ +]M_C5VB@"EMU3_ )Z6G_?MO\:-NJ?\
M]+3_ +]M_C5VB@"EMU3_ )Z6G_?MO\:-NJ?\]+3_ +]M_C5VB@"EMU3_ )Z6
MG_?MO\:-NJ?\]+3_ +]M_C5VB@"EMU3_ )Z6G_?MO\:4+J>X;I+7'?$;?XU<
MHH H[=5_YZV?_?MO\:-NJ_\ /6S_ ._;?XU>HH H[=5_YZV?_?MO\:-NJ_\
M/6S_ ._;?XU>HH H[=5_YZV?_?MO\:-NJ_\ /6S_ ._;?XU>HH H[=5_YZV?
M_?MO\:-NJ_\ /6S_ ._;?XU>HH H[=5_YZV?_?MO\:-NJ_\ /6S_ ._;?XU>
MHH H[=5_YZV?_?MO\:-NJ_\ /6S_ ._;?XU>HH H[=5_YZV?_?MO\:B6/5!=
M.W^B E1^\V-\WM]ZM.H$V_;9,"3=M&2?NGZ4 0;=5_YZV?\ W[;_ !HVZK_S
MUL_^_;?XU>HH H[=5_YZV?\ W[;_ !HVZK_SUL_^_;?XU>HH H[=5_YZV?\
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M_DZVBZY/H#&2_D>9;EAFW3G;_NCU]?7]:R?^/3_2[W][=R?+'&O\/^R/\?\
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M76GW4]RPPJ)"QV>PXX^O^2+I.HVZM>76GW4]RPPJ)"QV>PXX^O\ D^DS!3/
M61V()P5Z#ZU/1_94/YG_ %U#^UI_RK^NAY>NDZC;JUY=:?=3W+#"HD+'9[#C
MCZ_Y.MX>\*W%Q=&]UE&1A_ PQ@?W1_4__7-=U15T\LI0DFW>W0SJ9I5G%Q2M
M?K_D(JJB!4 55&  .E+117JGDA1110 4444 %1S@M X""0D?=)QFI*CN #;N
M&5F&.0O4_2@!T8Q$H*[>!\OI[4ZFQ8\E, @;1@-U%.H **** "BBB@ HHHH
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MS*\%L7SN,4+,8XB<D911P2.A-;] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5!<13R;?(N?)QU^0-G\ZGH
MH I?9;[_ *")_P"_*T?9;[_H(G_ORM7:* *7V6^_Z")_[\K1]EOO^@B?^_*U
M=HH I?9;[_H(G_ORM'V6^_Z")_[\K5VB@"E]EOO^@B?^_*T?9;[_ *")_P"_
M*U=HH I?9;[_ *")_P"_*T?9;[_H(G_ORM7:* *7V6^_Z")_[\K3);:]$1SJ
M!(]/)6M"HY_]2U &5]GN_P#G]_\ (0H^SW?_ #^_^0A5JB@"K]GN_P#G]_\
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M[)??]!(_]^%H^R7W_02/_?A:O44 4?LE]_T$C_WX6C[)??\ 02/_ 'X6KU%
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M^_*T?9;[_H(G_ORM8VI>.M*AT*'5=#N;/6[>34;;3V>SNU=$:65$.67<,J)
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M==47/!TTIM0T5M5?1V6ENRW?-TTT9NZ1X@U#5O)G71O*L)"W^E&Z4X R,[<
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M_L74-%UU+/Q#>Z5%?W\T_P!LT]3<++,J!;A;>% RH=L@QY8<>:Q*@$FO5Z*
M.(^&5O)%;>))SI5SI<-[KL]U;PW-N86:-XXB'VD C<<GU!R#@@BN?UO2=$O-
M4U6_N?#?B'0?%CI+:QWN@)=?Z2N[,4GG0@0MO^4GSL%2,-PH->ESZM96VL6>
MES3;;V]CEE@BV,=ZQ[=YSC QO7J1G/'>KE 'FML^I>'_ !&^J>-=,O-3DO\
MP_:6S2Z=8/>*L\>\W$.R-25#LZD$@(=O)&,5RMSX5U^T\(ZC8S:7=O/_ ,(7
M);1Q11F7:YGD9+<%<@LJ%1M!/3CBO=** /(]?MKBPT;Q_IFH:#J6I7FNP^9I
M\EM8/.DR?9$C2,NH(C,<B.<,5/S KDFO3="C>'P[IT<J,DB6L2LC#!4A!D$=
MC5^B@#DO!MA<P3>+5NH);<76N320M)&5\Q##$ ZYZC((R..#7%Z"E_\ V;\-
M]$;1=6CN="NPFHO+82I% 4M9H\B0KM=2QX9"R],D;AGV&B@#R/P[X;N;?PY\
M,(9=&EB>QOI9KM&M2#;DP3G<XQ\N7*\G'S$=\5(--U&QU9-5N]+O9]-T_P 6
MW=W+;Q6K2.8Y("D<Z1 9D"R/G*@GDL <&O6** /(Y]&N]6UG^U;?1[R+2[WQ
M99W<5O-:/&^(H2DER\1&Z,,ZCEP"=H)'(S/XQM[VS\0:M+X=MM5EO[V6&272
M[S1/MNFZJXB$<9\U1^XP53+/(@4Q[BI!R?5:*  9VC=P>^#1110!R_C/4I--
M6T>&:5'?>JQQ.07/R]A_/W]ZY<:MJ-G&9[S4+J2>4X2%9FP/8#/Z_P"3T7CJ
M:&W^P2NF^4>8L2CJ2=O3_&N1_P"/3_2[W][=R?+'&O\ #_LC_'_)^8Q]2:Q,
MK/:WRT7X]CZG 4X/#1O'>_SU?X=RX-6U&SC,]YJ%U)/*<)"LS8'L!G]?\D&K
M:C9QF>\U"ZDGE.$A69L#V S^O^33_P"/3_2[W][=R?+'&O\ #_LC_'_)/^/3
M_2[W][=R?+'&O\/^R/\ '_)XO:375_Y>;\_([O9P?1?Y^2\O,N#5M1LXS/>:
MA=23RG"0K,V![ 9_7_)!JVHV<9GO-0NI)Y3A(5F; ]@,_K_DT_\ CT_TN]_>
MW<GRQQK_  _[(_Q_R3_CT_TN]_>W<GRQQK_#_LC_ !_R3VDUU?\ EYOS\@]G
M!]%_GY+R\RX-6U&SC,]YJ%U)/*<)"LS8'L!G]?\ )!JVHV<9GO-0NI)Y3A(5
MF; ]@,_K_DT_^/3_ $N]_>W<GRQQK_#_ +(_Q_R3_CT_TN]_>W<GRQQK_#_L
MC_'_ "3VDUU?^7F_/R#V<'T7^?DO+S+@U;4;.,SWFH74D\IPD*S-@>P&?U_R
M0:MJ-G&9[S4+J2>4X2%9FP/8#/Z_Y-/_ (]/]+O?WMW)\L<:_P /^R/\?\D_
MX]/]+O?WMW)\L<:_P_[(_P ?\D]I-=7_ )>;\_(/9P?1?Y^2\O,N#5M1LXS/
M>:A=23RG"0K,V![ 9_7_ "0:MJ-G&9[S4+J2>4X2%9FP/8#/Z_Y-/_CT_P!+
MO?WMW)\L<:_P_P"R/\?\D_X]/]+O?WMW)\L<:_P_[(_Q_P D]I-=7_EYOS\@
M]G!]%_GY+R\RX-6U&SC,]YJ%U)/*<)"LS8'L!G]?\EHU._LE:YN[ZY>ZFX6)
M)F_!0,_K_DU?^/3_ $N]_>W<GRQQK_#_ +(_Q_R3_CT_TN]_>W<GRQQK_#_L
MC_'_ "3VDUU?^7F_/R#V<'T7^?DO+S+@U;4;.,SWFH74D\IPD*S-@>P&?U_R
M0:MJ-G&9[S4+J2>4X2%9FP/8#/Z_Y-/_ (]/]+O?WMW)\L<:_P /^R/\?\D_
MX]/]+O?WMW)\L<:_P_[(_P ?\D]I-=7_ )>;\_(/9P?1?Y^2\O,N#5M1LXS/
M>:A=23RG"0K,V![ 9_7_ "0:MJ-G&9[S4+J2>4X2%9FP/8#/Z_Y-/_CT_P!+
MO?WMW)\L<:_P_P"R/\?\D_X]/]+O?WMW)\L<:_P_[(_Q_P D]I-=7_EYOS\@
M]G!]%_GY+R\RX-6U&SC,]YJ%U)/*<)"LS8'L!G]?\D&K:C9QF>\U"ZDGE.$A
M69L#V S^O^33_P"/3_2[W][=R?+'&O\ #_LC_'_)/^/3_2[W][=R?+'&O\/^
MR/\ '_)/:375_P"7F_/R#V<'T7^?DO+S+@U;4;.,SWFH74D\IPD*S-@>P&?U
M_P D&K:C9QF>\U"ZDGE.$A69L#V S^O^33_X]/\ 2[W][=R?+'&O\/\ LC_'
M_)/^/3_2[W][=R?+'&O\/^R/\?\ )/:375_Y>;\_(/9P?1?Y^2\O,N#5M1LX
MS/>:A=23RG"0K,V![ 9_7_)!JVHV<9GO-0NI)Y3A(5F; ]@,_K_DT_\ CT_T
MN]_>W<GRQQK_  _[(_Q_R3_CT_TN]_>W<GRQQK_#_LC_ !_R3VDUU?\ EYOS
M\@]G!]%_GY+R\RX-6U&SC,]YJ%U)/*<)"LS8'L!G]?\ )!JVHV<9GO-0NI)Y
M3A(5F; ]@,_K_DT_^/3_ $N]_>W<GRQQK_#_ +(_Q_R3_CT_TN]_>W<GRQQK
M_#_LC_'_ "3VDUU?^7F_/R#V<'T7^?DO+S+1U._M4^T7U]<RW,A_=PK,Q"GT
M S^9_P EPU;4;.,SWFH74D\IPD*S-@>P&?U_R:?_ !Z?Z7>_O;N3Y8XU_A_V
M1_C_ ))_QZ?Z7>_O;N3Y8XU_A_V1_C_DGM)KJ_\ +S?GY![.#Z+_ #\EY>9<
M&K:C9QF>\U"ZDGE.$A69L#V S^O^2#5M1LXS/>:A=23RG"0K,V![ 9_7_)I_
M\>G^EWO[V[D^6.-?X?\ 9'^/^2?\>G^EWO[V[D^6.-?X?]D?X_Y)[2:ZO_+S
M?GY![.#Z+_/R7EYEP:MJ-G&9[S4+J2>4X2%9FP/8#/Z_Y(-6U&SC,]YJ%U)/
M*<)"LS8'L!G]?\FG_P >G^EWO[V[D^6.-?X?]D?X_P"2?\>G^EWO[V[D^6.-
M?X?]D?X_Y)[2:ZO_ "\WY^0>S@^B_P _)>7F7!JVHV<9GO-0NI)Y3A(5F; ]
M@,_K_D@U;4;.,SWFH74D\IPD*S-@>P&?U_R:?_'I_I=[^]NY/ECC7^'_ &1_
MC_DG_'I_I=[^]NY/ECC7^'_9'^/^2>TFNK_R\WY^0>S@^B_S\EY>9?M]<U+3
M&%W=WL\]Q(?EMS(S*?\ 9"Y_7_)] TO4H]3LUE4;),#S(B<E#Z>_UKS#_CT_
MTN]_>W<GRQQK_#_LC_'_ ";NDR7MAJ"7,>Z;4)_D2!3P1UV_3U/;^?;A,9.C
M/E>J?]7]7V.'&8.%:',K)KKT]/1=ST^F3 M"X5 Y(X5NAI8RQC4R*%<@;@#D
M _6FW !MW#(SC'*KU-?3GRPZ,8C4%0I ' [4ZFQ "%  5&T8!ZBG4 %%%% !
M1110 4444 %%%% !44"LIDW1K'ER1M_B]S4M06RJIEVQLF9"3N_B]Q0!/111
M0 4444 %%%% !1110 4444 %%%% 'GWP\\&Q0>'+2[U$:U:WR7MS*8&U.[AC
M'^DR%<P"0)M(P<;<,#D@YYY[Q;%?V7AGXCZ'%HNK7E]K-R]S8"UL)98YHWMH
M4)\Q04!4QOE6(8X& 2P![A?B3X9:(SFYODM%D,37LFE726J$/L):=HQ&%# @
ML6P,=:ZJ@#RJ^T?4W\3ZG*FG7;1OXQT^Y1Q Q#1+;1!I <<J"""W0$&NC^(9
MEAF\*7JVEY<PV6NI/<?8[22X>./[-.NXI&K-C+*,X[BNJDO[6*_@L9+B-;JX
M1GBA+?.ZKC<P'H-RY/N/6K% '"W+W?C#Q59W6D6U]8V>F6=T!>7UI+:L]Q,H
M1%1)%5\* 6+;<?= ).<86C6UQ<Z=X$T2TT'4+'4_#TJ/?S363Q10+'"T<P6<
M@)+YK, -C-N#;FP 2/1-9\0Z;H(MQJ,LOF7+%8(+>WDN)I2!EML<:LY ')(&
M!WJ&V\7:'>0Z9+;7XD75)FM[3$;@M*JLS(PQE& 1LAL$$8//% 'G.A6&JV^H
M6.C>&TU0V,5I/;I%KNC&"70P(Y ##>*JK)ES$NU?-) W!L FG^#]&^?PM97A
M\7+>:*<FSETRW@M;)UC:-_\ 2! @DC.X@>7(Y<,#@\D>G7.M6%GJL&FSS,+R
MX@EN(H5B=B\<94.1@'D;UXZG/ -95[X]\/6%O;2S75Q*MS9B^1;6PGN'2W(R
M)76-&:-3S@N!G#?W3@ Q/B)9QS>)O"MQ>V^KR6%O+=&XETE+HR1;HL+DVW[P
M GCT/>H;J#P_?^$M4LK.V\8W$6Z">3SH;YYT,<JNKQ?; 0Q5E#%%W$A?NMP#
MU6I>+]$TNWLYIKMKA;Z,S6PL;>2[::, $R*L*L2@#+\^-OS#GD4RZ\::%:P6
M,HNY+L:A%Y]JEA:RW;RQ<?O D2LVSD#=C&2!G)H \\>U\0:II.J&:TFUBPMM
M2L+N2[GT8V%[J<44YDEB>%@OG&.,1A2$0/@J 3FMKQ)K)OK5M0\.>&[I)OME
MNEQJE]H$SO& LFV5+8[9I6C)4 [<#S,@G:P'43^-M AT[3[U+YKN'4U+6:V-
MO+=23J!EF6.)6?"\9.,*2 <$@5I:3JUCKFE0:EI5PMS:7"[HY%!'?!!!Y5@0
M05(!!!! ((H \;32]8N[[Q!,+37+R.YUO1+B"ZU#3Q#-<1QRJ'D*I&@ 4)R"
MH95 + 9I?%:Z_J-A?VB:?J=O-'K23+I6FZ&1;M&EX'-S)<,C><[*%;]TRG)P
M5(#5[?10!Y)J.G:@=;UJV73;]GD\8Z7J".MI(8WMQ]E#2"0+M(78V><KM).*
M9/87W_"(WWA)M&U!_$$^N27,5Z+-S =UUYR77VG&Q=L>!@L'RFT+TSZ]10!Y
M1J&@WO\ P@OCQ8=*G:\O-=:X@46S%YPKPE'48RP&TD$>AKU>BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "HY_\ 4M4E1S_ZEJ *E%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!)!_KEJW52#_7+5N@#QOXD:O<_9/%FIZ//JD;Z
M(GE27TVN/8VUK,(XV2.&"+/GL3("?-4!B=H8C 6U=B]UB;QO?3ZSJT+:;IMO
M<64=K?RPI!*;3S"VU" V6 .U@5XZ<FO1;OPMX?U#4FU"_P!"TRZO60QM<S6<
M;R%"I4KN(SC:2,>A(JRFD:;%'/'%I]JB7,8BG58% E0+M"L,?, O ![<4 >:
M27C^)H]>GU[6;S3O[.T:VN;5;:^:W15DM_,>=T4@2#?E<2!D^3&.3G8TO_DV
M^S_[%-/_ $D%=9>^&=!U)K1M1T33KLV0 M3/:1O]G Q@)D?+T'3'05;6PLTT
MT:>EI MDL/D"V$8$8CQMV;>FW'&.F* ,2PL)-4^&-I8074UG+<Z1'''<02,C
MQ,8@ X92""#@\5Y\OBK5_$GA/Q-JZW=U92:#X8GM9TAN"FW4O+=I6PN/FC\M
M-IZC><8KT:U\$^&M*G^V:#X=T33M1C5A!=0Z;&K1,5(S\H4XP2" 1D$C/-&@
M>%;?2-"O+"^\C4'U*XGN=09K<)'<O,27!C)(VX(7!)X R3UH XVQT9Y/'.E:
M3/K>O2VFH: ]_=J=6G4RSI+"H<,K Q9\ULK&44\#&!BLOPY>W?B;5_!EAK6O
M:G'%<Z%=/+'!?R6[7LL4T:*6:,JQ;;N8E2"<'/!(/KBV%FEU'=+:P+<11&".
M41C>D9()0'J%)53CIP/2N=O?A[HFH>(K.]N[#3YM.M-/ELTTN6R1X<O+')O
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MD?X_Y)_QZ?Z7>_O;N3Y8XU_A_P!D?X_Y/KE%']D]I_A^.X?VOWA^/X;'D?\
MQZ?Z7>_O;N3Y8XU_A_V1_C_DG_'I_I=[^]NY/ECC7^'_ &1_C_D^N44?V3VG
M^'X[A_:_>'X_AL>1_P#'I_I=[^]NY/ECC7^'_9'^/^2?\>G^EWO[V[D^6.-?
MX?\ 9'^/^3ZY42LQNG4RJ5"C"=Q1_9/:?X?CN']K]X?C^&QY1_QZ?Z7>_O;N
M3Y8XU_A_V1_C_DG_ !Z?Z7>_O;N3Y8XU_A_V1_C_ )/KE%']D]I_A^.X?VOW
MA^/X;'D?_'I_I=[^]NY/ECC7^'_9'^/^2?\ 'I_I=[^]NY/ECC7^'_9'^/\
MD^N44?V3VG^'X[A_:_>'X_AL>1_\>G^EWO[V[D^6.-?X?]D?X_Y)_P >G^EW
MO[V[D^6.-?X?]D?X_P"3ZY11_9/:?X?CN']K]X?C^&QY'_QZ?Z7>_O;N3Y8X
MU_A_V1_C_DG_ !Z?Z7>_O;N3Y8XU_A_V1_C_ )/KE%']D]I_A^.X?VOWA^/X
M;'D?_'I_I=[^]NY/ECC7^'_9'^/^2?\ 'I_I=[^]NY/ECC7^'_9'^/\ D^N4
M4?V3VG^'X[A_:_>'X_AL>1_\>G^EWO[V[D^6.-?X?]D?X_Y)_P >G^EWO[V[
MD^6.-?X?]D?X_P"3ZY11_9/:?X?CN']K]X?C^&QY'_QZ?Z7>_O;N3Y8XU_A_
MV1_C_DG_ !Z?Z7>_O;N3Y8XU_A_V1_C_ )/J\K,)H@)50$G*GJWTJ6C^R>T_
MP_'</[7[P_'\-CR/_CT_TN]_>W<GRQQK_#_LC_'_ "3_ (]/]+O?WMW)\L<:
M_P /^R/\?\GURBC^R>T_P_'</[7[P_'\-CR/_CT_TN]_>W<GRQQK_#_LC_'_
M "3_ (]/]+O?WMW)\L<:_P /^R/\?\GURBC^R>T_P_'</[7[P_'\-CR/_CT_
MTN]_>W<GRQQK_#_LC_'_ "3_ (]/]+O?WMW)\L<:_P /^R/\?\GURBC^R>T_
MP_'</[7[P_'\-CRBVMIC<))(AN+^<[8HE_A]AZ =S_D]_H.@II49FG*S7LH_
M>2 <*/[J^@_G6Q177AL!"A+F;N_Z_$Y,5F$Z\>5*R_K\ J.X(%NY9F08Y9>H
MJ2F3DK Y5Q&0.&/05Z)YHL1!A0ABPVC!/>G4V,DQJ2P8X&2.].H **** "BB
MB@ HHHH **** "H+9E8R[9&?$A!W?PGT'M4]10,S>9NE63#D#;_#[4 2T444
M %%%% !1110 4444 %%%% !1110!YYX.O-/L/@G/<ZR\:6$9U W!E(VE/M,P
M(_'.,=\UBP_;CHOA[0KM-5?5-.\.VT]]&^MOI5K:*5(,DTL7[UWS$5QM=1@D
M[<DGT"+P/X3@U!;^#PQHT=XDOG+<II\0D5\YW!@N=V><]:N:EX=T76;F"XU?
M1["_GMCF"6ZM4E:+G/RE@2O(!X]* /(/"MV=5OO 7B#6+Z^DN5\-7\LMQ]JE
M.[RGA 8H" QP23D?,0-V2!BUI&JW]MXY\%30/J=O9:XTQVZGK[W5Q?1?9FD$
MKVPW0Q#?M(,;<9 PN=H]5'A[11]CQI%@/L,C2VF+9/\ 1W8Y9DX^4D\DC&:@
ML?"'AK2YA+IOA[2K.02"4/;V4<9#@, V0O4!W /7#'U- %;Q3K=CH+6<XT[^
MT]<GWV^EVD2#SYF;!<!B/W<?RJ7<_* !G)V@\/J7A[5M$N/!D(O[,:Y?:_<W
MMS<-;M+;I-):SLZJ@9&* ?*/F!X!/<5Z-J_AK0M?:)M>T73M3:$$1&]M$F*
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M9(+8,((GTZ(K$&.2%!7"Y)R<=36GIFDZ=HMD+/1["UT^U#%A!:PK$@)ZG:H
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M:U3_ +_)_P#$UKT4?5Z?;\6'UBIW_!&1_8,G_0:U3_O\G_Q-']@R?]!K5/\
MO\G_ ,36O11]7I]OQ8?6*G?\$9']@R?]!K5/^_R?_$T?V#)_T&M4_P"_R?\
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MR?\ 0:U3_O\ )_\ $UKT4?5Z?;\6'UBIW_!&1_8,G_0:U3_O\G_Q-']@R?\
M0:U3_O\ )_\ $UKT4?5Z?;\6'UBIW_!&1_8,G_0:U3_O\G_Q-']@R?\ 0:U3
M_O\ )_\ $UKT4?5Z?;\6'UBIW_!&1_8,G_0:U3_O\G_Q-']@R?\ 0:U3_O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCI$6,:,QSEE4$[FY^8Y?K'AG2]<N(+B^CN$N8%9([BTNY;655;&5\R)E8J2
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M@G;UP"<4 4[;P=H-I975I%IZFWO+6*TGCED>0211)L13N)Z+QGJ>I)/-5O\
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M1N5"$ 'D4X> ?#BV,]JMG,JSW*7;RB]G$WGJH42B7?O#[1@L&!;G).3GHZ*
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MC*&X8<=%<:V'U Q^*/$-[IOAO^TM54WT>HR6Y\Y&7R(O-5@<;#,RIG#%1P<
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M1BX"PM&-Z([$_*!*221Q7L5% 'B]]JEC8Z#H]A:^*6UIKN2ZE>YB\43P6PF
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M0_N;IT#.N20=X;;)N'W1BO<J* /.O$<VG:C\$?,T^:YO+.9K<%K^1I9F/VI
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>sttk-20211231_g10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M0W5N;FEN9VAA;0    60 P "    %   $*R0!  "    %   $,"2D0 "
M S@X  "2D@ "     S@X  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHUVAU.8PLAFA!A(.T[@7!'SE5^8+@G!PQ56[>@ HHHH **** "BBB@ HHHH
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M=5YUX3M/$&L>(])U/6=!_L.TT/3Y+.+SITDGNI'$88D(2%0>6>"<DX]*]%H
MQ=0\(:'JFLIJE]9&6Z39D^=(J2;&W)OC#!'VDY&X'!Z567X?^%A<74LNC0W*
MW>[S8+IFG@&YQ(VV)R43+@,=JC) )Z5T=% 'EOPYTVQTCXS_ !+L=*L[>QM(
MO[*\NWMHECC3-NY.%4 #))/U->I5YMX)_P"2[?$__N$_^DS5Z30 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2N=9
MTRSOHK*\U&T@NYL>5;RSJLDF3@;5)R<D8&.]<_XGL_&%QXGTG_A'-2^S:3)\
MM^!%#F$*<E@75B693@ # *C/!K=O]"TS5-2L+_4+1)[G3F9[5W)Q&S8R<9P3
M\H()!P0",&M"LY1<KINWH=M*O3H.,Z<>9V::DDU=W6GIH_7NMRBBBM#B"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R\=
M>'-=OK_5KGPDVFWZ7Z6D>H6MS<^4\#V\GF*RL 1@J<%6QC@CN*]&OFN%TZY:
MR -R(F,0(X+X./UQ7)?"S3]&B^'.GSZ4J3/?P+-J$[G=)/<L/WIE)Y+;MP(/
M3I0 G@FUU?5=7N_%VORZ8'O+:.UL[?3)_/CBA5F8EI< .S,W;@ #U-=K7!>$
M['3M%^)OB#2O#"1P:6MG;SW5I!Q#;W;-("%4<(6C525'HI[UWM !1110!YM\
M&_\ F??^QSU'_P!IUZ37FWP;_P"9]_['/4?_ &G7I- !1110 4444 %%%% !
M1110 4444 %%%% !1110 455CNW?4)(&@D6-0-DFPX8]^?Y?3Z5:I)IE2BX[
MA1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q=<\'>'/$L\$^O:+97T]NRM%--"#(FUMP ;KMSU7.#W!ID?@GPW&E]&
M^D6]Q%?D&XAN@9XVPY< (Y*JN\EMJ@#<<XSS6[10!YE\$K:"SM?&]K9PQP6\
M/C"_CBBB0*D:@1@*H'   P *]-KS;X-_\S[_ -CGJ/\ [3KTF@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KA_AO91W46I^);NXFN=8U"]N(+HR2
MDK;K#.Z) J9PH4#TR22>]=Q7':S\-=/U/6)]4T[6-;\/W=T0;IM'O/)6X8#
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M.WS/@9QG XZ "O6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXFN[/9]IMX](5I(-XRN]1)E<CD9ZBO4J "BBB@ HHHH **** "BBB@ HHHH
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MR>#PT]]/J=GJEQJUS)?S7-A_Q[LSX&V/DDJH4+D\G'/-=10 4444 >;?!O\
MYGW_ +'/4?\ VG7I->;?!O\ YGW_ +'/4?\ VG7I- !1110 4444 %%>;?"/
M_A9W_$W_ .%J_P#3'[!_Q[?]-/,_U'_;/[WX=Z])H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BJNJ6;:AI5S:1S- \T95959U*'L<HRMU]&'UKEHO
MA^\-OHL*:U=%=)D+@F2;]\-W ($H"X0L/E Y(P F8R =G17!W?PUFN9+QU\0
M7D?VJY6X \VX(0KG:N/.PPXCY/S#:VTKE-G=1KLC5,D[0!DDG/XGF@!U%%%
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M6!IKJ:.&)<;GD8*HYQR34E<SXKD9]:\,6+!3;7.I%I@?XO+ADD0?]]JI_P"
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MM6M>JM?;U_0****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK)%)NR7]NAK)NO'?B6WCG(\,Z8QM;^+3ILZS(%,TA0*4(MCN0"1<DX(.X;>
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MW/FKY84=3NSC'O5#_A+_  U]AN+W_A(=*^R6L@BN+C[;'Y<+G@*S;L*?8\T
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MTN-CJ%ZX5[R,$JUU*RGD]"""#W!%;MIXET+4+I+:PUK3KJXDSLBANT=VP,G
M!R> 34USK.F6=]%97FHVD%W-CRK>6=5DDR<#:I.3DC QWJ[4Q4DK7V_KN;XB
M=*<G4<)+FNUKI_Z3J%%%%:'"%%%% !1110 4444 <+>>&/%^B:M>W/@+5M+6
MROYVN9M/UBWD=(IF.7>-XV# ,>2IR,DD=:M^'_#&N'Q GB#QKJMM?:A#"\%I
M:V$!BMK17*[RNXEF8[0,D\#@"LS4_B]8Z;<7SC0=8N=.M;E[%-1@A5HIKM>/
M)4;MW+C8'QMW<9[U?T#QOJUUXD@T3Q9X6E\/W=Y"\]DPO4NHYPF-ZEE VN P
M.,'C/- '9UXM"/ATVJZY_P +4.GCQ$;ZX$@U=CQ;^8WD>1NXV>5LQMYSG/->
MTUYK8VGBKQM-?:@/$EGI<5KJ-Q:PV TB*X>W$4C("[N<[F #<8&&&* -?X6'
M/@]_LWVG^R1>S_V2;K=YAL]W[O[WS;>NW/.W;79UFZ%9:G8:<8=;U?\ M:YW
MEOM'V98/EXPNU>..>?>M*@ HHHH \V^#?_,^_P#8YZC_ .TZ])KS;X-_\S[_
M -CGJ/\ [3KTF@ HHHH *\V\!3_%,^/M=3QW:6Z>'I/-?3WCEA?RB)1L1&3:
M[*48\R(#\B_=)(/=ZK%JLUJJZ'>6=G<;P6DO+1KA"N#D!5DC(.<<Y/0\<Y&3
M]A\;_P#0P^'_ /P0S_\ R90!(^JZ5XTT#5K#PKXFLY+B2U>'[7IMTLSV;2*R
MI)\C9!!!(Y&=O!K$^#W@;5?A[X"71=<U*.^N/M4DRK"S-%;JV,1H6P<9!<\+
M\SMP>IY'X._#C6?!VAZG+H&O:6'NM0N+>>2\TF65V%M/+ N-MRJ@?*S8VY^<
M@DX%>G:?:>*HK^-]5UG1[FT&?,BMM(EAD;@XP[7+@<X/W3D<<=0 ;=%%% !1
M110 5YSX\^'5Q=7X\4^"I?L'B*W/F$(0%NO4'MN(]>#T/J/1J*B<%-69TX;$
MU,-4YZ?S[-=FNJ.)\ ?$2#Q9$^GZE%_9^OVN5N;.0%2Q'!90><>HZC]3VU<%
MX_\ AT/$,J:YX>F_L[Q':8:&X0[1-CHK'U[!OP.1T9X ^(QUJ=O#_BB(Z=XD
MM3LDAD78+C SN4=CCDC\1QTSC-Q?)/Y/O_P3MKX:G7IO$879?%'K'S\X^?3J
M>@4445N>2%%%% !1110 4444 %%%% !1110 4444 <_XN\86?@RQ@O-3M+N:
MWFE\H/;*C;&P2 0S \@'IGISCC.GH^IIK.C6NI10301740EC2;;OVGE2=I(Y
M&#U[\X/%0^(/#VG>)M*_L_5X?-M_-23 X8%6!X/49&5)&#AB 1FM.LTI\[;>
MAUSEA_JT8QB_:7=WTMT_6_HNX5R$GQ%M5O##'H>L3(;V73XYXXHMDMRF[]VN
M9 W.TX8@(.[#!QU]<Q#X-\K[)_I^?L^LS:K_ *G[WF>9^[^]QCS/O>W3FM#D
M.;U7QI)J>LZ4EKJ&OZ):S07?VB"PTM+NY6>&5(]KJL,^ ,MRO!XYJB=4\07>
MF7-W9^,-8C2#6;?3HUFL+6&9HY'C#-+');!E?]XVWA00%.WN>D7P1JNGZPFI
M:'K=G#.)+QF%YIS3J5N)5DP LR$%=H&<G/H*L)X)EDL)_M^I1RZA>:G!J-U<
MQ6OEQL8F3:BQER5&V-1DLQSD\]* ,_6=5UKPSXGT:W.K3ZAIL5G<W6I&ZAB\
MV6-7C7>#&B@%-^< #(!ZG!I8O$NJ2>,ELA=AK1M>:T"B-.818^:%SC/W^<]>
MV<<5U%QH@N/%-KK#3#%O9S6I@*9W^8R-G.>VS&,<YKEK?X<7NELLFC:]&LT.
MJM?VYOK(SK&A@\@0D+(A8*O1L@\#(/4@&I\0]3U[2/!][>>&UM4FA@>62YN&
M/[E5&<JFTAV/0 D =3GH<OQ_XLO]%6Q@TV^CLY)$4SSO$)/+$DB0H=I'J[L!
MW,>.1D5T%_HFHZSX.O\ 1]8U&U>ZO(9(3=6MFT2*&& ?+:1R<?[W/M4&H>$$
MU W\KW92YG:V>VF$>?LY@.Z/C/S#>6)'&0Q'O0 [P;?_ &_3KG&NW&L^3<%-
MU[8_9+F#@'RY8]B<\Y!V+\I'7J>6\.:U>:OJ+"\\3>*$G_M*>$6]OHB&SVI.
MRJOG_9"-NU0"?,]>0:Z.P\$6<GVJX\5Q:?KU]=70NFDDL%6*)E147RT<N5PJ
MCG<23GGL-3P]HW]A:6UGY_G[KF>??LV_ZR5I,8R>F[&>^* *FG>+(]4U7[-:
M:3J;69ED@34_*0V[R1DAAPY<#*L-S(%)'!.1FK>W&J:WXNN]$T_4Y]'MM/M8
MIY;FUCB>::20N H\U'4* A)^7))'( .667@VYM?,TV;4;6Y\-M++*=,ETY6:
M02,6,;R,Q5HPS$@!%;A06.#E\W@Z33M22^\%W-EH;_9UM9;9]/\ -MGC5F9,
M1H\95E+M@AL88Y!X( ,Z0>)[CQ#H^AW_ (ADL)38W,T]QI<,)^T%)(U1B)HG
M"DJ^2JC&3P<5-:ZMXE72]=TVV:UU#5=*N?(CO+L^4KQ-$LBRNJ+@L V"JA0Q
M'\(/#SX.UJUO-.OM-\21R7UK!/%//JEF]SYQE=78@++'L *8"C( X[9K7T7P
M\VF6-^+F\-W?:E*T]W<^7L5G*A0$3)VH%4 #).!R2<F@#C;CQ3J;Z%X3DU#Q
M%_8D6H:8;B?41!%F>YV)LA&]2@W;F;:!N;;A2.:U])^(BWVEZ6_]CZA>W=SI
M\-[=K81H1:HY*[BCNKL,JWRHKL-O3IF\/#6LV7AC2])T/7XK0V5H+262:P$R
MS (%WA=ZE'&,CYBO)RK<8S-;^&J:G8:=IUO>VL=C8VR6\7VK3DGN+?;C][;S
M!E,4A &6(89"D 8.0#6O/&")J%U96.E:G=I:N()[^WB1H;>5E#!6!;><!E)*
MHRC/)&#CC_#7BYUT;2]8UCQ%XLNVDBA>ZAET-(;0%\ GSC:H-@+9R),X'&[O
MU3>%-3M]4O6TC78[/3]1G%Q=0-8B68OM"MLE+[55@JY!1C][!&1C2L/#L-KX
M+M_#MU)]IABLELWDV;=X";<XR<>O6@"W8:I#J-Q?16\<@%E/Y#R,!M=]H8[<
M')QNP<@<@UGZMJER/$VEZ/I\JQRS1RW<VX [HH\+LY!QEY%R1S@'%6?#FC?V
M!H-OI[W3WDR9::ZD4*T\C$L[D#@98DX[5GZW8W:>+-+U2QW9:WGL)'$1D$)D
MVNDC*",J&CP>?XATY- ',WFO^(_#%U>?:]776Y[?1IKZ^M_(C6&QF&#$J,BJ
MVQB7 #EF(3.1SEUSKOB'0_[0TB?5SJ%Y(E@;:^FMXU,!N93"_P J*JL%*EER
M"><$MBM+1? NI6>B7VCZSJVGW]GJ$4BW<T&FR0W4\KC!E>5IW!..VW P ,
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M4?#&E:KKFG:O>6J/>Z<Q:&3 Y&#@-D<@$[AW##((R<L\*_\ ('G_ .PE?_\
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M#+G@ S<$Y]*[N@ HHHH \V^#?_,^_P#8YZC_ .TZ])KS;X-_\S[_ -CGJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTJ'2[K>0((;O[2NWC#;]J^_&.U:58WA6V@MM#46GB"Z\00R.72]N9XYF8''
M:-54@8].];- '+>*O"FH>(M:T:ZAU:W@L=-F^T/87%FTR7$@^ZY*RIRO) .1
MG!(.!6;!\*]+FM+_ $_7Y!J>EW,0MXK14:#RXA.9PK.KY8ASU&WA0,=2>[HH
M \M^!.GVND:5XRTW3XO)M+/Q;?001[BVQ$6-5&223@ <DYKU*O-O@W_S/O\
MV.>H_P#M.O2: "BBB@"MJ%A#J=A):7+W"128W-;7,EO(,$'B2-E8=.Q&1QT-
M>9>%M8\ >,O%VJ>'= U;Q)<W6G)YAF'B#4/)N%!"LT;B<[@K,HR<9SE=PYKU
M:LVR\.:'IVJW&IZ?HVGVFH7.[S[N"U1)9=S;FW.!ELL 3D\D9H \;^&&J:9X
MBT'Q->Z]HWB#PS::!-+)<NOB'4RI):6652GF ^8@ +XR69]V%W 5Z!X$D\(>
M)(?[=\'ZOK&HPVTS0%KG5;]XP^P$@Q3OAOE<')4C)XY'&1\*_%/C'QU:Z[:_
M$CPK'I=O&D4<,4NG30I<K()!(K"8D.,!00/[W/6NV\,^%=%\':,NE>&M/CL+
M-7:0QH68LS=69F)9CT&23P .@ H UZ*** "BBB@ HHHH **** "N?\8^#-+\
M:Z*UCJ:;9%RUO<H/G@;U'J/4=_K@CH**4HJ2LS2G5G2FJE-V:/)/#'C/5? V
MM)X1^(K_ +G[MAJS'Y'7H S'MTY/*]#QR/6@0R@J001D$=ZR/$_A?3/%VBR:
M;K$.^-OFCD7AXG[,I['^?0\5X;<>/_$OPPN;CPE]LM=5CLIHS!<D[FCCX)CQ
MVR.,'E<G!Z8YG-T-):K^M#VXX:.:OFH)1J?:71_WEV\U]Q]%457L+V#4M.M[
MZT;?!<Q++&WJK#(_G5BNH\%IIV84444""BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HJ,31-<- )4,RJ':,,-P4Y )'H<'\C4E !1110 4453U/5]-T6
MU%SK.HVNGP,X02W<ZQ*6/098@9]J +E%9NI^(]$T1X$UG6=/T]KC_4K=W21&
M7I]W<1GJ.GK6EUZ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O*O&NJV7CFXN=&TOP+?>+$TV9X9;Z*[2RCAEQATCF9@6(Z,!QV.:]5KROP3
MXFN_"GAD:3J/A#Q-+<Q7EW(\EOIV]'$ES(ZD-N&?E9: +'PRA\.Z7KE[IL?A
MS4- \2&W626/5+@W,DT (&8IBS!HPV 0",''%>F5YQ!JEWXF^*OAV_@\.ZWI
MUM86=]'<3ZA9^2I,GE; #DY^XU>CT %>-Z3=^.=,\5:K>VFE:UK4N+@_V9>7
M,EO",W"B,":7,#?NRS#R53 &&W$@U[)10!Y)\*+[5-1^+'Q'NM>TC^QM0D_L
MOS;'[2MQY6(' _>+PV5 ;CIG':O6Z\V\$_\ )=OB?_W"?_29J])H **** "B
MBB@ HHHH **** "BBFNZQ1L\C*B*,LS'  ]<T .)P,GI7 :YXDOO$VI-X?\
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MRYK:F\<15C2E1C)\K:;71VV_K_)!1115& 4444 %%%% !1110 4444 %%%%
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MHW#_ &0.I;_9&3R..1F2/Q7H$U[:VD.LV4D]VF^!$G5O,';!'&3S@=3@XZ'
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MQ</<1M T!3[X=' 9"/1@..:N:??VVJZ;;7]A+YUK=1++#)M(W(PR#@\C@]Z
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M8VD8*,D@#/'Y5Y19W6LW4>DZS9Z#X7L=?\53;K&^2UWM:6_DF5C+(,-+(5'
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M]EN)(E:6#>'\IB,E=PX.#QD=:FKLA&VMV?,XC$>U]UPBK?RH****T.0****
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M-)*[,%55!(!)) Y(%4&\;Z0NK:'8@S-_;L#3VDZI^[V@*0&.<J3N&..O'7%
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M10 4444 %<'<>%?%N@ZC>3> M9TU;*]G>YDTW6+=Y(X)7.YVB>-@P#,2Q4Y
M)..N*[RLK5/$=AIGAJ[UP2K=VMK&SDVSJV\CC:#G&<\<D =\4 9'AKPOJUOK
M4OB#Q?JD.I:P\/V>%+6$Q6]G$2&98U)+$LP!+$Y. .,5UE<OI/BG5)M>@TKQ
M%H']DRWD4DMJ\=\ERL@3&X-@ J<,#T(Z\],]10 51M=;TJ^U&YT^RU.SN+VT
M_P"/BVAN%>2'_?4'*_C5ZO+[3X<^*+64IIVNV>CO9B[%CJ<,7VF63[1<I,WF
M0NH4852OWFSNSQC% $_@G_DNWQ/_ .X3_P"DS5Z37DEC\*/'>G:]JFLV7Q3\
MO4-6\K[;-_PCT!\WREV1_*7PN%.. ,]\UI?\(3\3O^BN?^6U;?\ Q5 'I-%>
M;?\ "$_$[_HKG_EM6W_Q5'_"$_$[_HKG_EM6W_Q5 'I-%>;?\(3\3O\ HKG_
M );5M_\ %4?\(3\3O^BN?^6U;?\ Q5 'I-%>;?\ "$_$[_HKG_EM6W_Q58G@
M[1?BYXE\)V>K:K\0KC0KNXW^9I]SX:M_,AVNRC.[:>0H;H.&_&@#V2BO-O\
MA"?B=_T5S_RVK;_XJC_A"?B=_P!%<_\ +:MO_BJ /2:*\V_X0GXG?]%<_P#+
M:MO_ (JC_A"?B=_T5S_RVK;_ .*H ])HKS;_ (0GXG?]%<_\MJV_^*H_X0GX
MG?\ 17/_ "VK;_XJ@#TFBO-O^$)^)W_17/\ RVK;_P"*H_X0GXG?]%<_\MJV
M_P#BJ /2:*\V_P"$)^)W_17/_+:MO_BJQ/!VB_%SQ+X3L]6U7XA7&A7=QO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y#J]Q;W<MSJ^BZ!J6D:;=7+6MQJD1@>U
MN\OY1>>S9_WD9;@O@/CG(%>O5S7_  KSPL-;_M8:2OVKSO/V^=)Y7F[MWF>3
MN\O=N^;=MSGF@#*\&:';^'-9:UG\(6VF7SP[%U/3@9+>9!SMRWSQ>NQACIAF
MQ7=444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!Y_]A7I-% 'FW_"F_\ JH_Q _\ !Y_]A1_PIO\ ZJ/\0/\ P>?_ &%>DT4
M>;?\*;_ZJ/\ $#_P>?\ V%'_  IO_JH_Q _\'G_V%>DT4 >)?#[X::YX@\":
M?J?BOQK\0-,U:?S?M%I_:KP^7ME95^1U+#*A3R>^>E=)_P *;_ZJ/\0/_!Y_
M]A7I-% 'FW_"F_\ JH_Q _\ !Y_]A1_PIO\ ZJ/\0/\ P>?_ &%>DT4 >;?\
M*;_ZJ/\ $#_P>?\ V%'_  IO_JH_Q _\'G_V%>DT4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>sttk-20211231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M0W5N;FEN9VAA;0    60 P "    %   $*R0!  "    %   $,"2D0 "
M S0W  "2D@ "     S0W  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_?C_ .O1NU'_ )_(O^_'_P!>IJ* &QQZE(N?ML0YQ_J/_KT_[/J7_/\ 1?\
M@/\ _959MO\ 5GZU+0!1^SZE_P _T7_@/_\ 94?9]2_Y_HO_  '_ /LJO44
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M %'[/J7_ #_1?^ __P!E1]GU+_G^B_\  ?\ ^RJ]10!1^SZE_P _T7_@/_\
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M &5'V?4O^?Z+_P !_P#[*KU% %'[/J7_ #_1?^ __P!E1]GU+_G^B_\  ?\
M^RJ]10!1^SZE_P _T7_@/_\ 94?9]2_Y_HO_  '_ /LJO44 4?L^I?\ /]%_
MX#__ &5'V?4O^?Z+_P !_P#[*KU% %'[/J7_ #_1?^ __P!E1]GU+_G^B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<_ZL?6JM2:C=V]I
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M-<3%)HU16W6X,22*SAF.< C&!GTKUK^VM*_Z"=G_ .!"_P"-']M:5_T$[/\
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M_P"+-=U/6[G29-+B@T&ZTW3[*YFB:>XFF )=C&[(J\!0-V<Y)P,9VOAQX/\
M^$8\)Z.MY]OCU*/3HH+J";4YIXHW"KN"QF1HUP1@% ,#@<&NC_MG3/\ H(VG
M_?\ 7_&C^V=,_P"@C:?]_P!?\:/:T_YD'LJG\K^XX_QCIFLCXF>$_$&F:+<Z
MK9Z9!>QW*VLT".IE5 F!+(@/0]#VKE_$7@/Q!K/AKQ'?OHYEOM<UNTN_[)::
M$LEM 44!V+",N54DJ&(Y R>:]8_MG3/^@C:?]_U_QH_MG3/^@C:?]_U_QH]K
M3_F0>RJ?RO[CF-*\/Z3>:;JVD0^ 6\,6VHVC07$OD648G4@KM_T>5B2 Q(R
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M *"-I_W_ %_QH]K3_F0>RJ?RO[B[15+^V=,_Z"-I_P!_U_QH_MG3/^@C:?\
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MJ5I:6L31N3*LJJ6#8;ELG QCZ&@#TO\ LG3O^?"U_P"_*_X4?V3IW_/A:_\
M?E?\*X[PW\1O^$I\;:=8Z8L#:1?>'3JJO@^:DHN!$T9.<8'S C&<CK5SXDWO
MBBT\+S_\(C';1-]GFDNK^XDQ]EC1,Y1!RSGG;V!'/6@#I?[)T[_GPM?^_*_X
M4?V3IW_/A:_]^5_PKFOA/>W6H_"G0+O4+F:[N9;;=)-/(7=SN/)8\FNPH J?
MV3IW_/A:_P#?E?\ "C^R=._Y\+7_ +\K_A5NO*;/XA^*%\"2>-;\:3-IEK>O
M%=6$%G*DPA68Q%UE,K L.&P4&0",B@#TO^R=._Y\+7_ORO\ A1_9.G?\^%K_
M -^5_P *Y;_A(O$'B'Q/K&F^%&TVTMM'"12W6H6\D_VF=T#A%5)$V*H(RQR<
MG@<<\CXE^,^JZ9H6@:CIVE6P>YN[J#5+:;=(T/V8_O?+8%>P8@D>G% 'J_\
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M]+EN0>HX(XKS3XK:=K]C#XC\3Z_XZO="TRU@5- L]'O&A,LVT_+,NT;RS 8
M)P-QR */9P[(/:3[L]>_LO3_ /GQMO\ ORO^%']EZ?\ \^-M_P!^5_PK-\%7
M>K7_ ('T:[\11^7JDUG&]TNT*=Y49)4=">I'8\<5N4>SAV0>TGW95_LO3_\
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M6;@2'MD*003V<.R#VD^[/1O[+T__ )\;;_ORO^%']EZ?_P ^-M_WY7_"N?\
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M"2=X?#MK+?074-K+J$NJRR*4:=KN-E8H@!&,OT)' ZFO1O[2MO[S_P#?IO\
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M_P#"C^V++_GH_P#WY?\ PH O451_MBR_YZ/_ -^7_P */[8LO^>C_P#?E_\
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M<].!V-==_;%E_P ]'_[\O_A1_;%E_P ]'_[\O_A0!R<'@G4HKKQ_(TUJ1XE
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M=R7]_-&NV,SR ;@@_NC:!GC.,X&<#KZH_P!L67_/1_\ OR_^%']L67_/1_\
MOR_^% %ZBJD6IVLTJQQNY9CP/*8?S%6Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!KL/PA\6_P!O:CI]Z#IS^5]BT][;;P<[MTTF[MTQCGKGB;QI_P F^ZK_ -@
M_P#HF@#I=-\8^&-:O19Z/XCTF_NF!806M]%*Y ZG:K$U)'XI\/S:V=&AUW39
M-4#,IL5O(S." 21Y>=V0 2>.@KFM$M_%D?P]C<ZGIUQG1?\ 0X;73I(9ED\D
M>7^\,[@X]E&3Z=*K^ !X7'PA\(?VD--$12 Q?;/+YO\ G=MW?\MO-\SI\V<]
M\T =#)\0?!D4[0R^+M"25&*-&VI0AE8'!!&[KGM6OJ.IV&CV+WNK7MO8VD>
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MVUU&SBN]/N8;JVF7='-!('1QZAAP13[BXAM+:6XNI4A@A0O)+(P544#)8D\
M <YKC/A"S+\%_#;1IO<6 *KG&X\\9K'UJXU[QKX%UW2/'FAP^!+2>&-(=0GU
M>"Y1I#(,*0, #(48)YW8% ';)XR\,2:3)JD?B/26T^*0127:WT1B1S@A2^[
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M+JVNKK)W2VMLT"$=L(SN1_WU^5 %NBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH[B)IK=XTF>%F
M&!)'C<OTR"*3V&M61WUA9ZI8R6>IVD%Y:RC$D%Q&)$<9SRIR#R*HCPGX=716
MTA= TL:8S^8;(6<?DENN[9C;GCKBD_L2Z_Z#NH?^0_\ XFC^Q+K_ *#NH?\
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M3!X>T4::FG#1[ 6,<OG):_94\I7W;MX3& VXDYZYYJ'^Q+K_ *#NH?\ D/\
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MT.D6,9@F:XA*VR#RY6^](O'#')R1R<UG_P!FWO\ T'+[_P A_P#Q-']FWO\
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M?_Q-']FWO_0<OO\ R'_\31[2I_(_O7^8>SI_SK[G_D=!17/_ -FWO_0<OO\
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MKT5D?V)=?]!W4/\ R'_\31_8EU_T'=0_\A__ !-'M*G\C^]?YA[.G_.ON?\
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M3DQR;-K?7"UI5I"3DM58SG&,7H[A1115D!1110 4444 %%%% !1110 4444
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M8'<OEQ;QMYP.>N0:3Q#KESI.K>';6V2)DU343:S&0$E4\B63*X(P<QCKGC-
M&[17*6VK>(/$EW?2>'I]-T[3K.ZDM(YKVTDN7NGC.V1@JRQA%#@J.6+8)X&,
MI_PDFMV^H>%K+5=-M[*YU2[N+:\C63S0!'!*ZO$P(X8QJ?F&0&P0#0!UE%<Y
MJFLZDGC2ST'3FM8A=Z9<W0GGA:39)&\2K\H=<KB0Y&0>G(K-T;4?%]]XLU73
M+K5-$\G2I+<2-'I,RM.LB;R!FY(0XXSAO7':@#M:*** +5M_JS]:EJ*V_P!6
M?K27MW#I]A<7EV^R"WB:65L9VJHR3^0H FHKBK?4_'-]H8U^TMM(6*6(7$&B
M2Q2>>\9 (1KD/M60CG'E$ _+D_>JTGQ)\,O;V4BW-T\E]81ZC%;P6,\\OD/G
M#E(T8@ @@^AQGJ,@'5T5@W/C70;:WL9ENY+L:A#Y]JEA:RW<DL7'[P)$K-M^
M8#<1C) ZFH[OQYX<L[6UN/MTEU'=6WVN+[#:S73&'_GH5B1BJ<XW, ,Y':@#
MHJ*Y=/&$,GBYK9;JR.B#1!JHOM_R[?,(W;\[=FT9S^.:LZ9XWT#5C.(+R2W:
MWMOM<BW]K+9GR.?WH$RKN08Y89 XR>10!OT5R@^)GA4[@][=1,MI)?;)M-N8
MV:W0 M*JM&"RX(P1D'G&<'&XNMZ<^J6VG1W(>ZNK9KN%$5F#1*5!?<!@#+KC
M)&<\9P: +]%%% !1110 4444 %%>1_\ (1_Z96$?_ ?,Q_)1_GV/^0C_ -,K
M"/\ X#YF/Y*/\^WA_P!K=H?C_P #8]W^R.\_P_X.YZY17D?_ "$?^F5A'_P'
MS,?R4?Y]C_D(_P#3*PC_ . ^9C^2C_/L?VMVA^/_  -@_LCO/\/^#N>N45Y'
M_P A'_IE81_\!\S'\E'^?8_Y"/\ TRL(_P#@/F8_DH_S[']K=H?C_P #8/[(
M[S_#_@[GKE%>1_\ (1_Z96$?_ ?,Q_)1_GV/^0C_ -,K"/\ X#YF/Y*/\^Q_
M:W:'X_\  V#^R.\_P_X.YZY17D?_ "$?^F5A'_P'S,?R4?Y]C_D(_P#3*PC_
M . ^9C^2C_/L?VMVA^/_  -@_LCO/\/^#N>N45Y'_P A'_IE81_\!\S'\E'^
M?8_Y"/\ TRL(_P#@/F8_DH_S[']K=H?C_P #8/[([S_#_@[GKE,FSY+[=H..
M-_3\:\F_Y"/_ $RL(_\ @/F8_DH_S['_ "$?^F5A'_P'S,?R4?Y]C^UNT/Q_
MX&P?V1WG^'_!W/6HL^2F[:3M&=O3\*=7D?\ R$?^F5A'_P !\S'\E'^?8_Y"
M/_3*PC_X#YF/Y*/\^Q_:W:'X_P# V#^R.\_P_P"#N>N45Y'_ ,A'_IE81_\
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MOPJ6H95S<0GRM^,_/G[E34 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_IUN?\ OW5JB@"K]N_Z=;G_ +]T?;O^G6Y_[]U:HH J_;O^G6Y_[]T?;O\
MIUN?^_=6J* *OV[_ *=;G_OW1]N_Z=;G_OW5JB@!L&H;8S_HET>>T52?VE_T
MYW?_ 'Z_^O5BV_U9^M2T 4O[2_Z<[O\ []?_ %Z/[2_Z<[O_ +]?_7J[10!2
M_M+_ *<[O_OU_P#7H_M+_ISN_P#OU_\ 7J[10!2_M+_ISN_^_7_UZ/[2_P"G
M.[_[]?\ UZNT4 4O[2_Z<[O_ +]?_7H_M+_ISN_^_7_UZNT4 4O[2_Z<[O\
M[]?_ %Z/[2_Z<[O_ +]?_7J[10!2_M+_ *<[O_OU_P#7H_M+_ISN_P#OU_\
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M &G_ -.5Y_WY_P#KT?VG_P!.5Y_WY_\ KU>HH H_VG_TY7G_ 'Y_^O1_:?\
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M@Y@HHHH @M@H:;:CIF0YW]_<>U3U!;,&:7;*TF)"#D?=]JGH **** "BBB@
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M1*X''T-']EUNK7X_Y;!_:U#HG^'^>YYU_P A'_IE81_\!\S'\E'^?8_Y"/\
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MV76ZM?C_ );!_:U#HG^'^>YYU_R$?^F5A'_P'S,?R4?Y]C_D(_\ 3*PC_P"
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M]GQ_\]9_^_S4?V?'_P ]9_\ O\U6J* *O]GQ_P#/6?\ [_-1_9\?_/6?_O\
M-5JB@"K_ &?'_P ]9_\ O\U']GQ_\]9_^_S5:HH J_V?'_SUG_[_ #4?V?'_
M ,]9_P#O\U6J* *O]GQ_\]9_^_S4?V?'_P ]9_\ O\U6J* *O]GQ_P#/6?\
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M_LJ+_GO=?^!#?XU>HJR"C_947_/>Z_\  AO\:/[*B_Y[W7_@0W^-7J* */\
M947_ #WNO_ AO\:/[*B_Y[W7_@0W^-7J* ,R#2X29,&[CPYZS,-WO4O]E1?\
M][K_ ,"&_P :GMF4F7;([XD.=W\/L/:IZ */]E1?\][K_P "&_QH_LJ+_GO=
M?^!#?XU>HH H_P!E1?\ />Z_\"&_QH_LJ+_GO=?^!#?XU>HH H_V5%_SWNO_
M  (;_&C^RHO^>]U_X$-_C5ZB@"C_ &5%_P ][K_P(;_&C^RHO^>]U_X$-_C5
MZB@"C_947_/>Z_\  AO\:/[*B_Y[W7_@0W^-7J* ,Q=+A^U,-UV/E_UGGMS[
M5+_947_/>Z_\"&_QJ=67[:X$CEMHRA^Z/>IZ */]E1?\][K_ ,"&_P :/[*B
M_P">]U_X$-_C5ZB@"C_947_/>Z_\"&_QH_LJ+_GO=?\ @0W^-7J* */]E1?\
M][K_ ,"&_P :/[*B_P">]U_X$-_C5ZB@"C_947_/>Z_\"&_QH_LJ+_GO=?\
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MG7*TFUUV[M:]NO\ D)5Z<.1\R;2?3?LGIWZ?YFE9P-:V4,#S/.T:!3+(<LY
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MP:]-KSUO!6N&RDT'&E-I3ZN=1&IM(_VP S^?CRMFWS QV>9YGW<';GY:]"H
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MGV/^0C_TRL(_^ ^9C^2C_/L;^=_Q_P"!_7J;>5OP_P"#_7H?\A'_ *96$?\
MP'S,?R4?Y]C_ )"/_3*PC_X#YF/Y*/\ /L?\A'_IE81_\!\S'\E'^?8_Y"/_
M $RL(_\ @/F8_DH_S[&_G?\ '_@?UZFWE;\/^#_7H?\ (1_Z96$?_ ?,Q_)1
M_GV/^0C_ -,K"/\ X#YF/Y*/\^Q_R$?^F5A'_P !\S'\E'^?8_Y"/_3*PC_X
M#YF/Y*/\^QOYW_'_ (']>IMY6_#_ (/]>A_R$?\ IE81_P# ?,Q_)1_GV/\
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M^+_C0!:HJK]INO\ GQ;_ +^+_C1]INO^?%O^_B_XT 6J*J_:;K_GQ;_OXO\
MC1]INO\ GQ;_ +^+_C0!J6W^K/UJ6LZ"ZNQ&<:>YY_YZI_C4GVN\_P"@:_\
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M[CE)_!.HW,B1M-:I:*!\B.V7]C\O _S])1X)NKB\BCO9X$T],%HX6.Y\=!T
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M>_7WQCFO5:*;RQ.RYMO\DNC7;_@"6:25WR[_ .;?5/O_ ,$****]<\<****
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MT=3D#"660^9:"Y.Z5#(BJ1@LP,GRX!&/1I=*TZ=+Q9["UD6^ %V'A4BX 7:
M^1\WRC'.>.*@A\.:);Z/)I,&C:?%ILI)DLTM46%\]<H!M/0=J /,[O7=3M-!
MFT>V74=.O1J]M;7\6H:R95MHYD) CO 'D57*J-S#>IEXVY7$UW-KVBBXTV]U
M6WLK"YO;&":.#7);VZL(Y799',TJ+(BR815))*DL5(XQZ1;^']&M-)DTJTTB
MQ@TZ4,)+.*V187W=<H!@Y[\4VT\.:)8:7/IECH^GVUA<;C-:0VJ)%+N 5MR
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MY^@=)U&_D\MM/NH;.,XVF%E,F/;' _S]#V<WT;_7_@![2"ZI?I_P2G_R$?\
MIE81_P# ?,Q_)1_GV/\ D(_],K"/_@/F8_DH_P ^UPZ3J-_)Y;:?=0V<9QM,
M+*9,>V.!_GZ!TG4;^3RVT^ZALXSC:864R8]L<#_/T/9S?1O]?^ 'M(+JE^G_
M  2G_P A'_IE81_\!\S'\E'^?8_Y"/\ TRL(_P#@/F8_DH_S[7#I.HW\GEMI
M]U#9QG&TPLIDQ[8X'^?HC:3J-])L>PNH+.+^$PLIDQ^' _S]#V<WT;_7_@![
M2"ZI?I_P2I_R$?\ IE81_P# ?,Q_)1_GV]%\-RWLNEAKU-D?'D;OOE/4CM[=
M\5D:!X=,[)=ZC"8X$(,-LRXW8Z,P[#T7\3775[F7X6</WLGO^/\ P.QX68XJ
M$_W45M^'_![A1117L'BA1110 4444 %%%% !1110 4444 0VZ[3+B'R\N3US
MN]ZFJ"VV[IMID_UASO\ 7V]JGH **** "BBB@ HHHH **** "BBB@"%5_P!,
M=O*P=H_>9Z^V*FJ!=OVY\>9NVC.?N_A[U/0 4444 %%%% !1110 4444 %%%
M% $,JYN83Y6_&?GS]RIJ@EV_:H,^9NYQM^[T[U/0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%0WEG;ZA9R6M[$LT$HVNC=&% G>VA-17._\ " ^%
M_P#H#0?FW^-'_" ^%_\ H#0?FW^-:6I]W]W_  3+FK?RK[W_ )'145SO_" ^
M%_\ H#0?FW^-'_" ^%_^@-!^;?XT6I]W]W_!#FK?RK[W_D=%17._\(#X7_Z
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M * T'YM_C1:GW?W?\$.:M_*OO?\ D=%17._\(#X7_P"@-!^;?XT?\(#X7_Z
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M .@-!^;?XT6I]W]W_!#FK?RK[W_D=%17._\ " ^%_P#H#0?FW^-'_" ^%_\
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M-(M3ACMV%N![\]:D_P"$!\+_ /0&@_-O\:+4^[^[_@AS5OY5][_R.BHKG?\
MA ?"_P#T!H/S;_&C_A ?"_\ T!H/S;_&BU/N_N_X(<U;^5?>_P#(Z*BN=_X0
M'PO_ - :#\V_QH_X0'PO_P! :#\V_P :+4^[^[_@AS5OY5][_P CHJ*YW_A
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MQHM3[O[O^"'-6_E7WO\ R.BHKG?^$!\+_P#0&@_-O\:/^$!\+_\ 0&@_-O\
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M=C\G _S]#ZU1_F#ZEB?Y&<3_ ,A+_ICIT7_ ?,Q_)1_GV/\ D)?],=.B_P"
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M*/\ /L?\A+_ICIT7_ ?,Q_)1_GV[:X^%6N74J1/=:>EF@'[M)'!?'8_)P/\
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M\"4_QH_M_1_^@M8_^!*?XTW_ (1S0_\ H#:?_P" J?X4?\(YH?\ T!M/_P#
M5/\ "C]WYA^]\OQ'?V_H_P#T%K'_ ,"4_P :/[?T?_H+6/\ X$I_C3?^$<T/
M_H#:?_X"I_A1_P (YH?_ $!M/_\  5/\*/W?F'[WR_$=_;^C_P#06L?_  )3
M_&C^W]'_ .@M8_\ @2G^--_X1S0_^@-I_P#X"I_A1_PCFA_] ;3_ /P%3_"C
M]WYA^]\OQ'?V_H__ $%K'_P)3_&C^W]'_P"@M8_^!*?XTW_A'-#_ .@-I_\
MX"I_A1_PCFA_] ;3_P#P%3_"C]WYA^]\OQ'?V_H__06L?_ E/\:/[?T?_H+6
M/_@2G^--_P"$<T/_ * VG_\ @*G^%'_".:'_ - ;3_\ P%3_  H_=^8?O?+\
M1W]OZ/\ ]!:Q_P# E/\ &C^W]'_Z"UC_ .!*?XTW_A'-#_Z VG_^ J?X4?\
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M4_PH_=^8?O?+\2I_;ND_]!2R_P# A/\ &C^W=)_Z"EE_X$)_C5O_ (1S0_\
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MN_,/WOE^([^W]'_Z"UC_ .!*?XT?V_H__06L?_ E/\:;_P (YH?_ $!M/_\
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MN_,/WOE^([^W]'_Z"UC_ .!*?XT?V_H__06L?_ E/\:;_P (YH?_ $!M/_\
M 5/\*/\ A'-#_P"@-I__ ("I_A1^[\P_>^7XCO[?T?\ Z"UC_P"!*?XT?V_H
M_P#T%K'_ ,"4_P :;_PCFA_] ;3_ /P%3_"C_A'-#_Z VG_^ J?X4?N_,/WO
ME^([^W]'_P"@M8_^!*?XT?V_H_\ T%K'_P "4_QIO_".:'_T!M/_ / 5/\*/
M^$<T/_H#:?\ ^ J?X4?N_,/WOE^)&NNZ0+MV_M&P *C]Y]J3)]NM3?V_H_\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>sttk-20211231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g3.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M@4)B&L/'WK'X_7X%G,$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MGX;$R8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , J%";$
MF93WAZ3JE^=<.*^A7E7QK/8O&ND&7+41+K)M7W"!FYI%RFVX(++GQ%70)DY1
M=/%VC=..-NV+=JLY?J.Q5A<J?BY27V)1Q][+>X*1@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@%3;_]6=4A8U6U'&J O'T-9%LP^U+
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M=FU)/&^%S=TO&*7CW+ZX*1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MXZT.SJWVAZCIW$T:,)5*EG;QJ6=\XP66J-.LW"O-K\VG"2D_>;DH5-8E8\4
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MXG8Z)"WK*D]XUM8N5*K3G5CTDM.L_4UJ$6G%U[]5L>MM:$XR/G63L P#9/\
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MY:EU6Z4X=(I\\\1W/.184^LZXB;@U<5GSRS"+KOM11M()"^;11GM3?6^D0D
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MM;C@_A[6W"$;W3]9E9PJ82J3M[VA*4J3D_K.$*E)5%%;*3;QNSTW9Z#'G*,
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M ,/U0[F9*:UOY[U]/?T?E\^_GV*U_MKAC5;?>532M0L=5I+PA:WD9Z7J,O\
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M1U&L^*>,X>/1IF])H(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI7.>JNZ"]1=Q?MA<TJL'G#S'=)[&6Y9RZ# ,!=;X&V4*6USKGF4Q(D-74_\
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M)>-68PZ_DAK9M/.&EYY]OL9?O! P!@# & , 8 P!@# & , 8 P!@# & , 8
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M5RAU:+FCW<;79P1E*P#71EXSV+F()T-=R=G))%T@V)_>98DNE]JWA3BWZ*/
MVLNXNN'[O4.&[ZM<.M&G3G"ZTJ$)[U*2LJE/UU-<V725"ZI4Z:?+ZN44D9OX
M0^EUQSH\[:UXEL=.XCT^A:JE4JJG.TU>I5C)JG6=W"L[>3<,*LJMI4E4E'FC
M.FY,NW7WP>;%(E&ZURWM' 4<25XZ? J>C3Y](R:6MZWVBWG,Y^K' TU-:VFM
MUQ7A=WTEWUMH]'N.4U^;-PU]$3AJPNJ=SQ)KU[KE.E)2_(K:E'3[:MAY2JSC
M.I<8RMU"JE)-QDFB^\3_ $Q^(+ZTJ6W"_#EIHU:K!Q5_>UW?UZ#::<J5%0IT
M&\/9S3<6DUDN)Z ^&C3D]I6(0"E18:H9K4Z9=>L9/I!^5:OE#ZS=Y*P=E+JN
ME3TN&SAZS:OSD@?OWLH82%NRDS1T\6;OA1?-G''HBX5XSX1I<*?D='2Z.G03
MT2XLZ482TRM"/+!TTDU*G-+DJQDI<T&UAY:>#> _3/Q=P7QE<<6U;VOK%359
MXUZVO*LI1U*C*3D\OI3JTFW*BXJ,8M);;2CHFL'SGZ5J0DN)L2@;215;J=I\
M'J_A\BMN$DT^.M\\OALGKP0<^R,W/R^FV;RL=%COT-ZT["-%?FGK0/B?Z.7I
M/X>NZM*UT67$%G&3]3?:5.G-5*>6H2JV]6I"K1J22RZ:=51SCG;/0GA?Z1_H
MKXDM*=:MK]'0;MQBZUAK*E;U*=3&9QIUE!TJ\8O;UD7%2ZJ.&B.:_A5FW#=3
M?S=7,)*"[H?PQ[/4 UPC)%4 @=$FBR#7\I".Y>$9R4F.5=.4DVC>)QR0$'^N
M'2Z2*+!@2(,>=PA]&GTC\0W=+]UM.7#>F\R=>YU&K2_*)4^K5O;4I592G+\U
M.HX*&5)QFDXO@\8?29]&7#5I5>G:O#B34>5JA::5&=2DJG1.O<35.$(1?UFH
MMN6.52@VI+!*W@D_<3&WZ]%UI:EAVM5DRZB]W+U[ #]G,P\P;]OQB [1.M64
MK$L0K?[E(L0#+MVBHD@/>:><=&-%E5.1Q=Z ?2Q3OJ=I8\,T[O2;&$J&E4]*
MOK>O1I6TJDIRJ5YW$[>K4O;J;=:\K3@G.K+EIQIVU.A1I?+A/Z0?HCN;&I=W
M7%<;+4[N4:^I2U>TKVE>I<*G&"I4H4XUJ<+2W@E1M:-.HXPIISG*=>K6K5;X
MTG\/7U'=Q=BF<AI:@Z]462V:G5C-F3.8=#OIZ^U(0FL^UW1U0_VE\TVSN?,X
ML$&J*<$.F\DTU4".^U>C_P"BIQ/J5[;7G'$Z6BZ33G"I6T^C6C7U*[C%INA*
M=)NG:QGTG.-2<^1R4)4Y\LEU#TA?2QX1TBQN;3@CUFOZQ4ISIT+V=&='2[6<
MHXC7;K14[EP;YHTU!1<TE-2@VC;Y/_A<^5Y=7L0A<: F:O/0,'V"CEF0A\VX
MG#QLN^=F'^YRN;8EA%B[+'B!,X05EXHD^;E"YAZ ?@G9-TOWN)Q)Z(N N*-"
ML>']1T.A"STJA&WTNK:9MKNQIPBHJ-"XI<L^5X3G!MPGC#7*VC2_AGTT^D/A
M;7]1XAL-<JUKK6+F5UJMO>I7-E?59-MRJ6\VXPE%/EA.FXRBE'+ERHI$1^#9
M:W"SOD1ZG@RC+7"W3'LGY_-;*;WI/K;=%VHTO) ?VKTI]!-9ZBS01^6^EN!O
M.ODWU@N7T/.$G=^LCQ3K\;3GYG;^JL'44,Y<(UW1?A]52<&_%YZ&>X_3/XH5
MHZ<N$-$E>^K<5<?E=ZJ/K,8525!-2:SB3@JL5X)^)\_@;PRN9S5\RN&<QG;O
MU?6%HV!34^(G7&UNH1I@HU<H,(7&N=)"HD@^#D>0I@NV:*R(X\%F69 XY&\)
MC6N?.!?17P5Z.Z=1<-:4J-S6BHU]1NZLKO4*T4DG&5S4680;S+U=*-.G%SFH
M0C&7*:\\>^EWCGTDNG'B;58U+.A4G.CIEE1C9Z?2FYN2EZB#DZDXKEC&=:=2
M;C"#E*4USOC?%LHLW%[&CWIX2R6<P&41T+7=HNFZ/7:4/E(-\_\ R(EQCKCG
MK[.$E0XQW#B1=QM-F** 8<S5ZUL[]8E@#Z57HVOM=L-/XUT:VJ75SHU"=GJM
MO1A*=:>GRFZE.YC&*<I_DTW)2C%+%.<VN:7+%[$_1*])=AHMWJ/ FLW-.UHZ
MO<1O]&KUIQA2_+E35.O:.4G&,7<0C"<&\N4X)?5BI,U0_P!O]F>?1Z&# -H/
MPHJ%+SNWGOI4L/61KRKATBB=<DG"72:,MLJ0M^@,J-@U.^=?:P\%BZAJ*."2
M&U&#\_+2XQ!?;V*$TD]^/HI^C:^TJC?<>:Q;3MIZE;*QT2E6C*%5V4I*I<7C
MA))JG<M0A3REF$%.+:FTM OI;^DRQU%V'H]T>ZIW+LKI:AKU2C.-2G3N:<91
MM;)RBVO6TG*56HD\PD^223PWZ'\W0-'!@# & , 8 P!@&"R.M(/+I?7<]D8!
M$I+*F(R,O7A99V13W&2DLC)"&R @U9-WB(YT[?Q<L4"Z7(M'BC1D1?<L>FW;
MI?OL"&)9YO\ ,EID)ZF:!#R,FLJ:1RQI.:B]B2^,3Y*=TN,#UR!ED2EL*EP6
M9UZ<@#$>QBRK^OB\86&N7Y1H2Z^WR0Y]YB4VL;]/M7D]G]IU+SP_Y*[B[2*F
M:B $HP.@5K5V@PDAV4FD-1ZZU5"5R%'3D[(7KAY/;(5TZ=S>UWKA>T#VER*A
M*8K</'WUP9??M\.GD?AWXI\M2Z6M+2<PPD>*/IQ5US-EN+9MAY"2MG54E#NZ
MUM[N$(3[JO"UAC!\&AS/NQ5XZZE,F!"&PF0FC0=R[:.@RUM[UT\UW,K?>1O.
M!%'T$D]JH$K_ $IEQKJ^G6GAQ%_/EP@=,(#67)HE4R$>[!-4^GH/<3= ?N60
M.B,K&?9).4(F'09>V_3I[,]?/Q.DAOB_S3!)4/L()!B+^;LID"L3F<3.R[1L
M:4E9O'J[GM21R42&2V%-I06E9857-H36(BW4D>EMMAAAMRAKEP%CZXL,O]7A
MWS]YT8#P#Y)C0F1 1M3]+ Y''&T)[#&Y[9LG%QFOVDF%S!.M*V8269EFM35<
MI(P80D\K*KTHA B&PPEJ^CKEB-9-D R^_P#M[ON]]F]T2',?+%%3R4.)O)86
MZ6F#JPZYM523B)E/(P=XG-3 2<7@19L3B\G#NV;,/'39T(ZCS15"-2 :>/-)
M((+HFRO+L,OOW7GU/Q<WE:CK^/1F5V=%SI"5PP+(XW%95%K'LZM). C\Q4&=
MS$&,D-93&'F&PF7IA13*5C^'OV62"V* DTD^&<_9-B,GR#>3O.( U'SL>JN.
M!2$-/U](8TB&7*C14=*U569^I*W2&1]B21 L14,KN6G0H".)#> #%0GL\F+_
M "A1:%T!.6^KSUZ^UY?Q63&Y7XA\QS1(>F;KIZDH.E%R2WE_';"LZ&F"!#T)
M)=RZ[1)\W#YF",2:$6=(.&;Z6UO(GQ2O2:8>/#U(QH;' +,<";7P\$^BPNJ\
M.YW<8\?^;H:ZASR,U<+$KU^0K,G#M(%Y,H@#=4W5IREZPY;M7)M9JLRA=;R4
MX!#C':+@;PZ(*21=HO*4T#209;\>_P 7E_%%6?3WP\N;<X%#ZB.5O6@E3=_O
MSCB31.S9#*Q\T])2A"669/(Y,(1<]:'2;"1$>W_4KI:<O))3LSY1B+8E'60>
M$B@ZX)]UGI\-NS\^OM+7+^5:9)><X#Y9. 2I*HZVC=/1R*,&,JD\-D0G\!GT
M1,58<$S& EXK*8_)(E((-%Y"*-QLN'?,S ELY;*I<\_5[#+SG.^_MSGKG.SS
MXGP;>0_/32U>KF1@;C<V_+!U8Z+9>:V [KYE9;\)N./K0&4^ZE2U1BK0?!>U
MF#RR!L':S=TFZ?*+GE%W[U5<,O&/U+/NSUQ[,F43/SO4%@3<E8DMBSHI*S53
M2*C#KI.5S(6*D%52ER[=EXE(8P(D+"+GV^W3\@N+)F STW'U2)'L 3&;?O/K
M@3:\\_:C&(AX_P#,T$*#3,6IR(CGXCSR"\H#^U47I1NCYVCA$D6&U5VQ+O7[
M!Q'5"19\\,*.6RQ21K*);D) IIHST@&7W\<_;W.QICRY2% /B16L8J68F2@
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MY1(0O<WHA.RJIMJ>60*DRM/1-G(^. [!C-"0';$@6!A.Y/.DI8[C#QYN%O\
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M.!SA!TV76$P\0Q(+;<-NNDE72A)!WV_[UOZ>WW3GZ[7*WUG.A/0L;@# & ,
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M=_0=\BHX]!HAE'SM!OR^+*D&[/A1(6JNJ">>ALTP!@# -%<^_OZ/?\_%Y_\
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MC28N:6?,I,+.1@LV55:&1K9J;8"BVN.D7P@MQI @R;MWPET1$)8278VK8)&
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MV5\(66@]]-)U_2M6B23MK\N'+F"R I7369LG'T=:[69Z8+_4[^GUOALB2?\
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MM)*+O(/LFZ/%UFA;!J:1/^ Z1!LI,:X<$G:<(L$)]+7#X0>$<=]L=.U6O2O
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M5K?4&]J5:G.*[>MA)2\W!'J!S'QWL8 P!@# & , 8 P!@# & , 8 P!@# &
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M-O?5VOJU*M*$7CJZ<9.23]G-'/;[3U(YCP[Z, 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# *HV[:4TB?I_R#6@,DBUA]M*7YS.1R@]@Y
M6*:@E<,I#&M(/W#=1Z-^Q%5E%U?N]=M]LXWI!W]<CK7&@+78 P!@# & , 8
MP!@# & , 8!5CU7;$PJ491#J'.&+=:?^IZ%J>1;?,4G_ "M#[ EW(>1MVO*N
M]::OEF6]\M7R?S5:*?[8GK?6"5OY/X)LM/@@8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%$/?/^]?S
M#_\ '?X]_P#Q@#8*H_WW\E_J+WX*1@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M;MTR:;!YVRZ7Y:K[X$'>8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & 4(^)V&5->&K\:LA*A8GV#BW+)LU8]/WW>]6%$%%.6J*22KCK>D^.
M^^])<[W]#CKKK7T>=[T)77['CWX>"F7OBQO7M771)*Z\_%)U]VS^ QSU%!U
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M*1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 5C4
M\?T2M:Z5QN DP=R9M.?Q1:1YY:UJ.ZJ96A]R=QW\1V=,N)DK5+69\BU%?JS:
M$/X<(%E5Y*AI.3N%S*@G.V-O)9\^I9S! P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+Z2B\[IEIKZWHMM5J4*^H6U*M2DX5*<ZC4H275->#,8_IE_#@_QAJN_?8_\
MQ6?7][7$7_-5Y_\ B7S/E^^'0/\ G.T__(_D=F%]9?#TD9D3'P=\5J3-'2;
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M1MWWI=%9/@#KW5F0AG9P2FW)O2=D2.!RFS T;^[BW>WD(A<@A\6DQO[W38=
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/^^M\\<<\Z^7/.M:D@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sttk-20211231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2:"17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $.X<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C R.C(R(#$T.C4S.C V   "H $  P    $  0  ZAP !P  " P
M  C@     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M!@$#  ,    !  8   $:  4    !   1/ $;  4    !   11 $H  ,    !
M  (   (!  0    !   13 ("  0    !   5+0        !@     0   &
M   !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@
M)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R
M(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C+_P  1" !H 0 # 2$  A$! Q$!_\0 'P   04! 0$! 0$
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MC[/%_<%8##[/%_<%'V>+^[0!%,BHR;1C(/\ 2F4 %20$AFPI/ Z?C0!/N/\
M<;]/\:-Q_N-^G^- !N/]QOT_QHW'^XWZ?XT &X_W&_3_ !HW'^XWZ?XT &X_
MW&_3_&C<?[C?I_C0 ;C_ '&_3_&FHQV_<;J?3UH =N/]QOT_QHW'^XWZ?XT
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M** #-&:*I76M:?9R-'<7]K!(,92295//MGCU_&@"[FC-9W_"1Z3_ -!2S_\
M A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_
M *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &
MCFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\
MT%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_
M (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^
M!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_
MPD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\
M A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_
M *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &
MCFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\
MT%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_
M (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^
M!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_
MPD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\
M A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_
M *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &
MCFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\
MT%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_
M (2/2?\ H*677_GX3_'\?_U4 :.:,UG?\)'I/_04L_\ P(7_ !H_X2/2?^@I
M9_\ @0O^- &CFC-9W_"1Z3_T%+/_ ,"%_P :/^$CTG_H*6?_ ($+_C0!HYHS
M6=_PD>D_]!2S_P# A?\ &C_A(])_Z"EG_P"!"_XT :.:,UG?\)'I/_04L_\
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MK^F6^H:==QWEE<+OBGA;<KKZ@C_(H O44M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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M%+10 E%+10!Q?AO_ )%W2_\ KUB_] %:-9WAO_D7=+_Z]8O_ $ 5HT %%%%
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MZJ%R/NCIF@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH *D\*_Z[6O^OT?^B(:CJ3PK_KM:_P"OT?\ HB&@#?I*6B@!*,>U+10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DZU_P A
M+0O^OUO_ $GFK6K)UK_D):%_U^M_Z3S4 :U%%% "44M% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR>7,RCS$/56'#+^# BI:Z;XH:#_PC/Q-\4Z:J;8UOY+B( <;)P)ACVS(Z_\
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M?$%B$NM?"J^GW48/EVBJ0D<JGC<=\C,IZ!PI&0:\_A[*YYE7G%KW+--]-O\
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M]?H_]$0U'4GA7_7:U_U^C_T1#0!OT444 %%%% !1110 4444 %%%% !1110
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M9,[DLX7"M.#T9&==JD9Y/;!P ?2E5[R\BT^TFNKB58;>%&EDD8X55 R6/H
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M7_!GP]\+?#G3'TWPGX:T?POISR&5[31;"*TB9SU8I&J@G@<X[5OX'I0!\ ^
M_P#@JK\%O!_[/^BB^GU%/&FCZ/#9OX173IHY'N8HE0HLVPPK&6!^8MD+_#D;
M:S/VOO'FLZQX=_9J_:8?P3K-OX>\,ZBVHZUH$RJ]U9V]QY6R4@' XB^5FV\O
M'NVDXK[<O_@A\.=4\6+XIO? 'A>\\3+*LRZU<:-;/>B1?NN)BF_<,#!SD5V4
MT$=S"\4T:RQ.-K(Z@JP/4$'J* /SI_:Z_P""AWPC^,'[/VO^ OAQ=ZEXX\8^
M+85TNUTBUTBZ1X6D9<LWF1KN88.U8]Y+;>V2.:\<?"&;3/VGOV/_ (<^)0;J
M>U\#SZ5J"ID\K9S)(O?@8*C'I7Z%^%?@G\._ FL2ZOX:\!>&/#VJR@B2^TK1
MK:UG<'J"\:!CGZUL:AX%\-ZKXHTWQ+>^'M*O/$6FH\=CJ]Q91/=VJN"'6*8K
MO0,&8$*1D,?6@#\:/AK9^)OB#X%^)_@KQ#;9M?@?X#\1:3;S'YF>ZFNG^8D\
M)B*-HP 3\L9YYKM_&_AR]\7?L3_L9:%INLW'A[4=2\5QV=MK%H&,MC+)<3(D
MZ;60[D)###*<J.17ZIP?"OP5:R>(WA\'Z#$_B0%=;:/3(%.J A@1<X7]]D._
MW\_>;U-,'PC\#+I>@Z:/!?AX:=H%PMWI%G_94'DZ=,&+"6W39B)PQ)#( <G-
M 'R7\,?^";>J:/\ %3PSXT^*'QN\4_%U_#-RM]I.GZLLR1P7"D,KEI;F8D!E
M1MJ[<E%R2.*\Z^%OQZ\-?L-_M2?'7PS\75OO#VG>,M:;Q+HWB/[%+<PW,$CR
M-L/E*SG'F8!52 RR [>,_I)6!XR^'OA7XC::FG^+/#.C^)[!'\Q;76;"*[B#
M?W@LBL,^^* /S@\7>/K']O;]KS3;[X6VNH7_ (3\%^$M7M[OQ%):201W4MU:
MS0I$@<!AEI4"AP&/[T["JYKE/@_^V_\ "[P+_P $\];^%6O:C?:9\0[31-7T
M1=#ETZX+333M,(W$H0QJO[X!@[*P*.,="WZI^%O!^@^!]'CTGPWHFG>']*B)
M*6.EVD=M A/4A$ 4?E7/:I\"_AMKGBC_ (274OA[X5U#Q%YBR_VO=:+;2W>]
M?NMYS(7R.QS0!^:WB[P7<:/\ ?V#=!\0Z?M:?Q3;&XLKE.L4]RD@5U/3,<@R
M#ZXKC]0\&>)/@+^W+\&/@M?2-=^#O#WB_P#MGPK=3?>%A?2QL8?<))"Z\]7W
MGH1C]=?$7@7PWXPNM*N=>\/:5K=SI-PMYITVHV45P]G."")82ZDQN"!AEP>!
MS3-<^'_A?Q1KFD:UK/AK2-6UC1W,FFZA?6$4UQ9,2"6AD92T9)53E2.@]* /
MS[^&O[4'PQ_9M_;6_:@;XC>)O^$=&L:EI@L?] N;KSO*AE\S_41/C'F)UQU/
M7MTG[,'Q M?VG/V_O'?Q=\&6U\?A]I7A:/PXNK74+0K>W)ECD 53ST5FVGD
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M6?%NG?%FRM]8O-,N=*F\+6?BNVM[BW&EVJEF&FJJ;PX=2)!YBE2I QBNVNO
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M?1/>O4_@[81?\(R=:!5Y=5;S58=5A4E8D]N 6([,[4 =_1110 4444 %%%%
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MG8J/*GOTA-M"P+J"))5*[ANQD5Z5GOUH 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LG6O\ D):%_P!?K?\ I/-6M63K7_(2T+_K];_T
MGFH UJ*** "BBB@ HHK@OB=\:/#7P@LS>>)_[;@L$@DNI;S3O#VHZC;P1)R[
MS2VT$B1 #GYRO )Z F@#O:*\QB_:,\"_V7I.HWU_JFA6FK:M#HEA)X@T'4-+
M^T7DJ,\2*+F",[65#B3&S/R[LD ZGC+XS>$? *Z__;>JR6KZ#:6E]J$<5E<7
M#Q0W4TD,#!8HV,A>2)U"("V1R ""0#NJ*X/P?\9-"\<:Q_9NG6'BJVG\MI=^
ML>$=6TR':N,_OKJVCCSR/EW9/. <&I_B!\7O#GPSO-*L];?59+W51,;.TT?1
M+[5)Y1$$,C>7:PRL%7S$RQ 'S4 =K17E[?M(> X_!^N>);C4=3LM/T2Y@L]0
M@O-!U"WOK>:=HU@4V4D N#YAECVXC(.[C.#6MX/^,6@^.-2FL=/L_$UG+# U
MP\FN>%-5TJ ("H.)KNVBC+?-]T-N(!., D '=45Y=HO[27@#7]:T_3K35[T?
MVE<?9-.U&ZT:]MM,U";YMJ6M])"MM.7",4$<K;P"5S5=OVG/ \FHZG96D?BW
M5)-.O9].N9M*\$ZW>VZ7$,C1RQB:&T:-RKJ0=K$<=: /6:*\M\0?M(>"?#?B
M/6M!N&\27VHZ*8UU$:/X2U;48K4O$DR*\MM:O&"8Y$;&[(!YQ5?Q)^U%\/O"
M=CI^HWM]K5SI&HPV\]GJVE>&-4U&QG6X8+ %N;>V>(L[,JA-V[+*,9(! /6J
M*X#4/CAX2TGP;;>)]1NM3TO3KJZ6QM;;4-$OK;4+JX9B%AAL9(5N99&PQ"I&
M20I(! )J/0?CQX*\0Z3XCO[?5KBT_P"$=MVO-5L=4TRZL+ZS@$9D$KVEQ$DX
M0JK%6V8;:P4D@T >AT5Y=H'[2'@GQ'JVD:="WB/3YM6D$-A-K7A35=,MKF0H
M75%GN;6.(LRJVT;LMT )(KU&@!G7ITQ7PI^T#X13PO\ M+$RJ(=)\86?V>60
M\(K2J86.?56"R?B*^ZS7S!^WAX0?4/A_I'B:W0FYT6] =A_#%+@$_P#?:Q_F
M:Y<1'FIM]CY3B7#^VP$JB6L/>^[?\"G^P?XFDC\/^(O!]ZVV]TJ\:00M]Y03
MM<?0,OZU]6=*^ ?@EXO7PK^TEI&I(XCT[QA:+(^WHTDH(?Z?OT?\,5]^;J,-
M+FA9]#/A?$JM@%2OK3=OENOP)**9R>:7UYKJ/KQU%%% !1110 4444 %%%%
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MFTO.)GR2Y!ZA$#OCI\H%>9B\QE[>.#PJO4?X'=1PB=)XBN[01Y3^TMXW2/\
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MD?*'9%4NJY57WA3@"NZH **** .+\-_\B[I?_7K%_P"@"M&L[PW_ ,B[I?\
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MHRI##&[:>C+GHPX/YBNBC6]HM=SZ'(\[691]E5TJ+[FNZ.VHHHKJ/K HHHH
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M?X:\)67Q"\(7WA[18H[1!<>#+I;N6!3R#*-5V!R,_-Y> >=IZ5T/_"1_&_\
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MO_0!6C6=X;_Y%W2_^O6+_P! %:- !1110 4444 %%%% !1110 4444 %%%%
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MJ&ZC-?O!TKBS# O 5%!N]U<T3N.HHHKS!A1110 4444 %%%% !1110 4444
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M44 >4_\ "Y/%W_1"/'__ ('>'O\ Y:T?\+D\7?\ 1"/'_P#X'>'O_EK7JU%
M'E/_  N3Q=_T0CQ__P"!WA[_ .6M'_"Y/%W_ $0GQ_\ ^!WA[_Y:UZM10!Y3
M_P +D\7?]$)\?_\ @=X>_P#EK1_PN3Q=_P!$(\?_ /@=X>_^6M>K44 >4_\
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M@7<FMZ1\9_$%S9R:7#%(VB6=O.LKO,0T32R[20H0;P%)W;N2%VC/Z=U\@_\
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M&=P/7.>ASFOUA_X*4?&[5?@_\!4LM!N9++6/$MW_ &:+R$E9(( C/*R$'AB
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M110 4444 %%%% !1110!Q?AO_D7=+_Z]8O\ T 5HUG>&_P#D7=+_ .O6+_T
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MI0 !VI:_(7J[L[ HHHH **** "BBB@ HHHH **** "BBB@ K)UK_ )"6A?\
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M.3O)W"EHHK0D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8O8[A5F$=LS1JR[]G )/!!7//7.>O IVH3&3PA89VB!BJ-\ROO7D  ;1N)]
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M&C4-:N],U"ULC+#-]H)'GLNWR,#.7&><]!TYJEKD:W<.AP3*H,C@CYE.3@'
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MC*(LB,G<K;EY&,!>3_LC!]^M6/#\$5CK.IV]M&L68U<1@;-O QP<GOUSCVH
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ML?[,CNUN6%RMGN+>2)/O#YCZYP=N<5[;_P $T/BWX@\.?M!Z/X'^URW/AGQ
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M* "BBB@ HHHH **** "BBB@ K)UK_D):%_U^M_Z3S5K5DZU_R$M"_P"OUO\
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M %%%% !63XF_Y!L/_7[:?^E$=:U9/B;_ )!L/_7[:?\ I1'0!K4444 %%%%
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MFBM84@1FZ[54*/T%<Q\*OA5X;^#/A&W\-^%['[#I\;-(VYB\DLC8S(['[S'
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MEI:0!1113 **** &XHQ^%.HI -YI12T4 %%%%, HHHH **** "BBB@ HHHH
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MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
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M^B(: -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFM=1\6364UI#?3.LX6WC\P(SD&=3C;Q\Y(QMS>_X)/JL?AOXXS+'YC_\)K<
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M5M/XVD6XTR7Q?K4=Y?Z^MO*9C<A5M(&0S@E2&:3>21G RWGWQP_:F\%^,/\
M@F_H_P +M)TG5G\9:':Z5IFNV+Z3<1QZ*]O(BM--+Y8C7S'CVJN[),N" 0:
M/T5U3]K7PCI?CSX3^$IM.UMM2^)-E]OTB6."$PP1^4LF+@^;N5L$#Y%<9[XY
MK0N/VFO"\/[2"?!(V.L?\)7)I)U@7BPQ?8O)P3MW^;OW\'CR\>]?$O[0VO\
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M 'D6=2-@,;G)/&#SQ7BOP,_8UF_:,^'.J_$_QA\1?B1X+O\ XGW%SK%]X?\
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MBBB@ HHHH **** "BBB@ HHHH *D\*_Z[6O^OT?^B(:CJ3PK_KM:_P"OT?\
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MT.]D_:)LM;\9>+-:M+6>^D\#M!'X3MA&'OBB+"%O#&98 "0=V3M!Y(^S;?\
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M.":^D/BQ\=O ?P,\+Q^(_'7B>S\/Z-*XCAGFW2-<,1D+%'&K/(<9/R \<]*
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M?[87P@^,6J:'IG@WQK;ZYJ.LFY6SM8;6Y20FW0/+YBO&#%A64CS-NX?=W8H
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M]KKX2^'/'EKX+U#Q?'%XJN=8_L*+2H[*YEF:\VPL$(2(@*1<0XD.$.XC=E6
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MUBC::4G8I/W@H&< <U]#?#WXC^'/BQX1L/%'A'6+?7- OU+6]];$[7P2I!#
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M$/3?%.G3^"O(>Y;6FE\NWCC3(<N6P4VD$%6P0>*X_P"$/[8WP<^/'B2X\/\
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M+B-)!;VJRP2A2=K@'#(W(SR*]3_X*-0QV_[1?[(2Q1K&H\8X"HH XN=/ _0
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M<?A+X5UFTU?1/A=X+T?5K-_-MK_3_#]I!/ _]Y)$C#*>>H-:+?!7X>-XBO\
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M_F):ZU817<2/_>"R*P!]Z /SMO/ TL_[+_[3^H>%_BW#\:[S5;BRFUBZ\/\
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M 'RJ_BSPM\/?VFO@IXI^(%_8:5X7N?A@EEH.M:M(J65OJ0>.2;]\Y"1NT#*
MQ(R#C//.SK_BCX6>+?V=?VIM0^%6F3)I\UKJ3ZKKEO(6TW5M0:Q+2RVO[QE.
MT% [*B!F_O?>KZMUSX;>$?$WA:W\,ZQX6T75O#=NL:0Z/?:=#-9QJ@P@6%E*
M *.  .!TJ[HOA/0_#?A^+0=)T;3]+T.&,PQZ996J0VR1G.4$2@*%.3P!CDT
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MU\8?V:K6_MH;NV/C224Q3H&7>EC/(AP>,AE4CT(!KR3]M:'6M)_:\^%VM/\
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M]%%% !1110 4444 <7X;_P"1=TO_ *]8O_0!6C6=X;_Y%W2_^O6+_P! %:-
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MGP5U7XB>!?@O\53K=E;+J%O\7O&?B5M/O,B12EX(VN#YN_(VA(D+!E*X)!H
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MB[4H;BYT_0]/GU&XBM0IE>.)"[*@9@-Q"\9(YKY5_8G^'WQ.^%_Q'\1Z9?\
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M7Q\K-RO8 ^U/%?Q@T_PK\6? W@"6RNKC4_%D5]/;W4>T0P):Q*\F[G)+;T
M&/O$D8 />[N>?7CZ5\-_'7X%> ?B?^V=^S]JFO6-OXEFUS1]0N+O4K2[GBAO
MS9P0RVDJ".7:J!G9QL.&##)85Z'^R_=0P^*OVGWDFCC$7CN[>0NP 1?L5O\
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M$$NUEWQNH96P0",@CJ!0!?HHHH **** "BBB@ HHHH **** "LGQ-_R#8?\
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M3Q/KNBZ5X1\0V6CI%<7-WY)M1:12QR-<-(JHBDRKM(8Y[XZ'PC]A7P-INO\
MQE^*7C_1;W^U?AYHVIWN@^!Y$4"WBBN+@W=^8,<-&9G14<9RJD#TH ZW_@IQ
MHGB'5OV9[B71O$O]@VMMJVGF]M?L$=S]M5KN%(EW,08]DC))\OWMFTX!)KC/
MB%X5^*\'[6'PQ\-Z-X\L9_',GP]U"VU'QQ?Z-&!$@O(V:YCL481F3(C0(6V_
M/N.0,'Z/_:L^#^K_ !V^!NO^#]!O[+3=9NGMKFTN-05S;^9!<1S!9-@+!6\O
M:2 2,]#7-^$_A)\1=0^.?@CXE^-;GPR+_3_!]WH>K6^@2W!B:[DNXY5>W65,
MF+8G.]@P)X!'- ')?!7XG?%QM%^.'@?Q%XB\.^)/'W@&ZCBT_P 4ZM;_ -F6
M%S'/;":&6ZCA!$809+!!R!MSU>OGCQ9^UQXW^$WBSPE=VO[4G@WXPW>H:O:6
M5]X)TGPW;QVXAE<)*T-[;EV)3/!=ESG.#]T_1/Q _9&\0_$&']H^RDU^QTJ#
MXD/I<FE7$.^5[<VD$:LERA4#:[QA2%9@48D\\5Y9XQ_9%_:+^(W@W2/#U_J?
MP?\ !VDZ'?V5_!H_@S3+NU@U)X)491<R-'F-5 9E6-"I;&0."H!WOC/7_CM\
M2_VK/'_PZ\!_$BP\ ^%-%T?2]0;4;C0+?4KFVFE#_NX4?:&63:Q<R%MOEKLV
MY->E_L<_%/Q=\4/A=JG_  G<EG<>*O#?B#4/#E]?V*".*]>UD"^<$'"9!&0.
M,C(QG V/!?PCUCP[^TE\2/B%=7-B^C^)-+TJQM((I'-Q&]L)1(9 4"A3Y@VX
M8G@Y H_9O^$>L?!_1_'%IK-S8W4FN>+]4\06[6,CN$M[F0-&K[D7#@#D#(]&
M- 'DO_!3C1/$.K?LSW$NC>)?[!M;;5M/-[:_8([G[:K7<*1+N8@Q[)&23Y?O
M;-IP"35;XBZQ\<]-^*_PT^$6@?%*TCU?5O"]_<ZOXNN_#UJQ$T$\)%W':#Y=
M^UO*$9<)B0L02!CV7]JSX/ZO\=O@;K_@_0;^RTW6;I[:YM+C4%<V_F07$<P6
M38"P5O+VD@$C/0USGA_X2_$36/C1\-_B-XTN/#*:EHWAC4-)UF#0I;@PO=3S
M1,C6ZRIDQ[8^=[!LD8!'- '&ZI\4?B%X-^)'Q,\)7GBYM9_X1?X5P:U#?-IM
MM"9-4_TE9+LHJ<;C$I\O)C7&,=:\EL_C)^TQX9^'/P7^*5]XR\/^(+7QQ/IV
MA'P9<:.EO#'+>0LMO?2W: 2,Q<)*\:*B#>548&ZOHGQM^S[XB\1?%SXH^*;:
M\TQ-/\4^ 5\+64<LL@ECN@UP=\@$9 C_ 'J\J6/!^7IG,US]FKQ/JGP%^!'@
MF*^TE-5\!ZMX=OM3F::7R)H[!0)A"?*W,S8^4,J ]RM ')>"?C!\3/@C\=/&
MW@?XL>-K3XB:5:^!Y?'5KJ=KHT6EO9QPSF.6V"(2&7CY69F/ R1DBOF-O^"C
MFOW&DGQZG[0GANTUG8UVGPD;P->/9X!)%HVJ>5YGF[>/,!";^X7FON;Q-^SW
MJ'BK]J2[\?7\]A+X.OOA_-X/N+(2N+QY9;LRL=NS9Y?EEANWYR?NXYKS3PC\
M%/VI_AGX:L?AQX6^(WP_/@33HUL=/\4:II=S+X@LK1>$58!_HTCQJ HWG! Y
MQ0!)\1/C!\3/BE\3/A/X=^%?BZU\%:7X[\&W&OR:C>:;#J#6(#6TB2I&X_>2
M;7\K:6"8E9L$JM>:?'C]HGXA_#WXR)\./$WQWA^#=AIVDV!T_P 6WO@B/4AX
MLN7C'VJ9N/)M427Y=J@ <Y)KZDU+X-Z[=?M'> O'YU.WO=+T'PU?:+=O=MMO
M;FXFDA990D<8CP?*8M@K@D87' YGXY_#_P"/>L^(=4'@?6/AQXK\&ZHD0?PQ
M\2M)F:&P9%P?)DMES,KM\Q$P)4]#B@#TCX!^)]<\8?"C0]4\0Z_X8\3ZK*LB
MR:SX-N3-IMXJR,J21L1PVT+O4<!]P'&*]&KQ;]E/X!3?L[?#2[T&[O[&]U'4
MM5NM:NX])M!::?:RSLI\BUAR2D*!5 !.>">,X'M- !1110 4444 %%%% !11
M10 5DZU_R$M"_P"OUO\ TGFK6K)UK_D):%_U^M_Z3S4 :U%%% !1110 4444
M %%%% !1110!SGQ"UW5/"_@/Q'K&C:8VMZQ8:=<75EIB9S=SI$S)$, GYV '
M SS7YE_!3]L;XM_%::SO1^T;X*\/>.GU!H[CX9^-/#2Z7IR()2@B3451I&<@
M#" [\L03P,_J%XBT^\U?0=2LM.U:?0K^>W>*#4[:.*62UD((654E5D8@\X92
M#BO@OXM?L9?M#?'G0V\*>/-9^#NM6C3*A\?G09D\3+"L@<%52-84) "E$905
MR-W.: .;_;\T?XAZG^V!^SS8:=\1'T*+6;Y6TBWBTV.Y@T2\1H4>YVL0+HL9
M,CS%7 ! X8UU/BWXF?M!ZU^VM'\#/"WQ7L])LHO"MM=7NMW7ARTN"LRPH9KJ
M.' _>228_=L_EJ)&P.%KT']H3]C7Q?XD3X$ZK\,O$&C+XE^%(CBM1XN68P7Z
M(D"AI9(0SYS ,J!SYA^9<<ZG@W]F?Q_:_MI1?&SQ%?\ ALV=QX3BT>]LM+FN
M#(+[9$)&C1X\>3N5L%GW8(R* ,GP?\7OB3I/[>6F?"'7/&#:_P"'K7P+%J%X
M&TZU@-WJ PLESE(PR;CD^6&VC/2J/PS_ &GO%Z_M4?M*:)XHUMK_ ,#> =,_
MM*PTX6L$7V=$C$DG[Q8P[9 ;[[,*UOCM^R[\3[S]J;0?CA\(M?\ "MMK=OI/
M]D7^F>+XK@V[QY<!U, +,2' V_)@H"&.2!3_ &>_V./&_@?XV?&7Q;\1_$.B
M>*M.^(-@+25M+$L,Q+\2@PLFV- "50"1S@#)SF@#SOX;_$+]K;X^?"$?&_P1
MXPT!([R]D?2?A<=&MS!=6T5P8762^E9)%;Y'/# -MR&0G Y#]MZU^)_B;]J;
M]FJ/_A,KCP1=^()XI[#16LK>]3PUJ"^0LLAPYCO&#2$#=@84A3AC7H7AG]CW
M]I+X7_#V^^#_ ("^*OAC3/AC->22V?B*2*[B\2:;!))YCQP^5B+.[)W;P27?
M!0$ =Y^TA^R#XV\97'P3\0?#KQ3I]SXM^&<NZ.?QU-<W"ZGD1$R7$\8:5F+0
M_,,<^8<%,<@#/#/QB^(VG?M^:=\(M7\6G6O#-MX%BO[I/[-MK?[7?+M5[G*H
M73><MY8?:,X K#\#?M&?$/6/VEOVH/"MWXB\_0/!FBM=Z#:?8K=?L<HA#;MX
MCW/SVD9A5WXI?LO_ !GN_P!H/P;\<? >N^![7QQ;Z!'HVOZ9KD=V=,>3#>9)
M;E 9"A+X56*$;%)8[B!%\%_V./B9X'^*7QU\6^+?%'A_Q!<?$'1WL[>YLA-
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M#OB*R:"*+Q DTOE1236\,A,)5RC,-J?*V "5)/RKH/\ P4H\5>"[[P7XEO\
MXWZ1\3DU:[AC\0^ 4\'R:7_8\,HRYM[WRU\XQ'Y<LQR<'#@EA];Z/^QOXR^(
M7PA^)N@?&GXE7GB37_';J_E:;/.^E:#Y;B2%;."5@,"0 D[4W*H7CEC@>"_V
M9?VC[P?#_P (>,_BQI&E_#OP;)&5N?!4]]9ZUK<$0"QV]V^454V#:2I.>IW-
MA@ 4?BO\8?C;KW[=_P#PI[X>^,['PYX>O?"RZ@UQ?:3!>+8-R7N8U(5Y9.%5
M4:39\^2,"JWPI^,_QEU;QO\ &[]GWQEX[LS\0/#>F?VGHGCVPTF!7>!@CY>U
M&(]VR:+  ^4ELEBH)XWXN:'XUUS_ (*I&3X?:UINB^*K#P0MY:'6K9Y[&ZP6
M5K>=4(=8W#G+)EE(! /2O>?V:/V5_%W@OXD?$/XJ_%;7](UWXA^,XEL9H?#Z
M2C3[&T4*!'$90'?(2(8*C CZL230!\J_L!_$GQ5\$?V-_B)\9M:\7R:_X5L+
MB],7A":QB5Y-4=[<+<O?$F1O,9PK(00-Q;D\5WNI_%/]J?P;^SQI_P"T;J'Q
M \.ZQI$UO;ZS<_#J'0(H[:/3YF3;LO 3-O".K%2?ER?F?&#V/[/_ .P[X[\!
M_"7XA?!'QMK/A76/A-KJW<ECJ&DK<IK$=Q(T>R21' A54\L-L!8[@.2*R;G]
MCG]HGQ)\)]/^!GB'XE>#F^$=KY5J^MV-A<C7[BRA8-%;M&?W*@;$4$,2 HR7
MY! *OQU_:F^*?BOXT?L]:)\(O%-OX6T;XE:&M_)'JFF0720^:&/FMN3>6B3+
M!5=59D /!K[5^%_A_P 4>%?!.G:7XR\6GQQXCA,GVK7CI\5@+C,C,N((OD3:
MA5< G.W.>:^>?&G['.JW'[1WP%\7^$I])T[P/\-]-.F2V%U/*+MHPCHGE!8F
M5N"N2SJ>M?6F!Z4 ?F-\4/VQ_B7)^TO\0/ ^M?&*R_9XL=%NOLWAZVU'PBNH
MP:PFY@DL]Q(I,*.%5O, ";9.,[>?0?VM?VD/C!\(?V+?!/C.Q\8^%O\ A-[[
M78+*ZU[P9Y6HZ9?6S17+!XC<1%?FV1DX7A@<'!Q7<_&;X&_M$>*/$6NV>FZW
M\+/B7X&U%S-8Z7\4=!)ETC.?DA-K %EQV>3+85<C.2?*_%G_  3-\6Q_L:Z1
M\(O#WBK1[[Q$OBQ?$U]>:H9K:Q3-O)$T4 1)&P,IC*C=\Q^7(% '=_%?XU_%
MKXJ?M=1? KX5^,;#X>PZ-H2:UKGB*;2H=1N"S!,1)#,=F/WT' P?F8YP #G?
ML^_'SXR:M^T!^T#X(^('B*POO^$+T=9M/CTRPAAMXY/+!6=<J9/WB[9"DCN%
M+E1P*Y3]IAK#X1_MM:%XR\#?%;P7X%^)&HZ#'::OHOC^UO(-*O[0*528W<<?
MEY(A4!#(AW0* W)6LK]B72]2\??M0_M/:I#XFL_'$6H:;!8-XKL5V:?<7<L?
M*0E2W[I"KJN"WR1J<MD$@'._#_X[_M3?$/\ 8QU[XT1_%G2=,/AN:XD%FWAJ
MTDGU6*)D\SS)-OEQ!0Q"!(LMM^9AG(]Q^)G[6WBAOV/OAC\0K?QOX0^&&J>*
M(X#JFK:S;7%W)"-N)CI]E''*9I-PW!9/D5>&/.X6_A-^QCXU\"?L%^+O@EJ&
MIZ!-XJU>.^6"\MKB=K%3.04WN80XQCG$9]LUSWBS]A#XAS?"3]GV/PSXD\-V
MGQ)^%#>9&NHB:72;MC(DARXC\P8\M?X!D,?NG!H YS]D/]K;XF^*/VIKGX8>
M*?%-]X]\+WVC2:E8ZUKGA./P[=DHH8/%!']Z%OF&7Y.,C;C!^9/@_P#'3QO^
MS[_P3^USQ%X!US^P-9G^*K6$ES]D@N<PMIZ.R;)HW ^9$.0,\>]?;7PY_91^
M,]G^V!I'QP\>>)O!^LRW.D3:;JNFZ/'=6R6&8F2..T#HQF3<%8M(R'YWX.!G
MR!O^"9?Q0;]D.\^%G]N^$?\ A(9O'G_"4+<_;+K[(+7[)Y.S=]FW^9NYQLVX
M_BSQ0!Z/\4/C1\;-8_;RL?@_X%\:Z?X=T&^\,)?R/J.CPWJ6C['+SHN%DD?Y
M0 C2!,G)'&*L_LS?M.?$70?B'\?? 7Q<\0V?C5OAK:-JD7B"TL8K!YX%1G97
MCC"H/DV$<?*=X+,,&O15_9A\4C]NRQ^-7V_2#X6@\,_V*UGYTOVTS;2-P3RM
MFSGKYF?:LKP)^RCJWA?]HKX_>/?%EQI5_P""?'^F_8X[&S>:6[6'RPLHEC,0
M7E0W",YZ<4 >#^&_C=^U%X[_ &6_&'[1-E\0=!TW2S:WTVG^"UT&!X[6WA<Q
MM<)=,=_FQE)&6.02*^WG&X8^R?V0_'VN_%#]FKX?>*_$VH?VGK^K:8MQ>7?E
M1Q>;)N89V1JJKTZ*HK\RM-\;-X/_ &1OB5\/?#G[1/P^UCX76\%\-,M7MKFU
M\4W+.0XLTM9UCVQ22/\ .ZK+@/( PP2GZ1?L-Z/?:#^R-\*K/4;:2SNET.%V
MAE7:P5R77(/3*LIP>>: /=J*** "BBB@#B_#?_(NZ7_UZQ?^@"M&L[PW_P B
M[I?_ %ZQ?^@"M&@ HHHH **** "BBB@ HHHH **** "BBB@ J3PK_KM:_P"O
MT?\ HB&HZD\*_P"NUK_K]'_HB&@#?HHHH **** "BBB@ HHHH **** $Q[44
MM% "48]J6B@!**6B@!-H]*,#TI:* $HI:* ,_7O#^E^*M'N](UK3;/5]*O(S
M%<V-_ D\$R'JKQL"K#V(HT'P_I?A71[32=%TVSTC2K1!%;V-A D$$*#HJ(H"
MJ/8"M"B@!,#THQ[4M% "48'I2T4 )@>E&!Z4M% "8'I1CVI:* "DI:* "DI:
M* $P/2C ]*6B@!*6BB@ HHHH **** "BBB@ HHHH *R=:_Y"6A?]?K?^D\U:
MU9.M?\A+0O\ K];_ -)YJ -:BBB@ HHHH **** "BBB@ HHHH 2BEHH 3 ]*
M6BB@!*,>U+10 F!UQS1CVI:* $Q[48'I2T4 )@>E%+10 F!Z48'I2T4 )12T
M4 )12T4 )@>E%+10 F!Z4;0>HI:* "DQ[4M% "8]J*6B@ HHHH **** "BBB
M@ HHHH **** "LGQ-_R#8?\ K]M/_2B.M:LGQ-_R#8?^OVT_]*(Z -:BBB@
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M2'Q#=?#;PC<Z^9A<'59M"M7NC*#D/YICW;L\YSFN]50H  P!P *6B@ HHHH
M**** .+\-_\ (NZ7_P!>L7_H K1K.\-_\B[I?_7K%_Z *T: "BBB@ HHHH *
M*** "BBB@ HHHH **** "I/"O^NUK_K]'_HB&HZJZ3K%OI-SJL=RETK27(D1
MDM99%*^3$,Y52.H/>@#K:*Q?^$NT[TO?_!?<?_$4?\)=IWI>_P#@ON/_ (B@
M#:HK%_X2[3O2]_\ !?<?_$4?\)=IWI>_^"^X_P#B* -JBL7_ (2[3O2]_P#!
M?<?_ !%'_"7:=Z7O_@ON/_B* -JBL7_A+M.]+W_P7W'_ ,11_P )=IWI>_\
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M_"7:=Z7O_@ON/_B* -JBL7_A+M.]+W_P7W'_ ,11_P )=IWI>_\ @ON/_B*
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M7W'_ ,11_P )=IWI>_\ @ON/_B* -JBL7_A+M.]+W_P7W'_Q%'_"7:=Z7O\
MX+[C_P"(H VJ*Q?^$NT[TO?_  7W'_Q%'_"7:=Z7O_@ON/\ XB@#:HK%_P"$
MNT[TO?\ P7W'_P 11_PEVG>E[_X+[C_XB@#:HK%_X2[3O2]_\%]Q_P#$4?\
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M*/\ A+M.]+W_ ,%]Q_\ $4 ;5%8O_"7:=Z7O_@ON/_B*/^$NT[TO?_!?<?\
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MHHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH
M,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T444 &:,T44 &:,T44 &:,T4
M4 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:
M,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M &:,T44 &:,T44 &:,T44 &:*** #-&:** #-&:** #-&:** #-&:** #-&:
M** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #
M-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:*
M* #-&:** #-&:** #W[T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sttk-20211231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M0W5N;FEN9VAA;0    60 P "    %   $*R0!  "    %   $,"2D0 "
M S@S  "2D@ "     S@S  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+F2[_D>E6/B;0=4OY;'3-;TZ\NX<B2WM[N.21,<'*@DBM)W6-&=V"JHR6)P
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M)-;IM.)4^0YQ][#LV0.G->D_!KQ%JOBOX6:9K&OW7VN_G:823>6J;MLK*.%
M'0#M5\KU\A=$^YU&O:_IGAC19]6UV[6SL;<#S)64MC)P   222>@%9/B/XC>
M$_"2V9\1:S%8F]4- CQNSLI_B*JI*CW( K@OBY=/K?Q5\!^#2P^R37?V^ZC/
M_+0(?E!]L*_YTGCRQU?0_BM>>(H_#>HZ_8:IH+:7$NG0"9H9BQ/SK_"A'5NG
M-1?W>;S?X+]7H.WO6\E^+_1:GJ\NM:;!H+ZU)>P_V:D!N3=*VY/+QNW CJ,>
ME1Q^(--E\,C7XYI#IIMC="7R) QBQNW;-N[ISC&:\:M](U!_"O@[X3WKE)S
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M7R?7:,UZ+J_P9\":O=6=Q_8%OI\MG()$?3%%H6(Z;O+QGG!SUR.M$=E)[/\
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M9]@0/PKZ/HIOX;+NG]P)V:?:_P")X3IW[47@JSTNUMI=+UXO#"D;%;>'!(4
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M6=MX?\"OX7@CF!N[G6 S*4(/9TC)'?Y<G('(&:]KHI1TLNB"6NI5U!'?2+I
M-\C0.,*OWCM/05YE^SIH^IZ'\+WM=:TZ[TZY^WROY-W T3[2JX.U@#CCK7J]
M%$=&WW5OQN)J]O+_ "L?,OA'Q%XS^&WBGQ;]G^&NNZU#J>IR31RQP31*%#O@
M@B)MP(;.:ZGPMX>\7?$/XLV/CSQGHC>'M.TJ';8V$K$RLW.-P(!X+$DD+T
MZU[C13CI9]5_E8&KW2V>_P"9P'QPTV^U;X/:S9:59W%[=2>3L@MHFD=\2H3A
M5!)X!-;GP\M;BR^&OAVUO8)+>XATV!)894*.C! ""#R"/0UT=%"=DUWM^!3=
MTO*_XV_R"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"J68@ #
M))/2EKG_ !OHKZ_X1O+!=1N=/C="TSVIVO)& 2T>[L&Z$CMF@#4?5]-CTD:K
M)J%JFG-&)1>-.HA*'HV_.,'(P<]Z'UC3(])&J/J-HNGE XO#.HAVGHV_.,>^
M:\\T.SMM3^'?POT_4+=+FTGCMFEBE7<CE+&1U!!X.&56Q_LTEOH^GC4X?#K6
M<4FD1^*YF6U9 8O^/%KG9MZ8$KE@.GRT >EVMU;WUK'<V4\5Q;RJ&CEA<.C@
M]P1P13+^Y-GIMS<JH8PQ/(%/? )Q^E<=\.K:+2]:\9Z19 )8VFM;[>)?NQ>;
M!%(Z*.PWLQP.!DUTVMW*'0]03;+G[-(/]4V/NGOC% %S9=_\]H?^_)_^*HV7
M?_/:'_OR?_BJGHH @V7?_/:'_OR?_BJ-EW_SVA_[\G_XJIZ* (-EW_SVA_[\
MG_XJC9=_\]H?^_)_^*J>B@"#9=_\]H?^_)_^*HV7?_/:'_OR?_BJGHH @V7?
M_/:'_OR?_BJ-EW_SVA_[\G_XJIZ* (-EW_SVA_[\G_XJC9=_\]H?^_)_^*J>
MB@"#9=_\]H?^_)_^*HV7?_/:'_OR?_BJGHH @V7?_/:'_OR?_BJ-EW_SVA_[
M\G_XJIZ* (-EW_SVA_[\G_XJC9=_\]H?^_)_^*J>B@"#9=_\]H?^_)_^*HV7
M?_/:'_OR?_BJGHH @V7?_/:'_OR?_BJ-EW_SVA_[\G_XJIZ* (-EW_SVA_[\
MG_XJC9=_\]H?^_)_^*J>B@"#9=_\]H?^_)_^*HV7?_/:'_OR?_BJGHH @V7?
M_/:'_OR?_BJ-EW_SVA_[\G_XJIZ* (-EW_SVA_[\G_XJC9=_\]H?^_)_^*J>
MB@"#9=_\]H?^_)_^*HV7?_/:'_OR?_BJGHH @V7?_/:'_OR?_BJ-EW_SVA_[
M\G_XJEO+RWT^SEN[V98;>%2TDCG 45SGA[XB:!XFU-[#3IIEN!DHLT>WS0.I
M7_ X/M5J$FFTM$*Z3L=%LN_^>T/_ 'Y/_P 51LN_^>T/_?D__%5/14#(-EW_
M ,]H?^_)_P#BJ-EW_P ]H?\ OR?_ (JIZ* (-EW_ ,]H?^_)_P#BJ-EW_P ]
MH?\ OR?_ (JIZ* (-EW_ ,]H?^_)_P#BJ-EW_P ]H?\ OR?_ (JIZ* (-EW_
M ,]H?^_)_P#BJ-EW_P ]H?\ OR?_ (JIZ* (-EW_ ,]H?^_)_P#BJ-EW_P ]
MH?\ OR?_ (JIZ* (-EW_ ,]H?^_)_P#BJ-EW_P ]H?\ OR?_ (JIZ* (-EW_
M ,]H?^_)_P#BJ-EW_P ]H?\ OR?_ (JIZ* (-EW_ ,]H?^_)_P#BJ2QN&NK8
MO( &662,[>AV.RY_'&:L51TC_CRD_P"OJX_]'/0!>HHHH **** "BBB@ HHH
MH ***\M^+MGK$FL>%;L:BL6C0ZYIR_8XU(>>=KCEG;IL50N!ZDD]!0!ZE17G
M?B31[+QM\1;O0]9C:6TTO1H[FW42,FRXFDD7S1@CYE$0P>V37/\ AY%^*D'A
M./Q89;JT30&O+BV$K1K<7!D$0D<*1G 1R!V+4 >R5!>W/V/3[BY*[_)B:3;G
M&<#./TKEOA=<W<O@D6M_=27DVFWUW8"XE;<\B0SNB$GN=J@9[XK7UG5M.;1;
M^)=0M3(;>10@F7<3M(QC/6@"WYNJ_P#/E9_^!C__ !JCS=5_Y\K/_P #'_\
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M/_\ &J/-U7_GRL__  ,?_P"-5>HH H^;JO\ SY6?_@8__P :H\W5?^?*S_\
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M'_\ C57J* */FZK_ ,^5G_X&/_\ &J/-U7_GRL__  ,?_P"-5>HH H^;JO\
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M44 5;K2M/OI5DO;"VN9$^Z\T*N5^A(XJT!@8' HHIW8!1112 **** "BBB@
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MA1113.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\C\;Z#\1+WQE?7'AR;4%TU_+\D0ZD(EXC4-A=XQ\P/:O7**S
MJ4U45F[';@\9+!U'4C%2NK:JZ/E6RM?$4WB!(K%KP:J\I4%9BLN_OELY!ZY)
M]\UZ]\-]&\<:=XCGE\6RWSV36C*@N+\3KYF]"/E#G!P&YQ_.O15L+1;UKQ;6
M 73#:TXC&\CTW=:GJ?804E*+?S?_  #NK9S6KTI4I4X*_9-/\PJUX=_Y _\
MV\W'_HYZJU:\._\ ('_[>;C_ -'/6QXAJ4444 %%%% !1110 4444 %%%% '
MF?C&QU#Q)\0+C2M'U8Z!/9:$9)KQ8@[74<TC+Y9#<!%,1)8?,"W!'.8/AYK5
MKJFL^&;N.S33$O/"NVVM03M013*K*I/)&"I'?&#7;>(_!7A_Q:T#:_IXNGMP
MPC=97B8*V,J2C E3@94Y!]*37/!'ASQ'86EGJ^E0RP6/%JL9:(P#&,(R$%1@
M 8!P0!0!C_">1+CP=<W=N0UM=:QJ$UNPZ-&UU)M(]JW=9DU'^Q;\-:VHC^SR
M987+%@-IYQY?7VS^-:5E96NFV,-EI]O';6MN@CBAB4*J*.@ %0:W_P B_J'_
M %ZR_P#H!H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U?\
MX\H_^OJW_P#1R5>JCJ__ !Y1_P#7U;_^CDH O4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !5'6_^1?U#_KUE_\ 0#5ZJ.M_\B_J'_7K+_Z
M: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5'2/^/*3_KZN/\ T<]7JHZ1_P >4G_7U<?^CGH O444
M4 %%%% !1110 4444 %%%% !1110 51UO_D7]0_Z]9?_ $ U>JCK?_(OZA_U
MZR_^@&@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5'5_P#CRC_Z^K?_ -')5ZJ.K_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JCK?_(OZA_UZR_\ H!J]5'6_^1?U
M#_KUE_\ 0#0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *HZ1_QY2?]?5Q_Z.>KU4=(_P"/*3_KZN/_
M $<] %ZBBB@ HHHH **** "BBB@ HHHH **** "J.M_\B_J'_7K+_P"@&KU4
M=;_Y%_4/^O67_P! - %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_ /'E'_U]6_\
MZ.2KU4=7_P"/*/\ Z^K?_P!')0!>HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "J.M_\B_J'_7K+_P"@&KU4=;_Y%_4/^O67_P! - %ZBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JCI'_'E)_U]7'_HYZO51TC_ (\I/^OJX_\ 1ST 7J*** "BBB@
MHHHH **** "BBB@ HHHH *HZW_R+^H?]>LO_ * :O51UO_D7]0_Z]9?_ $ T
M 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *HZO\ \>4?_7U;_P#HY*O51U?_ (\H_P#K
MZM__ $<E %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*ZNH+*TE
MNKR9(+>%#)++(P544#)))Z "N=MO'FFWOA.SU^QM;^YBOYF@M+6.$&>=U9P0
M%S@<1NW)&%&3BJ/Q)>>6STRP;0-3UK39[H27\.G(C,R1C<J,&91M9]F>>0K#
MO7-> [\W?AOP;/-:W%C''K]_'MN@JEF:.[*D8)[L4_W@1Z$@'HOA_P 167B2
MSFFLA-%);3&WNK:XCV2V\H )1QTS@@Y!(((()J?6_P#D7]0_Z]9?_0#7+^!)
M4N?%?CNYMB&@;6EB##H7CM85?\F!!K=UJ/4?[&U FZM?*^SR$K]F;=MVGC/F
M=<=\?A0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %4=(_X\I/^OJX_]'/5ZJ.D?\>4G_7U<?\ HYZ
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M4 %4=7_X\H_^OJW_ /1R5>JCJ_\ QY1_]?5O_P"CDH O4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9,_A?1+G1!H]QIEO)IXD,HMV7*ARY?</0[
MB3D>M:U% %/2])L-$T]+'2+.&SMD)*Q0H%&2<D^Y)Y)ZFFZW_P B_J'_ %ZR
M_P#H!J]5'6_^1?U#_KUE_P#0#0!>HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJCI'_'E)_P!?5Q_Z.>KU4=(_X\I/^OJX_P#1ST 7J*** "BBB@ HHHH ****
M "BBB@ HHHH *HZW_P B_J'_ %ZR_P#H!J]5'6_^1?U#_KUE_P#0#0!>HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5 'KUSD<<5[;16\*TH0<%U(<$VF%%%%8%A1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 51UO_D7]0_Z]9?\ T U>JCK?_(OZA_UZR_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J.D?\>4G_7U<?\ HYZO51TC_CRD
M_P"OJX_]'/0!>HHHH **** "BBB@ HHHH **** "BBN=U_Q7)I.M66CZ;I%S
MJ^HWD,EP(8'2-8HHRH+NSD 9+J!UR: .BJCK?_(OZA_UZR_^@&J_ACQ%:>*_
M#EKK&GI+'#<!@8IUVR1.K%71AV(92/PJQK?_ "+^H?\ 7K+_ .@&@#/HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^(H_M>V_YYWG_@#-_P#$4 7J*H_VO;?\\[S_ , 9O_B*/[7MO^>=Y_X S?\
MQ% %ZBJ/]KVW_/.\_P# &;_XBD;6;55+,EX% R2;*;C_ ,=H OT51_M>V_YY
MWG_@#-_\11_:]M_SSO/_  !F_P#B* +U%4?[7MO^>=Y_X S?_$4?VO;?\\[S
M_P  9O\ XB@"]15'^U[;_GG>?^ ,W_Q%']KVW_/.\_\  &;_ .(H O451_M>
MV_YYWG_@#-_\11_:]M_SSO/_  !F_P#B* +U%4?[7MO^>=Y_X S?_$4?VO;?
M\\[S_P  9O\ XB@"]15'^U[;_GG>?^ ,W_Q%']KVW_/.\_\  &;_ .(H O45
M1_M>V_YYWG_@#-_\11_:]M_SSO/_  !F_P#B* +U%4?[7MO^>=Y_X S?_$4@
MUFU)("7A*G!Q93<?^.T 7Z*H_P!KVW_/.\_\ 9O_ (BC^U[;_GG>?^ ,W_Q%
M %ZBJ/\ :]M_SSO/_ &;_P"(H_M>V_YYWG_@#-_\10!>HJC_ &O;?\\[S_P!
MF_\ B*/[7MO^>=Y_X S?_$4 7J*H_P!KVW_/.\_\ 9O_ (BC^U[;_GG>?^ ,
MW_Q% %ZBJ/\ :]M_SSO/_ &;_P"(H_M>V_YYWG_@#-_\10!>HJC_ &O;?\\[
MS_P!F_\ B*/[7MO^>=Y_X S?_$4 7J*H_P!KVW_/.\_\ 9O_ (BC^U[;_GG>
M?^ ,W_Q% %ZBL\:U:&0QA;LNH#%?L4V0#G!QM]C^1IW]KVW_ #SO/_ &;_XB
M@"]5'2/^/*3_ *^KC_T<]']KVW_/.\_\ 9O_ (BC2 W]GDLCIOGF<!T*G#2L
M0<'D<$4 7J*** "BBB@ HHHH **** "BBB@ KBM4U73]$^+%K/K-Y!8Q7>C/
M%;S7,@C1W28,ZACQG!4X]![5VM5-2TG3M9MA;:OI]K?P!@PBNH5E4$=#A@1F
M@#EOA4?-\&SW<:L+:]U6^NK8E2-T,ES(R,!Z$$$>QK;UF/4?[%ORUU:F/[/)
ME1;,&(VGC/F=??'X5L*JH@1%"JHP !@ 54UB-Y=#OHXE9W>VD5549))4X H
MS:*;YR?W;G_P"G_^(H\Y/[MS_P" 4_\ \10 ZO%?&/P^UZ;Q==W&FV;7=O>2
MF99%8#:6.2IR>,'],5[1YR?W;G_P"G_^(H\Y/[MS_P" 4_\ \16U*K*D[HF4
M5):GSAJ_PJ\4Z2T?^B+>JZYW66Z3:?0C:#G\,>]7--^#/B?4+);AFL[/<3B*
MZ=U<>Y 0XKZ#\Y/[MS_X!3__ !%()XR2 +@E3@XLY^/_ !RO/^J4;6L?1_ZQ
MX_NON,3P1H5SX:\&V.DWSQ23V_F;VA)*G=(S#!(!Z,.U;U-\Y/[MS_X!3_\
MQ%'G)_=N?_ *?_XBNF,>5)(\*K5E5J2J2W;;?S'44WSD_NW/_@%/_P#$4><G
M]VY_\ I__B*9F.HIOG)_=N?_  "G_P#B*/.3^[<_^ 4__P 10 ZBF^<G]VY_
M\ I__B*/.3^[<_\ @%/_ /$4 .HIOG)_=N?_  "G_P#B*/.3^[<_^ 4__P 1
M0 ZO'/B9X4UN[\62:A96-Q>6T\:!3 A<H0,$$#D=,^G->P^<G]VY_P# *?\
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MBEF=C@*!U)-#TW!:[#J*IZ3JMEKFE6^I:5.+BSN5WQ2J" Z^O(!JY0 4444
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M<EJ/Q5\$:3XE_L#4?$5K!J6[:T3!BJ-Z,X&Q3[$@T=;!TN==11UZ44 %%%%
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M5L'!_$'C%7:;36C#<****0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7#ZRHN/C9X;AN &B@TN\GB5AP)-\2Y'N%)_.NXKE_&7A"
MY\2-87NCZU-H6L:<SFVOXH%FPKC#HT;<,IP./4"A.S3_ *V:#=-%#P^@M?C!
MXL@MXQ'#-9V5S(%& TI\U2WU(5?RK9\7>&['Q)I)AU5KA[6%6D:U28I'.0O
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M;96VI?#'Q(=0@CG:^O\ 4C="1<[R)9% /T &/2NG^'5Q/=_#/PY/=,6FDTV
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M_P (_#-I<MY+)_9\5UN99 N,/R.#V/;I1U2_K:_Z!T;/2J*\LU/_ (61\/\
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MD@XR[9R,'Y*S/ ?C%I_A/;^)?%^I1KL,[7%U(JH JS.HX4 = !@#)]S1TO\
MUV_0=G_7WG=45B:AXPT+2/#2:_JU^+#374,LMU&\3-D9 $; /D_W<9]JH:/\
M3?!^ORZ=%H^MQ7<FI2/%;(D<FYF1=S!@5RGR\_-C/;-.SO872YU5%<Q!KEU8
M?$.70-4F$D&HVYN],<J%*[,++"< 9QE6!.3ACZ5T]+I<.M@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFGSM%"+:>^O\1JP>,82-,D'&7;.1@_)69X#\8M/\)[?Q+XOU*-=AG:XNI%5
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MOP>L=7"RV/\ 9L\\4<HRCW"(HCR#P2 2174?$6RTU/BU\/+T1Q+J<E_+&6
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>sttk-20211231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M0W5N;FEN9VAA;0    60 P "    %   $*R0!  "    %   $,"2D0 "
M S@Q  "2D@ "     S@Q  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_J_XT 6:*K?VE8_\_EO_ -_5_P :/[2L?^?RW_[^K_C0!9HJM_:5C_S^6_\
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M!9HJM_:5C_S^6_\ W]7_ !H_M*Q_Y_+?_OZO^- %FBJW]I6/_/Y;_P#?U?\
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M_J_XT 6:*K?VE8_\_EO_ -_5_P :/[2L?^?RW_[^K_C0!9HJM_:5C_S^6_\
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M?_OTO^%6:1F5%+.0JJ,DDX % %?^S;'_ )\[?_OTO^%']FV/_/G;_P#?I?\
M"I+:Z@O(!-:3QSQ-TDB<,I_$5+0!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^
ME_PJS10!6_LVQ_Y\[?\ []+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\
M[]+_ (4?V;8_\^=O_P!^E_PJS10!6_LVQ_Y\[?\ []+_ (56\/?\@&W_ .!?
M^A&M*LWP]_R ;?\ X%_Z$: -*LBWMH+C7M2^T0QR[?*QO0-CY?>M>LVQ_P"0
M]JG_ &R_]!- %G^S;'_GSM_^_2_X4?V;8_\ /G;_ /?I?\*LTUW6.-G<X502
M3Z"@"#^S;'_GSM_^_2_X4?V;8_\ /G;_ /?I?\*Q/^%A>&/^@G_Y+R__ !-;
MME?6VHVJW%C.D\+='0Y% #?[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4
M 5O[-L?^?.W_ ._2_P"%']FV/_/G;_\ ?I?\*LT4 5O[-L?^?.W_ ._2_P"%
M']FV/_/G;_\ ?I?\*LT4 9VH6%FFFW+):0*RPN01& 0<&K&F_P#(*M/^N*?^
M@BC4O^05=_\ 7%__ $$T:;_R"K3_ *XI_P"@B@"S6-H5E:S:+ \MM"[G=EFC
M!)^8]ZV:S?#W_(!M_P#@7_H1H L_V;8_\^=O_P!^E_PH_LVQ_P"?.W_[]+_A
M5FB@"M_9MC_SYV__ 'Z7_"C^S;'_ )\[?_OTO^%6:* *W]FV/_/G;_\ ?I?\
M*/[-L?\ GSM_^_2_X59HH K?V;8_\^=O_P!^E_PH_LVQ_P"?.W_[]+_A5FB@
M"M_9MC_SYV__ 'Z7_"C^S;'_ )\[?_OTO^%6:* *W]FV/_/G;_\ ?I?\*/[-
ML?\ GSM_^_2_X59HH K?V;8_\^=O_P!^E_PH_LVQ_P"?.W_[]+_A5FB@"M_9
MMC_SYV__ 'Z7_"C^S;'_ )\[?_OTO^%6:* *W]FV/_/G;_\ ?I?\*/[-L?\
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M.N[[XA?\(CXC\+76@7LT!N;-I;J.<3QC/79PIX/ +=#S76^)M87P]X5U36)
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M(UI5F^'O^0#;_P# O_0C0!I5FV/_ "'M4_[9?^@FM*LVQ_Y#VJ?]LO\ T$T
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M )FK_MR_]GK2K-_YFK_MR_\ 9Z -*BBB@ HHHH **** "BBB@ HHHH ****
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ML[?_ %FGVMV8[>ZY!'FKCYL$<$$&JDVW=;MIW]-B8I))/9*WW[F/\$](FM/
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M_D V_P#P+_T(T :5(Z+(A210RG@AAD&EHH J6NDZ=92&2RL+6W<]6BA5"?Q
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MD_Y^YOR3_P")H GHJ#[/)_S]S?DG_P 31]GD_P"?N;\D_P#B: )Z*@^SR?\
M/W-^2?\ Q-'V>3_G[F_)/_B: )Z*@^SR?\_<WY)_\31]GD_Y^YOR3_XF@">B
MH/L\G_/W-^2?_$T?9Y/^?N;\D_\ B: )Z*@^SR?\_<WY)_\ $T?9Y/\ G[F_
M)/\ XF@">BH/L\G_ #]S?DG_ ,31]GD_Y^YOR3_XF@">BH/L\G_/W-^2?_$T
M?9Y/^?N;\D_^)H GHJ#[/)_S]S?DG_Q-'V>3_G[F_)/_ (F@">BH/L\G_/W-
M^2?_ !-'V>3_ )^YOR3_ .)H GHJ#[/)_P _<WY)_P#$T?9Y/^?N;\D_^)H
MGHJ#[/)_S]S?DG_Q-'V>3_G[F_)/_B: )Z*@^SR?\_<WY)_\31]GD_Y^YOR3
M_P")H GHJ#[/)_S]S?DG_P 31]GD_P"?N;\D_P#B: )Z*@^SR?\ /W-^2?\
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M/_\ &J/-U7_GRL__  ,?_P"-4 7J*H^;JO\ SY6?_@8__P :H\W5?^?*S_\
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M'_\ C5 %ZBJ/FZK_ ,^5G_X&/_\ &J/-U7_GRL__  ,?_P"-4 7J*H^;JO\
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M'IM/K0!8HJ#?=_\ /&'_ +_'_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\
MO\?_ (FC?=_\\8?^_P ?_B: )Z*@WW?_ #QA_P"_Q_\ B:-]W_SQA_[_ !_^
M)H GHJ#?=_\ /&'_ +_'_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\ O\?_
M (FC?=_\\8?^_P ?_B: )Z*@WW?_ #QA_P"_Q_\ B:-]W_SQA_[_ !_^)H G
MHJ#?=_\ /&'_ +_'_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\ O\?_ (FC
M?=_\\8?^_P ?_B: )Z*@WW?_ #QA_P"_Q_\ B:-]W_SQA_[_ !_^)H GHJ#?
M=_\ /&'_ +_'_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\ O\?_ (FC?=_\
M\8?^_P ?_B: )Z*@WW?_ #QA_P"_Q_\ B:-]W_SQA_[_ !_^)H GHJ#?=_\
M/&'_ +_'_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\ O\?_ (FC?=_\\8?^
M_P ?_B: )Z*@WW?_ #QA_P"_Q_\ B:-]W_SQA_[_ !_^)H GHJ#?=_\ /&'_
M +_'_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\ O\?_ (FC?=_\\8?^_P ?
M_B: )Z*@WW?_ #QA_P"_Q_\ B:-]W_SQA_[_ !_^)H GHJ#?=_\ /&'_ +_'
M_P")HWW?_/&'_O\ '_XF@">BH-]W_P \8?\ O\?_ (FC?=_\\8?^_P ?_B:
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M^F7_ (]_]:C^T_\ IE_X]_\ 6H OT50_M/\ Z9?^/?\ UJ/[3_Z9?^/?_6H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0)_R$)O^N2?S>IZ@
M3_D(3?\ 7)/YO0!/1110 4444 5M2_Y!5W_UQ?\ ]!-&F_\ (*M/^N*?^@BC
M4O\ D%7?_7%__031IO\ R"K3_KBG_H(H LUF^'O^0#;_ / O_0C6E6;X>_Y
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M7DN2R,A\T?*V,CY%]*LU!;_Z^Z_ZZC_T!:;=VV1%<J2)Z***104444 %%%%
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M_P#)_P#^UU/UJCW_ ##^P,R_Y]_C'_,]BHK'\)Z__P )1X7M-8^S?9?M._\
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M":--_P"05:?]<4_]!%&I?\@J[_ZXO_Z":--_Y!5I_P!<4_\ 010!9K-\/?\
M(!M_^!?^A&M*LWP]_P @&W_X%_Z$: -*BBB@ HHHH **** "H+?_ %]U_P!=
M1_Z M3U!;_Z^Z_ZZC_T!: )Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"CI'_'E)_U]7'_HYZO51TC_ (\I/^OJX_\
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MB@4K#&D:DY(10!FGT4 %58M,L+>[>Z@L;:*X?[TR0J';ZL!DU:HIW8!1112
M**** "BBB@ JYI'^MO\ _KNG_HB*J=7-(_UM_P#]=T_]$14 :59OA[_D V__
M  +_ -"-:59OA[_D V__  +_ -"- &E6;8_\A[5/^V7_ *":TJS;'_D/:I_V
MR_\ 030!I4444 %%%% !7GT<.H66J^.+?PC9VXO8XK..S@W"&-#Y.!C P !R
M!CMBO0:* /+?A+!J>G>)/$^F7FAQZ9!;&T0[=0^TLKK;1@ G8NXLOSEN.21C
MO7IKK<%SY<L2KV!B)/Y[JEHH @L?^0?;_P#7)?Y"IZ@L?^0?;_\ 7)?Y"IZ
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M<],B*-"AA(:,J"I!R".U16_^ONO^NH_] 6H[#3X[#2K:PC9S';P)"IW$$A0
M#D=^*=:((Y+E5W$"4?>8D_<7N:':^A,;V5RS1112*"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CI'_'E)_U]7'_ *.>KU4=
M(_X\I/\ KZN/_1SU>H **** ,W6?^7#_ *_8_P"M:59NL_\ +A_U^Q_UK2H
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MKO\ ZXO_ .@FC3?^05:?]<4_]!% %FLWP]_R ;?_ (%_Z$:TJS?#W_(!M_\
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M>-'V*W_YY_\ CQJ>B@"#[%;_ ///_P >-'V*W_YY_P#CQJ>B@"#[%;_\\_\
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MX0_G63WYNW],ZX:0]G_-_2_KS.CHHHK4Y HHHH **** "BBB@ HHHH ****
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M=+11161L%%%% !1110 4444 %0)_R$)O^N2?S>IZ@3_D(3?]<D_F] $]%%%
M!1110!6U+_D%7?\ UQ?_ -!-&F_\@JT_ZXI_Z"*-2_Y!5W_UQ?\ ]!-&F_\
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M10 4444 %%%% !1110 4444 %%%% !1110!1TC_CRD_Z^KC_ -'/5ZJ.D?\
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M_P"B8ZO51L/^/W4_^OI?_1,= %ZLWP]_R ;?_@7_ *$:TJS?#W_(!M_^!?\
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M *^Z_P"NH_\ 0%I#)Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"N+_\ H)HTW_D%6G_7%/\ T$4:E_R"KO\ ZXO_ .@FC3?^05:?]<4_]!%
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M^E_]$QU>JC8?\?NI_P#7TO\ Z)CH O5F^'O^0#;_ / O_0C6E6;X>_Y -O\
M\"_]"- &E6;8_P#(>U3_ +9?^@FM*LVQ_P"0]JG_ &R_]!- &E1110 4444
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M)_U]7'_HYZO51TC_ (\I/^OJX_\ 1SU>H **** ,W6?^7#_K]C_K6E6;K/\
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MNRE+J%9/E.=I(Y7\#D?A2E%QE847=6[?ET_R^1?HHHI%!1110 4444 %%%%
M!7.^-&>?2(-+B8*VIW4=NYSTB^]*?IL5OSKHJ\\\52/K?CRWT6QG"RI;&W?'
M6)9?FF;V(C10/>44N7F]WN:TWROF[:_Y?B;_ (9!U:^O/$DNTI='[/8\?=MD
M8X;_ (&V6^FVNDID$,=M;QP6Z+'%$H1$48"J!@ 4^KD[NYBM$5=2OHM,TNYO
M;ATCC@C9RSG X%</\+/%7B+Q))K">)HA&UM)&8E,/E,F_=\N.N!M&">?<UH&
M%/'/B 22C=H6C7(,)4\7ERO4GU1#Q[G/) Q5O7C_ &+XJTS7BY6WN,:;>#L
M[$Q.?H_R_22GI:QRR<G-5$_=7X^?R.GJEK&EPZUHUUIMT6$5S&4++U7T(]P<
M'\*NT5*;3NCK.%^'&IRM=:WH][$8KNUNO.D#?Q,^0Y'L64M]''UKNJXO7O+\
M->/=-\0'(M]4 TV[]$8\QO\ F,'/:NTJ=+NQK4N[2[K\M HHHIF04444 %%%
M% !67XEU'^RO#5]=J?WB0E8A_>D;Y4'XL0*U*YWQ'LO];T/1VSB2X-[+C^Y"
M-P!^KE/UJX*\M1/8H:_ID6F_#^R\,),0UXT&FJX'+!F D;'^X'-=@BJB*B#"
MJ, #L*Y;4;5M5^)NDJ21!H]I)=L!T:24^6@/X*Y'TKJJ4G?<RAK*3^7W?\.%
M%%>>?$;QQJF@W-M;>'$CG>/]Y>,(C)Y0_A5L<+D;CSS@=JSE)05V==&E*M/D
MB>AT5%:S&XLX9CMS)&K'8VX<C/![CWJ6J,MCE],O/L?Q(UG2'&%O+>+48O<@
M"%__ $!/UKJ*YKQ#'%9^*/#VKL=I\]["0^JS(2N?^!H@_P"!5TM-F5.Z<HOO
M^>I%=6T5Y:36MR@DAF0QR(>C*1@C\J\T\$^+=<\1A_#]C]GLQI\7EM?RH7D*
M*=JX3[N_CN<=>*]0J"WLK6TDE>UMH87F;?*T<84R-ZL1U/N:TA-1BTU<MIMF
M9H7A73]">2XC#W5_-DS7UR=\TF?]KL/8<5M445G*3D[L:5@HHHI#"H$_Y"$W
M_7)/YO4]0)_R$)O^N2?S>@">BBB@ HHHH K:E_R"KO\ ZXO_ .@FC3?^05:?
M]<4_]!%&I?\ (*N_^N+_ /H)HTW_ )!5I_UQ3_T$4 6:S?#W_(!M_P#@7_H1
MK2K-\/?\@&W_ .!?^A&@#2HHHH *XGQ#=6]]9W7@GPA;6S75PC0WABC @TZ.
M3)=Y .-Y#$A.I)R<#)KMCR/2O,8?@?9VDEPUCXY\;60N9GN)4M=66)6D8Y9L
M+&!DTMW9[#VU6YZ%:6,>F:)#860(CM;=88AWPJX'\J\PTT1M^RM<API/]C7/
MF;O^>GS[L^^[/XUZ%9^'/L=]IUS_ &SJT_V&S^R>5/=;DN.G[V48^:3C[W'4
M\5S,_P '- GUJ2[.HZW'8S7!N9=&CU!A8RR%MQ8Q8[MSC.*IZMW>_7[P@^2S
M2V.RT7S/[!L//SYOV:/?GKG:,U-;_P"ONO\ KJ/_ $!:DDA66-D;< PQE'*D
M#V(P14%C"L!N(T+E5EX+NSG[B]V))IR=VV1%621:HHHJ2@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH K:E?1:7I5W?W.?)M87FDQUVJI8_H*\@\+?'>X
MUSQK;:9>Z3#;V-[,((&1R9(V8X7<3PV3@< =:]CN[6&^LI[2Y3?#/&T<BG^)
M6&"/R->;>'?@=H_A_P 6Q:RNH7-S%;2>;;6TB ;&'0LP^]CJ.!TK"HJG,N38
MU@X6?,>G4445N9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!1TC_ (\I/^OJX_\ 1SU>JCI'_'E)_P!?5Q_Z
M.>KU !1110!FZS_RX?\ 7['_ %K2K-UG_EP_Z_8_ZUI4 %9O_,U?]N7_ +/6
ME6;_ ,S5_P!N7_L] &E1110 4A&Y2#T(QP<4M% 'G^L?"C3IH=*AT6;4;:&S
MU".XDCDUR]VB,9+>6/,(5\G@C!Z\BM.;1=>TK7M4N_#<6FW$&K>6TWVZXDC>
M"14$>\;4?S 5"_*2IR.O/'6T4=+?UT_R#K<S/#>BIX=\,Z?I$4AE6S@6(R$8
MWD#EL=LG)JY;_P"ONO\ KJ/_ $!:GJ"W_P!?=?\ 74?^@+3;N[L">BBBD 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HZ1_QY2?]?5Q_P"CGJ]5'2/^/*3_ *^KC_T<]7J "BBB
M@#-UG_EP_P"OV/\ K6E6;K/_ "X?]?L?]:TJ "LW_F:O^W+_ -GK2K-_YFK_
M +<O_9Z -*BBB@ HHHH **** "H+?_7W7_74?^@+4]06_P#K[K_KJ/\ T!:
M)Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOCJ2=_+T/PWK&HD_=D:W,$1_X&^,?E5FUN?&5[AI;#2M*0_PRRO<N/P7:/\
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M74+65)4GC#$IT#8Y'/((.1@\BKU6G?4G8Q_$FE2ZC8Q3V#^5J-C)]HM'QU8
MY0_[+ E3]?:L+Q!JPU3P/8>(+5&C>QO+>ZEA/WHBL@65&],*S@_2NUKC-?LE
MTF_O,[5TOQ$C6UV6Z03LA1']@_W3[[3WJ?AES%RC[6DZ?7I_E^O_  YV=%8O
M@_4)=4\&Z5=W&?/>V42YZ[U^5OU!K:JMC*,E**DNH4444%!7)ZVQ\5:VWAF
MD:=;JLNJRK_'SE;<'L3C+>B\=ZO^)M??2H8+/35CGUB_?RK.!\D9[R-CD(HY
M)_#O5KP_HD/A_1X[&!VE;<TDTS_>FD8Y9S[DG^0JEIJ8R]]\BVZ_Y?U^II*J
MHH5 %51@ #@"H4_Y"$W_ %R3^;U.2!U.*@3_ )"$W_7)/YO4FQ/1110 4444
M 5M2_P"05=_]<7_]!-&F_P#(*M/^N*?^@BC4O^05=_\ 7%__ $$T:;_R"K3_
M *XI_P"@B@"S6;X>_P"0#;_\"_\ 0C6E6;X>_P"0#;_\"_\ 0C0!I4444 %%
M%% !1110 5!;_P"ONO\ KJ/_ $!:GJ"W_P!?=?\ 74?^@+0!/1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >5^+/C3'X?\42Z58Z8+R.U?9<2M*4);^)5&.W3)[UZ3I.IV^LZ1:ZE9%C
M!=1+*FX8(!'0CUKS;Q9\%8_$'BB;5;'4ULXKI]]Q$T6XAC]YE.>_7![YKTG2
M=,M]&TBUTVR#""UB$2;CDD =2?6KERV5CBH?6/:2]K\/0MT445!VA1110 44
M44 %%%% !1110 4444 %%%% !1110!1TC_CRD_Z^KC_T<]7JHZ1_QY2?]?5Q
M_P"CGJ]0 4444 9NL_\ +A_U^Q_UK2K-UG_EP_Z_8_ZUI4 %9O\ S-7_ &Y?
M^SUI5F_\S5_VY?\ L] &E1110 4444 <7K%W'X\:Z\-Z3^]TM)3!JU]CY!M(
M+6\9/WG/1B.%&>=W%-\.,FF>+/&Z7L\<2B>"Y0.P79!]F10W^[E&&?8UIO\
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MGQZ3;P:=;LSQ6=G! C.<L50,H)]\"H@GS-V-*M5RIQAII?H:5%%%;',%%%%
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M^?-DMHV?/J5!-2V_^ONO^NH_] 6J:LVC.+YDF3T444B@HHHH **** "BBB@
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MH3S*]CIZ***S*"BBB@ HHHH **** "BBB@ HHHH **** *.D?\>4G_7U<?\
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MO_\ ':/*U7_G]L__  #?_P".U>HH H^5JO\ S^V?_@&__P =H\K5?^?VS_\
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MH\K5?^?VS_\  -__ ([5ZB@"CY6J_P#/[9_^ ;__ !VCRM5_Y_;/_P  W_\
MCM7J* ,_10XTYA(59_M,^XJN 3YSYP,G'YUH51TC_CRD_P"OJX_]'/5Z@ HH
MHH S=9_Y</\ K]C_ *UI5FZS_P N'_7['_6M*@ K-_YFK_MR_P#9ZTJS?^9J
M_P"W+_V>@#2HHHH **** "BBB@ J"W_U]U_UU'_H"U/4%O\ Z^Z_ZZC_ - 6
M@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGK3/[1LK2[N8[N\MX',@8++*JDC8O."?:KD[R;1*V-"BJ/\ ;>E?]!.S_P#
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MO(DL;70VNC!@?W,8X(]Z -&LWP]_R ;?_@7_ *$:TJS?#W_(!M_^!?\ H1H
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M15<7]FWW;N \XXD%+]NM/^?J'_OX* )Z*@^W6G_/U#_W\%'VZT_Y^H?^_@H
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MN'_7['_6M*@ K-_YFK_MR_\ 9ZTJS?\ F:O^W+_V>@#2HHHH **** "BBB@
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MVR_]!- &E1110 4444 %%%% !169KFLC1[: I;M=7-U.MO;0*P7S';)Y)Z
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M/X7*KN'O@9]*=F+K8GHK*UO69-,:TM;*T^V:A?.T=O"TGEI\JEBSO@[5 ')
M)Y& :QM6\<OX?\*:CJFNZ3+;WECN46D3M(EPP3?F*38-R8ZL5&W#9'%):CM=
MV.FNHGD:W*#.R8,W/08/^-6*Y:Z\2ZW)XAGTW0]$LKQ;:S@NI9+G4F@8^:7
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MCVY53@C<,C''&:=Q\3;-/#^N:K!;((=+OHK*-[N?[/'.9!%B0L5.Q/WN<X/
MSWJFFG;^NP1UM;J=Q169X>U.;6-&BOI_[./FDE&TV^-W"Z]B)"B9_+\:TZ6P
M;A44R,\D!49"2;F]AM8?UKG!XJU"XE>ZT[0S=Z/%<FVDN$N#Y[,K[&=(0AW(
MK9R=X.%)"GC,-YXTO-/OA]MT1H+":6>WM9I)RLLLD2.Y+1%/E1A&VUMQSP<
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MZ;_O^_\ C4]% $'V./\ O3?]_P!_\:/L<?\ >F_[_O\ XU/10!!]CC_O3?\
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M^.-4TG7-+F2WGGMO%5@[-INDS7&)))T?]VYM@Q25"0"'*G .<K@X]+HIWUN
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MD+2B8#;T;;P/0@Y[5T5CJWVW6M4L/)V?V>T:^9OSYF]-W3'&,X[UHV[\W?\
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M/^OV/^M:5 !6;_S-7_;E_P"SUI5F_P#,U?\ ;E_[/0!I4444 %%%% !1110
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M_P#0C6E6;X>_Y -O_P "_P#0C0!I4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '$?%AIE\)636L<<DXUG3S&DCE%9OM*8!8
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M*&&<=\&K-8;%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !17G6I_&SPYI6K7FG7%EJC36D[P2-'%&5+*Q4D9D'&15
M7_A??A?_ )\-7_[\Q?\ QRKY)=CE>+H)V<D>GT5E^'-?M?$_A^VUBPCFCM[G
M=L6=0'&URIR 2.JGO6I4'3&2DDUL%%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *VI?\@J[_P"N+_\ H)HTW_D%6G_7
M%/\ T$4:E_R"KO\ ZXO_ .@FC3?^05:?]<4_]!% %FLWP]_R ;?_ (%_Z$:T
MJS?#W_(!M_\ @7_H1H TJ*** "BN2UCXG>%]%OFM+B]::9#AUMXRX0^A/3\!
M6UH?B/2O$EF;G1KQ+A%.'49#(?0J>15NG-+F:T%S)NQIT445 PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKG?$O
MCOP_X3=(M8O=EPXW+!$I=\>I Z#ZXIOAKQ]X=\5RF#2+[=<JNXV\J%'QZ@'K
M^&:=G:YG[6GS<G,K]CI****1H%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 9NL_P#+A_U^Q_UK2K-UG_EP_P"OV/\
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M^MKZU<D+/:S+*C8ZX9212:AIEIJB0"^@$XMYEGC1G(7>OW20.#@G.#D9P<9
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M%A<^((Y+'P_=PSV<:6&QW2-2H25]YW'!^\H7W!KNZ*:T_KMJ#U5G_5]#AX_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF17!W(V>A4C';%2Z3H.GZ)%*FGQ2!IFW2RSSO/+*>@W22%F; X&2<5HT4=+
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MF5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\
M0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MV
MJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E
M:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"
M/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK-^W:
MI_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK
M-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\ R96@
M#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T"/\
MR96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W:I_T
M"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F5H^W
M:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C_P F
M5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ?] C
M_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S?MVJ
M?] C_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H TJ*S
M?MVJ?] C_P F5H^W:I_T"/\ R96@#2HK-^W:I_T"/_)E:/MVJ?\ 0(_\F5H
M-9_Y</\ K]C_ *UI5C7']HWTMJLFG>2D5PDK/YZMP/;\:V: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sttk-20211231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g7.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 4L"8 ,!$0 "$0$#$0'_Q  ?  $
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ML>22FUW;Q$/*PI$$PTFU4^=MIL7(C=B=Q"(#-[!J"U=9H?2JFOW.6;,7C$I
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MF*Z<K!9[C45\YRE%&HW6J"1S4V:EV-"S8/9;?)4#Y$%9ZE*4\%5PO9;1*WZ
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MMQ?W^J2!^TY#O^DN$;3E/K<7]_JD@?M-P[_I/_'PC:<I];B_O]4D#]IR'?\
M27")];B_O]4D#]IR'9__ .E_>X4;CVE=<G537F_1^)-R'9QUC#VSV?%Y0]21
MGKV'H3))"&HS)CM7)[8J]H(B0/QG3NO1754G[V2AI%J?(DIQ._6WQQ6 BM8]
MJ I%9:C?Z;C-416]&LL_-=UN7E([3]Q&OB<A ("0(PXJ$_)*!O(]+U&DP)(C
M61M*:H2GMM3KA^ R393C7"F@^*GO7S._1Z#1)BE,F.FDE:(ZSMT@EZA"A:SI
M0])$!!#H_C;6PHEO;_:ZX!ZX*)&#!"4)^" B'D&19*]3;O!NKV+N'")PB<(G
M")PBU^]4<?YH+[3W/_JQZT8_^Z8E\W]_[G(]2.'>^_=L"+8$Y43A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$6ONS?S3/*_ZT^1_=^BW)F.!\846P1RHNJ+)
MY!FY4>A<)G%$*U*8(I4C62)G3*DQH?T11Z<]8 TDP/\ / , $6/?CA%\WUR:
M[_5]"_[*6/\ Y_PB\?7)KK]7T*_LJ8O^?\(O/UR:[QYSZ%X_]J6/_G_")]<F
MN_U?0O\ LI8_^?<(O@G%L5K6S2POL\G<3B++*'UHC4>=9 ^(&UO>GU_,]&SM
M;:J4'@)5J5^>IA."AB %.6:J,&!,288$AUK6Q>ZN[1KRVV-1)JSF<:G<>2O+
MQ'CWN*O"-[;2WI@7&MSLW#5H3#20J4BHH6,AR+H>0,A:E$>A5)E)I3C3/JZP
M-J[[PJG")PB<(G")PB<(G")PB<(H%]IRXTVU:-WTKO\ 6V:GJ3V$PD2UNIMQ
M,:;,EI2F7Q\AKK^)N!62QIUMAO0VZ$JA84(L";'Y: 3@W@$)<G(J?=!#]0&_
M<+75= ])K7[/NXW=@V.I4F(Q*:-*^J;&4T*W)T3W7E[MD="0UR"SV!A=B+&:
M9(8F<'C"X@9$@EC^LPAPG:SRUUH=FW9EKQR6SKCRQTZ=.F.G3R^YTZXZ<(O/
M")PB<(M?#ZH'_D1[-W^N:ZX?V[_GA%L'\(L:R&F:AESJ>^RRK*XE#VJ 46H>
M)%!HN]NIY:<O!*<LYP<VI4L-+()"$HD SA!++#@(,!QX<('''=1<)^9SU]_6
M+IS]K"$?]!<)7:7VT?C@L?V!!=1*M1('*>513# @<U>4")2;44;78/5A*&>,
MG &N*KC09"2 1F1FE@+Z8[O?[V<8RUV^U"26Q[=;NS'(XN^6'9Y_J4I']I!+
M_P!0^$3Y8=GG^I2D?VD$O_4/A.O6J=:?+#L\_P!2E(_M()?^H?"=:9E_9Y9\
M/DI2/[2"3]^!YX2NTE1UMNV>S#95]B%2ZFV*1@:J+;'N3&1W7.0N3,_5*;:R
M)$FCA'LZ'IVQS2D6H%O5GM(P!1D.RK*Y0;C(G 98[_:F?AK6&&9[A'+6T 46
MFPM3'3ZPJP5>T2F-M+^;04X0"3[!9KHET53 Q\<8P4)$X_),8(V?+5)A1Y28
MLUN.-#'RCU@2A?1\*8US.0JU%::7TP /3/>QTZXS\>OCX?-\/FX57[X1.$3A
M$X1.$4 .U:_2SM]OZDJ^/[G3_P!>$7Z[*K/7LV-&/ZEVF_W%-/T\(I^\(G"+
M@9-'&^6,;C'710]I6]U3^K*CXY))%#WLLKO@,ZMTFB3HR21G/[P,8]::'9"I
M[F1E9.R4886,BP?^97K#]4>Q'_O?;:?X;.$Z_"G=XI^97K#]4>Q'_O?;:?X;
M.$7ISJ]5.,YQF5;!XSC/3.,[A[8XSC.,^.,XS=WAGW9\,9^]PG7[];D_,P51
M^JK8+_WP]L?\-W"+H]H47KN@C4'9+"L.=Q]B0W#"9C%EDRV#LE]7NMAM)X@Q
MN/ D5D324.ZIG<3L8]<AJ5P(9G3)8S%2 S!BL1I3/<=V'7L\SBL0P71C46>L
M3FYP:>V#,V0:.^ZY<7./W;('=&2KMM]4"MI-E8C<#O0R!-(BAGLBS!H54,-*
M+(BGLIK-]5.:VX*JP*$1%K@,.B\(93G%0T1*/M$<;5#NN,<W90B9D!#>F4.;
MB=C!JYP/*3A-6K#,!&I4C-.$'&1YQ@B[1PB<(G")PB<(M?O5#^:#.T]_J8]:
M/CU_TIB7W/W^-9?CV]2*^]\>4$=9W-^=#3"6QF0*W-P.)2+%YQ2)"08I5&E(
MF\A4N5C+(+&,*=(F/4G9#Z,DDPP009(L _FN*(]\ED_7W_QJK:\_[!^$3\UQ
M0_ZI9/\ M56U_P!1^$3\UQ0_ZI9/^U5;7_4?A$_-<4/^J63_ +55M?\ 4?A$
M_-<4/^J63_M56U_U'X1/S7%#_JED_P"U5;7_ %'X1<U'-EJAEKTCCT?>I&M=
MW#!^$28ZN;*;"SQITYRHPOUUUB") 4/))!N2PGJBLFF8"25@9I@ ")U>'M48
MTW:@ZQ+&4]^2XM@] 17-FVB+)=,V7D[,6JF6!ADA-]'F-8P%4K>O3 :RAC"#
MT"52:Z&MF2L &>C]:5W=OX>2DK4&R]8W?)IW$H*;*3'>NDD&72/$@A,MBB4*
M.Q(PFET9-;U4D9VPMPRI:%(1J2">BI$>6:0J3E#!XE*[*MU4]N6Y2 X53A$X
M1.$3A$X1:^[-_--$K_K3Q/\ =_BW]_\ +IR9C@?)%L#YQUQG'EUY46/7*HJH
M>EZIU>:QKUW=5QPE"YS=(7&U[@M/%TP(]6L5MIRE0<+&,8$8<:,><8QU%X8X
M1?#]8^E?UH*N_:_B?_1/"+I4ZB6M-;-!3[,*NKM V'+2F\LU!4*.1'B5G%G&
MEEY0QN*.Z\ ,@(-R)0-,%.6+ 0&&A&86$13/6O/B,,0_7'T=_4+%?_=KEW^#
M#A7J\*=_@Z?7(T=_4+%<?#_*U2_S^Y6'A]WICX\)K?7K';YLN[7Y8NNL+KRI
M7FUX<"2P1_LNLV2LVXFK':8$LTV>CLEP%W31M.P*U$7/9LY$>B<U*!O4L9A>
M"TN"W#T"8936LCEWU4;H'OWI?7T8*1P"*S6%19>V7W/"6J+Z_P ]9&D[%-OR
MC%FNOJ+9$4A 7%V5C7OY:I6668O %2J>E2!T4EI%,IB,]G8E=CY8Y;]M7X#!
MR58O"I>SS^)1F;1T2P;#+F!HDK*-P;E[0O&U/B AR;QK&MS3I7!O4#2*2A&H
MUJ8A20/(BS2@#"(.*KK6NU=HX1.$3A$X1.$3A$X1.$3A%3OVNVS,0J:EI55]
MT:4[%;-:]6'7SFKM";TZ&/HH]7Q")Z2)FH#K(G=_95C)+"7?#6^154V9,5%.
M2= <CR8K"61DFO9K:JL>RJCM05_O5 V>4ZT=J%&;=L"%W'.JCGF_T[B[S$HF
MW.3:V+K.=H*TD+&Y6YS:6IALS3)WHM \2;*)60)W D;AJU@(.L\=^NI-G?O6
MR7:^W>K]%/*>.7%?M3UQ(U*<E65'I5-F)L?O5#_ I:<S&K,N*9 9GK@M<I3$
MI!Y"+NG9P$6<5%A*RMW"&F?:N,5/P]#;U8["6FS0%ROB/RZ-N%8QXEYCL[>D
M:!A7M#NN<I5,3C82?A0W(FX+.R-YGK#P[$K53:WJRFW7LHNY;17S:]>2JDZ<
MH&&0.8W/>CC/#V,=I2)^C->1>(5?'4;_ #*0/ZR+,K_(5BH:AYC,>96IN0!R
M<O?\+U2HI&VGE*"NCKMR4'Q]I=?DTA;Q.*DH&ME*6A:&7WAMFQSFRY"WN3(N
MC=E7A5TMJRFEK'#%Z*32)"]:Y6HXMLDE1;$RK6XF*E'(DIS\<8V%"6ZRRB/V
M[]RUC+VGLS(PRSN(J9FX[^:L64&"AD31F;)8._X=1M<E714*P3TE95(U9*8+
MH<C"A$J&$@!XC!8#PJME[A$X1.$3A$X1.$3A$ZX^/"+Y3D:8\S)AI))@Q "7
MD0RBQB[@!^EP'J(.<],&=P>,>6!!"+'V6,9P1M;5X"A2!%@>$Y&!8'Z3O!)+
MQGTG7O9'C['J'.1=1=<9[W>SG/7KG.<D7U8QTQC'GT_+\'ECSST\\YX1>>$3
MA%$;=W9*6:IZYV9=,+J-]N)]@\1E<G*86U<VL["TH8K%WB4.4BFSZY+DHVR,
M-J)G/">!G3.K^Z+CD+2T-AJA=@].3;KR]J[+LW?2^@*#>;7:8L1,Y68M@$3A
M<0.=!LK>_P _M*91JO84UN3R%(X'-+*9*)4V">'$I O4HVHM6H(1J3RP$C(H
M+F[T[4$S'\RT93E&8W*-M5+#4V<6#.?S/8J^55 ON7%GFN_R/S8 <E-K:IAX
MX@%E$K%)_1J@O'LD>#.$6.-W-O(C978V[7SNUUD-IJ;S2G-K*!40IVF: Q$M
MO>NP6?6$E@<$>74ME43 UPD\&?E$5+3MB=W=V8*=0)J*/R>2413%[*C.!=FO
MHQD(@BQ^9>IW'>#G&<=0PQJ"+'7&<XZX%C.!8Z^ L9Q[N$4_N$3A$X1.$3..
MN,XSY9\,\(L&..L.N#RX+G=XH2G79U=%BEP<G-RK:'KEZ]<L.&H5K%BM2SFJ
M%*E2H,,.//.,&:::8,PP8AB%G)%\7YD_5[_4Z4?^U9"/^A.$7WG:T:^FM#5'
MP4S6J-B9)DS6(TL[;#6%L;4,[CV,A8Y<0C;T*8@,@:@YQA Z=SUM-@(?1&A[
MH>A%W6NZOKRI6-1&:TA[#"(^K>761*6>.-Y#8WG/KZIRM>W<Q.G" L;B[K1#
M6N2L6,GK5IIJM2,Q0:88(FO8N^<(G")PBAPX;.RQ-NO#=6,U(\-D,D=4V9/@
MVZ_+VY*CD3W E-5@&QPAC2+53FN:D)%DEDOT@>DK2G]L)_9;*4X>I.2DHBQY
MM#M%?T!LE\K;7&K*SL9TJ^C#]BK='9LWD,-".&GO<E9(O"8$*/1N1A4SB7G0
M>:FIW"0811YD S(L+O6\O&,H":*P</M(+)>G-9;D-J:"*].H=:M 4U/YJ_39
M[;KA]O7Y'Z>>29K%XFGCJB)FPJOU=Z0=ID:=WD:5Y=1(I:N;/5RF=&2ZRNO'
M7C0E#S0NS:]M[MX>TOG56S>)V+"G/6C79.WRN%/S;)8\M4MJ6+H' A(\-"E6
M@4F(UA!R54 H\0B%!)A(\!& 6.7\-=J+8^X1.$3A%AU\L.Q&QX7M[70DXD;>
MD4&%)'YOEM3H4+F2'N]Q4F2/<\;'4@HSKGH6N0)3PY#GO%8QD(LD7%_70M/_
M %-5B?V;TG_A+X1/KH6G_J:K$_LWI/\ PE\)7JX^3>:?70M/_4U6)_9O2?\
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MOCR?"K+_ .DR/_G2_P#_ *7(W7>0(!NZW Q%H0;):'B.P RZEL@N31%LC@E
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M6V>Y9;HVEV/9.J-6-C4T=@M4SS%LQ38.PE5?0I<RQJX5$(C]HUZQ2%L9EB]
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MN'F*AQG C"L]W,%C8LXP,(<X%CO9_0XQCIX9SXYZBU YS+7:)7+*]8!;(Y,
MF2^C#*B<MZF4WQ0QA9CTMI,.PM[6^BM8+'-YB^0<_P"!V4QQV&\Q%,BDP".+
MH\I+\!Z4V*"+UE<@2(2^TJ$/IC\B#WCS 8Z^?I!&]<YZ],?9XQ@'N\<9\<^'
MESH@O&U 1$6^U10L.F6C(A'2'^T,3MIFSBFPD5VV/I0$V6RPD1$@B3)CJQ8
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MI>_@(DP>YD.!"QG+G-1RBOF_Y%Z17M;/A?P>9*]7$1*A,(C!>$0ROBEF<.:
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MIQ&$D%B*#8V\?1MOB&RV6.PWQ9Y]HF1PBT2(X3*]2"/C]**$1F** 1=(!@Y
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M5SI+$LL*>:JFS.4*B4%NQR40R3 C$54D>$3A%KX_5 _\B/9O?US77#^W?_\
M%QLUD46P=PB<(G")PBZ%:G\K*POV%2?_ .#+.=9Y:?-+E)]2WC]UF+]:X?Z;
MNCZRL7WB6M;$&?''C\?F\N[\_NZ8_'X<\9H_S@_4_P"(KU,&,P?]9%V^J!\-
M54J=+OMBH=_M&2?N<=_H_'\?IYG[T9OI8N/]ROC[M'[5A3G\^CF]/K&YO[Z%
M56=H7]N;?/[+4?[FV7F=N<WY[WM^I*^S+6XOHP?03S??5ML[KVMX\FZE#3'Z
M('^R%_\ &!YTBS_I$C]M*^W"L]G#K'B%OD5UC^(."^?\A\=^;_O,BQXX]WT?
M'F_=F_1Y'[&5F_\ R<.:_G<O[^G+W^MKQ^]3UWCGW7Y:<(G")PB<(G"* ':M
M?I9V^W]25?'X*Z?^$7[[*O\ 2V-&/ZEVF_W%-/"*?G")PB<(O49GQZ8Z]<@S
MXXSCPQUQU\/C[_HZ_1GB37HD4()=PSC+;O=F4+M3<.&_J40+:W!A51357"'N
M.R9Q7(D2%::I; MV4H@.!8CB< RH7$&Y&$L.,F8R5C'46,!R+F!>77I <FN0
M/*2/DQ>]VWC/M<,N1.CGV2*4),F5: 8I1F"888B8H6F?$,30D"(0Q A9=Y'\
MS/*7EG<@Y077:KLDV**=/D0R[9'.AG3IDB+HS.@)<F9"(1&\ ]88'-0X(B5*
MG9'7.?JE66ST7MNO)<VN5D;HWM;49*),8E!:N&3!4R99'#O =A8"%5Z@H&#
ML?9 Q@8<]T>,\_+OWTG^0-TFQ&RB\KZ]?9+/:)TVQ]&"78HYYF?R:?Z\2XC/
ME]"(S/5PQP@END^'[%W>CWRWO$6OU\5T76)$^9*ER[3-FQ3+7!*AEDSY/P>5
M:(1)/K(88/612XW$1, #$S [6V4(YOI75$O;DJE$WR6W80\HDJS!6%1*9? Y
MZH*+/P0,PK!@,#[H\ ,&'.<9S@6<9Y^OSD7Y9N4O-S=%_6*&;#9+UG6.VV83
MNB(_4SY4<<LM"2P,)!:(0Q.[PC/-_H675:+CY\^5%SVOU7PF[N2-[V2?ZDF*
M7ZV3?_)^7&QHYZ4)#@,P#+6OS^\'^UQS6^?\N']2'6Q>K<.'9]F%;!O8=]?8
M^Q']-:Y^'_['+?/[OO\ P].;&\Q?Z%?/[>37;\4U\NI>9GI_?TYS;?57*#M^
M%W=Y.K[2?T&/ISS/B\\X<!P'@O;PJG")PB<(G"+7[U0_F@OM/OA^9CUH_P#A
M,2]_Y?ASTF?4//7X(M@3E1.$7C.<8\\\)YID6,=.N>G7R\,]?O>?O\?ACKG/
MAC/"*M_M%@X!!Z_%CO8R*7+QYZ"SCO"RSG>/3&<>_IG'7PQ[NF<8YJ#Z7,^.
M1R?Y(F7'/E>LO:\H)AD3.@\'P(%HV-7)<#<U%L=Z-DJ7,Y2WV8Y<J8!=LJLV
M 1B'UD[H0F%RX>,P@MD3E54VE02%DRU1/2HLQES=6S$1U1+@MB0+\:Q)E>%Y
M#48XX!ZP-"4LP%0 @0LAP8$/CD( 8QHU_"J_3=?Y%-\V\7,)OK1<XM-H^"&,
ML#&?C4BBZ()+/0,1@MQ/R'=!M1MINV[_ (28/5^L^#2S,B@<Q >LZ/29XHBS
ML_Q@'=[%ZXSC^!^;==>N,FQBR@8QY^.:^2B%U\<]!8QC/7.>G7(O#./+FZ_H
M[S9DWFEY>]*T3)Y-HMDF&?.BBB'K!R?LSRX07C$,#PPBC,0QH0-?^4\D0^D9
MS22Q+DP017QR;,'P>#U9(_+\TO$  .F2&<CN-=9H7EGZ,_BYCP8CB%ZVQ8'@
M?!68]D;]NE%/V!V!Y_TK3<R_S/?.Z7]7VG[(6HWII_0G;OKZX/O06VAS;!>/
M*<(G")PB<(G")PBU]V;^:9Y7_6GR?[O\6\?R^/)F.!\0BV".5$X1.$3A%Z3_
M -!C^BQ^+/"+3H[23[=F^/#_ +]1?[O\0D8SU_+X<TQYTOGO>WZTO^ZEYZ[U
M[<>BC] /-Y^YWU_BB_%!H7EC^B!_;8YT*#\U:/V8^T%L+'@*M\>#K^,*8CSX
M+<D[.+[2ZB?V-NG[JY#S=_D-\U+E_<X/$KPO](_Z<.<C^T,W[O9U-[G;%A).
M$3A% MX[.O7F15!;%5R!F4/+Q<4IG\YDMRK4$8%<:":SF6*Y@DE+!, , 3&M
MS@KD-J3P?)281#,VQYF0B)4DD&A/:UP4KX[GQTZZM9?9DT3;VL<BUAGCU/75
MB?[?L*\D]@$.;0VV-')_9T^E4\EZV/.R!E(;42-W#.)=#'%N.:5*5QA$A=F)
MR M L,-RUK3JX;]:QIM79+#T%CDMFUC2V"WSL10S;=2PETNN#TY,8TRQ.QGL
M+,ACRZ2" _PZ2O<(E3VP-;<S2"25R\Q)T>4R-,I5G9=" .7"9;>/FN1F79[:
M^RV0ZIO"9M>XFT:B)TS37T.B[@0CC$AB[2HB3U&HE/$RI(M5R!AB\T@,(GS0
M1A8F4XED:1+UJI8 ]<2I:UV*5\'\]?@N==M%=>)0V;&([ A[?83ILY(94_6#
M*9BSQYUE")/(H,R5PWL,6>Q,X5; RQ"'1MG;(J0F&)0WJ$QKH8H4.:Y6J/*J
M2M;Q 5>U_"($.2/TO%#(I'XKB52DU(HDTC"P-25J"]2!0@1H$:AY<@I<*W-0
MF1)"CUAIQP2"\#[N":UWKNW7K^+RSC\?X_+A%4%VSDYW6K#4]XL#4>R:&K)O
M87!E)M61W"N<HR^M;&[3&*-K*Z0.;FNB>#,/<7*C6J8IYZ@]G+(LZ+U#:\(7
M1&G2.!3V\&IQK[3@L*Z*U#OU)+NK&^)G9/9GQW5\AKL%SE#%V=J:;G(=@))+
M&(MMCSG/79]9RHZ\@A[KC+XVN[>\FKRE>5R4],K O]*EC5ZJ\:;AU\ R/ACP
MU3\=ZL(NS6;6>[;L32.8V#8D0NZ-U0C1*D]3;+VO1LH,J44I?5J!RD;)5T_B
M"AXC!4I^4 $;V](U:-*N N2%+"Q!&5RH^NS93/3%2(H_ZW@:JA9553998]?I
MVH26,3APL%WM==)&]&M5)1KU-C/[S(7B7F86%*D^7=>]N9QN2,EX5# 4'&":
M;6WLV;\K9SC'3KGIU\OR^'S^7W^%5XP,.?+/7Z,9^?R\/'/AGPQX^'"+7S^J
M!_&)=F[\?X)KKAT^GOO_  BV#N$3RX1>DX\!11IN<&#P4 8Q!++,,,SW YSD
M("P!$,8L].F A#G.<],8QG@TQ?!\":=0[L5'V<.M:^3C]4D:9-<]55BIU]WP
M%-R#U02X^#7EG \J4*1R.:3'E.P'V45(QM'KR<XGUL3,$032Q$&$EJ0B3A"N
M )X#6L$+@F$@ B'I,'- ')<!C2H J5>!.W4AZIV8NI!:P@ESKY]7DIW!&<@7
MIRE4?/4 (7(5 "ST2PH!H0J4AX0GIS>\4: (PY!CK/+0?YI<I/J6\1_]+,UO
M7ZUPG^?+GQ#WC8B'!%#:)=:BG6Q=:XY?3R_'[NO<\^F?#'CCQ_!CKX>,T?YP
M?J"O65ZF0_*F[/61!L<9,+<&/4^S%2ITNQUV*AOE_H*2?N;=\>>/=^7PYG[T
M9C_Y6+C_ '*^/NT>(RQW=ZPKS^?1S>GUC<W]]"JK.T+^W-OG]EJ/]S;-S.W.
M=\]KV_4E?9EK<7T8/H*YOOJVV=]ZV\^:AICS!_LA7_&!YTBS_I$C]M*^W"L]
MGS'B%OD5WT^0D$_8?'?+RZ^QD>.OT9^;ICQQCF_=F_1Y'[&5CC^;AQWK^=R_
MOZ<O?ZVO'[U/7>.?=?EIPB<(G"+P(6 XZBSTQ\>$7Y](#KTZ^/3O>6>G3X]>
MG3WX]_OQ\<<(H ]JP((NS-WVR'/7&=2;XSC.,9Z9QFN7_IG&>G3.,X\<?'&<
M9QX9QG)%[>RJ_2V-&.G^I=IO]Q33^7S_ #\(I^<(G")PB]0O\\Q_0"YQ.,)X
M^&S7>IF> \U1CN[C&=@G_P!_^049\_+_ $N\O'W9\.ON\\9\_#S#]*%ASM7C
M\8@BZKGVD_HHS6_?H_A^;>[B8BWY0O9X<OTV97 U.&V@(41\XZ##CQQX9Z8S
M[L>/A\>F/=CRQCPQTQC&,8#A+V:T?&,7QY(<OE#.85 --K9XO0YHCZ/K(.@
M/XJT.U _2L[EQ0EF]RE-VD77^!T:Y?LWK+^YS.\?W_C^]ST5MOT#<@?JRY/N
MA6(O1;_TG.<?ZFY2?XFN):\F<]<_<#_:XS]/OQS#=H^7#^I#K1*].8<^K[(6
MP;V'>?\ (?8C'^NE<]?_ .3EV<>[YN;&<Q9_D5\C9/D]\)7F9Z?P_GOFV/\
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MTQ2HM2+)?>/ I*1HRSP&Y$$XM*G 9@02"\!(OJ3)$J,L121.0E+$88:(M.4
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M *QD>-A4M=D1VEHK+'W7N/N1MM7?MG.-6DTA:V*ZS)=%F:LC(7$I6*5SVB[
MA[//02%<4@<:X#8K8%E&H1SB0%"J.*FG57PS5B^HT5:H5KK54990PWU!LC6?
MS^ V(\6W%G%<M='%Q=WE#9D@;VI[G"A\=UBYX=I*Z-R18Z/2UQ4'$A%G.1%=
M>-.I>FRM/]>;>:E;18L#420E1/72S$S@9,ITWR)CF;VV)V5W<XG*6J3()+#D
MCDT)BVU:QQ9V9V%0B&H3F-@BU2C!I%U.5Z :=S5-7"%_H>(FMU41U/#H6UMI
MSZP-2>')7/+T5#W]L8'9L0S2)B>A'/)\<FA#^S*G=2M<E2(]8O7'*">]58_5
M A8"H?V;8"PX  ':9ZWA $/0(0A")_P$(<>6 AQCH$..F,8\NF,<:UL1;"/"
M+P+RS]&?Q<D6!X'P14_]L5_*'K__ '6TW[D)-SH_+W^B+-^\P?9C6!N?_P":
MUV?7\G=_T?:^W9W+7'%^A%]&?Q<Q% 'C@ Q,4([2 M1S@>'ENJKR.RWSTUSV
MKZY\.^7[L_J%=/#[_O\ ''NYWBS1"9R"Y61PU'Y.O6 .SO#9)@(W!\-H8E;@
M^BV&^%0Y_P )KG[_ %7LJHR@\L_3GX_#&?=]'X?CTYY/Q@]-_P#8'?$1Y:Q7
MNC#\J:X! F1E]C2833OIFI4:79_RQ4-Z9S_H"29^Y\G'?&/R_P"SF??1F^E>
MY#_V*^-N=EF>SPWK"W/X">;B](AA^4;FK_[Z'VJJWM"_MS+X\.G\5B/[O\3;
M-_B^YS.W.=\]KV_4E?9EK<3T7_H)YOOJVV=U[6\> 4-,?H@?[(7_ ,8'G2+/
M^D2/VTK[<*SW%AUCQ"WR*ZZX@<$Q_P#0^.X_^Y46>;^6;]'D?L97V(5_.Y?W
M].7O];7C]ZGKO'/LORTX1.$3A%C":TM55D8E()]!(_,4\VAZ: 2Q!(DF75K?
M8@C<E[PD9%[4K&:VF$)W1R6KR3PI0+"U)H3 J<9(3^B(L/YT7U#%61M.BU_K
ML=<GRDJ<G1\;48,PV:D)LH2)<-\$IS(124EOSEL)?,NV7,IJSEK I"WYRFR1
M8#[2&"0RLNR@W6@5>Q=DAD+BNG%WLT;B\<;T[4RLK6EKA_ 0B;T"4!9"<DO&
M<BS@ ,9&,0S#!",&(>2+MW95=?X&OHQU\_S+M-]?["FG\L?BQY<(I^\(OE6+
M4R!.:J5FA)3DEC---'GH$LL&.HQBS[@AQXYSY8QXYXJ2  8HB0!#""8B20
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MS"&!CTXR#* $ +.Y;,#@HQA'CNB\\XZ9SUQY=/#'GG&.F>ONYY41RHC$ >C
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ML(J@D2XF<-6K!G&+.M2M:C;W%&)N6)P."(SN#-0K  5HSA@'WP>E3F%B*%D
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M*R#. 8P'&>[C&.$7ORF3Y-+/R05D\H)@"CLE@R<4 [)8C0%F9QD8 &Y**R8
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M=CD:98JY_LU69._T5L8\'GJT!T=SW$J5A5J8XU+<&0E>,0GQH93T;<_F]TK
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M<)Y6KA6%J0UL64]$(NWK9*NRHMJO'9U=:VEJHA'E.X,J!>^JDIJE6WO()G3
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MP[LHA,6S4^;RE"EQ F3Q1-A4]GX>G$X)<3:18,4+G$I0<<</!F,#-'U'D(0
MR+/<QG&X?-598K7S=W5##:;59##.O$&*RSC+F1 WA:808IAAB#.\0A$#0DXG
M!:$<\UOBL?.G>T,$JR3#%*L;?E&[[#?%F!_)MEF&(6.WR(X(8F'1)$9!A/1
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MWL<(G=#_ .3CW>['NZ]/O=<].$6OE]4#_P B/9N^/_ZS77#K\^.^_P#X??\
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ML;ZU2TZ7/C/!)%*1LSR]R!:Q@8U[D97+>Q.:]88\GK5QN3#%0SG,P[ RN];
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M,[XL5M*LB.Q&[.J,G6'!RY"W$H/:;&*5,>'AK$4BL3.0N33Z_P"T$61"P6#
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M]3H(?(-<-=&YAE2VQH@DCCTX-S7%@."!J?%#P6UN"U ,HP*Q*C5''IQ!S@T
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M9/G&&&=$8HA!+ABC,,(#Q$"@J5EWF3M=FL7+^[K3:Y\FSR)=EMW2FVB9!*E
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M617JDV'QM(N?FM^7/HBG9V*(CZ?+:C5.!3\'?57)'5P4*!Z@[GJ+,QN8:/7
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M"R03@D8G*.DN2!/WXXN[BA05D(THNBDNF(Q?*BC)S)F1NV35HU=VT4"KL&B
MC&0C /0JYZ!A B#D!Z[LJR=C7U/[V4I$?8DLEU#BCB_I61L3/JTBRKP 0M>2
M41);FL)"78Z0."%*T)YI0,IB.Z7D/YR5_G0.+Q?&%##$&B$3Q14+@ DX MUU
MH0A-1%"(8"#T@((81"Y!#D9T+<":A<W_   3LC ]X0M.(QX8ZXZ65>'ATQ[\
MYL[/A\_GC'GUYQ/K"7,P1$LYCERXRPH #&(F  RH]6VQRS, *TAH[XO@Y?.E
M."AOI;]3EZCP2)6PCW"HNL+7E+S><_D%6.45L2Z24\9I1R,;Q02'..$S["@B
M=F4LM>%8:8C=3Q>G!D;XO^Q]%]#'%_5$$)>O1@A%-K-%4]F#!<NEDP,.(Z9,
M1Z6UXG8;@VZBF'GZG_[(X73.=.HP#SQG!=E7CCPSG&<YQG-G9SWLY\^OPQX\
MA)B^4>D!\D$"FT4 ?;D7)7SB$49!?H18&*5%%+)&('Q6-3BY-%"^:?4X>IJ_
M>"G; AU(UDUZ8,-5RMGMJHEEC73\K9/9JX;W\EY$V'Y>UBD+:W!4,^#P$S5G
M +*,_OMBO/3O\34CXL( #8/3KS\*,^5:C/'$<C',BB/:7+8]9SHTU<=@%V17
M3 ?S&T:Z8Z]/XYMY^'7SSCK9^?'X9^/NY11P  ^-![%08@8(ND299B,+DQ =
M-A%0TK"&-,@^"M7K2NH=4%>0BJJ\9BHY JXBC!"(7'B%2]<2QQ:+M:5E86@E
M8Z*EKDJ*;FM$E2%'KUBI68 D(CSS3,B&(H  [!@2[<<>]SW9+N_"J<(OR/\
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M 1MS[U+-#]3^=DJ%*F MT]C)RD)!.%8OKEW?W3#\%!P>,. V23C 3#.^+'V
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MH(I/JW6MCI'7578"!P&\S/Q';AO\E.[9CCO;+K8]BOQ3F8.3D&X"8#!I)1F
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M$H+DX8 AF!8[:G';L?)MBDG%V>KM4'!^CZ)PE#/"KEM:960F]NK&@-6U?.;
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MWC+!@T)M24Z^36<B9FF1PG=VHV>MX\;'7&S"18(8GZYJ4D4B<J@?[PBY1@+
M;8:]1N6HGD[&01PE.NN\A^W'+PHKB6]#%:]B:-K;4S+$H7#& E&A1)2T;-'X
MU&8^@P4G3D% P0A:V=G:T@2RP!P2D1(TV AP647C&"JI#VAWK+NP\D.ODU;
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M+PO78+6"I;5E:TF<5>PSFU&CM']?:MBL@B-R0>).\>E#&X4L%D<U*B4NK?2
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M=F_KX.U5U^\R='<%2Q17(Y_=D:UY>9-'2MI*Q1,R]".7ZYS>N;,=WF7J==)
MY('BX*"$]I; >QM2&4M"52VX8V9^G'"K\*_BFANP4OJ*T12AG)=J69;]AW R
MI"ZWS5ZIUD;TW*I[65=N#E8=))=BF-:WD#G<\IZ9363K(U*@JFH<I(!''BQF
M%VEK(!>*IU-^'O(/L*M#QC&,8QCRQC&,?1CPX1>>$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$7X&6$SN][&,]W/7'7&,],^77&<^6>G7QQTS\_NR18&#K
MI!$5^#V+CRJ012=/,3%#;";X\X$(XE:S4BP'Y+++"CQJ-0F=Y'",B5%1:4HQ
MMLA2MJY2Q+7%>PX2MB8HW'P/<L]  $&.@?#&,8QC'NQC'EC&/=CYN%5^N$3A
M%7O>.\B2FKR8XXF35K/:%BQ1+7MI8D9LIH63O3!X?2E1U<RBYZX:AOD@35M8
MIQA"(<F6-D<;*Z;F213B:/)4/+&M;"K4S<X;^'#OPQ4@W=+7.QAK48U.,A"9
M3%J0R=0VS(R064TJ9&QE&8>RH+,CT3G'92PO<9=9G35H!9QJQ)&R03B('J&A
M_+"J0DJ.L=QTX4:-V=FH$WK&?3YB9JNMBY-@,F0<=66A+WR"P N.2**2YZ&7
M-)NRQ>4!9G:5-\6<6B#1H@D$FD#PJ3+FP@#:A6."<N.W8WM?<JM=>Z"G=IK4
MU1M-&$GO,$V.:+-D6R]P2!!G8&@3F67PM9;^L=T"-9%K[>ATQJ->XUW6<P2N
MJNK[@HF1-3S(SR5T=]"[3MQW;-^7"KJZSW:[=ZV*:TK.$5!"(Y7-=,1,9A41
M;\-$9CZ92N5)&5H+.--2M2$QQ5+%13:A";E,V(/3Y3-B "=O0E)T25.055&S
M8/G^*[[PJG")PB<(G")PB<(G")PB<(G")PBKMW4WB%KK$'YVKN&2FS3ZUL&H
M$MU2."LC)8T>J6)+K'J]TM*-V"Q1Z9$V)&)TXT#*'N5P7/R+=&WUAPC+FL$<
MG5D)%1<@'+',%NPMU.*]RD'')C%]I(K,&)96[^MH>6PY?$WT5JPNU*BF3X\.
M9[PR3.$NM/VO74!F;4R(V$38I33/UK!+JM=5B!K2D&L9KD<4P;;C0@\,">Q1
MLW-V4@>%[5IG&8U4]TW#>'IH4OJ&WY:^PZO38PZP>62L]LF$T01*7)$\GEC-
M&#6Z&1'(,2AV6.B21$)\,S>H7B*=?OUN5=FME$6'9QD3J6-52@10FJMC"+>=
M[NMZ2#,VBUVE35*H\^VMJU9R(;2Y.-RO,RA;XJB$/MOY5&0BQ:&D*!;(37A0
MU-F9'.&M##A5377K'W+8!KRNH34\.9*_KJ.-T1A<;(.2,$:9RQ$-3.C.5J%H
MD3<F$,84B(M0I.RF1DY"F1E""F2%$)2B2"ZJNZ<(G")PB<(G")PB<(G")PB<
M(G"+K,QF<2KZ..,OG,E88A%FCU3#G(9,\-S R(!."Y*UMX5KN[J4;<CRN<UJ
M-O2B5*B0&K%:=.$?I#08R15VP#M!%KEL[:E$V72E_5L:FBE)OU2-#SK_ &-)
MCSCK#=[,B+J98,ZI1%<]?Q:/*I=!BB&:;/K^QQ3"$Y0GRI-7M#H,9<NC1W!Q
MW8-@[$FN "EA*9=752Q9-LM>;;':KF!< B4/G;@B=726X;C'EY2*&^MT"]F9
MD"^QAH)\^K&F$#31(+RX.+TX_)YH;390YH%3BN)S&(UV/^."HJD4^D-QW!36
M[,%UZB('VS3WAUI5I3V$HDE.;5@;8U+Z_+I^^_:,52,=![D,,,&\!K&6.34]
MLQQA;Q2\CDIIC=A*E*=W9Q/O5LVF.I312\>+F,MKZ$PVSUKG:!D998:I4NJ*
MG*KL^:E3M/1;%)%"!H,>HS&'8@#BG39:TK&RO*UW2Q%O;&,PLI01GQUO&]3W
MX53A$X1.$3A$X1.$3A$X1.$7%/KXRQAD>)+(W9N88]'FIP?'Y\=UB=N:69E:
M4AR]T=G1P5F%)4+<W(4YZQ:L4FEITJ8DT\XP!8!"P15JOO:*I(EM+':SF%4W
MDSTW,Z:GDQ@DXC5%3:Z2I\\P:>5^U'36).>NHKE-<JH>(C8\9=T+ZX,;#[$]
MH(SY4)N$]-R5,5;>-^3=K5H7\\IQI$+:[$L-MVE$(]#9C7I5CEM3J"2*7,$:
MA#LY&)E:Q2_J&F*C);)A%8W%);)XZ[M.$3 [HT"54->X1- ^9*>[7OV=:HMW
M$N6#;GDRB>PF+,*JF=<YM'(F#:6,.TH=+#KQU>V&!VF:\6]KTIBC0OG>DLS6
M#C4:L=*H=7 QU;FQ59[*RY9(RBE:"=6W9JJ*;.J^L;_.;%FNQVP5#5;4*Z3N
M-7O\5J>#24B=LB.W*C53=H/V6:)(WL[ B:7:R(R],30TE-:;#HYUZS,B:=J%
M2X\YE;;Q[C^"*U0(<!"$(?# <8QCW^&,=,>.?'/TY\<\(O/")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB^)Q<FYG0J7-V7HFMM1EY.6.#BJ(
M1(4I6,X#DU2K4F%$$%X$+&,C-,"'&<XQUZYQPF."@5N%MX_5.S/T>HTR)/5B
M1->C26(^R2(3&R8K5*E]CF7BN8F^0R"/\.=Y)9MWR-PA\ JN#9GD+$O<IF@?
M%;N/N,<<EQ4 '7FQ8#$JO#6^EI!8B\F[)>Y6)0D!I2ZK7E5_M-K7S.E,,KVP
MX[9U@2;9&M:6CD4@]?Z]W+KO9$J='A)*]A+<F%KV0AC!LYJY]9X_)6S)D0*D
MTQQI@,-^8(;#<[YF<<MW#J:&Z_Q [4,JNF>,K;?K;7>+O,FKN95Y151FSXT@
M35*'6.@:*\.<H*4A6("(LGB3@S,$ND<CBS,CE[,C>37I"7';OUM\-^U11I[7
M^QK2O_:JKK@8JNE,3E,RBGYJ^/,+U-FZ&N\E=H 3**6V9UF5N:V8S>H;+1EL
MZ",S^GW:9J4<8<6Z/V5!)TC/R61*IMUD-]-'B5W\;8"(RQM#&0N=77#0UMK7
MEW?EHG-^=L-B$E 6XOCH8 !SF[*BR FKW X.#E2@1AP^F1YQRHN=X1.$3A$X
M1.$3A$X1.$3A$X1.$3&<9\LXS]'CPBJJW"V^E#'8L.K#7.;LLK>43C.HM?55
MLD5E*BV)#&$;"Q2B7F:J3PQ&VUI*-J*=A**02HFE5$K<GHYA=U[\X1!V=8ZP
MQ]Y+D!0D@\1EQ&P[>H*/=9P)5M.I*O&V9]53]K>QTY;E1WKM-")8=!4>[]+"
M0&M##$KTJEQB,?)JV0U(-7,GB:3!LE+<[US8B%X050X1J-SN>1.,E3\7<:%O
M]4N[@YN&;C6H!,M[HWLC2^J8C+M=)Q%4Z*;WM!Z-<KGL^!3XFLZFQ-6IR>$$
M[?&5Y%6RF7LKR).PQ:&K6V4-<2>97.(H8HD_LD2@!Y</'9IU#FC-<)[;5S;;
MU7;&:TL>M'JX&[&S'R;62^,H#;:45/"9_46S6M;H-XFDHJ2T$3=F)16S*GS.
MSDD(D35'K2J^:,19ZR+2)KCPKKO4ZLN'5M#\,E>DQLY3$U-[66K7N(D*!"B-
M='93ZZ\.HT",A$%P=UW<+$N<U1:<!BQ6(L CSLB'W0XS@."JY;A$X1.$3A$X
M1.$3A$X1.$3A$X1=(L6QX34T0=)W83^GC<6:#&Y.J<#R%JX\]P>G-&QL3,TM
M+6E7/#](9"^N+<Q1R.L;>XOL@?'%O9F9O7.:U*E-(J,$VW%[SE^2M$MF50VJ
MR2ZQ[.J2I:W=8<^0ZC-UZB>901!)-1]EJ)?&WB2T=OU4BMK5JI%7<SA[!7[K
M$U\H;5D:7QSY9SFH"Y,VV@>AJ"SO3^KWC=G++5DNG=6I!#:DMJR,N^TDA:A0
MZ.0A&XS6W%E(TG*9Y))A3.O+E/6B+$A5Q2O$[DLCD-L.WBF>12@EO6@1NY[(
MC1($A\M:W*$OA@^6T4)[L,E#Z^+#O/9AOKV?GV)5\2:HWO:DIB UK%XG(2K\
MUKNF.VH_5A5%@3-:Y6*OC5R-C@86WS>XZ>?*KB3>.D9>IE$*E1"Z(-\N?BX]
M_@?&FG-5;EKC1N:Y322>2..LL(M*W\,$HN>%5Y*7Y\I<%J-R0] _3F L\@:V
M8;.Z3(&$BJ3.!30WK7HY&W&O8G5W2*GQS)CP!IOWX=A![*A2CQX8QCX<*IPB
M<(G")PB<(G")PB<(G"+@)5*HW!HS()G,GUJC$2BC,Y2&2R-\6D-K,Q,3.D-7
MNCLZ+U0RTZ- @1$'*52@X82RB2QC%G&,<(J,[!WDN8^P;%>&.Z8"ST]$K294
M]$R9\K*Q(<S.,S70XIZD.GV^49E$9+L:I%EG,TP;%6K5H1.OTQ$@6(8N]+%4
MX?G9FK*Q6M;%S;"E30U%:XP[6;XU=N =LXU%':GTPP19FS*UJIE?(IS9#CK%
MK4POSY;Y.N<,F3'$AVS"ZP(@40)D,@C<H>XL19<FCS?'G>O*<]KD,$+.9X^F
MP>M+B3L??DYK7$Y+H6[UQ6)<R+;JEV5_I1DJ>HJ#C=BRZI[/33F*V'LA6<OB
M*Z82.0P:VF6P(:=3#0T%MJJ'QF4%P>P<(K/9%Q<S1I6/ 6M;#GNZ^KBIK6WN
M4G-1->WM4FKR];A$4XVJQ00J#0ZSF UQA<IN/7J11QG?H,Q[.UTD1)8LKL>!
M+'1<W*"D9KRUH9(T+Y=%%,523=\A2*Z_%%8R . !" /Z$(<!Q]&,=,>73&/H
MQC&,>6,8QX<(OUPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG"*OG<O5Z]M@W6-R*$6Y%6YAIM;$+,K>@);$ +JJN&X(H_KG8:/9)U$:YO#U
M BVY.RDUNDB3>T'5O80\VRZHK"=HK#6-J*@@=>>8X>>T4IBL;4W1D,OI=8EA
M%UTXUC6]_/3^R[U:77-"E*A +8>)(F1.FM.!/:-4A:44Q];9HQEWL:%&OT"N
M&,(X59$>4LD[9!O;F1V8;,"#E6GXU'6I ;-ZRYF>H$PUXH5GA\+&@:(JKKJ)
M*T 4->K5U?S2/V W064)$1)@OD9.UL<S&)J/!"A0L:9 [JU@'%0H4%J2A<E]
M^MFL!@HT2R<V9N693%(*M9;OJ=M;;(8Y!M>U73"4"*FS*QC[#($,MJLM]5'.
ML/OA!83NM;F^.$PKVRU)4A2>9O:N/J6= W*6.M:HF%=M=[ZVX<&:Q6I*4J>A
MHL*%4[ (U7D8,7GNJAIC3<4A*6NBDH@@]S<C\=Y6YN)J=*E3"7.*A4K]52ID
MN#L)TQ!19%E'A$X1.$3A$X1.$3A$X1.$3A$X1.$5=ASD[6]O)8U3S.YK+JY/
M1\6IBR:>J& R@J!HKABCX>O6SJT)6K)0B>[,C:>9-IE0O4.3.08W#4;6%Q=F
MXM[L"/NJ<N6 =@7<$[-V[:^?45%JA]3?K[VE9M[QVQ\QZFE&V5E'$09S872<
M3-D>:.VY=; F/YGJ[$L^8(M!:CV+N^OFRQKA9\TY(YLM4@>JRQ9:R-QV"JX:
MUKCID):G^R.\9AJL"PK3'-6';K4Q+;^UILNL8&J9R)DZIH\^1E')O39B<@>H
M/+F"=-\.EX" &&BB,V4QP$3E'=*4=&-X7"$F4@").:7'R42Y+85I[@KZ1IP6
MM5W4^D9K)9Y-M8U7)!T!-,J*T9([(FZ85&&0+!.L*OEMG[NZ-B!@3Q +LSEH
MDP)B\&LJEG1MJLC*Q^LZJK2F(FC@=2P*(5M"V\Y4I116$1YIC#"F5+CLJ%JH
MML9TB-)ZTM/%DY6I$4(]2;G)AQ@Q>/"+O_")PB<(G")PB<(G")PB<(G")PBP
MALS-K K77*^K$JB-YF-GP2G+*E]>Q4*%0Z"D,TCD.>'>-- 6E&:0M=\KGA(D
M(PT(CR%KKD?L]&>2I4E&!*C$/M59MVP:$2/3VN5$)VKO:ZG'::[=7T=0["E6
MBUN\EBUC2B:MI++<=419L9FF-)&2-@/=)K8M51!'$D"6OV"7X:ED)7L'M= 7
M(.Y# ,(GIEC4X[A78,W4Y=2M8EVN+))BWR3Q1_?Y2")MXD%:P=ZK*K8K'(.S
MFM+ SP^$22P[7D1+BO4KWV3S:626P9+(IG*W]P=7!6026B1)BXDOEVUKO--#
M>HX))18VG-\;'*Y31%O7'56PMCH[B@=G49!UEF2AGDIT$B4(=JFLB*,QX9&U
MIVP<.2*X#,?5E$."QN8FEX<&!2UC,7%Q.&S?LUU<5E'4369N:V-COF^JDAH=
ML'Y[M-]46!(6*)R*X8;!IS9$V?J[K5XLM$A-7N3C7=5OT:KA8H0NBE(4D9C6
M5 L5,Y0!*",^9;)B.YJ]JGUCPQC'PX53A$X1.$3A$X1.$3A$X1.$7'/"E>B:
M'58U-_M9T2-JY2VM7K!:3VFO(2FFHV_ULW&2DWKB@!:;U@S&2R?2>D'C(0YQ
MPBI)3OL<G79L6%LK9ES7-=\EO&J(W'K0A":P4<,25Q=K_+&5@>:VIRMSXZO9
MZPM.I;.<\06*0EX9'J2O$EBK+&YZ=)Y YNKTX%RPB8-0XXTVOG2M*9A34U!T
MYE.N;HYR6P;79+1E:B)@AA#K%:_?ZZ(D&%4E<)A+K0M$,EM*VG>Q+PL>1*DB
MR7S@]]9F5*A:FYDBD1C[:!4!84)?)NS< ,!ADN V!0V32VTT)VR8*QEMW5H?
M33I15E1BO&<,EM2LBC9DGG#)8\"BGIR%LN87I2 Z/V7'8[Z:3&$ML,>&UN=B
M696D"7'#QJ:>Y<#4M,->TMKVEL%L31!;C7ADAK\6KD'V/KMC66!7Y<1C04DU
MGC3&)*W+GFKD<^D^$*Q%%EAB-X.'&")4[M[<N>2D22>6'M[VJF0;MILIEU^[
M&R\(<!Q@./+&.F/+][ICE57GA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1>,!Z9%GKG/>%WL]<]>GAC'3'PQX=>GQSGA%YX1.GY?X
MOA_CZ\(G")PB<(G")PB<(G")PB<(G")PB<(G"+"MS:XT1L.B8D%W5/![-*BZ
MQ4X1A1*F)(O=(TL7I\(W(Z.O/<+=V/+JB#A [@:UR0MV0=4+D!4DSDG)';!9
M,B\6C,(CK)$(9'F2)Q.,M2)CCD8C36B8X\P,K:0!*W-+*S-A"9N;&U"F++3I
M$2),2G3D@ 446  0AP1<]PB\=/?]'X.$7GA$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A%'B'ZDZQ5]9SG<T&H:K8G:3NH>EBV:L$.9FQY"X2;I\J75"8E3%D-3Q*^
MG65O#40B=)/G.1/JMP$+.<E7)HY;#L4A\8Z8Z8\L>&.%$X36M>:<(G")PB<(
MG")PB<(G")PB<(G")PBCN;J3K$=;V+]'0U6YN7#F2^BL3$.9@R,V2)T0FQ-+
M%"D*7!2F8I&H0FE),%!)LG2-0LMB=V*0_P +\*N<'UK':I$8QT^.?I\^%$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%Z35!!&
M2L''%%9.,"23@P809--%U[I9>!9QWS!=,YP /46<8SG&.F,\)YH:H()&4 XX
MHH9X\ED ,," 1QF B'D!819QD8L "(>0AQG. A$+ITQG/"+C'.1QYE-2IWA]
M9FH]<9@E$0Y.:)"<L-%GI@I*4I/*,4&9]P"0C%X9\/#A%R1BI,44(\T\HL@
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MEFSHG>I*[@KF/#4KW5+(4,M)7DX-1F%-BG$H;&Z1#,:2T.3GE$E<3O2*B2S
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sttk-20211231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'Y:^@(8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!L$OK@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              I,   /C          $
M                 0             #XP   I,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   I,     4F=H=&QO;F<   /C
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *3     %)G:'1L;VYG   #XP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      5?P
M  $   "@    :@   >   ,;    58P 8  '_V/_M  Q!9&]B95]#30 "_^X
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MMS[2X7G%^S#9M<P6;W:?II8YVRO_ (/WVILMG6!=D.PWMV/KI%#; "UCQ0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M$H9, ,/SA2U=I[-69HZ><J6[;9I&2132N@NO>US@Y[JUP16R7;<>[H^+8@N
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M1.NV/\N@"9%EFZ<V:*V+(#*7?6-8LD@-7K5*^;DFJJBWX*T^XQNP*Q!^XBY
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ML; V-7=O,']D29N*W#*U--RS8V-TQ?-'\0D6?3:*M1,X0.G(@0"& YSE/<]
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MK[$L$99L!.5!!%LBDW;(I-VZ"94D4$$R)(HI$ "D3223 I$TR% "E(0H%*
M   !EP:UK0&M :UH :UH   Y  #D !R '(+1[Y'RO?)*]\DDCB]\CW%[WO<2
M7.>YQ+G.<227$DDDDG=:N2N"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M%P=AK-<ML8XA;3 0UDB':9DG47.QC*6CW"9P$#$6:/D5T%"F 1 0,F/D,Y1O
M?$]LL3WQ2L.[)8GNCD8>1W9(PM>T[@<VD'D%W0V)Z[N.":2%W>Z-[F$CS'A(
MW',\CN.9Y*OS8OI9<KVR34L^OHFT\]W<5!7;VO1=E?T99!S[@.5485J=2!$
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M[SOSY\U]$9'5<FM^C/\ 1+:ID)X,OKO0L]2,G<08YF0R4&.KM'<V"C%7B:
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MY@Z2RBYBEWE0=IV7"7<A-@"^;&NHP/ R5EHLOL%['RG8#J^;.(-:'#RN$$
MJJ8HZ0GTUDLO8TIUDV'=C:TH]^+S?=DELF)\^[2T0[.:7]6UK@[BX=QMSMVK
M[.5CH&%83LQ^$,VRBF#27GOD&\7]M2;=JDD^E?LUJ8S:/^?<D4=?)MS&1;?%
M^"D(D(4<H\KF/ED=%'U4;GN='%Q%_5L+B6LXR 7<(V;Q$ G;<K5\[XI)YI((
MNHA?+(^*#C=+U,;G$LBZQP#I.K:0WC< YVW$>97+YUKJ3")A$PB8150^I5K3
M7+UYRQ8GE!I;RP67L+24#8IQW5X1Q+ST&LK)MUH>8D5F1W<E%JH))(*L'JRS
M51%--,Z0D(4 NFDK=MK<U$VU8;%#@<C+%$V>01QR#@(DC8'<+'@N)XF@.W.^
M^ZV7T?Y"^UNHJ[;UQL%?2^5GKPMLS"*"9O5N;+#&'\$<C7$N#V-#@XD@[D[V
MAUVLURGP[2OU. AJQ L 4!C"U^,90\4S!94ZRH-8^/0;M$/BK*'54^$D7WJ'
M,<WDQA$:?+-+/(Z6>62:5VW%)*]TDCMAL.)[R7'8  ;D\ALM=6+-BW*^>U/-
M9G?MQS3R/EE?P@-'%)(7/=LT #<G8  <@N;SK72F$5=_77G]M/Z=/C_RT;-\
M_P!'[$<[_P!__AEJP>WO+JO^#Z6WK]WQ_5NKSI?];NN?X*H?S\*Q#*JJ,F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$4>=S\H\\]#2<-,[FU?!WR5
MK[%>,AGTFZFFJ[%@Y7!TNU3&)DX\JB1W ?% %RJB0PF]@E Q@&P8;5.H-/Q3
M0X?)S48K$C99F1L@>U\C6\#7'KHI-B&\O)V! &^^P7DLT:ELL=9@9*6 AA<7
M>2#V@;$=NP[?,HM37I,<3RM]IUP;ZH8Q,366,\UE*4RD[ ,!;EY1)!.,?32B
M\TI()KU\Y'"S$K%TW37.Y '95B((E+:(>E;6<5"Y3=E'RRV7P/BNOBKB>HV(
MN,D<+6P"(ML AKR]CBT-\@CB*\+L#C'31R^YVM# X&,%W!(7;<+G^5N2SGP]
MW/GOL-L[:XX3Y*U'<X;86N=)UNKW*OG<J0T\T?V1RZCU'C1=BY.BE(3;QJ)U
M6CE= 3*-SB4JAA()3>#!@LCKC5>6IS4,AF;%FG.&MF@=%68V0-<U[0YT4#'[
M!S6GDX;[<]QNO5#C*$$C98:T<<C-^%XXMQN"#MNXCL)'8I:Y5%[U7#M?BFP[
MBVAW%(S\["1=!ZGY3UIH6NN6PN7M@K]DJ0[<-(3LK%JM4F*D<T<7F!>1Z:#]
M59Z9B]073:E!)12-NWF>>W?V;>;ZU._9Z"3Z^S[%H\Z:$Z:>;ZJF]^HV^IH"
M3T_SVOSY0(;5%DL5J0MSFPSM9F[YLR><V"M5D:XG+FI5<:UZHM4I9>-25E#R
M$TY,+8N-OFW'T?9_6GH]1]F_VKH&P>%]I6N+ZZ9,I*A MOOMOG?HRKF>NI$4
MV]'U*GSX2>C[!XAU12L2W[%=A"':M@>,E <Q8K/FOQG'R[G]GCY_ZE'R>C[3
M\_S<AOS,9NH-5W'E/H>Q]H25NUO%FL_6T9=-<,KV2\)ZT=U^9Y3A-,66&VK=
MJQ4[(IJ:;6?UAR\I5O5AIZ'7<BA7GQVZD^ )2H]?FW[?ZM_3R[_6MGQ'SSN_
M>E6VWNJ[MZ7%0VP'W<\KJHT<VM,)$3EVZ(L496(N_1</8(9A,)4).DU7Y6O3
M\HP1F;$RL<C-FB&R;U$IX'=_5V^/.I/M]GCG[/5WXOF^ []PARS]A0MUK$;I
M:L)\O[\L#:3;; V.C3>P=06>A1MNF9%..AY2V2N@-L1\2C)7&6.H>1U;)11K
M1#P:L295@QGL^E"?G^SQS^U32]-*X[$W;OKN#HZVL*)^#.P9/0M/I\_JU6SR
MNNYI37E%FBV%O6KC;*W49&_#"/;&W92EK:5YA$G?'-#, 5^R%E!@>CO\?G^5
M%<-DHJJ?6$T_LO<O*4?#Z_CHRZ0]=VQ0K1L[3,KM -,MM[4!FZ=L'.KT]CF>
M1R,(\DY^1@91DS=2+)K/NHE*#67\OB)J$44O1 TAT5KI7;UDW-2FND8N/UES
MWH@VC?V88C:\XAL+2U<FHRP;,LS*ORLS"Z[D+)5I:G0;.K-WA'SF/@$I>40%
M=PDNJ0]OM^1>@/"*$6_^^='\\=&<Q\L6A29G-P=2VEU7Z? UQ%DY+68QJS=+
MC;+DHY>-C1D&[=M5(V-^"FY>R+M)X+5L=%@[43(L5:G]4W1>WNF$><H.E[5B
MFEAN>W-9ZRW7.P$4UU'M?96AT@6VS2J;*(3;F>&1JJ1'ABNY>!C8R8^S9$(I
MXZ,V$#$70_62<-U>8]3E2714,':W&P^TBI#CX#>U4\CX*81^G]'T'(Y'O[/2
MBMNR43"*E[U"MD.E^AM>U^)\NQY[U+;=P)LDP.<'>VMK/":;TJR @ 8AW\;,
MR;ZQMTA #@W:K*E,!0'SG<YEG:/Z'-:YZ+<9+4EBII+#!NW&^69S7S%@[2'/
MFB8X#??AV(\]TZ)M*PZ[Z7]$:>MD#$4K<NH]02..T<.&PL3\C?=*3R:TTZEB
M,./891W[*T30FM&VG=-:VUJW HGJ52B(V07+X\O)H6Q'$X_.8 #WJ/I=9ZZ.
M<?)C"KY$1'*3IW%,PF#Q>*9_B5*&&1W>^8,#IY">\R3.D>?W2=(NJY=;ZYU3
MJJ4GAS69NVJS#OM#0ZYT>/KM!^*V"DR"(-'(!G(*(.\__&-\._U;=*?^IJMF
MP\;^M747[ZQ/_,E7HP_ZP]7_ +^P/\XD5C>554-,(F$3")A$PBK8]2'_ (EQ
M]_-VQHX?_P 7+A]/\^6S2GQL[_J[DOHC6P- _JFJ/]4\O_PQ=JLGRIK7Z81,
M(J[NN_XT_IT_UT[-_P!.HYT,M.#_ +BZK_>%+;_ST?U;J\Z7_6[KG^"J'\_"
ML1RK*C)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB^%$TUB&353(JF</!TU"E.0P>?/@Q3 )3!Y !\" _4,(OL         \
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M$5U%%%#+G(*9!1$QV;H8['635I7Y;LL,LT-D2537$3XG\&S7%[N/B(=V ;;
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M5L>I#_Q+CW^VQH[_ /-2_P!W_?\ _K+9I3XV>_U=R7T1K8&@?CZH_P!4\O\
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M;N3;%78S6UI2;OZ\XGJBK4-NNV6([K$(SAI)2?>O_":*SSY5LJDJDFDYCO\
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M'?5WUQ)RG/-C?.*'4M3A%R<? V4WX;%4GI=[&3K)DI)-#MD1=LW+DZ!2+)I
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M$7V72DU2$73*J0JA!F_R%"E, '+Y'VF 0\CXPB^QZ3YV+_"WWI</Z=HT@/\
M7.81:9NF><"_PN@-)E\??[MJT4/'^>=PBTAZ?YI#[^AM'!_3MBAA_KG\(OS]
MM#S0'W]#Z-#_ -+-"_Z_PB^1ZDYE#[^BM%A_3MN@A_\ R#"+S'^N]ZM/*%*V
MAR#I9C)S6PYK2_4//?5]KLFMG52MM/6H%1D[.27@HR9C[,<%;F %(HC$N4&K
M?X:J1UGR15"CA%?YJ#U)^*MO:CUYM]OT3I^C1>Q:G$VYC6=A;3UU7+E!-99N
M5PG&V6$4M"QXJ7: ;X3UD=4XH+%,03"(><(N>?\ J+\"Q@B#_M'EYL(>?('W
MEK@1#Q]_T)83#Y_F\><(I(ZUVAKC<E-BMAZGO-6V/1)P780UOI<VPL5=E!CW
MB\>^!C+1B[EDY%H^;.&C@$EC"DX052/X.0P 1>/KUG/6DJO.GJ:\YZ]?Z%L%
MH5X+V1(;'F)5K>HV+2V,WVYH]"/;1<8U5KSPU?4@SV<BKAV[6D2O09'(F@W^
M,4Y'U?9^?N^U1Z?D]A/CZ5Z2-8>I[P9LVIU2PM>MN;X>5L=<@YM[5I#=FOTI
M: >2\:U?.(1^FZF62@O8M9P9BZ$6Z0_'0/Y33'\D"E2)ANFN;[$9,D!T#I.;
M.J &3)$;4HLB<X#X\"4C2=6,(?4/N#\^$636-OJ<F0JD;:*[()G\"11C-1KL
MA@'[A*9NY4*;S^;P(^<(N<3<MU@\I+HJA^E-4AP_SE,.$6MA$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J/N\NM+!IC?4O
MJBE]&4VSN-FU&O5>V\N[$J=QK$=62WQN\JT%)4WJ:BU*6KVF;K>E7! K<3N=
M5[ 2\V#,\>\@TWY%Q(ND>CWSWK#1FRMNL3/]LU#>[#6]&I%ATILK1%#T@K7J
M!6IB:4A+0YFM4,5->[]GI*3>NV3O<#"R3+Z001(FZ:Q:CM5$Y%?QA$PBJ&T[
MZLM<VKTK ZD<Z4L]0TSLK9._-.:4Z&E+577$/?\ 9'-+=RZV='R%.;^)FIP1
MD8V=-69Z2<JHRP0;L5D&?QD?!%!3U'2:EW-TM#WJG;%UUM.MIZFCH1_#UYQ1
M+^UBK(2P311DUYA/[<?1"A(U)FBUA$%6$:JO\Y(.VKURL)D_F/IOO'&9C'BG
M%=AMW:L-FQ>;D<A' ^*O)+#'3BJPV(Z["0TOG>&=8X.:6N:XN<M&=*E5S,EC
MYVQSPBU3E:;?6/<R5T#C'U,+'M,+#7$L<TA'&]SY8MQ&SB$^"]7ZQ],A37-/
M:].4F<V1M*'92L38;7 ;E;Z[A9!NA9)Q>)0)KZG[:ID%#.XZ)<LXV2!M68T[
MY^S<O54?<X^MLTCK4X_ 41!H36\T-D/LNLU8'Y>M),]Y9*^M8N7O=CJYD8>!
MKV^1S +P.L=9M*Y*7$X.G!]SF?\ O[!<?-%&^U!,Z=C2V>LZQ('LKSQ-CE9'
MMPCC+@^4N,K^]#JWT"BE\RV@%5Q#[PE-L34J _7R/N,IO%<!^H??]?/^;+-\
M),#><NCM=Q$=H=I\D]_X-HD]_8#Z.Q6 ZMA9^J874,?KQCCS[/[V0_U<RN1B
M]??X.R(^Y3GG7Q?:8Q#'E)^3D@]Q1]IRF_WTWOD2B'@P"7R AX^OUS@.E/"C
ME/@]85COV3:=M>K_  ;Y.??MZN_LZCK?%-WZRIFH0#S,N,E:!MV[\SR]/IY%
M9!CJ%_@Z@>T2Z+Y^1$/ @,A!/GX^?N\&$T[(>X?I]?(F ?S^?.=[>E'3)^/!
MJ&/]WIS+G_EU7E0-?:;WV?8LQ';?:2E9&WKVC=]GI5&G1WI'<.[4ZKLNU]/;
M+M-2T#:[='6)K5J73ZXC6(*&.5D,A&5)B\<@JK"-3(+^TK\Z2[H3.0 $"F2$
M*/D^G6G3SK:-7"V+&*9)!'8MS]?3ONZSA,SX*$T#9&]4' 1QS\$DSFN_4VN8
MY5NYTGU8LI%%3K,L8AA#;5MYD99)[)'P1GA:UL)Y%LK>)Y:[FW<*_IM5O\'M
M8M6S9;3G+CA9LW00565UHB"RRB*94SK*@+4 !10Q1.?ZC^4(_4?&7SX3]*]Q
MS9]6F\\?3V^]^RLHU[I<C<9!QW\U6T>SNY1$?5WH>,_P>M,/II#EQ0 #S^1K
M6-__ 'ID_P"_W9Q/2AI?N9GG=W+3>;'_ !4F^/D4'7VF1_CDQV\U.UYSYXAY
MM_4MFHG_ (/BD'@-!<S* '_0UO7 _1X_X9RF/U_S?IS@>E'3?=5U&?5IW*\_
M;7'CTJ/N^TZ?BRW'_N:-@_\ \!V[_;LMH=Y_@_*8C[.<N;E?'_0US2 $?S_\
M[*D_TYUGI4T]MRQVJ'?N=/7^?J):WZE(UWA'?$CR;_W./F._J^M;)28] 4H^
M$^7>>U_YT]>ZV#S_ />6,@_F_1]WG\_TS@>E3#_WF UE+YN#3MGF/..*1JY?
M=MC#\6CFW^;AQDIW_P#4ODLYZ"0"'P^3]!&^GT\4#5G^3^':0#ZA]WGP/U_I
MR6]*%%^_!I77)[SMIR7V_J_J7/[L:7[5Y\^;^Q4O/NW'E^?\ZJ'[C]/GTY^L
M-TDV9S]#26K*8A0HJJ.:;JM&AUBLL[,Q=R3DU@,S@TK$1Q(NF;UH5R#MTC\8
MC=$OP (0%#T+5_33D\9<J5\1@+5&,Q-FG^Z.C-4LS[O<.""!D_*'A WGXW.+
MRYH8W@W=3=2=(>0JV8(,35-0"(33C+4I!-)Q/<U@9$+$9;"0QX+_ (SW ACF
M\#M[2.<7WHT:*TCJO5MNT3J"XW"@4N#J]EN5PUSI66L]BG(AJ1K)RLX_<RJ;
MAW).GA%5'*ZS=!8YQ\JHIG\D"ZT^E.M/1J6IM)ZR$DU>*60U<')9JF1[ 7FO
M.)FF: NWZJ0L:7Q\+BT'D+54UO5L5:\[\7FN*:"*0N@QSYH'.<P.<Z&1KR'Q
M$[F-VYXFD<R5)6/Z6]&1D)$VNA^?V'@0 OMU%I$1 ?S 'PGBAQ'[O'@!\YW#
MI4Q'^$T]K.+8_P"$T[/R])X97;?3V\EW'6N.;OQX_.,[]W8R78#;?GY7+\Q6
M?>;>U(C>^\J[I/AG2U:_:KZJCY5??^X%8YO2J/5+++M57M:U;J&&K:9HNSWA
M5ZY+8+HLD4(."C%RHNG?VR](D%]Q&4AS-"#(UX;E>&P'%D5ZL^I9 :\LW?!)
MY30XMW:3R<TAPY%6+'9"#*5([M=D[(9'/:UMF%]>7>-Y8XF.0!P;Q-/"[FUP
MYM)"I(]6GTX^/]_]YV;;-YCMO'M#P:FIM=M"WF,AHJTHL*1"Q4-'5A)S5Y-6
MME91;:-7<2)E9'YZ0*Z(+5%N(";3NM>F&?2^IGX*KAX;<%'W+[OGL32QRRFQ
M%%8+:@C#FL$<$K0))&R<4W$.#@:..@ZFU]/@\P,=7H0SQ5@Q]QTSI6R3=;$)
M&LKN:]K(> .;O)(R8..XX !N9T\Y;N],&1T/1H?J/3W'%<V=%1R\)*U:#H%8
MO3>(A8=VO&59I+VV2J[5Q.VH*VTC#VJ2;I)LG,\=\HR &XD*6WMZ4-+.:UW!
MGANUKOUMYIVW$ ?C,I.:[M^,TEI[B01OEHND'3$D<;_==B,R,:\QOJ3.='Q-
MXBQSHFR1N+>PN8]S3V@D<UV*99_X/I8CJ'E=,\KJG5^ASM]81T<8?(C_  1B
MV;42#Y$1\D]H@/W?7.7PGZ6'=G?_ +:SO] 79]WVF!_CT@[^=2UZ_P!B_,L:
M/]*_X.@^6^.CKG4\&X ?)5JU+;-K)TS?7P9+[#LK(J)BB/DHID()1^[Q]V/A
M/TJ=N><Y\_UM9[L__;S\RD:]TN=B,@_;]Z6MO;U/T'SKB%]&>@^L ! ;.VA3
MC!_ -2>F^FZ]\+] II,]@"@7VC]2@*(E_F$/ 9/PGZ4[WYIO[K3>>'TX]0=?
MZ6&Q.1/_ )6SZ>T&'?Z^SN0=2>EZT3]M,]1#N>CE^Y'[$ZOV[)D2$/N^&2U-
M[$D;V>2^ 4*IX\![O(9R^$W21[;&4&VWQL#FVD=W/>AOYPN/P@Z3W(.3 V[=
MZ]@?_P!?COY\EO4*SS+$E *5ZU?J"UXQ0_<RR6RZO;D2^/'M 4K%J!V!RAX#
MS[CB(AY\F\X^$[2'?;R(]>"S7] 4_"!I(_Y6C'H,-@'_ )7>MZWG'427Q5?7
MCZ($X")DPN>FM)W0H?41#XOQ]8L%%"A]/(>\H"'D/ >?H^$[1_?=R ]>#S7+
MT_W/[_E]2@=(.D=^>8@Y;=L<PW]L8/@<UOD=U]&PYA-">MI0;(0OCX:-[XHH
MIP,'CP *K596$7.(_03&*8@^?N /.3\)VCO_ !]T>DX3-#V_V/4CI!TB?\LP
M?(R8\O.?O?CSK5_;;=TQ:GF)]2+T_P"W(D#R5.W<I;C@5E?K] 46J]_.1,1#
MP BF@/@1'P7P 8^$_1??DK8__),U]= ;]_/N\QYKF-?:0.W]FZP_^F7_ */'
MI6H/?_J(Q9DP3W7Z6=R('@3&/&]34PZI? B'@!B[(5/W_F$/>!?_ )^!TGZ*
M/^5;'FYX?-CLVW)_L=L-M^:YC7FCC_E^D.>Q_51S\W./ZMSW<UN_QI/?<0'M
M>:O]/:[>WP!E:OT=N.M"IX^\R:-HTXH!?/W@4ZP>!^@CG8WI+T2[D,T0?]+&
M9AG9V[\5!O,]WK]'-]WFCO\ ."COOWF7Z1&0M^7UE^IH@@FF^'=;604P_=!H
M775+.!Q_0B%IJ<(;\KQ^0"OL'[@-X'(=TFZ(;VYKV8W+'EY^5'L^GNW76[7^
MCF_Y>IGMV $Q)V__  MOG7,QWKH7%$@?A1Z>&[V:@?\ "#5MS<_6M+[_ /FC
M#<X=13Z?4/W,GD?IXSB.D_0Y.WOV!Z74,FT>UU,+K=TB:,9OQ9R'E^#!:D]?
MZG"\GY >ST\H"^H#VSO7OUEJ&L<PJ=?<)6:CV.=D;];YNQTR(I\_3I&,01!B
MFQU[=I^3LEL1F&[(8,CH\5%LHY2:7<N5%%6Z0X[/]+.D\1C77*5QN8M%[8X:
M%8212/<X$E\CYHF-CBC \L[.>20&L)/+P9+I+TY!4,N)L#+W7.#(JK([55K0
M02Z:>>>L R%I ;PQMDE>]S0&-;Q2,L>]"NA=&U"B=$.NC^D=D=$S+K8L!'TR
M7NEHD)B.CJ@UK#9V4[2%DRKKP4XYF7TJWE_@R3UF]:,XI1$$C$4*.=T1K.EK
M;$OR-6":I+7G-6Y5F(?U4P8V1ICE;L)(Y(WAS3PM<#NUPW"SVE=21ZEQ[[7N
M9U2Q7F->S 9!+'Q\#)&203<+'/B>U^VTD4;V2,>WA<P,D??/ER5F3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB810NVUZ?W,&[=RQN]-A4V=DKJT/45IEA'WJ
MY0='O3B@/PE**ZV/0(>:9U*^.JA($0=0"]EBI!1@HU:%()DVJ!"$4S_83W ?
MV%]X%$@&]H>X""(")0-X\@41 !$H#X\@ ^/IA%]81?@@ @(#]0$! 0_F'[\(
MJ#M#>E=O"@=):O)?K;J6<Y*YTWGU?T!J9I&(V);:=QF^IFDRT7I.P8J09A56
M4#1DK39"A(1CUVM8DU&"*S-FF1P!XY\]_/[1Z?'=W]Y6#//3/X9!E\G5N;]9
MZS45EXB7?26JJU%Z\EI8(AZ5X$5+R-9:L',C"2( JTE8UR<Z+MFX63\IJ&(J
M3JDIXZR]K\ABL5E0R*Q%$S*X^KD(X?=,?5OEA99CD$<S-FOBE9LZ.1C'CFU1
M(V&Q :ENM4NU39JW?<UZK!;@%NE)UE:P(IV/8)&;OC<0-I8)):\PD@E?&[<N
M_3,]/.0<KO7_ !5S,^>NE3KNGCS3M)<NG*Z@B91=PX6B#JK+*&$3**J',<YA
M$QC"(B.<HHHX(V0PQLBBB8V...-H8QC&-#6,8UH#6M:T     !=LTTL\LDTS
MW22RO<^1[CNYSG'<D_+V ; #8   !:!?3"].DH@8O$/+P"'W#^PO1/\ J7.Q
M=:KB],7TS>676E]PFWUQ'J$UG3ZZZ;2K([)TO7OM@-<)[*D2T4L0,[#"Z_!0
MD&"!*W\N/V>$:5,&0?!\>7U'T^/S^I<N)W<X^?DX_4?,K'@],/TZ@'R'$7+_
M )_J8HO_ %-D\3OPC[2I$D@['O\ XQ^U=J:<$<AQ?V4VA-%T>NP4.U79-:A7
M8TL'2CMG)U5%TG-3C#-H18BIUUC*D,S!-<5#_,$5 1#*AD=":6RN:BU!?Q44
M^3B=$\S&25L<TD/"(9+$#7B&9\8:T-+V'<-;Q\7"-JY<TM@;]\Y*WCH)K3W!
MTKG \$[VM#0^>($1S.X6M:2]IX@T!VZZN/IC>G:(B(\2<P"(B(B(Z8H@B(C]
MXB/V+]1'\X_GRX]8_P#"/<.WN'8/5Z%9.MD_#=\AV^CZ%%CN/TRN*T.->IEM
M4<1Z%#9J>@=K'H TO2U3&WA;RTN8-7AK 14*$G]NA* V&*^0_??SH(_ _=/;
MD%SCVN<?E)]']?SJ#+(X$%[B#V[D\_6N[\T>F-PJKSGH52]\1<\#=CZ:UF:W
MC8M+T[\(!LQJ;##.C.?.PWSGVN,H+H9'YO\ ?/S8K?'_ '3W9'$>S<[>L_;Z
MU'62?AN[QR<=MO-MOYMN78LW?BP_3J_Q(N7Q_ITO1!_UPN"2>TGVE.)WX3O:
M?M3\6'Z=7^)#R]_DTO1 _P!4+D*.)WG/M*?BP_3K\>/VD7+_ (_J7HO_ %-_
MF_1^;";GSGVJ%O</%&IM45CF%'DWF:H49>Q]R<W1NW4-+:V81!I/3R\M.)7H
MMT1K$:D4U.!D+8D\\D"@T0;F3!==,IP V)R>"PV8,#LMBJ61=5+G5W6X&2NA
M+MN+@)&_"XM&["2QQ ):2 5B\CAL1EG0OR>/JWG0;]2ZPSB<P$ASFAS2USHW
M%N[HG%T3N9<PGFIKK^F5Z>+I=9RYXHYE<.7*JB[APOIRD*KKKJG%159952',
MHJJH<QCJ*',8YSF$QA$1$<RK6M8T-8UK6M :UK0&M:UH #6M
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MIC^G<H<RBG$O,)SG,8YSGTS13G.<PB8QCF-#"8QC"(B8QA$1$1$1$1RT!S@
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M13_PB81,(H+>H/Q4MWOHDNA'&[[WI&M/K5#6&UOJ)%P4LXN49"?&7;5"P,;
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MP,'_ "<7Y13W@H?M_1]D7]*3\:?TQ_);])_K]D_N?_-__GG'P?X'_/\ P?\
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MY1<PK]\A'O'C0Y5EHYH(@02*46$3")A$PBA]KSNOF_;/5>R>.=:W0+MM[4-
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9,(F$3")A$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sttk-20211231_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "1P  !T(          0
M                   !              ="   "1P
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "1P    !29VAT;&]N9P
M!T(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   D<     4F=H=&QO;F<   ="     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3001       ! 0 X0DE-!!0       0    *.$))300,     !GW
M     0   *     R   !X   7<   !G; !@  ?_8_^(,6$E#0U]04D]&24Q%
M  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U3
M1E0     245#('-21T(               $  /;6  $     TRU(4" @
M                                                           1
M8W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0
M   4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9
M E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M
M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,
M9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I
M(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-2
M1T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M     %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N
M8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                9&5S8P
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO
M=7(@<W!A8V4@+2!S4D="                             &1E<V,
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ                                  !V:65W
M   3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4
M %<?YVUE87,          0                        */     G-I9R
M    0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [
M $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D
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MAG#@<3IQE7'P<DMR
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" "[ E,# 1$  A$! Q$!_\0 '@ !  $$ P$!
M          @%!@<) @,$"@'_Q !B$   !@$# P(# P4)!PT+#0 ! @,$!08'
M  @1"1(3%"$5,4$6(E$7(S)A<0H8&21"@9&Q\"4W4G*AP=$G,SA6=G=XDI>U
MMK?6)BA'4U1869BBU.%#1$5&8F-UAI6EQ-/5_\0 '0$!  $$ P$
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MC9[7HVK01E651</'L@Z%94SI\N D22(4?CY^NGH]5@&G]'O<'4;CB"M([F:
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M$G R6\+2,@- )"D)A/=3-U-TA 9)>O)^K*F!-O85^]U-U\QAX#UQB 9:5B@
M>!4X,]9@ &$RZ7(%OK1_:95VV1EOU%-+6V]Y CN+\OJZ(EV )\#-13[_ %\=
M[$&Y<7MY8RU_V/4-VBDN6E:>&WW=@+Y;7&6Q4-R:,DFF#BUE)6'&1&"V"8\0
M:&/X<[*(:=AK%'MY6#DV4K&NDR*MWK%RDX05(<H&*('3,8 '@0Y*;M,4?80
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MFZEFY3;/4MRLK3K36;I8,<4.K6]T1K%&N>1:9!/FB2,DL1RC#(LT/BTBH=J
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M '(B #VP0354T=/3Q23SS/$<4432^21[N36M:"23]PR3L"N$DC(F.DD<UC&
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M2S0O>[C8*5?MB<"8#KLV*[A$HE#Y@*B90$..1 1#5)7S/IJ&MJ(P#)!25$S
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MDFI3G)W_ (>L=.?V+*S+8C6F;&89!?YLY9?)FV+))E!AV)10<;9ZU1JU%Q0
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MJ.-WF'JQBRA06*Y)G(Q\ECV,JT.TJ$DSF"F)*MY""2:%CWQ)(IS%?>J15,Z
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MKI1N=V5UV, <*HJI@4K%0=('J/F, ?O5<D!W& .1;QG "(\<B/Q'V#W]Q'V
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MDQA  #4.<UH]X@ [;]?)<@QTA+61NE< 7%K&ES@UH)<X@ D!HW)Z#==WR]N
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M78'5NK_\K;KE$/\ %EJP?_\ DE'4'L*J>FL;"?C3W ?A"?7P4_WS5)MG06I
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M$T1-$31%CC)&8,78>C64OE*^U:@QDD[%A'OK1+M(EN\>%3\QF[8[I0@+*$2
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M-$5L7&XU^AUZ0L]F?$81,<F!U5!*91590X@5%JU03 RKETX4$$T$$BF.H<0
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M\1C*DW4+I"7UH9LZ:-TI-J*2[F*<E*LF)DC 8CUD)^14334 # (AY$#"7NY
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M^8AKU&-^3IL@Y?;I<I&>N$B+NQ9S"39IZA8H** U;E:E*@W 3<)I   0OW0
M   UC+]8;V[#C=*D$[GWAC?ECW#C;&W0YV6\?]#W9FSW&:(L9:SW 74P<[W=
MO><^3B<=LDDDD\R2O2'42WT@/(;H\M?_ *^3_P!VT_3][!R+K4Y_Z?+;'(,
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M0#AW8SPY'%P_L]W</(>)&,[+9J3LF[*NZE[G2VF^],4G=&6H/=B4L=W1DQ5
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M&9IGPETOMO?NQEKFM$1A (!/%L2 !FZK=>A>+4VDBI'65T%>;K)*7"JBG:V
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M'?\ ?)9OY_OPV'Y<#W#4C?K']*!-SS_-S]=66.V;M. VUM>/+,U+CYCN1CX
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M!L,!;[-:U@PT?Q7:'/(<?/D./V\ZX+DM@.TG ]/W"[?,P4#(C!=U3)/)I7D
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MYC@X ^+78PX<B"05072VTMXMU;:ZZ/O*2OII::=G(F.5A:2T_NO;GB8X;M<
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M@@ AP/N Z<T6NO=#M\90;62RC2&Q6K,BPO+C (% C9-%4_"]@C4R@!6YTE#
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M'ZG7GN=N7@MW6_2KT"1Q.M&IFN<>(M$- [A+MRWB-7[V#D<6!Q<\#.!^_P
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MB#L>NRIJ,0P2BRPRB1GD<")VYT7YS/#+)',8Q@746[CJ&Y,(@8P]Q?82B @
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M;2Z9NFS7[+U^S6!C7WEP>BZ$"JQ-;4D4)*8(F(*I1:3MT7D&Y@$BU>9,WQ9
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MH&7HV^W:7ODM1Q:W^N-\03",+3$*EC!M,P:<P=X=VZ39HO55G+-,C1XX/YQ
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M8.%U$4$3*ID.=7L[3' ..?;6JLEOKX*9M7-0U<-(Y[8VU$L$C(2]P)8QKWM
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M.3N\Q4J^SA)+(]I4NMU=-17%2P6A:-81"DP\!950H.3QT6P:B"!4DO&V3X3
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MFA@(&V6U)4Z:(OPC5B+W0^Z_==D6Z.<*UO,&/X)[0F6ZXDKF.-QDUL#7*8X
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)1$T1-$31%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771902520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Shattuck Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2575858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 W. 5th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-4690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STTK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,080,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,363,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2022, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627777341048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Austin, Texas<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771970568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 92,268<span></span>
</td>
<td class="nump">$ 157,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">176,536<span></span>
</td>
<td class="nump">177,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">19,462<span></span>
</td>
<td class="nump">10,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">288,266<span></span>
</td>
<td class="nump">345,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,938<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">298,585<span></span>
</td>
<td class="nump">348,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,012<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">14,574<span></span>
</td>
<td class="nump">7,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,586<span></span>
</td>
<td class="nump">16,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue - related party, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,799<span></span>
</td>
<td class="nump">39,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0001 par value: 300,000,000 shares authorized, 42,338,898 shares issued and outstanding at December&#160;31, 2021 and 41,779,183 shares issued and 41,767,431 shares outstanding at December&#160;31, 2020</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">389,408<span></span>
</td>
<td class="nump">382,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(117,067)<span></span>
</td>
<td class="num">(72,093)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">271,786<span></span>
</td>
<td class="nump">309,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 298,585<span></span>
</td>
<td class="nump">$ 348,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities And Employee-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627777177480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - Parenthetical - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,338,898<span></span>
</td>
<td class="nump">41,779,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,338,898<span></span>
</td>
<td class="nump">41,767,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776008440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 30,017<span></span>
</td>
<td class="nump">$ 9,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">56,563<span></span>
</td>
<td class="nump">37,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,723<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expense from operations</a></td>
<td class="nump">75,286<span></span>
</td>
<td class="nump">46,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(45,269)<span></span>
</td>
<td class="num">(36,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,974)<span></span>
</td>
<td class="num">(36,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investments</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (45,471)<span></span>
</td>
<td class="num">$ (36,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">42,032,384<span></span>
</td>
<td class="nump">15,506,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,032,384<span></span>
</td>
<td class="nump">15,506,067<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627768518184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Series A Redeemable Convertible Preferred Stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Series A Redeemable Convertible Preferred Stock </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Series B Redeemable Convertible Preferred Stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Series B Redeemable Convertible Preferred Stock </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Series B-1 Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Series B-1 Redeemable Convertible Preferred Stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Series B-1 Redeemable Convertible Preferred Stock </div>
<div>Additional Paid-In Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,093,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Sale of redeemable convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,319,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Sale of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock', window );">Conversion of redeemable convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,093,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(550,571,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,319,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock', window );">Conversion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (82,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (34,548)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="num">$ (35,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,487,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,771,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,041,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,064<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 49,063<span></span>
</td>
<td class="nump">$ 34,427<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 34,426<span></span>
</td>
<td class="nump">$ 82,613<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 82,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,664,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost</a></td>
<td class="nump">213,530<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">213,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of common stock previously subject to vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investments</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,767,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 309,861<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">382,012<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(72,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">557,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of common stock previously subject to vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investments</a></td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod', window );">Exercise of stock options and ESPP purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased', window );">Exercise of stock options and ESPP purchases</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,338,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 271,786<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 389,408<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (117,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities Into Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Value, Conversion Of Convertible Securities Into Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627772169624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,974)<span></span>
</td>
<td class="num">$ (36,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,467<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premium on short-term investments</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(9,272)<span></span>
</td>
<td class="num">(6,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="num">(1,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">6,924<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue - related party</a></td>
<td class="num">(29,034)<span></span>
</td>
<td class="nump">6,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_IncreaseDecreaseInDeferredRentCredits', window );">Deferred rent</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,116)<span></span>
</td>
<td class="num">(33,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(7,926)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and maturities of short-term investments</a></td>
<td class="nump">201,575<span></span>
</td>
<td class="nump">37,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(204,092)<span></span>
</td>
<td class="num">(183,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(10,443)<span></span>
</td>
<td class="num">(146,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the exercises of stock options and ESPP purchases</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from the initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">232,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">330,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(65,630)<span></span>
</td>
<td class="nump">150,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">157,898<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">92,268<span></span>
</td>
<td class="nump">157,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash financial activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized loss on short-term investments</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid amounts related to purchase of property and equipment</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,738)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sttk_SeriesB1PreferredStockMember', window );">Series B-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from sale of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from sale of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_IncreaseDecreaseInDeferredRentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Deferred Rent Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_IncreaseDecreaseInDeferredRentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sttk_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sttk_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627774988776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has two clinical-stage product candidates, SL-172154 and SL-279252, and has several compounds in preclinical development.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $117.1 million as of December&#160;31, 2021. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents and short-term investments of $268.8 million as of December&#160;31, 2021, are sufficient to fund projected operations of the Company for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and in which the Company&#8217;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While the Company has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company&#8217;s continuity plans will be successful. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has already experienced disruptions to its business such as work-from-home orders for offices and similar disruptions have occurred for its partners. Specifically, the outbreak has caused disruptions in its ability to manufacture clinical trial materials, including the acquisition of raw materials needed for such manufacturing, enrollment and treatment of patients in clinical trials in process, and slowdowns and shutdowns of the laboratories and other service providers that are being relied upon in the development of the Company&#8217;s product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic or any other health epidemic may impact the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to mitigate its impact, among others. Accordingly, the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s business, results of operations and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775047624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates. A change in the Company&#8217;s estimates occurred in the second quarter of 2021, which impacted the Company&#8217;s revenue recognition and related balance sheet accounts.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), which was mutually terminated pursuant to the termination agreement, dated November 8, 2021. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on one third-party contract manufacturing organization (&#8220;CMO&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on three contract research organizations (&#8220;CROs&#8221;) and a limited number of third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $14.6 million held in operating accounts and $77.7 million held in money market funds as of December&#160;31, 2021 and $2.7 million held in operating accounts, $80.2 million held in money market funds and $75.0 million held in government obligations as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of highly-rated U.S. Treasury securities with maturities of more than three months but less than one year at the date of purchase. The Company classifies its short-term investments at the time of purchase as available-for-sale securities. Available-for-sale securities are carried at fair value. Credit impairments for available-for-sale debt securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2021, there were no impairments related to credit losses of short-term investments.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded against gross proceeds.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of stockholders&#8217; equity on the balance sheet because the shares contain liquidation features that are not solely within the Company&#8217;s control. Upon the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in the fourth quarter of 2020, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into common stock.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"/><td style="width:62.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Rent</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense on a straight-line basis over the term of the leases and, accordingly records the difference between cash payments and the recognition of rent expense as a deferred rent asset or liability. Incentives granted under the Company&#8217;s leases, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the leases.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract which would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgements and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations. </span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee Board members as compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company adjusts expense for forfeitures in the periods they occur.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible notes, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on short-term investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes: Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU removes certain exceptions to the general principles in ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year, with early adoption permitted. The Company adopted this pronouncement effective January 1, 2021 and it did not have a material impact on the financial statements or related disclosures.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements (not yet adopted) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective </span></div>transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The FASB deferred the effective date of this ASU until the annual periods beginning after December 15, 2021. The Company expects that the most significant effects of adopting this standard will primarily relate to (a) the recognition of right of use assets and lease liabilities on the balance sheet in relation to its existing operating lease agreements in Austin, Texas and Durham, North Carolina; and (b) providing significant new disclosures about leasing activities. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627774980520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-Term Investments</a></td>
<td class="text">Short-Term Investments<div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available for sale short-term investments by major security type (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have an average maturity of 0.43 years as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775057192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2021 and 2020 was $1.4 million and $0.6 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775008104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued ExpensesAccrued expenses consisted of the following (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776045000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future minimum payments, by year and in aggregate, under non-cancelable operating leases consist of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized rent expense of $0.7&#160;million and $0.4 million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heat License Agreement</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a license agreement with Heat Biologics Inc. (&#8220;Heat&#8221;), the Company is required to make payments of up to $20.6&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products.&#160;The Company is required to pay Heat a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents.&#160;The Company is also required to pay Heat a royalty on all of its worldwide net sales, those of its affiliates and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the payments aforementioned given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company&#8217;s officers and directors. In each complaint, the plaintiff cites the volatility in the Company&#8217;s common stock and alleges that the defendants made or are responsible for false or misleading statements regarding the Company&#8217;s collaboration agreement with Takeda. The plaintiffs in both lawsuits seek a ruling that the case may proceed as a class action, and seeks unspecified damages and attorneys&#8217; fees, expert fees and costs. The Company and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against these lawsuits.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div>Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776068776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text">Preferred StockDuring the year ended December 31, 2020, the Company entered into various stock purchase agreements with new and existing investors pursuant to which the Company sold an aggregate 550,571 shares of Series B redeemable convertible preferred stock and 1,319,964 shares of Series B-1 redeemable convertible preferred stock at $62.88051 per share for net proceeds of $117.0 million.The Company&#8217;s Series A, Series B and Series B-1 redeemable convertible preferred stock converted into common stock upon the completion of the Company&#8217;s IPO in 2020 and the rights, preferences, and terms are no longer applicable<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775141304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement - Related Party</a></td>
<td class="text">Collaboration Agreement - Related PartyThe Company recognized revenue for the allocated up-front payments using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company used actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. In August 2017, the Company entered into a Collaboration Agreement with Takeda related to the development of certain ARC molecules, as amended in April 2018, October 2018 and March 2020 (the &#8220;Collaboration Agreement&#8221;). The Collaboration Agreement was mutually terminated pursuant to a termination agreement dated November 8, 2021 (the &#8220;Termination Agreement&#8221;). Under the terms of the Termination Agreement, the Company is not required to satisfy any remaining performance obligations, the Company will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. The remaining deferred revenue was recognized as revenue in the fourth quarter of 2021. The Company received cash of $3.6 million and $14.0 million in the years ended December 31, 2021 and 2020, respectively, and recognized total revenue of $82.0 million through December&#160;31, 2021 under the Collaboration Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776068776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#8217;s outstanding common shares on December 31st of the preceding calendar year. The Board of Directors may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. As of December&#160;31, 2021, there were 3,912,408 shares available for future grants under the 2020 Plan and on January 1, 2022, the share reserve automatically increased by 1,693,555 shares. The 2020 Plan permits the granting of options and restricted stock. The terms of the agreements under the 2020 Plan are determined by the Company&#8217;s Board of Directors. The Company&#8217;s awards vest based on the terms in the agreements and generally vest over four years and have a term of 10 years.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) became effective in connection with the Company&#8217;s IPO. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. As of December&#160;31, 2021 there were 393,689 shares available for future purchases and on January 1, 2022, the share reserve automatically increased by 423,388 shares. Under the 2020 ESPP, the Company issued 2,106 shares of common stock for aggregate cash proceeds of $0.1&#160;million during the year ended December&#160;31, 2021. There were no shares of common stock issued during the year ended December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan and the 2016 Stock Incentive Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418,923&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.88&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.55</span></td></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the years ended December&#160;31, 2021 and 2020 had weighted-average grant-date fair values of $16.38 and $8.93 per share, respectively. As of December&#160;31, 2021, the unrecognized compensation cost was $11.4 million and will be recognized over an estimated weighted-average amortization period of 2.48 years. The aggregate intrinsic value of options exercised as of December&#160;31, 2021 and 2020 was $10.8 million and $49.7 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&#160;31, 2021 was $5.9 million.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, its Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options granted under the Company&#8217;s 2020 Plan were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"/><td style="width:43.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted shares are considered the issuance of share-based payments as opposed to the sale of stock and as such, the Company has recognized compensation expense for these awards based on the fair value of the award on the date of grant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to these shares:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued under the Company&#8217;s 2020 ESPP were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"/><td style="width:43.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627859071368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded no federal provision for income taxes as of December&#160;31, 2021 and 2020 due to reported net losses since inception. The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows for the years ended December&#160;31, 2021 and 2020 (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,687)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are as follows (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $13.0 million and $8.7 million during the years ended December&#160;31, 2021 and 2020, respectively, primarily due to continuing loss from operations, general business credit carryforwards, and accrued expenses.</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had gross U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of $97.4 million and $47.1 million, respectively. Additionally, as of December 31, 2021 and 2020, the Company had capital loss carryforwards of $2.3 million and $0.1 million, respectively. As of December&#160;31, 2021 and 2020, the Company had gross state NOL carryforwards of $0.2 million and $0.2 million, respectively. As of December&#160;31, 2021 and 2020, the Company had gross U.S. tax credit carryforwards of $7.6 million and $4.5 million, respectively. The NOL, capital loss, and tax credit carryforwards will begin to expire in 2036, if not utilized. The NOL, capital loss, and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or credit carryforwards are utilized.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2019 financial statements were filed, the Company completed a Section 382 study from formation through October 14, 2020. Although an ownership change occurred during 2020, no deferred tax assets were impacted by the limitation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of our liability for unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:65.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s gross unrecognized tax benefits, if recognized, would affect its effective tax rate. The Company does not expect unrecognized tax benefits to decrease within the next twelve months due to the lapse of statute limitations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December 31, 2021, the Company has not accrued any interest or penalties related to unrecognized tax benefits.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2018, 2019, and 2020 tax years. There are currently no federal or state income tax audits in progress.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775118456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party</a></td>
<td class="text">Related PartyAs of December 31, 2020, Takeda held an approximate 5.0% ownership interest in the Company&#8217;s outstanding shares. Considering the resignation of the Takeda director and percent ownership of the Company&#8217;s common stock as of December 31, 2020, the Company no longer considers Takeda a related party.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776045560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsNone.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627773550216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates. A change in the Company&#8217;s estimates occurred in the second quarter of 2021, which impacted the Company&#8217;s revenue recognition and related balance sheet accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), which was mutually terminated pursuant to the termination agreement, dated November 8, 2021. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on one third-party contract manufacturing organization (&#8220;CMO&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on three contract research organizations (&#8220;CROs&#8221;) and a limited number of third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $14.6 million held in operating accounts and $77.7 million held in money market funds as of December&#160;31, 2021 and $2.7 million held in operating accounts, $80.2 million held in money market funds and $75.0 million held in government obligations as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of highly-rated U.S. Treasury securities with maturities of more than three months but less than one year at the date of purchase. The Company classifies its short-term investments at the time of purchase as available-for-sale securities. Available-for-sale securities are carried at fair value. Credit impairments for available-for-sale debt securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2021, there were no impairments related to credit losses of short-term investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded against gross proceeds.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of stockholders&#8217; equity on the balance sheet because the shares contain liquidation features that are not solely within the Company&#8217;s control. Upon the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in the fourth quarter of 2020, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into common stock.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"/><td style="width:62.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Rent</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense on a straight-line basis over the term of the leases and, accordingly records the difference between cash payments and the recognition of rent expense as a deferred rent asset or liability. Incentives granted under the Company&#8217;s leases, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract which would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span> and will recognize the payments received from these agreements as revenue when the related costs are incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div>A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgements and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee Board members as compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company adjusts expense for forfeitures in the periods they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible notes, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on short-term investments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements (not yet adopted)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes: Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU removes certain exceptions to the general principles in ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year, with early adoption permitted. The Company adopted this pronouncement effective January 1, 2021 and it did not have a material impact on the financial statements or related disclosures.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements (not yet adopted) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective </span></div>transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The FASB deferred the effective date of this ASU until the annual periods beginning after December 15, 2021. The Company expects that the most significant effects of adopting this standard will primarily relate to (a) the recognition of right of use assets and lease liabilities on the balance sheet in relation to its existing operating lease agreements in Austin, Texas and Durham, North Carolina; and (b) providing significant new disclosures about leasing activities. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467743&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627778057640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of property and equipment depreciation periods</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"/><td style="width:62.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property Plant And Equipment Estimated Useful Lives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627774958504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available for sale short-term investments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available for sale short-term investments by major security type (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776067112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776056600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text">Accrued expenses consisted of the following (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775147528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments for operating leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future minimum payments, by year and in aggregate, under non-cancelable operating leases consist of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627859101800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan and the 2016 Stock Incentive Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418,923&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.88&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.55</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options granted under the Company&#8217;s 2020 Plan were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"/><td style="width:43.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued under the Company&#8217;s 2020 ESPP were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"/><td style="width:43.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to these shares:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627777989640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of income tax reconciliation</a></td>
<td class="text">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows for the years ended December&#160;31, 2021 and 2020 (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,687)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are as follows (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of our liability for unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:65.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771899752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 117,067<span></span>
</td>
<td class="nump">$ 72,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 268,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627772111016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairments of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">92,268,000<span></span>
</td>
<td class="nump">157,898,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember', window );">Operating Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">14,600,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,700,000<span></span>
</td>
<td class="nump">80,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627772120664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771967208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">2,448,676<span></span>
</td>
<td class="nump">2,753,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">2,448,676<span></span>
</td>
<td class="nump">2,742,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771970248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Schedule of available for sale short-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 177,096<span></span>
</td>
<td class="nump">$ 177,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair&#160;Value</a></td>
<td class="nump">176,536<span></span>
</td>
<td class="nump">177,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">177,096<span></span>
</td>
<td class="nump">177,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair&#160;Value</a></td>
<td class="nump">$ 176,536<span></span>
</td>
<td class="nump">$ 177,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775123208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, average maturity term</a></td>
<td class="text">5 months 4 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775846072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 12,718<span></span>
</td>
<td class="nump">$ 4,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(2,780)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,938<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,823<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,521<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776904424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627777125720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_AccruedResearchAndDevelopmentContractCostsCurrent', window );">Research and development contract costs</a></td>
<td class="nump">$ 10,253<span></span>
</td>
<td class="nump">$ 5,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">3,320<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 14,574<span></span>
</td>
<td class="nump">$ 7,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities And Employee-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedResearchAndDevelopmentContractCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Contract Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedResearchAndDevelopmentContractCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771885720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of minimum lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 1,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 7,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627777910056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_LicenseAgreementRoyaltyPaymentsMaximum', window );">License agreement, maximum payment</a></td>
<td class="nump">$ 20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_LicenseAgreementRoyaltyPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_LicenseAgreementRoyaltyPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627772050840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received | $</a></td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares) | shares</a></td>
<td class="nump">550,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of preferred stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 62.88051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sttk_SeriesB1PreferredStockMember', window );">Series B-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares) | shares</a></td>
<td class="nump">1,319,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of preferred stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 62.88051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sttk_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sttk_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627768496184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Related Party (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 30,017<span></span>
</td>
<td class="nump">$ 9,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sttk_TakedaMember', window );">Takeda | Investor | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sttk_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sttk_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627769098072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th">
<div>Oct. 14, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from stock plans | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.38<span></span>
</td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="nump">$ 49,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,912,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,693,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,795<span></span>
</td>
<td class="nump">393,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock in percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Contribution limit in percentage of employee's eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue', window );">Maximum value of shares per employee during any calendar year | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee during any one purchase period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm', window );">Share-based compensation arrangement by share-based payment award, annual increase in number of shares authorized, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">423,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775940344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,467<span></span>
</td>
<td class="nump">$ 1,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,267<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627771995112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, beginning balance (in shares)</a></td>
<td class="nump">2,742,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted (in shares)</a></td>
<td class="nump">325,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised (in shares)</a></td>
<td class="num">(557,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited (in shares)</a></td>
<td class="num">(61,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, ending balance (in shares)</a></td>
<td class="nump">2,448,676<span></span>
</td>
<td class="nump">2,742,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, vested and expected to vest (in shares)</a></td>
<td class="nump">2,418,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable (in shares)</a></td>
<td class="nump">1,259,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">23.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in dollars per share)</a></td>
<td class="nump">12.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">10.96<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">10.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 6.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted&#160;average remaining contract life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted&#160;average remaining contract life, outstanding</a></td>
<td class="text">8 years 29 days<span></span>
</td>
<td class="text">8 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, vested and expected to vest</a></td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, exercisable</a></td>
<td class="text">7 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627772109240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of 2020 Plan valuation assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.40%<span></span>
</td>
<td class="nump">75.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627768992040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details) - Employee Stock - 2020 Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627858973912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of restricted stock activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, beginning balance (in shares)</a></td>
<td class="nump">11,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards, vested (in shares)</a></td>
<td class="num">(11,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627769073416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of effective income tax rate reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit computed at federal statutory tax rate</a></td>
<td class="num">$ (9,445)<span></span>
</td>
<td class="num">$ (7,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">13,045<span></span>
</td>
<td class="nump">8,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment', window );">Return to provision adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(3,108)<span></span>
</td>
<td class="num">(1,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount', window );">Other permanent differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1,923)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M', window );">Section 162(m) limitation</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Change in uncertain tax position</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Permanent Differences, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return To Provision Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627773598216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 20,460<span></span>
</td>
<td class="nump">$ 9,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">3,520<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit carryforwards</a></td>
<td class="nump">6,194<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">31,437<span></span>
</td>
<td class="nump">17,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(30,331)<span></span>
</td>
<td class="num">(17,285)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(578)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627773598792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">97.4<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627776924792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of unrecognized tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for tax positions related to the current year</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase for tax positions related to prior years</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="nump">$ 1,404<span></span>
</td>
<td class="nump">$ 783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140627775047624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=sttk_TakedaMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sttk_ShareholderOwnershipPercentage', window );">Shareholder ownership percentage</a></td>
<td class="nump">0.050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareholderOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholder Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareholderOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sttk_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sttk_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>sttk-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:sttk="http://www.shattucklabs.com/20211231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sttk-20211231.xsd" xlink:type="simple"/>
    <context id="i37b06acb50a449ef9343f66141212130_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id391983719f643a293d7ebe4bde080c8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9e4df91ba02947e29a776bfdd375a444_I20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93d907eb546d4b419a06e844b32e0c37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6085e2e606c14212b39aba95286e4bee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa3d82eadadb40ab92d3249bab64bf52_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b2ca173e0004d11919d92632a37774d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e12961d654945e09068f8b39b05845b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dae071f8e3d4bec9f3b7ed2455cd014_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief9145f0685d40abb21ee4ec19d9937f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2e6543ccfb74775ac5df4a5733524f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia24b53685d3540c7a804b8f394e399a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i108a91c3f6de49d7ad25831cb4cbbac8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia46bf273b1e0431682728738c320b383_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d28057558bb4a0295c8315232a69252_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82048836e6fa4e5aa557a2623e6ff0f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a3683f766ae45e09c86c03f022c9e01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8eaebef00de14f10b1d30533510da470_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d204922a202445caae9e3f732504db5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic115a1576f394c55b1a7bb9b66af7321_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if11f7173c81c46b2b06d4f80310b846d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic14f82c5bd594e0c86f407f962585613_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaac2c9de295f4a84843194e8e6f933cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bb89c4e37124b489c0152e257cc9e7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafbad4a0cb66454aa263e9cc4b0b02cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae4c24644ef446b38a0bc1bd5b7b9dad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b7b805cabed4fef89935fc4a01cc352_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1da23b727bc545ce8a8626f9c21738f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2978472561c24d05b2c48b66c0b36df6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3f0d368be5c4c9cbee436c3481aa483_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b8eeb11b3ac40f1b3c9e84a79462ae7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie30e987b03ab4ec59ff05cf3acc5e3a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55c9db39c55b45f684b6bf134143d66a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7c736cc6e69478988dbcd443d316c34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314de4ca010e41458b9633658578103b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if34e74c583cf482a8c7f8c3fdc28de97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83035001040e4d90ac2aa8830614906e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cbb284a8c1342259be91fd8741fe70a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0f3fa86426e412a8755fb1b72e9c76a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21a6c00e553649a9a7fd199a899a8098_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sttk:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ef03e1dffea436194212535f30c3f7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifcfc895622274a9fa067f83a85414b73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bc6f8f8312648d79a5c147096aa6201_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7e8869244b74fc28985b69bc05e3793_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id283059be4d44a2e824a82620e3e234d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i524cc2fcaa1e4182b2577f5ace25f6fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0256d931b38f4e8ebd1fafc29f3baef9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d2830e52a30463b83b72e983bfd983c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82c95f2381594579b82d242587361ef8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i199bf9783e444bf89f2a5c5f09e19ee1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8507d1aa293d4d058b8d4ea3b458979e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4739b7937ffb414cba8e7cf3495311be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56b4d224548b44d2b88ff83fa65e5ba7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34cfe1bf8a0f4d1e8923ff1731e97dc4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i022cbf9c4d41418ca5d4cc35b286630f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6b150d14a3340bdbbda062f1916514e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7705c519eda74dc58737c23718104aaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia854a6038a4a4bb088d1e1adb51da387_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifef12007a5ff492690c14861cd4a497c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dc2651a89a543bbaf7e68cc3e676d0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c94c0bd8ebb4b1bb951ba7df8bdb437_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide31a45817b8402c950886d450a9c631_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4178f0dec2b24b44bad57c8e7393db7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0e6a315dca248c9aa85cda7c35059e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d2329b727b8467788e859b46061df44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd9021bd3124402f8714a57978b7021a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06b6ab46fb514d5d8d7aa64487be02ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c436ab0261649adb338c58e3639b366_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia94f371b06b64697b125dc4b3ab1f16a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83fa63cc109d410793fee3147230e084_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1717f2eaa0f544379a47d6697e8ce5e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfaa1273d97b46978197a4b2f339b0ec_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="ifa51a2a2b1c84fdfa550195209974723_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8842228fdf1940c7b1002d140baf64ed_I20201014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-14</instant>
        </period>
    </context>
    <context id="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-14</endDate>
        </period>
    </context>
    <context id="ibd7daecd893b478db292941cdfb8d361_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iaf6c1f46b13448baa40f5da3fc4f9b3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i913ac2af34fd4ec98af9b2bb3e0c81da_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i285a21f9461d4185ba105fc77795dd4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied1cbb318d64475ea98211bc07f51f73_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie81735796faf4a8a9e36cbc592eb5f3d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i978d55b8117440bcb06be5d1eba9a7db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6a0ec0b83ac44b2a0e7939e7f49c2e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dd78bd931e046948447da6b4292615e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76d2b249a41e4985a2641c447e8e27d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1853d269d625472aa52bdf974466c9d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43ef9bb233dc4b89a2c5f083ab045bbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfb12636928d4d21b00a09885bc9f550_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i592680b58da94f418a342d39beb4d6a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1394695528d34d00a6380d9c1031687d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56b14739a6c64b198bf3d0441927bd8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e068c367ec34e2ab303dcd0a6d4da40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e4714dd5ac54741bc7b7aa1ad1ce320_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic68499c9c9c54c7ca37c93a1819e89f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sttk:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF8zLTEtMS0xLTA_469d06e3-2bc5-4ed8-ba57-237abd82d33b">0001680367</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF80LTEtMS0xLTA_58f9f2a0-98e3-4400-ab71-7b6303a384b5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF81LTEtMS0xLTA_c0ea591e-b557-48a1-9e30-736d236b33c1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y180L2ZyYWc6ZDljNGQ3YWQ0ZDZlNDFmNTliMTI4YmVhMGVjZTUzMDMvdGFibGU6ZWYwMDBhNTg4ODIxNDcyN2FlNmRmODEwYTZiMzA5NjQvdGFibGVyYW5nZTplZjAwMGE1ODg4MjE0NzI3YWU2ZGY4MTBhNmIzMDk2NF82LTEtMS0xLTA_10580521-eae6-429f-b27f-74a7e0572e38">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0wLTEtMS0w_31f163b6-9c40-4353-9e20-429d03b53ecd">http://fasb.org/us-gaap/2021-01-31#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0wLTEtMS0w_5cd945f9-9202-4d21-9fbf-20327c19355b">http://fasb.org/us-gaap/2021-01-31#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTU5_ba93af6e-610a-4e5f-9e03-27b6f6464c79">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YTc1NWZlYTY0NmMwNGY4Zjg4ZWJiMjAxODllMGIwOTYvdGFibGVyYW5nZTphNzU1ZmVhNjQ2YzA0ZjhmODhlYmIyMDE4OWUwYjA5Nl8wLTAtMS0xLTA_c8c1ba07-ea03-4c83-b418-25ba8f5e3518">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8xMzA_cbe30ab4-e7c0-4250-a74c-54efbf8245f8">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8xMzA_11d8685c-3083-4d78-9c2b-235d51e34733">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZWViYTY1YzgwNzBhNDlkMGI4YjM5ZjEyZTBmNjM1NTEvdGFibGVyYW5nZTplZWJhNjVjODA3MGE0OWQwYjhiMzlmMTJlMGY2MzU1MV8wLTAtMS0xLTA_dfba2f95-2e86-4542-b286-9aa969a17373">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTY3_0d2e5577-b94d-4d6e-b04e-89f321f0df37">001-39593</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTYz_6dbe7a68-eaca-46ba-86cf-3fd24a715bd2">Shattuck Labs, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YmZkODE1N2YyODcyNDU5ZGEyZTdmMjExNDdiZTVhYzAvdGFibGVyYW5nZTpiZmQ4MTU3ZjI4NzI0NTlkYTJlN2YyMTE0N2JlNWFjMF8wLTAtMS0xLTA_041c1bb2-1ec4-42f5-b7bc-bbcab743613a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YmZkODE1N2YyODcyNDU5ZGEyZTdmMjExNDdiZTVhYzAvdGFibGVyYW5nZTpiZmQ4MTU3ZjI4NzI0NTlkYTJlN2YyMTE0N2JlNWFjMF8wLTItMS0xLTA_0824393b-6d9d-498e-a66f-909201da85e1">81-2575858</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDIw_c1105c09-a962-44d5-958c-11f8a7344867">500 W. 5th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDIy_8f278b0d-1438-4da1-8591-2d2308a38db4">Suite 1200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDI0_0027e5c3-49b5-43cd-84fe-194d155ee86c">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDI1_d442ed42-85c5-40e8-a22c-e7099c03d94a">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDI3_ebb72a50-abf4-4850-b9cf-8fddb46f3a41">78701</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDM0_7a5532a9-3164-48d5-81a6-a7257cabfbe8">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDM4_97dead23-71a9-46fd-94d7-df7723e7098a">900-4690</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZjgzM2E0NzA5MDNhNGU2MWE4ZDVkZDVhMjYyZDRmYjMvdGFibGVyYW5nZTpmODMzYTQ3MDkwM2E0ZTYxYThkNWRkNWEyNjJkNGZiM18xLTAtMS0xLTA_6f6bc9b9-1836-4d9d-8826-9ac99223f093">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZjgzM2E0NzA5MDNhNGU2MWE4ZDVkZDVhMjYyZDRmYjMvdGFibGVyYW5nZTpmODMzYTQ3MDkwM2E0ZTYxYThkNWRkNWEyNjJkNGZiM18xLTEtMS0xLTA_740e5f99-4e8f-4837-8076-886ce356708b">STTK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6ZjgzM2E0NzA5MDNhNGU2MWE4ZDVkZDVhMjYyZDRmYjMvdGFibGVyYW5nZTpmODMzYTQ3MDkwM2E0ZTYxYThkNWRkNWEyNjJkNGZiM18xLTItMS0xLTA_eb2ee0b7-b7f6-4747-9e87-b03715fb9d0a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTYx_1561d737-ebae-4448-a95a-b5ec73783ea8">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTYy_caf168a8-052e-420a-a2ca-bd8377f515d1">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDQw_20c3361a-4e06-4504-9012-2e168656de06">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTY5_17f6f0cc-f646-40b0-a9f8-3e77b00e9366">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YjljNDgyYzYzMWNkNDIxZTk2NzU0Mzg4MjMzZWMwNDYvdGFibGVyYW5nZTpiOWM0ODJjNjMxY2Q0MjFlOTY3NTQzODgyMzNlYzA0Nl8xLTAtMS0xLTA_fcf8adc6-926a-4f69-a782-af7468d2c88b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YjljNDgyYzYzMWNkNDIxZTk2NzU0Mzg4MjMzZWMwNDYvdGFibGVyYW5nZTpiOWM0ODJjNjMxY2Q0MjFlOTY3NTQzODgyMzNlYzA0Nl8xLTQtMS0xLTA_dfb0cd09-ef46-46da-9c51-d309b818b67d">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGFibGU6YjljNDgyYzYzMWNkNDIxZTk2NzU0Mzg4MjMzZWMwNDYvdGFibGVyYW5nZTpiOWM0ODJjNjMxY2Q0MjFlOTY3NTQzODgyMzNlYzA0Nl8yLTQtMS0xLTA_5e2d81fc-1ed1-413c-a898-4491f4fa10d3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTcw_34b1c567-7839-422f-add4-ed022540c752">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTY2_f1641144-e787-43c9-ad8c-9010a1789da8">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zNTcx_518e7333-ddcd-4e6f-978f-2dc244e4bc82">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="id391983719f643a293d7ebe4bde080c8_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5MDYx_bb8d3d21-6ded-43f8-9a3f-58bd0152e48c"
      unitRef="usd">690080047</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9e4df91ba02947e29a776bfdd375a444_I20220301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8xMDk5NTExNjMyNDg3_8834322b-2c23-4f86-bc69-ee09991bb070"
      unitRef="shares">42363901</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xL2ZyYWc6NDgzY2Q1ZGEzYzZmNGQ4ZThiZDI2MWQwYjljOGYyMWYvdGV4dHJlZ2lvbjo0ODNjZDVkYTNjNmY0ZDhlOGJkMjYxZDBiOWM4ZjIxZl8zMjk4NTM0ODg5NjA3_5e113a75-c352-4618-a6a3-6da34eac8212">&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Documents Incorporated by Reference&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2022, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181Mi9mcmFnOjUwYWYyZTBkMTdjMTRlMzlhMjM2MTU3YWMxMmEyMDM0L3RleHRyZWdpb246NTBhZjJlMGQxN2MxNGUzOWEyMzYxNTdhYzEyYTIwMzRfMzI5ODUzNDg4NTY4Nw_9ffd6168-8a06-47d7-a07a-3fc16677f792">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181Mi9mcmFnOjUwYWYyZTBkMTdjMTRlMzlhMjM2MTU3YWMxMmEyMDM0L3RleHRyZWdpb246NTBhZjJlMGQxN2MxNGUzOWEyMzYxNTdhYzEyYTIwMzRfMzI5ODUzNDg4NTY5NA_2cef5c04-9e72-4795-931b-1861abfb03c9">Austin, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNC0xLTEtMS0w_69dcf049-2f54-4d59-8a3b-cda3bce37ab7"
      unitRef="usd">92268000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNC0zLTEtMS0w_b928c8a4-eb56-4104-b9b9-04b7272c4d4d"
      unitRef="usd">157898000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNS0xLTEtMS0w_8ecf89b9-7c14-4ee4-b66a-903b11360e9f"
      unitRef="usd">176536000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNS0zLTEtMS0w_39a9c20e-2653-4e5e-b10a-f6afd7122af7"
      unitRef="usd">177551000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNi0xLTEtMS0w_574245fc-e845-4819-98c4-246baa71cfdd"
      unitRef="usd">19462000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNi0zLTEtMS0w_8fc0d8fb-bbac-4124-8267-83cada4ec227"
      unitRef="usd">10190000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNy0xLTEtMS0w_ba87d4c8-d5d5-4137-b871-16dd97cdaa28"
      unitRef="usd">288266000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfNy0zLTEtMS0w_f1e60539-a07d-43f7-8194-2ef43d2f1896"
      unitRef="usd">345639000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOC0xLTEtMS0w_82235092-81c2-493a-98ba-6af67cd408d8"
      unitRef="usd">9938000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOC0zLTEtMS0w_b546e533-2d22-4c8d-ba71-4ab1377e5181"
      unitRef="usd">3000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOS0xLTEtMS0w_70f4503e-bd5a-41f4-9a79-4810a3656bd6"
      unitRef="usd">381000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfOS0zLTEtMS0w_68eb386a-ba70-4cf0-9e07-315f4a7d83f2"
      unitRef="usd">349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTAtMS0xLTEtMA_3111e5f7-05ed-4f16-a575-a0d06d178e35"
      unitRef="usd">298585000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTAtMy0xLTEtMA_996501d4-5a3e-4cf2-ae63-45d22686b7ad"
      unitRef="usd">348988000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTQtMS0xLTEtMA_8d926b57-2a77-45fa-8d8d-bb49319b533d"
      unitRef="usd">10012000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTQtMy0xLTEtMA_44ecd80f-de28-4378-934b-43285bc05e25"
      unitRef="usd">1754000</us-gaap:AccountsPayableCurrent>
    <sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTUtMS0xLTEtMA_2928ffc6-7b2f-453f-96e5-347b9ea55807"
      unitRef="usd">14574000</sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTUtMy0xLTEtMA_9b39f3ca-6186-48b2-b252-6844a68f735d"
      unitRef="usd">7352000</sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTYtMS0xLTEtMA_bd6da7c6-9c40-4b27-9ee4-f2cde5c44480"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTYtMy0xLTEtMA_ef24076e-3d5b-4f7e-9d24-e946bc2f8f97"
      unitRef="usd">7728000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTctMS0xLTEtMA_da4c2ea7-448b-4a04-9e16-24ad6fd9d33f"
      unitRef="usd">24586000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTctMy0xLTEtMA_57b0e94d-0d5b-4f93-bedf-e1d87e560d14"
      unitRef="usd">16834000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMS0xLTEtMTkxNjI_860becf9-077a-42fb-b12e-c2c9c61cc5cc"
      unitRef="usd">2213000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMy0xLTEtMTkxNjI_dce19839-88e8-4879-be87-eb7496627de0"
      unitRef="usd">987000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMS0xLTEtMA_c0df00bd-31fe-47bd-bda7-c2c83e0b09dc"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMTgtMy0xLTEtMA_6a6c44c3-db32-4b47-b8a0-8acd6fdcfb4a"
      unitRef="usd">21306000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjAtMS0xLTEtMA_32b005f1-534e-4c99-b741-48a728f90968"
      unitRef="usd">26799000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjAtMy0xLTEtMA_e40e899c-5bec-454f-9be4-8459e8e9569f"
      unitRef="usd">39127000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjEtMS0xLTEtMA_ef396d3a-7a0a-4999-a229-94df70b8ebd3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjEtMy0xLTEtMA_ed4b5143-425f-49c8-a6e3-dc11f7c35034"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzE5_6bd5adce-8352-4bc0-80e1-617d812f148c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzE5_d31e9b06-59ff-4136-80a4-8b9295f29f02"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzMz_36fdacee-8d65-4c65-81b8-4c19d3afb10f"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzMz_4f786e65-4843-472b-9f11-a844de765590"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzU1_3e7ce2b5-2d05-4872-b7cf-3661f5c0dd80"
      unitRef="shares">42338898</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzU1_4531bcc4-ebe2-4731-bab9-6f68ba6dadba"
      unitRef="shares">42338898</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3XzYy_7f121abf-883b-45f5-a5b5-f017131f53d4"
      unitRef="shares">41779183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMzMyMzYyOGQyZDQ4MzBiODY0ZjBlMmNlZWU2M2I3Xzkw_cdb101dd-c95c-430b-99b8-b76fdc9c117e"
      unitRef="shares">41767431</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMS0xLTEtMA_d2cdd3f0-4a04-4d3a-a4d8-3d799e6eb588"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjctMy0xLTEtMA_6e81f1e8-2f3d-4a6a-9e25-95b069ff5174"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjgtMS0xLTEtMA_e7442bde-30e1-4e6f-b077-13bf45492442"
      unitRef="usd">389408000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjgtMy0xLTEtMA_941220ac-28e3-4313-ad3a-c21a8c431604"
      unitRef="usd">382012000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjktMS0xLTEtMA_2d7ad700-500c-476d-869c-b1a677eba9e6"
      unitRef="usd">-560000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMjktMy0xLTEtMA_760c48ba-a286-4756-a91e-daf961577a1c"
      unitRef="usd">-63000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzAtMS0xLTEtMA_b32a2e6c-3f29-47c9-96fe-964e10df8ae6"
      unitRef="usd">-117067000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzAtMy0xLTEtMA_c00a53c3-c65e-48ca-bc06-34b9fbdee36e"
      unitRef="usd">-72093000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzEtMS0xLTEtMA_3f5e39c4-d2b0-4cb2-8d9b-92561b7d9e8b"
      unitRef="usd">271786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzEtMy0xLTEtMA_2585d2cc-cfb9-4f1a-a7bc-e2dffb3a7837"
      unitRef="usd">309861000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzItMS0xLTEtMA_1a5e1c52-ebc7-4896-afe7-cf306ac3f3bc"
      unitRef="usd">298585000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181NS9mcmFnOmE2NGZmYmY4Yzg4ODQ3MTI5ZGZmZGVmODRmZDUyY2Q2L3RhYmxlOmYzZTI4ZDc4NmI5YTQyYzg4NDliZjJlYjFlNGVlMWE4L3RhYmxlcmFuZ2U6ZjNlMjhkNzg2YjlhNDJjODg0OWJmMmViMWU0ZWUxYThfMzItMy0xLTEtMA_8d330048-80eb-4c72-ad51-1a5893af6e86"
      unitRef="usd">348988000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0xLTEtMS0w_6334f400-355f-41c1-970e-fde6bd98fcb1"
      unitRef="usd">30017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMi0zLTEtMS0w_5219352e-0d33-4fa8-9ef2-fefa53fc365c"
      unitRef="usd">9934000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNC0xLTEtMS0w_51fb20fb-c4ea-408d-9951-52cd369480d7"
      unitRef="usd">56563000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNC0zLTEtMS0w_7ed45eb0-e2cf-4cf1-93cc-82a5592fbddc"
      unitRef="usd">37483000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNS0xLTEtMS0w_13ed277f-36e0-4c1f-a3a7-62972577330f"
      unitRef="usd">18723000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNS0zLTEtMS0w_173824dc-54de-49ed-b4c4-00d69dba5b80"
      unitRef="usd">9382000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNi0xLTEtMS0w_f72a4da4-60ab-43cd-98af-efc90226333e"
      unitRef="usd">75286000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNi0zLTEtMS0w_06f6bda6-1b40-48f8-a698-51107817b04c"
      unitRef="usd">46865000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNy0xLTEtMS0w_bfc88656-6413-4c2f-9fb1-400f8f6c1862"
      unitRef="usd">-45269000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfNy0zLTEtMS0w_492e59d9-1cf9-4f48-8631-c624059964b7"
      unitRef="usd">-36931000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTAtMS0xLTEtMA_a4480e91-6b85-4162-b1f5-dcc8978421d8"
      unitRef="usd">625000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTAtMy0xLTEtMA_fa5e8210-38db-4728-94b1-6952a1b88172"
      unitRef="usd">549000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTEtMS0xLTEtMA_e1ac12c5-13fa-48ea-8b7b-3e1800cb5162"
      unitRef="usd">-330000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTEtMy0xLTEtMA_71500d6a-1b73-4e2e-8a39-85861018cd8c"
      unitRef="usd">-221000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTItMS0xLTEtMA_fdebaef1-a7a3-4c89-8a71-778a2eca9ed6"
      unitRef="usd">295000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTItMy0xLTEtMA_28dd22ef-4173-457a-9ab2-f60e525cbf87"
      unitRef="usd">328000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTMtMS0xLTEtMA_e8f83c0c-225f-47d4-af2d-bef88df99469"
      unitRef="usd">-44974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTMtMy0xLTEtMA_1535b785-780a-4928-85bb-4748ece86a01"
      unitRef="usd">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTUtMS0xLTEtMA_96d219ff-f9f8-494f-9fb7-090707dab276"
      unitRef="usd">-497000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTUtMy0xLTEtMA_ecdf179e-f0d5-4c16-ab01-80ee561e5296"
      unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTYtMS0xLTEtMA_13b5e598-c28c-476b-810b-e01d006543f6"
      unitRef="usd">-45471000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTYtMy0xLTEtMA_31710516-db22-4dff-9075-9f3abd875587"
      unitRef="usd">-36720000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMS0xLTEtMA_559d0646-72e1-4647-b4a3-64f5d574be23"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMS0xLTEtMA_e66ccd2d-836f-4bdd-9455-86650c98cbe1"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMy0xLTEtMA_57dd03f5-fe58-48b7-987f-18bd4f49b05f"
      unitRef="usdPerShare">-2.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTgtMy0xLTEtMA_fa33af83-54dd-4b8e-a3e8-639ec7937888"
      unitRef="usdPerShare">-2.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMS0xLTEtMA_d500af2d-15d0-4418-88c4-8574d5a1d2b2"
      unitRef="shares">42032384</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMS0xLTEtMA_db9fd0ff-3cf2-40f9-870a-0d27622093e2"
      unitRef="shares">42032384</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMy0xLTEtMA_a0b9d30b-a05a-416b-9b72-3385a5cdc9f4"
      unitRef="shares">15506067</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y181OC9mcmFnOjM3YmNlNjljM2YyZTQxN2ZiYTdiZDBiNTE2NmVlOWY2L3RhYmxlOjgyNWNiY2RkNjBhYTQ2YTY4ZDAwMWYxZDk1M2VlNGFmL3RhYmxlcmFuZ2U6ODI1Y2JjZGQ2MGFhNDZhNjhkMDAxZjFkOTUzZWU0YWZfMTktMy0xLTEtMA_a55a0e7c-d1be-480c-911c-42ca15b6731b"
      unitRef="shares">15506067</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i93d907eb546d4b419a06e844b32e0c37_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xLTEtMS0w_24f00559-419b-4e59-a3e7-8823c6f07f52"
      unitRef="shares">1093019</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i93d907eb546d4b419a06e844b32e0c37_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0zLTEtMS0w_720923af-c297-4de9-a1ce-67b350c4cb8e"
      unitRef="usd">49064000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6085e2e606c14212b39aba95286e4bee_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC01LTEtMS0w_0719a3eb-1211-40f8-b790-2227d7c639a4"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6085e2e606c14212b39aba95286e4bee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC03LTEtMS0w_0157da03-a7c1-4d03-b7b3-4236973775b9"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iaa3d82eadadb40ab92d3249bab64bf52_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC05LTEtMS0w_2f01c2cc-f3bd-40c0-8aeb-aec7e8e86af3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iaa3d82eadadb40ab92d3249bab64bf52_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xMS0xLTEtMA_4b4f8bfe-807a-4bfe-a207-612613d19987"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i5b2ca173e0004d11919d92632a37774d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xNC0xLTEtMA_b91fd403-b82a-4cf0-b4c2-159b068bb921"
      unitRef="shares">7600877</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5b2ca173e0004d11919d92632a37774d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xNi0xLTEtMA_00845c5b-b064-43af-9e08-e3cb1faf044f"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e12961d654945e09068f8b39b05845b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0xOC0xLTEtMA_849cca49-5d7c-4e73-abb3-3c1c3183ec97"
      unitRef="usd">887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dae071f8e3d4bec9f3b7ed2455cd014_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0yMC0xLTEtMA_bfaa9eff-e044-4fe4-bd1e-33f28a803f51"
      unitRef="usd">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief9145f0685d40abb21ee4ec19d9937f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0yMi0xLTEtMA_4ee1e3f9-84c2-432f-9a52-a7cdfe4cc224"
      unitRef="usd">-35490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2e6543ccfb74775ac5df4a5733524f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOC0yNC0xLTEtMA_10b5e161-32a4-41f4-acab-671c911635bb"
      unitRef="usd">-34548000</us-gaap:StockholdersEquity>
    <sttk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOS01LTEtMS0w_178e6d9a-3898-4a01-8e90-00829dc52ad2"
      unitRef="shares">550571000</sttk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfOS03LTEtMS0w_e23878ca-1595-4a52-b725-0882947bc2a4"
      unitRef="usd">34427000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <sttk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTAtOS0xLTEtMA_00d0f36a-e0f8-417c-816c-11ae4be6c4d9"
      unitRef="shares">1319964</sttk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTAtMTEtMS0xLTA_f4f19192-d6e6-464f-88cc-cc793b7a6b51"
      unitRef="usd">82613000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock
      contextRef="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMS0xLTEtMA_cc7295ef-90f9-4e49-b178-0d86d0bea1aa"
      unitRef="shares">1093019</sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock>
    <sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock
      contextRef="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMy0xLTEtMA_efc04e16-525b-44bf-ae70-7df3f6e7e3d7"
      unitRef="usd">49064000</sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia24b53685d3540c7a804b8f394e399a6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMTQtMS0xLTA_4c188480-e3ec-4b23-9473-a6be87d40a5b"
      unitRef="shares">7487151</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia24b53685d3540c7a804b8f394e399a6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMTYtMS0xLTA_3bcd12eb-df50-49cf-8db7-7441874a5de9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i108a91c3f6de49d7ad25831cb4cbbac8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMTgtMS0xLTA_9b23ae5b-fb53-40c9-b27f-7796ef496d2a"
      unitRef="usd">49063000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i19888de1e7884fa4a308e50d86fa7c3d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTEtMjQtMS0xLTA_9f019cc4-74c2-4729-b44f-f6465f986e0f"
      unitRef="usd">49064000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItNS0xLTEtMA_bb003238-0146-473b-91a9-0749cbf5ea23"
      unitRef="shares">550571000</sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock>
    <sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItNy0xLTEtMA_7a218e8f-6995-4d15-a8bb-01cc74048b95"
      unitRef="usd">34427000</sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia46bf273b1e0431682728738c320b383_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMTQtMS0xLTA_cab7c44a-3d16-4560-9e28-04b1ccf8538c"
      unitRef="shares">3771363</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia46bf273b1e0431682728738c320b383_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMTYtMS0xLTA_7cfe0fd9-7dc5-4d1a-8250-66f670b44062"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6d28057558bb4a0295c8315232a69252_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMTgtMS0xLTA_7adb40e9-6cd4-45a3-83fa-caae7777ccdb"
      unitRef="usd">34426000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTItMjQtMS0xLTA_c34b90b4-2e48-4762-a2ba-663c196909a0"
      unitRef="usd">34427000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtOS0xLTEtMA_d1dd4134-0a8e-43af-8866-44367c130991"
      unitRef="shares">1319964</sttk:TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock>
    <sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTEtMS0xLTA_1c70a286-2b50-49f9-8635-a0396bc69399"
      unitRef="usd">82613000</sttk:TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i82048836e6fa4e5aa557a2623e6ff0f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTQtMS0xLTA_d7a43666-d68c-4e5c-860e-ead7fffacaf3"
      unitRef="shares">9041739</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i82048836e6fa4e5aa557a2623e6ff0f7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTYtMS0xLTA_7c37340c-e155-47b8-ae55-c484e8f686a1"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3a3683f766ae45e09c86c03f022c9e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMTgtMS0xLTA_56a552c0-5a1e-4c27-8b8a-278c6a221dc4"
      unitRef="usd">82612000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTMtMjQtMS0xLTA_8e7b3570-271b-4c79-a229-cefb5cac93ad"
      unitRef="usd">82613000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMTQtMS0xLTA_9942518f-f2ab-480f-bac8-2c6827e665d6"
      unitRef="shares">13664704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMTYtMS0xLTA_264f4ec1-10fa-4a97-b9b8-8d2fddce4460"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMTgtMS0xLTA_04a69ea4-1803-455a-aeec-36ade46d37c3"
      unitRef="usd">213529000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTQtMjQtMS0xLTA_367337ea-5318-4d3e-8075-5f32fb43ad80"
      unitRef="usd">213530000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTQtMS0xLTA_a3e83f6d-23c6-442a-a44f-0253a0a110f9"
      unitRef="shares">181449</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTYtMS0xLTA_f1e0cedc-df00-4084-ab3c-12bf6a9993c0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTgtMS0xLTA_2a659859-3d66-4f87-b27d-0732937d8fb3"
      unitRef="usd">229000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMjQtMS0xLTA_3aeb89af-532e-4d6f-a3ab-2c489837222a"
      unitRef="usd">229000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icbb0272e93944ebcb32adaa70c314a85_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTYtMTQtMS0xLTA_a7671d50-3991-4110-9fee-887d3068c9fe"
      unitRef="shares">20148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica929730112246a5a5aef0a89ad5029c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMTgtMS0xLTA_63fcfa75-61b4-4e19-bd6c-88888342f588"
      unitRef="usd">1266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMjQtMS0xLTA_fa3ffefe-2c4a-46d7-8f9e-f727b1e9d57a"
      unitRef="usd">1266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8eaebef00de14f10b1d30533510da470_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjAtMS0xLTA_1f0ceee1-8d2d-4958-a31b-90872b9cfc31"
      unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjQtMS0xLTA_4a5ef4cd-3f1c-4c6f-904c-a715fcaec894"
      unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6d204922a202445caae9e3f732504db5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjItMS0xLTA_03d56b8f-0758-42ff-8de6-ecc2af550e19"
      unitRef="usd">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjQtMS0xLTA_3850e2f0-ebcf-4f3f-ae81-58933fdfbc16"
      unitRef="usd">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic115a1576f394c55b1a7bb9b66af7321_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMS0xLTEtMA_11543442-09cd-4a9a-b252-a810d3b6563f"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic115a1576f394c55b1a7bb9b66af7321_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMy0xLTEtMA_0ffb58af-cf23-438d-b61b-18ea7334781b"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if11f7173c81c46b2b06d4f80310b846d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNS0xLTEtMA_a8d5485e-8361-4d00-a1c3-447ba04df780"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if11f7173c81c46b2b06d4f80310b846d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNy0xLTEtMA_29a69e37-a423-4701-8996-4efd4180f916"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic14f82c5bd594e0c86f407f962585613_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtOS0xLTEtMA_f7d11694-bfed-45b4-85d3-b7a3a4f59dc4"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic14f82c5bd594e0c86f407f962585613_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTEtMS0xLTA_9735de96-963e-4e04-8cbe-92af1c6a397a"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="iaac2c9de295f4a84843194e8e6f933cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTQtMS0xLTA_fa0b9499-965f-42d8-8d33-d7b2147b66b8"
      unitRef="shares">41767431</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaac2c9de295f4a84843194e8e6f933cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTYtMS0xLTA_c047df41-0ee5-4949-94ae-7a828e4c0152"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bb89c4e37124b489c0152e257cc9e7a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTgtMS0xLTA_a86bc432-2cd6-42e1-a890-43a5f7c0892e"
      unitRef="usd">382012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafbad4a0cb66454aa263e9cc4b0b02cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjAtMS0xLTA_fa900999-36f9-42d0-9bb0-cf329b7e27de"
      unitRef="usd">-63000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae4c24644ef446b38a0bc1bd5b7b9dad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjItMS0xLTA_49b3e027-c436-46d2-a540-91c92c882570"
      unitRef="usd">-72093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjQtMS0xLTA_b5c95e80-2cfe-4b85-9cf3-465ff6e589b2"
      unitRef="usd">309861000</us-gaap:StockholdersEquity>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod
      contextRef="i5b7b805cabed4fef89935fc4a01cc352_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTQtMS0xLTM5Mg_d33902cf-e600-48e5-84a9-f979aee74737"
      unitRef="shares">559715</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased
      contextRef="i1da23b727bc545ce8a8626f9c21738f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMTgtMS0xLTM5Mg_e26fbc47-4bff-45c2-8c9b-1151c12257cc"
      unitRef="usd">1929000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTUtMjQtMS0xLTM5Mg_997cf9b1-312d-4d95-9cc4-6cdf9d3acaa9"
      unitRef="usd">1929000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5b7b805cabed4fef89935fc4a01cc352_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTYtMTQtMS0xLTM5Mg_ef7f605a-ff53-41d7-b8f1-c0fb8652ddec"
      unitRef="shares">11752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1da23b727bc545ce8a8626f9c21738f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMTgtMS0xLTM5Mg_7a361fc1-4d4e-463a-8f2b-3d1c682d2be8"
      unitRef="usd">5467000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTctMjQtMS0xLTM5Mg_c6089c91-a927-4108-8b0f-9fcb3c8d6909"
      unitRef="usd">5467000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2978472561c24d05b2c48b66c0b36df6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjAtMS0xLTM5Mg_c0480fc1-3043-45f6-a991-4ebead44e322"
      unitRef="usd">-497000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTgtMjQtMS0xLTM5Mg_7f673a8e-72f5-49b5-83f3-52fa0d07388d"
      unitRef="usd">-497000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ic3f0d368be5c4c9cbee436c3481aa483_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjItMS0xLTM5Mg_e2a93420-88c8-4303-a01c-2f3e160cdb8c"
      unitRef="usd">-44974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMTktMjQtMS0xLTM5Mg_739cc5b7-1a44-475d-9171-02b0ab3f929b"
      unitRef="usd">-44974000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7b8eeb11b3ac40f1b3c9e84a79462ae7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMS0xLTEtNDEw_1ca1401d-a3fc-4a2f-b565-1fec94b71ddf"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7b8eeb11b3ac40f1b3c9e84a79462ae7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMy0xLTEtNDEw_1bcf410f-d748-4b10-832b-7206d432600f"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie30e987b03ab4ec59ff05cf3acc5e3a1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNS0xLTEtNDEw_c02c5bde-8e8e-448f-a7de-95d6fd5853c3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ie30e987b03ab4ec59ff05cf3acc5e3a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtNy0xLTEtNDEw_58477a6d-e125-4d50-aeb9-42bfcd702bfd"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i55c9db39c55b45f684b6bf134143d66a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtOS0xLTEtNDEw_6e3874f9-f1ae-4284-aad0-188eb694a457"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i55c9db39c55b45f684b6bf134143d66a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTEtMS0xLTQxMA_85bd89d9-2f4f-41f6-8975-1ee19ac65879"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="id7c736cc6e69478988dbcd443d316c34_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTQtMS0xLTQxMw_561ec897-c5c2-4bc6-9179-7a6c28054df8"
      unitRef="shares">42338898</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id7c736cc6e69478988dbcd443d316c34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTYtMS0xLTQxMw_2ca0ef0e-7f12-4423-a8ee-a7c7084685f9"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i314de4ca010e41458b9633658578103b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMTgtMS0xLTQxMw_61521477-330e-474a-a952-995e866381bd"
      unitRef="usd">389408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if34e74c583cf482a8c7f8c3fdc28de97_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjAtMS0xLTQxMw_52ff3bd4-5dd6-46d1-b69d-f28a1cf991f6"
      unitRef="usd">-560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83035001040e4d90ac2aa8830614906e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjItMS0xLTQxMw_36defe3a-041f-4829-a485-d6128a700dfc"
      unitRef="usd">-117067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182MS9mcmFnOmNiOGE3MzljN2Q0NDRkYTQ5MDZlZGE1OWNmMDJiOGZjL3RhYmxlOmNmMDg2OTQ0NTkwZjQ2NGVhZWJjNzljYjk1NTBmOGEyL3RhYmxlcmFuZ2U6Y2YwODY5NDQ1OTBmNDY0ZWFlYmM3OWNiOTU1MGY4YTJfMjAtMjQtMS0xLTQxMw_78aedc74-f18e-496d-8b49-afc577eeb929"
      unitRef="usd">271786000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMy0xLTEtMS0w_e8f83c0c-225f-47d4-af2d-bef88df99469"
      unitRef="usd">-44974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMy0zLTEtMS0w_5e5b23c7-e38e-4df3-aa17-93b8a2706dcd"
      unitRef="usd">-36603000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0xLTEtMS0xNDA0Mw_7ab8833d-49b0-4e17-894b-72187ccba9dd"
      unitRef="usd">5467000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0zLTEtMS0xNDA0Mw_fc50d7dd-9f1c-4035-912e-3d83df7a2a33"
      unitRef="usd">1266000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0xLTEtMS0w_137273e7-82ff-45a0-8241-e117a59e5f1d"
      unitRef="usd">1380000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfNS0zLTEtMS0w_7ebf123c-e469-4e02-ac2d-e83816b0ceab"
      unitRef="usd">618000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOC0xLTEtMS0yMTI2Nw_00668d1a-6b9a-48c6-88ff-04e5d34525c2"
      unitRef="usd">-3035000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOC0zLTEtMS0yMTI3MQ_28a7740e-b74b-46e6-bf67-409f4a2d0cfb"
      unitRef="usd">-1000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOS0xLTEtMS0w_394a9368-d8a5-4e62-8ec4-9182ce661236"
      unitRef="usd">9272000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfOS0zLTEtMS0w_947b8964-1e12-418b-bc72-3af26c5efb16"
      unitRef="usd">6835000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTAtMS0xLTEtMA_d8b83636-03f4-4210-b337-fff9d2794ead"
      unitRef="usd">32000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTAtMy0xLTEtMA_f5da0d61-785c-47bc-a296-7c21806674c6"
      unitRef="usd">326000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTEtMS0xLTEtMA_e42bb22e-af32-4fbd-8b1e-fb7cfce5fa32"
      unitRef="usd">7866000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTEtMy0xLTEtMA_837b70f8-0b9b-45ed-8191-f242e497ca45"
      unitRef="usd">-1751000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTItMS0xLTEtMA_b651e5c4-12ac-4d25-aacc-199c26858cc7"
      unitRef="usd">6924000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTItMy0xLTEtMA_21337310-0f4b-47fb-8d8b-bb4b5c85f199"
      unitRef="usd">3313000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTMtMS0xLTEtMA_66cdaf78-44c4-4e87-a3f6-792c5d97141b"
      unitRef="usd">-29034000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTMtMy0xLTEtMA_864c4448-6bc6-43b5-ab34-6b2a4c4f5dc3"
      unitRef="usd">6569000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sttk:IncreaseDecreaseInDeferredRentCredits
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTQtMS0xLTEtMA_1dfcce5b-c7d6-4dd9-93f8-cc2a415598ae"
      unitRef="usd">-1524000</sttk:IncreaseDecreaseInDeferredRentCredits>
    <sttk:IncreaseDecreaseInDeferredRentCredits
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTQtMy0xLTEtMA_bb40e0e2-8bce-42dd-b15a-92f404237ac4"
      unitRef="usd">-89000</sttk:IncreaseDecreaseInDeferredRentCredits>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTUtMS0xLTEtMA_ad155b69-969c-4de6-8af1-32fd1d34cdb6"
      unitRef="usd">-57116000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTUtMy0xLTEtMA_cf83235a-5cbe-45a8-bad1-f5aab29cd7ca"
      unitRef="usd">-33659000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTgtMS0xLTEtMA_6f41de69-e9fc-447a-b655-8f636e445b78"
      unitRef="usd">7926000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTgtMy0xLTEtMA_c4d10997-80a4-4d1d-822f-d154e9619f72"
      unitRef="usd">727000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTktMS0xLTEtMA_46904d4e-0abc-4230-848c-3db886ed13a2"
      unitRef="usd">201575000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMTktMy0xLTEtMA_8afbc39e-bba3-4778-9e79-8957c61325a2"
      unitRef="usd">37595000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjAtMS0xLTEtMA_bb056427-e5ea-4380-a439-d146af707bcf"
      unitRef="usd">204092000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjAtMy0xLTEtMA_a1b08050-e37c-4304-9fcc-e7a4a2aef87d"
      unitRef="usd">183190000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjEtMS0xLTEtMA_6ec918a5-aabb-4a1e-99a4-cf3144c46565"
      unitRef="usd">-10443000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjEtMy0xLTEtMA_b907b219-a794-41f7-81fa-97cbc48dfe87"
      unitRef="usd">-146322000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMS0xLTEtMTg1MzE_5a145144-58af-4609-a5e9-6342fb31fe51"
      unitRef="usd">1929000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMy0xLTEtMTg1MzE_6f8c3583-9864-4aa6-99d2-192d6acf2724"
      unitRef="usd">229000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMS0xLTEtMA_51b74531-96d5-46d7-a830-30897ada839e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjQtMy0xLTEtMA_402b4fe2-a4e3-4ddc-9eec-8b4adaff2c39"
      unitRef="usd">232301000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1cbb284a8c1342259be91fd8741fe70a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjUtMS0xLTEtMA_14d7ed93-030d-4c45-b499-426f06275cab"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if0f3fa86426e412a8755fb1b72e9c76a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjUtMy0xLTEtMA_51f71dfa-72cb-4c5a-8be4-50d188ffc0cc"
      unitRef="usd">18738000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="i21a6c00e553649a9a7fd199a899a8098_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjYtMS0xLTEtMA_66bbf33a-fe6d-420b-b4c6-1bd53304f8af"
      unitRef="usd">0</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjYtMy0xLTEtMA_923c3c1f-0826-4330-9f70-a8df366aa598"
      unitRef="usd">83000000</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i21a6c00e553649a9a7fd199a899a8098_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjctMS0xLTEtMA_6ff292c0-46f4-425b-9df8-94bc705bde57"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjctMy0xLTEtMA_8d0187f4-760a-4e79-a251-4ff72b001b1d"
      unitRef="usd">387000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="i6ef03e1dffea436194212535f30c3f7d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjgtMS0xLTEtMA_1d1efb76-3526-471b-b520-3682aea0a568"
      unitRef="usd">0</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjgtMy0xLTEtMA_91fdfdfe-7162-439c-a4d9-630ea932fee2"
      unitRef="usd">34620000</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6ef03e1dffea436194212535f30c3f7d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjktMS0xLTEtMA_b874dc2f-8009-4691-bb6f-2c42111543ba"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMjktMy0xLTEtMA_26a035b3-0326-4a2e-be95-388e9ceea5d5"
      unitRef="usd">159000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzEtMS0xLTEtMA_2a623548-b7de-465b-800f-12dcc1baceea"
      unitRef="usd">1929000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzEtMy0xLTEtMA_9b1967c4-0aa2-4001-87bb-84b1cb24c7a3"
      unitRef="usd">330866000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzItMS0xLTEtMA_ab890c77-6f59-42e8-832f-862903e169d3"
      unitRef="usd">-65630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzItMy0xLTEtMA_2570b95f-7aad-40bb-8005-0d953da76cd9"
      unitRef="usd">150885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzQtMS0xLTEtMA_c0b72bac-73dc-4549-a59f-86c6a8c37873"
      unitRef="usd">157898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia2e6543ccfb74775ac5df4a5733524f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzQtMy0xLTEtMA_78bc92d4-302b-4aa6-ad17-cc64f7666517"
      unitRef="usd">7013000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzUtMS0xLTEtMA_c6d85e43-194e-4276-9c7c-204aae9a0dd8"
      unitRef="usd">92268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzUtMy0xLTEtMA_2a3c5119-d1ed-49dd-a136-0f850618729e"
      unitRef="usd">157898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzgtMS0xLTEtMA_db6518f0-8f7a-4845-be69-fcc46d6bf437"
      unitRef="usd">497000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzgtMy0xLTEtMA_9607979b-3c36-4fdf-98ae-ea994aecc413"
      unitRef="usd">117000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzktMS0xLTEtMA_113127ba-0407-412a-81cf-5b84ccd637d1"
      unitRef="usd">392000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y182NC9mcmFnOjIwZDhmMWYwNzlmYzQxOGFhOTIyNDNhYWZhZDQyODFkL3RhYmxlOjdjODFlZGViOTk0NzQwZDI4MWQ1OGMwOTg5NWZjYjQ5L3RhYmxlcmFuZ2U6N2M4MWVkZWI5OTQ3NDBkMjgxZDU4YzA5ODk1ZmNiNDlfMzktMy0xLTEtMA_bb0be8a8-01ea-403f-af7b-f07155486d12"
      unitRef="usd">454000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183MC9mcmFnOjNjYjFmN2FhMDhmNDQ3YmNiMjJhZDJkOWY2YWIzMzhiL3RleHRyZWdpb246M2NiMWY3YWEwOGY0NDdiY2IyMmFkMmQ5ZjZhYjMzOGJfNTQwMg_d4f28e63-7387-48a2-8be5-ad71a81c8072">Organization and Description of Business&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shattuck Labs, Inc. (the &#x201c;Company&#x201d;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its ARC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and GADLEN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has two clinical-stage product candidates, SL-172154 and SL-279252, and has several compounds in preclinical development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $117.1 million as of December&#160;31, 2021. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#x2019;s cash and cash equivalents and short-term investments of $268.8 million as of December&#160;31, 2021, are sufficient to fund projected operations of the Company for at least the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and in which the Company&#x2019;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While the Company has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company&#x2019;s continuity plans will be successful. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has already experienced disruptions to its business such as work-from-home orders for offices and similar disruptions have occurred for its partners. Specifically, the outbreak has caused disruptions in its ability to manufacture clinical trial materials, including the acquisition of raw materials needed for such manufacturing, enrollment and treatment of patients in clinical trials in process, and slowdowns and shutdowns of the laboratories and other service providers that are being relied upon in the development of the Company&#x2019;s product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which the COVID-19 pandemic or any other health epidemic may impact the Company&#x2019;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to mitigate its impact, among others. Accordingly, the COVID-19 pandemic could have a material adverse effect on the Company&#x2019;s business, results of operations and financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183MC9mcmFnOjNjYjFmN2FhMDhmNDQ3YmNiMjJhZDJkOWY2YWIzMzhiL3RleHRyZWdpb246M2NiMWY3YWEwOGY0NDdiY2IyMmFkMmQ5ZjZhYjMzOGJfMjQzNg_4e69aec3-51aa-45ed-97a7-96c864a556bf"
      unitRef="usd">-117100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183MC9mcmFnOjNjYjFmN2FhMDhmNDQ3YmNiMjJhZDJkOWY2YWIzMzhiL3RleHRyZWdpb246M2NiMWY3YWEwOGY0NDdiY2IyMmFkMmQ5ZjZhYjMzOGJfMzI5MQ_f19c98ae-23d2-4ac5-89e9-90bf3f131b35"
      unitRef="usd">268800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTU_f4f2f601-28db-4162-bea2-8decc2b3d5d1">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates. A change in the Company&#x2019;s estimates occurred in the second quarter of 2021, which impacted the Company&#x2019;s revenue recognition and related balance sheet accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), which was mutually terminated pursuant to the termination agreement, dated November 8, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on one third-party contract manufacturing organization (&#x201c;CMO&#x201d;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on three contract research organizations (&#x201c;CROs&#x201d;) and a limited number of third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $14.6 million held in operating accounts and $77.7 million held in money market funds as of December&#160;31, 2021 and $2.7 million held in operating accounts, $80.2 million held in money market funds and $75.0 million held in government obligations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of highly-rated U.S. Treasury securities with maturities of more than three months but less than one year at the date of purchase. The Company classifies its short-term investments at the time of purchase as available-for-sale securities. Available-for-sale securities are carried at fair value. Credit impairments for available-for-sale debt securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2021, there were no impairments related to credit losses of short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded against gross proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of stockholders&#x2019; equity on the balance sheet because the shares contain liquidation features that are not solely within the Company&#x2019;s control. Upon the completion of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in the fourth quarter of 2020, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock were converted into common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Rent&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records rent expense on a straight-line basis over the term of the leases and, accordingly records the difference between cash payments and the recognition of rent expense as a deferred rent asset or liability. Incentives granted under the Company&#x2019;s leases, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract which would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and will recognize the payments received from these agreements as revenue when the related costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgements and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee Board members as compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company adjusts expense for forfeitures in the periods they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible notes, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,753,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes: Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU removes certain exceptions to the general principles in ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year, with early adoption permitted. The Company adopted this pronouncement effective January 1, 2021 and it did not have a material impact on the financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements (not yet adopted) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective &lt;/span&gt;&lt;/div&gt;transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The FASB deferred the effective date of this ASU until the annual periods beginning after December 15, 2021. The Company expects that the most significant effects of adopting this standard will primarily relate to (a) the recognition of right of use assets and lease liabilities on the balance sheet in relation to its existing operating lease agreements in Austin, Texas and Durham, North Carolina; and (b) providing significant new disclosures about leasing activities. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDc_4dc1d227-c60f-4dd3-a16f-4456da7ac322">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTk_827fa348-a4df-4325-8930-09df77e0d8f5">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates. A change in the Company&#x2019;s estimates occurred in the second quarter of 2021, which impacted the Company&#x2019;s revenue recognition and related balance sheet accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDE_03c82b81-0c38-4fdd-a486-9d63fcaee0ff">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDg_1bf2266b-9508-4cbf-b593-a801015fbce7">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), which was mutually terminated pursuant to the termination agreement, dated November 8, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on one third-party contract manufacturing organization (&#x201c;CMO&#x201d;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on three contract research organizations (&#x201c;CROs&#x201d;) and a limited number of third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTI_86ac3392-9486-48a7-adab-03f951844479">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $14.6 million held in operating accounts and $77.7 million held in money market funds as of December&#160;31, 2021 and $2.7 million held in operating accounts, $80.2 million held in money market funds and $75.0 million held in government obligations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifcfc895622274a9fa067f83a85414b73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTY3Nw_fb69d4d1-0669-4e4c-9e41-0b7ee959c78f"
      unitRef="usd">14600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2bc6f8f8312648d79a5c147096aa6201_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTY2OQ_6e476c56-9387-406d-9db2-873584eaccfb"
      unitRef="usd">77700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7e8869244b74fc28985b69bc05e3793_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTY5Mg_0b8a4731-bbb0-4536-ba4c-25fce0ec6e6d"
      unitRef="usd">2700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id283059be4d44a2e824a82620e3e234d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTcwMA_08d669c7-5629-40d4-b7b4-8c501aab4d67"
      unitRef="usd">80200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i524cc2fcaa1e4182b2577f5ace25f6fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMTA5OTUxMTY1NTcwOA_c3a54394-fa30-497a-938c-6467955c0ed3"
      unitRef="usd">75000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODc_cba0ee45-9ade-43c8-8404-17c8206db87a">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of highly-rated U.S. Treasury securities with maturities of more than three months but less than one year at the date of purchase. The Company classifies its short-term investments at the time of purchase as available-for-sale securities. Available-for-sale securities are carried at fair value. Credit impairments for available-for-sale debt securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2021, there were no impairments related to credit losses of short-term investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDI_e049259d-c241-4091-a011-82e5cd663965">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded against gross proceeds.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDU_79340142-682b-45fa-993c-7306233ccbac">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of stockholders&#x2019; equity on the balance sheet because the shares contain liquidation features that are not solely within the Company&#x2019;s control. Upon the completion of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in the fourth quarter of 2020, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock were converted into common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <sttk:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODk_c0822559-ac37-489b-a2f8-23c736038973">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.&lt;/span&gt;&lt;/div&gt;</sttk:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTQ_c150ceb8-2572-47af-b84d-fc38c21ccc91">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTY_5087c067-5eb3-4829-b8b4-da25650999a9">&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0256d931b38f4e8ebd1fafc29f3baef9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMC0xLTEtMS0w_3a14cac1-3d7d-4e89-be05-36841cf29fa9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2d2830e52a30463b83b72e983bfd983c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMS0xLTEtMS0wL3RleHRyZWdpb246MGVjNjc3MTRmYjA2NDE0Y2E4YjY1ZDI4NTE3YmQzNDNfNA_76fd80f1-ca89-4746-a7b7-eb3ec43d687f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i82c95f2381594579b82d242587361ef8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMS0xLTEtMS0wL3RleHRyZWdpb246MGVjNjc3MTRmYjA2NDE0Y2E4YjY1ZDI4NTE3YmQzNDNfMTA_de776b0a-2b7d-422a-89b7-cef0147d8f69">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i199bf9783e444bf89f2a5c5f09e19ee1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMi0xLTEtMS0w_44ff88d0-e72d-4559-bbe5-fda077ed5b6a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8507d1aa293d4d058b8d4ea3b458979e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOmIzNTNkYTg1NDdmMjRmZDI4OGUzYzNlOGY3MjBkYTEwL3RhYmxlcmFuZ2U6YjM1M2RhODU0N2YyNGZkMjg4ZTNjM2U4ZjcyMGRhMTBfMy0xLTEtMS0wL3RleHRyZWdpb246OGUwMTUwYTU1ZTZiNDNjM2E2OTI1ZDI4ZjBhNTA3MTlfMjk_4c45fcfb-d741-4110-8f80-f2d9f99ecb69">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTM_999d3735-966f-4431-9b6f-d2dd260d6a6d">Impairment of Long-Lived AssetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfODczNQ_4dd85978-8bd2-4b9f-bf0a-1bd2ce158600"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfODczNQ_f2744070-aa96-4a26-b3c8-1bd5508bda68"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODY_7b95fd31-81a7-4816-898c-eb7559990f9a">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Rent&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records rent expense on a straight-line basis over the term of the leases and, accordingly records the difference between cash payments and the recognition of rent expense as a deferred rent asset or liability. Incentives granted under the Company&#x2019;s leases, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDY_e0db53b3-05be-444f-8f1e-95deb52edda2">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract which would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt; and will recognize the payments received from these agreements as revenue when the related costs are incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTc_ee9d1792-bf52-4ce8-a744-f0f8489d4a88">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgements and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTA_38e33a5e-28c1-43f7-8f59-d8b843b1580a">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee Board members as compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company adjusts expense for forfeitures in the periods they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDA_e2148f46-9a6c-4ec3-9c53-f327b9ff58d9">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTg_5b52598e-6879-4d4f-a2d6-0c768bf15c58">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible notes, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyOTE_1d1e3b22-3dae-46a4-b347-72f2da7e1169">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,753,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4739b7937ffb414cba8e7cf3495311be_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfMy0xLTEtMS0w_a3bcf090-17ce-4696-b963-504823276105"
      unitRef="shares">2448676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56b4d224548b44d2b88ff83fa65e5ba7_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfMy0zLTEtMS0w_25b93ee8-c40b-4a51-b555-82c51e1b3f00"
      unitRef="shares">2742022</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i34cfe1bf8a0f4d1e8923ff1731e97dc4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNC0xLTEtMS0w_49d3783c-0954-471d-8385-deb8436ea164"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i022cbf9c4d41418ca5d4cc35b286630f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNC0zLTEtMS0w_56bae901-2ac6-4425-9c96-f29e179e0043"
      unitRef="shares">11752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNS0xLTEtMS0w_f5ff233f-8b80-4a0b-8495-d6bf9978408b"
      unitRef="shares">2448676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RhYmxlOjliYmE5YWEzMTM0MDRjMjliNWE0MzliYjUxZmU3OWY3L3RhYmxlcmFuZ2U6OWJiYTlhYTMxMzQwNGMyOWI1YTQzOWJiNTFmZTc5ZjdfNS0zLTEtMS0w_c6037922-21d1-481b-876d-493359006947"
      unitRef="shares">2753774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjczMDM_f308255f-64ed-4eb0-a2ac-992fdf89528f">Other Comprehensive Income (Loss)Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on short-term investments.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183My9mcmFnOjJjOTcxY2YxNzlkZDRmNmVhODJjN2RlZTUwYjE2OTA4L3RleHRyZWdpb246MmM5NzFjZjE3OWRkNGY2ZWE4MmM3ZGVlNTBiMTY5MDhfMjcyODg_c3ff5092-0feb-40c4-aa0e-c5dfaee908ef">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes: Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU removes certain exceptions to the general principles in ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year, with early adoption permitted. The Company adopted this pronouncement effective January 1, 2021 and it did not have a material impact on the financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements (not yet adopted) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective &lt;/span&gt;&lt;/div&gt;transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The FASB deferred the effective date of this ASU until the annual periods beginning after December 15, 2021. The Company expects that the most significant effects of adopting this standard will primarily relate to (a) the recognition of right of use assets and lease liabilities on the balance sheet in relation to its existing operating lease agreements in Austin, Texas and Durham, North Carolina; and (b) providing significant new disclosures about leasing activities. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RleHRyZWdpb246YTg5ZjUwYzBhNDU5NGE0ZDgxZGQ3MDY1NGI3NzE4ZTNfNTMw_00e7f47e-04e9-410f-9ce1-e2ac9a987e80">Short-Term Investments&lt;div style="margin-top:12pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s available for sale short-term investments by major security type (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have an average maturity of 0.43 years as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RleHRyZWdpb246YTg5ZjUwYzBhNDU5NGE0ZDgxZGQ3MDY1NGI3NzE4ZTNfNTMx_e465872c-5f06-4b98-bc6d-cae0eb728b31">&lt;div style="margin-top:12pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s available for sale short-term investments by major security type (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if6b150d14a3340bdbbda062f1916514e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfMy0xLTEtMS0w_7c70e10e-c0df-4c0b-a293-08be2b0039b8"
      unitRef="usd">177096000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="if6b150d14a3340bdbbda062f1916514e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfMy0zLTEtMS0w_7246b850-bc10-44f7-9335-0027170241f5"
      unitRef="usd">-560000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6b150d14a3340bdbbda062f1916514e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfMy01LTEtMS0w_36eeb373-9905-4354-8a69-96f8d3442164"
      unitRef="usd">176536000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfNC0xLTEtMS0w_f430a8ed-0ccb-4c28-8c0f-9903cdfc910e"
      unitRef="usd">177096000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfNC0zLTEtMS0w_6c685db5-55ae-4a31-983d-1486a680a9ca"
      unitRef="usd">-560000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOmEyYjIzNzdkMDg0YTQxNjlhNmM1NjkxZDQwYzZjNDAyL3RhYmxlcmFuZ2U6YTJiMjM3N2QwODRhNDE2OWE2YzU2OTFkNDBjNmM0MDJfNC01LTEtMS0w_b857bf9f-cd5a-4a18-a68f-913476fc5cf1"
      unitRef="usd">176536000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7705c519eda74dc58737c23718104aaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNC0xLTEtMS0w_bb1b49bb-2c50-4008-aeef-8187bf2b2f80"
      unitRef="usd">177614000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i7705c519eda74dc58737c23718104aaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNC0zLTEtMS0w_7f88005a-2fb1-412b-9b5c-664bccc85caf"
      unitRef="usd">-63000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7705c519eda74dc58737c23718104aaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNC01LTEtMS0w_f63a56b6-01de-446a-9d54-a414472ee3c9"
      unitRef="usd">177551000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNS0xLTEtMS0w_f2c9d595-a12c-43c9-b228-018ecb988f28"
      unitRef="usd">177614000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNS0zLTEtMS0w_52ef4f88-09b7-4790-b44a-7968d7345df3"
      unitRef="usd">-63000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RhYmxlOjczM2EyZDJlOGIxNjQxYjFhOGVkMmEwMTY2YzVlNGQyL3RhYmxlcmFuZ2U6NzMzYTJkMmU4YjE2NDFiMWE4ZWQyYTAxNjZjNWU0ZDJfNS01LTEtMS0w_807490f5-e551-41d2-be40-0eb2e6611e93"
      unitRef="usd">177551000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183Ni9mcmFnOmE4OWY1MGMwYTQ1OTRhNGQ4MWRkNzA2NTRiNzcxOGUzL3RleHRyZWdpb246YTg5ZjUwYzBhNDU5NGE0ZDgxZGQ3MDY1NGI3NzE4ZTNfNTIy_17d1ed9e-3fc0-43f1-afe9-079d53a2d904">P0Y5M4D</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMjIw_69304edb-4b66-43d6-b83f-8eb723d0006b">Property and Equipment&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2021 and 2020 was $1.4 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMjIx_13a08d8e-63e5-4128-9c31-2989ea6d6de7">&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia854a6038a4a4bb088d1e1adb51da387_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMi0xLTEtMS0w_ed8d4139-d043-4203-86ae-67f982f9bde4"
      unitRef="usd">5823000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifef12007a5ff492690c14861cd4a497c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMi0zLTEtMS0w_a953acaa-f818-461c-a53b-69fe02fb817b"
      unitRef="usd">2790000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7dc2651a89a543bbaf7e68cc3e676d0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMy0xLTEtMS0w_fb392de4-eff1-413d-8961-560571217865"
      unitRef="usd">3709000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5c94c0bd8ebb4b1bb951ba7df8bdb437_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfMy0zLTEtMS0w_225e361e-6b69-4883-bb9a-db5f050ae7e6"
      unitRef="usd">1073000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ide31a45817b8402c950886d450a9c631_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNC0xLTEtMS0w_60fcb472-cfda-4655-a668-4be7b5c05d8e"
      unitRef="usd">2521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4178f0dec2b24b44bad57c8e7393db7c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNC0zLTEtMS0w_cd9072f2-1fac-44c8-9ea8-293e54a7426e"
      unitRef="usd">355000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib0e6a315dca248c9aa85cda7c35059e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNS0xLTEtMS0w_2089ce27-cdc9-438f-98d6-3ffabbdb3ec7"
      unitRef="usd">459000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d2329b727b8467788e859b46061df44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNS0zLTEtMS0w_e3f7d1f5-1168-4306-94df-1ac1c146a0b7"
      unitRef="usd">157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idd9021bd3124402f8714a57978b7021a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNi0xLTEtMS0w_727b17b4-ba74-4d31-8ac0-cc2a3e17b0ae"
      unitRef="usd">206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06b6ab46fb514d5d8d7aa64487be02ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNi0zLTEtMS0w_3a2a0ce2-d4c9-4751-ad99-7be2c6e9c5dc"
      unitRef="usd">105000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNy0xLTEtMS0w_81f0a0b1-b641-41ec-9b73-f0798cde5329"
      unitRef="usd">12718000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfNy0zLTEtMS0w_2e5ea52c-70f5-4f1b-b8fe-5d96b464bf6f"
      unitRef="usd">4480000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOC0xLTEtMS0w_3aec434e-49cb-498f-8060-ed01ef34c8af"
      unitRef="usd">2780000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOC0zLTEtMS0w_90f033ce-7e93-4b07-b6c3-843750f98145"
      unitRef="usd">1480000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOS0xLTEtMS0w_958c647d-d938-4996-acbf-964a8422bac6"
      unitRef="usd">9938000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RhYmxlOmU5YmMwMzI4Y2Y0MTQ3Mzg5MWJhM2MxYjdmYjEwMTI4L3RhYmxlcmFuZ2U6ZTliYzAzMjhjZjQxNDczODkxYmEzYzFiN2ZiMTAxMjhfOS0zLTEtMS0w_00c8b2dc-ede6-4603-8f98-afa540d6637c"
      unitRef="usd">3000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMTgx_0866fca9-e3be-4642-8de1-98f180b69b61"
      unitRef="usd">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y183OS9mcmFnOjA0MTdiMDgxOTc1MzRlMzg5ZjdhNjA2N2ZjYWVlOGVhL3RleHRyZWdpb246MDQxN2IwODE5NzUzNGUzODlmN2E2MDY3ZmNhZWU4ZWFfMTk2_02eed971-7d72-4639-98e5-a319f3ff22cc"
      unitRef="usd">600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RleHRyZWdpb246NTg4OTUyNGU3ODFlNGY3M2FjZjMyMjMzODg3NjQ1NDdfOTU_6b3eec56-79b1-4808-8e39-9ec66875e81b">Accrued ExpensesAccrued expenses consisted of the following (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RleHRyZWdpb246NTg4OTUyNGU3ODFlNGY3M2FjZjMyMjMzODg3NjQ1NDdfOTY_69b29494-f992-4840-8d34-b26548006d3d">Accrued expenses consisted of the following (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sttk:AccruedResearchAndDevelopmentContractCostsCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMi0xLTEtMS0w_2ad8cc00-3e15-496a-a450-60e2b93c89fa"
      unitRef="usd">10253000</sttk:AccruedResearchAndDevelopmentContractCostsCurrent>
    <sttk:AccruedResearchAndDevelopmentContractCostsCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMi0zLTEtMS0w_e3c39835-bd83-46df-a07f-082bc2872c6b"
      unitRef="usd">5382000</sttk:AccruedResearchAndDevelopmentContractCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMy0xLTEtMS0w_9152b531-f6f0-4a32-8c00-b47d7824753f"
      unitRef="usd">3320000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfMy0zLTEtMS0w_66862890-b5aa-4d17-b9e0-4022087dcf6a"
      unitRef="usd">1551000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNC0xLTEtMS0w_ab002828-a7ad-4669-a42b-12480011c662"
      unitRef="usd">1001000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNC0zLTEtMS0w_aaca37ad-1a65-44be-b181-4ff29456a3d8"
      unitRef="usd">419000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNS0xLTEtMS0w_1150d837-243c-4bd9-981b-5555881b1370"
      unitRef="usd">14574000</sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184Mi9mcmFnOjU4ODk1MjRlNzgxZTRmNzNhY2YzMjIzMzg4NzY0NTQ3L3RhYmxlOjVlOGE1MzFiMDM5MjQ5MGNhM2YwYmI1ZmU1YWY2MDkxL3RhYmxlcmFuZ2U6NWU4YTUzMWIwMzkyNDkwY2EzZjBiYjVmZTVhZjYwOTFfNS0zLTEtMS0w_b2131a50-c5e8-4a44-94f6-648cdcb196a3"
      unitRef="usd">7352000</sttk:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjUxMQ_6fd3074d-45fd-4cb0-b2a0-67695a9f28bb">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, future minimum payments, by year and in aggregate, under non-cancelable operating leases consist of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized rent expense of $0.7&#160;million and $0.4 million for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Heat License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a license agreement with Heat Biologics Inc. (&#x201c;Heat&#x201d;), the Company is required to make payments of up to $20.6&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products.&#160;The Company is required to pay Heat a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents.&#160;The Company is also required to pay Heat a royalty on all of its worldwide net sales, those of its affiliates and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the payments aforementioned given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company&#x2019;s officers and directors. In each complaint, the plaintiff cites the volatility in the Company&#x2019;s common stock and alleges that the defendants made or are responsible for false or misleading statements regarding the Company&#x2019;s collaboration agreement with Takeda. The plaintiffs in both lawsuits seek a ruling that the case may proceed as a class action, and seeks unspecified damages and attorneys&#x2019; fees, expert fees and costs. The Company and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations &lt;/span&gt;&lt;/div&gt;Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#x2019;s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjUxMA_9644f087-1ed8-400c-b7c3-8e433280b790">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, future minimum payments, by year and in aggregate, under non-cancelable operating leases consist of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMC0xLTEtMS0w_afc463c9-5515-4227-85b8-bf1b5dc15c8b"
      unitRef="usd">1058000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMS0xLTEtMS0w_4d93c2d6-647c-44e2-ba91-fea11b36cd42"
      unitRef="usd">1089000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMi0xLTEtMS0w_fff34cba-ac92-41d7-8dca-6b0c802a4149"
      unitRef="usd">1120000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfMy0xLTEtMS0w_e8a3f530-0ea8-41c6-b5c6-f9ec72a76b5a"
      unitRef="usd">1152000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfNC0xLTEtMS0w_de24485f-d480-496b-9cb8-b3a63e883fc6"
      unitRef="usd">1093000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfNS0xLTEtMS0w_779a8247-4914-4724-ad6e-c825e00b3501"
      unitRef="usd">1721000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RhYmxlOmMxMjg4MjlmODVkYjRiODA5MmEwYjIwN2VhOTc5Yjk2L3RhYmxlcmFuZ2U6YzEyODgyOWY4NWRiNGI4MDkyYTBiMjA3ZWE5NzliOTZfNi0xLTEtMS0w_6cd84a25-d557-4a45-9d6c-087347bf600a"
      unitRef="usd">7233000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjQ1_26413a32-8282-4392-899b-1aa6e2244ff4"
      unitRef="usd">700000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfMjUy_16a9216e-ca38-49d2-987a-0195e4852ad2"
      unitRef="usd">400000</us-gaap:OperatingLeasesRentExpenseNet>
    <sttk:LicenseAgreementRoyaltyPaymentsMaximum
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184NS9mcmFnOjZlYzZhNDZjNzAxMzQyZTViN2RiMGQ1ZmE0NTg4NjcyL3RleHRyZWdpb246NmVjNmE0NmM3MDEzNDJlNWI3ZGIwZDVmYTQ1ODg2NzJfNDQ3_55c51611-2d67-4c53-ade1-bfe54f2c6ad1"
      unitRef="usd">20600000</sttk:LicenseAgreementRoyaltyPaymentsMaximum>
    <us-gaap:PreferredStockTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfNjAy_1735ba4a-57c3-46f1-bbbc-d2212e4eccf6">Preferred StockDuring the year ended December 31, 2020, the Company entered into various stock purchase agreements with new and existing investors pursuant to which the Company sold an aggregate 550,571 shares of Series B redeemable convertible preferred stock and 1,319,964 shares of Series B-1 redeemable convertible preferred stock at $62.88051 per share for net proceeds of $117.0 million.The Company&#x2019;s Series A, Series B and Series B-1 redeemable convertible preferred stock converted into common stock upon the completion of the Company&#x2019;s IPO in 2020 and the rights, preferences, and terms are no longer applicable</us-gaap:PreferredStockTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if36ac2c795a0406099cdddb4c1a27568_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMTg5_39e02c77-e66d-457f-bede-537256546385"
      unitRef="shares">550571</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5b5f732ae3904b4dae0c1c358489e213_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMjY3_fc23fda1-ff1f-4411-adce-942a37d0d3b5"
      unitRef="shares">1319964</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if11f7173c81c46b2b06d4f80310b846d_I20201231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMzQ4_0b92c03e-5ef7-4c17-8c10-fc04e740114d"
      unitRef="usdPerShare">62.88051</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic14f82c5bd594e0c86f407f962585613_I20201231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMzQ4_707c316e-796b-46da-813c-2faa9714c192"
      unitRef="usdPerShare">62.88051</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1c436ab0261649adb338c58e3639b366_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y184OC9mcmFnOjVhZjJmZmJlMDdkZTQ2MWJiOWMxYTAwOTMzNDJjODQ3L3RleHRyZWdpb246NWFmMmZmYmUwN2RlNDYxYmI5YzFhMDA5MzM0MmM4NDdfMzgx_410d5b80-86dd-40d2-9803-daa8675f968c"
      unitRef="usd">117000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfMjQwMQ_454e3c54-4f0e-4ebe-84b3-f0518d3815af">Collaboration Agreement - Related PartyThe Company recognized revenue for the allocated up-front payments using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company used actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. In August 2017, the Company entered into a Collaboration Agreement with Takeda related to the development of certain ARC molecules, as amended in April 2018, October 2018 and March 2020 (the &#x201c;Collaboration Agreement&#x201d;). The Collaboration Agreement was mutually terminated pursuant to a termination agreement dated November 8, 2021 (the &#x201c;Termination Agreement&#x201d;). Under the terms of the Termination Agreement, the Company is not required to satisfy any remaining performance obligations, the Company will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. The remaining deferred revenue was recognized as revenue in the fourth quarter of 2021. The Company received cash of $3.6 million and $14.0 million in the years ended December 31, 2021 and 2020, respectively, and recognized total revenue of $82.0 million through December&#160;31, 2021 under the Collaboration Agreement.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfODM0_66a2bc1f-dc61-4d16-897b-0945de90f02a"
      unitRef="usd">3600000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ia94f371b06b64697b125dc4b3ab1f16a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfODQx_1ec4797e-8445-40aa-a772-dceef84407cb"
      unitRef="usd">14000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185MS9mcmFnOmI0NzA2MjZlMGQyMjRjYWViZjBhODNmMTI0MWY1ZjgxL3RleHRyZWdpb246YjQ3MDYyNmUwZDIyNGNhZWJmMGE4M2YxMjQxZjVmODFfOTQ1_6ba98a27-073d-4148-84f5-454b0edaad82"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNA_f8ca83db-1eac-42f7-a78d-847b68bb8946">Stock-Based Compensation&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#x2019;s outstanding common shares on December 31st of the preceding calendar year. The Board of Directors may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. As of December&#160;31, 2021, there were 3,912,408 shares available for future grants under the 2020 Plan and on January 1, 2022, the share reserve automatically increased by 1,693,555 shares. The 2020 Plan permits the granting of options and restricted stock. The terms of the agreements under the 2020 Plan are determined by the Company&#x2019;s Board of Directors. The Company&#x2019;s awards vest based on the terms in the agreements and generally vest over four years and have a term of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;) became effective in connection with the Company&#x2019;s IPO. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#x2019;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. As of December&#160;31, 2021 there were 393,689 shares available for future purchases and on January 1, 2022, the share reserve automatically increased by 423,388 shares. Under the 2020 ESPP, the Company issued 2,106 shares of common stock for aggregate cash proceeds of $0.1&#160;million during the year ended December&#160;31, 2021. There were no shares of common stock issued during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan and the 2016 Stock Incentive Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the years ended December&#160;31, 2021 and 2020 had weighted-average grant-date fair values of $16.38 and $8.93 per share, respectively. As of December&#160;31, 2021, the unrecognized compensation cost was $11.4 million and will be recognized over an estimated weighted-average amortization period of 2.48 years. The aggregate intrinsic value of options exercised as of December&#160;31, 2021 and 2020 was $10.8 million and $49.7 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&#160;31, 2021 was $5.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#x2019;s industry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Prior to the Company&#x2019;s IPO, its Board periodically estimated the fair value of the Company&#x2019;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#x2019;s IPO, options are issued with a strike price no less than the market price on date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options granted under the Company&#x2019;s 2020 Plan were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The restricted shares are considered the issuance of share-based payments as opposed to the sale of stock and as such, the Company has recognized compensation expense for these awards based on the fair value of the award on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to these shares:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued under the Company&#x2019;s 2020 ESPP were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="i83fa63cc109d410793fee3147230e084_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTAyOA_198c385d-e15e-4290-8e28-184958dcc123"
      unitRef="number">0.04</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1717f2eaa0f544379a47d6697e8ce5e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzOTAyMw_4733cdd1-2839-440c-a48b-24b6d2e02e82"
      unitRef="shares">3912408</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="ibfaa1273d97b46978197a4b2f339b0ec_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzI5ODUzNDg5NDEwOA_2c049f7b-6287-44cd-8ce8-8f4efa412bd4"
      unitRef="shares">1693555</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa51a2a2b1c84fdfa550195209974723_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNjcw_b1d8dfc0-aabf-4666-8dc6-52eef85bcb23">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifa51a2a2b1c84fdfa550195209974723_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNjky_b6673646-e545-453d-a413-cd3ba71bd898">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8842228fdf1940c7b1002d140baf64ed_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA1OA_99c718c7-1182-41bd-b775-0c7b0e3b47c0"
      unitRef="shares">395795</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA3MA_998788b3-5aba-4671-9643-f2aad9e344e5"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i8842228fdf1940c7b1002d140baf64ed_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA5MQ_da0571d0-c283-4bcd-a454-b9e257a3d845"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue
      contextRef="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA3NQ_afdb0bc3-9ad1-438d-a821-6f7a7771bcf0"
      unitRef="usd">25000000</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i8dcdb00122c94a4ea32e686d7cc73a60_D20201014-20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA5Ng_1c280f2c-ba22-4b8c-8275-4e16c4c9fe48"
      unitRef="shares">600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm
      contextRef="ibd7daecd893b478db292941cdfb8d361_D20210101-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTE1MA_d620ef57-f234-4776-9ae8-19cf1f0a99be">P10Y</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="i8842228fdf1940c7b1002d140baf64ed_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTA4Nw_c7e947d1-d9bb-4bbd-b43f-6bf028714cd6"
      unitRef="number">0.01</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iaf6c1f46b13448baa40f5da3fc4f9b3a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzOTQ2NA_e97b563c-485e-47e3-9c52-be4df20d50d6"
      unitRef="shares">393689</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="i913ac2af34fd4ec98af9b2bb3e0c81da_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzI5ODUzNDg5NDExOQ_5a98449f-06e2-46f3-9843-54ee5a207433"
      unitRef="shares">423388</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTExOA_43efc6ee-f8df-47b2-bc35-e7104d3df6d9"
      unitRef="shares">2106</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTEwNA_29462bb4-0ef8-476f-98f1-b7b91ed4367e"
      unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i285a21f9461d4185ba105fc77795dd4e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfNTQ5NzU1ODE0OTEyNw_f99ca7df-19ac-4a95-acf3-a27a5f17e4a9"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNQ_623d2835-049d-4a5c-bf9a-a84b86293c2a">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied1cbb318d64475ea98211bc07f51f73_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMi0xLTEtMS0w_7ab4cf12-0e19-4870-98dc-b43031ecb1a0"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie81735796faf4a8a9e36cbc592eb5f3d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMi0zLTEtMS0w_82df9ce3-1f79-413d-befd-2db64fcfd508"
      unitRef="usd">531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i978d55b8117440bcb06be5d1eba9a7db_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMy0xLTEtMS0w_e5426298-1a10-4f68-8fae-47cab65129da"
      unitRef="usd">3267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6a0ec0b83ac44b2a0e7939e7f49c2e8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfMy0zLTEtMS0w_f90c9577-b374-4a61-805f-efcbb3f9abd9"
      unitRef="usd">735000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfNC0xLTEtMS0w_68134111-aef3-430b-89be-29ae1c7275c5"
      unitRef="usd">5467000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjVmYjVmMmVmMWExNTQyM2I4NmFlZjA4NmI4MzUzMDQ3L3RhYmxlcmFuZ2U6NWZiNWYyZWYxYTE1NDIzYjg2YWVmMDg2YjgzNTMwNDdfNC0zLTEtMS0w_a577cde6-8a04-4872-bc6b-fb7619e4914b"
      unitRef="usd">1266000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNg_7bb24ac8-b18c-4393-8656-d272a75ee421">&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan and the 2016 Stock Incentive Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMS0xLTEtMS0w_d1942458-2879-441c-9e27-ba9577c5fedf"
      unitRef="shares">2742022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMS0zLTEtMS0w_2a9af510-19fd-4885-b897-cd627c5af17e"
      unitRef="usdPerShare">7.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMS01LTEtMS0w_303c082d-17e3-454e-bdf5-09e9a72ce66b">P8Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMi0xLTEtMS0w_109468c5-7368-4aa5-99ae-95845664823c"
      unitRef="shares">325671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMi0zLTEtMS0w_24b4482e-04c1-4a20-bf91-3cd3226f628d"
      unitRef="usdPerShare">23.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMy0xLTEtMS0w_e7b50c8f-419c-4847-b3b6-e780560acb7c"
      unitRef="shares">557609</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfMy0zLTEtMS0w_12f5b4bb-8cf1-4a1e-b38e-b505f8b53db1"
      unitRef="usdPerShare">3.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNC0xLTEtMS0w_f1045c1f-5a79-48bc-921b-60677aa880e5"
      unitRef="shares">61408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNC0zLTEtMS0w_9e20c7e1-e3f3-4389-adcd-669ef39cc3ee"
      unitRef="usdPerShare">12.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNS0xLTEtMS0w_db3ac5fa-8286-47db-82f2-32c65945c534"
      unitRef="shares">2448676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNS0zLTEtMS0w_cbe3b997-63b6-42db-b2d7-cb90b90e9fdc"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNS01LTEtMS0w_e6306c6d-b0ea-4a8d-af61-b1d4cd396859">P8Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNi0xLTEtMS0w_06b82025-00d8-4d31-8a03-9794317a08f2"
      unitRef="shares">2418923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNi0zLTEtMS0w_25930cae-4522-488b-8d19-423341bf7644"
      unitRef="usdPerShare">10.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNi01LTEtMS0w_0b26da85-d6e1-48fc-869c-60b8e83af190">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNy0xLTEtMS0w_4ea51021-5a44-4d67-918d-bb8cdd3eba9f"
      unitRef="shares">1259440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNy0zLTEtMS0w_39b2e20c-2651-45e8-8105-82a2b7633400"
      unitRef="usdPerShare">6.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOmJiMjFiMzVhYWZiNjQ3MmRhYzc1ZTk2N2IwN2I5MTUxL3RhYmxlcmFuZ2U6YmIyMWIzNWFhZmI2NDcyZGFjNzVlOTY3YjA3YjkxNTFfNy01LTEtMS0w_125b5230-23d3-44fe-9702-13956f585a8d">P7Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5NA_f64f5b24-6e8b-41db-ad3f-88187121736e"
      unitRef="usdPerShare">16.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzMTc1Mw_5bcad1af-a1ae-4788-9fc7-977851423a7a"
      unitRef="usdPerShare">8.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTE3OA_1b2df4e4-4318-4f10-bce8-d42e4aa81c72"
      unitRef="usd">11400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6dd78bd931e046948447da6b4292615e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTI2Mg_718bdedf-28d9-47d9-8dcb-8b99c80fba06">P2Y5M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTM0NQ_29dfe12f-e6a4-420a-bb3a-c0bb32959d2c"
      unitRef="usd">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTA5OTUxMTYzMTc1OA_975099db-bc9d-4aa3-82a3-24054caa6611"
      unitRef="usd">49700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTQ1Mg_4f4736e3-d5f7-4494-bf54-18f15ff6ba1e"
      unitRef="usd">5900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMTQ1Mg_fad1eec9-83ac-4b59-b40c-88f2fc0a3c55"
      unitRef="usd">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6dd78bd931e046948447da6b4292615e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMjYzOQ_82f77bb5-c190-44f3-bc8f-e6eb7fb4d654"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzNw_ce253642-ce14-4bf4-98d0-67efce8855b1">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options granted under the Company&#x2019;s 2020 Plan were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued under the Company&#x2019;s 2020 ESPP were estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMi0xLTEtMS0w_cc595adf-00e4-4e2f-8082-b4129e54a005">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMi0zLTEtMS0w_808f38db-3998-48da-9925-ec79ec5fefc2">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMy0xLTEtMS0w_1daad8e4-c4cf-4407-bb54-167d484467c1"
      unitRef="number">0.814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfMy0zLTEtMS0w_d896405b-1e57-4669-9a1f-c3ac19f9f302"
      unitRef="number">0.753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNC0xLTEtMS0w_e8e3bb8b-a1a9-4ccd-8a71-e1ecab9c0e41"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNC0zLTEtMS0w_972b4836-a182-4583-b93d-28ae27cc354b"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNS0xLTEtMS0w_c74172c6-d3db-40bf-b9d1-5d2f54f9ecc6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3052bf41e02049b8b87f4da3260714e9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjZmZDZhOTM1MTUzNTQyYmZiYjE1M2QzYTI5MGRlZGM2L3RhYmxlcmFuZ2U6NmZkNmE5MzUxNTM1NDJiZmJiMTUzZDNhMjkwZGVkYzZfNS0zLTEtMS0w_7f733cfc-ca68-4d26-b47a-6294416bd6ae"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RleHRyZWdpb246YjcyM2EwN2Y1YzQxNDQ2YzkyYjdlMzEwY2NiNmRiNDhfMzkzMw_d3716628-3760-4580-8193-a9f2cb46b146">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to these shares:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i76d2b249a41e4985a2641c447e8e27d7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjg0OTk2MmVkYzA2YjQ4MGRiNDZlMTFkYmIxNzdkOTcxL3RhYmxlcmFuZ2U6ODQ5OTYyZWRjMDZiNDgwZGI0NmUxMWRiYjE3N2Q5NzFfMS0xLTEtMS0w_bf522af5-7dd8-4f47-bb51-dfc3fdd21bc3"
      unitRef="shares">11752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1853d269d625472aa52bdf974466c9d8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjg0OTk2MmVkYzA2YjQ4MGRiNDZlMTFkYmIxNzdkOTcxL3RhYmxlcmFuZ2U6ODQ5OTYyZWRjMDZiNDgwZGI0NmUxMWRiYjE3N2Q5NzFfMi0xLTEtMS0w_dfe6bd1e-c764-4fc5-898b-413f9b405e95"
      unitRef="shares">11752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i43ef9bb233dc4b89a2c5f083ab045bbf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjg0OTk2MmVkYzA2YjQ4MGRiNDZlMTFkYmIxNzdkOTcxL3RhYmxlcmFuZ2U6ODQ5OTYyZWRjMDZiNDgwZGI0NmUxMWRiYjE3N2Q5NzFfMy0xLTEtMS0w_eecf3e38-4c21-44b3-b08b-6d83186e1a94"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMi0xLTEtMS0yMDM3OA_9bb090ea-5a13-4697-9e61-9988845d7ec8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMi0zLTEtMS0yMDM4Mg_4419fbaa-80ce-44cf-9715-de1f825449df">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMy0xLTEtMS0yMDM3OA_d3dbdc17-039b-457a-8716-783be73cac99"
      unitRef="number">0.813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfMy0zLTEtMS0yMDM4Mg_6b63a96a-1510-4a49-b583-ccc18eb60e00"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNC0xLTEtMS0yMDM3OA_f3d08896-36fc-4421-8d32-da7a485e6db6"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNC0zLTEtMS0yMDM4Mg_0774495e-ee8a-4a41-b701-89dde307308d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNS0xLTEtMS0yMDM3OA_1d61d9c9-c51a-4d73-bdbd-96f9f0a49710"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5ed361925c3d44e1b4685d7fce88d1bd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185NC9mcmFnOmI3MjNhMDdmNWM0MTQ0NmM5MmI3ZTMxMGNjYjZkYjQ4L3RhYmxlOjNiZjIxOWE5MjFkMjQwN2M4OTgwN2I5MWU4M2Q1Y2YzL3RhYmxlcmFuZ2U6M2JmMjE5YTkyMWQyNDA3Yzg5ODA3YjkxZTgzZDVjZjNfNS0zLTEtMS0yMDM4Mg_8ba96cd8-f12f-4456-96c9-6e8baaa26758"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjc5OQ_77d5d709-96e7-42c0-ae9a-beada8adb744">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded no federal provision for income taxes as of December&#160;31, 2021 and 2020 due to reported net losses since inception. The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows for the years ended December&#160;31, 2021 and 2020 (amounts in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are as follows (amounts in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties regarding the realization of the deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by $13.0 million and $8.7 million during the years ended December&#160;31, 2021 and 2020, respectively, primarily due to continuing loss from operations, general business credit carryforwards, and accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had gross U.S. net operating loss (&#x201c;NOL&#x201d;) carryforwards of $97.4 million and $47.1 million, respectively. Additionally, as of December 31, 2021 and 2020, the Company had capital loss carryforwards of $2.3 million and $0.1 million, respectively. As of December&#160;31, 2021 and 2020, the Company had gross state NOL carryforwards of $0.2 million and $0.2 million, respectively. As of December&#160;31, 2021 and 2020, the Company had gross U.S. tax credit carryforwards of $7.6 million and $4.5 million, respectively. The NOL, capital loss, and tax credit carryforwards will begin to expire in 2036, if not utilized. The NOL, capital loss, and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or credit carryforwards are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2019 financial statements were filed, the Company completed a Section 382 study from formation through October 14, 2020. Although an ownership change occurred during 2020, no deferred tax assets were impacted by the limitation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of our liability for unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s gross unrecognized tax benefits, if recognized, would affect its effective tax rate. The Company does not expect unrecognized tax benefits to decrease within the next twelve months due to the lapse of statute limitations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December 31, 2021, the Company has not accrued any interest or penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2018, 2019, and 2020 tax years. There are currently no federal or state income tax audits in progress.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjgwMA_eb6b5ca6-f587-4c75-a7f1-e1f5d1467bde">The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows for the years ended December&#160;31, 2021 and 2020 (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMi0xLTEtMS0w_5895adb5-1d52-4b4e-aa6e-920b3c9ad53a"
      unitRef="usd">-9445000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMi0zLTEtMS0w_aaa7ed02-8a9d-41fe-b79d-0be4021d84ee"
      unitRef="usd">-7687000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNC0xLTEtMS0w_a1531a08-c9ae-4419-8487-626ccb7b2995"
      unitRef="usd">13045000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNC0zLTEtMS0w_0b4295d3-4285-44e1-8f06-8582d4b5cd05"
      unitRef="usd">8717000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <sttk:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNS0xLTEtMS0w_dffd62cf-f9ee-484f-9cab-90b26858548e"
      unitRef="usd">0</sttk:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment>
    <sttk:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNS0zLTEtMS0w_b8b89229-f448-4272-9860-a606b348d87c"
      unitRef="usd">-745000</sttk:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNi0xLTEtMS0w_790fbd8a-0e0a-4da8-9e30-35bcaa294e9b"
      unitRef="usd">3108000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNi0zLTEtMS0w_a4cc159f-30c7-4251-9f39-0525a90ae34f"
      unitRef="usd">1114000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <sttk:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNy0xLTEtMS0w_33a89de0-9034-4665-bca9-cb8d9e7d8744"
      unitRef="usd">0</sttk:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount>
    <sttk:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfNy0zLTEtMS0w_a8364266-d535-44e8-aab3-4cd137660db3"
      unitRef="usd">119000</sttk:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0xLTEtMS0yMDc0NA_a491d661-62ea-4e13-ae8e-18817fb63a74"
      unitRef="usd">-1923000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0zLTEtMS0yMDczOA_77f6d7f8-1ef0-4f6b-8300-3b124848ddef"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0xLTEtMS0yMDc0NA_88581f59-f9d8-42ba-89bd-0170b6b44981"
      unitRef="usd">809000</sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M>
    <sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0zLTEtMS0yMDczOA_2d86dce4-0b0e-4d1c-99cd-d8db55d1c6e5"
      unitRef="usd">0</sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0xLTEtMS0w_68bc1544-bef8-48b0-b80b-3f92263c1266"
      unitRef="usd">622000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOC0zLTEtMS0w_223f6a1d-62b2-41d4-8654-e0e48c05c55b"
      unitRef="usd">223000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0xLTEtMS0w_9f24706e-3c55-49b9-9591-108b04192c34"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfOS0zLTEtMS0w_140edf0b-b55f-44d4-b2a5-655c82420cd3"
      unitRef="usd">487000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMTAtMS0xLTEtMA_b46a7575-ce1b-499e-bf76-aed63684ec34"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjBjNzgwMjE3NTA0ZDRkOWJiNzY5MmVkMmNmMTFhZThkL3RhYmxlcmFuZ2U6MGM3ODAyMTc1MDRkNGQ5YmI3NjkyZWQyY2YxMWFlOGRfMTAtMy0xLTEtMA_f914249e-e226-4c03-9217-96b6637773dd"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjgwMQ_ee26788b-5333-43e2-83ca-657139be9006">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are as follows (amounts in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMy0xLTEtMS0w_5f848a78-0f08-48dc-8a22-cacc2f466e9d"
      unitRef="usd">20460000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMy0zLTEtMS0w_f58a90ae-86b7-418f-810a-652c4954b63b"
      unitRef="usd">9891000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNC0xLTEtMS0w_fb8858f1-8776-4564-a7bc-2d94644cef08"
      unitRef="usd">3520000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNC0zLTEtMS0w_4ea23b5f-e908-4ade-80a3-874db2455b1a"
      unitRef="usd">1345000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNS0xLTEtMS0w_59b2e81b-f26a-49cb-b6df-bf310d461cf1"
      unitRef="usd">779000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNS0zLTEtMS0w_720288e3-3bc6-47bd-ac4d-f15ee6754463"
      unitRef="usd">182000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNi0xLTEtMS0w_10ac4e28-900e-498f-921c-66dfbe310ff0"
      unitRef="usd">6194000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNi0zLTEtMS0w_2cda3a25-6e34-4725-88dd-d432b2a8d912"
      unitRef="usd">3708000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNy0xLTEtMS0w_f71de687-5099-4e6f-8075-efa113b86e4c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfNy0zLTEtMS0w_f1ad8e67-96e3-4731-a937-7999f20b99a5"
      unitRef="usd">2631000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOC0xLTEtMS0w_32f99dc2-967c-4600-841a-c6df17eef71b"
      unitRef="usd">484000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOC0zLTEtMS0w_a1cd9d88-9cf1-4d1a-8164-856dcb59a65b"
      unitRef="usd">27000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOS0xLTEtMS0w_87c775f7-ce9e-49b7-ab91-3bbf9e5dfec1"
      unitRef="usd">31437000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfOS0zLTEtMS0w_68beb275-1ae5-43ec-bd8e-b8f8f5b6ab7a"
      unitRef="usd">17784000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTAtMS0xLTEtMA_e3bf9c0c-822b-4596-a9db-47d5458428f0"
      unitRef="usd">30331000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTAtMy0xLTEtMA_053eb2ef-17ce-4b98-9d50-449912506866"
      unitRef="usd">17285000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTEtMS0xLTEtMA_78dd4297-0a4c-4522-9969-b8b6ce2cfa02"
      unitRef="usd">1106000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTEtMy0xLTEtMA_62203f8e-2d61-48ac-a153-e71e358c3fa4"
      unitRef="usd">499000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTMtMS0xLTEtMA_2cfe9611-1411-4066-9908-f6ba6094ba4a"
      unitRef="usd">578000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTMtMy0xLTEtMA_5565ffd6-4853-462c-bb67-e736f34f6e79"
      unitRef="usd">121000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTQtMS0xLTEtMA_9d21785b-714f-42cf-8b7c-b92d22a00cf1"
      unitRef="usd">528000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTQtMy0xLTEtMA_74127211-8072-4cb3-9e5b-18bd48883ad0"
      unitRef="usd">378000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTUtMS0xLTEtMA_b568da48-99e4-46f2-a015-7453e8001e33"
      unitRef="usd">1106000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTUtMy0xLTEtMA_f6f83f2f-e37b-4e21-bbac-5b86330a81dc"
      unitRef="usd">499000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTYtMS0xLTEtMA_796f4e92-def1-40af-821e-93356b54027b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjcwYWQ0Mzk4MmJhNDQ5ZjNiMmVlNWIyY2U5Y2JjY2I4L3RhYmxlcmFuZ2U6NzBhZDQzOTgyYmE0NDlmM2IyZWU1YjJjZTljYmNjYjhfMTYtMy0xLTEtMA_45676308-f326-44f9-9c21-620fe92771ef"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfNzQ5_21dce1ea-b499-44b1-80e3-c117325ba8a4"
      unitRef="usd">13000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfNzU2_22c1c2ec-8a0a-4096-8996-9b884406df8d"
      unitRef="usd">8700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idfb12636928d4d21b00a09885bc9f550_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTAwNw_e20f39dd-b101-4cfe-a129-e2f98a271210"
      unitRef="usd">97400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i592680b58da94f418a342d39beb4d6a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTAxNA_0885bb2c-0859-410b-b5b3-49b06fe6f297"
      unitRef="usd">47100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i1394695528d34d00a6380d9c1031687d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTA5OTUxMTYzMTU4OQ_0454f1a5-5f3b-4214-ad71-352bcb632dd4"
      unitRef="usd">2300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i56b14739a6c64b198bf3d0441927bd8c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTA5OTUxMTYzMTU5Ng_626cf9fe-7869-4604-b69e-80ddb96f89c5"
      unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3e068c367ec34e2ab303dcd0a6d4da40_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTExNA_b0169653-8bcd-4408-a606-ef0b36be1a59"
      unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i5e4714dd5ac54741bc7b7aa1ad1ce320_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTA5OTUxMTYzMDYzNw_e6ece89b-a775-4f9a-8715-edae1484acf5"
      unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="idfb12636928d4d21b00a09885bc9f550_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTE5Mg_ebfe3f5d-650e-4e67-8453-ce53ad0ce357"
      unitRef="usd">7600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i592680b58da94f418a342d39beb4d6a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMTE5OQ_aa06b8bc-8353-4f9e-9095-63f8e96310fc"
      unitRef="usd">4500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RleHRyZWdpb246NTIxNzUyZjVhYmM1NDU4YmIzZDdlM2ExMWUzZDljMTZfMjgwMg_a00381f1-781c-4662-803d-f44f762444d1">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of our liability for unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMi0xLTEtMS0w_25189aee-dc22-404d-a510-dca8bf200910"
      unitRef="usd">783000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia2e6543ccfb74775ac5df4a5733524f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMi0zLTEtMS0w_745a4072-35b5-4586-be98-800923647a14"
      unitRef="usd">560000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMy0xLTEtMS0w_1273daee-d359-46bd-8a75-ee541b7395d5"
      unitRef="usd">449000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfMy0zLTEtMS0w_8475bf9d-8b5c-4ed4-9bea-ed3ebca209aa"
      unitRef="usd">223000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNC0xLTEtMS0yMDg2Nw_99f7660f-726a-47d7-b324-c6ac5daa9acb"
      unitRef="usd">172000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i73f2d7b21c5b44ab936e62ec14b2391e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNC0zLTEtMS0yMDg3OQ_0e102bfe-a916-4934-811f-4d7df9f8d35a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNS0xLTEtMS0w_d3318950-d2f5-414c-b2c2-6bf858259d8b"
      unitRef="usd">1404000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3f3f5a50ece747008b59441f4cb5f1a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y185Ny9mcmFnOjUyMTc1MmY1YWJjNTQ1OGJiM2Q3ZTNhMTFlM2Q5YzE2L3RhYmxlOjJiNDA0ODQ4MmY3NzQzZjk4YTc1NzA5ZTE5N2Y3OWZhL3RhYmxlcmFuZ2U6MmI0MDQ4NDgyZjc3NDNmOThhNzU3MDllMTk3Zjc5ZmFfNS0zLTEtMS0w_88db76b9-5798-405b-b5ce-32d53efb193c"
      unitRef="usd">783000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMDMvZnJhZzoyZmY0ZjFmZTFmOWI0ZWFmYWQ4ZDZhNTVlY2FkNzAyMS90ZXh0cmVnaW9uOjJmZjRmMWZlMWY5YjRlYWZhZDhkNmE1NWVjYWQ3MDIxXzkxMg_b16b3f11-fd6d-4e7d-872c-116714aec1cc">Related PartyAs of December 31, 2020, Takeda held an approximate 5.0% ownership interest in the Company&#x2019;s outstanding shares. Considering the resignation of the Takeda director and percent ownership of the Company&#x2019;s common stock as of December 31, 2020, the Company no longer considers Takeda a related party.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <sttk:ShareholderOwnershipPercentage
      contextRef="ic68499c9c9c54c7ca37c93a1819e89f8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMDMvZnJhZzoyZmY0ZjFmZTFmOWI0ZWFmYWQ4ZDZhNTVlY2FkNzAyMS90ZXh0cmVnaW9uOjJmZjRmMWZlMWY5YjRlYWZhZDhkNmE1NWVjYWQ3MDIxXzU0OTc1NTgxNDIzNzg_6ee82e6d-bbc8-4ae1-a1e8-b23b85e4699f"
      unitRef="number">0.050</sttk:ShareholderOwnershipPercentage>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMDYvZnJhZzo2OTY5NjdmNTk1YTU0MjhjODEwZDhkMTI5NjQ0YmQ5Zi90ZXh0cmVnaW9uOjY5Njk2N2Y1OTVhNTQyOGM4MTBkOGQxMjk2NDRiZDlmXzU5NA_b22d6e61-a105-4509-9fd1-19b2567c3f95">Subsequent EventsNone.</us-gaap:SubsequentEventsTextBlock>
    <dei:AuditorFirmId
      contextRef="i37b06acb50a449ef9343f66141212130_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNzU3YWUzMGEyMzQ5NDBhYTQzNzFlNjYzNTIyNTljL3NlYzo5Mjc1N2FlMzBhMjM0OTQwYWE0MzcxZTY2MzUyMjU5Y18xMzMvZnJhZzpkZDgzOWZjN2MwYTc0MzNlYmUwNDA1NTE5MjA3ZjQ2MS90ZXh0cmVnaW9uOmRkODM5ZmM3YzBhNzQzM2ViZTA0MDU1MTkyMDdmNDYxXzEwOTk1MTE2MzQxNTU_72c3db57-e321-47a1-9568-59a9d49d31dd">185</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@D;#X90*QF60Q/YLJY-855AP"5M-3"4$TW\74*AZ%H3!Z>"1'W)T!S2)2W:
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M*5 -W@CH[SNNJ>3X8"Y?FLNVU;]02P,$%     @ 3#!O5+H\FS!_ @  PP8
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M,,BP%:H=F6U@9..FSE(:G&%N6>%7!I1-P/LK*<UC8 =9_]W*_P)02P,$%
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M5P;P?<.8?'U1"Y3_BQC_#5!+ P04    " !,,&]49#UO@+,'  "[)P  &
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M[QLPQ=?:)G[Z&+*=%)$'9JF]M]@2Z>:;8IL7.5V57XJYIWE.X_)Q27S&:06
MO?] :;Y]47S/9O=]O?/_ 5!+ P04    " !,,&]4Z/T)6]<&  #D'   &
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MW4D.NN1#4AS+L9;V#)H+ZG72@T"T;Y)GOD8UMLK3 4,+^2IA%N(G:5'^O+>
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M>H9VP5^5\D5T'7_)*5R,KN6?( ](30OPO':0S/Z"#A@_[5W]&U!+ P04
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M\WR0$.V=QD.+[_.H;2ZTC0@Y-@&(J5W*@4Q2NAF%0[L\3:-YG@78XC16Z/C
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MR</B/"?C/,R*%/YU1]'1;R]0;[VXW4RH[4$!T^[T?JP&V?P*'QZ?&Z:WG33
ML:'4^.R\"$ /@AX<JWHOHE)9DJ0W6WH#4;L .F^4L@?'%9A>U>5/4$L#!!0
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M)L*EAW_Z"+:-CVUD#T_W.%Q!,.1X ]8K:\/PP0[&7U\7?P-02P,$%     @
M3#!O5"!QSZD$ P  O@8  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MG55-;]LX$/TK VW1D]?ZL)TXK6T@3EJTAV*-)ML]%#W0TE@BP@^5',7)O^^0
MLI4$2()V+]*0,_/FS8A\6NRMN_$-(L&=5L8ODX:H?9>FOFQ0"S^V+1KV[*S3
M@GCIZM2W#D45D[1*BRP[2;60)EDMXM[&K1:V(R4-;ASX3FOA[M>H['Z9Y,EQ
MXZNL&PH;Z6K1BAJOD/YM-XY7Z8!228W&2VO X6Z9G.?OUM,0'P.^2=S[1S:$
M3K;6WH3%YVJ99($0*BPI( A^W>(%*A6 F,;/ V8RE R)C^TC^L?8._>R%1XO
MK/I/5M0LDWD"%>Y$I^BKW7_"0S^S@%=:Y>,3]GWLY"R!LO-D]2&9&6AI^K>X
M.\SA4<(\>R&A."04D7=?*+*\%"16"V?WX$(THP4CMAJSF9PTX:-<D6.OY#Q:
M;7@(Z!Q6<$6VO%FDQ*#!E98'@'4/4+P D!?PQ1IJ/'PP%59/ 5)F,U JCI36
MQ:N(EUB.89*/H,B*_!6\R=#B).)-7L"[1MU:QR<./OSL)-W#I?2ELKYS"-_/
MMYX<'XT?KQ2:#H6FL=#T_\_RCP N.R=-#=0@W*-P@&' P.-!O45W'%$VBA$7
M5K?"W',084"0ABS<"B=MY\$'.&@[5S9\@D'4#I%O%GD^;=2 X<LC3 5X)SV%
MDM+<(N<X'W)\)PP!H^T;639/BGFK*LYD0$:L!2',9MEH=IJ#;X1##W8'5^@D
M6VN^PA57%5N%4%HNX$@&NQV:[ED&(OEHDI^-SDZFS^#\G?\V$L&;DV(\GV>S
M'%J>6 0#5C+NF#C<EHA5!'^3YZ?CC"^84JP5X^N''M_^-2_RT_?^6/]\]-!1
MH/KGM Z^XS<JK=8L3[VO:]D,$^;=5F$4+J9'S_#YO/F' >()B$1"C L:Y$>'
MDFA*Y$5THM,>0O?&@K*FYFF(ME6R#'2?._OI(TW1Z.JHG)YY=89Z>1EV!W$^
M[S7I(;Q7]B_"U=)X4+CCU&Q\.DMZIL<%V38JU-82ZUTT&_[!H L![-]92\=%
M*##\LE:_ %!+ P04    " !,,&]4)^QZ=S $  #I"0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6RM5MUOVS80_U<.:E%L@&/9BIL:C6/ 23>L#]V"
M--T>ACW0TDDB0HDJ/^)H?_WN2$NQ@3A[Z8LMDG>_^]TGN=II\V!K1 =/C6KM
M55([UWU,4YO7V @[U1VV=%)JTPA'2U.EMC,HBJ#4J#2;S2[21L@V6:_"WJU9
MK[1W2K9X:\#ZIA&FOT:E=U?)/!DV[F15.]Y(UZM.5/@5W;?NUM J'5$*V6!K
MI6[!8'F5;.8?KQ<L'P3^E+BS!]_ GFRU?N#%Y^(JF3$A5)@[1A#T]X@WJ!0#
M$8WO>\QD-,F*A]\#^J_!=_)E*RS>:/67+%Q]E2P3*+ 47KD[O?L-]_Z\9[Q<
M*QM^81=E%[,$<F^=;O;*Q*"1;?P73_LX'"@L3RED>X4L\(Z& LM/PHGURN@=
M&)8F-/X(K@9M(B=;3LI79^A4DIY;DS=*;+41(4:;RB!2R!V<P1TJX;" 6V%<
MOTH=&6.5--\#7T?@[ 3P/(,ONG6UA5_: HMC@)18CE2S@>IU]BKB)\RG<#Z?
M0#;+YJ_@G8^NGP>\\Q-X1P["O1&M%:%4+/R]V5IG:/7/*W86HYU%L+/X\2'^
M(<#W-<*-;CK1]M1&N:Y:^2^=&7S$UB-08X,C$:&4SH.6[\Y*0[F#3O0,:,%;
MV58@(-?6G7$3%"#;SCMH4%AO< J?J<&Z3O4LQV@O2+I:%Z#+T?">"Y.?!)V!
MI&<M"KX7*N!8@LB],8$T.49M#$[#UA<5,M\H@T\==3HM^0B?50;_<MUL*8 %
M=&C",&MS!+U5L@KQ"RYL?$4M1P4V_W!,B:* )OA"Z ).17XG70WWX@$+$:E&
M.HQ4D-=*=T&,@I"C<30R87-W XVF&>45V@D("X)$BF *-IV1BMDL)_!'[O06
M35B!: OX(DQ><R_,X"<V\.[-,LMFER>HA=/YY<]3B.5P@C_9;SP'7O5 'M/
M"3YTWE@O2"!X/QR$J3KJ%D'R=_V(#?-<QCX]XG9_H/@"LV_D=\P56[ <)EZ\
MJ'6<'FFAU8Y"_MU+$V-N2<&6/<2JY^N)2_/EW-MCM)U4*N UE,D ,#8" 5,Y
M4>4B%R$?E10N@S2:*7].MQC.=2^4.U"C=FKV=3$)R:, @^[BL"%,)7.ZYS <
M&;Y'@O.E-%2,+5;:R>A^C:J ;3^4F!\#=C*A5+4'B8S9?PX'75^X[ZO8DUP
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MIUAZADB,YW,V;6>ABN/83??Z#[+/MAN\:1P90FHOS@)OQ"\>3_W&$S9DN@8
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MK?B11!<"^'QK+1V-D&!X=A<_ %!+ P04    " !,,&]4$%WZZ]P!  !6!
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MXF^5JV!Y269(S0$TS5:P6%1,( 7\ "^I1@./8Y0[U6PU2\ZXLMO#XIH2I]S
M!F?&(!G.:/AX5;Q.ST?N+0JS@0>/"YH35^JJ)!VF 7^[W1E8)'QVA%T&DM'%
MI\;>-B*J%KD!K  7Y$&+NAIX84#XKM@XN\\T!_?*Q;.7/A&P*JYD(6'2URSW
MTT<+6Y:=<XD\#Y3 _']T"E3*(4O0U"Z$6 /#D!J,#3HB6UJ+T[7"=]:J1EX6
M#$G$;OBY+?XT;O&GLQOTC3*N^ ?H@NX;Z;<-&.:.5'-LU__E00MZYH:> 7,+
MB '&P)W#D@:SIGG7WI+\UL0;#5"E*KJ#%8:KFB90#>XX8(QUQ4&9[ GP+8W?
ML# 4J*I:FQKMB4'V%JA<#M29GE*,A]:ZO46[#4[^$XP(=JH%'P["0@UFX['7
MRG>.30\X/$V2"BK*=AQWHROVUH.PJAMX&13.=CZ,"F9-3%(@.Y*VRAF3S<2[
ML*SA#; YR"G<X<:7M?6L@K8A9I 9LS7@2C15)="WM;#E_(N"/,/3E\4[M O%
MQ8OBU[77[D:M:U3V0P=S^ YMAP<=MJAV) ;:H0P3A7Y/"S 5D(4&@5?!@F.#
MBC/CE\#IG4@T<!YL-;HU[W$:(7?(T)<#4B]?@.8@?8O"PO/$N^9S-"Z$P\ U
MF]:I#0U0@0LI6Q ]KJ,)O[TDIO;G?OP"W*X]851N@QQI,*RN175T8+B#G&$Q
M*NQ_<5SC7 *NB+4N#(Q.IBSYD'OK!!MPT7W0 +!514W+ $X3Y<P4(-=GS@MF
M'XAA17YZ:*50SMZ3F$1R:922=Z)LF*Y6+DS(@V]&5Y#<^>]=M<5/ KOVZI@[
M[)ZW(GUBG4.!A;UCQ/O"US#7H58ESX'@(?CW1,7. ,H"5WED#GE><J7!=$-
MT9LKO>798Z,] O86+: .U 56:K3)S,BTRU&:R=V/$[T("[+P$ Y>@E,QP!OC
M/]&SK/3H1:VC?2-<JWIB0KSD85/B(_W=2EL0S$2FM<GB>;%&D:69-3+!RS$
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MO2T:9>@J.6PSS*,,5QI*RIC7WH?%9L?'U8RCBWWSP^[;P:FYB?;;>#HVW!F
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MQ@O0?:DI??W&.QC>X-7_4$L#!!0    ( $PP;U1,HN$>V (  ,<&   9
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+U5VV[;, S]%<(;AA;(XDLN[;(D
M0*];@14HFK9[&/:@V$RL599<24Z:??TH.7&SH0GZM!=;O!T>DA8]7"K]:')$
M"\^%D&84Y-:6@S T:8X%,VU5HB3+3.F"61+U/#2E1I;YH$*$213UPX)Q&8R'
M7G>CQT-56<$EWF@P55$PO3I%H9:C( XVBEL^SZU3A.-AR>8X07M?WFB2P@8E
MXP5*PY4$C;-1<!(/3KO.WSL\<%R:K3.X2J9*/3KA*AL%D2.$ E/K$!B]%GB&
M0C@@HO&TQ@R:E"YP^[Q!O_2U4RU39O!,B>\\L_DH. X@PQFKA+U5RZ^XKJ?G
M\%(EC'_"LO;M=0-(*V-5L0XF!@67]9L]K_NP%7 <[0A(U@&)YUTG\BS/F67C
MH59+T,Z;T-S!E^JCB1R7;B@3J\G**<Z.)[G2]N,=Z@*NY *-I89; P=W;"K0
M' Y#2TF<:YBN 4]KP&0'8)S M9(V-W A,\S^!@B)74,QV5 \3?8BGF/:AD[<
M@B1*XCUXG:;DCL?K[,#;JK,%YSBUP&0&%T\5MRN88%II;CD:^'$R-5;39_-S
M3])ND[3KDW9W]9EN4U8)!#4#MF!<N/X"72HPC [&C\&Z,? 7>J]U?V\:=X4'
MIF0IC@*ZHP;U H/Q7>XR";I_7,[!^LP:O=W-VI+Y3!4EDZL/[XZ3^.BS>3M%
MF*[H<_SEG.K.K<"N2H0#5JC*V;FD!*HRU&-S.*!^IUA,43<#A9."</EOS(B$
ML?!%*V/@7M*&$5[[S<EWRC(!EXQK>&"B0IB\RF8 ]^U)&^9J@5HZS8:5F^=[
MB(^.6M&G/IT.>OWHT&OZK5ZGO\;?4>*^P'_KB?YW/?VXZVCU.X=K1:\7OZ6<
M5^->^]##K>52H)[[%6H@=>.M]TRC;;;T2;V<7MSK%7_-])Q+ P)G%!JUCWH!
MZ'IMUH)5I5]54V5I\?EC3G\:U,Z![#.E[$9P"9I_U_@/4$L#!!0    ( $PP
M;U1&^-?\T0(  / %   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(54
MVV[;, S]%<+80P(8]2U>+D@")+U@ U8L:'=Y&/:@V'0L5)9<26[:??TH._%2
MH,U>+%$B#\^A3,[W2C^8$M'"<R6D67BEM?4L"$Q68L7,A:I1TDVA=,4LF7H7
MF%HCR]N@2@1Q&'X,*L:EMYRW9QN]G*O&"BYQH\$T5<7TRQJ%VB^\R#L>W/%=
M:=U!L)S7;(?W:+_7&TU6T*/DO$)IN)*@L5AXJVBV'CG_UN$'Q[TYV8-3LE7J
MP1F?\X47.D(H,+,.@='RA)<HA ,B&H\'3*]/Z0)/]T?TFU8[:=DR@Y=*_.2Y
M+1?>Q(,<"]8(>Z?VG_"@)W5XF1*F_<*^\QU1QJPQ5E6'8+(K+KN5/1_J<!(P
M"=\)B \!<<N[2]2RO&*6+>=:[4$[;T)SFU9J&TWDN'2/<F\UW7**L\N-IO?5
M]@68S.'ZL>$U5=S"X!O;"C3#>6 IB7,-L@/@N@.,WP&,8KA5TI8&KF6.^6N
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M4L.+R\P#-:AZ<(SLG))R:4B7SJSI(41E VB_DM+L'5M@>EJ7?P!02P,$%
M  @ 3#!O5+)I.)BS @  P04  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&ULG51-;]LP#/TKA-%#"V1U["1M&B0!DG3#=BA0M-UV&'90;,86J@]/DIOV
MWX^T$S?;VAQVL2F)?.^1$CG=6O?H2\0 SUH9/XO*$*I)'/NL1"W\N:W0T,G&
M.BT"+5T1^\JAR)L@K>*TW[^(M9 FFD^;O5LWG]HZ*&GPUH&OM1;N98G*;F=1
M$NTW[F11!MZ(Y]-*%'B/X6MUZV@5=RBYU&B\M 8<;F;1(IDLA^S?.'R3N/4'
M-G F:VL?>?$EGT5]%H0*L\ (@GY/N$*E&(AD_-IA1ATE!Q[:>_1/3>Z4RUIX
M7%GU7>:AG$7C"'+<B%J%.[O]C+M\1HR76>6;+VQ;WXMA!%GM@]6[8%*@I6G_
MXGE7AX. <?^=@'07D#:Z6Z)&Y;4(8CYU=@N.O0F-C2;5)IK$2<.7<A\<G4J*
M"_.5U5H&JG+P($P.*VN"- 6:3**'TP>Q5NC/IG$@+HZ(LQWNLL5-W\%-4K@A
MJ-+#1Y-C_B= 3"([I>E>Z3(]BGB-V3D,DAZD_30Y@C?H,A\T>(/_ROQ:^DQ9
M7SN$'XNU#XZ>S\\CK,..==BP#M]AO:>NRFN%8#>PJ0/CTZU*76MZXB8(!95X
M:451QP$UGQ,L"Q32V_-O7<110F[JB:]$AK.(NM:C>\)HOO#,3Q5%O4;75;7W
MMZ2]EAZL7^ %A6LJ):F9BL)A(0+VH*;[=6"L^9 )DZ'B%_./;L@L];$/3!M*
MI-P4C0,^/Q7:UIPNH8;2UIX8_-F$]:1P DFO/QKS8L#F^(K-(9E)VF=SQ.8H
M9?."':X&\% B3:=-(%%)[S)-X,%R6?<I-7I>BWP"E[UT,("WKC8^:"N-KFB&
M!Z=">ML.ZW:[^;1HV_+5O1UN-\(5TGABWU!H__QR%(%K!T:["+9JFG1M [5\
M8Y8T8]&Q YUOK W[!1-T4WO^&U!+ P04    " !,,&]4@04'N@<%  !2#0
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MB64PW<7M M*-[_V5)GN3_+2R;QT8EV#WUUK3/G#7:7@]\[]02P,$%     @
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MEO%7N08E;'DB=S/.4E<9:W7?%KZP^<FZ;XM7V/HPW<<%UH[NK6"?FG[E_<]
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M])!!;H?=-M!B9>?%7&B</G:9XP<"2). ]Q="Z%U@1E#SR3'Z U!+ P04
M" !,,&]4FQ6XQ/4!   (!   &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q]4TUOVS ,_2N$3QN0QHG3=$/A&&B:#>MA0]#LXS#LH-A,+%267(F.FW]?
M2G:,#&AZL4F*[_&1E-+6V"=7(A*\5$J[1502U;=Q[/(2*^'&ID;-)SMC*T'L
MVGWL:HNB"*!*Q<ED<A-70NHH2T-L;;/4-*2DQK4%UU25L,<E*M,NHFET"CS*
M?4D^$&=I+?:X0?I5KRU[\<!2R JUDT:#Q=TBNIO>+F<^/R3\EMBZ,QM\)UMC
MGKSS4"RBB1>$"G/R#()_![Q'I3P1RWCN.:.AI >>VR?VKZ%W[F4K'-X;]4<6
M5"ZBSQ$4N!.-HD?3?L.^G[GGRXURX0MMESOGBGGCR%0]F/U*ZNXO7OHYG &F
M-Q< 20](@NZN4%"Y$B2RU)H6K,]F-F^$5@.:Q4GME[(ARZ>2<91M2F/IZB?:
M"A[T 1WQP,G!%?P0U@H_,?BP0A)2N8]I3%S1X^*\9U]V[,D%]A7F8YA-1Y!,
MDNG_\)B%#FJ306T2^&87^,XDCF"%6P*A"_CRW$@ZP@;SQDJ2Z.#OW=:1Y8W_
M>Z?H;"@Z"T6O+S;!==Q /@)Q0,L7EM= /G8$XO&]-9SW>>=0&4VE@VLHQ-&]
MI30^6ZQ_(]^%W4OM0.&.*2?C3_,(;'?O.H=,'7:]-<0W)Y@E/U6T/H'/=\;0
MR?'79WC\V2M02P,$%     @ 3#!O5&)\I+%: P  0 T  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&ULO5==;YLP%/TK%MI#*[7%-B$D51)I2S>M4J=%
MZSX>ICVX<$FL <YLT[3[];.! @D)ZZ:V+XD-YUZ?>[@<F\E&R)]J!:#179ID
M:NJLM%Z?NZX*5Y R=2;6D)D[L9 ITV8JEZY:2V!1$90F+L5XZ*:,9\YL4EQ;
MR-E$Y#KA&2PD4GF:,GG_!A*QF3K$>;CPB2]7VEYP9Y,U6\(UZ"_KA30SM\X2
M\10RQ46&),13YS4YGU-L PK$5PX;U1HC6\J-$#_MY#*:.M@R@@1";5,P\W<+
M<T@2F\GP^%4E=>HU;6![_)#]75&\*>:&*9B+Y!N/]&KJC!P40<SR1'\2F_=0
M%>3;?*%(5/&+-A46.RC,E19I%6P8I#PK_]E=)40K@ P.!- J@#XVP*L"O*+0
MDEE1U@73;#:18H.D19ML=E!H4T2;:GAF'^.UEN8N-W%ZMI"F(Z2^1RR+T-M?
M.5^;9Z31*;HV#1/E"2 1HW4;!#7HZ (TXXDZ-O OUQ?HZ-4Q>H5XACZO1*X,
M5DU<;3C:E=RPXO.FY$,/\+F \ QYY 113,F>\/GCP_%VN&N4J>6AM3RTR.?]
M19X3M$B8*7E;I>]7!HXN-:3J1\]B7KV85RPV>,RSJ&4^04LIU%XIRW1^D<Z^
MK[<S0@,RFKBW;<6ZJ,%@A&O0%M5!37702_5U&.9IGC -D7EIC(&$G)6OI:'.
M4B$U_UU<V$>[3#UL$3JE08M127L/BASD[=>\_?^2. .]CZG?X3 >>[OZ=D$>
MQ@=X#FN>PUZ>5^RFH=?36D&=+WC^/A[5BXV>MH]''07]$?5V9.Z":# ^(/.X
M9CKNEQG,#K 2281X:DSN%BQ1U2,!P8VOXN=7G+1LG#RMYE6^K;8-\'A']#TH
M@@-OO^JD<55">]G.1::TS,N=W&P81ONEA%VBV\D;%R7>"RC?."'IM\)_5[[K
M;-2WF]VV\EV4Y_L'A&_LC_3[W[M<9ESG$@JV,;^SXU[9&\<BPQ>0O3$T$CRQ
M[$%'T('?Z?<NB/C! =4;/R3]AO@QCGD(CS)TTE@7&3^_WK3Q,XJ?5N\J7_O<
M0?%P1^\](()WN]QM'6_MM\4')I<\4RB!V$3AL\"$R_*X7DZT6!<GWANAS?FY
M&*[,)PY("S#W8R'TP\0>HNN/IMD?4$L#!!0    ( $PP;U1W,?VJ20(  #$%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;(U4W4_;,!#_5TX1#R"Q
MYJ.E&U,:B;9,VP-3!6)[F/;@)M?&PK&#[5+87[^SG6:%4;:7Q'>^W^^^G6^5
MOC,UHH7'1D@SB6IKVX]Q;,H:&V8&JD5)-RNE&V9)U.O8M!I9Y4&-B+,D&<<-
MXS(J<J];Z")7&RNXQ(4&LVD:II^F*-1V$J713G'-U[5UBKC(6[;&&[2W[4*3
M%/<L%6]0&JXD:%Q-HHOTXVSD[+W!-XY;LW<&E\E2J3LG?*DF4>("0H&E=0R,
M?@\X0R$<$85QWW%&O4L'W#_OV#_YW"F7)3,X4^([KVP]B3Y$4.&*;82]5MO/
MV.5SYOA*)8S_PC;8CL\C*#?&JJ8#4P0-E^'/'KLZ[ '2\0% U@&REX#1 <"P
M PQ]HB$RG]:<65;D6FU!.VMB<P=?&X^F;+AT7;RQFFXYX6RQT#00VCX!DQ5<
MWF]X2RVR\ Z^,JV9*S$<S]$R+LP):6]OYG!\= )'P"5<<2&H%2:/+47B^.*R
M\SH-7K,#7M,,KI2TM8%+66'UG""F%/H\LET>T^Q-QCF6 QBFIY E6?I*0+/_
MAR=OA#/LRSKT?,-_E/44%H)1/9]7]\?%TEA-$_SS#5>CWM7(NQH=#)W6M^0L
M; 7Y88W2EO\*"GRD?3?X6HL"[;FG=<O^4*2#41X_[%?M;YMD,.YM0KSQWO0U
MJ-=^*0V4:B-M:&"O[??^PH_["_V4WH.POG]HPF-RQ?2:2P,"5T29#-Z?1:##
M@@;!JM;/^%)9VAA_K.E-0^T,Z'ZEE-T)SD'_2A:_ 5!+ P04    " !,,&]4
MLF!H.8@"  !Z!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R-E=]O
MFS 0Q_\5"_6AE;;R.^TJ@M0FF[:':E'3;@_3'APX@E6#F>TD[7^_LR$H+23J
M"]CXOG>?.]M'LA/R694 FKQ4O%93I]2ZN7%=E950474I&JAQI1"RHAJG<NVJ
M1@+-K:CB;N!Y$[>BK';2Q'Y;R#01&\U9#0M)U*:JJ'R] RYV4\=W]A\>V+K4
MYH.;)@U=PQ+T4[.0.'-[+SFKH%9,U$1",75N_9O9Q-A;@U\,=NI@3$PF*R&>
MS>1'/G4\ P0<,FT\4'QM80:<&T>(\:_SZ?0AC?!PO/?^S>:.N:RH@IG@OUFN
MRZES[9 <"KKA^D'LOD.73VS\98(K^R2[SM9S2+916E2=& DJ5K=O^M+5X4#@
M1T<$02<(/BH(.T%H$VW);%ISJFF:2+$CTEBC-S.PM;%JS(;59A>76N(J0YU.
M;[-,;B G7U_P7"A0Y#-9XDG)-QR(*+#*[3+LE\_GH"GCZ@(-GY9S<GYV0<X(
MJ\EC*3:*UKE*7(U<QKN;=0QW+4-PA&$.V24)_4\D\ )_1#[[N-Q[*W>Q&GU)
M@KXD@?47'O&WH*]TQ3%7S(;8^E"NR)_;E=(23]W?$R'"/D1H0T1'0CR  BJS
MTH;(88N7J<&KH4DF:AL$!TJ/EK)U'%O'YHIN4]\+XC!QMX<5&UK%X770&[V!
MCGKHZ"3T3%3F$-#V^B&X!$XU'HX5U%"P<=S6Y>0 ) S-+KVA'1KY<>R/T\8]
M;7R2]J<N08X1Q<-@GN>_(QH:1?Z7<:!)#S0Y"?0H-.6#"S5&.!EN<11?1>\0
MAU978?Q^B]V#SF"Z\CV5:U8KPJ% F7=YA7K9=KIVHD5CF\5*:&P]=ECBSP&D
M,<#U0@B]GYC^T_]NTO]02P,$%     @ 3#!O5(Q/C-YL @  IP8  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&ULG95=;YLP%(;_BH5ZT4I; 1/R41&D
M-M&T74RJFG:[F';AP"%8-3:S3=/^^]F&HG1U&FDWP<?V>Y[W..:0[85\5#6
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M!LT."E<+:R..9?:O++0T7YFQTY.Y"0)*B3$LM(@>X7R&FC*N+N ,?% )E:B
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MPUP]=<"U@=I?,R;W$QW /I[Q/U!+ P04    " !,,&]4_8R+]%,&  !F'
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MJV1H75LDAA4M,O7 RV]0.]37?!'/I'F2LK9U+!(54O&\!J."/&75F^[J0+0
M;G "X-4 [Q#0.P'P:X!O'*V4&;=F5-%1*'A)A+9&-CTPL3%H]"9E.HT+)?!K
MBC@U6B@>/5U.,! QF?(<3X>D)KZ79(%')BXR('Q%I#%;&K.H;08[/09R/@-%
MTTQ>(/!Q,2/G9Q?DC*2,_$AX(2F+96@KU*MWM:-:VZ32YIW0YGKDGC.52/*9
MQ1"_)K#1T<9;;^_MQ.MDG$%T17SW$_$<SSTB:/K_<*=#CM\$WS=\_JG@)U1
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MUDRN,+%W2?C>*.A7T)Q'P@ZDJJ-,5W)29-;EKEVU&>X"+VBM9YV1+3H<^\G
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MER63#PM*;-]^?8"FC4>^,^@;* X;?V/!A@2_7AN#YR!TT?@/*/X"4$L#!!0
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M^=PTK4Q^1HML*8G]:5^H1$/[/'1;%\7$Y"VJ.T'SP^<+AT\OOOT'4$L#!!0
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MJ[_^.=K<TTH7]3&?M7^@IY]02P$"% ,4    " !,,&]4!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M $PP;U0N>MG6[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( $PP;U297)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 3#!O5(W!
M?57-!@  AQL  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( $PP;U0?I$K"$P(  %X%   8
M  " @0\/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !,
M,&]4O?P1>#,%  !X$P  &               @(%8$0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ 3#!O5+H\FS!_ @  PP8  !@
M         ("!P18  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( $PP;U2I!!2MS00  )<0   8              " @789  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !,,&]49#UO@+,'  "[)P
M&               @(%Y'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ 3#!O5.C]"5O7!@  Y!P  !@              ("!8B8  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( $PP;U0;2!E/=P@
M .83   8              " @6\M  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " !,,&]4>3BJJ5<@  #K9P  &               @($<
M-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 3#!O5"Z&
M8^IL P  '0@  !D              ("!J58  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " !,,&]49QUP<>8"  !B!@  &0
M    @(%,6@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M $PP;U2^WT^'@0(  &$%   9              " @6E=  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ 3#!O5%:> -WL!0  B0T  !D
M             ("!(6   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " !,,&]4(''/J00#  "^!@  &0              @(%$9@  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( $PP;U0G['IW, 0
M .D)   9              " @7]I  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ 3#!O5(MCGC8S"P  &"   !D              ("!
MYFT  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !,,&]4
MP6=P,.4'   C%0  &0              @(%0>0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( $PP;U39(F6N<P(  ((%   9
M      " @6R!  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ 3#!O5!!=^NO< 0  5@0  !D              ("!%H0  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !,,&]4A0 K/5,?  #W:0
M&0              @($IA@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( $PP;U3H4UXN; ,  (\'   9              " @;.E  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 3#!O5$RBX1[8
M @  QP8  !D              ("!5JD  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " !,,&]41OC7_-$"  #P!0  &0
M@(%EK   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( $PP
M;U2O]Z&2DP(  &8%   9              " @6VO  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ 3#!O5+)I.)BS @  P04  !D
M         ("!-[(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " !,,&]4@04'N@<%  !2#0  &0              @($AM0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( $PP;U0I6+U\# 4  *<,
M   9              " @5^Z  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ 3#!O5':-I>%: @  204  !D              ("!HK\
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !,,&]4]PKW
M>TD#  "T"@  &0              @($SP@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( $PP;U091O$D[P(  'X+   9
M  " @;/%  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M3#!O5(2E0#(+ P  ]PD  !D              ("!V<@  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " !,,&]4\2.J=;@"  !^"   &0
M            @($;S   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( $PP;U2;%;C$]0$   @$   9              " @0K/  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 3#!O5&)\I+%: P
M0 T  !D              ("!-M$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " !,,&]4=S']JDD"   Q!0  &0              @(''
MU   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( $PP;U2R
M8&@YB (  'H&   9              " @4?7  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ 3#!O5(Q/C-YL @  IP8  !D
M     ("!!MH  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $PP;U2?]Z<QT@(  +$(   9              "
M@=7K  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 3#!O
M5&Y)'8T0!   [A   !D              ("!WNX  'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " !,,&]4P8^GLP(#  "5"0  &0
M        @($E\P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( $PP;U1-&DR^UP(  !,(   9              " @5[V  !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 3#!O5#U59)!' @  CP4
M !D              ("!;/D  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " !,,&]4$C"Z/I0#   D"P  &0              @('J^P
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( $PP;U0*0>IA
MH@,  + ,   9              " @;7_  !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ 3#!O5%Y?2O,F P  1PH  !D
M ("!C@,! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !,
M,&]4+I?!^?0"  "@!P  &0              @('K!@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( $PP;U3(%['1ZP$   \$   9
M          " @18* 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#
M%     @ 3#!O5#KSCDI' P  ]A0   T              ( !. P! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !,,&]4EXJ[',     3 @  "P
M    @ &J#P$ 7W)E;',O+G)E;'-02P$"% ,4    " !,,&]4K@A3^$($  #^
M(0  #P              @ &3$ $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ 3#!O5*&7ZI3) 0  H!X  !H              ( ! A4! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3#!O5"BT:!/# 0  B1X
M !,              ( ! Q<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #L .P 4$   ]Q@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>342</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BALANCESHEETS</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BALANCESHEETSParenthetical</Role>
      <ShortName>BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/ShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Collaboration Agreement - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty</Role>
      <ShortName>Collaboration Agreement - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/RelatedParty</Role>
      <ShortName>Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/ShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/ShortTermInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/PropertyandEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Short-Term Investments - Schedule of available for sale short-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Schedule of available for sale short-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/ShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Accrued Expenses - Schedule of accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Commitments and Contingencies - Schedule of minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PreferredStockDetails</Role>
      <ShortName>Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/PreferredStock</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Collaboration Agreement - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails</Role>
      <ShortName>Collaboration Agreement - Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Stock-Based Compensation - Schedule of 2020 Plan valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of 2020 Plan valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of restricted stock activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sttk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/RelatedPartyDetails</Role>
      <ShortName>Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/RelatedParty</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sttk-20211231.htm">sttk-20211231.htm</File>
    <File>sttk-20211231.xsd</File>
    <File>sttk-20211231_cal.xml</File>
    <File>sttk-20211231_def.xml</File>
    <File>sttk-20211231_lab.xml</File>
    <File>sttk-20211231_pre.xml</File>
    <File>sub-certxsection302xarn202.htm</File>
    <File>sub-certxsection302xceo202.htm</File>
    <File>sub-certxsection906ofthesa.htm</File>
    <File>ye2021consent.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sttk-20211231_g1.jpg</File>
    <File>sttk-20211231_g10.jpg</File>
    <File>sttk-20211231_g2.jpg</File>
    <File>sttk-20211231_g3.jpg</File>
    <File>sttk-20211231_g4.jpg</File>
    <File>sttk-20211231_g5.jpg</File>
    <File>sttk-20211231_g6.jpg</File>
    <File>sttk-20211231_g7.jpg</File>
    <File>sttk-20211231_g8.jpg</File>
    <File>sttk-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="441">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sttk-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 107,
   "dts": {
    "calculationLink": {
     "local": [
      "sttk-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sttk-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sttk-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sttk-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sttk-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sttk-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 386,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 19,
   "keyStandard": 323,
   "memberCustom": 6,
   "memberStandard": 28,
   "nsprefix": "sttk",
   "nsuri": "http://www.shattucklabs.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - COVER",
     "role": "http://www.shattucklabs.com/role/COVER",
     "shortName": "COVER",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Short-Term Investments",
     "role": "http://www.shattucklabs.com/role/ShortTermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Property and Equipment",
     "role": "http://www.shattucklabs.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Accrued Expenses",
     "role": "http://www.shattucklabs.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Preferred Stock",
     "role": "http://www.shattucklabs.com/role/PreferredStock",
     "shortName": "Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Collaboration Agreement - Related Party",
     "role": "http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty",
     "shortName": "Collaboration Agreement - Related Party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Income Taxes",
     "role": "http://www.shattucklabs.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Related Party",
     "role": "http://www.shattucklabs.com/role/RelatedParty",
     "shortName": "Related Party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Subsequent Events",
     "role": "http://www.shattucklabs.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.shattucklabs.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Short-Term Investments (Tables)",
     "role": "http://www.shattucklabs.com/role/ShortTermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.shattucklabs.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.shattucklabs.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.shattucklabs.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TangibleAssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TangibleAssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - BALANCE SHEETS",
     "role": "http://www.shattucklabs.com/role/BALANCESHEETS",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i0256d931b38f4e8ebd1fafc29f3baef9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i0256d931b38f4e8ebd1fafc29f3baef9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Short-Term Investments - Schedule of available for sale short-term investments (Details)",
     "role": "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails",
     "shortName": "Short-Term Investments - Schedule of available for sale short-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Short-Term Investments - Narrative (Details)",
     "role": "http://www.shattucklabs.com/role/ShortTermInvestmentsNarrativeDetails",
     "shortName": "Short-Term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)",
     "role": "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails",
     "shortName": "Property and Equipment - Schedule of property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sttk:AccruedResearchAndDevelopmentContractCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Accrued Expenses - Schedule of accrued expenses (Details)",
     "role": "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails",
     "shortName": "Accrued Expenses - Schedule of accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sttk:AccruedResearchAndDevelopmentContractCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Commitments and Contingencies - Schedule of minimum lease payments (Details)",
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails",
     "shortName": "Commitments and Contingencies - Schedule of minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i1c436ab0261649adb338c58e3639b366_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Preferred Stock (Details)",
     "role": "http://www.shattucklabs.com/role/PreferredStockDetails",
     "shortName": "Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i1c436ab0261649adb338c58e3639b366_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - BALANCE SHEETS - Parenthetical",
     "role": "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical",
     "shortName": "BALANCE SHEETS - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Collaboration Agreement - Related Party (Details)",
     "role": "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails",
     "shortName": "Collaboration Agreement - Related Party (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i3c4307d746f9411bbc79cd1eae089f2d_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of stock-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i3f3f5a50ece747008b59441f4cb5f1a8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i6dd78bd931e046948447da6b4292615e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Stock-Based Compensation - Schedule of 2020 Plan valuation assumptions (Details)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of 2020 Plan valuation assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i34d426856ed94d4da725aa14e7577ebc_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i62d6a6f7758f43c6afcb27e52ca0cc16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i76d2b249a41e4985a2641c447e8e27d7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of restricted stock activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i76d2b249a41e4985a2641c447e8e27d7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "role": "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails",
     "shortName": "Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "role": "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails",
     "shortName": "Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ibf22e3d9c8e14c7f858b405a0dce6aad_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i3f3f5a50ece747008b59441f4cb5f1a8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)",
     "role": "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails",
     "shortName": "Income Taxes - Schedule of unrecognized tax benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ia2e6543ccfb74775ac5df4a5733524f6_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ic68499c9c9c54c7ca37c93a1819e89f8_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "sttk:ShareholderOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Related Party (Details)",
     "role": "http://www.shattucklabs.com/role/RelatedPartyDetails",
     "shortName": "Related Party (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "ic68499c9c9c54c7ca37c93a1819e89f8_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "sttk:ShareholderOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i93d907eb546d4b419a06e844b32e0c37_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i93d907eb546d4b419a06e844b32e0c37_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - STATEMENTS OF CASH FLOWS",
     "role": "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20211231.htm",
      "contextRef": "i37b06acb50a449ef9343f66141212130_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r46",
      "r91",
      "r92",
      "r205",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r212",
      "r239",
      "r240",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r396",
      "r437",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r212",
      "r239",
      "r240",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r396",
      "r437",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r204",
      "r212",
      "r236",
      "r239",
      "r240",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r396",
      "r437",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r204",
      "r212",
      "r236",
      "r239",
      "r240",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r396",
      "r437",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r45",
      "r46",
      "r91",
      "r92",
      "r205",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_A2020StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "terseLabel": "2020 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2020StockIncentivePlanMember",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities And Employee-Related Liabilities, Current",
        "label": "Accrued Liabilities And Employee-Related Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails",
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_AccruedResearchAndDevelopmentContractCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails": {
       "order": 1.0,
       "parentTag": "sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Contract Costs, Current",
        "label": "Accrued Research And Development Contract Costs, Current",
        "terseLabel": "Research and development contract costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentContractCostsCurrent",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "xbrltype": "stringItemType"
    },
    "sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Additional number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)",
        "terseLabel": "Section 162(m) limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Other Permanent Differences, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Other Permanent Differences, Amount",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision Adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision Adjustment",
        "terseLabel": "Return to provision adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_IncreaseDecreaseInDeferredRentCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Deferred Rent Credits",
        "label": "Increase (Decrease) In Deferred Rent Credits",
        "negatedTerseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRentCredits",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_LicenseAgreementRoyaltyPaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payments, Maximum",
        "label": "License Agreement, Royalty Payments, Maximum",
        "terseLabel": "License agreement, maximum payment"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentsMaximum",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_OperatingAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Account",
        "label": "Operating Account [Member]",
        "terseLabel": "Operating Account"
       }
      }
     },
     "localname": "OperatingAccountMember",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant And Equipment Estimated Useful Lives",
        "label": "Property Plant And Equipment Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of property and equipment depreciation periods"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sttk_SeriesB1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Preferred Stock",
        "label": "Series B-1 Preferred Stock [Member]",
        "terseLabel": "Series B-1 Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesB1PreferredStockMember",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails",
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, annual increase in number of shares authorized, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage",
        "terseLabel": "Increase in number of shares authorized, percentage of capital stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value",
        "terseLabel": "Maximum value of shares per employee during any calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period",
        "terseLabel": "Exercise of stock options and ESPP purchases (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_ShareholderOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Ownership Percentage",
        "label": "Shareholder Ownership Percentage",
        "terseLabel": "Shareholder ownership percentage"
       }
      }
     },
     "localname": "ShareholderOwnershipPercentage",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased",
        "label": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased",
        "terseLabel": "Exercise of stock options and ESPP purchases"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails",
      "http://www.shattucklabs.com/role/RelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities Into Common Stock",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities Into Common Stock",
        "negatedTerseLabel": "Conversion of redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecuritiesIntoCommonStock",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of redeemable convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Value, Conversion Of Convertible Securities Into Common Stock",
        "label": "Temporary Equity, Value, Conversion Of Convertible Securities Into Common Stock",
        "negatedTerseLabel": "Conversion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityValueConversionOfConvertibleSecuritiesIntoCommonStock",
     "nsuri": "http://www.shattucklabs.com/20211231",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net amortization of premium on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r182"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r48",
      "r49",
      "r50",
      "r427",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r57",
      "r58",
      "r59",
      "r94",
      "r95",
      "r96",
      "r327",
      "r439",
      "r440",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r277",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r274",
      "r275",
      "r276",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r241",
      "r243",
      "r280",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r243",
      "r270",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r88",
      "r139",
      "r142",
      "r148",
      "r167",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r324",
      "r328",
      "r336",
      "r360",
      "r362",
      "r413",
      "r426"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r43",
      "r88",
      "r167",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r324",
      "r328",
      "r336",
      "r360",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r157",
      "r174"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "negatedTerseLabel": "Unrealized loss on short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r154",
      "r158",
      "r174",
      "r416"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total Fair\u00a0Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r156",
      "r174"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r244",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid amounts related to purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r29",
      "r80"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r337"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r87",
      "r88",
      "r109",
      "r110",
      "r111",
      "r113",
      "r115",
      "r121",
      "r122",
      "r123",
      "r167",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r210",
      "r211",
      "r214",
      "r215",
      "r336",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails",
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreement - Related Party"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r191",
      "r417",
      "r431"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r192",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.0001 par value: 300,000,000 shares authorized, 42,338,898 shares issued and outstanding at December\u00a031, 2021 and 41,779,183 shares issued and 41,767,431 shares outstanding at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax asset:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liability:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r61",
      "r419",
      "r433"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r127",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r221",
      "r222",
      "r233"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r221",
      "r222",
      "r233"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue - related party, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "terseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of available for sale short-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Debt securities, average maturity term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r297",
      "r414",
      "r425"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r15",
      "r346",
      "r351"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r303",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r78",
      "r180"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r109",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r333",
      "r334",
      "r420",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r109",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r333",
      "r334",
      "r420",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails": {
       "order": 2.0,
       "parentTag": "sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r120",
      "r168",
      "r217",
      "r219",
      "r274",
      "r275",
      "r276",
      "r309",
      "r310",
      "r332",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r439",
      "r440",
      "r441",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r207",
      "r216",
      "r331",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r185",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r289",
      "r295",
      "r302",
      "r311",
      "r313",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r105",
      "r106",
      "r138",
      "r287",
      "r312",
      "r314",
      "r436"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r285",
      "r286",
      "r295",
      "r296",
      "r301",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit computed at federal statutory tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Change in uncertain tax position"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "General business credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r77",
      "r397"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r65",
      "r136"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r166",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r412",
      "r422",
      "r446",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Deferred Rent"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r88",
      "r143",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r325",
      "r328",
      "r329",
      "r336",
      "r360",
      "r361"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r88",
      "r167",
      "r336",
      "r362",
      "r415",
      "r429"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r88",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r325",
      "r328",
      "r329",
      "r336",
      "r360",
      "r361",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r124",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operations:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r51",
      "r53",
      "r59",
      "r60",
      "r79",
      "r88",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r112",
      "r139",
      "r141",
      "r144",
      "r147",
      "r149",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r334",
      "r336",
      "r418",
      "r432"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements (not yet adopted)"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Expense from operations"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r141",
      "r144",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesScheduleofminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r93",
      "r133",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails": {
       "order": 3.0,
       "parentTag": "sttk_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesScheduleofaccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r322",
      "r323",
      "r326"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r70",
      "r155"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r244",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from the initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r72",
      "r273"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from the exercises of stock options and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock.",
        "label": "Proceeds from (Repurchase of) Redeemable Preferred Stock",
        "terseLabel": "Proceeds from sale of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromRepurchaseOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r69",
      "r155"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sale and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from stock plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r179",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant, and Equipment and Intangible Assets [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r181"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r362",
      "r423",
      "r430"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r183",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment depreciation and amortization periods"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r238",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails",
      "http://www.shattucklabs.com/role/RelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r238",
      "r354",
      "r357",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r352",
      "r353",
      "r355",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r283",
      "r398",
      "r452"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock",
        "verboseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r219",
      "r277",
      "r362",
      "r428",
      "r442",
      "r444"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r168",
      "r274",
      "r275",
      "r276",
      "r309",
      "r310",
      "r332",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r140",
      "r145",
      "r146",
      "r150",
      "r151",
      "r152",
      "r231",
      "r232",
      "r399"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue - related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, proceeds received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Preferred stock sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of preferred stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of income tax reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r243",
      "r269",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum rental payments for operating leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails",
      "http://www.shattucklabs.com/role/RelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r244",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r250",
      "r258",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valuation assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r294",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails",
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock-based compensation, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Awards, ending balance (in shares)",
        "periodStartLabel": "Awards, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Awards, vested (in shares)",
        "verboseLabel": "Vesting of common stock previously subject to vesting (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividends (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Contribution limit in percentage of employee's eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per employee during any one purchase period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted\u00a0average remaining contract life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r252",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, ending balance (in shares)",
        "periodStartLabel": "Options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r242",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share-based compensation, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r264",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term - years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanvaluationassumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted\u00a0average remaining contract life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted\u00a0average remaining contract life, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted\u00a0average remaining contract life, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock in percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r87",
      "r88",
      "r109",
      "r110",
      "r111",
      "r113",
      "r115",
      "r121",
      "r122",
      "r123",
      "r167",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r210",
      "r211",
      "r214",
      "r215",
      "r217",
      "r336",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails",
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r57",
      "r58",
      "r59",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r120",
      "r168",
      "r217",
      "r219",
      "r274",
      "r275",
      "r276",
      "r309",
      "r310",
      "r332",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r439",
      "r440",
      "r441",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r120",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r41",
      "r206",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock issued under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r219",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r42",
      "r217",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r217",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r88",
      "r153",
      "r167",
      "r336",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r16",
      "r17",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Series A, Series B and Series B-1 Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r344",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r344",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r344",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash financial activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r1",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairments of long-lived assets"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r10",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Preferred stock, ending balance",
        "periodStartLabel": "Preferred stock, beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/PreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Preferred stock, ending balance (in shares)",
        "periodStartLabel": "Preferred stock, beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTOFCHANGESINREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r207",
      "r216",
      "r331",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government Obligations"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r237",
      "r421",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/ShortTermInvestmentsScheduleofavailableforsaleshortterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r284",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase for tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467743&loc=d3e20905-112640"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r453": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r454": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r455": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r456": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r457": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r458": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r459": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r460": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r461": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r463": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r464": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r466": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r468": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r469": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r471": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001680367-22-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001680367-22-000005-xbrl.zip
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M\::&C&'6]TV_:[;)IY>:EFZ;TT>H;^K?ZX>\ZAS4PG/C(!@"W_;,('*)3:W
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MYUO,";D3$&& '101PXL"UW)\QS7MM0;0,V7;/2!X* ;U RZLP(G >B ^L4V
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M<EXQU@F0^0/[E<:E+-"67! ^2.K?6S$A;3?,QDT_(TR-WG#&-2$^=Y,PLZ+
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MQ(]X)+,NE"=T)I%RI_6><362NKGVXX 60C-G[I&^")D8C9RO9JQ@2,;3 =;
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MBREQP#AB2I5N +_B(5)T<\RL(TM9I\=50TS-XUX @QMT"R\ L6I5)B>$4HE
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MS%K@O2%@@!/.CEH29!3S^ AZG+L;">V3]^2[EE?*K.G*K<*%FD*G]V]=< X
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M<[+&D%%4:'%PU9:4_8DI"%ZBR"% DI0UZ_\",1W*5Y(X3DF$Z7)"N3;3A!%
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MH8$[E_173%>%DQ=['B7VY:#O<,=B,Y10V1+TM^2.<W$-V$_JC#A8NT0=V\W
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M4VR$#R 5CGH]_< \/S=)$_33;_U"I14B1]&A4OU+8BNL7"E]2Z2H^];SS_#
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M?4$8UV>ZWP2AG%Q43IT-7U$YTS1P<J7-6"H0)M!@%!H.@1?D3"A74?E1>RW
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ML0RPVV@9YJO=WUV:9>&W%583\>@[LG2G21>6#<,P^5\T_WTJ :<QVG?P&1-
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MLKA*6'AD-(UI.Z,>+PIE\<]UI_.&V$HEBD?B*=S2[I-\":4 UV(_]Z#=Z@I
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MY/!IZVGZ\<PM02HN26QTH6(D(EIY[C)(TQT:;9YFS#LZV,)OD#%BMC0DKRW
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M<')Z4J;,PT3:52+P3E.;F5]%S.ZY>6!RWTII95P$B^.&B<%=H"?UH;+W<82
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M2^'?X:=^&!&Q5$3GO*1\8<5 "V3B5QQ'R-%4LC?C/4S;;WLK-9U^0NGJYN4
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M)O:9=&3>]@)2)P[T?KEG)!-[ZBT$DJ^ FV)XX'GX/]3"X9BYJ4C$\>;F1:*
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M*%U$1.W,A$-6\P36:#T8];!TQ,7F_3W.^><Y]M::L1=?-JIKFF]/D]5TP6I
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MF=>K>MQ9G !MO2Q:B"]"J943,L@GEP0@2Q7>D%D3;R,\2]]US08I>CNSPZ!
MU08FG:Y0+4:Z3H332#8FHA,P8IJO3B_-R0<Y6:QK5/.DYXWVEXH24)Z)X-<E
MLL>80*275O2??S(GNA5>DNR3/4:EQQ[5BL(C#.V&^PF;(:Q U?EQ.8_IQ&>D
MCD>V3<J#JRDBEE/G=*NT__!\: ^3#<*ZG#!"/2>$'.')ZR';@V'E#9 +)JB?
MH%!CFS(JP[''BWO.D142UDU"$!%#IZQU*A93'QASA1@G2/3%^4E'@]I88LHO
MWJKLZ%Q&U>/Q=@QK932Q[(M-?T[,$"BZW;('<W/94\N7*)@O&6>C'3(Y35>L
M&S/2A;UT*E4T"MYK1U'7L/&]KI>DR6Q6!PF$0@M6>@;<J]\F2TM<]B.J*^DH
MD"% H2H6$U5V=\E&X_!+P6/TRT6<4 ]Q"]?,WW>FT2RJD>!M!0F [*=#1V:S
M>G@MR;J& 2NO;*N29@OJ='%&\"7F@0 P[+SMK*F1$T!)JAP7J2.]@CL05"M>
M;E'N:?U'$]@/IN#P2&;T4,F,%&Z!I39/7_/Y^(T>R&EY!N^AV30>PV&23NW<
MH!/FEV".!-.<7>#D$!%JF&0VVJN&F636<V Z,VYL4 J?,J307 ',K;U@LX)E
M-V&'.WOP%5\.T\5[2\2:[WKV5? $EZ(60]A/8H58DB<^I*UN*V&E&5/@<?AR
MTUZ7N4,,>GS@:/L ZJ06C.+!AMN+PGK(/%PVRANRSC>4[I+"BUFRS$]VG%WJ
M9M@19D#*3L&IUP!EESZ3<4PY?54<2Z3P&4OT#K!.EZFOT"3O4C'16N*I_).<
M][O+A**(1EY@/J>+'UJRGG1+F-F=#:BWMY@6BCB[&!@LB?!=U:5]A*FH^3AE
MKJ>>0<'T;%&NG'/4<4SJKM[<CK+TI0/"(?FUF_"W]M'#J"Z)@8GEQZWB)W54
M7*(F<!3-($FRJ8^10;KN<;C4&W$-VB[Q#7C]B)0VS6?;L)(A/0#Y)IMF1=HJ
M0*/M"6;>4H/4FN6"T/O)G4#YPK2]0QPIM-^(*X#.L?!'V;67I#,]VH&);^1T
M*]/ 1\C/^L&XSR*P\(*6(6WD[7;?]<'+;SFC3)@PSC>P'VA@%K>&PVO_&,Y:
MPJ15<]EO>\Q]QT5O*EK'%G2D0@3)P3>-3B6_\G5[W6>!=;O3T#-5\N, ,8;1
MA/IF?805-:B:^3>B-I?0] E6LEV @6*/JKPQ)2=/W@;7$C^=]RMMKF]1OFG2
M=SEO=C<-?)O"MY*2=WBY5A#^NA7[H; 3);W#@@TU"5?'TSN,DVXV4;'\),*[
M-')V+IC"Y@%MM?E+Q.>OVW!B2SV@BEJ4#("2+_C-1XZ5A",34J BN\B<)3@R
MC^3#9>(#W@^-GV%'1^K"(P.I<-!8+MJEEP?(C>E&I % 1C//[K.+,JE.54F'
MBA#7N>U"-C&/O7'D7^UFN XGK3%\LOQ=G8<X]^&9J==CT\P5G2KCJW!0+L\$
M^<D;X%$R*N)$OCX"G,A#V=09 CSOCXU$H9; $.07-C9TAM@9WI&S,K+_& [*
MG6UU]%@#CMG@F/46X;*IKUNE?)FU+KZ3^%,LK,_@</LOGI==,.N4L%?N>NL*
M1MZ9V^%$/\EY5=R9$2]*4'1!E:O3GO$-<<XE]]#FSBP?R!)KDJ*L8^)%]Z08
MI+NA<1!58ASM<>9J)!-P,?0W.XX5$PPLRWOSHD+:=6@4+@"?UN?A<S2+PS5%
M 7#[]('V>A=U$XX!S].J;7?E9:OW!$>GWY-A+($UZ@M]6G[)='5(A6<BZW1D
M+@1-I39$ZFSMKV3WZ]A*^T=[OK<:HDYB[)>I7,PFB'@*&9F[+99<8G\G%9+0
MET4^;4OG[)ZN(\':?HQ$(@D+<_10?=1=2I,,RL+B0E>7[##,'2I$;-<BJCR!
M?[H7MGI2KMCYZK)MUHOO(?=-W=D_02670_QQ[B[<YRW=P6&JT/9FGS1SV=3:
MG.92'+&RQ2LR6'O1*_?WXJ^0WU;)@#%&@YIBP^'Q*?;GH:S99/^[]1"7JU@E
MJ7R(*'"Q()C0:>?]-J [(V(4XKZ1B]44BR 'D['Q5M%[]=<PG'ORT<0+K1+?
M=KVN6SJ>8?K(VQS'_4!)LHI#]5A>J<*47X Q8 DSIAP??"PUS+T1"0>K4CLY
M9\6,[8^:R?JA9';U_5/.'[CZ*4]C) 9DE6"B9VRB>YTU82<V)W._ZQT 0)6<
M'=+2%M8L6AZY:'@R?@Q[ANAFG/$QPZ-=<&2C4%ZQR4>#,*<[<>Z86Q/N1=>)
M^CA25TAS[;'$[E,'I4I 3!TD70^:.$@/E4DUJ%@)^N2NDH>R<3_T,A<\TV&8
ME^T53'3B340>FX0[)^9@"*VPY1;=V+,YH/_1MIY.?O31K'B;)>C#/A1'X73Q
MFN_5.YJ6> %7UQ3+H9]Q1DBSDK&/=-?4V\2EJ(TJ"P:9TV9N,/PHN.9*\6AY
M+7 R3D:3'@4OY-7#79%0WIS'P[WMAYRM!WD@R7!ZIQ<)%DL1EMME?:Y7QHFK
MH6'\XIZ6)Q8#K?JAE+/AE\#I&5\B;35WR)HC1U[DX'^TPR[&+>EW)HM#5Y@S
M^NFX##V(K-1,>00%UZ>H*X_[]8(YONXIRT#X!,I^,DYF\(*X5.CDUA@6[Q[G
MEJ'83?]=[PM&WR^N"X?_$=T#0P<->I>$\IWMOMXBZ7]TX8!*V"(@K=R%/'B)
MQ3.B,Q^-P)C8>ADV&]_4A&@-'@WQ^[ 1AP>NG3JA(Z1Y>IU%\B8P\$$4F\-@
M4USP5MSJ5]&M_MW?]C=$JH]:+P_<&'ZPREU: RQF?'&&H D9(+%FLRDS3HW1
MBTC3N%P8C[3A]^RCB 7!V%XCO5<4"$36R8%7BZX5/JO%(>2J"A43=V$F&J[
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M0>'>K!<:]UH^1(YB3TX<9MN]_\#)'A.U+4S^UAK+4K^4!!XJSTLC9S_)-@@
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M8",9041F_0QQI">=">$D G>8]0;&4#FATM4_K_:#)8G :XJNY0&)*+307%.
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MJYHIT"@\S9]#7'T="9AL8&SHA=P5^.A^VY)'(I'V.K@V3(9#Z?"KH<VRVG*
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MC=6*^.UJUQ&AND^Q:^;3MNL_N%&3:%T.?)]"$'O"NO#S#Q;E&*%T7R\O047
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MA.Q!&'?Z6BI*5R>C 13)RV]''W.S+,<8V>''%%!C^LK</9/MKG(!T3];/,$
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M>9HLKA'TP Q*)Z<':UI>2'2L_VW?&;'_97O>[B)Q@</%F?=+ G%P42I>4O*
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MI RQ"W0 F$-><BZ;1T% @HBC#&.3DJF,<FLF B)K#D+ITT4E056#08.[G#*
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MJF&.WYU9=PTK<LTH-B:J#0XKR@RV%R*["]\W5-!X"Q^SM>0;J!8/[)I'O-4
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M77TP?-+5!UO7A@+[U?LF)QTIZ'0NS1(PR+1>MUNOI:EMN9T65C1U7_S*DHJ
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MCJVM>884$H@K+S%4LMLZHS5B!LN5$F^FC#/Q(L!061KL+W3857+AFAPF[A!
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M'B_?JHXOP:N!".*!1;$OK-8_:(]/!98_ 1M0I*8$FPX.90GS%YULE?^&B@F
MHEL(G0?%ZV"4M1#L><,%<\_WE*/)?(ECPL772$8FKW8$4' &4%WHML>E]3D\
M,0 ;$!0$KTDEXTP(H&OX5,<(IN:X(&!>6ASXQ.NW9ZV@ J&+> -)2JR9F+(
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MJKV'K0.\;<NA"CGO>7)OJXQ2%0[ESN&$X397K^L.#'2EM+L90HVLX4]P0LJ
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M1)K<A<L\F#5K_W!=U+.Y6"1?T7S9K/'N_'N)S2JT:NAJ'E:P%5K2IX07_.
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MA,>L<+LM1##['L $L8)'[A" +P-[P8$9.SW\A(:OCW,I5HGZF[12 !_-V.&
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MT8*/&9IA16^LKW<D!,D7_/ W4LGO>A/EJ@C*%Y#K##32X+4!?7 &-0OF$ES
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M0V[63AS8*? G9):GB=1UTE5M'6^=A2JE0%N&:#X7MHU6B2JYE!_D2LIM+87
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MPT9JOV^P;]I0=U4(N^UULL*6*!A!>"77DTJK?AB4D&ZH:,>9($@#X&B(M#!
M-C:R31M0.DI8.S"88)9)8>8*52HYGR7+&523;*J=(,0/SP;NP:6Z@JX"7"=3
MYP)K5<AIT=>FB2Y-Q<9$:*0-%]7/F[75&"Z+S#A?<KVA?$]N=I(21 J47RSY
M.75=*G9C6;%81E2!"YV0F]I@RD^I?<A*%^,4W.#" ZIMBC)S@M[D.;3%?1$U
M\$[\Y6UP0T^O&7AP ,W !VCBNK<R<;V>A8ZTLXGK63!NNYLXUX)>O(V)4[;)
MM:SQ'4S3G8JW]OOT?JTCWD_V]*X+^I-HNUT+O$O*'Q5>_N!U?4N.X)/X*"HE
ME2)5B U'9!N^ZUK@2 RT:=7Z8]U@,,4*W"WG[ ]#2Q-J1Z#[M[#/Z]_+9'XK
M<$Q[:WN/5\3WE59KR];Z PN9S.RM.^IUO#ON;6]X+UO;-?:4)O@0^WL )NJM
M%7W_34??GYR9NBD)P?)LV0.LDP\*(W7B,_1+4%D_U?)G<ZI5AH^^.G_[5LO5
MW4J_#\]"[+:JO5ZW9EV-F[*FU^!&G,N)R ?\BI__U7&E&8B$F&'5L+P,8)
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M_D(@8BA_AIQ73.7+/S#=@CK^2/:S60*ZL)Z&9>W0.7*(& FZZ@NV\?QM2LA
M!=J<R"/4;TUI@5P7.!#0R2D%F5[C%4BJV'RJ-5 :"MR?H#P\:W2MF1 +BD*#
MQD,\P=QZX.S8\,(VDT84B3K*"G77JX32X&^$4X?'TH9]IJ-K;DXGY=7(S2$$
M7OS$4I[2<A-;*C"MK-/-+\ :#UZ.&_8K0..Z$)<YF;\LYPP\SDB% =7F5+=7
MBL:52&T#"Y((^1*C&>H>@S4'4B?D<0J^Z:;-Q<56@55EB$&JS8&J'&-;O:39
M^2@6UCD+<I3,)LN\X! %6G 8GGQQ ??G*=4]M$N;*$V] //!;H^<^,3L$]8@
MZ!(D>5]#LHZ2B+-TI)$33.$.7\C]89\\%/AZ#%_53[Z5P+)3-&-MI0_-XH)@
MD-[0#I$+9BQ#<:6JD%A\(-4$TE/@IV83K*?:L%!TM<+CZ LH+]R?8>M0>A;P
MZO*64,"2/D?"H]QQ,PSK><K'GDD=RC"$3U^">XUT;>&FP=]'XVAN6?H9^OG+
M @TKRAH[Z$DZEPXL/?OP]M5:J,IYJ:9\#>N/$,?*A*$';$Y&N9-D##C3;=G_
M&AO5QNMNJJHG48Z8-J10.H*FF3,F'"YC@B K1RL?(SXSGP=%$^&*MO8^>?&U
M-;KFWF92+Y:=(\O%\EKQ0&-XO3QEY\7NH,TE?Q S;65,K@?U$+>*0**C4=_^
M[14WV>L,>[ .;#A7)9OYO/B18R-:$E]\#\N_/^L_[HP':\N_X6"OGFC?QU;L
MSUX,.^X8%J)\\,FE3@LJQ"<?9,NR/[VRB-$!E$7LL_A_VB/IIX- >F%9J.ZI
M:\*OKE";3!2<%FMF"IS!PS=5^[-5;K?3AV58]Y71<7R.=X ?J5A GBJ+%9>;
MX$UYP]8=HAN-?4U0T+/B1.0GX8"/V)IED9ARB2/7[5_S;<HV[I!*E_^OX$NJ
MO%)?<S:7Z^YJG&,NE<-UG5*X?MTKKO&)\5H%V@0!<%8BY5,=W-H?+<PM-$DA
M+::"/) ]*(H-2Z!O*#56HAKGHM@+7?4W1:.2;>)\L5.8S0ZS<,<<!;*LTF1B
M"*J)$ZG\9+EP61>-UH<:\;X+@1?NDM,T45!6PB4F\AW)0LQPE'6W)+Q*8TU%
M]>)?4$Q=5"6_% \3?//+#&D5OB53T:$EU71A6=*<C3\.MK +B3 !OR;+E)]X
MN^%\P H$*Q86E 1 *T@ *<F%%*W%VJ97WD=J_#SY44&,6W\*I69,1"KB1&6H
M4NSN@2P=Z&EV25)FQ:9U9NM3D%"[BMQ?RFA1/.MYHEX%4U'++;^A(D_X)2L?
MMCGR]_N:4):2;-"K*M<<"ZW-<FPZ>+'+1L5\K EM40&JP<"=U]]<BR9CR)=3
MC1CHI5C]EF#OP5FS/TNGPIK'H\L,K 94RI*7CX7U< D>!BS2FD!M]] _]@Y:
M[^!.+VXR5KUGF 10\3X=RY=WBJM.J]9.DZFP$R]T$G*4T>IILUY.&7S.XZEY
M<&"7Z1$_+\3.*[/>T-Q:2F%,OL JB43'W2&YZ&##YDHM/4<4N5DY-#4/_!<V
MCP("E1.H5#391VL#]7=5NIU()-$X8_139RN@^1;^(4>9H.2G7#Q0MTQ<(TDK
MJ?K7UR1JPW?9LO%"DF<"I'8B,@X*QX#M1#+X?GD13/619D1T.5MRYJ,2@_N"
M1D(Z.F!HLA#(N/4QL4RYR PVMM)KOV7F2:7;"NSF%)?T\,P!2L#-%Z%MB8B2
MU= )*$QLU.4U2N%XO5OEKG=.:]4,!?6WT"/674YR#^9<&[UAF*4+@PHFRT=I
MLV4>IH]5%=O?E((I]'5#;OYOE"^J/;-47DMY73K#"V\HGYYH?\A$F.H"=)F,
MPRFM'U<PD6'9G@"I]3=W^:(]/Y,W02N,I:R8$ 9=A-]B2VL2V_F5A8)\D)L'
MXJ4,6LR9$6:BOY2;5Y,Y5MD3.J+Q0R2'5 &&7Z94C7IU*B#)%F =;_0!ZKRK
MS['F27)()5<U<?M#5&88?FX*XR [1EZSX@ZFFY\R?]JK73-O;(NE?50YTF#*
M^=NUSZH#!4]G=K$J'RD]!UR\)=1H@^-HHNV@X%ENN\8H'NNN0U5'S0&K&\",
MJ]VVW6Y5Y+7B80,Z#32\ 2 #Z;]*U!W8UA_-[$W&0Y37DIMOE$=6EY_2Y0U!
M7LYKKJ^+JH:<!%-4H>)*>LQ\#7I9^6Q1XWA8C]9A'',_=CWI!*6+JVK72^EM
MW/D"5X I-'&@::(T,(%7F%WNM-;'!$[ -QT7(,E4!O:==/6_LRN07EH!@5=4
M?GIH]O/=3>6T^OPVV!]X!2@6!D2HKN%BL=Y&!TJD>__D^Q*0'CX">?4V%G@Q
M (=YYR&>5%C'+,S24O&N%41J$W=U491;=4"=5.U:L5A&JB)*_W*!\1J+>)N/
M?&JNE+H=0;$=N:S8RVU5.\?JMH?N!5>*9?E'TVB-.U1.FIGO3^ F\"D1:"!T
M4*K-+RWAA$"U$#.DMQ C3==JY]GR\LIJ(%#EA!R8RQ'F0!<EJ=LH_GH-DPJ=
MZDQ-BAPH.$EU\Q%-2Y7KP\I5"KX4;)>%D!(+P883 5MT=8,)^OTCNX9[6EL!
MO!C$& //4MXOBNE<21&1.J4O98BGH'H*\Z3X6)B23 I!&_P7'%K02I>(;2%?
MP%7G=I4]5IFH]U:[]@_MR,?(:JEK0IL5@1M#"#N@9787!'Z,FB+73Z\MO0[F
MDA<3-A#HG%VCKQ"CN.8&_/].Z[7&=@,Y* .^E:X<<0F;!UN@8']PL-B7C%=Q
M41A\ 37OMDYD6!Z_ZI*@OA=H$9/.P&F6YB*6WB)AY46?\-4EH#AR-K$7S:HG
MTL!X0A4%KENF5M5^D=F6IT6>3)9*Q8SI@CI;W6N@NNI4R3AW.^X$H4!U].SF
M5"K=@D*?)JH0G>Y+M$57IN6$)YY3I&,Y$]%:X:>VH]^#[W*.+3"_HDP?2RL(
MD"T'6JJN;K>A/0VU[1C_!,#'*[F%I9:?<M1&:9.TYT&24XN,4M2:[_*W$/\'
M30>>BPJ [M=I(!?W/+S*H*M,9U42[*34^4I^![2*P&:HSUD-229(U%2AZ"J4
M\0%4H3P>.,>Z!J!;@!%M^4$'OL3M8A2F4LD>*0?".%!H)37 GMT9B5%A4=C!
M)P5@"H)[:%[$Q09U=<KJJMLU,6A><,LS^F80<+7[UTH)%HKQ\VV;U)S3 AFH
MJ$JH4+^^2@XK5#$=PP ;\?KM&843U^V3U>( ?2A9J@P*&2D%QHJ/[;3.I?MJ
M>LO&ZOF!/.+1_-U;CQG.*4G1QU$HM=*Q37&<"C>%+2S!$H2EA;PV_@#6?:BH
MPV[6M?Z.4C7O5>MK%C]:ZBP> )&T"$Y.@<?1XO7<=LOK>NZ>]YN_$V"Q2]WF
M>99F<,V@[3TPG542W-K>&!D##,_M)3;@KLRY\EES6KY2RWAI^0R&[K;Q[+F0
MO)H)&,5EZ_<\NY;W[6-LW*-T[_E,FGYY6+S3:0?U5VB(7Q8')C\*HT2>D6K2
MES3I4$W:0!3SO>%_SGX]AR[G3LL \*G?M;<]"NI2%G!/Q?N6"CSHW"^"'4.X
MGT+1?*)BAR+$)M#H8?PCE7/'EO=/6%!@22/E&7.^MTGS%] I'429EF%E;VN_
MIO YH+_#_)9@CS$S=PU50UQ[!\BVR2>J.M*MG1J_>:KCREA4 \I0B.DG%5M*
MX#XF9ER: #?9N\VRA!RK<]L38<=+\%P)9F*W9ZI>_3E"L)BYE<MTZC>9NELA
M D_][^W--@E"-SQ4_&ZNK$;EA;0L-ZU)U0[A*I=FL*H@9AU@0[T2+4Z,4CR.
M*[VXR9 $2/=?:A$K.!X0+4-,@2CK5:IN6J[IL_21C!@IS;%[)2';LE'CVPIU
M&L8%@RK[.H"#H,=G!U=@KP&J89K,Y"V>77@]$9WDMT8.5N*YRQ5J%/.DN LY
M<UFNX5B"A=SZA>H[4^<>.C^K0LHFC$T'5[DR@"\(1HRMI+.%.WE.@7X:A-_U
MGT]^5 ;N/,@G02H*Y^SS5*Q@9:FJSN,A5W0?I-6:'RD"UT&A+3/P@&])QM4I
M9'DV9U ?@UG=7S- X@8\+ R 07 J8C1\6!V ,IJU\HQ7!0]^#$H)56V -K2R
MD+QXUF);59R6JVM0-^AE*HY<CUS#D</"?N4F"!V#0B67*:!>OTUGCP%>DA[L
M-*&X\// *I\$0*86 -7QEL7RI7)PZ/'J.LMRTB].8MRL-,%2I%Q_MQQ,IWA]
M0GCLM%T9P'U@9L,45B:I 5!#/5]DV+],/IJ<3U&8W"4DMA5XY ]NISND9TP8
M!0W4(:E],L4(,:-/D?N@!5OJ28,CC1Z&2^71E=,%(9D*W'#/?6$9AWPY-1F2
M\U?'NJU:!"EM'#=5E^X6I?N8*MVY$E.49  W,Q!@4%<NA#R+?I .6J=+DU
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MH!J%-&;0XK,Y O3DLCB#[N8LSBWT=?SLZ:5^MMB'4:=UQ+;\-VW+S[4MW\4
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MYK%'E.;N4RIP9,&>(A>3UB$9PZ596^>\;=3E]BL-*[)84FBG %P!N(>(;A6
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M:<J\2;XX%_-_Y^%6"&*H$LI&ABUEW'!L+6>*1"F9H%08_U&2M>E%Q^>Y^E-
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M4A%O")%,. ?0QMN"ZZ9#VZWW[?W@)$9"7N@K8*GZN=,+L3=ZB0BN/M,@K3T
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M+"DTK&G(L3=/PSRFX$F&B'34$7&N$[(*?C0BR!2$%LRS@AR%AA4:=A\T[-?
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MO_ECVSN*;^PH;J<4?6E>NT3\W%DXWM=I@[U22":1-PU%C33+T1U)30[421,
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M2;;@_4&G.@4[AU!>C8>P H;#J1F?R/P"OL![DV'4-ZJD]=.A7+>VY121.KT
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MH]Q)7JX^U^3DYOKS,8A\@Z/8/P)?Z;C"<IL[^F0S^A5^/EZT3Y4F3+XG&PA
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MF37C7#/.U?#JK1GGXS+.B1Y,J1:*&0TFKDT)3Q%0 ;1?(IU,.#5I&F<:2_B
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M>,BPS '.@"0BBC5A3LH\BV ;<_;F7<HV!6CG\TK,_+$^ Z7;'VWO#<#06.'
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M82$MX"Q?'2'\N#Q2:9K%*4^)3="9G,0&I'84$VUB);-(&9$+X(MTC@ \6;R
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M_5 =;AV*?F)&R%OG1SJS.<] JII<*6"$:%;SV)%4.<H$UH(:;'NU7+4+'I=
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M"OG6#FG0J;BXDLDU M?F1YV=Y?;,4;(,C(NL7< V\;S,;9].109MO^9(H&X
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M\O Y]!PX G!>D"Q Q3F%MB9*9 #7:';:9_"YKL96](>@!OSQTHE_8P:OF$*
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M0]?%[-FWQW3F41N222]HFZ8?>@'U9D/?H2:4^X6RWGWDJ.=N2X^JPC3F4IP
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M.SQ='F.IQ[*MYW<=@3SZB]XZ_O'=_P!02P,$%     @ 3#!O5&(FCK!?&
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M)&()'&8.-B &(E$$T6>A9-.$S\/6(GW[(-T6!/TW?'V83.?O<7IT+F_Z+GW
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M^__Z=CQX\A7'D_YH^-=?^)_9+T]PF$:Y/_S\UU_^\>D5N%_^U]_^]*=__Q\
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MC+[SEZ2#@]FKO=,)? [AI/=Q2CMSW:1)NOB:?IST<K(N!$Q05-2@HF) .VH
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MDV0D9Z%-:;P-P#XP'K565XN3@N_)Y[=(9O+L[-H[L_!39$EXVKXAL.IP2L'
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MACX8]JZ5'G1PY%U'P:W3@RX*6F=IHJ3=# W'"DF1G2,U,(_.2X&*NS8W\9:
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M\V4^Q!]HJNR J[N?5AL0[9#RD.X=Z&^S4;X>OL=Q?Y1[03+A1-'@0RU5CSI
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M_^ONM5>?4_M4_<X.=6KOJEJ%_8)=!L@?*JLI S@X.,#3RQ^ 7:' 4X*![0!
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M+JTA!&('_?=B7IKH7T'_H?DO=;P<(Z7@;FOI::MXR;*_.9M?4.3RP'I_=;:
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MLHB<M&CA'4KP8B8G!OT!W6.)LTICK?F><I:IMLZDS"_;]UFFE9YQM78QNUV
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MZ_N?O9$4AY2860K53NJ!Y;U[+BRW<OL2;F/SKQ-_]0T+'!S^R\P1WTHDG;"
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MJ:9\)P#:F-J!XV=TE'G/=1;4K?&RO,L_C-YG(CL+NY"]]#$9J4/KC^[N<2R
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MC4*7N>#$X8[Z=S R5DI=DK^[9@7*^7J)1SKL^TL3*%/2L"-@QF@Q[6]6.N.
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M!8@FUHDZKL()4MB-%$+2WS*[2[/#H_\D\BEE< 2.Q2KG<L9!K\=[^;*.,2P
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M7=8BA,*JTNYV(E['J/+2 \Z-.,UGVS+@E6L6C ZL,U*QZ^?-.<DV*;RW7UB
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MB$6#3FEUT4R+E.,;B,C#XHV**"?U(H6+(SM[>KJKRM1)P-K'_@W]@16;XX;
MA!SU,A50V&& /+2T5+9#?WG'#K;Z[*PC3T%01IF(&-\W;12=&HRPH%4H!(]M
M3VV_<Z103C0RW8P6F4OF]NAD\YK5(A"HA%@FQ+W"F;G=C_MRAEE%05W;>$[%
MWIZT6I*BDZ'GC:0$+NZ)7O6?7C36,[CQFH/D9HISAA4;$>N;(H>WQ'*S&EC@
M_NGPZ0J\)W[G%A9X&[!QCFI=-2C\)?N/R-)OO=VCU[9\EG31@05B';3OT[."
M4R_\!5KW@BY$ _(M3E"_?2J" #/53(63</P&OM&Q?8%A7569M<4"V=?*3Y?A
ML4ZC_VP[)3//1[)96_H$7;1A 8;L4[76;ZS/L( _"#.YQ7,E_C@)/B)[<(&Q
M0.?^$OT2_1+]$OT2_<^(BB/F5O7O#-3A(AKBK37_]C1"HM3ZR:07-%(;IOYP
M(F^,O[1Z:8>W<0"6FPB^IFJMFCJHKV1._WJ'<^5^KYA*5T-VI R?#(>]0$/M
MF 4F2EHZ.KZBEU'#N7_#.L[ !Y<O2"0.*-UQZJB]*\M3@[X55-A=X#AJC'A5
MZN'H<C-KO@95$C029K F:!GSD6TC9A#:UC!4G_^MU1$MX[[EJ_^A(6U^,+\H
M,BKLRDU**?(0'Q^[U42/-KQ6<K$==<4)&0Z65(^U6[GE"O:>,@BH,(T*5^!3
MM_XX9;+F9Y[9=$WJX'S,S_Z?>_W-U?4- ?B'[2S$"H(JX8S>%8_U]HENODYJ
M*]>=]&<NQH1I4)KY&%<^\PPPOJ=$FI6&*HF*ZARXF>]/:2)=A?$I@YIC&&W+
M,2*ZHP)>9K5WC2=F$8AOB$\UPA_Y61:P@,1<0D:<JUL/SY46!)K5=,0+2O,*
MMD>K-7XX;@D1M=2VKX.$OBXD,7##BSFDHRL[4!TYD\]?DN?_$>TBY@?G+/U,
MZRUX$RPHB*Y^F([OL5]S0:8]55$N2VNXU1 >83,)?9\R;5J!J';(T>)?%K0I
MB3J1$_\NN!HL/14CQ1V]P.3( JJQJDE4H)T1#2($&[E6J36H\%<?($B>9C4]
M)F!<*8^0VLU!/PD][V EWOIAD!:81!>I/%,:;/LC*)&SJP[O>'6LH1S/:3:E
M'*E%-[MU5]93RJ7XV$]I?]*_[BP/4@_<^"23D=85OER6;;W2?&7@X>1>:?FA
M>H2 5:-?Y'KH>X54]IF\_1%)_K;-NJ,-J2E94C1^9+E3[4_:"-$OR"FH[!1J
M$2S\:%2\K8ZDEB@A]/#M]1>P@LX-DXL>AMTT+XVYP,[COK.S58G]@T:)C8*'
M!_'A+*(331IE@Y9EF/Q5K6DK6HHEF/MN!Y5@A7//\1 5)06\Q:;O$YNK5BXK
M\3?6.0)#LQN:&GJ)2[/7[%FS&.D6OD*&W+H]IA:O3'"C ^/+,*FFM9-<H_IN
M8$YCQ[GAFR\A+)Y!?4\_F*PKWE<;1@!V&&,HN;F_#EHY-@"YH/FU5_[T6B?C
MW$Q1]E!LYM2#C[@QA;@NXW%'Z99H M-TY(^],@XL\.+!MG;V@QH%AMA:-^7R
MKU!<MWFD(J[$\:ZTF72'SF:6(%HK@O^(W'8ZMT8OMG2?/XUN!H?;9SAQIG=@
MG.6H']Z14!G=[BUEEE(/IRFU]F!>DTH:EDFX%IKT+/5[O@7?C10F][OVLF]I
M\]&DBX@R6)S:V6-__AQ,X I?S+>:Y4%>=A&9>"FI#\$K>H!(EEH?+G=7%FBB
MU 8EALB.3MN?UDW9XMW1NC^^6N>4+2!3%"=8M4]G61-R9HHS7M* BLL#(TG5
M]5$I"/S46R54BYT^5BZYPA]"C:ROJ!Z+CX9DMG^\+I*Q8G1VJWY,=(^H-Q<3
M+-:$6JL5.?F1PN)HVK2\QT6I.(MCUS;OY^[61V"Q8O3HIVZ?UST+;7S=2#$_
M'/ =E.SCK$<6(/_D>UKWPE-A(;V^L67UJU\L>EEG#(PEM;Y#^%0< B=Z@!5Q
M&3NUN[($_3.,Q=.>K[U@3]W*EHS,'YKP3'EK.7^H^Z:@?DO3;RV ]^Y]5/DQ
M:V232O%YU?#%?%T4G+=_;LTYYI9(4J/$D"L/[N"9$AJW.T6\A>_E/-Q^?O."
M^6-SU+P\8T *4N&T_> V=Y;@#-.3B":GHOPB/X+P,R,L0'0O$>:-_/EUP[8Z
M>^8'#UGJ02=#^6>/?4'N]>%'TRI(>)@<*F$1]@Z^ Z^"0S='#'=.Q;$ QX#5
MW 5F(>-PE04QM26E=1P>NEL-EQXX54J?/9D3J76G7H@YF)88!%R72(\&!OVT
M1D%>K!28M*W=KX/<68L!%)95]D+KSU\;\\PEO53,6';WVS[CG$: ;IR!QHX"
MW#=V#*;)7#E3!_06:I"*YE2 X <"S4FY4!E)I!8IV-<\2: QSVRSP9_(A=KS
MMQL62K.R\.K*D+8-^Y4G,F3+P^0P;J6*T9MH_'2?O%DU#FK(+<7,SKXQBJ\!
M;PLE/4(^HF>?R_181)N#QIL8ETDA!1"E\OR)O,D<=5B(J<E<WTP/,*O#9244
ML[,A5E%ZIC8UU]DB-.$98'-"XXN(,?;JHAGMTUFTI)"65VB]^8D>[Z#;BX&@
MPW:4 ^6N5AS]'C7@>#6Y5#RZPJLUY""ST0<+(#*\2P:T@KQ_VH>*+1"H3;4,
MXQ<4=<-=;*I!Q]J,889]!SAN^ZN2QL!W&2YW%Q<!K>.-B"/R0AP->U6:A_7W
M'I^G4?;&Z\8_W.+E5JM!4]T5F/U:E&]^7Y<PQ=<YY3LC1^*@S/,8^QBR4J>_
M?5KEGYF?E)<)\.?H5U?Z]?('1[+G$Y091E4IW;XUF?01.>;C^%7E.+\8"SPX
MPP*8&[18@/KO^\:'^K+]\"$L0+8O?OSQLJYSP@*75; (QZGN$RR0$P@_(XK&
M E&Y?^R6^O(<ZU[X8. O_0SAPP@LD 1_DW!>] $+C+3*7>!U8X%N[3]V]9NI
M_&YC >DSN;Y[)7(;LUC@4^OGOHN)2?@WBVPL<,4*"R +_]@M-H^Z]PH+9%ZP
MKK%,L1[LP->6OMK '1U;#T'#6"!("([6^T/O2;D2RU]4(7,B.SENW8<>",LA
MQ"Q^TFY@@;;7K9@/?^Q-OXNWE=N AY\0(,+/3BU.[IZ\89U-*S^_=H %EA]9
MG#WY8\]I5*4R^Z"U\RQDMO,BH/PL_>QS_(Z&P47H"19 W0)=W/EC#_$M=T;K
M9&GE0G['$@O(3E]H7-C]K[VA_;W@; ^%!=C^;SNCB%%_DMI]D36#[.?)[RA1
MOWW:Z!]8H%GEXKG(I8D4+595CA=SL<!]^DL+L(/0Q:_^D3+"V7\8E'L*U<8"
M;TDN+4!!BYGL_[,J6G\8,7I>6WBI"3[\C##ZS'']'^A1\&]'.%S,3<"_X5[J
MK70AYO[G>-+]-W)1.&1+[A#G-P.P8P&&^C]'TR76'X;(U1RQ_@1^"S\*>*SI
MGZ+I$NS?#F"=\XT_!^PO@R^BM:=,^^]-V0__M_(_V-6 YT^A9"OW_YSA"QN&
MW@^&CG!S7[3\'D!8X ^GCVG(N?MDPZ\S^M?R^LL9_R><X3!YI+,.7V&I6[W(
M^FVQFBDD+Y^SN7)9+-J2R1_^V7CP7\;[CT?RZUZ#204<+$!XU"MWB*;%C+?^
M88>1C,*ZY_3,:MS$S8S;NJ/_/'93GD0\T?DMZ"0.ZZ//G*QRZ]A,ZNULZ$X'
M)OYA]/ Y-A0!6*!#3D[N\."W*%/_.ZU*%.D>!QM"Z+B+"OZ)PL]QZV>Q_<7M
M[:"0.!=VUJD:QVMV.K9S'"V<D@MGLIVS?UI7_^Y2^VMA_:\[)]?I&22 **T?
MR?@ZI-IVQ76+WK!80,55'L^;+8J[J0:10KCK<C-TUV9_V8CI=C+*Q#%D8D6M
M[3M9WI]\*M+Z[RPI(TZGBG5A! U!=G7VAM;"P!C5:;N*CO)UM[&"_X+YQ5-3
MIH\3%@SGE3R@/ M,(W6>;EMTKHXQ+=PC;%.I*MFFX]:3=*$FM(TQFFKTN /<
M/FS!$G^"L?[OO)A+E[A5];53R/-]=@6.1 ><7H/XK1JJTB1WOLISZG2M)"IQ
MW'P51\BV1O&GV!S^]V)S*ZRT',Q 0B3>^&$&7*$Z1ZD^\"+4J"+C2I<-\N\G
MF(P%_AV%JO*<?/6;':>-60KLBTQR7\^:2(>^H7Z.5W1'=8A0X@>U[W].7XZ2
MZ%=/.SEMF/:O$Y[UW';X'XCL8AW:9VPJ*2(W*H-'$XET-Q.Z9:/J'F@O:IPO
MO5/4=$L951_# L662O\?>U\95M>2);JQ  D22" X"9[@[A(('MSE$()+#NX>
M"&X!@GMP.3@<G 1W=W<_N.M+;L],=[_)?>_V3,]\,U_WC_JQ=]72DKUJKU6K
MGJKZO?];?R,H#-QEY4O]W.$)X?R,F_ZC)1+SM$=U._/G(:-!.%$K54W9Y!5&
MPHOX&SECC"S<*%N<T.309=07OFA8W<.7,M$,?2\(#Y/S :Y^6]E2QT5W:5#9
ML'=7NBDGC]N1"+/Q-67%=:1RP-ZE"@?=1UDAQ6\ LQ>FW-=J&9'VB=S:VU[.
M!([X[*WSH4D1]SS+F08UNPV3]^N?)4+E<2BC:_AI<04#>:ZWKI*P1 TY,LP+
M)[<.^@02;0V*8GD!>D3(^DNDQ(L2(>1MN.T*M=2NXFT"G89E&H:%EJ%W&J8.
MBE40/GK3)_B4\:^_Q.J7 ITRLY$M5G,1@=1M_$;3/:T""J6C:R4CX/W=(L&R
MO0_8[RD@^$B4-AI.B!*0BHU&=,!E#J=GBZ"_\EDHU2#[%MNU]Y53H[<Y#0FQ
M3R_-4(FQ^V3WYV]%SI>B\K5E58=RK7WB4H=H6#JFM:K)8/8&WV9_/PTJ9Y_N
M32>;KY0JLQBSD4PR@,.)&B&%IJ,W&T2/$=.LUB@ED$*)4$9J2[]B^%..Q6(&
M$E: $=;J S<O-8JP=W>X,96X\<NLV%/;SPC #<E]20/9VEM;/ ,OA0E>QE4]
M8"$B(CI9'$2&*.AXYEW,:!XTS!>8%A6EYLJA?^*, 9L^C=GNHYB7"&UA2[)\
M>1QB)=?3IC'!)[+LB6+R3&UZ<(1=S!:1PZ]YW"D@10/QO2;]<'DN'2&-(]'C
M9UP4"-"O]8W'RXP!;'V8H.K(U@5^7_\9^GV*(4:V28T67Z8R64GJS]^C+_$7
MP5TG_*_X97D?L_<D2@?71^KTSZ6'8+YEK>$Z_2V04L9X&<,_[<+A7'.4Y+TY
MF*ZD-3<]L][D^\(:#;?NPVJ*1?20CH><JMWFN+#"[(0M"EMI\%F<QK<9%F\$
MW^_]:C8&CP6N5OA6 L%4QXH7./E.1LVL A!+?8&$@_+\<MFTCY$2"%:O%I,,
M07(N\[6D9H?MON9PO;7@"N@S5PD!39Y+$\A6@P_6SFJJ%+"U^1?C_/NA8 #%
MH#Z4Z:O$,>[#$%0Z,>804I=62T(SCO'\":OI^-DEO5#"J*WS\ W5&WLVCGM
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MFR7)"(,O^R>_OELZ(_%R%%P]O\+P3E V,NWN<Z6Y7?6RRK@NV!1,_J  <OJ
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M11W-(@O=]-?04(BLVP!#)S/SK49BL>FJ+.-\4 "5>%U9D@Q1ND;SS9(R*Q+
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M><E2$F%;[>.W2F2W7&PZ3S!<4:>52P]+,*S'JW'M2EF7;&>NG%<U,@0^PU$
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MUA?:>_[)^JE5Z20_,I&[9]?IJT!'][SC-=@T<WC#Q=!?HUK_-=/_\+K\[U.
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M>#!KBJ##PHK8G-*=BZ;G;ZK[L?E7_/,R]I<U_D(3X'K1[(;32!DB:5O^TB<
MH9UBQ0<GZI#TCBH>E:F-R)>ZZC"C)&FJ#J=N.)3OO(FV\&)"I#34%-8AGW],
MB3]CXMA./1X>^4U1/$8-EH4S6B!3^0%;4[XH,0M 1;WW0Z?C@Q<E&A)XR OP
M%9OP,;\&U2&9H*^77MKAUVNC#)L_$F1ACP,6C8F\)& [ZC8W;\K"NF44^:F5
M4U^'K)WF9@3,?.I'^_C66S6$=$6]\QL=JHX)0OJO!:T.*Q,K)D06 PI>=I*/
M*@XBT?]Y&?NA1<&-K)S?M/B,%0+)G,"&5Z0PUFV00.!3 3]1\=$99+O5Z:.0
M=A<>Y\V-D4?(K_6#\Z(P1DYZ(O3H]U;&4CZ19;N#V_YX,[:9.:D=I?BE*N^!
M;C0-?5-"*C51!#-.%Z#A=V#%Q0[Y-(LRK+/G?ABQLEGPJ#+)!^&NK4[8Y&)[
M(36=7!^\N1'(>>W@I"WR?JQF]((_%S-">[G+K1\;,X^9&U,VL-[ NR%()8A!
MA#YYVOFSA'+1"3\A<D1*_>+51[7<W]']V#3-7]54)=Y4'J,PAL?EK@B,;M/\
MN\0;?Z3\Z3<NI;C@54S:PR^_X][[59'\>1K=7O%GTK=-!%KM0X[PI:I2@K'M
MZ=O&-3#X*&1F5=\+8] A).*8""XBJD_2O7C+Q:@XQS3VW!QI/5M;4ZS;TT4>
MOH7KFR#38D328<)QZA.*>:9#OP9+$I\\LRN/U)RJ"+1Q%JU<OVUYBA^[<E<V
M3Y:/ "*"-V'$<-D>8[&;K>7B%)&SYJZ+1V8DK6</O?#D]U&,9I,6_6$O?HM[
M0&>$K4%:=F1_;YRP058LJ!\;U51#N5P?P0M83<(0VA:5S-H>UQQ+!)E&.1_0
M#0MIZ3,.$'ZQ]H9;^A)RPK5<GW.M)_CLHJDYY:47R[1,85960I.A-*W_YRN?
M=8E.\5L6G$DW^GL@@L/S^M&VX)4&.^"@K$:[LK/F(U-2BJ <LR)?_WAFQC26
M;&P/I+ Z.1*9S7;)(E6B]^"!S>MC5W<E=<,Q.TN8>8%AU:%%LA%Z53']BG D
MRLVD;^M'D)\C/)Z5)![7*L)L?I)+Y9?:V:LWMD97\RA[E,'Z;J5U+ 7&>-PT
MLP@I M'K/)#;=9_<G2OTHH)<D:S;.BE)AB+&%(T/2S5ZD=$)POUINP#VPDL;
M-60<R)(6(9AUA3'PP^Y^D44D/54'K;W#.2,<(_<DJ,MVE ,ODO.P'0#VZ$^U
M:!L4SV6AB>YS 2&SXJ5^?8O1JR%$7BY&Y99\YNGJ,]IR_+.%5><KLA'O*Q+4
MKE\# <UD,?I^1%[B_.8)%3XZB<NIP4TE]O0\76\<!'0;1E9KZ-R@[0_[2'BO
M[G"ZZS7C2NI#]^DQLNX!U!MR&-G0)]Z;ZA*W8E8'?N@=&]PVCV6(G;N:,H@'
MN1Y:'\D1PV59<1TL%JU&&.3<67<8D5S3+F8V#RW>\B LE9ZS@'V I1A\DMJ6
M\K/]& GW[93ZXVB$MFCY]OZA6?= ^X1#I+2Q.?NX[VVJR:"XDQ1BHL,ET64
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ME$<M_G;'N_Z?O.5*GO\,/?B/*4 9Y1FL['$8H4D/::W'E_^+F;)_!H+\[U+
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ML".;W-&%V/9>I([[BJJ.4]!]W]7<=J%6.%Q7VE;Y:PV?JHAVA<^=9Q#N&Q2
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M%8@J_CH(/1>9Q,2Y$7 %9/]XNIJA_GEC#7_9.^7,J0Y]/66GPLGTZ 1K*(%
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M/N%+DHZ#W@\D@^4]A"SY+UR+\)1O.IJS+ NI^8T%--%$?=9IL=>,\LNN^3A
MG+U9/5X"&M\6H9W-(A;1 TP8,&>1];<>N(!;)YUFHV/HYK,!K'>L7$P09L-H
MBQ4*'H5%C6$E1L_ROM9ZOWV.Z4V2YFC!N'4<S!+>YX:5FACZ@)NNR^(B)(J)
M;J!@-/2^O Y:ZC[!&"0X6D[D]'PT.HZ$-Y=WW$B7L*GI+MJ\S-M&=8&+KK$]
M>H/KC;[2,2?73EVB7G7B!;VU15Z09T)DD$N?O:ZF*7RY=1_L0C3FQ)+(U[\1
MJ0$5FA]X"=$)60Q9#>+E>L3<@,/%C8TX*,C*G]M[AY;WUN\-.Y!$I0AI?^]%
MU/N,'!FKIMY.,#FC&Z&EBJ+Z]9WREI6GGJ+2:S:Y$"@")7$_[QKY;KU=KAW,
M51;,?T!22KP<S.Z#-4QB(]J=/3&JC@/8"Y$A]HC!!J4<3JH%4OUP<223=P%Y
M<4)+RJ-&=E\-P]41V-,($ 80BTUNT7H,-)?ZF-.TQ45H8 *03</$35?, 3H%
M&KMJ396A1@)UMX3TN.+%^B*8Q2H\]2IBPEZ6[2Y'8LOG]9ZC]SAO"H332SE#
MAT@L_TL\YU0M:S*Z4MH+2Q+^F^Y@SZM.%B($=7@7##L_<2X/Z)OJ-V)8SA)M
M1"/+J,7<J].8$='OFY&7,*;_"Q :L)&+]9DSLO;;JQSE"F[F)"/D.!^U9@77
MHX=:J%5Z;@%[UL,K^N_&Y+D7P^3(QI#-K"U/L2U&K&G,%L\V/\'&3RN,]NR=
M5$ZZ%G+59ED$90@GT'M-5+V)CP+LC<<$NYU*#4*\B\K?:+\R< SF9GXI]GP.
M(:.B.N49X4:U%:*ULO<3ON#D6KT6M6Y,4L8ZA@C%K7R%?LPEOAOJ[*1&%;;-
MPO'50+BU,Y5B)W?O\[,%5X"UA9+DD VP*/0>UGKUU'TCG>6!4ZV<>=])O82!
M#OR8J=!7C?^MO;,*BBOJMG5C 8(3(+A+@KL3B* =W)W@UC@T&BQ <+H)C07W
M0.-T PT$=PE.&G=W"X$DA[_.?;M5]^%6G;=3M>?SVKO6F-\:8U7MFKE!+0Y0
MJRC$B1--/%E;F*9DYUX^46#<R<E*][AIY>%G.+Q YV),Y)/*C"]',B H"S#@
M_M1HXDFE77"E=^F!2'Q> ZE>S\LN>T-<-MZ"+FH[KUY&I9GD+FG"0-_M5#30
M([TJ419IZ*TI\^4^9APLC!F3UD-4EM:U@^!J0R",LG8V7L <C#:%);5.5GV5
M E,7P(\R)Y[N:J4L2?Q3LY!U(*?ZQD+LNC==1R/?BD>V:E0/TZ.E<X@94\.R
MU!^H/)7E%X%?S;@AP*HJ<+*-\GXNCUH6$<(?NE-FG*WP!;O;X>8$>5*VF:;)
M#IFQGM@_+>)JL08P#&'&!Z&"ZEB:<E]^TA'5H5X2']"-*&/ .Y'1>L*?L[;,
MI1@JKQSWKC7N2?3D*;]#*U"?.;BN&$H:>U&M+[[U@B&:,[+[M_]9Z -;^J"[
MZU9X0;-P#ES*-=W+D-K>VI0GX5F_)#SK!58.XNQY#,B-<-]!-#5SO3F@K#W7
MB1U*OF+:( /M T.&9'%PH[0X4&<640%NUK"I=V-+Z84J_"71>ED*;^L'$VC
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M(I[BU4S=CV/9@D(VO M"?<XWA%@KI75'^UE]*Y)390?(I,:Y6*!++HS%1GG
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M><$,3V:5!L/[#U-8M819+;\</ZE>6-F_D<[[?'U*> @&_[:'<.8$B*Z"8'M
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MD<*_XTJ^*:.M*D?L\(ECEKW)\BB[_4W 43 ?QW)40>:&JEOBV* 2E(/%. G
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M \_B7CX)^=G'HB)_4X.SKIG3HRL4=?XY-IG<TN%30F?5IM?63SS*DIU;OW\
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M;!ZJ-&\5]_<D"/@/@.?\7)UFWKX-4DW:.US//Z/"@3'H:'/GL<#F)O*#R)8
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MCOPH8?/59XR/XO\>=_&_]3]2N/]^_A=02P,$%     @ 3#!O5 CM+SZ.B0
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M^JL1!#1T=$P,3$(L+$)62E)*UG^9[EH!?'0$:A05) 0Z !$? 0D?X:X#H $
M!!2$/^@OD0("(A(R"BH:.@8FUGV%Z@< (@(2$B(R$@H*,O+]4^_[YP R/@K!
M(YXGJ _53-'H[ EY_:(RT.F?EK<1J7\_8.![[>"/@4E,0DI&SLC$S/*8E5]
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MW&O;6B[2?78<QWS.4CV4_R[[1Y4_6#OU6A7>ENO%#1LIWG=JZ#]O\1Y\34'
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M<Y!FG[@;6T6YFQDY=#&I.M/-\\7!;E'\I4R]OP@IGTW<*L@7H$B)\04 2P
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MRZ@!*UVXXJT$ZAJ[DWW.$_N2Z?F93=9#EJI H8_N7WE"'Y:G%,1,UC,U48<
MZ\[I>,VERU=@SN+K.9ZJPD+=&3=22[=@TD'' %#4*(WBZBZ_%!$8%NH1=AO!
MF<M/?CS+79'V8+3]3(K1'%%.&N,-0?:JXYAVOIHTY5 P_9B7PL&Q=DV0/*RB
M&58=SU*TEQWD_II;TBPJTO)FOX2-N>.6H&ERM:D^?F9 < %$'+^NVNPA0QNO
MB8W79W#=N+*'?3C@&JN*AK/D@[709NL%Q=E_S_ZEY7C7J5_->M[ DTA7<3>>
M'[LM&3_M8E"!2.A](T;V#]G)R](@I\X)J2I.&^+=XM?NON"YJ,96C,&1IB-1
M;4L9P,Z#,ZIP6NXF2#""75:L/SG@$%'IS5/W\!V&,!TQ]VS)$7+N%L]U>K**
M-P(MV/!XPY?3$^<=$^<U]D]$%#BRZA7H+1_U@ C-Y;TH3?RSWD7+_6HRFH;P
MR3('L\&8N 3CB7_?%EGQ27W&'2"WP  EC^'/(PUXBL5%]I-'#X::F%<DNIZ5
M/_,14FSDR*IGBSW\^0-(Q@4YWR>!&=GW)8+P@-.8*EJ:RM)5G3C14H-2.K:!
MM>N$%B+J%75FS8A^[UH>RS<&Z4,>4A,RO]8+BAKG_7?.3<R*HU4W>"I)^K$C
MBQ7Q;HPUGB(A!"X&SX1GZ5 ^O</5":1'PC+*O^]GT(OQ(F=EB^^-@K!&O>(C
MPVZ/T:=E7Y&MZNRZO\T&BI>,F9Z_-5\-/HD(%&671*BN]L';A+VMOTG[P#@K
M6(X1;?=Y[YC0+'61<B-I_^=G;"D,'6/=GV]=*@ED"HP5)[6CLO;Q&Z@?"'D7
M$#G>#EC"!=&"VD73DEIOODS?'@FISZZM@0EOV>C2NV!]81Q+X>Y,X:0CNO;K
MHGG8\'MX>2A-[8,;4?I33SN0BX/?<LQFQ\ERM.1-9MT'<B&ST,#9'<(\JP,[
MA78SI) L^\4;'\7O"PJC.U)5LKF?VW*4[6(R&;,_U.O^X$'^,J43EI'\.-0Q
MZ925!6E@OXK*A4/Q2J7Z^UI==?W$FVKDEH<=Y47V%PAC^297W;$O$1?#+Y8K
MBI?3<&R_7H)T9$3;EL7J$[24@@V9V6NQVYZ6VZT(V_4!;&.'1@VZ9[<TWXN=
MW:OU#9FZJ&3MGM=&S= -T KW6"+9_Q2]C[=CEAF2.WUP[@/^&07LR3/U3D*"
M"C9BVCSDO9FA$OM]59FEAGVX0K4"M(1YA&-C=&<Q<._;TT%RI@2'@"@#$'96
MW'Y;24T(L"K0@K/-L025_4KEJ#YAWH(_$]=(7'ZA5NE'CT2I=@<@V&2?K"2E
M=_*@C8NSF5I_<A[K:&6YBI)[N"?9OJYY!_AA;K'RV6+4Z[_#MG!^^O&Q6MUC
MVD@\ P(TZJ^^#+\6HU*F@Z"O.)S;[9D^^.T%,]:\<W/B47+Y*@0!0@2$C_!;
MR91S(PPFBR;9A#X*A+&"20P.4N^ J?'PF:;'$X>8[]I8!/N$-Q#PQH81[EU9
MD"A>H+-:WF987N(X)EZ5-=^+.HFWVJ^ER+<*'\H>1@1=/[&;F'Y9B#QI)221
MM2XR[/$I!8TFN!@&?&LXI(X!%>N!283R:L_#:D@1XU^[5#KZNAP4^_\8Q&6M
M25RAPM(93U<>W2?7C\/5%CRB4\2O:4F@9U$0K$4#"TM80T%/;R?&3B!#5>Y2
M4ZX6&Q8#\S:OG6920KVO-]+B^A4.!I5M5<<6NO7"TH/93U&.KM/+^VT.9!FT
M=5:<4P)4>[*7GO$@,:P0(FBW21T9-C/? ;/WK)#4Q-08LR075-6">:T#C\BR
M$EPP']UMJ;C.\^KR;OCL*L5'H/*MX\ASLOA_<6WNG@V"/GIY-),T$J=/Q:C0
MTYI%?6)X(Q'!L%+76HQ'"*\8;==Z9W>\;[Z,9;[5/7:)N;XCCN&X+&PC($4R
M1-L,>_&,/,7[DXOPO7>WW$Y3H=0)J;2=&H:WT/=U:1<R[W!'+&Q/<4D)#6]>
MTQ<L;'M@;NG%VC^W=.&1(X\D0D,2$8]^(A5GHR&H%:6CTP:VX2'$+[*2\.U4
M-M08#26(:9# Y(E]W,7GZC)^$: ^?LJUD\H*62B?6W#7]_F^DWG,Z%5&P[IJ
M2=9[AEKR76,?BK,X$NV@;1A^C\&$;A2:.>Z -N,[P%SNFMWV,L9+_P[P;[GM
M:Q!EXU1,'X!3!TUP^QROW %,E@^%.GJ*/T=[1F"X%;!DJ>_3;V9H$F)'*[P%
MJ+;IORX0%!LK).\841X2'5',)&+'Q],]IS8;8E%_YKU84D]S"SO!2K5\\0L6
M'ZM5^>^]<=<Z&BQD2!2FT$A)B?(+/^VR:M<;L1PM]N++!?=GSVU-]GHM6+*:
M8#@RX:J5?P.7.]2A:#ST![H,MI3FKR7P%(/&64U74ZFUG<971US4/6=Z9QJ&
M&^X +(K;[ 7B.V"Q] ZHR/I;#0U3B6H95=:O\82V2:4N#N^ &#Z*]EOZ.^#]
MNUV:0Z;QJB%ZV^OWQ5[I?"YO]YF%NZ74]/G5]#KYJRUQ=)^^LL%?,RRURPQY
MG!CP3QQNHO^LD.VE"Y)%YBWKH1^>$+I^E$9R!V38RM\!K>@M\*3ITD?P $O[
M8K>8CG@'B&A<SF[\>\XJ,0JE>EK](,17]*;RQQ0.F2ME].%62*,G-U@*(V:N
M(U4-;,R1IM/3<_3L$KC#?-K;?;>D@B'BYOEXN-LD>@/9EX;%$Q>G:##!-SL7
M08S!9-/%[XZQ*0]#/7+^V9LS1%1]@Q,5Q2E1G7:JP=GQO#^+P[%^W2\?0^3;
M$AV[=^.IUPP?ETVJQQGA^>)O=@Z+0VF?- '8AA'1@HM[TKP*%RI(H9?()-R&
MLF;522)1ABL<%($(42$5JZ[8V?@__,74'!$-]?IM'T>IF[%T/287 D*I2K)Y
MTY^BT^<)M%USP)5!!PU7ECNBJ?<X\2REIW^#KC2.P.9'H_?ZQ0Q'J[BI-J6O
MQ]\,-1'E<2<4:<">KI,0Y-B0@D*]7B=V!Q!;ISUN\F9K4^/MP&4:HS1A.3NY
MM2PKLIX(XSCWY"Q:ZWB=/ZR@I'6FY"+49225_GQ\03GB964].E%[+^=M%BP4
M*N$VU.*Q><WHF&<$]Z!HTF(QB?9JM&NG[GPN(=R[>GH-H>M?2@O#35Y=L&V
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MM31UB0\U[8XF#:^*-&EW15M[#,;&PP);,O4&4!:F:<M&1O;6+ ,U(B %[9)
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MSA/M?E[N1U@JM3S@VYP6%LNL?!88Z9%^*.5;\G^Q]M91<3;9OG 3W)W@DH9
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MJ=#UI\94>=9<V4;5C,FC\**6>NV0'>ECN>1P:@4Y9'0J!@JT2==%A53R]"M
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M"K%8)^/N?#.D]9UDL\Z-AXY\"BCK.'ZC/)GXO(IX7C((6HY9(MRUT I8V=:
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M?/->*T/;4.W$49-(,X#M"KNMAUV&'/48%H34Z2VQSOE)R>C):HTGU_B)U2M
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MQI%KQ7,ZV!0MJN:X;61/]-.:]1,V3;XDI><_%^&'.Z((I?&3_2&;U+)&&%!
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M:?L=W>G3OLB%RE\\; S9;O[;PQ][]!]LX64('8ZUV8=KQ2M9.7.1M"BZRM.
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MM/9%>6/VRB[QI(-MBV4"C!2L[2T'Q\JDN"MBKS<^!'P^:+H0-P%U?O\5B+$
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MX!<X68N(N)59F%2$:=:\G-R>64XQA+@":*H$T6!1]W[T+!5=FE;<V[",%NW
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MX$]]WYJ/3_MN$DY[4X;$&-]MBNM5Y>474S@@1G-UT8A(X[_-GZ)C<?K7J16
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MO0O(Q,#',:<)O@??L]M ##S^2(QN;M/12,R1_M6%^+-M,1=B$;TY.;KFTG!
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MU[MW%!(P$Y2UZ0(-NIHL&][QS(G=>BR )A/2TK7B&-@T+]='"API*K2+DPZ
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M*/"2-!68OK&P3QU(+0;=O@V@24_RVW[9WKH_83KE>5_VU8N?SX$?RO[YLR(
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MB9F0ZC>SFZS#_<MR(\4=XLSRG241<WM<P]9UO,%A7H3ZW.3)PQ6,-/-:WG/
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M(SA*/+L8IA<(%#DB$T4V<SA1!+9C")WAKP:62MUGDT&S@?+W,/PKT0IJ1!V
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M.6DJ$R(%LT 6X@72^-@#0C(C-!QI?....<6@<QUXL5?YXX'&9Y@(1_Y9IRM
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MQQF4VK+W#_?V^9IW5%0G3F"]3:1*FN^>9'Q %UO"06E!"VE2CW"FGVD*H*G
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M/U^G?P,;<E*;J#?P;4;UM/EO7S@J#'6V?67&OI&,E:+JR3U)6"H]$!WV[UV
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M]!;$";X"*,+7K!5D1=Y:>=Z7%?K-T8D)J'YMR,:4+H;H1+: DBM <HO]$;Z
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M8U?-[7%\U]F*%2(@W(W;2&W@U-F"Y3$EP7O/>,%/(ALF9@72@Y13OG@[I]:
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MTU3J#\/%-5=<@%ZXN&KFU-0[(C2IHVT41L\HG*-[AG.H,3H(41MS0_$C+1R
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M.ZR)KQ,YC,>>9<.:[M8R,"?1!(@\C*BX C35:5#9)6--)XH"E"S#]@8#G"H
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M;HMJN34K8\7VR"F=D]O1W#-#A^F)FQDWY_PE-[&(-)CT,LEO*Z:'AA&L[K:
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MO039C"A:_<A H<5&M(>Y7<^RL+T2?(/%9S(@Q&DY2!-$FK1;:9Y+M4N$"%1
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MT@9IW!K,;"/-E0$XDE!?,*9 TQM^,X3FJS!B<]0/KMA?1C&DS>(+(&?&K8G
M4!.Z6VB:(A%+:8AWT0&,DR:>\3VI6_G%>N8O.MT@Z30JV=91<;49;))J:G;3
MQ !WBCW%N*+D3$!G2A-1-GZIPYUD/F\FO-0<-E8H?=FBK"D[63I*02AY5^BF
MANL/L"Z=6UN4@5F)$<WMN,[AW1)!=UD$K31=SAA*(T,?2=N4H-:ILK?!W71O
MZG,H5/,J7!9C9\2V$9F=A@M#6<<RVQ-+7.P0PK@%#:99H[2[A7' U[4H<7Q$
M#W4B,9J$RRMBW>>"VN<Z#&^-XTRV]YX-(TJXK%G,7Q?SLIWV^V(\;X>&SJ[$
M/I<2R_DQ]%6T!J,Q+,U'<10$P]ZLJ;(JG0HJ#2!:>BLZLF0*&ZSG-L9!"@B5
M->P@(I[*J #E694.M,684#AQHXS2'5@2,41*DI8U7PD3AP/S7@P@HM:3 CKN
M5QN83!S1)5*' !K3XQD&A/R-2\ 8U/C#^1(M!3=(2LNM00C!=X]/NTU2CH1H
M2^?:!6PI<2.R"V6""+,#.=\(T)*3AU:;H;UA9][#\RF!@XZ0F@,G8\!1B:Z8
M2;0'[DM=SW>F9RJ2JR(6G+.SBC<*NF]PK0G/]]$TX3B!Z>,+@3,%09M)Z;29
MI-+G)[,&J#GMDH)A<2#,(0>F4R<<3+U=\@@L5&+F-U+AJ;40MDQ!:%:3X+K2
MD)^FZ"1 '85H.* Z.F^;T*) B%6.4N->RS=F00\93MI^@_G,QMC 75P.H'60
MPEMKN/9UPLX,BI\+DMHHG4RU_ +%NGF"\61 >G@N3YE)L6ZB7S10B7*>R>W9
MU";IN>GBF6BQ_"YY!(IAE'7-8-@>YWH##XV(]"F[ ;A]:"\UG1MX,<<3QIE&
M<%A'N;GDZDWC)M5XR?3PJ)TFG8G+-)EYDVWLO$TQ78E;PQNQP7P]%D?C_J9#
M6)JRAJ$:7ZUG\WZW,['U&0'C%$Q87.Z1.@_8;MGO3*^8E^/?=LM]C,;A@0=D
MJMLOD7Y[M:DTD/0ON/(5U-W[I5=[K?9ZO)]]ZO=V;\CWLP7AFE^T#L-3OJ2=
M%[+C7G/-?.]U8?#XV\(-^;U.S8@NB^O#B"Z=J#@-*\'-KPLKP8@\U\F+8>&$
M]SKY'7)!.#*,FI0DLIQA[VASX[#GV4=Z.-TBZ!X-=:$6W8%A"H.Z!$.W&:2%
MM%KMW?O*5ZUZ-;:]8X<&'&-K7P^V)U2]&MM1YBV\R A.H%FO&]Y8#X$($FF1
M:(?I-;Q)N$41& GUT,9W$5WB..]3U+^:#-F);&]/H[J!D>='CQT5=IS#2:57
M[[B3>:5C,UD<7L>7R<_?UZ\CWI6CN=\EM(T;L G;AUR(@ ZU8!PY1-B.>:B-
M8B8.VQ!L&.WSP:O5/15K^^J3 ;4QM-="6]T>@]"-XR1[;8+JT01$DG2+HHGC
MG.U3#=25G.-?>3Y.6_]48K+33,DI2T_R*5>=DZM/V,#+BSBK3W%.@.*D-\PY
M ?MV?\2P]MU7;C1-V6OZ"?=.7\F[NGE26*?;[J(PV>JU]Z:.0KH$T:*8-H+1
M$ V3QWF?3BFNPG^S=*+=D0T0<0C"U+V3X- C2/L0U#X"0<=9[5.=GDD>N\7&
MR!QJT4SAM9_=<*I*IV=N+8UHX=A'P>,5C]^X;K'FO\><7;OO^Y7F[-3';/Q?
M/V>[NU<UO^.V?'5S/6;'QP/=;]:0FZC;U(I\)L["HW1H.G:G;GR0T_@@R]GK
M[54(3L\C.U[G>C7@X!4>T?4"1S**Y='ND3]L(GORA\K2*(JUY1_<';E$0*V#
ME-P]V(T;C<K65G&P=5#*O*@XG$2+XX[S"B:G:B=X4D-O@+D[>8IN,&SG7:FX
MI\9$)Q#LSN(YL74G%!Y1"B,KUHF4Q7N#<W1_R,X'KX'B-P!35>E:#@0JP&1Q
M&J3:\\+K@@H;,B?:.RLK/PVZ9*+K!%29^#3X="\MN+93C4Y&HTV_CPR,7/-R
MSPR<4>EDR=[P'U6SM;.O0J<CN"8V:F9$>6-?C0K7I^-T%9JK,Q.E)K7)C\)7
MU#QVX^J4@E'M%2G>]KK:]?G[4W9D<Q2'D</0_K5G>;M[IZ)<'FV3)U,N3TFY
MCKSBJ!0W Y0?)]R_=9)=GM3N4_1J;Y)/=8Y2QUC<4&ZU4;<C>R>A[1U*=_2J
M)YSMM?TJQ=?,@3%"+ZAW/ X*ZHFUCQ5=6_W&U5U=\O[M:ZZYU].C>Q\'X1-K
M[M\^?<UR=V:=4C2:O#@*08UI0.CQ^E<M/#V3O5/GXMPKG*.,$>3.\>I7WKZ6
M/C>.;']HC<SS+KKHHL,2T_G]@U?^$*XR$L>)?]/XZU0Z\6LHPZ^F";*S6 =&
M]JNHPBAQHH-[WWYE;3AVGN'!]N&=K?\?4@DCN @Z7!3N?QLMV#_(\/^$7SA9
M[O\S7L$P3_ *QW[\.EYA=_>J >2*:'1RO#D>AZ3 */:%G"H870/&/]JMC>C:
M]/*H8.PE-<:UTLV<O2,SKY5L_W3,ZPF13]O)XR.@;(S"6O:S>)U<SS&X_@<;
M'EGLB=F?T]YNO>7@3OS!??F[E=\3B*Z9S[Z^0R=6.J4%_ H#=JHQN<'0>&*?
M9N&W*6A0+'I5#-O</-+D!?;:<K)C*;748PX&GID967T0A@Y#C1.X"M4-W6"Z
M*O: ?;YG0TKSS;G*GWYPCI7N=V'_3T]<07?5GER-S9$\6"].H7(W& :\NL2]
M;YP7V0V&S0OEV!^$N :RZ\CUY#AP6I+KQF^T+IITW]GS?_OP&3H5QY.)KNL
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MV^>?=R I'GN;B#D2L4=>\??"8\ZKW_VA=S_TKXOW:<A/G_FMC_[XN=L'_?+
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MH.XZE/:QGKUL/R[+%?M/VAC)OO1>_%&JZ<_'ZJP'T83"#_48R@A(6=?QBT@
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MC'+9GITQ:X"B'F^'M8!EO@CZO599[%H'3\BW_BU6JI,I_PN_(\SDU\W,,*9
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M(#[IQ&[NVM"4CP,X/STQ#B:,_)GKIZ S_%@ 97GR;Q<YE1*_]X6Y[B9J2E6
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MN^6RU<#3:EY^YW>HYHCP?N7>DL+FK?$\2G+7*5SN'N\)KH4&-RS7F(S;O0G
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MUE7(JYFMD"B 028'Y7,E@[T5RO[JW3*2D ,-6+!;BTCR0,)-#5G"40X?]X
MDYU/,2W!/9[<LY.*=U.#+5>*_-F+#FUJ7?XCI6X_=_05 1;8P@-S1<RB8HEQ
M*&K+Z)=;W<S*.0J*#9#/NGG;-*'F)YK@JPDC=47,TNEB(W2=*P*-]FXW;BUL
M;EZ)$S/B7A\>[.>4\^YY5,A.K]ZR-*UM=->T=:<W@U,/5YF"812=@F/<Z'S\
MRL?A]O=X?SZ:_81?=<2I/Q@.!?Z=)KE>9!N(R4?^N5*)HT=.7"M C[&XCI4
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M#I7@R^@E0K%EH&F=MN14)P[48*H.OI=WOI>U:*FW^%_6?*?Q-?[ H/T+-7T
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M]>5<\>D$U!I;,IKP=-2[W'4S +R?.(:(2C:3$5\J58/9CX'P97(!!F8>N_&
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M42%+-F?54+^LDD KZ%S=9D+9G#%(GG,S,"@Z6-YK8?E<JEH;K$+EE]6O*F!
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M'""2&?*]0^AM3>=G0'$#3^PTWR*=HPH#,G?]\S$>*I>4R '-74.NO<GX%B[
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M-*PPPK;K,].YAGHQ4N(9;Z>-S$9!MD0:!Z; ]>TDO=""('I])]<[;42IG&8
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M?4^#J2,WB&!/+)*S&=I8+QSE"5XXN@4LW/;F#7&)8-(>%[J\J:JSBB!^12
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MTQ8RAH_QW\DL=PQG/QN9")"]U7-YVR-TUA^N@*.,;GQHJ_YG@YAA[\Z+;D2
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MJ^\4BUJQ@N' RVW8\9A31B?/>(_UTH_!@X82G,IE,;C/^U$Z,DN]0!W9!B=
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ME"?W),/>GT>TMPD^KPASVT\6>ZC PE2T(069%@?4TC\=#_IU'-_);*^-2F-
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MVA%L#H_8IJ/VL:>^-B]\]M/:?H\OLUC3!AZ74T*G7%%X< :5UO.$$I4Q82C
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M#>DG@ZVL]XP[=_U32 QXCP7TW2/O4M<&LOL%))7K[/<SG241DOF_LXFTLGE
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M,N=*%65U_N<RM?_:IQ(V(<P&'563P.6"COZ=:! LA!G+B\@=A>, ,R1N.$
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M"?]BE_VG^?]7L^6#=]IY=*<_:V,-)';BGNZUAD*:M)5+JC*"44 _U(EWA6O
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M8FZMQ;>3O\0>S[P^T!H^M=).:"L9GE:76I,4WNM+160WHAP<LX\JCMHQ7%9
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MV+#!%J#EP@MWYE4@SXX#=#YB '>H#CS/';T2G+VB0K""ZD8I=\?UG,>=0>(
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M@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R
M7(!<@/R_H[_^^\+6U4:1VY=;6>GWVVUP<7!^?;&$A_WB7_KUGAA\8D)"@DND
MQ*2D),0D)&3D5)?)R"G)24@N7[E,24U#2TM+2D%'?X6&GHJ&EN;WVVUPL77P
M\(GP\8EHR$C(:/[3]/OM-CA$>$A<$,?%VVW^?_!V&Y3( $-N-""N9I\;0CJ<
MQI.#*_$DNL"[PN'80\*7[OB]ANBK)%N#P7KP$=(>9]=^P [R63T? PSI#V(
M'#JD/09XD:") 7(*LM%XPH@A@O@+D0N1"Y%_(I)J>8K0@2,AJ/N@O#1QDP58
MXJ;R(4T-!F@+PP",RDN<(Y -7CL,\(P$+7$A<2'Q/UW"'0-<U5)&7M)I\S[*
M(6,>3OOV'\^V80Q Q)J, 6[\$K*$7XA<B%R(_"LBSAX"B66<A(8,ABP4#&QA
M<G^-_7B WP$AS]\PGPXQ!JB:@&X?0C8B'>62/T.WZZK.4&QG'(S ?&Y*FH:%
M9K?B!LB^DF)IL,O),C+UK*OY2I()*OKA3&U"TX[/:N85;WIZ_>&//8J$%;ZU
MP"O]814B54&:?U/!Q'02^<)+^ SEAN).JROC-L4 +U.P'L6R @/D'^@25-#4
MZN+H65@7!X]8DGNUJ*UUKW=:F,\U#[CQ!<7_"/-^3$_%V0TBS,HZVF"\5VU7
MM9ER%I[IR[+Z^O->--C,H_$L5+DWAV3LWZR$!=?CM$#5>R-N@FKJ[S[&4IY2
MGT[4V2#2T3?>8X#)G2+T*W45QMK?=3RR)!!Y2VX1991P@AKRK -/YML222+?
MI/%4S!CV8@/&!R\AUF_"U[*/4;@&$09UAM-K8K<X_<4RQ#)\V'4)4+_-H:4*
M7/NW%=R#F3! HJ\6=A090P]!II*92]!3.B_HV5$,!E"AS5/!I]'[QZRY9'DT
M/8D*3D!1DJGK@XU0/G78 YF' 6[?4F$Z:@MTA-.N/5\T*Y8H<) <T+\]*K'Q
M(+1&AW=:I#/DDGD_$2>3$[0\3JM#+KBZ=-,_;O53VMY=WZ3QV/@K4K;3/?;R
MQCO<*80,RR$*Y*.Z<.%GS9J+.Y;Z,$ZPP8U1*VWB_0W'H;GP4.TRRJ=O.)W?
M."<B;_M6Y9VP9DQ (A64BQ!YJDTC=5KNOD5SW*D"U][>(ETO?7FC=XN/GX)D
M,\VP0JG !11_#.:H2WF2^+W9?7=_;)?+QE7A2'8M1,K^[TZQ_P[F_[N1;EAG
MLVVY3S4$W3Z"'F8Y A.YT3RXZX,1K<+PUN3";9\TM@[X,HNB=X5*!7SB40.Y
M=L>NI6 X6"%@T@U&9!W1=IV*D02QMZN]DYUB?265[*I/V/W#!Z1 #Y[G_(=R
M-"5B137I3)%ZV>[8(MO33W%Y&O*H73K%]N4G\]U3A;1-I#QL=_US,,L5.8LF
M.4=J1US=UK'=1YKY34^\'5Z5M)EOO?-0VMA, W:+_RVFZ%S8)XM 0UV4#W/E
M)LJSJ2&]4FQGJ%H,,!*Y@6L:S9-#(8PP*)JQ1)3U^.^,"#1.'O?7LSJ_L0N?
M%LF5L-PM(?0AU/<;\+[BSQ9Q6,5LOM &FT$\UZ_5DR 1,<R2F<&Y=<6//<.M
M)Z=<F#90H+453H-FAT&CA9JYR\TYU'W@,P5C='QYH#2Z-B%"4,UHG3',K<.D
M6=*SV'$Z'.I=A<@]$[YZY%0\CJ<A]H CZMZ8[CV?'S^B@3W[<M25Z?VOFK4-
M8\+0VBKK*'VG0=['!QFD=-^+2+)OF-( >JI8UAX0L@?9%U][:Q7;QQ7#R/-5
M/ -0]+SO!:5V,)UI=#C++-C.^2K8O'V5X:B]9"UNQ^.5S?B(I'WAB/!$<>*A
M45K@$T27"ZQ*LX'R<V/XIT!CDRFZZ8\/75-NC:E]L@A)TF#95WH 5^_98YI[
MR-6@Q-T:[Y>!RNI1CY:YQ;I$Y_"8P$_H!V@L^K2_0^FS;<W]4JD?9\)C9P\;
M(N!O\UE,-7E.(.].*FCA1J$0A[W(1AK/ZS57,BO;VN@-]RWYEL@AT1JYQ.I(
M7,ZQR5:D("JG%A(YV7$G;=Z<^J&M($M!1X16B)C.:YZE2-QK&H:XW*X@R4H2
MA3;K@KX[12U3NW;QO>ZG@0^W#4Z,'E1OTQ@2QC9;%X#I;GR<\$Z'?C#I:)<1
M^-83IJKW5501J$I3\#PW I<9-GQJ@!5FVBVAD*I^)0W3=B1C#:^@'!F0VD7?
MR@P?AQ=?7\.I&]8\%L4RGMA,=]S<]-X(<E$-]AJ 6W=/-+[R]8=&>1>GR^,?
M%98(3WV8D_XL$C49>C_VB)-V#T*@;#]@J.TQV#$O_%&K=X_+6% 2(FB=:/N8
MUOKM?7SY!- 813JQNFP5$V$G0L#<]I;Q)Y>@MSLK8".6Y[G;FUP-]1MGKM$.
M:V&;$ZVUB.&Q!UI-&\Z/_':?Q,_C,?C9/BTE+.&"ZVXV'F=6<"IE0UP"2Y\.
MN(CU$HX]UWIK,3E6:6*6-LTH81!4 MJ[FWBHIRI"S//K%;[_SRP#)<, O4T%
MV(FDW/(,J&#\!EM QC1:HOR[L%$#\7 .3C3//^9\6-79CA,:JHZ.#,\K4>!'
M-V%]3A4VPLB]FD-V=L>4!\334R?XQRC];V;#>UC??U60! TUPP"::Q6.?1/0
M']?>02:W(9L*8Z *59H_S38T>O_]3)N\['9*T(%UK?799WHL3H8Z4= ?3!2H
MX&G(YFVO_QU;>GOB U)SF5^9" '1G_!F4"CCO\3U\6UU$B5-==ON4QF6 4?&
M_:II?Z:W2L1.W>/1O1^F^CAQ8V\V/*W]=+S?L0ZO=%95OQ.[I>Z5?AX?*WG-
MM)E7<THJ=7XP)9@=C &,$7DEBO.-/UT\[C+>6W:IN)\%TNN EKU76*>GI^U7
MM7-S4S!H)YX99&64Q4X%WAPB&WJC^#I#8SLG[_WV-"T'P+$=U%'EV_>+=Y&#
MFS^5+,,ZAN.(O4:T>L^>'[LA^B#+486PAD@ATSV#4&IWVT $A3O.R_*J>))W
MMJ<1\Z3R98PGW_@7L\/.3I"<RM0*_"57IJ@<>5UXOX$T#X@&WXOQ8H"0R;FT
MUX=RV*G!]RG:O*596R#>GZ^8*_NKY#F$=$V\9Y&FM.F+G/(0DC]:[#NV54%:
M^S[SX*(N2U;O8SA=U][E.\RUC'X)=Y]GX70_R^]!U2:I0.9H5QO%4*4'>F.6
M:[ZO*W*5YZ+%XY7*&:#"=\;/O:9KOA;/X@@)_T@Z?J!XZ\O.5;9GSH86X7?I
M3"L* 5%S!@-4'X#-)Q/HD&7PC*]4<./&HR9H.T0#U2#0$:1#>#/"IA5=6(&C
MN90DZ_+$R>E[ODE%)?6>*E]@;\?L98J/>+[YN<UIGE[K##UJ":;YM,8R6O=/
M%"E6U#O[@J]ML3*^E)K1<N&8ALV4!9;X/4W/[U4TT2U-4-E#;1T,6@8&9_*S
M=50+YJ>U% N8RJ\GK\E^[BW]FN#,'$Q;;9'B$)NE3,MWL 7%'?CR7F(?R?7T
M\$RYT[FZ?+C9HSA)6K\\5HR>-2?A3M^P=8H+XUJ[;>*3NA0SC4)E""^ZHC6'
M=GW<R<9:89'TZ) V>>G9FD/X'KUT<I_7C<,G7)"5=T[1KS(E^QLEK1OS:34]
M6OM15#"***-N):*ANJXV]-"'\*57$!(QG*\(YH3/98%WX%U5'5""+<:CD=K6
MFV'1<\;\.OPBQBMXAP+]>8HU6>/KT _!S9+"X9Z;L:?)&F/<#3U!\;?[$""A
M!029)[0.W5(_^7F:2EI<1^H=#V%I=Y;I\R,';$X/JMHPG8HN>MWL 7F" :0Q
M ![Z:5Z*W-L/;<IK#7V0-@62KOGKX\U!)9(8('(7 ]3N2E_1,'XR/<NV%"V^
M'R)GAQ_YH[J\3"8\-8!E)WY'[IB#0:A\,)GOT8_+7Y__O+&<J1H,,F")+C.:
MN9,'+4%1Z A_'BGX::WM<<9F$3RH3"<4?'53VM_UP];9<6K-P%L:]D]A-1]<
M\O*HRLL)&1[&$N"T/&\H"'QVSMOCL7!EERNRX7O>L-"5IQ1,T\L+7WK/!#XB
MG;9_'E<M?&"VO>MJ>:_.,N9,_6#P\J/-1YZ,M?9(7K3U1F[T&?7ZS7_F.O^&
MR84[(/M"FY"C;3IT"+]:33/6'!R[J1C HAJR@5-K#V CM7_(_]'C%F_]2LPJ
M_TC,['&#_P7H_S)_\*XZ);*W/#I;.-.1=/H[7YQ#YO@O3#O_9>Z#2R.?6V'5
MGM%!\<1C4[J_C>Y^Q[5_:R60HA-U=Q9;0E?6Y8E#S7N<8P)K==RC_K2#VV:O
MWK"^IHI.<@^Z$YMAFK01[#K=QU7_OKEOM?^+0J?B@PA2Z',</M/-5AY[95@L
M4AM^+ZVD7A*:M,Q.R,2-8Y7@W+N-'<B53Z!OX&.L3+3Z"7;69]G"E=7&IMY-
M^;V[>4E.)DE7]M=LE,S.E,0B8(_XM]UB@I6TM8Y=7)X0?D>SOZ]OB/7%VHNX
MDI#EIGBVLU'?E&+ I'89>*".(@Q-":M$9HKK0]^VL=#BO(FX]\Q-!@-XM!9%
MU- ][UA>"5KQWF[8"LRFM(UAB/I\;YK7Y,SMC/EKT$K\ZV3N,^%H#M<H/T<#
M-"$3CC)\TNU+G1-_)_=/^)0%!ABL&)%G.V82A2Y%#"Y9,NF8F!PI31<FZE27
MJ0I)_= W5"LT0OHC\H;=7)3AB!D,$)5\6&'Z91+Z=-I[3Z=FCL<3W9G=Y(8B
MTEDR[8GG-]G*Q1Z)K6[=X3Z&5HY/ >;D\!4,\+!O58W0UX,2 E\CJ)R9*<AL
MEH)C@+)PR=@@FD>&/M7H1$C^M#>9\C0SI(;J!V2EB]\PRN$>_QHEX@>*<F?A
MPY.68S;F;=-;#7TE#IL>SQ7<0K4KXOU?OU7>2W!<5[;?"3CW7#XNH:JW&JE8
M'!TC'VCXYHDX[84^*&=[X5^;QM:E0SRO1L3F<BY1*D84_\"^3ZG]+1,:=^?A
M?%$%&Y7C='SM/4AMY5JKA2P19PT[\G(QDG]G:TWHH:(.Q63:@@_T1Z"@0)UZ
M%-]CJM'4]+5#%/&8GMJJA<G[YTES(J+)E@1U/DJHC<H@[G.V#5LO#$#C%"_B
M*O3X?5R+(<VL!@9XUM^Q]?I0G:GL&\1N $#X+A%&<"8J?-K-D7N1$WMYM/K-
M\UWI9PBCO,G#5J,(XX>T?(J)R*;TQ\$-\15FS6^V>');K/O^;P9N_]:3]V^B
MM/$*$[E)Y(O:/R[.A$C^.Y*__T02^/=FHDA6=A(D_,FJ-")I^U"]9', -Q$#
M*+*_9 WZ\@VR%PV_<\Y]'([P](:3M/.CWEY*-QE9.[?-O[WR[?/K)(&S#^+6
M]8N?.%HE#6<?NGB!O_=P>0CUQ/7<]U8H(U\\2$/*Q[RG?A<'?LWFXP01/XDG
MZQFM"C&V$_8GVYSX/"YSF-XP[E:G<;\N++-<V;G#_7+2S9BKEG=S>9WAV7?J
M)&)( ^9"A=P_-=H-^9];5P29G\L@!;,[6JG'JP)O/*;:MB2N*II3HTBU+[VI
MSI<ES;(OSKO!S,M T(QF_;+^UBC#]$1@-$@*JXV.5F2-L:W758D]^<+40<NV
M4X-W[?3*7^=+MU*L]4?=!"E,<FT("\6*"&?P<!%&6/=.O+;>;5DO'8=F1"@;
MQ*C!LL,EF,RVA_V<W4B-&LA:'M_D4KLO*O*((9XXJY/X!$(4W.=_+]N3>9Y[
M@JU3]-W@=ZN&*Q.5GHG-KD_<8VU]\156-:HTGP9;,7[AFVW9.V-]^'%4Z#7Y
MDVQII^"B+V>L^8W=";;^L977HTRB7ZK]#.S@1)7#L\9]6E,1'>=2VI6.R=NM
MEP/ 0JXBKK7IX:)=G #A6VK 1Q:PU9C^/OC%HV==)VJ>":[\61EO.Y@?3O'B
M2,,KB!7D[BT@['9]7( NY$/&XOL^AK;! K_O:*:>I;*/!H6K=#7J!:EP)<OH
MG"+]W-B4S8R3:/*=JQ7=I WZ/7CV<]][*7X W$KCY0OBU'L/ZMPHYK\C[\ (
M(Q;W PTJP1UJR<;#%1)1A*DNSM6$#EP.4E7]1<3G[WT^A,@,5H*MC^W@V%A:
MSUL>K"#ZA&+OR<<L^:BV;TH:*P(OLKK2$VZ-Y*',^V?SM+Y#+<*AV]<-W_'-
M3_E[GR?0UEGY+9M-W=_5HC><*5Y6EU_8[$D]/8N>J*KR=IN*:#>-B/CI=6X6
M$,>W]D592/'>-Q4AKBW-5R\-]8U33E\M)L<^:?5#%4/MH)1( 03)"@4]V*AS
M)Z!L(R7TU&5U-*_S95Y)>D8&Y97C10A9@ QV.'H6:!9F9Y:#P<$2;3+2#R10
MPIZO1@]GMLN"+-"]8JJYW_N*']Z5V?_6K6&@^#;S.: ^%X<J?1-GA</%9"A:
MI[(ATQ64""M3@4%B6W$VLV'Q4Q55$0H/\J^-NGCL]S9<)JWI#7Z23!;:DYW*
M4O8CFPIL=Q]VKT4IK*)G=<L'&=%-M:44:H]Z$%'HDW1_,;I'H7=K]8T<'^N^
MT9I3DU0O.#3+(;9B<+?!]?[)!W%',W-6'4I+$P=*JFMCE5;5^N(]:4LD7C_I
MLQ%D:J5F.8.'51:H-"66AXB\[BM9/%G7S2DT[,#<5OMS<[0V3&)*MBK]6EX+
MM3@^]4J0:VV#+'%%E[KAVM(_*H.N^R:$X^+JYQ<\&=4:J UR=W-->=]#>H=*
M9HRC-!8@O*%/[$V+8JU5/V"O_;^<;5\X[3\Q 2V;Z7*S+<RS':W0Y-1B?3O:
MZ5@[_)@P(""TY5F26+G*B>3,L,G](N*R% ?)]9("N>0\(7\/AQ-3-MQ I]%U
MU&N($T68W&!8L[CO\AQAEUS0Q'/"B%U)VFO>JMY)O'EIFY'QZJ1E3;ZJ3V5E
ME.:\X6;'H2VA#CNMI&#/#BGX<W3BLB636B#4R+NAX:4+-A98CQ_OA[3?;18.
M*D;WIRH)#)M7(%47S0V_=DX'=5H+4W?PJ%FU,W/%SL8&9HP')$P5M0?SP,AC
M5H1I'-%7$4U^)5T.W@[2<77265\H14A9!!Y/N<15?#ZUFSW*S>3S,A*4R6].
M?,!_OT+(,<GEQ+D7 X1Z])6"MTY6(%V"W@+0>@6=Y?5J!XE-5BU/V@PMQE.!
M%4%6FT=%K?.AK4.TBQC@0U5(;<+S8%H(".Q#H$TPZGW4='=IC4*@W,:(L[@/
MCYF4G.*&Q4'T6*<K!;/GP[U.'?PII#J,(A+)6RSD[-TBMW(O/3Y&P/D%2NTG
MFG9D7%!=KVY$P+:YY5/\Q#3EI[7$^F(:T.E7;(+7".N):GX I^Z:YX.7AK<B
M(/DS2)E1#S&.RQI[8NLU0M_#_5^NCZT?)H] I:"+KZL1DQT0JE8!,T3ZW3$)
M%%-G Z%A3?K]L&6'RB0_0^WTU@.:IV:H]@WW,QT-@HE@Z#L31/K-,:^@FU<5
MP]^Y"!9TJK^$]Q:P^!WA3:00%E@C:@Q3;\".4$>-7*F4ZN=UR?*^5+2>\5.<
ML $@D.'\,E(%L;24'<XX&**@O+A  N[^NK3;%+24>@Z)M!VM&L][G8\_^7/_
MG<Z\B_ZE\Q?6L2/H[\JTP5Q(]6$D):S,"*'G#=OKS)*9W'&NW7GJ9&BT@^?>
MF^#)I4UTP/FHR>,[VU6WAT8!.>B^5CPX=]?@Y>T3R(RA!1><LP^B5)>[=<+H
M,E[Q>6?6:I]!K6?N8UDXTRO6NOY 081+L2,;3(^_0EH?7A2IX)L7* SK3?NR
MTEF!-WDE-76+,'6M.PIZ(A^_SO1QN^W:'=&DU:1&/K%7;!+F;P_7DL]%D?(C
MJP?D$=?0HB_&JG:%K!>M7R7=+(+3;AD>OY^:Z<%OUL2C++X=+TE<FO,((%3!
MUZ[UUS,Q>'<G 9:;FBM9%EEA:5KC<?1X6)7V4\B_>&4.U(5P0ZO.":-;'F.
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ME[+JX ''>HAG2]GD,P,!%=I.M -U^0HM[>'@-='B71/K1X0>*E66,+N.!9)
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M+TFFV:*K06$@6U(\M'.7YW3@VR7VEDD7'?H=-F5D4DE!MYT9>PK51DVU1[M
M7U34'. X G#*S=,/4[W4ALDBTZ,S"Y:6[<&22MG$36>>-8FK43K:Y>E.M(]Q
MG!SW,UB'?Q91N.U51%KXN9V21C.3C\,8'!'>2KLZXR>[Q;GEU363PFJ[CO([
MJY^#0QCH6(Q3+!P$"./BY>-Q *F PU]ETJ,^TAX\79*:88?[I_8?-='*CO!C
MO?(IX<%BHEUQ/"LY'KC)LX0@[N]Z-:]K?KQ4$5%^>I4C38&0,5:9R'(FVSZV
M&[_KP#G=]*AH.VE&D)*OH'(!WDMFI>>8[6;\%2_N*7.V(C2O_O(9FK2S87\X
MV;=HJ<>1+W[@\&6,<G/RB\KTB!ANKY.@>?FVA@#VQ.<'#.5Q9HD95S8X?Z5J
MP%^I O!OYF6EA0MF@YSI(!*"(GSWZQZ3$_#E-DTTR13LB"*??6D<XJTB9W]*
MXO.^Z9;G+1O<YF]-/?QPH;;6.4^-;&_?(AO]U)H2DO#77&'"3 IJEXKK!2/D
M#^L#A*H32=A[?F(:*YY*9@BBAU:!@-+6J]JB?KL+XMS<LRQ&?3 -*:68CNJ]
M>]0/9_O,5-+E'_#&]0$"GDH5\03^95G)_,MR\I2IA&IC_U^3E>G:ORXG3_%=
M%:%N_Y*LB)BVVH[@]A?LN.G'H6MU$S2:,S7JTYXC-6J]G)+O]XT-TJ8R*$4-
M-,2ZE3.Z?B4U_-94VP6L"@V B2%D[.7JG,DA=I*/HES)LM%J^I-OJOG)7T0<
MS1LUO?J\KM2SYP?M!J.X]A61EQUNDC[97MXE)MOTD:+'<SMP<(B(NE*/:]VK
M'[?K:VL\/DH)%JC/5PP(W-S[TR(>OTE9<0\U5:1C;?@I0XFFVD1I:5+/]+S6
M&'])-5%QR!MJ6@>+8"?+N!]=W$JJA"IXM^QD\-=Z YH4<M#1V&7]NJIK0)#;
M8IF(,9/.BX8?+95^2A;DS;E=JN+R1=W&5@SVM]D#GS*'WNR5_\UA<'5YUL3E
MRR^Q36Q.Y=R?52^YV=P)WE*+AZ;:UO75T:P_B^:5]FJ?$K V*_G1S>2_ '=D
M5I$&Z71< ZK*!0M"55'!F7,;L<B(\<+@:&^]@'YTQ.7WF9_ VM @H!;:-\<C
M=9&@?LSYJ1NPD[(.[QJP; _<M$\F8[9S/)/5"7^+G<?A#K<G]3I81C["MF,Y
MXT&DZ(_MYR4UY\^;;/%XSS]15/>."F*K3ZV?H_%7DC_.=+16)<45LH6='-(:
M/8ZIS59]R(+-;%7&"$!\G+*)^6P,3X168<]+_'3+2L2<DW:1[-]2^C>39U)W
M9)M<_S(8_U,<J-'4G\DOP/X?6<CEY\6^!>UY;99UB>9RBU&*Q3NCO\Z<I?/S
M">LW8EZ;V4.A'TI,H3/\7[PGL91GS-C3%2O#G+=J\?1#)S*/F8D10.&J" EG
M..@L-G,5XN?D?.)ACIULB#4TD.DXN*6OSW%VP5TL2HH/<"\;DAJALI<,#=]$
M,?44>XF%<;QCVPEQIU'TQWOSU)WD*0#7#Y_J9'E_7SAVR8.SST)APTQ#-YI@
MD3 P\Y7F%H0+/(T\L=:Y4SSM_BESH9%M\SB<VZ/,4E,1>"2[BQ9 T>^>):'Y
M$1!\CYH+M<ND:F]^;5L )V+)IB_:P>V]F N6?4$@SHPC&_9^^L07S=G:!;IK
M#S:<AO'Q-]T;9G 8OQW'JFL&O?4HP/RRP*=ZR&?8E_8!&H0PM3NRESB5X'>9
MN"?Z[HDN]%G?P+C$901.K#7>\6B"F7;A+S U,PM*,XQIVF)&Q"O]#4(8_XIL
M\_T>)7/QX8Q_ZO%:_,S%AK*&NHXCZ%C9_2R7(R146B<]]1H0X%/G,U1I<^:+
M*XV38TLCH.Z<;T,MVCG(EA[+FK06&$^B<EKVDNJWYB4/S*@52=JE+O5<S*F!
MKUQRONH5YL<P1I';#:]F4C:KPN=7V80S(?JS_?W/G"S.;, GC'>8PDJ?5W,$
M=WOKD#4:R<9@"2:>\Y I[%+6: RY27+_G):6L\Y^>+S^>V0Q"FIU09B-*"/W
M-9=G#0II3#@H.U=^;]\F*PV3KT=[K3!<F='A[HK%\Z:GJ0USPN+7F;/N2ZWE
M#]R&?F[J,5L2E^9N5D8S3;X-'_>(.!A5_H0=7Q)3N08X^LZ-Z/Y(8A+3B=PY
M<Q?Z7F2\=WAK7_5#+ XOYT*TJH.^\QZJQ,3C> W84Q9C=+K^D3AX<HEVO)2A
MI#33"O?% &!%ZK9Y#&)Q%R*R YY8,M/(1/V&B@LNF)@)P+8"C@0V9D^9F[:H
M)C!B*#B,XRH-IH8<T(W?(>JU=715U*ZCL](4E0#GC3>VO?7RCS[=?U/!J)-+
MM<^8-G924WL-\(-^ABV%2J<%1!A#M\VY$%L]_/<Q5C.E_-6#N^%[1&3VN?TL
M3^85,Q/=@)]J!))[#"X!/+] LYEGGR=/B'V6VV19&FX.\%F3DJF@ZN>FI/BO
M7 /Z7)\' OTQ'$^9WD%8+::O 9W[2NK WA;ZYABW7ZYJAD^:C2DXE1$Y,3TM
M^10AD6_?YZL;YN;W_893;3Q^9BW6B!F9*P&]K)U<)9]_7L%5(&+7E#I]M*78
M(#0O.X%Y[@DT/SPTB\NV0]GKVTLKXV<_DBX\X#E>:!2.%CK_,&Z/DIV@"?3P
M]93L3G6E,Y]%[2^%BPD[D-6T/*&-7)GI,CIO3V=H\Y%"6Z[&$#Y?XD&?2<OA
MATDKKX6]%ECBR]RD;H['*KXW#[#Y*$=56:[3IGV4Q/Q[,_/MF E73XE[%Y81
M#2G;D;U?D: ]LX_0#V'P>O?A2<Q/;>&XSKC-OCAH=-PU@*&HE.0M[(YF)'PX
M;142<>QACVB>B3@0)KV[0W.8[]&K&JJ&8HXJ4,1/<7Y2?DE<N@M6Q:5.917C
M=GQ,%^#G_4$1-H\T[IKQX9VL@@@AG+M+- XV^X8X,II7#$X6Q2OE54%VCM2W
M&5076EM^1Y0MXP5D,(QAH%S[Q&4>\KMK_)%\)X[ 9Q,B0:J/742@ZQF(;?8(
M)5,17S?].<!<=<CF[X97N-N2/.N93#!CE%D@(O,^L3WBAAITFGKRVJF!2&W-
M'HRNA7;0?^+&2QH4+9B.5ALAKW^5K-T7DTCF<TAZPM\=$Z8->X2&(,KH3(U%
MUHU(DF6_G96W3/ G,LBVS:Z] U@S76CAFRO"=M<>^G##!-#6A3#5)G2,:'V1
MS;3@KF=RL,6XP[>Q/'^RG"3XPG=?NZB 6VQQ!Q:_/U&#\4K>T]=V7VF:H7O7
M/A+%A ')85)9L\IYJKES'CSMML5=;!E#'!^$LY\W6KX?:K,V(\5E',6?$08+
MV><L+:&9B25!%+MJ7B+?OJ$#C.UM3@%=%B_>V+\C[,?V^SV4T7(I8T+S6J\Y
MZB!"NZ34K1&M$2+-8AV>ZY+>U<%#T7&,[N]47SM+4%2)WOU-*O6J9[NCU&L=
M]U<$SZHC_EE ?1W:.!<=,7(6D= %H>!X4N5+>O^7#L-@MF39K,_0[<^-6FU[
M["IT@B9?'I66K='T+(==$"^'A8:*O$^P];V/F$!47'(T0B]@9D!3)>/'5=97
M#@5K/X=/C\5? ;Z2EA6496#L43'&#>A39*42<KJTW$/_0N&JC+Z3X:IV7])U
M?ZC(R9*7N=URDRE7#5J<(2[K?2F"T9K&LGG8MWF6-J) B.;I^J+'%(NSO2L/
MU\8LW\_98&<;^-IQ<6*>F+A(D)-4X9SQ4J&B"U$-(^Y=AM4C<#M-/'2HRK2K
ML3&02 E.)/RNG:VD@<CP,7SG31O_0%GS<?"#.-/0+OZ(C"<3:\CJ\X_5_%0P
M/N3D$DV,_J2K)@$:ZFH5J+VR,+]8"3?]:/-&GE9(R;^2ZQ _20'@+:/XMO6.
MZ[Y:%X38Q5%9#T42C&A,T5>D/PSE(I^#]%1(]@K&'85:Z/$5)X*7*%<(#PK^
MP-&X'_^<S??]\#]E^_U3I,[]]]4;_E-9O>5_4@$"MQ]D#_HM"HSX?0W(@FCW
M:OX^CZ]WCEYBFL! \C!DHZ?&[USS=IC9U.S##,,68K+M $<2^!EW>TA(/,IL
M4=8?A<MPT>^O 6;3A]2=:N4Q0QE6^N_O/,71D[-^HZ*G>#LE1?>6"K[&THJI
M<:^P5X!*5L_)PS;F%'TZ?*8P3 'N2ED$?5)E,6FTD6P];W=KF$L438>1Z7 6
MHQUQCXA7)_&"UZ="P6<H%24ZO<$L_-=49YH!,(H2C^<[FS?WER9<VIJQ@,KQ
MM$^X;YR<1.U15:5_>*]I5Z3;D!M#O?19CL3:\O'%*'X(S+8:Q;O5JQFLC0;K
MCU>9@O<DY\2,>I(YL^ZTU:1 N*72W!8G-I=CS%-_CR"LP_BO :L0F&4@ ASF
M4 6)^+'+S$ ?>N9"8&ONF-U9-'\5?]:G,9[">K4W?*36:)$[]HF;[[ 5O:#Y
M4LH\W^3E!<)/5G^Z6IT'X=X)"L.2(T'[%,!N9VI[9OJ6FHF3#T6_7DJJC-UG
MUS9WO!<83YGT)MN7+:NT:/DL *V)B"%!FW?J:\VA:TWB#VXH+\Y\.R4\+UGZ
MY4/^=]8LQ Z\AD25 _=9(E\=/"1M/?@E-])LX5'9W6#MCY'R+;/7:<Y(>$V3
M[OK^1__#D"=O31.IPO08*\T)OU:^NB$5O2"")M=54M(=,U"@X54NS>K0@H_4
M3*KFO9;<5?0M_K.@? ZG??8O^$"QY5\>W>XM1#]0F\VH^;4J[%V4>XB+NJ2Z
ML=IC>%EH_A33[*^S8(MHE<.22;Z[;=R_=[\P@B=JCKM=[WU08%6_%\'$'A7(
M\P@0<'<E<$9$5*8 =W,Y*@.G FUZ*8S6Z4B%'9L:V<H^0"XV+)@$'UNQ@:MX
MV8()Q00XHD?QN:*G6E$!%_PX&$>T]]KA_;Y72,60M,)M,<_ PB>V[F!>A]&%
M!5$!2L4'J6Q"]XLL3+ON#'EEX.=2XAS1])!2VUP#:%VO 63HA#;/]-8P::G5
MP] 6UA]3IU>\76?D@^^8&MOMDHD^;[C>[V?#X]U8OP,WL2*EV&$61P["@$!*
M:?75&;0ZQV:F-#PO-&OPM4A>]GW#QRQ-\5[]B;RIBB]^^E&P]@1QJQBU=.>T
MG7PE#?=A]VCL7*(H1^W)TJ(&MB5/4C.R>)?;^9ELI]W'T &VN'<BQB=QW';=
M60S-/?+B62T=NL_'?$8G-J%[CAM)N/8\/:5GZP%OV&_IKDV(%YN03+Y#:]WZ
MWW&YJB<Y.;@%.4.\_SPC^"^EU/+\ _EN=BJ7-D0,\;1A&5MGJAN[?XSOF1];
MIR1^\8\%Z&D9SL93:<M96>D!;E@<ZB^J@COHK$)[R1_HC>S=^ 7C&Y4Z!N/(
M7=@AZ_FZ8 YN>K+86_\\@5V3,NAUHDG#?3<RB.?\ N\DV<_&:0E*<7(6)4"D
MGYX?MW<8GJ?N)YQ>-%>[Y$Q0::G5E"R+1T+/NP%__663P!=1+ _6*]+4Q&F_
MN"ZH]#K,I&/^LER?:W@+[:O^\I9*!:!Q_XLB#OY7A;JLJ/YDUR"#&Y44L_)1
MRGCH_?FE[/#F 0-EO4?Z-T-+Q[AP)CFR8@F]!;1)1>G[S@?,(LZ7<C NE'(H
M3&"U^*$#QKA4U=W2%NBWOQ+AJ*.6\8B2IJXR-J2&^GOPW,;=^SU/W"GQ^WPH
M/'8[F(&33;YW*B^?\W>FU6'<RX0SZ+S5.I%XD'T"C>>+<%5Q$EGGUE%4Q&7@
M*>4K3RW\P8Q_2;CU8WI& ',POJM4V*-5=5EH:8EPYGT/IT4G/OG?E63%<.JX
MCF"&S_&]-K@)O787:LR3?XP1 GO5\K'-E\$'Z''9)4@K3?8Z;\=3?>GKS@MZ
MTZE!8V$Q,>)(13(5SK"?7=PI-.]P*LWL48'=J: >)M\N'W8D<[XS@I0$[;5Z
M&/9=Q-M7[9U,4,6"LA/2*+=C4\+TF:!*.Q$4BE.33'=QEN0G*XF2S5J+N5?;
MCD(I="TQ^0:-F]D>#Q79>#+64!C9"=R.[V#HYVI*>3F7H_NS#T?PL8U\3G#Q
MWO_VUN T\_3[/$$/MEUT+&)$4-3?'<I<TSA?M>B0T;_75Y]W"R!T6D?5<N&F
MGN9MIV)6T",(6Y@"JA7!'_ZZ[BAKS#%CF$ /EWB=]X?VEU<;Z?XC;Y2?;W3I
MNB!@M?>M^/D[>_IEK:TRC^9UP.T9S).D054Q%+9&3$F-UBNF5CNJ3JG[BZ=$
M>O&*NKK:1^_-$^7Z!A)BORM"ID!V(S1#:T2^#+_ +TU_=;!1G8>P/]8?P\5)
M:NL=2F35$NK'PVF_(#H30'Y&'K8MBD+-F7V*']?&6[C>KBE;K9;#J$-[>Z\!
M<TDWF-:S:DD,[0R(?LFX0R]88!''<)BH$:PR_.L:P+WUR7IO,BOKV*-)5NQ2
M-IH'KYXJX5UT]-G8[PN@$H8?79@%,T#N&;6$?MAD :CCWF?W1\5'2Y%=\52.
M&&$&D:"HLB;\HMJH%B"-_YNC:T -1OSW Y(/U5!>,JD?<S\M_#P>9(Z2!H/(
M2WQX/+@'NT3=DO6UAQ)M2K.Y%>XYP3T%M[))2#=YOD4YVU0O7##&2!E^\DXT
MY>:O+_VU?Z/ =F1__$]D^,?'%^R"E7J?-Z9K&(G/QI2*?R_2U5W9O.!)I*U7
M560D#:]F*[';*_C@3##;JCV)=:D1;19'5+J@!T4U)4I3.YB_@#=G71];VH(+
MFV(J"AUD1#2DV#9 \Y?M8!H?4F1O.$MX!I/HCII:@%"0X11A^=DR>:D7'74+
M<]F<NF^'$202(U%@8S3TS6P[&5DEU#:WH9DG\5*<)?2!G_VZVC*:<^$0P7E)
M$Y4=(V<KV&I3SN\2WCO8B6<^L[GB!=XU5.*F?(L=\#3 G MV:E1#;$GR>S/H
M@J#N8';8(=<GTDN>WN/^DF\X+^_VL>%Y@?50.FUNK?=DV3P2.J8%AI@R4CS,
M/^Z30^,%)=G#?BX26+[U<MTV*?$.%AO"F_[Y.S6\QXD_:\#V:##;CG"T]/?W
MT@_D&275G?QK4=47796J>8N]KC2#[!9D5XH^=C :I,F-J6T1W)94KY#JY,SC
MJK>DF\.3>O'=^PZ-S>EC&?N31GW34OSSU%:N-=52.R?^I>C6=>]K +'BT63#
MN+STN%WRT<+0H(HORS9$RF=>H,*FA23T,:M]6CCAV6.RI^*G./"6N(FL[6XH
MZ7[,2GCU8;#HQ5"5Y;)<HW&A6[3/\,Y8GT^$(>,UH"*D28,QAD^0*G\*:UWV
MQ3XX4=QM%@U2^;T/7[FZ##=2.+DGC_7SJ;:S=VD(4;$ -L:YB8U&ZCD"-R9>
MRY.8+]+I['7[7EP#HDS-##[X044NBZ: "2*E^51.QOU/KP'>/DH7A0]NI.6D
M;&ZY0PB]O*8<M,>BY!)Q)K4]][1#D8A 538%3H/%D[%?DA:[O /J(@V5I43Q
M1941DU_JEAL/#DJA4RW,6?@JV!X-;-#"ZMC*6%O"T;B70K^6<5P&4U[^VF5F
M;=9*-DKKW8CZ N1F[X>GK!^IW2?X=0NS) 94U_K$\CTCM#&X?5C/_!'LX5Y9
MB4"&.-TU )0KU.D9-^;JLO .KW?0U^%$!%U]*8\=@S +M\(;NU#7@ XU!"^7
M\<1I/Z_+/LDP5+'A645B;11O;S]WA<-._L_%A"\S._*[R[16/VKC=]M:B"+<
MPE^$P2!NN0;^L<IGK]LQ*N<R]D<.5H0>DK%=':H@8^ WK>_E6HETO*0%A]10
M1TMC6WV".3KSQ G/;'- 8E\??HV2_4T_&!QT.-*-)H"4"0T"VU\>^Y;:)<O>
M:Z#/*.&1L&4VCMF7SSJ++X)5%(@&JV<[NJ1J?I05-=NNF>#RD[ZSTR=KC9KZ
MQ<7X_D[TN]]3(VB5%K$;2!<,72'%\/.W_E:'N&O8Y5#.Z&QLT-")5Y:A U>E
M,AD\S';5*F9.^>\M5_;*E!;G#E88<$9-/^/0)&>Q)$3)ZHU6_.BT:BKKAE36
MAK=P*9<L>*SUI%H>%(-"7$'$MA6_Z/%2O9N_05@?'ZLS)G]H.I NJ/%G?8A3
MD1,[..';H8QJQ88O=UX#_C8#90P[A*'U5SH&=+/%1Y?7@$]36>P9^,B8;A!)
M?XZ1'58$Z5.89=@3J^ILN<K0J)9B_@S^]07\2U%4K. +!W'I#SW3*<CU[1NL
M*G(-8+H&V/S.UQW[7N7_>MU\X%)Z1A":8768Y@X7J+7I^;F^%0E$JV#%K@%C
MTFC?/X(=SZ\!CPJN 4$?U]RO*%I#KP%H,XCO4:K?$XPADJO'AWT,IKG*CHXM
M6^$GJQY8A-O!I9;MSJ;/V7^?G<T,O2>C($& 1)=T[C^ #105[\!K@ZK2O3K
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M]0LL-'?IC!ZY!< *OT%?O\>E(D\"5/B;<I:O7(EUB]W 4Y%BRC3MT3]JI3K
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MO,8]#>M&BDU[YK4?[=6$]P1BX[X^;K.P6,-E8[< ]T.0SR^;%2Y!"*K&0^P
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M)LR5H2P:RS"6Q^'2R$3,QYOL)'BDR?5Y[C#S$>@PT_/$%\WEVY7NO*;<!HD
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MLN\67E@S?C0M>.845O.E_25XYD^%>O5^^:%_A:]#^WID]W?@29EZ4QHYVQ@
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M)2/]"R!#ZU_(=([RKG#MN(YEYS<C"#',>3@!N"D<FQKNN3[&C1E"H5BY2G4
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MR<G)">Y+3IBP$L4: _G ,OO"#6DP%[HT-*CO5E'(R"Q/NO&)2@V]+P[ZC"7
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M"K-SJ _==?_4U,1^L6\VF:_5CM7;Q/W(;?C"D(/AMR.-+M2I*/-F^(HIHBI
M'['[/L^R/Y??#L6*?\<[*P2 &EX;N-)XI[OP"N?32D,46VTB4""-EN#8R:<?
M\Y]PW*VMX>!\UH$.A0WM6[807B<G>DB=0\2,]H*<I%D$%3R_<TQ"\V;:0+S
MM5*_I/=:PCSG.UF]6D&!V P4V?T&:]=C?B/N4*%51J[)=^45J,#@O<(@6W(N
MGO@>PV,F])]_F T.-R?J[\Z/O_56YG[J"E&D8(FY.+RD9AFE*+"I-C*Q=U]H
M^^W2]1*-@\1U=_>G44Y^35";/'*:SBR[AR]HDFGV3'G#2"$?C/7/DD"_ENN\
M#3"SJ$QYRD=7A55^8;Y<<*7#[QS0/TXIN)]"LU,Z;J[$LO()6TLO3:2[9@!)
M"$8ND2&:.!G">\*01,G?:*R.ARZ?7FXI2"VX>RD1*U5DK_MJ)G.,#S;/8)Y:
MC^3=<U#5:",14NW63:X1R'SVAO)'HQ6/(]9H;US5J(]H0'ZV5T7[ZX:X:YWV
MN'U"M=220AVI=Z.?LZT5&!"'TUB "<ALM1.?XI'! ?EZ#')::/ <T0QQ,M3M
M^O#Z"W*:WBP[V/>UWB?#*98(:\_; I/SG(Y.D3/QAIR?RE9G$9$?'G,RU)_,
M[N<2T/E#>N^0Q1MLI.)$V%3UPA8(^03_L\CQ QW?Z/'H$0U@_Y$W82$KL5P^
M@A*J4&XI:D/E?I?77[&7F3+:] E*^/&*(LY;OSSL+/&!U;#L <U=A[.'*A.T
MKN60[#'T:9YX8$']N@G5_YAFR4&^E[3NX-7,M#=6/:M7Y40%7;(-M0]=#=W=
M[F((A^%AFL K\"SZ)G$T'PZTP"?]6I:B7[>#X10/0S"HH=+8]A-U4LE&JJQ<
MG"2*3&GE%^<SCB")5R/MZ8/K2Q(9LBT$E-1=UQQT." *AG&"RPH:V@A6SUB#
MU5E>6>::.I<00D& ^^&<X%4^KEU))B6/ZV,I*;'3ZEZ[/EPL+E!D!H2OV3S'
M.KNI&-3S>H#?7#Z# N/FZ^D-U@[(+/I=7?MBK/M5=Q7[>+OE2ZZT^T:4Q]!L
MKZXJB9<&L. J(VGARG)():+,^%[<M"TTK VFF2NLAK;G.5S6X.OQ%P!^7U<8
M:;C2P?HEP5+]?R\A=)8>&O2-?MDZ2N%XI:O%)=A#Q_"L[6YTR^ (DBQ7@8SU
M%K680M:HP>6J)E_R3A/5>R#&6I7>V0.!WJ%P3AO8@=12ER"TWAF%BBKWT3W>
M'C";I!1590"__\"*U.(N)]J>9P1'E-_1E'I6+WQ+2] 3&N#/XD:<2Z[DC>57
MFY";Q^BOD>@T&7:_>H]\XM39SH\('YV8HJ*:S8MB2[HW2J*8L=*&?/J*=9ME
MB+'3?<QRFWW5!S#Y9M"<I@L2.'Z)IJU[[S3UA>%)/S3;F5J5(9)*\W+$Y/"]
M0H:54@_P\WF&RP$^VI/I/_^T<PZ9[: ^[P Q%7BGK'6,;DW 'ZO_P$#<=0(D
MG$GBFH+1P$HO;5,>.II"0T/#D_PN,6@6\G%3_2,:!&@7U>"44+#ET),O#*[U
M1TSCL)=TS=9.-MD&??J=E4D16YY)46@7R6^8,U95VSUS VS)99($P/.2LP4V
M>!-Q137;WN;4'-FT-5HH0SIJJ='2G5.Z(^+UZXDA=YX7R4G,Z;@!,OFPQUG6
M<9SEPR!XWKU+"=,<>R]8D::;)APX4TB1NO>1N=]\":),% NG3BL;V,]UP"RF
M/0OO)TBQP-\^&:**@?^0P"W:N1[CL^R!G-D]O6X)>S'[UD='E0/M0PB BE_O
M46IIB2+_1<#_Y<H[+.SH\=?=H&6<*M@>NW&@ !**0[7^4(J@NT,Q)/EF;O.N
MJ>Q@=E!X"=MP;V>8(_WWJHR1HR@(7K8KU/]B!.!H)UR_M.^]:J4.7*SK52C!
M$ V1Q(W)>S]CJ-B<M*91SX';RN))9#U+%Z&RV26E(>V_2],T1MSO??8PL>^(
M4&4O'GM*;.S_.4^?JA9D](?2-16^&CFQ?;;2.$W?K-17%YLN]^;\ZU82DN8%
MH0]2??*8B2V2I]*"4W5-2=SJRM-@ TDFW6T/2E)O6",P&QG=?7"SVGXQ;Y'M
M""@3*=MBIB2X3&QE%=*)<I,0B%3NNN?N$VHUK8-X'8<@XO1]K\PHM-28'3[U
MVC5,<#?3'MQ.GPC^D\BFDL4=_DYYU1SP4M+IQ9&2#<Z+XTQ 2_%!_YKJ-&IB
M#^5B?>-7+5B"FQ0PV^HQN$1[\I0>.NUHHN3OHW%LND. RMR;7,O)X"TU3S1]
MT8<SZ1.TR282X#Y2)A)T[1K%8I;4)[5.$U+-W8O7.AEL,;S1XMF>>B#26R=G
MK<HR:(%)'SL49*$(0!]@R&T=1ZHP4?3T#!@$.3.!D:1Y+=[#W)(4!UCB?+:\
MMQ"Z?"#-8QV=%U]QUAR!.#U^-:KIR #SPR3F;#_>5:!T&?;/X\VV6'=LV9V$
MIE$!HO/DT 2N,#'?8F>>7DW%DJ*2"KM?=+Z8/+Z?\89@.^2=;^O'.GB1O.5G
MQ,=LRE@3>S ;/KD2EL4SN[G)"P[>_05\*"E9Y16.B*ER=D8V_H*6ROG9.H[X
MI<I)>"U#F5C9&'TN96/<2/3R6-G \"X+>0HEZM;/^R+J?DS!,7H-7'1G?,FT
M7\LPCU1[HS>PK;JMU-O0V_;8[%PPH+EORL3$U-=K7.F*%\#3M^,$ZES/CFWQ
M9: @W[K3;C/4)A,&1;^1EECZ$&*XJS[%B@3@I+DI5]_GN4FG5G>RA$1?D=#:
M)''PA5E1.3%L6XY'[ 4JC !]V^GLP)\307DJ'A?O/O%\%81CJ8[ ,+Q<EMUG
M0SCV[KY"OFC&*11\7A)1 &ISG;EY<^[2FK@O11?\6 6_BHCH,33LA&9UF9-V
M-SD1<TIPK7L"<MNG;^F3>WCH\2R;TC13$JUU;+4IDY.*7DO2]G(EQ^TDB2$'
M8I&?TK?$;;/.%+^HNZ7?VGI83UJ3&U4U '@U^,Q!T\)$%!CNZ7V6$;XQ,&;7
M:1#,!$[.YZ U$S&;;%5!190U248;**]<BVI>M^>J5319BGC_%V#_MM=KPD2R
MG.X?1!<710FF2Y0.HTD%^KF89F;NI;9PH"(/5X85G [$L'.],GXWCO9(JW$O
MZI>M2O624M>.GV,P14C(>I>B:[?#OJATE5=@5D#5P=D)&G=@.KRHZ^XBL+O#
M@/(3]7)?-7'GK'>8JL1I>_K'^:R,)59%=G;*(!;G\\."\$1%VB_5O J%+4D'
ME)\;\.F,<Y6HLK,',-G^ I!'_<>1#]/>W9V?TX/#X$>)M!GP"R6K&FHID[^
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MXQ>RBLV-2Q='",Q742C97\<>V)DE9@VZ(_JCJTFE[K3#K@:%Q?<55%1"B?.
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MR@1L83SB%_B;OU^JGR:*H4\X E;&]T_B+S<%W?1'[[:V-9K<)7O.G,4%^<!
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M;6Z(,DR]/S9U3DWL4LAAC%SDH86?G?"M7[)7)I)#:'C/?AV-R\"F8:3"%RX
MA@)5:)5Y<!\/++HNP<I9B6/JB+^M<BWY68K3)!W?A5 =S>M6NQ2^'53$@/>
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MH[ _;TRZP.AU+^C:!O46BT+;<,_=Y$1N]HE59<$PY3Z:!B33SAFIBU-%#*5
MI1K H@->)^]%D7PID-)\)AN"S0E",(N@7X??Z5EO-7;U>RI=E_=PTCNE8[9!
M[AOI[L24ZF&WL&[$0WJ3>% 3_TC(*<C=@Q[H1M^)6\IQ_"NSY7<YVM(7@$LE
MM*JB@MH+UI78(@[J+;E40ZY37!<T';)A. 4Y&^E^L<$9GX*8G4E4D[^\JRX
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M_08! 0'IO42E*DUZ"P1$FHBH/WI7FJ$C @$" :17 06EBH @57JO05"1+BU
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MN_&Q(T\S;(/KHA<A3<+)F6FY8MN5>PS/CC\V??3@:C=.P527'GWH)X<Z!^]
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MR6 !V\1!(2"BCUJOF_+:L1?OU/@T.*%'*;68G45VQD;F;SO[%93(UG8>F%#
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MGS5;7)DM-N$B-(X^_:?'29<?I=+7QS,2.@#F@;J!P7 4-B8M-B4N&6),W>=
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ML(I^/2(;,6?@Z,I&WQKH3>O?L:[N^U>FCV^,27F[F,BUXI.&\/AD#10/?I.
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MRTZ93\N /NX=@.1*J)',^6/TMG%S$F]0TA;_P]GQKKOE!N0O%37E&C*Y@)*
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M%5JY1IKY$+<MKH@KT\[K0NA"=BASJMEORH$[.W[2KUUOF/+ WU=S9Z'URU)
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MY!D+@,2W\_1A6%T"$( '@Y##A KMH4W;B,IWA6\<8G-VWF5WS/^0YKEB&^*
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MV%>]Y$3\9,I1[]TN4HI]O[Z ?>M]$LQ7W\M5]T)5XIDDL[[KLJG9!@0>VM4
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M2\*?K5]O,71E5;^0#'4*$LNB);E55T?<:8E;MS3%D<%XJ;1<K&[3 :*HXK[
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MFT8<K8Y11/M0:@B'GS5P.1S,EI:BC ^YSN<]8;N_TCD1-R#=L@O8*'D"NR*
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MD4>WN[O9_8$4L+/JY/,)]8[.X00H1Z*\)X:XGS0T-^0LV>L "6HMR+@I?:^
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M)4<N^%"8NRM%EJ)L)@*,V9( "EKF#$JX7;RX'6JD\W7$*$5G_\'6&BAJ:4I
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M/JWOS+*2CTT1D89&W&L/9V:N$1W2F?[[6UA8,_SA-AG(IK;IG"8WQ"5*;'D
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M4B'3(J&A,3//<OJTB3TIQ23)?3!C G\:]C)C$6?Q1+CSUFMP MH%U=0=FVC
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M%!+\W@@!&3DY)04E Q45@^ EEDN"_\>$^P+0DA,LD_03$5P!"&D)B&@)<"T
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M $0)&MNZ)>'.:C&05CH-=^&3<B;W[$]BS1S;[8_;E*V'$P)\H 7))=HI]3B
M$\5$WF"4+Y*,ED!/*7I%@)D[$5?:\:D7FFNR[RCG@)!\)Z9ARGY1W/5KT7WK
MI]*37P)6:N"OS%EK$&--%C0;J>Y&WMHDF RO-^EN=PAX3#-:/.,<CRB7\+AW
M7PLY71EF,BRA5P;# 4:YD]]^W=ZI)O8OC$LC?JI,6J %\ZYUF!VRLDK04$B
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M[(R2WZ:<U+4,!XAP'IYQXN_Q_]C7CS^JL/H&;L>TGS7CT:SQ9)%)"0H'5.$
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MC/**HSUI5J]Q,#[G_XI'_,Z72]LNQ>^3I*4M&QL;_PE,[9Q GN7/N9.5+'W
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MU]'C2WFIE>>A*$6!/W@B=_I-3$\D&:K);=V-QZ6UY; KF89_.3WWD'W9.?0
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MHJ$8[FS4#6X:52T"&NI'LSK=I4 &/TF5\%X)4=P^6%Q+)1G#X4W9X,-DL0G
MA#W8\1 %T<&$"OWSP4B!!]OX[=S2QG<7HKE"3<2 GMF22BF5U/W*TWM([C:R
M%JPWLO A1&:TGH$_%RZ4#";VW  !<53^ZG9I3'?'2/PV.S^;_'VF?:3F7"E*
MJQ&K!(2)KGW9?GG!7Y0S:$%-/>F%5 )34R 8).VUF">GM+>\H.!6='V:,_@"
M_M$ ABN[/!-/U+L +#.53=87?U^4;!A&&*G0 E:F!]K+=Y9>6+C=IHY2'&[
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MG6PC$?$E48/,."*O!6'DM0"X84^[1T+U9CS_-@+_0QS[;9Q!\RD18^JA4*.
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MN-/N@'>OZ*)W\X:>>+#\L0LSO7&5[],HG7^AHSKB]5(BH' &*&5:5X%\D91
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MS:D9.)*=^H$%->RTC34U/O)+L6G:=RJQ*L];3@Z2$SN3)6\8J4G&85#)W7N
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M4K!]F'2;FGWBX-,)E&=AXPID"H7+"+(J*@IQQK0=Z$$/"[P<[P%2DC<I_O>
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M7M;*L!.OH8=D9RBVP9T73>H=EMTC7]5=Y]]#G,G"#,YRTY:8[4W,N/(W^/N
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M-BGF6-H7,/%HB*VMAL,N^T>NL=^D>V<M'O#EI7CR]U%-&KM2J !!N%\"G22
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MD[A>B6<MM<8*2:?#:T),(]S>X.,S7P!(DB\5^<G/+-P O]"KF=NO$,7]]8D
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MZ525OFN>J+;@[>6,[4-9VC[9A,RI69W_$5'LV1_WP]>6;^H!; :\FM@A#VD
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MFF=1.L,#HEOTVT( A"/= -DE4>;)BE!E>4-\RSLE*SL !B;\ X"'^ . T1<
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M)OH^)Z 5WL<^L]7C9XL'(OFN;:&Y?G=:S2\4$38<$5: #H6QSRPR::?LMB[
MI-6?WZE[D#I+I<(-HW;,386W"PX N>HVK+@A!5H@;==MH$;30.XQ"X:#PB2:
MQ@Z\\KP@DZB@,K]V2*GIC/U\%_WI X8,-"Z8!4)^V"J( *@3&0=@DY_5!>X!
M'"R;?<^QW/E94."S)TR^"5 K7M>0 >TB_LA+%=RO_JI1%]K5&T*>Y*>9:GJ!
MPL0[70SK@D6#I1.:&D7!)^^54F^?]-(;!"E[6=.?GWR/P V2)_*S3#(*<S5_
M UO="H;2%7#7[)?RC%7CC0!GIX5.UBL8]3M0WX-[ U(7C.8-9A48')LTN@$<
MZL.^^AN.)E:!\T7Z7>12_1WRF-V$L%$&_K3O5W+!NWO# ?;!/ '3J@B1A?/,
M)"@"$:_<ZG,FHRT9\.P8_5'/M'C5Y?OSUJ#?E4? ?_-9%,)+A0K0A;,**J 7
MX<L$;"M*_<B%/, QNTR!;[& 0[M^OX'VI(#E]4M"D3FI%7H(*[((=U]P*(%:
MN*)9O\,I( */6\7HPTY',"F?0"]XM[_1,;(C]_PRB1T@'S:![O9P7]Q0D,]H
M;OU:A?DM*R9W) UZ'F>2_LCCPE&(XR2T"C&R\M1N/WYU--]5Z)ATKCY'+"=T
MCNTE8;H06TJN-+<$L#":H*_OH(10;,RQK8[$^E(')]3DT=2%!/#2VDQ"/OW$
M<M2IU])4RZJHB^VTHI_'-MRL4!S#W5(8!64LK@@UC^^\#1@CBJ&%H%,!&O5C
M"H603_DF^C/OYNX23([!WG$*;%2!JB:7C5LP+B$ !]6G)B+<!Q#!9G93;][=
MYS?U1JK-MKG$D@]IF!6%GV[M@%S2N0\:@,+Q85[;PC[8WCNG+7@H_AV:M8_"
MN'Z<5'W>+<C^VLOH;M;;E]NHS(P"9NG1SKW^H$4/'3*LP$U/(ZM (P<U98\E
M:E;GICPF\QZ909UQPLLR/D2Z0LX#8Q;\,>1<(23MUX?X>COH^Y$*8< PQ_VV
MR[<H<L*T[>]R;LT)GAP3>K U-$T.7_#3F7KD6XQWWJ>U"^_]1 BD*J$_"$I^
M9^<DB5SEW(EPLA,,I0H"0]$$)R0Z@*X\'23MBD"\LC\!O,*R2%^F$:R!SU!&
MBWGM_+(":3WRTUG.C_8U&,4=7@TFWA$ E26I. &ENYPE>R")RR.].S=4DAP8
M4-_HO?1MZ?:,VAP/JKK?V, L0^WF4/AG0/W;]IU,0_L(KT]^4]:)E-&I*XNN
MU[K^F >C-R3I->N=ZV&#8&F%G_2)3)MQ1=>]F8U95_M1P1.;2(3H2CV6[ZQ(
M +>+=:!'@<DFV=/OHJLG; @6$- @:2Q.4="DGAZ+P -0S_5S;?2G@@R#/-G8
M9/4+P;-IJ$CBF<W?G1APS!)29]ZS4R89^)//D#.'H6J>MS@ WD*$-<,JE9TP
MY HY4WQ6DZCJ(F<Y,?RP$#K%GH;XX!];)DS?Y6"\(F5WVJ0&UDVM0Q9]CXI+
M=ICMN:KQDUR[""O?7?Z4%2!39.F2=L/VXP="5KC0/9),F83P'78JW(M?M $Z
M,$0-O N9IX1DXPO3*C7;\'NBG [&SVAE(8V^(Q[_7@EV!64P(.@>[KID^K!@
MW/I >7)X;F=V4GV[O Z^I<$*[N\UD:1^7)KEWGT^\0U$KFXLJ!CMU4\*S80$
M^PP'ZP:#9N,!ANRN]LWM5*=$D,[!NP?S=SU%(54?(Z:\8_2)[J?\L-OS60 "
M$=[":36Q*4WO8KGMNG3#:8"35D\?3MQ#]:J'Z*V\[353I-.H@=+^W7P"^^]#
MGA=K3_(.BZ*;N85"TK_@6#H^M?A)!UJGPS9,F0F)BT">A4@/5RE1&/FEWY-K
M38_2*DISTD7VNWKK@/HA7R_0 EP(%(HVS0A5?$9.ZNB8/F5)8&1@C6S$J^ ,
M+24IFW\P?9'< F67=U!I%)4^36WKY-=W-XO>O[J'NSIH#*^A0!3!QJ/*+2=M
MT\UEB< \W<V#?J^F5QZ -(+9AT.ON3V8ZAG[XPJAO6YFJM0-YO.K L8&Y^.!
M63_W&]M2A:H]0DJD#YZCQDL7)R#)]#!6417HF?@Y4(9Z7U7DY%>C_00&P'++
MLQ&"Y] 1<(3O@G4(U"9F:>E#K+:K4/'M^C!;^@QKHB <H^A 4]R:G@H%[_>3
MR9W>S\QEN*D>7X-:ZA-(@\BU?P[,;W"XB]/U?C;M'<4O \$Z6F%NZP&A@%%>
MQ8/*Q7*?"V.7L@M]:"/Z^/LMI"^81.G+C>\CS:,[_QUE%,U<#B_K1F7]*) 2
MPM[MMUE."J-4:^I;J<"DE#ZD<"=Z UD@=5%I9QS(0,A<&^GP,G6$;Z>69K[Y
MREMN=0;)4,8P7DUQ4J&DT!YCC#^$%R,NDL7'GOJ0=@%K+ ?>'SK3?M:GEV[5
M6_'M0DNA=M=G:,./ &N^VQ*H_659'ZAI3R*.W5*JGWGV+#WOM2POE]CL]-%6
M)9?[24*?JTNC3KQ/ST$?L?JS4.:H?I0C!2S(H@_E.P?+VS/2V45%O1OAS<U(
MP0+G6-A E4F<10Z^ C3FI>E@I^RRV <N QSF5@%],J"RF7K1O>S 7Y/AE:G?
M.#2I3ZU%]7Z4Z;V/K6>K\*L=*YSF35L?CT4\%R<4J1!5.*;*3(VT(GF(H* ,
MHK;$DE5#MJB]O2"N_[U)WKE7 B?L:]:%'D(?%%/T)S-LK=5&+U&JN[IO8[[C
M(I>JKED33'X 3,H4CFH*XJKOP@LGW^MP"P("^1+.$Q5D,;5QS8%Z_2ACBR/*
M?C[KIGVDC^>9HJ+WB"K/]%^H(DU"17ILVE%=GR+C_G9P8#>/]*1$0B?ZSHJ@
M#,ERZ]8+&.DT_#!R]VY<=\L'F."_YG'%4U5,\VP-'O;E6)5S+;-BDY<.O#+9
MK:$#JJ_49?N\"N$[*!Q?"XJ$W+S5S>;^$O)9Y>8-"=JX$+4;1\]BH NU>GYN
M3>+8-3$)5&7LLK6%US,!Q2FC/W&3&<B)=O'O.5B<?[E=M+^%6>>#KFDZ&[F+
MX\3EDW9J_N'7&?H@.QK*HT0GHEOM%JJ^*BUY-UFVP>^ON3*>Q+N?Z6\)"+FS
M;H&O$,&B9MLY?&HS^OI&"-_D$H4YG_*(\3?&9 ,,4<ZFY;$!HYLF/7?.>86D
M!JJM;$,JU_TR^$F(5F:]88+1T,O2;9A=!T0M@FX//9.?9=O8\@#YUUVZ'4>-
MA'[[ KC9E8R.IIXGAV1)T_M$6TAQ?A5]"H] ?M?.#35DH:\>^< N-LL VJP?
MC3]*U\<NC^+-!1[@=Z=(IAM I#8^D)/:R'DCJZK6CKYA//OW?NRX'(;:\BK[
MG;,?Y7S\_<[-EC[RUYC)_D.(S-S/9=FJ4PX$%6<8O90&I.[;^X*+[>%OSC0*
MOY>0Z*)5 $^^>6.=QV@V4[:WP/>1C,T/B322J E^Y,W4R\_599BF%3F/-UK[
M@'V:$SYBBX\@\J)RK^[+L2M$DLHH$HGIK36]6E5(]*[O->ZM\:$/DRY/86<P
M=;DDQ!6PED*G",)=S3'APVE\H'G9Y<BREUO:^E^R1 /'SNLX0C/^'"EF0J\$
M#]X8/&/MX+=UU<2:G;=FI'Q:1AN-(SKDJ\Y".T8MKO0-6&;&"25S.^ZU_@M?
M!I*CE;Z/06MS@>#;S\9*B>J$%S[=T@)[&Y*G^I]9HWVK&^-:>'V42W!U#1^#
M)5D_@?.:G"9*WV7^G;H/WO+MEJ7^RY->Z\LQ+X$$>/!LEG>'7*Z7?0R[(O?U
MN133Y-=RI2;++#9LK$SM9B/TV:'HS5>"OLT_WV6X?H7Q77.,9\0WQ"&TW%07
MSYM/+,K@>T^[Y:(\6DW$N=GS1#?EFIG(A\/;+7A-'L B[K2.TCT(G->/;]@4
M'SIXI([A"ZSOO#"LR5_174R<?80JRHY*%<(Z\0:RL(4]Q4ESQ3V&?5)3^Q*C
M=RP$DS/!9W:'&KG^ALV F)1,[Q@R;@?H3MCVV_@X5<<12J]U#T5_?@A&WYV$
MG1%3\.X3-H\OI9*?246W#S/!JD:AIZ-Y>O97T>^E.I7D/;XA4,3-#S+)GU</
M&"(Y;EVG%4KB,F8S+(CG&+7J6Z?]0+"&./O,+.T*.E1E8O;DI/I)V+\3D@W*
MP$CRTB0B>7[Z;J8JG 7]D.J\M4>_CJQXB<5VM7W?-L;QU=&[GJ-*H&"+6J"9
MF4>08NJ),50Y^I5F,W_#)7)@++0H"022IC',?QXMT6[A9Q.73$(FK"RW)/ -
MQ3ZURY@^!3L=.)^HO-=4[8M/BU)91MG?OP KQB>^+/HU>C( C"-^VK.!K>,+
M!ZPC1,XK?$PTY8JW^/:L,M;Y0*S"<(<?F;IXO\NFXDA$JVX6=W#3=V:I>WM\
M3VG^*\GM,.Q.LEUF)LJT)=.:,0]@R7QH\/TIY8".94[E",0Y>Y LXE%@^UXQ
MZ;TP^7U$Z>/R#1O]I;.P?++,G:7LXY3EDU3UNTS',/M157N3?Y[-Z7W]A1BW
M"D!76RHGG@^XEPIX$4A8GN'LMJ(!-9S?O7,EJ4J&^1SFPS]'7R9OSO.#+G$R
M>/J>0?$H1=Z6>79C!3!:HV(+S1C9)$@5Q=OU'+S%,D*,%?(N+N*OO+T6XO:Z
MG% <WV_G$AM2<(!#\*32I]6O<5EWJTGZZQ9O\/' C3XN,M=R<7T63#/AU\0Y
M[>EV?-E7P[?/%S]O Y4_E25;3/G:<U6>FYYR'>0A)WK:7)S;S2HU^LR 1W+H
M^ )TIY0/AQ"EST,1(])+*C'^=[$U08AA%A3>T9^-UZ19))0):I8$W<X8_:!E
M29F%&X;3/12O6L!L:%2HRN>PJE-SN1C;',^6U$QJVDG^O:?=TQ8;BWB%B0G?
M?5@ZMS&AJ?JJ8ER(HM;J"+5'^JZ<@6Z*#Z(\2NI%%B]BOQZ/-+D'B07(FW5\
M+'O^YO*#'QQ%9@7?]SSP3E@VNU<3+/@&N28Q]<[Q;?#ZE;P[SM.W*,V\M_%@
M*$/HZ0("P:NW1D@F2<?A2U_X$M_0HSZTB)$;4(*FWAV)A^";P2HO"?8)E-C#
MXN!@G"=9 8*A\]$SXCZ1#V?:B8[+P_.D.S=S$EDHX;<N!\@^<R<"A2ZC(D;L
MJR?@EK!-2EY=Q78N"6)ZTP8V:F--**'S!ZQNP\+ E%^.IQ[E_LU%"6[:M6'[
M3IE&%U4+>P60LB7%A[+$*T^81W&;/PIS!P&!K6H.<O'5EBM1'G5EW7TO_SR5
M:0,Z]#8R9?')RR) ?/3^G>'4*8]2I=8&8/>VO=<TA !8D^+Z7*%GYP[['JQ+
MX=A/JA#>V]AU"Q>F:CA\CB+)%'$]:<YF)&^%Z/[^+BY8I< ([[O*?487P7WK
M*9;5S-M9[L. H:<8K;=J'(<#LM#""0JQPCGRI^X,0[?M$3@TXCGENK>B5/#?
M47Y-$^3#*H*-0:/Q58732T ].=-%FR93W_>F<UZF[Z<&\R05UEQENYT.;H'K
MNJ[JP-"M)F:52E%8EONN@+-/Y?L01[@"%6)1H3XZ@:<9_?6N NQM64.,X*-X
M#%FY@Z8SUEX JA3R9ALH9[?=KF 87TE%K/SO+>B?FR!FUNTH<_4YIRZMV'4^
MS=7$%B>]MK.'EL/YCF]3JAS4.E6RFG!:IYW/6)=</M>6QG\V?,GM=L9\9SB%
M((O5 3&ZSY;UNPI2@MET&&] HW1W6%T/$>X$^YHZXZ_P\+</$I]W,HI+LD'E
M)/F*1S.?)[S]['*J)]6Z4>=^L  YG6)#?$,:J)[8_#RF.V6 <+K24]<&(G18
M\HIZ12!5GIP+,773:94J<=^J)^=\(3PE@#)>6WLHMZ"^-0 \5_3W'6'_17M&
M\D(>5T^.J+QRK8F&-KJ_;CU:/X ,0N>OP6FIH/'4QB:WUE.X,UV'2V;IFP+=
M?JR &<E\O7GB"8N*VI%M$P'D'-8GXK[1V+%)Q0BCF!6)7%5&]HLV;</S_LXU
MFD._B(_@^;)^)X!+S"WUP[\]$MB9W>V\D22-4F=77X;J6D1RS!71Y$^!"-;A
M,[R_#_.ZS2XA,]V1T_GF2NI1.;[;B:=Z]!4"6.#>4F@3DY6DM+@Z\ER-"BZH
MK.=&CY!T?_,OW^25ZZ=JV_97@.? 3;^?8 I4J$CJ*WN,9T&D/NQG,IH'3P-
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MMPHW[]N*4@7#X69SZRH?#')TU8*&HYEC94FG9(F?[',YV1N<O\SO?M&/ JN
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M*95>,9R]&,@U*+K?L 'EQR"QBVM.:^E"]8,MH)J[ELWC:S\"\_:9/.-1@//
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M9E4SE4E(J=6/XN$\BM;!#?[DRQCI(H .PR],G@#<53BKGJCD/MQ>73GV%77
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MWT\K7<U5X4#'I-H7E_'%.3(8S:%F@/IT?P$6T5I4R\4Q*/2\)+5Q_T.YKGA
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M18?$\,D!A,\=ZO76JZ1D@890F@QRBXN%[>35*S #6NY+ITM9EN0BWJ0U8&$
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M+ICZ#B:WL _P\J,2DG\(B-FPJM6 BZ8F4V@TPDK\J2ER/$F%/8-=KPXJN]$
MCE-=Z4=/Q#J7FP+@TM!'B:(AOTE#A?M3P*OX;#=J%J5!+=,NAN])0U,YZ2>P
M4SD,(MQ$?X8BQ^XWSQZ00!2T/EYK +KQB'!(4LXTX$KJ%HB[)+IA9J-"#WM6
MJA&VP^4-THK*!TEY&OAXNQO)?.%E>E089%F:4K?E"R[AEX([AJ5#?V0DB'8R
MZ1?^0!*++94(Q1H>=!GQX8MR*G;(38+;6HU\1JH51NT,C(2048)I#CM!THT(
M.96]"+?<-_S-Z*,W*<XD>U1T"]-@]7,8LG347X+'<]UX85PC#DN#M=S@NC#^
M=G]104!0 A0GB?G70"3#JI?T, PD ^_.;_'"IU H8E\#>_[^T+2$31@071_K
ML$+0I7X3[VN[2#\U(B;;#+@C0)M>NG&>$3C.8]1T. [::C/6S=O_BEKLP<J_
M;7Y]!TA_H'5JX+ZE7<:&JJSG'Q!%BJ:-79IF-"-?]M4FL^]*;<LER1.KALS&
M% @I>>-/6!1 /1^4-K5C/#?I]-1 #>E*57*0/.H+<;^ES,D%=8T>^-5U=/'A
M(^WZN"@N&VOZJ??[6(S%E%2JS 54.<GNCT[4&HZ,8):[<0T>IX6M2TG?E6.&
MD'_82.S\.6Q@\PZ8I:[$7SYN;'DMWEQQ':_\DF3B2M8XD,)$:J=)%YK*KN&*
MGKAH8F;'.\2T]-FD*8(ZU?0*256+Q[-0WG.@3S $DCB3+_D7+ ];LS;1""/A
M9(_L02D_<2@; M<[P)MV5\\M6.E/V?]OEO*4X6VLIS4>J#>%2(""9/PZVOTQ
M_O88['_P%6O%".<"MBG:K"L7.QMR;]$>OL',L!]-5@99O%C/F(]2>V\VY!*Y
MVB5MM6$- GH=]BR+_.1Z2=0U)GZ8)6]!QM0:![HT<3%!G**0A4B#='"6G'U8
MC,B4]Y*#VXML<H[I9VGAD#[L\.\A<0DAB1KU%J8J-CQ^H#:B?'@T^9_D?",B
MG\C];4@B&.6,6P0584<08L6Z ,G1SREB1&T2%U>=;"+]"\;8LN8&X\7ZQ%>^
M'J8X&YFS%3*.%ODVKAA)UEIU63',> 5+'U3?M';LX9R*-KKVB\I="]3@V:_G
M<,6"&>M?9@8O$1J#!0E8XL.)1UBRS8BF6:+-"-RG';(?P%MQO/99;I@\L8,]
MOG^@&]TK11%&XDZS<)E6XD-R9V-]NU5=XMLDZH#75/6E6N?V$M*RKBK*,S+;
MZ"@:$T?E72C^ "_E]R,-^,*0B>U4KE-/+V65SF:P877;8!GC:V:D*CO>3GG2
M3S>I+A?<" 3:U@H]^L31 FJBD^E604FB5-:/C5K$YN(4NH=TAB[J#QTSSM(0
M9%_0AXY XK1;5KT#G9J;4Q2)NQ-$#5$@U%>Q% UGDQ[]XZ?,#=SNC#,C(:#E
M\O5G+8QZ+FX#1D&R+0W+O6GS_D+LD_T:+:L9.KGHW\8TL)":UR\Z.G&+@TW+
M!Y$!?#FL(3*UKQT^Q0LJ)!_B5%WFD%JL=DK#G37(%9C;*CRIF4^."KBMHR?]
MA\\DYZL5<M^\#K+U&[:SC3ZS-.;Z3F9AJ$[@E?\WVUTN$>*Y/[J#@<'*>JM<
MJZ!&3P2S9J#"G=NXS5.D#F7 TNWIJLPV=GCS-*W'*F1R42B'Z ^TI*XV!MD.
MYM9\2C<N'/@X,<OLIT;A1.R"=$2ID[7S1:EHA4%8]\)0E*$D]&_0$&..W_2I
M9<=G-)'*USCP5Z2 U;@'NKHMCD 7]2OA'(&O&4QR>!D);1WE$HN[QJ&\0B+B
MZ'?!A=D1$I:D40K^)VC%N>T0H5ADI/^> O$R:A6'-8J<$&%2TI"//^G1*R6V
M)P<5-207IN=D1I/P?F&QKO &[Y/!0^($IB<0H!J?6U(<^QM'XF]DXCAJ@1*7
M6'FHYR %ZV]B[+[;(I#(<&M58&HYHS,7IHU:BDZS9%.6;9+6*%58Z\CB7QJ5
MV<65FZ+99]Y-PZB0UK9H'\LBG!J=O*0TK9V,.WFBV]:-N#*M68&3J5PJA8K+
M;>X5<];Y!'7JJ;X/:.EP3!-NT$(__#*PR/V#0D?A4TE?IN,IQ41U%W3T]%0%
ME*>LH2'1S2-?>DZ6/!OW/2SDCAX3Y4K47ACVT"OF3D*"<C9>1>E5RX%NL[N!
M;X/X+-D)UE'_##.B]E4)+@V>\:+R+[-A/IS=@IS5+T':1F5QL2RY>7)IE&90
M,U&!T\/A@S4.X;SDH70#]%&7]'@V.#5<SQ)BYARN+Z-B].T>D6$X_=$T?.L_
MC RG&1G#.#%Y5EZ1F&)S<4"QGE'R7),MJV2.X[?^6B1)@ R&(L3R[+:*Y"UT
MII#TF]8DI('-Q2<:=5HGCZA=O'= P(JTP[(=$_IH<3])5-&XU 5!\G)^U*+:
M5XG@WMD"Y%(!8F3W:XC87M]XL=MISQO@"A@;I@N(<PD*2^/^VFWS342T=P&=
MEMNDB!AUEO 447;5=)JJ/D&GE3\9:L6Z/@'U:P2S414F($/DFTYZ*,5NM(8M
MS4KK9Z9295/Q)-'H$3R'+8XR+^*ARF]X8*YC\!SV",0&T!DP O$GZO'6:P5S
MT\CHPZ.5#".ID%%S$ V)]X.=0PR6AQ:FK0;[)$:)4D!VG(KY@90&@:^9.+OA
M@K>8EK!DC/[[$!"A7T5G/1:F-^L+_X_G)3*MR_@N3(7H1CI/D>&Y4T/T^QW:
M%\V'[!VV;W(,!N(_Q4L1CV(]J"KI1WIJ6,;@U_@^?S_:R,S)3,7.N2V>56TK
MY22CEIC;X7T*!U%RK?BUP=/1-02HM9\&==]_Y$JP*/\A ;K!&8FRB$^=P]3.
M1SIC'WA8)4FHCOV5WY4HU$:"Y*.831F-4UI^1!%K6;&VBHV0<@0.[Q^J\+)!
M8 U3&[ND%B<I7);P[Q@Y-8L8?@>04:[1374ZXXJ)*XE];1%% 4-_*)9F4*4]
MW#B@LYQEZ2DFK[<.L_6%]ST<KX)S;5&>L.' D&UR81J,L=?<O<=)Y(,KMZ//
MB$@@\PO%*R6_IQ='O?M"Y57M(9D:,NM\-BY?SAL$,(_TZNQ9XWXJ_NO60<OE
M4[[?KGB3V]-^Y_:][]0[8/#^[0"V%>E?W+[:QHIM?P"?@X-U4PB-OP<@,3/!
MXISYXR#[<=V[.?+>.V2; 3]@+8?QL>3V:A2A[%5%>+JJ-5:*2 2G:R?"XJ,1
MA2<B0?UTV6T>/47ZFN3&H!^I%/!%H;&Y&%MPR/\7MD:"Z[?P!G [[;WXG<Y;
M1C\4_9U#=%"I1[DV>+5&U59+=PNZ==7DJ9UV)@C1X44U5.-W6 8B^LCGGX>?
M=N-[ZFY,Z]4/KC^/FMLDDJV2:=I.2'\V!C5)- LSPYZF5HAA3Z(51G+"0HG.
MQOBC"@PCY@]9TN&'MQ 9Q#5QL+(6\H+1V M%UR6B)>>_Y%]B^1NUF\HJ>H3&
MX8PX'7X:RSC>N#ARC3J[;=,:+N297F)GP<LP6IP.#P?**F,<BNS">BH MA;<
MU3/W>8H2O3/;;1\Y9%8<=%QI,'*-)T2RZ')_T,RO[(,BN1+$H7P^D&3@C8Z&
MA\429"7-!*2^W/[\F,X+0XRLNRO)3^L\[0E#8BP7C2Q0<!SOKQNM_IO^(GJT
MTXCH.&:K_B:_0<,@DB)\I3A\PNCR:]27F7Y35E-TM@OHMV!?[5Y^4M:><T@(
M_W2B8&_J>6RI428 _(U@/_TKZ*9N4O;_-1F#[?-)T2MI*"*<[Y)YV\GTM?:E
M1Y6;_I]+4AV_2G4A14J>R2)$C=XAY#NF)J+# C+=-Q$V,Q:ZZ,GUE%8S!/D:
MF'S%EH(:P72 S]?@>.R1;P1OGX"\!UMM:12/?.0;+JM\(M?NHRFHQ+"]I/)#
M>D78C#NXQ?V!4^A$BZ G<D?DQ.YMIQ1/[?7:#NNVC36S79<#VQ2S9G&+@!KY
M336^7-B"!]8Q!S2B//2OV.DW.P7AWUI<$]?NHXM,K$[K73K*Q-=5BLGN>B-'
M(=/O^(182''#LQ/=H(%YWX-\RKL^H%PP0<$S$X>B&F%/PX?E^*K^,,DQR[).
MP2^TGN%&4 B$-4J#"!8B@X -E1/=)KTI23RY! !T@S1?/WMD-.NU2DVK49"O
MU![S1B2:.7J*5KIWTK&8#J.&+K%*9V&TRP5L'\*YENNC"$)^>R7!',9/3%L
M>G#H4F@IE45T3"(Q!F9$.]+U$12<HB<*8Z4KE&O-F/%WDUKP492<_R*6)M@7
M#D# F<B>=XQ\[-O53=!=!(6\$!C7J:&B%3"&_W 78>ZE,K7?]\^$J4UZ,K@V
M&\VU94 2^;YK1W'2!L51$_D2NT8^QKW C2#B^GT1@GP&W;4CR32\Z#/8?P V
M&%M<!#[$R1@&@@&?*=KEB/8&*(?W<%#+S^?-,MD7PJYDBZYIB!";NII+L_:?
MR7N4WI3"W^:%P0GUVR)\OZ=2LCS"2T=3J_C226\%:YCQ_Z946@O+99M;'1N6
M!MV9C@Y6P9USYC3CR1(4J\1B:?.1%DUG"'E/XP%E1G1]2;AQ. 9B))[]5(([
MAS<MDUJ=#<,\FSQUVEEP%HLSBI!1^'QTD-!>I\BGJ-M'+OLU+I5QA*PD5^S\
MP"4?K9,EEUS.)]VZ;?:*GQ(IB&+:3",CQM]0Z;&+5N!HD:KPJ[3 $&N66QI%
M;'Q65G CU>N:8L=)GTYYY?/A"6&4KRBRR<;06LCA[!E_98NB68A0H##JQ_#F
M!]4R]03E(DEH&<7BS-E@LM!C%T+/44J&LB R_$S5CZ0TC"7>P2K%@ ZSJ ,)
M;;K3<V%ZR22Z3/AFB18J1R32\YCT.D_P?C9"R1(M15C]81@MD<C/.TB/D^!_
M"J$65]M3LL ^ODJW($*/:\(FH;V&GPNK\]4VIM0,7M4P4KZ>6F2.W$LC2$PA
M+]L-[5Z$OP ["EG0Z;:#8YKNQWC4 $WOX,=&[1EJJJ*E\6#8[6"UPADNC(]/
M?"@0I+^PE ^$9_S2LN<<9=UHN(2]KC37C--LFM2CLRI]3KG])!<(A;1EN,\2
MZ FCP> 1O'I %PW-@;?FZO^*8)2>J_4[(-,L!;SU G?E=,_?=ZGGM[>7EY7$
MZ$9P=T>\3)+RS[D_%+C!?HLBC.(EGLMK3CI=[14H4_!;)S6;V 8_NE]+<\TR
M3'AMW9:\ ]QH/1AL^=!]_3VZ7Z>?W@&?MR(_14V\7@BT(G.38B29CR0"5_$G
M#(SZ?;M[MI:"U4))W!$<9:<9FCLC7F,Z?8])!=+VEK)Z1NTRTQC.[-U3MOV*
M_>;"N A7<?K<FBIZII?K$_]/(8_"7$\M,1!1G<--_)78+$Q3CL!5Y]BA]!.1
MZ;.2^2?:^&A1"C*A%DET&M[@</FBK[=5J15$7X1DY/,;AY3X62LN<')X*.N4
M[^(.6\::T'1D:JT3<^F7$S&D5)H-J=\V1W:=G*2LUJY9?;4KJE-A*A!M2O9Z
MC"-BT+8Y6]'=+SR](ZC[XV4>6%HL<F1/."EU5A&'5N=:&[Y?Z#^=N_-W6'5Y
M6^C(.5KEK#6A80<A6@)3^7;&8AN4ZP\+/;<C;K7C]V':@,41\],J0"VM!-@7
MH1%=N-I3+T?5E,JS:KO,9V7>$<G*T;A.$10&"_($<^T?*B@I$M.L5-O1LN%K
MZRM:X:.-WZ?H)5 Y.1CH#$5'9RLIY_?B76[3KJF_753^QXS2]1\SRD64_MN_
MBT,^QK:#N@9!97H_!@B06C)/]]VWZ*R,XFSXN\Z#SRKK=N_H!,53A!K4XDMD
M8I :07;H!QS4?VI2&UMI)OO./-YL!6S#%G8$D0=<H(8[?/S'[U\!3 R"P^-"
M<*Y03;U<F*#QN&^US_*6N*UQ95F_UCXVQF6I&6*^W.S[5!&'UO_(1K)TQ(%F
M P9.$'()*5"80HCOEE2BYS9()&=^AD:+E%7G3"_XV"FX50C234!:UZQI+!\^
M%N)EOX]ATNRX"WOMY#@ ,0E?ODJSNK^\\?E:.^_G7*>+7RP^(BM1@V1JZ#5L
MUM3:<J,%!+VW?+3,C]X<NUL6"W(%1)#OA-X!8,CI,+-78O'3$I]V52].E\$=
MS$>,);EX>[EE;[>RN1-C]Q>]K?TWC3[QA+Q+YMXAFL?UOKXR!K^:.L(>.1UP
MGLFCQ3]]5S:8P./P[/F%^'(3.<V=SVD/'$?H%P8\LX\$W-68X9Q,;]EF'+\I
M5VWQX[P#9B;>',!Q67R^WAXNVUCGC57 )CTQEG= Y2G'O4!X:1XR85@:;-GY
M_^*Z'&DUKL7V\]L9D]\/A/KK20&0VA27GH;&\W8TW<P-^I->KU_]4MSS?=*Q
MVLESTSM@"AF4]Q.<626P-_CM3^V?X$=8G!%?7_8MUX)V)? KP45]9:WUVW5\
M!TR<.QEQ1;XB/;TVQS6A77/,/3]99=GT)3X*WW>UZ'D('+@_.4V^=%^% 587
MM=+:0I3^) !N,#@6U?TX+F[OT:M=M&Z_W(\5:]7G\F72<^9!TU#/:>.!B^6(
MP'-&M)Z"^K]GLPCZUX.E[\ [H.-CW#N@'\_AH>.!M^JQR_M5C^L=\&A$EN21
M:'?5,=7U#CAM&5YE^"X^9L&31_N*\Z+]<SM\AU>M5QRR_X&&^23F^+%YIP.4
M-\H#R77O_ X@GKUFN.:[[E1;6(QK9-2,.2R[H;!]>MO&(+RK63:0F;!^LPF\
MW/N?,(S9>[(UQ3+^TOD.^.">=_8.P+QZZ?1%D@9"[M6@:T$Y_M,:]%"\!1'.
M&%V:!6LZNR;Z=*E-\R,K>)L]0T5[^.IZSQ$X]WIM;M4P="KW8)P""^-^(G/4
MQ?6?UUV*/N3_[&YX11%H0^;&(\QL]IWTR6_%Y/VH!19<]+1/^"5VKY7HZN!3
MTBQW8K-TKT&T?^Z(NU\R\9Q-0.:N=TAX YX6!K\09=U[<6>MGT;!4<#V06<J
M?,1V&,'\3NIOFFE1!&>"K@Z9@#B(2&"/ H 8$6&*XH05CC[@&F'*OH@D(-O:
M$%&=OWO.:N1='^E?7WPH.+TM52(P=8WE&]<JH&-.#RHZ_NQ(-2_CW+)=RBM=
MB^ETXT5O*P'[.=S'@5V&2F]0X[+T18WZT^:BDV'I1'B#K&)\QU5FT^Z5NVBH
M2S0-*B[,^(+\SE'A3F#CE!<Q2?Q$:'Q[>C!V?A#IM.,X(SWJY7J-JU%K1FO7
MB@E +P4NQ4AF&>X:VK*L<071+MO3J">2(9DA'"QC4HD=\>,4F/%5-R5%TPP-
MK=S2"75T(U+(4^4K:<J26E^'O2)?X=)#HH;G(5T'G+$H1#9\:V:5[HD"5>%U
MXG9_/2BF)R=O>FVI)"AN3W%+'056:%3A>"%;$"X9MA5>C7]S/4T]V#:V1=TJ
MPB)FI>+;1<D5,H'T!'G,9/ZYY#KM?*)HRMAHQG["/@R9]=R (;.T\*[%' YA
M I6I9D3%E.+L11Z9JD>$S$Y28EY<1&^^'SD+E7<(?_8Z4;J4=2EK/A7A\C3K
M-UCHE@+]QACW[ZC^LO5-B=B\E+(>)@FNTZ@JR)8E5351YED<FG4(Y!;JW-^M
MH-RDM#LIE"=HSY,HJZQ4$4*_HYY,3DZLD6H(Z^=@T5E3[AES\C=B[S '2BK*
M::='%CS3K+O *[2R?E8FL;,^'EF.X;2Q.2>W]5Q @,^Q;7+%O),LP_R8ND>5
MR/(4;"F 5XV&@1[3?W55'Y2MA+:38V&&'UJ=S+:R5'E/8[76HOI%)YM6LS'+
M$..$*)E5I"HZTX>\M3P"2\*[I\E!A9 4<XS.UF+H)B.^EE9M;P#$"H9#S]JK
M-/IRU4^;M+7Z#HA+S/ TAK^H,:^4JI+-* _WPI\WX ;",ZJ'2B(F]2+Y4EW:
M#"?/*Z]]/AEKH*%*KJ]/?3T%,!FM0(AF)W8<M]/7=%TC?&DL(56]0?I-722H
MWM3=-SJ+H="T%N<*=X">@*[X&<O2/7&D/U'F:T)FJ@#AUZ3D3X>'MSW=@A1\
M@\RL:IJG*MNFUJIOBOVEZ?01M+7L"4':2IK/=*YSJ_;;SFK1<V4K3?<M)%4J
MY,EL32-&R2=$_M<F4AG*/6-Z:/0V*4DXTLOYLW/,DGB,X#6%_/QW@.W9^F)C
MEE53D\87E&F\_1BOA$J.GZ9C.X'#RH]P\=P\;&T?$TTQ]E$:7A4B(W1"#6=<
M(!W2E8Y)D)@2>&\7\Y?ZX+/O#(!6L?^8JK!TT_@BV3 31H6R$*!&1G^?H6>P
M_-R6U9K)KH,R7O<'B08YJCF1N\&L]W=MK-\<@B9ZSR&<-[!R#M#K=#X%#ENT
M9'QMJ\'T4)#^S:]#'^52=Z>S*&S7MEPM9,P<4[M /$D^?&62,4>4-L=3<,CU
MJR7E5+6Q6N=T";9$ "H F)X+OE]0,2>HV=2T_XR]A*1X!@.UA[!L !O[@_Z7
MPMP'E&"H@V1Y,5=)0 O[KYO&#M,U_<"7W1-V+:*NTZ:B+'*/+)9MQ:B58ECB
M6(6P)7]]F#+4X'CUR$\QW3ZX=N'6K>HG',.Y/H7&]E$BX=O,/1(DX)O"8#'#
M2 @L"6BD;TAX"0[HKK]I6ZM+.>%:GDR9=:0<68'?)*1UB1W75QO<18,'+;X?
M\M&C/1&908<!SG?=1^L) D_P5CV%_9 ?C0QV=W-EI>HEN\DT3YE6B5MPDDR&
M39/P@(SIZD,BQ!\H-XB%CE^Z]A5G1GMEI?M*M]!L#$$8F=HKQ'I"1,QSS-KM
M9 .ZU4:1%"MP.RY3IXC3HAWWF[[,-SK\WH;,,^!K]P/"S0/M ]9W0.[]& 4V
MZ>T[ (,6=>T75GENM,R;T&,/<=&536$7;'<=$18*PJ>A4_DYPD*89R*_RX #
ML::W!)*[V=YU&C[1,/5+!._(XT?(0.\9V/,^PL<,PKTYG,>GFS]<4&76E--H
MXA.N=MWAYR>K^P[0TA7PS.T"\D]<S?W-RK$UJA9XH;!O2ZB-V=04,RB2B;1B
MI9S-*=;FP=3?M3LD<$IK[)A23,J%<H3(<)QL%*$.YS.+\T2*"V4@F)3SQQSN
M@KF.)[DGPT'TSS&%=\M% =IC^JSD?;2MA5_*?\#DE)MFT<7VLOZH=,P^ZT@B
M-9C)$1F=_PYFK&!A^N X> F$VDFN/3=Z/ P\SBG$K4**NV-=L[,;K\LJ6+VH
MJ_,Q52-F+HH3WZ^O,J?%M':4E#E BH*+Y=%F7W+DK.J6U=X?C[&R9+,)SHU;
M'>)$V?$25#%\31Z!VIS2P<:VIS6Z9ICK?Z9U<\I.^V3%P'5X,2V8'<9_<8 #
MS(.MAOR/J8EI[N#JI8\!J>.?RTU,N3D.2QO7KX1>P2J0:TIW-0-^&^,,SU'U
M[P &X/9_P>9MTO.B<H-04*[D^>#YD_L[H,^#O\47E+>./)?7 (S;NW92*7NI
M]UL.(^FSC;QM)31;";'&7?:86WY&C?-KL:I[1._*PIG4^ZVV=+K[FM@]>?-&
M"/)>R^XC<_3WNW5S[-WQ$XPKXP55@9C\UW$;O-Q5.$6F'>+P#DKYN;8Q[._\
MIUK%6F-'C+_<N]0/E;)$H!OF5%526 ;$NM-\V<[HH)]0;&E,HZ)1'-W5Y.W/
M&5=A8\/5"E_9_OE(,O:Q4O5# K9LC8GLO6]^T3K(\DZL<67XTLM5RT@MF<Z/
MM" ?1IW2^7+JKJ+-N#'=&-6[8EMFI%0Z/1Q2>V<L'5>=\<O/%1*3\%'Y3SS'
MG4S928OP'G>]N,!?^7DF8F/#K:#6J&;3BS#AZO;/B'G:YLYP))B[2HP5LRPD
M17&-U%RS/"EGNN5");"A)=T@+19J!3RAZ.!N7']H^'GJ*9G,JHXEQ56>E/_.
MR!7"['T7/H6\ QR>"2\8N9PNN-2N79^>>MWNC=RB[F@S)K/> 2F]-G^>-K58
MVX^*BK-._!I/+ \=!6#46'X/!N]IF( +5:,5W+M#4=XG[Z!Z7K^G&HZY^SZO
M#+^,\YS9M]IFGX2NE=T6W#FYW[(;M[<_[O-;?^XO,Q H_>MN-+-#K[,F:CRJ
MJ=)F2.]V5'*5*6I)\5+NFXU.8A7436 ISAUK,'8B8RY=$DF04/&>O"1S$,O(
M-\UN@33Z@,'?1R3)#,\/#GINKU;"6>VZA=[N$CJSH(M2G@7W?)11V>VUU,K4
MG%U45J8JX2%R7Q8%[<*E[ ]E[TBV$AN:KXXV[IZ>-@PI8B!-DY8PQC0YL;&;
M-0;<4_((ZR!R""PPZX(-8Z=(^C3/0!TNG.<113#U/JWWL'V_TO6((LT64[;W
ML0].B1N'GA?8M0<D$T*(B$@XT4%5E7UA2N?*^IA3O/^,91B^OP/R@3?J+QK;
MF-FOQ7FV"Y=[;SFB[P![AVB?=\#F?KI3R?7JW:N%MQ\;0Y?A'7A&_#=,%FC]
M#TWR/>0O=_=MP3Q;^^JEZ3IS"K"9OTIX[>#>S85*&1B1PIKS:^,+E\'ZLOT#
ME?/_0N5+'PR'7_P6&[W>^J]+FC_,+?$.*"-P%&AF\3TW4_+*:3 @W<92RQ+[
M+&-P5>ZX0)U G#J25X2@2D2 H)U <FV8V@*O@).-\+'R:PH)&U?.^CTRG.'A
M=BZJ4G16$\CX9'0# [/>A-7*\9-.E(K+@G4A?D0NC!&PX-ZV6\[8L6.'@ITY
M:5!;>9 2ZI.TO2G3A&9D4B^UO0HC70NWR%"2KN=FE\S2RI:1K!T/]%-<A]#F
M$J=>R$J"Y^-9?^O1/G#9:;IZ 9TTI>;-2SE>I):,1IB\%H+40'LV5'VREMO@
M)/8T7_Z*S5ID!;RFM+W;&..QTO#)IAQST RMHM #,;.UL:"Q/!IZL3TR_W/G
MJE5)'4-<]8+SK /YMV,B6\_4"F=R!S+X"IZA %3F!2$[)X7@\"*''PT3&N >
M=-_8.V.]3Z4]8PNZ*+MW>+/A]0N3!!+1E.[&"IUS(JFT&I^.,C*V&9,J8UG4
M5*,#T:"!Q),.3 VM_*AEO*4G*%]R-(%=H7PVD::="I[*%S+EK?L'U2ER9:R;
MW<P*#>-W:@U>"OHLUF(=*W=T)6H]=8ERF9->_%Q?Z\D4!M/28SK[ @=6X1V_
MG6D:9SBD<8F]N&S$+Y?YI3:>K]:R*%MR4 OH57G>B32G:32JIBAJT9WR>PWU
MK5XOJ5Q7R;P4[(H96VS2PN'%>/(:#_*AD<RAH(:3P7!5=AUK*X=MHV.=DC?8
M:B9)GM,@^;/-?,KO'P>FMNU3IE+8-;"372UBKE3/I.(G3T"2N(0.8@J,Q;-C
MQQB(4UD#8B7SZZ,+/FLN2J8^\[&[.=1NG 6J)UHIGB<J/A.<-DEI6'B$.+<$
MMH0<;; N;R 6VY&&<C)QQ!+R-]E MY&>?3)0UDP;DJ.HD-]4E"?"*?[Q'6E.
M5;V[R)*HP9NQ0]Q&_$D( ;Z:-K#6IZQZMITD=R-NI66>N^4GYJO(SWNMXQ9Q
MN'0MS!F&.&.>SJI4%3JR[J:VVR]A\.2QK*452R..KOKSC-Q;JOF*V#R\X^S*
MEP$XX^IZ=%Z;@Z&IH:R_G\;[WP$:C+I-*W/#?@B9K% 1021H'^&0/K. O]M!
M=U2):/Y ZYT^<;HJU1@=N^LF;=:$T\]33^K 9?%YUMV2GCI(@1/**3_JU,')
M$3XV')A#MON<#(%>2!OP\X3_T[1^^: LE4BS1928D&+ :GM,QO&P,UW87'$6
M[%O'E.ASO8NSIQKDT])JRJD)93@J=$L^L?)-@3#)L?(J JL&FI-FIL3#9*^%
M2L<W"@1U-8,:Z6A].Q.FFLC"=(^'RK+34S/K6#6?#&GI\C$[<Y-3LD7RU&*X
MRW@*H?5EJ5E6.%ADW0(R9D6$K_D'7-, /",N$&PKT;^B_$\;O3T3 ]^!W:T7
M?#-N$!V_A6/2D1;PK GK6%M@SDU\496A6TIS!1($O/#FAIDXO+Z\?W1W&C%_
M!W **+T1]TB';)J=$J^$51*\+5"S]IU&A+X#FHO[.MKB)BZ<!#Q9?&BU\SKT
M"%UB#&3]^&/MY*IM[<X+5'16L>[VMP0:YW/\&D9LS6R=?+UTMRIH3B:THG[W
MR1IZ]#ZUKFQY:;T#"%H0+Y^^^C5BO0.P"9RC! [1!&QH3@>:UM65L#ZM8CZR
M;46CP6WO(<?>/OG\M4I*+^]Y^7"OS]5NIOH=4)_RNLYCV9<S\?SD>/^T>OD\
M?[OQ>*^7^H_JK,1>%<!#[[UYP)Q-I)^W:,N6^0 6CJ)F3W74$7J2? QV%ZNO
M<!9F4XZX_O1HK[K[:UK3M+0 ?42S,"6WNLAER4;X9*/+=/W2)JS"OF+82DF-
MEB7*- ^#0(K:<MQ&=O*S2*G#4'2#,)&@+:/D2FZA70T]ZIQ(Q%2F.+J;.6L_
MA78"&MOOF8JOZ2:QG!QM:[DR:/>UB4'']\;LIZHH*+PQ,7DJ["HK2L4I>]J1
M2N1)$T4L5,;C!C3QG(A6!'O,ATISS2&O/T_"%K77T3]Q427]*AY.T?!KK+II
M937:>E,YLCM_B;08\27PN 2!_G3ZOA?_"$,Q6F9P*[CPJ;[1EB$SN/FV+K:(
M9@T:BN4D)M'3JZL)DTE;*%DX;K1WUTA.MA 52O1<U.M%C+[Q<(V\O_K%<9_A
M+K[4#L-!?MY<!:ZHB//%+*99ALY,'Z0N#MHZ8SJ)SMQ/ >N2+-,S"2 (_++Y
M?N J%=@DLTH53J+>.MQ >+O:N=)13JN;)[5F!VA00)B*J*<BB<@\)?"K0R#D
M/+1I%C.9(7UCC499@/SPS??)5LFJ-=V H$;($?&7^M.CZ.42SOU+5'T?)DOT
M 2$ROR&2IT14HJ/$X%5,'HKXK=&HOU7B'P 40N:YG_@3+$QUA/?G%(OU7/<^
M$$^\#5,J>5<%K]EX]C2+RTY'SXPU03S(3'G&UF(^F_/_*%OG;X19O,O3AF%7
M/+]/<T@ZL7LF)K?D]E_:IEJ?ZY(%/+M\<L:?PX]_7RZ!:CWRTG+EFY3@VRR6
M(N_^DDJOOMXW9+L<WCO%]<UQ@N2*.$&P11%/OT.N-$2FRMCQKCQ(\HU=C2OI
M6Q[*%3_H$M"Z4HP66)+2S9@'>]3_&"A4A)%8E[@+EH'O#]  "E!Z.<A7&.PN
M#D=9R^#'K;1&/C8G7BZ36(6MO$#/)!_;C2\WKDJ*\]1\_** X83#P)C&0\XY
MI)7-S_YR#O6G]VA'#!1:YS +'R_:(/ IMK$:K/I(LZ<Z: LRY9Q1W2R#(GK*
MKYU;UR="EC%:S$/\DPL4V$2:LN^;L@]..MT?/8P&";2I6Z'_LR&QN'$1.TGH
MOFV)&"7?5JS!8H>%&'4$/80I$D1'K:\OJ5IQ0X9 1BJA4"F+Y?P1DP4*@/"2
M6N43.HC(M$;GZD6+FCZ$NDHA2(X=G6^8#J5$'/P9 #6LB51RGV#2O%H4J9,J
M<BQB#X%N_ST-;[D@^)>$OXCP'(:H>6\%2Y/!@&0JI=!&(&1CR=C/X")S#U-I
M"GB5$!PK&2&)*==QZ2^,QAID[<,XL/4H%(SK]YSLSXC,G\K7: O'(;/D!DA?
M\* =I<_RJ@#P:>&,E7L7-&:UF'Z!FCX>ILG&,I\14@G1^Q_F8IA4TUIEIV(S
M,QJ@VQ@DN@LK$=#_O.O5/*9Z&)ZV^3?]\=% 2&:-DCBR*$Z"#[3&@L!4 9AD
M]F/\MB2UEPG\4M%*!+Y 9Y;"!':X^HEPC8*\&28ILKC*2)R,5'IF#8J,+M9G
M!IZ7U?'FL2RS#"PZ>IQX86YMQVAY7Y449%F"])!M4A&('S\F,6?K=?_&Y"(2
MU"'W.B_#_@M^^,DN$M\-RCJ]>;QWP)G9BD4?<J@?,O,[@&6+9\]'S^*9R)*C
M] ]H)_"XROAI([\#(B&Z%E=>UCZ"Q_]6)'M-@M-+B(MW*[E0R\HX$Q?+X$CD
MXTU3OWY4M*<B$S(@^!82]!T^$)F$',#)F21U#A!1)\* WK0)DEIEKL@>L& K
MJ3RL,5_=?<)N%"(]*MNI8Z&L)Y5I&)W M?3(/%'[WB^Q<VB4L&NQF\A:#CY4
MK!++Z2Y==36TF >N1 [!-[MRGCH0-1:GV3S3!+%HKO20K-Z2)0_C5_R^;=>P
M9 Y57RZ0IF#OQ<W05JGPB^W'6!FO"H6Y#!BKI<RCDD>+SQ%J/^9OT:PN&.&O
MR%2+-IIH]"\P*^LC[BO<<,KK6OISPA##U4<\S3AW)S\!.WHJ:P(]_MGJH)OT
M#A",^]WPT#1 Q_7\G7^CZN#)!>OUQPA7*>_ARUU/GZ;>O6):&T&DP#>\3=\#
M'[](AF'HX;VW!\(UF!PDY"E-FG< .?\B@<]*34C,LLGEK[$ML/#*Z?EZ7%/4
M*5VAGU%L7^<8UMRC-V]'UWKH8X7CVP%,A"[6D_A<WG]YV>]O7OX\$:S\:.Z:
MD 1]"ALA_W&JTGB^2SD03E1CRE:N>G?5H)>^_/FD$VIG:-VJPU8X;!C6(EBD
M&$R7(63 KW4ZR.5I )Q/"=-3G5<G S8/ZA.SJ=['#MB%,LI\C5V+^SJ'T^EJ
M\)*1(]I2NY:NBIQR4M"BV%^F8?;M4TSK.)X"N:*L23T.L=HNW(6QH[RC^PV?
MEV8Z?_M7'.4^.]4O/Y*;+!OO>8QVU[#("FJH;?,"?MZMKR8'BI O?&Z)/#27
MIH&R*9[,M<Y 92>57HY6F9:M<<)S:/RZ$M8L$RZ9Q,G=[KDB;="Y&)G%LAV&
MY]-+@S"34]:8UCE[TTC7/N'XD8IMMGF5FQAO4:Y(C<(BLZ6BAH Z=:\?2T-X
MT'1L>$D4)R>2-B56!I,4$::$3"CPRDMS2;,JK/U9], 3['0L*FRET>R+*?2U
M>2+W.F3,"-WE=5RF@1F-1EV7FMU$;FR15%CW>\*H=<8*5)$['[Y%^E7)!XK5
M$FJV&JL?0DQ;#7DK]<@8[J(('Y#=N8ZC'\"UW&9 ;) T&!S'D <"@D+4FH+E
M>9IWMMO*^3XO=UE&2!ND6O.C:[:*HV6(DW#3!AC-:1EGVBL! &:MGX)$%[NE
MO@7/QDJ;9UR0&6<GPZ S4]N<//2A-]OID,G_Y"M1%;"0T7&::_5>,E"22VH3
M@ YQB&IIYOQ1BGB%.3+D1PR7-K9$&6G:HFL>)QYTX9CHPZF(#5BT-%B+7W5U
M>6S,ZGHT6$4]3:V);\%O5.1$M!60_CX1>#2KQH6[;2:PSL*.&[*Y'3$0;/US
M$:OS1T%+:X[F[RP4IV)K5WYT2J@42,8(*Y7%C9@'O*,G[+M?U-5J"G M2<<I
M\J(;IR\:)6)==;]2RRW5F,D(\-+V&3/M:^)>0M6XI= FX#TJ2R?WX",$;8%D
M*&.,)*@JI.Y_33H$E)%?PN_L_+27M 7:_-X!6+AL":+U;O^N@PJQ]*.A0;C#
MH'@'_)K@6O2PN)9*SE/<%'!)[]/<?LOJY&]L\-G17!S"N03& ?>OSE[>SM)?
M?/$N,P6FD>?? >%U2M L,*_&.KWEA)]4)'/HGPT+MDYQ*,X<MGZ_^!&693S/
M9!T:@E_''YZ;?1="N%Z>N'KX&SKZ>D-4S,SUUK*\WR84WO97/'(ZIA[/O7R+
MZYKH;!F*8'[*<6RIKO'46;E?V99\8OK_8\65P6KWD%Y1E[@=)(2#ES"@K]WS
M9!0!Y[T/(8'=1M:-!V%#RI]$.C:8^>;&<'XXL75L!3Q76G(_V/#5_*_A"^!:
MXYOJ^NRGJ'+Y0%/VANK[3/T.D/KO'? _A/7/'$C,#%C*?3O* HX&#^([+ V"
MSY^X7W%V9#Q)Y0-U!CDG;.]-Y;N4[+?[*D00K.P-5- 7M(G.>,@=M"/0,$HK
MK!%<%<.1/H;OV".6:PMV8$LA,9LRJS+-J_<[TNOKZGA^<[2*YRV.2\+J67,'
MM0S2B_P^6"%.)AU+,8>F$M-/-PA/+[#(0QGZ&4^,,@2KX9;P,GF5ENKV=>_C
MDF47Z7)A#K\(\VG"=*CS82+Q[\G?<(ZF0D2HW9"+V'CSG,1DDCD)2UQ/)1K6
M-[IK=613M:IBOS<7YXT+I0WE-=N-?RB1:^#Q]+MB?L#0S<_7[V^X^S8"C7<O
M'GU]=;[U_>W;!OF0=>%5;X]/(L@\AQTX$Z@3R;5O=F7QUBT5#DK[&3YY:P^$
M)>N4"SO1V8SS;NL6K5L:=M8Q%'E,+)EHGLI"G]!&*TB5?A2 23$/_L[?B*U_
MFR 5,R32#_F9D4?+!';_24U9:BVQ0F2+K,T F3*Q^H>ZLJ3)!==18)0 %.)
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M*$Y ]"BZ3(C(B,310TP%D'J/<J3"ASA3I WTTBBBWH[6/R[<^31(KEYF+P&
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M)HX+I).G,1[;'4AP'-W+WM76G=E=XJ&=?#/>WS=;$J-;>5FZO=3/S(]]L2"
M?S1 /V6ZZ-5Z(D.2OLQ.*G06LP [0RVG9-U3)S:.6"%*Y:,9,"XVIB:W T]
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M;'O9R-3RQ8Y<Q<#D$Y@548F1F>.Q:8K%H4E4J-DAP>#48F)9E%I +J3F#X1
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MVNP!_P@__R79Q9BECO&K%U&8[V^,?V;)/NU^T8]1_\; D,<77]@HC,&)J,2
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MR;B,0:$V$(FM 98==2\;_+^*Z# ^4M"9M.ISK<D(V5\(XM:PUHK"*R#*%E#
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MA/S+.=RE%:-!H6)3;!6:LIW&I?S1:Q][%%$@UAS60@F) ^_$>NY%)P$0&:(
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M"9=RW":ZJQ-1Z;P^*W5)\2N::QA,GXG(7'8?,5%I3;>S)3%[&#)UM/,Q08^
M-<F4!.O&'0_EZ:TD5')\9)6E[ %\@I:!T%TXIP//TA-PC(U\P&=JF_0\R^5'
M[@?F,ZCIAVM2XB=-N]J"F<,WA'1MQ:F7J1HX/M]D]@VP5: ?;)RNT6K3.WCH
M4E3E]6=T<:MBTYZ/^;JD])1)W2R;W_YN<I#%0@^T:G,Q<$2QX16PZFNS/3R
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M6_/9!Z:P3_V5^W ED!^HV#80-KNOQ.@J%81);;D2M]KG2Y6LN_6@DA.$L)8
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M5PE:$+G,_B1:Q=#7KI['JN&S4-0BJ^A%;$(77U3*EHV%Z4B(A2W+)528INR
MWJ;&(@'1A;Y<#7=0MGROZV?F]3M WBD^1PZ^KW]1B[BK_1RVRI^ ;3[(4' @
MC57.>GJ<7F 4<S&0IL2N?TQ@2)](0*,VX(9LI]Z')C$B]MG;*2Z2&8$R!,
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M!V-14TS1'L; %SX[ALX^!GRF/\.;PS Y?SGF_M[&Y7![S3^F*I!H3=H"Q">
MA#>KB_^C0=?^[':OZQ/PY/,)"-L8:ORI:)5WKY57@B7KIR3#_5JI0TB OK85
M.VTVC5%IQQ?JGU,4Z<_,-J"2Z!,$><M6,J(7G)#"R&JV\2M)M?M<N.;/5VZ.
MSG=)JY.=.= '>FW=T=T'(9^SGCVTU%&\,&.CE&^J#?SL>Q#B?9 /D01>>KO#
M1U8]U%BS:6$-75RMT8\I[X8[\W1/PA0DE-U&]&UW?/-MU7U7;9]J+\UW;+\6
M=3ZW<GXF3LU[W:.\]U@S#2L/[:#_H0A_3%\]^0 1^1G&>6Y<_RO VSE_R.Z"
MQ+K\5/@)M5@NS:>.<>LA.6GO)<OMR5??K93EL9!C=G#T->7ZT6(1_>CV^/#N
M9>CPXP5#-2??S];F]I5._#7+[/T*\7]KPNX[M,E[_>>FE86W"SLBJ\#0]'=D
M_A6X3T T$I=HWET$85/*PX[F^<XBC] 61=N4KV O[R=@P-MM^/"!BS\NKS_K
MT>P=9_H55E=_L'_P_T4-ZM++:R\E&8 P6 +ZR8O;?PC-G^IDTH^\:6=I:P?$
M3L94 UR$RF@4.+BRK1+1+>V-G*,FF8P<QQ68L!/IF[:$9F*8EMR#5)E4V ?V
MOZ)5^D9S+#E\<3AJM+B.)E.Y',O);EHBAW6(-N0<1\,S! XQ*@1%VT=^<RTE
M$=E8B>@<T9ZE$(@@R-_\KD0J)BBI5"R3V^1#&7PR%P\^1A0H#9"F3/1'':<E
M!D#X[P%W,*MU:S8)E1M6C&^QJW,)^0_]LGV 3T]/'C?[+LU#D?A/;&*<D7^P
MJY@\IG\!\$*)&'^L:IR;F4]@]-<F:F!]:2U?QK-Q<QT):0_[/P)ND/SJY!,0
MA/G(MZ@_1^O%AVOV.I"Z\5/]Z8KA^,SK$W"L7#?Q4I[>M0[WL_!MFS__YK4[
M;?.H@-E78.<3@&XU-II'IA9'U]3<<^[+ V4I9.G*/TXN9[YU,P.]>2?%]:'O
M5<KEQ@G]-O17Q$'SOSQS/R!V/M$_3ZK/(I$_?"@GY;VR$.2D*%VY??P3@GD"
M;W7I!V,^?3.\?71;?B)\U^!Q\9;ER@=Z*7LXJ_(3(8C;$L=$^02X;Q)N(:0K
M5;N"JE'0_BO1!R+EA;ST(=%W8LLWPRSH>0313.5QV";/UIMR8NQ?DVO+Q[\F
MUZ-"S*T?M@+OFH[OOW_^_Z3Y[$_K==OS<X2Y$?#[_?%^.IG@X#_H;UCHW_9<
M*F7<]NP:T89ZP#]Z"U_.]JM.F=Z\YW3;^?,)(&1G26]XBWW!*#K!_Y-S-C$M
MO_/V.%GWCVH3S'NOOGRXQ_ 9^ 3D[)U,LYS>3AB ;'S_='90_W-)=]B9C_-R
MK]K[=HZ 7QZFW^AZ ^E#PI= XV9:KN7F\>Z?O:7Q?0'I,/!5WM?&:#&N<+#B
MVT&<6]KTTG3_%@O?-,^,'_N9]+/9\E9#J]]EP'">XHT@\'SS3:N:J1+4CY0P
M$ A4QT]A"+H@+KO(9?X$U+??C3J;OY25UVPTR%,@"N8C7%8YFO=E:<!APEN(
M>ZQ)J?X9G!K^YC[YS^5JOW\O5SMQYK[PM_O9N;MMNJ8NU7?Y.!W=E7OZCHU^
M'#=0.KQ=>GJX.<T=GTP4.="[/KR.#7P]><@C/-!9Y/D$_$S@=_L$"*#Y$!+D
MZNG+L4PC\7)^ EA,K?E#'X_,;W(VITDOA_/#CE.MNR>DP_SN:2U;NH>7AF\^
M <U;T^QJ+P.(FZ3(SP1LD U;@3DN_Z1<IN7=\)H]OW;'S-K%/=[N+0UGG1SO
MW/&/9T\?> V'W4'&5%Y"F&*VW52^DW'F;G@YVKT)\OM;[H5*:^9[F!]/[QX)
M \-6.TVB_BF!9CJ/&9:=B]S;@ZCE>@=92<=M/KU] A#_S9>Q>]?]?GX<.UBV
MF9DGY'IJZ+?^3Y<*[DOYU?],[_9X_A,U+./A/"SSO%?"XRYR$MOY5XL/EW"]
M?Z!87<[$W<K,3I_)I;QO%6SZ=3ZZ3S?':O%*_ J\J']GJ_K[";F&Y+4>(CKU
MAD^ K3/FKRG0Y"&%&VU?L9VZE1G+C%,W'O"3[?D;"5AK!2%?+ C+J!/?A (S
MP?7AIZSOUQ1;_.1C;-Y);9BN3S[4JWQO/P'??WDU/':T[7&^OCR>,-VIN[^;
MNGP"?# ]+S6STO.*K&H>M?T>OW[;Z[\Z.GK\>.S?.)BFWQNPTEKO_#+%<\QA
M&IBNQ?36]=MWL)C_QLB/@=;/RX@7\R.%S,_\:OJRR.[F8ASR183S\)2A^K(A
M[I6]NBJ=NN""Z-75+NYD0OL1 OWY]G63UYLSNW7I^='/H:U[_8&MI2N24, [
MJ/0MCY)_4/UH%U0F\)]FU F??\RH#806=*%Q8"]_3#_6&=9"-:K^.XW\[/7G
M_W<:^?^B#U9(:^K6\\&7KM4S:YJ-ZHBUEGT;/FTVD%,J=_7:"(Y)Z\<F#D_G
MD-QSP70Y%S-&:L[&3HXV$L7(OS'+J)D=B@[,(!-S,EY?KS77ZO@;F2.7<SR6
M=&VSSBW.-\:DT;.)XNNZ&J7ETOA8>LF4$AIX.D<PZP)BO!)2QKW0,N]#>7(;
M'5H9!X4Y)_IKF=L7>S1NAN7#_O4/T7GSE9$^HYQO?+16M_C9$>U@MA&JEK\8
M.B_=D_5WO'6G-O8>]659799H#2Y6=;R@ H-BK#I<4[%M+&OUF;=!9% EV^(*
M3KG#]@=VS\C#<GVQDY^ !XINO_8%6KSGURY^#KV.X_5N7MQ,"?[%1FE @-"?
M*2-]%,7E2=$@7J+L&Z/S#9\56#SZ<5&HV][RR""A=YBNZ ]ZPV?C8F8806-T
M>W\YL%VP*3XXQ1BP;??*T?/F5YV'RB,@TR?@CJ7:SRMG=9SPYSXTC1DTQ(W/
M&5T4=[]).D&&R_5?7M"BO2/,,F;UX^&E\*!73.GMS0^Z_YR');>3'RM./M1C
M_\TO^R_M^?? F+GJS<2YV"\2U^W<6BCY1?]A4-AO54E^?6TX[U^",/Q_(0@;
M_Q"$ZUMI5-\C[(;7MZGU(^_'SFXE]9749JP9;Y0)>8[IG#5K7OV4JE/LO3N!
M3X )PP<CSPFFWRR9[ZKZ6HAYP_]IW?7P([[>\M/+VV>F]?X$B(>U_R4(5;EB
M_!DI47Z'.RNE^E,'[^^<7N\V[N^GGE=XKS7C_[VR!! 7NF>GMNQ.I3H_ :US
MGP ]%,N9U??<[K]P;'B;4>WQ"?B/J?JE:;/UH[8,:O&QKC6X3AS3K)0P</I+
MP@-1WX5R1![W$G<E$ ]&$!:M%J%=L:O6?8OR\*FZ?E]V\>J>T.Z] IO;/.Z.
M%D<^ ?!UC)^ W)6NZV\UT-72;VXIMF?]C]P"]%.[*K;?I;CG3)DU^9]_^PG'
M;0U?.;\PQ7J2T_Q[GOHSP[\W5W_]7)L@G<,,OHB^Y+U>Y>A\$FF;2OSQS3?:
MJ>0VX18W.:_%[WF_^E\<'N0O.G!X9N%NF^_8N&J"_034?!C&N+]^ GYCOW5P
M>=P^+]S]>-'L.-Z:;#:;?IOWPM7.\!/^B!M M*6%RIO%BF70WPN=X$;0_DH9
MEG<[X8-]$A=VW!I [AOQ_;THKX$;<2'3Z.T<PRV))ZEY3V+.HUQV5?1%][]3
MIG.CUOC^,VV"+?P=\Q,PZY3M5]XJ^?&MI7&M/O/FZ#'HGY/3TK<6/W.DP+M#
M/&Z^"1J#KOX.\Q5<E+S[V=8WF(-/P-;AD!,Z?\*6^$>7P'DH@^4MR]S3)X#W
MUIKE+6V,X%5W[9SZ=?0=BB_[EI^!)_^9-/#A3^M_>OOH_-B$GW]TS6W%'1HO
MQL5]?(_PF1X_VI_X0^!9P7"X8O$)H%W#??!@>/_=<O_&\R(TP+(7>^4$T9.0
MHPZ^W8K'L2?'AO0+(C+M/>7Y9%6ZD']!7&9OYXC#8OC@^F;G\6L@&'KO4S9.
MG(+ELW! ^>H 'U%VNA&"5K !M=QU^]G#_/+6*]-KG,GAX2W_W7_YEVKX6F]?
M5#OY34T^ <Z:*AP?;N]75SY;O1,%#CQRG97(-.6K?HU.FOQ%#GRY?]<=F.S>
M]>/=R5]6P,-]=U24Q?"P^4;H\>8\O!$GC#1#N[4L'>9V3^OI?:W:/W?RNGF%
M1(BW=_-&8$-W3WLEWA?[=)G/VA.T"(&]I.>;]K'B\CC\<^O2.8_?B8 P3<^N
MM##N'P.3]C^%U/"?@)577&X/.I<#9;^7N$,OGXO1ID_ *_RMWN#/1>]_\Z3A
MQ5%V.TU _T0XI)FXK95BO =J *__8I/4W-\IQ/7_&]^@KZ[%-[)U\6\GAMW+
MQ\[KLNW,$V23W_^?A\G;+],T]1.@Y9S7??\)B/)]\$.B, ZXAOD5<-'PSI:S
M_1=#4SI]XY)F/O+"\@QE\RAPMM>=J>:[:"49?NUH'6[HR;=5>9 \TP6L TTW
M]'ZW"M_DH72T3G?EA/Q%3^OK<_8YAK\S^<$7]R6&3S\*^]&KM<8WB5!4/99_
M5EU7_B*6>]'L\-L)SMG[XM8&45E>W-6S#W^:?EZN[L1XS:@GM("Q-]5V"6:T
M'T/))V#Y5^F'C#S[MQF[$R7Q!]^WCU.QP%[?!$)Q\;/VFO/5RN;F056LORM*
M?K+!^^X3,,UDUWT#135Q,-4]W?X:L_!Q7%<U=*?X K%/L*4^AM@[5GG=N6F)
M##?^_L>O:9CIG##SEV\1-_\BKA]FKS6K.])2D/G+MOG3/N:^3S;_=QNT5SR7
M]\61UO:W_UE ]@ZZ37C/SWKTXEO@>/Z_8*9+VH@.EYP#-5D=:")$R'% RFD+
MJ+412Y1_U,$<P>:I"D%99SX@  A$,1\&3;F+WK*J_Z: +&YE[".!CR4'S([I
MS>"8V6@IFD,3@2 KQ,*3>B $:/U_!T]\Z3DB_J>1$8_DXHW$/I+&NFNT5;'2
M\E@'ISA1S_5^[)',.D!MIA7>DO ,H;8$;+3$T6W%I%5+3(P"^.JK/1N]QUBN
MM90VI#80(49>R)I(F7JUFCE60;O!6G4_MEIG/.-I?G959RSSJ#^,[W**G&AJ
MV*._JH^S2:;[_/.#EZJT*CFJP %B 7!#)"=>Z 8:K/J^D$P&Y7W,5GT/Q>W[
MTQTM6+[!^=<<<"39[PNWYF&_F/&>(<U(. W$:2#96#Q>$1PJ$U#@CQF^2J(2
MT39ISQ2B<"Z&UI6/JLXB/N=61< F!DW,^.K(@D0DQ'K!597=L:2.;J$-@26+
M&FN%1G:Q*6I1D(R,80 /9+9B( -D.AA,R>;EQ,N&%>D2KW!<K*?'F]/!SAP!
M]I_;U]QSIX@>I&[4]RHI4[VJ;( ;!"8$U  [1>/ 7 U+%ZW:[,_P<['ST^@<
MP][Q^&;4H%5KHQ2FG9V?HB1U+/&MK"^?@%\H)D*]!CTIW[X!1_?W>)D-&.DS
MQL?9"A:<1P-%,I*,,<N9@(:(GF0BL.@]P* KEQ#.^WJMJHZT6CCR7)<"3HZ.
M]$/I!&JJ!N) W4B7G E&<(UA]&_L*+;D0H(:"GC!&@.K5$OMV>XC.$RQG7Q\
MK0>WM^C]KGJ.>Z&&M?(D,/G1 ;!DX1)D@.74'UIYSSA/D7F)-41&/[P02FH^
M >WJ^BL9CBK6F>^_)'0O<*[KE/K!@DU LJ06LIK10EAI>:ITV@FDBME 6[#?
M/Z+.Z^+O>]J<FC2M75MY_ ]DPL_G?+S/($_P6DE@HI<GUEA[OR#W0$M1CJ(C
M!^[7NAHW;4:G?G^0*(4SR5@$E=Q$GF7 _!K-^+8[S@@3+082'W#0J U#"XS9
M::+^#=V910"9?53"961(<!9]U)Z]QZOCL!.;QZ'COK<SS2!/QBF/KCB(T.L%
M-!TR0:5_U08.**H0*DUHA3S5/\SJ?@*<L.-[,<Y<>\^*O<F<JYHLA=&1^XA)
M%SG#L9Q"54TI64_WR[0?H(BJ?,IU"J2T))$1E"IL<.2R.V+YCC5\B(<Y_6OO
M4?R'F#;/LL.)A[BB\*9\8[WSNFTO76PS4M=RK^O'$DP[MC/8?6)GJ%4H?!(-
M PYETN !(.1%HFM,1#6<H[''MHN.]4WP27>-TF'V+3<Q\M%&R2R60O-?@O F
M@O2@@G L-[!\1",#6%6O[E1=]Y,6];:'E0G.7MC$_=P (VP6ZH$QP? U=F9+
MI[DJQL+QGC\D-\S1!-S;!%Q/3ARW4<YZKM7JFZ[E[+@BCF;"]$#24!U%813D
MG@MTHD!*X< I;)OA0G&J9U[C0_D$3&[31Q?-*DQI_ J9$_:HH5$*>Z:U*K5P
M^?(L+NR [1PX"!A:>!F PIWRL81#PJ$V[A#8\]$*;U,8]IW'U:/GRY2GB>[F
M)0_+7K93J68U[O8J&9C;:L3];/=^X5]FA7HYT:.R1-(04YK:D91@GL=S$WE(
M(E*>%/Y6;.@>7";3#_.A8(4<$D(MH3VCNI1#NX=9G:%MLSK8>^+LR+@>DP/_
M0ED^HQPP21E!!>[\A1M!<QR!&T19-)A(&L-!3 L8&8QV\J"=_F/%%$D0$2E3
M$RE!_JYACV@](>&R3?<)@,5:. -^Z<4_<Q?]8A]H$ NL8BE $08^%:$@$W7J
M]B483GL!IWC_:O[.#X:L/)=GZ>G_ "K8<]'=WFH7^)+5^ 8^20E#7%QM$25F
M)6$3I1/K-J$%Y)"!%<;M8C0/6V9-[3,6:E-Z&E2.0IQU&IVBY*),'A2A.M?H
M$0!AU>AJG5%:XVXC;*7DXL34F7?F#TL:-LQGY;\JJ^,0XP8"6:1"GFFM++N7
MA,BAQAC6_*B%*OS6,AK_Y?K'\CC0SG9:7?V;<=/:RJD*5 .[6S4NC6X@AF&'
M^*K)A=J 8*P?9)H:^!U]A;9>L74295%$\J\).!VAB]0&3 Y/DSU$#SRKAD'5
MJBTK_'(-R79 .[/!3#L.+''FL,S2>?> 1O',T7<61.09-!'IVIN>D)Y'LVDE
M-0=)#,]=YDY=Q9!2;C!0SQ=5AXB;E6Z+8NIGTUA0%?_+W137_?7[)\!-+O=\
MK[^?P%>?L/).PC?!U;RFLW<=P7ZM-QO3TL/L*IVMO!\_*\-'ZJ)132WYXZ.T
MCK;L"X+V7#$[NXD39[(K??D>S)Y:J^5[LO!>(IH.8_H@512/), 6%B?YB85H
M='!;7YN8$+X.583QC7W**#Q3^,VYI<(=G+U+H_GI"I1YV5S+A&*4*T+$&5,L
MAH.2$=&#9W%&MKM?]HYMC%&LDQ8 X!R"!D7O\?%ZO[3N :=#O;E>WYBNIMY'
MNFW=?Q!.N:)<&[(U2J!'#R+[Q<(MI(?!#];JF<CN7[RB1&)ST-VR4SD(4:"Y
M:&\' TTDDW^G%[$:[@^B]>T4X*IY+U0.I=HN1T98OKK6B<2PCOX:_+HP37*2
M&*_09P_E&/*M+540,B7 0 B['X;+CS_Z"#BM>(3SU';H^"V9^4#[W,DXMH\X
M%-8U T7,B#V"#IY1F'$0A3LL\(IGV='WO<'Q*@DSXE'T@$(%JS,7N)=E]&LL
M%,8(I6,DVC$_6!#P4XP$2%!,Z\9M8&%N=7!OI;NFV%*(BV</62EHTI=* >P)
MR@^ /=F"9R!EJ&9DW-85S-ZKD7ERZO&3))!RC+T_$KMIU'TD/[-JP&T["Y9+
M<EL]'(]D"'+>19Y(HZ D.;Y;KG- )J[]MD5O9->>VSMY'SIMTTG_ROID\QBM
M*)EGW3"63LR2CO;%(=P_(AMDQ%Z6=W]5'$S_H_GT>@]X,L_^1407<B\VX[(#
MKL3A: YT=I";PQ)]"R4\$JLAG<2NN3_X).,@'8WBJ@TX[B.%2I ,'O!E)"V
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M%@S9P+92,^6:9L,7&=OH@3D+TX4XD_9YA%"G%>IBYR9A>'78-.&CALP"Z_
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MP/$<77_(+LTT/ 3,K7E<EI1TJ7/$S_\@:0Q# 3OL;T-G L5:V3-''"\N?!3
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M=T8%]8XZV-P?_8!/,[&@VR\;^R=K^FYR9^[)9VA_=?%)\:#17ZVE[URN_IK
MF[\A'R3QROT6I)&)S/RJ4^=+L& _[[RL#0J[3/_JP^Y(*1&+U4'.)* 8,5^!
M(<!2>J&V_0F;5L<I;<!4P>5&@($:@$V8.N6#.:-71%3TF^QN?=&9=S6LAQQS
MI-0ZQ;@_-$8>VA\; (Q>#Z&?LB _#&,/^)E7HU!Y<"Z*72IOK>K,!P :MZG^
M*T$!P2N;MDHFWQ<FIT_#7VL]_.9S#)HHAZGAY N'ZD+P?06Z$40KM7S3%=8>
M.0V&81N82"I/$3*+QFUOPY>O&#*="MP*!H)>.G7]4ZA/3'I7<I#]\M_\Z(U#
MEU3JHM&)!IN^R SU-5A\ )#]%R.)3S]_:Z76^V4_D3D>?1II:V7[PYKSG65V
M0Y(;/?URRPG99^+1H--'3M;!E8T%2PG70H%0]W"3LY]WG7KV#F7KP@'V$?GP
M9_*CY1'[*/'F<-KRS-<C3M=*0H44[^W:]+Q)P<N7,!C%7&NR8X^Q.5>WB^<Y
M$WZX'<]OITVNZ_(T4:PHT8,'L8S*F8NCKM_$RXR"35I^5D#KA-X^&981Y+1Y
MNY:[OB:5C.'7U$(4LA7H'',/82]/7LLQX(EJ32CZ??PKB,>L<!XHS6UH=L^3
MGT*F(2E:IR!9W2Q,[1/1-;P7\E!)HG]Y<:M)D&B;7;+Q2"ZP0P_1FFP73F']
MT=6M>[5]HT 7X<0@QA:0?M_@^#CYB5\UO>Y[*7Y,/9/,>E6(6DBT M_T4P_\
MIZB;OGA;8^"5L3N,N&QVON[42(D+)W5T2W:MX[S B\8[%D9REK]H(#/QL"10
M-OB*)\30G393%\E <J!UANGM,^MI8$S/V&3#"/'S)R4[O!T#)A-,@=!5]3:?
M(;IM?T7K'#"_G;B_$K. S.W+IF;FZZ]Y(K/JH%G9PB4O!L9Y<L)GXYH=1)OM
M"0=-GZ$X1 L_V$24"B4>_@K <%O22)D4/D]@(;#MI)W06Z3]WZ9YK27^.4"\
M/"(2?7?WT^.;7TJE+,*7[ZG=<2(TNIBAG<=$L.Y7(^Q<)U $4?^X2:>';"[&
MSF*!\350SS:/>]Q&NJWV0W(IJVYZ*6)?;T,6UK_F2NJYMBNF8^&'NRT7-1X>
M-U65/HVQ\_QBBE\"5G68UJVDH! )?B;-0#2 W)?]32(0& 4I#(UMI&5"9KAV
MT"^@SH6C(_)$^XHIC-(7OA45K&B6?%NV,NZP)[+#E45/"&]Q&: 9?]/J<9"X
M*HNN8 G78:9G6@V=9TVX_ ^3ZR<U/FJOG#F"\IIC3*TOL^C^W.@T4R:>^2RK
M(=)K710/-J$U[4W#,QT[G\>?$G1WOK.'Q2$M=VD,16_&T>7W9;]5=J2&2_@@
MPW12J%SU"H\VAC'K3VE\/(E3U]NM([)=_\(!/YA%JMVG,,XCG*^U^^!!ZM&M
MTEIC]O*P52M=MJN&],R)FB)MNE(F%<>_XMP2*6/X UM0@PWMV1%-&JVV?ZS7
MNMJ>L)F#(1.\EMY>%-D:U6:[A%1,1489%@5/*=_D2TK/G,W:I1*G4H_S+(JL
M]<]8U(HZ,^==-3,PJVH]8:2,<UG46Q^46-Y,LIA.Y_EGO]*:%'+A)2;2]TU8
M)\ +U3?NE#-Q^'ND->.<22#!@L@MIS#D:+532QR_S0([+W2A&GBOR<5OA9O;
ME&-N)>].<WOZ*EY]N<Q%R6X,BJ?&:!Q-OSGVV1-8!.G;[ZH7G\&P@4V%EYZ1
M2YT#0';T8QS@%.RJUZY:HDSF""CDE6C6E+4=KY0@TG-,0M=6K3Q?BQLY663&
M?0(\-YOG,)!K+U,6_/\<Q_K/)ERQ*[X"JC*7Q^@B/W *8"W>>K>RZ1FDBZ+O
MR5!81,&FV%/H/%.?,$BGO&4J'PN"IGX_:L:5QSA091BXYRS9ZK.$Z1P8^IM&
M.LE,&/Y0:6UIS]&J"5H */OH$H9EVLBJI9;4YY@>E[VZ3F$FNG,+KRHDHAWZ
M[0 HF+^^FHWVV4X4<$M24?-[RTU'+CE@[U,;&6FQ7^I1C9U])!5*X9WVBZ5O
M^HTG!2!9G''66UW&OA4""YF%?>50RV96(R5NK/!LM]'$PY-P)?+C"H##C3X<
M[(S>Q9\.]7=K:XSPS7W(6F-QD5+=4Z3WA0 #GHX'VAJM0 NY?,18]2Q7M]0Z
M-15;/'5AK\KW&:QN+99$-7%^)55/X::67/VH*3U=+_=2*1Y&,R%4SUEZ[U>3
M2VKT'K^U2%,1G#3F"OT6(VWVT1.R"0"<?[B4KYU3LMNSE/@S)'%B2D;(E2RQ
M3S&/Z>8=>Z'XQ>:I>[<,P38!)/]%_K'4S.TF1,NI[?."8!-]Q^X#T$$RHFZ7
M;3(@4/-YQ=!0M[00JT+>ZE*Z3%][OTX!E^2C_-[M-3:C^#2XNC_#61##G+79
M]ZPGO.%P)5DF01MVL<&) 8@X/@]Y$]3U)6L+2QM@ZL$Y/K).O,)JX-X;B4&X
MS^SM)M,(RTZL;M(9C<+X]&W71%+C(6T7-V58Z\%:40B W,6I=V@&I?#1T:VQ
MIK4ZE58N[U#N#53OYOW)%:%RV]E]>S.WI3- LNP1?:-3UR(6Z%AU1')H9FVN
MDMY-1U+$1UY>>UO(;6_G;;L:5^_8B-YV@/T2K%BS!'1&W0[6>T1<MGF?JK(5
M\9/YU=2V=E7P9"77INH/<]!+&G#P7--8NQ*&4)]H:TL8$G%7N1Z#>N@H9.FP
MG17N]B&Q%T8]1Y 47\4\8+X6VCIC5WX]W!1UL_+7Q[8,AHOHIZJ?8(V?G4AN
MEM2G6^U-;]N26C'@S1>-GSGTIV?EJ\HF%, Y64W(;._<^A-"YT(JJY7HV[M\
MV;?K2%ER$P ;ZV.>WQRORA?2X.579(CAG'Z_,@6@CNP+J69*U!0]8;\J9TH_
M*:HB&'NO_7I &BR]R?9&O.?KTL$22:OR_S1/?&1U#Y6W#?+$I[Y7:]WZ_+BY
M;G[^V2?%Y/H"EN(K9CSA+OXJ5X/('+VC5M;[(7,9Y7?4")7TWO$\$B()?J2&
M(132!%-M]<86],E-5]/690!%W#.W9.T#PBJ6D @[G[<J?2NM]^*+Y18)\O:+
M*UZTS*[NF>#JS:EM[H!/0D\(B@?U7'+E?Q;5YE)-V9*X7[=:RI].08;Z,GHS
M+_=5*&-<[3BC0"BNSS9YABW%BMTSU%@LK>OT/A_UU :$3F@T0 T<[3+A.:<6
M4S--O,4E%PD FK"\=6_N.;2ZL"Z#!\'CWQU0/?1'#(,"A?W:,XLT78*N\QVM
MFZ!-C^]*D L2@5HG,;M#_=9>.<X%UUPEW')B7FESQ(8AWYJ6O7,3K8,GA-R&
M;+\+VGF''?M3[OWPAAZSY 4$MXH__#$RC2?O9["K4AE8JUWL6!<SS'%=,+P"
MHG0WM!W!HL17EL#%!!KOZ'W4'S\'!G HD:_YAFVB/OT_'R30$^(U%;(VE*.&
MD:UR=:.59?/"/3N8%TF0>O.-1NUDV][T&%5:32DL\)G(FI)*6V?/TMC7'R[K
M\(SE;97@FGZ$<-7E5EWYMV DLJ3]YX3ZL#VK&RG_#Z6)W#:T".&^S_C$1U[I
M&DWB)%E%^RZ#^ 4T%_+JBJ1.I%#/WHY:L5-V,'BGVI5T+=5'6;G=<LUR+?A:
MHL3',&01+K^D4*RT9?2M<Y%"[_@ZQVJ5!JP69:;L<L%R3.QD3\/ZS^<5-KUT
MO+C\A<.OX[5!H?;^&T"G;\7U;SOM7CU-<-K8SEL(9#2:ZK:M?A*M0;6%57>/
M,*S5V2[>LEZ/B;]*2RFUV+= -E*WVB[GB[78;ZBQN3_7\?#"2FB2YN(()=?9
M27%E[+#/FD9'$*'"+L:\5WR"Y&MV[IT.2G<9P\+0VTL>N@ [Z;VY^@<ZG&9G
M?;OV#YP-/'0L%QK/VD^KC:D#S#Y/D;WE#=?DR"];QV(T4O+]38EO&,OA'MSO
M 9-LGMH ]Z$Q%$@V-NPXS#7OB($0VZB1/?DPD%Z/+$^6T-5)([;.(M<'X491
MMXCJQ&&HR;KXJ4X+F>\M^[^3J'[]GW2$!NL05O&F>%U1*+7&+DW<.'/>H,Z)
M^&12G5AZ\Y,#^>_1C.3R*QX*Q&X-!KH7>152:_6<Q_.BU50FZ5]ZL.Z7RFA0
MDBWG9Q'DFWZ'VLG<I+J_8M4Z>_/?WT'*C2K[7Y9*JM-A#I"E3[;A6^XU)8@.
M(I^Z?!G]RC-PO[R6C5N@S6_9'T!&T.%0?]EQ)=E,)3-I_1+SCMM1L*S1"$OY
M%G+YK)>,OK=\GA_8BSA,\]RUVGE^R2>*MI_SF>/[%\XS,YN)N"##YFTSS6OT
MO=Z!U*I (DG))F3&3C.(1$ZT$7$QY+QP_ZM@BSII#U?P4L"H8M!!6E=]EU[)
M'O+H[:D<B)_UBS:$]:Y&)E+-UTY=PI@I.Z*C/]*U(%&J*,3* 5RWICR+VC>L
M8?=NG&%QG3R_#_EBY6#>;RL9)!CJ9MA9LALRPWMMQI)J[6/%D*>_Z@3L_ 77
M361423 +Y]4:;TK+3+Y7U,7WH1*PT+M4\?V!L.X7%Q1'OC)M\H@3S)[W,,N'
M!:>K.,C*\>3M/*0533W=(+_6)<75&@>CS*\59([<OKI:AOW6?2[5+))$;."Y
M(!"R]Z.KI,BGJ11VYH4:!'7>A/VI$.++WV564&XXR-=G3[*!9Q&8IS#W]<()
M;FI4NF3LPP(!A<RE8N-==7%ZNWPB5'/F:07T0=<+4,??M0.G6T(5C/T(_9:<
M#27'8*?.\TNO%K$SBG-Q0\/Y#Q)]SP2+L(OGY.XL-5TAG_!O4H6+O[F*Z[,G
M&IOFQROXI"T0L/O8TL>_\L5VO1;^MWX-60D5RVN[*8HR[%-!W<? ]&O"H @-
MR: BD64+P,<L67+(^>D@K_;G#*/A=2I*?1F%HBN]*R&2/*J'M](R1[I2R0R<
MVX>EH(U!2]J>SU^#UQSD GB<EJZ+Z[>[(JX[<P@]125Y4U93=.LWU#5=?UEJ
MDPG&92P@DUDIF4P%\8]4U8B4HJHW8AUXO9*DA%6>F)JI@EU9"\B$?UY3C*%M
M4IH'S#J0QY%LW6*=UYH@K:,,LAPAQ5!<IURKA8Y>/,6Q2\_KV)/%#YS10C.1
M&I)XH^ X\L]G[9.T(KM;:C:&0KD,U)"1Z9N&UV+)S^PM_6.-N;J"-&.C'6>V
MSOR:]0-"/4]J9$^*M[//,29^W/1R/;Q,<>PF ZKB'V^YYXEFI7%D\'!T^GW_
MA^ ->*B\X A5D=<TW\U^GPF\0TF;74([R1\7LEYN48ZF9XV<=JDQ1*:0?'CB
M!]O$RH:=C'9I$*\7$\0:U&/UOBEILK6Z2!*7O3T726!F$/"%K7TUA=\/1P;W
M-'6H>Y4A7#V6]85.>6UY+#8L&8F3=0ZQP:GWV*:S=<1")D._"+/_TE93+K+U
M>C#%0;QT&@6DP5'9"O:'Y9?ED+C2GV$,"()1#=\L?[?])AQ!+6,W>M('MFA^
M17;/*);4)M!6GGJ7RYL4J]TR,NDKJZIAX[DU+@[JJ3W,S=&:H*8R)T<ZVG(Y
MOZD2X=@>"ZF9)EZV1O/0$RHOF;ZKY>1R72Y%^]MB2S0VLRMCP-+*V^#JM@Z[
MM>J)OEDL9(0!XSIK](4@V:+XU>+//'W$.E-6A->#?=:$$5U-\%4ODLAX\:+:
MQM-5')%WLV> W!U0B=3@0C%ZO!&(<;M3T!=WCK,6(I;1*SDV)Y \VPR:-A+M
M20@@4.[!FY@S,07K]XT465&:LXG,SORSW^;(9E?S-<Q.X9T/U)PW8J9*XU*I
M(%UX7(+Y/*G=.*38@('?%A2IIVXJ(:U;OR@YW;$=X#%A07M='US<$$G5&:+.
M[[[+:+?@;KOKWW=#>\Q#Y_UBU;LB//.]RFH+CBYGQTK5;&>&[+JKO%WM*H:]
MF*Q!UJIEEI85TZ)<*#H\Q[Q&56X7LC!%X(4Y1G0^4HP$7+GKDB%.J*QF &^=
MI/0L.G3X.O<TS?%R2>2:W<IN#3V3MJ&<BZVGU@3J9>OM6KN5Y5SQ,W5-ICTO
ME!@88 M>VJV]DY%M#GV%6\QVKB#$:5Y\/G4'".DSU=;;I[&?',#7>ZK *R39
M&^YR(ZA5Y47'9U](0BPJ8K?!YY@KP&/VZHP*+/Y_<14TQP=>2DVM92&_[2.+
MA1L)'_)F'?:HNQI55K9M!)EW=15LZNDA/P"S-#6^6HX:U:X=,T9E'102.%1T
M+Q[>P=J3193N^//;KA[3@UE<M74JO<<9FZY*,AL\4%<9TY(V'[R;P%[U'Y/E
M971,:$ SIJ,GA@ <-ZJ9=\5(GZN?]I-:V(V1"T=,Y_:G+;^Y9PZ&"="B.KT6
MOJ!H^*(<+YWCTGL%YD_BA5[77=/]./DF7<)R# J%G52N\E#]@=05Z4=<=^K/
M]EK^S(05^S/=M@NVL/C;IHT4E\C#:\^JH+_&K*.8I*/LL?$-FI3N$C(Q>WT:
M7/5%(61=[D)0B(JBZ2$WKE4?8JF&R_00[O)^:MC_NJ85F;K3L[!)D"MK(<R=
M\U"DK%#J7)?O,+!>7/*DMZ0.%O8\0$XOUJ\9K#NK59O@J!]B7;F=5#]_3;7+
ME3U$+@_-$@,-_J$\(O"_.D:-SGV'YY'=SN0LB G].I6ZJ'M<BGS?G$)W)#,(
MUQ6T@:D=@>Q]QC7<#9*'-^X'(KC.E5\,ZM E:?,H;R-J2Q.;-5+5?)C>=SLE
MW>RPKGDU^I8"K?E'ZSO)JL7Y'P55#?V;$0V?X8&Q4#.IY2T2'A]BEY3?7_A*
MYDV).-)4J^;EJ5TY-"Q5_=6?*Q#J5O148-EWFKBK>NEGK+[_Y=PVJ6D*F1C,
MSIF)WZ$,DN?F<5?9;%WY$4:XN*;=/$RN,,F@ $X4;$,42D_^Q@^YMR289>?*
M1!=+7]K>&*9_V.A,P(9MP;0H6<^X%"HE1S8=TK_R?\[+\65U>V*S:$S"("2M
MX;4PWL&Q,E8X8YZ\P*)6[_J9>K6H"<_2.NV09:CW>NMN0\KTB]?R]30?,*[1
M;E6-;]DS"K(>U.?5W)ON1328;%;3JT[?LL7!D*4\Y@YEHD!7'*W1-113&7*Y
M0U.-3$@4GEO<#=N_ SYF+/GH9\*II7<MY^V"FK>%I_?T)A!EPJ2/[>43Y:#;
M^F= MP8=& =%NO"23LTSR.IW[50]/#G?(+V/^?<YJA!?>XF>-!NO$_YT/6:&
MW22VS+Y^O<N0UZ,88-MC 6*3GF1G*&L!A;,LV1!)(3_$@->X9+#P,HO+^E\X
MCMKQK&&X0A!KW#N@N; F51[-AN^\R$Z%&K:S(X_VCP7[IBWU6(_'KJ^Q0S;X
M:1//XK#\@+VO_\Q>%HVM$H09WE?AB]N-&1H-$?WEOZSK$/;;J25S:F_?W #P
M3\#>-V*M=N,GC#0UT%B/EG_3(##DGIF2N+D9TP;=5"0?Q-50#PR4J+4OT\I7
M<"./?%M'7?:.0912JMHFKM%(9YW1.84SYY9Z5'/Z/V#TGI 1-X:'D#,.ARA.
MDE1^$I<RD9LRONPGZ,FD8JK">=I35&!EB$XUQ3QL7K+K)3V<T\"H<"$=;:I;
M.<U(;OPB26*:_2,Y.G]J[DHV.; %KOR65(19/4EGY^OR#2"E;C&-R&Y1#Z E
MWYUK>W,-%(%__9T"E40Y':*D11H@F\EL0(FM?I5LXOD'-I9K3$;!:Z0OTNT;
M)UE%^P#<JF-\UT9AW.;4._.)GY<%;MXXF_LP;P,>U^E>JQF'R8;B!F%1M,NY
M=9YU2W50+AL9<JLV&^_LN7=Z(O/!]OG$U>3><PMJ4B\OP+9KR%F[H6 :8_H3
MFSNWJO&'\P[@6X\O&-V.O!*&5[.G)1.&UC$*O'B@LV*HT<S3@8]?*,(BZKHJ
MN@-'KML>A-0C0L8H)S_I+[ITUHHOIK_ ,$>S6OCR68&7TQ5;>7W /LIS#B*V
MCD!O"8LUQK]OB-S([(OBAL1G[\;_2GOA!SW$'279P@X3YFRYS<"Q![84Q/_"
M$6'1SR)6U8?:F]I8CF=[-E7?T*['Q#E,UG24-, 7B*^3HQV'7R@/-*64-44\
M2>=[(OTQFU6YI\#UQ4>"\SE*R3*_D@L3JG&I]/18_<X.9W)8DQRU<'K.'O*:
M*-<D)=[ZW]I6;?H;T39S$P\5F.-*-T+P%FK4XV>:C ^B$*Z%& 6EO$1/EY-
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MYN*FJ)(M_E9G"9+-"DFE4A7C]]&7-^L;.."?W L[5!1]XIBB!WW(?AJL8WZ
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M!1Q9ND,O.I\KAP'_=\9JT]V?J.SVQ3E-F1;/FB#BR*4F(FVVV,[-]%,0:#I
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M.1Z?2=EN-#)!$$(#3?9)3+Y@/NA*:_8PBY6'8\V]5D-PF]SJ%=P@6]BF9R4
M\WNE57+O^HT*U!QZ&*HLG"7T&*G=5LHIFY;(7YC'"M^VF.S^6B]$MH#1(S/-
M,'T2=?=D>8M^0.!7YM84=>;:VV%LBR)Q5%W!&_;B=5*Y$82>R%SN+[ECX@*Q
MSW$>0^=8+XRP',3QM\JO!-7SN-.DQTK.)_TV#D159YW3X(/GN@GRK.\-W*T,
M=,N][D;LK<;;S_(</\#H^4,2HU+6D&>E<_JRB6NA;!93>P)P"EEBA@W'9K9J
M8Q(2G/:ZN%%'G,$+)O;6=5I:"8V<-$QW2]+0[L?.6H3G%=#/"'!Y"72[N>M4
M,TZI&\'F)R%MS2>!QDQZ*89D:-)_*9L.E;?F5,L5;!R+$/2WVBJK<NI%E6=*
MBN2I4XT ];^P:34.4('$,;YBXC][)(O#'%OX)Q_EZ4%._F$CP1"ZL3C\ :O_
M>T;ZGZ*I9&KE?--V&^++J]Y%[64'1W\6G-P)S_V,T5W7Z85?^7AL5[G.8\1P
M='V')=0ESP?HULH*55GIBU;8%*YIX'%I *34U+P(.,[?/6X#YC=XZB^D3YT&
M)-C16LN@ 7V_;_].]8&M_52S:Y2%XA+8'0P*ER(4*TUB8%1CZ/5*^J"6<HT!
MY4:Z(1G3#!;@A+P#XV8!<[['IZ@<UY_+ ;68K2%3!:5E>H"]&.>XH=&("O[&
M[@0!92K V<K*[\67MM(JC@3D%+;]&@;H,0FZPC1L7L,6N/(5PI;)A-<0G!DS
M\>YQO0&74%*71\KIL$ /2(C*_5:[:>D1*XN[BK(6S<:O;16@>R*.(&ZO%[HS
MFFU^VL6)OD)U]<OH"6P*:0.I2IWN&Y5@)<]\<^70-?EFGD'][;N#A2-N.L#J
M\HJA&.-F_)5@.K'@JSH&B/X(&Y][16;\BP=ICN\[H*,]-_]:8P*_Q!B=/Z;\
M#IWR!$MD1@X6FO^)J5(',AU<>GMSI1A/7[D+-[[6'*E-XBZML16/+'-II*O<
M/4?/(@C 2,.$J^F4Z@*I L.^5UFRN-(D&FA:6J>]G0O\ISK?P_! G"W*UL#+
MIH]&1FYQRU^:^F!..]\W6<7.7#76+33)<?WL_(OUUEE<+KL"FKE?%IQ=Z"K9
M)JFX*2;UG!]-,>PZS\AR% D!\>JF:,#C6X&$C0SHSM/TW.HGCEXGA@8BPB6F
ME3@OE)C0  H^U6#K5C!>( =/4](PFNB3LO?%JU'HBO3_0IH7'D[G4B'A*/9)
M[9!Y,=L?\M:*C1N(D2 +&YM0ZQ**<;TB?-0HID%9+S]JN'.5ZJ-2S#B9,24G
M$Q<RY=F]\DWLT@4I&_A_>7[LZ99Z8?N:C*A5UB4+R_[:G3_7W[-N?'+L7*ZN
M#<[N\C5 D)#-4G5SU@1&!2)G<4T6A9MT7M2 :]I'_>,70Q:71K)R:LE5%;6[
M)N+HQ-Y>)PW\A[9<<^ST3 /AJE53/45-RA'$>9!OBO^-S8AJS*NR*@FM ]G=
M'<EYFFRG=-07@5(*3@X2_#0V]T;-BUOG3)BV!G;-9Z45BPX/!G*.I8U#-1ZW
M;^ZU8ZZ-VV\T#2_X0$F6O;E"$!UN1!5R*T#-HJ4 +IF1*?5LF[M=R)1,DT(Y
M=\ V;[?6@2L4#S5/^^+J%<80#]Q\>;_3S'9F^7 986_=*)AI_X7SN^;#+RUV
MSST5\.!./7^[ %-4:^'BI[GGT=J"\C9JNHEW E\<?K@ZY YFCL-].Q[PS' <
M*,"<VDD)(GF>[KU+KT)2";AHI(J_,#(U&JM9KC*;-K?+R2?B.1NE!^0ZE)?J
M^%-PX0?6-L17BNUFH*H]F&39.XG'5K)?18X><>?%X>((0<2@4!F/+ZW65B"C
M97TG+W<(I-^[+I.!N?E]:-L7$W,*&M[BQ-W8P6HIM?7''H2-8)N6OLW!OO6*
M]T+=KGVT<"*0*B,?;4)$+9&-R<NAY(BTER_LJWL'&:8;&XXQ_K>[8.4WE'-2
MR P"2#]9+'"X'0HA;)K!KUV;V/C@E=YWK=#,K)"]<)HB-/&H+L]BB,H^&RET
MB%_;X(FI)-##W%+ R6H5\(6KURU^*V0^FKO9:)C"C-;]=TM.Q%%[M8#??OWZ
M.9$!K+7X.TZBJ@T]2U43A7F]H%>(?ZGRT=GM5ZOFA"C#_12I?G\$7[ZQL:'_
MD7&C5ZJO)>ZJ0YNC&[MM+-DY==.7\PI..E,NGWQ=!)&:N*7.1E"+"!&+6BW[
M1-C7![2320VXJ( ]@^[)A1K33O4-]\46QB>[S*]2."19NIZ2/![Y O2>VV!6
M?3DCD(E]KS-Q[G)#HI1#J<\$Y%-%:7$,\H@6]D+NI>,8I+]0STZH>2P6?6QO
MD5-% !T>A9<>?EIN&[99W+C/'?30)[-,>>L0.T#3J'*OU .QL#4[_ Q1T0:4
M2HYR(J9*W0[\3I7(&M1IS.VEH^+HV$VN=K:Z#JJT>7)9=N[K'!C;B_CRWO0P
MBN#[,-G*W(S*0:8>NB$YIL?_N8CVWU_/[F.>9C@W^NW0ABKZK5;'BBVQ$K\-
M./T^^U;]GU]\S/O9S[I__G_*-\V(F49)C>$*>Y4@D^M0R9KN$0/R& HX9](V
MARYM]9 T1V63XM#VVLU9O(SR%2YJ@BA0984HG9IS5GN"N=E"7(0F>8BC(0/?
M(3B3AS(9Q0Y)U>#0=\G?GR9&5&$*^.D*2-@1%!4Q&L(%VT[)V?5T_ _"<:C,
M,<CBL*T>\'O]'_ZP1D7;O/W/:K&P/68UF-X5'_NIU+BU\[C*UX28M[L-DCIY
M!!-%%U5/YIEP<^E9D+RFZ"]Q]"918_?/.I:E/.O ))*=,.-.M20=8?N>FG^:
M)O@6$D,9C48=_4?]*[NZLQHT+=<&-%^9=G7Y'.F>-.B]*HCBD-(J(2NBU*7B
M([2B@MMGU*BZ:HL::B/]4U2G[(/LT_^%071=7\P*'G/+H!M[G?K^HQ+5_[_#
M^B]ADV5"IJ$S.$8%,A#ES(K")7-84E_MMGA+ _TB:BU1C*&H7@R1_<<-%'@*
M&<HB-0Q)92IBW]Y88(A^"M>D#X\/QK2C@68D8>#'I?]#3;'(B:KUG!78]YD.
MH$?&P.JW[YS<%*'Y7.2D!B[IQ<T+SG!"'6#6I)A*P0-&>K(-_?7U+BVG?=4(
M%<>,0L4XAKCMK*@=IK(@VS?\P7S!KYBXS^XMZ&+"]UEDYPS(H9?BN#Q[L:&,
M2[H3./GB>HJU(QP)7,4VT(A,NYI9F68&XN.R)+)FT:?A5'+?TG0ZFF<[ST-E
MSI,#OL^*_:/"TZ]1I>+KM-1O(Z*V$L7[6*/J:<<?2D]7JZWPYF3.B]_N,TLD
M[RN&.-/OTAZXX8LH$LN4.;.\I8\@A=[>S<KYI('FJ(^Y\\(/@EE$B2%].P]!
M88_[2K\A++*S<K>CT.*?SM%OFI.P1K&9]MEFY?9E;F:59'[N*UW\<F:1^4^%
M:/7PZDT5-;0T0+')+XF\XB7TC<-DMBE9CG:)@:4 -UT\[-LPUD'\:Q?76^V9
M?V%P?'K\NL8S/ '*R"(E7*A[4=G>W;L$KINF2% +I&9^EZ=;NLD!?3O\*NHV
MYL^IG="EX#2"3Q]\<+37I1RN:J(%I'"+X2D4#:]((ALIS=^E"BSP&JTW:TMF
MA7#G^0O+ZUN,FQ<+%!0EQL1DR7'K?,D#L5?HE:DY)/QRS[(E]N5"H6"ZX629
MY183DP;%2QCJ.766=35]7X5 *?*V&H)N?\X)([?YDV0S]]#VL3^B2R8H(G(%
M&7:.UJJ>Z9PL?\5NU$],$A._K4T3M!VD7;?8!/2-?S[DJ7?2,Z[9UX/K$X%_
M,9G3XB(/KH\=B8%.F7G4:68F?O+=ID)G*3IV$W]LH[ L1FUEY_"1_SUJ?)[.
M>^?(UL4C2:27S8](W&$E+9VN>#\5S.GQ7?9Q[("<-JRG=,>28KZ'/[F?@BKE
MRBVO:I(I)<3D'RLX94"U H4++&VM5M*FVMN ?]ZE?G;L(-3TM:)GM&VIW30>
M/K ^7-2X2*%R628E$7Q.-"=+A!QP)(L/#AHB)R[+#VOG1B$Z:PKP+QT6ZK&"
MZ"-;P&FGNL4#>=3AYIDAN9NQBS]^\4=%EU 2\Q_EJA;4:S,FU>[>$D=X93&5
M_/Q.49)\S#''69[=./OX)#\YN4D[P#!5O^BDQ5P@\=X'^7$#C]VSWNWL:K#+
M8Y@CIE2R(E,HRK2ERR$F5X:+BZ4X[[C-<\8MFQM8P@#C@1L:.9I)D^X(F109
M&O0HK 0,IR^2+Z'+<F8XCQOB8AE^;G7FCBP41''6<B@DBO ;',$$/DP$C4:+
MC F =X"!/WR_QJ$);/J5/ ^ZP$5^ 4[73=Q2?9#@U1N=QVXANW:F]-5T47@X
M103^-C5O$5=&1/D0=S:)(]T1N/HVGI)E"Q-A *V-Y!!5GQ<H79AA[V!H,$O<
MA-A24J'43"<#Y/1F(2UI0CZQX<3N1[R0,4#Z$T=2WM:$[8?D#@4 R]L)@P*C
M,18C")\-T[LQKN47S'7=."YKHMUU)"UZWB"2^'LK7TIZ)HTQ5POV4,G*Y\]"
MGI66SXS[>N'S#L=RY% 9J6-H,-AB,"7AF$;_&XA+5/"8G3,M++>*'6M#*]&5
MC/RI8'T>/UQY!7S"&BD>)Q'-_\V 2>;,>RS+67(P9'#GP!>.I:538AEYIU6T
M4 ?2IGH+ZU%G:]<?8RB[>&2%H$#SS85OWO [62=&-H\Q(J+)HRW\,ZIBM.U^
M$'SV_\5!J2%^<TD1X.N6R>GQ:<6N;7'"*%/'],;C_IQT9Q/K/I*IYNZEE?[Y
MNYU_8=0=W%Q7=RWU1800)^$^^+(R.7<MR8R&!#N7,T$02>-YY9B',(;/GX!>
MXNQ9R3=#P>6C(<Y<V6RV@_OTYZGEI&'0XN!]!?Y?'F\T2$040XAEKWXZPT-N
MYPP>7C__\)HE_U>_S"XMV;\PV!R2FGMU.$EKZ"M;CE#?TIH,^'5TUI:GEY-7
M\7BXS@W(M'02""E(36#:%02.9.;3=)$8\>;L$<NTKK.-%P%IS TOSCRUG@[#
MYQ_8:I@;'NTG&MAID]_+%*/2TOP/VAU9W!U+V+U5%63I+'W3A0'UO6<Y#+$W
MTT"*G%6;*P;JYMY@R)?=V_>DU/_7]=U3F^2284UXZZMBJ:HP]*L>6A=/K3ZN
M=]AB513K^>-1%O"PC_9$/WJ(Z)-R'Z GX1?7.W&RN.*^X;=C^)7PX4M%F+^7
MB&,4U;#!_6MP$?C^R.J"@&2<OYD8&#6(>&!CY6&$OEF7,#V2?930\\6W8EPL
M&\1/EB#L<^";H@2_"ZHXNF4T *RV\5AO=;STJP_TC.R4T@CRD;4SC81-+"=Z
M$3"T<LW+F%J;PN[V")KF/^?O\^G)AKV%CZT <8B*\V1**Q<8*-Q)ZF<^-LVJ
MM(;*AXHZY\5D>9QO;KZ?LLB-JO\=H:N W(Y9C$A+;*[@SM2@Q;+^R $MGS7,
MXL!L9//)DQQ>L'N@GS5Y%FV\V'%Q4 :8LV>3=FJ$OT9<KB7H[ ;FB%AQ<C4B
M>Q<Z>33"5&:UZ<6<6QFY O8+3;T\@;%2S4JR'#X^KH'F?M#*YX0LOU%OW.5Y
M5[5' [&X-BY%7P?;.('=N![5?HG;)HQ55L:B3;.$I<C+"TKE*5(+K^Y1(U,D
M$T1RFJ+OH897OP^@!4+RQF 'DHD-=-\0[^UH4P_%+YI/AUW&CG.^I@!FOM90
M$H6V;X$[:W6IWUL/4Q;LJQ[(:,1&RCO$]^VA@9.'[.FFB2B[=PP)^-O;( E>
M.] DRGZA.ZP"0,[N/KQU:K;]\VJ,9&U!>SL)[KSD&;^=TKCV?G;][V=@1@QJ
MLB;T=%/Y25=6#(A:X6.R%'M;Z_YV.J(7Q##BJRY^G"?:UYAB^X/14%JRDQ]Z
M'^E/F3I+=RVS%*I(;2'=YNRU+O)'#.6*D$?^P&UDD[.R_N&V[L+Y0H7+.;K;
M%#[%IQB:\J02W/1&I&'T!KSM['RHFB>S$I@!!F@P?)?P4@08#_7;>&\T#5AO
M+2H8^K<F\E P:QF#E)%<ISFYO2A"W:1VJE9VD%%L^/X4Z-FD<7$^6XPR"6;7
M;3F+J*F3TK^Y]=M9:-K+YP/?1U^RA(E]>RK8I2F5%Y+HD\J<V7Y761T@ /$T
M>[R91K Q"(5^HC#C=W<!Z].WL+(X>0T"_@ZF3:YVK-\_K#+7Z?AA.R[S5S@"
M.'5X'''H\BG["[U' '4/M;J=F[_>>!9SP^/'S[>C9^$&=UUQCM4&*PAZC_6+
MP(/U/PENG08#_5KN/X>GY"65!K+9E=1]GAQ]K3I[Q#0K="@.J\6]M80W2:W"
MQLPZ6]\XFTQ&=;:YMR8\ ^9O67J]V%CECC[KR=FU,:#,_B*98BH*[P%;DL8W
M6))B_^5,0/C[#'_)WU["/(P>B1EUX(L'+!@*1PJOEP/LB>08-YBKS1;S\&3/
M<3=K,CV$$@PF2\\[WR'//4?*[L55=[4AN*B7:'VL^'+G& /WO8_,Q8.9S/J^
MN0K,/"8^'$#4F%!/]H_KW553ME"V/?)XW(Y-P[?&'&%N'.3;GC,I&I 93AP)
M" <EUY/H?VUK+I:=)=2)(;2G)",^4!UTC*.G"?&M0\C_MS!CZ)"0YL$J;Q=X
MP8"P-\K9KWCW:KE<;]GZ+AD]I786[CLU0!PS9CSL$7*!#N![/9QJI6\36NZ.
M8>]3S<>;52@17R_O;BE%7S.[P6EV@<01SPYE1)[3*L3FQ>F\,'KE,CC+&B/'
M)1CX2KA(D<("\+-8.XO%[S&[CFP7VM]8(IHL0'Z[W\14\#$-VY+_4G5&"K*\
MJNF9H8EG43=#@KJY@(EA=6C-+W"]3SWJF+9NYZ=DIJEY-@]93^%*IG);:HT^
MK.1=_D5O7^=#=Q>00_FD^(/YI=^3>8X6LDA:[(G5Q+DR7MPD7NY6T:]^MBHR
M/\<.ZX:#I=UC?R4)7_GC\_)@@D^$-VFC!'JXOT7AO2:!EY@!Z )E[MMV5+OZ
MPJ75PWL4H-2=E\*,$[ %<2+77%H/F.[?EO63;P"[;6W:J"!3-8G3\BZK46[@
M0EJ1-"U099C6:^("*. R@(5FV?M0=P-T:F).>K^#,*(E25)J3 VJJXE$7=7D
MZS%LK#FV +X1P@Q_O1(<E&C]L3GU)X9;'9#(IQP=+@60;G0R68T#==95E1"C
M#_]KQ.CJ=R 6O 'MZ8_P.)NSVK;9/QKEZ6%PK-,+>';[V^B0;Z%+_23_R1)3
M'422QC<>D-,E;"0HU%70D(V-8+_HGLQ0VO!"CWF&96/YQ+A-3[ZJ9IB>KZY-
M2?%>J)H1N)=;4\T/IO 9AU&L8J]4\-BWQ/!QB,;4)(EB^H,QL^F#<IW/-B\F
M$]<[3?]WSS$1<8$DF;[K9,XS<TQ'">BSXO=X\5HAU:Z#7?>-B&C^80Z5**I$
M982&<DPMWYS6=J5+:5X^V%_8>P+_]G/*6YPA/@OH!;K[5>,VM.:@MDA0/G(^
M++=SY?([NIT@Z@*G3@+[76CVAOMGMX:FN!'C%IB2C'\YAAIB$+(7**DFC(5R
MS"%%(2:=BS [6!5S/@#J/1*LM$U>6SYHP"HWW <:09? \_/+GLX'O@W3+JGS
ML&$'RX*JBSI^WFP7,9.659FZCJ-J+?G/V=D9O%BO%"6D4>2/',*HR.Y55BXN
M+M,5#L?3!Q>;Z^VEH%S%;W"ORUI^>HC31%:+P8FVHJ+\.[=5M_YGS*]?&&PM
M?CJ87"$B-/_E4<U3G,</#)GOSN_,4I%:3?&YMT_BMUX5FE!6LLIVR540W7A7
M+_>]B8(?O_*YE389HA6I$^NN,5'IA-^ZTN9S1*_&<@'*H(LG5)88I_Z*0\=!
M2J+O/C<")BRX@S4E>U%5?=39*FV+S:QAXDA]R*Q_/_!19L)M\J9&<@3>4*:Z
MT1[$;_5H:;2 :OFAU@*9C-$4,7RV6$O/SMW\<.'5\;4L)T8^5N:JVBEV=#EH
MZXV=VU.@#;RO"F#':&54E8B%)P]?V;T_;]2.*$V8QE.UV.^T+2A'6KXQ:NG0
MSA47+6(T5S7$0;A/Z"5!C".^; Y(Q(]X:/Y#U_VOQ^*&CYZ*^?^/H_O_)>*?
MM!OP/,*20!]U\B-Y4KS7W]H,Y>?K=07] M-%,947'=3H#Q=]:$$.'+(VA+Y9
MZ+)-YIRP\)9>^CH4WWOAU53T#KP1X40KANW,T!34LP5QIN2V]I,<AEE+-RJ&
M4^?[J<0J9/+%6_=5<,YVTAD2T-;&\?M41<:6I52"Z^();HV]3_*>C"JUI/8&
M:DZ)? ,$D&-FF]G*ES&2%XOO>Q\*%C=<[Y"A)%R,E%LQX%,*F6@$ZC*C8-TM
MBSQN9;G&P ']AWQ]-P 1+!+R=Q(>/T*OJG8JT ^Q^<>J<T<TORF=;-8WG=(6
M0Z46 =!5]DTYWA;=4 ^X@-OAA#8%[X+ YG4"OY,/0)A'2#T$# MR'^L**BS2
ME^)ZLC_?+MC6CX_;6BQ4R00OJ9OEX(#;JQK8A'\<-8OJ.<_5LG!G!6-/.AVR
M".JE1-D<Y93*Q4#"BPP3P!_-,:W=NK]$9L:Y%U1L(:6F*<J""-$C#+]Y-< 2
M.RROD?'-+3S#]U8A>!B#2E/W9LC6G6^'(+.XGDAQG9.G;,&20(^M0,L+9'?Q
ME56[/MPX5&U33E>UUZSA*M>X$$?"WD.=:F+U*>FQ%H-/;Y(RTP): 8'U<2=&
MD6,O8A6*I<<G?6OO40RD,.;NSW=+V<TWW;AL$_%*"SPT.+>4,$?F?U\<E83V
M8)*P.0Z,+]4BZ.%"O"T[+G**[*^8?$%]0U) S)I/6,;U49??+AO=K_KDF=KL
MU\N/[OQP>Q;)!0BN2G",27N*Z]8N*MZ1*A:2YA(0YJ2<7%>$!@8E2DFU)?!'
M],+,;8L2KA"\;PDZ^:M'GNFJHC:*FOC WR-?TB>L+BPWC(/W+A(X&B+-V0J[
MOJ\(B+/N.O"\[*_W?6]C82_ZRL?7!%K-Y!HEZ6 1]6^X9*3XKS#Y>Q];B0/A
M/HGPXV&EX#F#TC>LS^/>/'])2CGS=K!L3L_6)GA6;!5K+%7A]_>TZI/O-[NT
MLRBY@%/J,@6G:)AKFDZ@,:\B>WIV67FVDS8PWY'/(!!#X: U7K0UD=5GZ#/Y
M5ZQ=&OEJOL*-B/K=VY77#.Q\5I\V?*?HT[)K0U/)*\1T<B9]RP=7=%:EN9)6
M$>"^D<$)>]0L42X_J$5EK-3VLSKZK.^?Y,N/VLA!V%>FH%_K'AOPLX>'O/?1
MR)]B7IDYLRJH6N7A2EPO7)55E.736T:':*"+ZT7;J\83/RE3Y,NB=PT40/Q%
M+MSP-:H8H\:;[@88JH0N)8)9+H>JU'Y."#%,[TI$*9>?$CW^.S)DNC/6QZY+
M]18IRF^31<?V:>7%"0NUA5?T*MC,W%8%P;LFX4'*D1=$>W<*Y/7U]0W+Z,4O
M[QD_0-*B4H$$@@ESG.3GW[P;O4C=E%5P\JNYR+0PU-?J)E/[X 4.Q-0]M!/W
M"0HW?DZ*\*$':5;K0O,;P&)7TAC<']2\]Z[A]UZ+=RVW:!O^M1=EN5Z)#(:A
M%O)-*+.X<#_=F-7QV!3=^<>^?V$X?\3O=?C'--!?[VU868/P>T. 3X//0YEW
M(370XYVQ,5;-@=U5^CD]9R;V/__?DMO5+)6((+_BN[_1UA*[JY^L=ZY"('-P
MOZ4O2S%,GD3KR7=C5L'.8TS\+?)"K!9CC18S?Y>8)RUMQF.';2GI7[9MIPZW
M 3%0?X9XUV.S5NFFT]83#[XY'8*I"'(%[F;WAN<PL;&1PF0I'C#"DNU E7F-
M53Z#SZ/VAIO9QUFKBI*S]M>!07#\<X[LX 5@.T4ZEW.&P@L35>Z#03\NVS^P
M<U5\;!K41B*'BCRG?VQ__JM#?4.^X6%//S9A"S#(S[)PH\08,)TC]@NX=4=4
MZYB%YR+ CHZAOXM5H9AD+Z#";@4G:=EQ)B,%FUKD,!&,8@"'UN.%]3 OM"V$
MR0('8;C>3@* E% Q1)F&Y03D@I!T^Y47;_FS>67EC2?JERIEM4?9"?V>2W#P
M;DH(FW55M^Z_M@#LSH'P8>;4BW--W#JLE5?U7TI*/\)C.\DN9,\_KX16)%3\
MNF):A%N9S+SZ6:6=JE=$4*S-)XL3/IF%""I%=JO:3)6PJ.MOW!KPX_#;YM5F
M?+>L8Q:4Y]L+LJ6F@FI=,GIG6*0B#]LIVG/571(H_90X82@XKYMQ!#>A50->
M=O7'O)) IZXSD=9Z,Q3Z[9+#"B*P6U:"(S0)XCV9$MM?O7!C)-=1O-'0,L(C
M)1@I6F:N]78H?X6$NS!Z=B\:\N*:QE:GELT &)"#0^438VKT+4NLPR)[9PBJ
MQB-M!J&>\K"0R!ZUO?%=A=6CX\=<GR'OAGC0BA:\^D,.#M4ZVFKAE:FSB'/^
MKY^<%>77SI?H3P^+(4K6T(], =]_G!Y^_%U\RU^:S@Q-[9>]'I5S;@RY.[WZ
MU7UW<[JD9#'Z5OWI_PTPR<[_?%?P&Q)6#.TQ!E*3>GEI619E8K\RZ?.MH&#7
MPTC"I$^D9A$?YVPF4L25P"5[IABZ/J9WRWY?[J-\DB%WOU)K1=; RU,%3E#1
MR>3C?'OVS+CF!81S;R2-++DE7G;,IN!ZEW9]2+A(J:DL-UO[!L_Q,T?6N%H.
M><HB73&JA.AW\"%F 49LS@1L/(9W)2LCUR(?\W-:MRV&;0@Q!IE6LSH.+"2A
MH5$D[1^4LN((O/UK6/3QC5U&M-"WI 6:H ]">+T/)'Y$1OQ$GS[- RLV$V3*
MDMO*1)L/.&_0:<SG#9*!?B=1Q)EF(J[+A=1,N1XG)6<Z5X1'"@"!;>"XX92V
MC0&)AIU^(I37PRN#>#1S_N X6]O*X#8Q0?!31J!V:O+I80RTXX+JBZ4;@?XB
MNASEIDM_1+?8KIUS,8A!7YS++YJ<>W RBY5(]*HH@7\5%9VI&J'CDPG"4,]W
MS(G1%\M6YOIA;B6N*59G9;5SKLT44]XR^(A]<K_#[6S&6Y2YEVS^N66B@UZY
M5N>9%D#5]]K\\XMLEO,)VO>RJIC<HL-SK[-M>0=9H+'/5B*U, 29.&9FWY$2
M$@33Z$U$?A)EPE<]#3^6X6X^6UCOTI1+LP30=&2]W#3Q%%(;/O3]WH =.]2P
M:SC:X3R=_"\,O3V="28H@3,+)?4SW$8>= ^\!A>W#$N4;I;0<"E PW.8K.HM
MJ((&&BZ@IW!\*X-YF"9[PI0TW"UX=X(1_X;E1$WD19(,?V^$_2N<;2%M7*)&
MZ#9F&5GWON+6';YZ\3[<+_GM?O3[W[2?W7^P8=L975U6P<=SHPA)P?G(T,M!
M0QZR@X5\,ELMK S#/#SV42".V"^CR&NCDL54 ,+8Q:K B<8E="29X[G5?HU?
M\GZC1+$S,_3;*#3]^*N@,_WW46AD_<-_P' IH98!\@MW1J_)J5(,0 Z/WEAP
M-]R."UY&BDW@>G;[T.XD)U>EHO@2A/S.RVF*"U8.+/'96W@H9E> V42_939:
M,+D;V: ,5!5AGHENW"HA*ML,\+RA6B)M% D94NL.]2;;;3)%M5\<O>IF+HZ2
M8=/X)9"KH$$_S-)8=<8XKI>=J?S[1 7&%W!N(Q.-K@E8@R\;M]D3G=TR <<:
M$?F'7[SF47U/(@A(P&TD*/5CC'[<176!4 P/%SMWYY8-&Z?@[?.I$E*NB2[6
M<C"B!F?7QI@R\@(PYHK;8SZ'3QY>I$/$E#5\1+DQ.MIZMFY"T=UE=TT#X42N
MGB%U;M(QTC-7:7E/[;2H81Y!P?$P2SX[+S][U99@+H#*S_M"84+9C7>(*UB/
M<)[DMO]!L**TV!K^=-UA-<Q'0X"F,ASN8BV8]\D 7*(SYB'1,6YN16+KX^V6
MS12SC55U$4?C$TW![&Z=VH)SNC%(W<1'@$BAK)1B5MCCXJBTC,)LY:TGE>L*
M U\V9ZC1'_,BYV-6!+)X,[)_@K%/2_!]F=K:\2OK-*IE&5TU*9I64E_O-73C
M.4K/3:>31<HJIA6P .)CGA4-<8H.;>E]2 ;H:%'B?YEG?[:@?VJ=Y/X.@&OP
MC#.'L2U@C%,>@-!242P.C<M53.QTW5EF"/"CF7LQX#WCWB X&00)9&^(5_W"
M\WW<>'(\P.6GGQ7)X)DB3W[^5<O$"=+OO!'_>B=F?HM(:'PACGF+VA ML>']
MP5S<T]O^P_HVYW+@IF[K7MS&\3K@&*PX7@0# <JY\L0'1E_L6K=2$Y!,I[B8
MS\MR:4"BRZ<K4B4U&R0KL>S4@-PK6P)[+Y;@R>3O1A?Q(N\U@H,EM0*+SW+6
M-I@IF=WQ_++$V\<@:I=V?$/W[DLZ\3U9D3T14$(F#?8L2;B)9FW^6B&ZXVLO
M2+ZZ0_ST?F3>M'ZGWLLSS0:$4ML;Z*CU3P.@5,?O('.TPZ45-#]\>\!K+TCG
MX\]PI.(MV=%TK(=BV9HH+E=/*'BK9J+GI?OWM>A$Q\^[APDKK.=F'99I-AM2
MI'UZ8OHV(-.0IQHD%FRYUW.Q*JVS[8(ZBS=!T3A+2A[7V:,Z7C]+0ITDLV6<
M<NKY5(/1Z;.$Y&DW9/&(?<!HA.*?M7NG'KT/+H$;^L*]=$7Y]@U++M1^OC,<
MIL8_&1T0\#[0O22Y@)6V7K<HC2/_;(::F0*2/=@ 6KNQ_6:^1]@[\%YTOJX;
MW9N]7EV^]&2:!6QO<+NMJ=?-97"%CWC2J7D%#N9@XIO2K'.[Z9T5B#<_DR5P
MI\ TH&@083UVTY:D'Q5GVL<!&?ROGAM-D--%T*J^:4^CUH;#V2$4'QRYFX#&
MPV5CVM/K(M8@X\'ZD?P(6H2E38]VYB7']<?C1?4E)V$-4KMZK+QT4/9P"RNP
M]FLKJF]8&>UJ46'9;7/\PY:VM5#?1.$,\%Y-*2%7<0>)NX>OWWJ0:%?6X6?T
M\L7+(B<^3]#IYRW.$:-Y+$JO*A)COUW0FENW[3FL!+^AG7GK(!'J/JHE5)+@
M(3<M/J7M>G[&L)??KUW8Q$(Q>6J"Q)/9[T.XQ;>NVW.*Y,AV,M!29G?MW.YM
M?&"YK(-^V>QR<F_X=3W&#WPITAU?>7MP+(4;.NJ;V0[ZT\)H]4,SDG\V9R'"
MQ Z7P\#@61!UH1Z;0JY>ONNF=8)0 :)6W/R7%Q[J3Z)$9^.[OS(GM=1Z%S:+
M>H(ST:NUA\%J%3TU>[S:2&>9MOO@Q&XCLQVB(YQD>]#I,V,!]\+/QF:9!Q&J
MW##!&_6?$..<[\L& D3N_QR4*1HU8M>XVG%\% \J1DF2!RBTSTA'-L7KL5'A
M)''6-R31<._:; K0#A4>&@7?.7Q5\>+?3&]@\'-J2- '=&:D&.KQ]CH>(T+)
M;64O5M[7GP6N6V?/$'6#GQQ;5>PRZ++3O-NQ/$-'M8*0SC-D:L"U R?+UB*,
M\>3'4\N]8,N-J$V."G",&+Z!#:)WY9",MX?Z"]C]?6ZG<5/2/:6OK3019T7W
M^W0/QHE-UQ;1))4NCX5V &^B38)Q9[^19TW#?@Z_B\9&;V>IK5=J\EP+%8E6
M.J=6,WPCH/^MV.YKG.CZY>:B5[8/S/W;#3TZB#BGR]66LHPN&&WP)95]8>QP
MO'MD1(5LMNGHJ-E"+.?"\%9>9W<,DZ$&IVI;:ZQ;<A"!8,[FUE_(E)QM\_+1
M(OSK#Z_YX-PQ]2==)T] [OK ZO635-P:26:224Z;U>1BX6OR))9VQ18R<VP[
M2X]&C9:)P3,C%D;[#]XP:*8"2_821LD7N)G-T@[K9G)[S/(VC"C@S[I"X32!
M%/FCT)MF[:%O#&]<M:K;"8 "N_9.YK H:I1M S&H$%^WBKS.3E9Y1DCG#QLH
MYC:Y3B=#NI%J,M]KO:O$:4RZR,_F"^IH/E-6/PN>_VUEJLD8'_+CO!!>2ZV-
M?."\!+SBYZH%C@B--,9-&J&3*DAC>(1T\#D."N4^OM XP2 S\P;-S@PDU;\G
M#1T<]?OV$*80UE\<['S\ )F*>7;<]!Y=^77 ZG^.A_+;;B4Y!0GX7XKH,N;I
M[#9T.Y;-%22%Y60JCIDT=7O+[8V5R.BA\V=;\%.L;52_^E#-4W=):B)EIYV2
MLN)1L6RR F-6850A$:AE%%**_MSJ27%\[1OD*.P/1IE 5_#E:V^=A0(N'] (
MG4&#@7>7P5$;/U7AGML(D4:)Q?''"/R=ZV3Z?/[FH_W[V(F[2%W[,7-^IW,"
M-5;PN<!I;];AJ,9L>K>YO !C.1[1X+"=G]X6V*1I_9W.XTL+_#P:,+7^5_TH
MJN]%T"MOMY*NBU72NS3'/^6,K/JS%PPTF[ ZO*0[@X!Z23?PQEC.$2JS?H.1
MP=MBS**Z*3->AX_H.?IN _OVDCO4V0$JK#%*,>/B[&;E1!9=>#VW>= :(X ,
M=01T?+L,*%VALE2L5FN=!Y9I[Z,5ODYN?"#OM#ZR" GP9//'5&N4NF2PCY/A
M\K2'&AR5[.@I)YC<[TS6Y*EJ#_4SG%\+, =V]O6A5L'9:'3N28AG@3>U^O,\
MU1-&!G70.HC8:/*95[U/3)LN1&)C9%#62V>S:*6X>**'T%AMQRC*_%D"!SU/
M?X_BW7<CM+>(1?U&-4J:2UK#*[9W[81=]*V)C6[')J9,[[ZK54,]02YNKB5C
MVM2]TU^(EU*?X5^]\G77E 8.4(:XOT:#S8[]$%'TDF60>Z!.,K1ZMSE4H(=T
MR@\=L@VK/ZW.><+K2G>/R=2WF#@P^X&<Z5R+%RJ>/Y3U2IYDE\[0MN*4#.%^
M$G7+%97NZ,RC8:*>V(WYRYG3PL^I;;HBT J^V5FXKQ>F=_&@.2[KJ#=8+(*N
M5X9<ZOP5D:CTMBY/7C+,!ZJ1"2)'FB-[U@H?!4<SI6IG)D8^5[6HY&>@QC.2
M#[FBJPXI<=T$7XJWGJY9/;7)F;88O5^<J!=R1'T+^"T^6BY%Y,B>X^A,)]56
M,YXTFMV4YB%)TY_$[Y7]4L ?_$LPS;&<[F.FS(3UC)K=NF#C>Y/[X!B)76II
M5_[MH+#77&WQKR$E9=2_0TSCWM;'P-B:&RJV[CWM] QK#\ KD2V:E]E0O,E3
MI*6\\I20SAV/G_T'[1QM<!;,IW308#N H_FRWF>TU]>V53#A[_)JWI\/;0?"
ME-@SK21WW0&/[J1AP7Z&RW],/$I6%$@4!;06RX'1CB()VH;H*S%-56VLMN:@
M6B+"L.R$^1>O37">  -B6X@O_\]PG0;)6E<I:M_P'O0]A8O/H1 !$]1.MI-+
MM_T<E=6F8?4\-0%J?TT)?6U3X1<K\2^,\:27<(F/I.2@*2Y,S#PO(;QJZ5?B
MC%+)59+J_9=I*L?8,3>,T#>+1;9KJ#3/-3U2FY+2L1P 3;XX>:)>SEJ5N*7*
MAJ'D;I"/3EM[!W-PQ<A]\<*WUB4/D79KG32-(EZZ^];E(LM PQ-P,4FDV>6,
MV6ZSN^,](KE53DH2?2.;(^-1:(M[E*T^QL0BH-Q98P<L'P$FDSLF>;?A'OI9
MNR#JJU&>H2 BI_R [OP\TKRV>]+MYN?_0,FCCN78QAIW'LIL,"FB%9(Y1!>O
M(#9^H-+()INCO?K2W\V%4C.PM@$\!?[:HFC:+]\2R A<))\ O,-'<H7Z-8./
M>3H$$=YY&A]?$=76@(@FY459!KK!^F/#QXWJ2E2?3C[=\8)6MO!MB%2WQ.SJ
MR7];S@W5'L?%9=CH;TW%*JP7'N&)U+@15/9/>$$D"P BM8&S@Y9+T\N!$>31
MK5HS>,^"3-;"N]RG$E+1B#SI@@A,4K=TE$2YF%_9%J-;?@!I69=0\([B_N:(
MW+'ED,/RB@!?,^J'4T.H># 7C//&S %9XK^^G(U%-GJ><Y\E;C[OA"D9I\V!
MG;#[\V?GK+_&#LHW^R0:JVY4TN:RJSTDMKSIM#+G_>2V4..AT#VQ\,OGH80=
MC$K2\C[Q1V:T.4*%++K8RGL<(GB)#+L,[_W(9T]BZ:$OW"3C*+R"'GK<4:#^
M(1,^S\:5^DO^/HXJ::UV1<!*CCK*VG<\VHXK#))2@JS*WV691O:79B+4DGEU
M#0ZCU:09M#U.D&6'&*+A5.I?>'*L['8N+[XM65Q2XZRF!!1JWN=^*77[$WBU
MW TK6L\ISX#8!3P]QB]1J62Z,MW)9L>N!R76V[&5_%IO_N@I+4<Q6:8!^'D^
M\Y+$N;R]4\"QI>GV]&G8PG1CT__,(7'TXF'+B#U%;*QVW*!A"^%_ZU^1UF[)
M=G< .QUDCE[6*T%U9:IZO&?_>DH;!J!*8&\M,L1I9SK]9DS*_"TV[.WW@-P3
MQ/NFREN32%^6J<16"]9U%*GOU51S0]+=Z8;.P?6Q4?%R0U5XTW,YKRVDU>S%
M-<+^,)BW&7[79J!II_.)QG&UQ=I=!72AT9X<F7EQW,0.IK0Y75D-:7,'=T^U
MX1OS[\A1BVM-Z;'XL<MO4JL&$21.T>PE=0Q0#%N_-A6'%3'<[$4LV,?$YW!3
MT1'KBWW=45K>_-R^F[ZS:=JPQL#8,GOWNUS^79I<#NL+OR]1EK7!E'W<F<UQ
M>6'-;[0$S,RGZ@'>K"W$T&!CZ=3< SWX5!:[T_!35^("UQ#VL$?@7Y8M0ER8
MZ"5'0ZV='DM[VQ>2-)AE=D&\4(J6L;Q61-9 1E62A0BPB*:R+=D3HS4SH\,
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M*SD(KGT2K#>NOQGM%%YTKN7+O)C^Z;&J,ZFBM0Q*5NI><T$4M8#"[FXFTTV
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ML[>A!CW?N3XH%67%>_E7<F%:FXLDZTP.GNUI/;9J#KL4&5&PK_CHD60*O[Z
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M_4%V6>ZR_#\M\(M^GQ@ 8%?090>[G$M1+2"N8"N7?QB7EC#NGV%>=N8_="3
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MN]("6O]77%T4I__'3JNF)BP+L72]S*N2K/B%@,/*SDI8AD>>3X"+7Y!/2E9
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M]3I\MA2[V7)I0@SE$R75;I/H3*T -(/X!<:@"5HGL7V]E^$*1;O6V<0$A?B
M%2$%=7"]XY$R3U?GF_C76\7FF*]QT.P,6&V"]=0<V#T#6K@5^^RR08_;BJD[
M*J#UR ($_ HYU4^&Q7B/K3(<O;4T;A4?&UDZA/&+65L=WUL+BWH=PV)DLBU?
MFH<?&",4"K5VT]7VY3I\;JND^-S2NLTMXQ.9S'XL :[%\!FR3+^#<QG>HYT%
M"1O[C.\T2[L(9Q )#W.2RD__KD:[8@HA]X4PZT^:#,:&3F;%^+EKOEG7C1X=
M992TZ*M7O-JXH<^YP)H01.&:C[3I\9E$$3X0FFSQDL.XL]$!6Q<Y^HZ2%IOS
MZHW>!HG4@1GGXSM1]M,'!^/%XKIJ(51JG,/'=QPZ>-FFY.Y/L[NA*G;+R>D8
MG&2\Y:9K#1>.X5&0>NGP."Z>KA[[,J)"TU'][^7VD,WBMH^;HT41U,-Z W\)
MG&PN,7./"("W0@#HF,8=1.O*L_!&D* [14 X\C_$&[S!\I]/@%QV_4JUG#ZN
MGE(#C$BXNZ0^4(E82_6E*XFN+G*V&@\^<KM0#PJSI*HY (&2;DASG<_P9+=O
MBJ'[4Y1IJB8LQN%+[,$)OY]9._*;&Z>M!S0?-P5KWPS0W%H(W73'F:+-RF-]
M.5/!'%)8:ZS%$*!$+-:F*:?#K4T'Q,M/;4/T]Y7U,2?KVIJ$*RP]J //-,6&
M?L5ZE<QTG"!$*-M$(D.<KJ<IS1CI_3K?)3)PUQ* 05H8PAAMHZL=Q1!S*U93
M#EN+,0D=T3)UF>N1LG0L<AMW(" #D8X6(= TF"5ZE;$"D[&");*0H5"!)9@E
MJ0N5+CA?BI RB.E1"/19;"L^/@%",_M5$@IBQI#C;O29C2;/MN=8"+Z:'5TQ
MQ&$U&78T G_**<"!*(15J,MV3W%4)>P,,4@QF,]4!(2PG'6*R(SK$.(E'SJW
M1] D$3.? ]#.#-''^AZ'VA3M^Q5&I0^>;%=&/AV;(:@71I3K(>D]ZU8BK1ZI
M#HMVCB-]?S\V^"$*OZ[UI+!KU4MU'$:.<=_$:LFI.K(\RMB+H$A4CKK. :14
M:M\>4OD)')\#2NWSCAXJ?/U$4O77)EP.'?[<""^:JDXR#QHHGI;<"'M7O(I/
MYG9\,$ \;Z78%*R&-&AE5VR5S)/%$VE0\4KWA>T,-UA/UO>KW[<05"N[/?J!
M<X"B8P*SM\[RSHU" A'.E%)EUO!7&R8BVU#)]UM1J$/2YBYI!J_*:)J0W.?O
M0&TC!JA*O?A;^A\5!0Q-3-_(A) %D.U\EY]HM896O/$ZM#%((+(8^:H%KJTH
M[C0UWG3'FKXY_AYL%+=6[6425:#/(;Q?4ES&+?JV,8=WG-!("+W,F6.GF87T
M$TOA-DWHL []>T'>)QTM>H>R(]Q: #SL1!#N"_=&0^N9AG'[]WO%*<5E4WCK
M?L=,'G"V(5"GR5)5W1SIH^;1&F Q'+>PWT&U.$RN0$TFZ?7XDTKEM)O\32HM
MXW1KZY9%(X7]C?)]=!V&RPWNHG4MM1T^<V7!@3JZ@[,9#10ZVV.3DTU##^8I
M,.&3]K6'L7#4Q5OT18:M;2>?I=Q])E B?>K[E+D#LH5F_,X!&AFPE&PTEONA
MC32P0Z\9%2^'&R%P_R[E;Z.5[/+!3(-KH7/I_4:1P5]=PU&Y+)Y';Y&1<@>Y
M[G&$=9\]T5\UJG P/.HK*7H[S](-K;H9D,UMK_I\M-5S_1,=\33M&IU'Q8&A
M"^!1*<*VQ\P83HYCJ E<O*E6"*Y7LL6F^VQ";K/J $*_3HJ22K^EI4P0^RA\
M_^*\@_I=L1[_?@ J"GK2Z]P'E;; \C#RDZ^68.L,?*L4;&NF)[EX;_:=ZW9)
M*Q^&W)VI7<)M8:=(KGQ4$]]A,/C%N#@O#\Z7Z'7(2F#8A$-V=Y]@LAR+/L0@
M>?:>-_F'>QQ6A% _Y;9_.:6$8FRR;HWE*\I5C]4;]_5;;+XLDHB27D8S9'-X
MR;ZAEI2B]+*P#T6VR>W[PD$V@#81/17G<U&^R\T("GXWL[VB?6RMMF_]O-"]
MG>:&R3D*,I3$V4.LE(;:E$K)<;#ZL?FN.]35*KB*&Z^3>\,Y6GXJH#;L[0:Y
M$:<@6+3D5G<#7!<\M0&N>#1;;(;_JC8;2S^*?7PMBSNB+/ SN,O_6#]9+BHA
M7K1@6$C+';\"O6I7)YJ)8\;EQ?*FW"!$$<YO!4N1&@_B41YHS</FW_9^I4BN
MZ-KV;M100.49"/Z@35; $A M1+EID#AZL^*-:UR2QM G'SI1@["8%(03B9O6
M54G8@9%41(\-QH4>-\9KNJ7OETU\?NDXO7 0!_C2C?PD22W8*%&=+1M46)"Z
M$V:4O=K!4D<$V9#]B!]0VG*0F,UEO?-^#<?<_18**/>I'UULJJ^;Y/+.-V1*
M-I=D-=N75A7.KP7$DMTAY,[3B-7&;/'VWMQR#H C)XG05V60T5BY2B4[[LJN
MAT35X/>)'WVK4:R/G^@1[FM5:8%>#4653+,.\7NN[#_NNF>>-Y_:JE2E(2%$
MR0.KD#]^$T2#E)!C9N)D<Y!6=K)?6DO7,VHXXK1@_*3&1O!$&9=,M+4AJ5:9
M.W=D6$(<UL/IAWIJ=RN3M4!8DY?P0?AF1[:"*>-*SIT(:K%0<D?JU@VU@@YO
M5ZH\C+OG -,]3G3P::J"'HYGZ;ZJ>D-YNQ8=*"ZW/ED>S=:0/47>?S/[<R3A
M+M3)*B'<:9+.]7T;1G?1S4"?X_!9(X_M[?V\E(:AW>\;6MHN$/'T(7Q2,>XZ
M#J\7OCS10Y3!#85KG:L'7)HZ=:QX6NN-VC;YV"PNNTP3GV_P1P-%[KV(-69>
M2<H%; [,/*/5^<A9TUY,*@.']$5,WX3X;HT==ZL-5'T^1BL\[.3P*-?]8"ZZ
MBV?"/3Z,/O))@$GYR:.^]=34HB?%Q<;W R1Q/(^B<D"ZR82Z=CO]8P=N/BLO
MY<A>'Z/B^J_A*8\NQ^?O,B8L=LB:*96L5/*)I=%;#GAMFX_K3XF %RL*">O?
M\&C&);+&)9$SN3MFD5D)8*"Y2!:6=<1<G#*4]\X!N(<&=Y_5W4Y."ADDZ#%E
MZ5C+KIMDV:Q0)[8'1G%'W>_MR\@&:G%':RC>46W61&CF4+B8[?7$2T3\W#6_
M5C>)^>8^#W_HL^*H("MCN^> RGNS2*XQ*M%$F16L*B-J7-:A.)IC87 +Z8LQ
M/RNS)VI$NI#<8_<["(OS[5TA^%[W-AO5\H_N%0MM=5?4,GZ$I2>,)+B=XO1*
M*8\\G1U+"Q$84G+H]-(B#88Q@N$D64-)0LP15&V(^L2/K-46C3DP%2[6)GLG
M+Q0BUDQ"H9J2*I ""(M6O9RX25J%44QC]*K&J NI6RRKR(SN_4D*1&:E>OGJ
M2E#\QCW#H/I)>J+#9_DVN&_H EXR%;Y489%M"?4M\56H,[*'P6HXAME'T8Q(
MGK<NE1.Q'219A(WIJ_B5JM4W<*3(CG/>N&T$G[15JE<]\/"H":DSTQ+"1Y%*
MR50,1?3J\H_@MG](_3"\AL+WXQA<^]3R(L6<S^FJG_\X3^J(4 R+^&C4T!MS
MO<#8,$@AB=I\?R!"7,UN5Y_0@6G_DD> J0H#?Y-T$R4JI0,3E_I$)QJ:;+)(
M@H3J*.JN,"[RW7T)MZY=QJ22Q?O3&^'W3VYLX36.Q;6]IWQ 346#_QS14/TM
M?IDV<.,]$.Z[GK0=V3D<)2I3;/7PQIQ3Y$ YFH7[>/B9](<B0JB+;BU&<.(=
M74_/^[83-Y2'QMA-7OM'>O22X=U*$[6RK(1]YF\.X35XKYU4WT4').2*;*4<
M=;,(I^!]C[T)Q]96H=2[/\8=3V\Y/:K:)HI67E&%!B^A5,,%?,42:'[05M=[
M,6D,+A%BF-,2#BK0&7H2"E'5<;@(DS'\F+)UI-91AOB,W3T6O8@7@%%VA@*K
M8\=GFM,NMC7<6W9P3PQKPO*-YYY6QF&!I,S8,RG583?8HK.Y%&,E6W'&!JA?
M5,:4%KX:A:MXDZO4WG-YHQ^*/_&FXZ.>9Q9(':>(-EPO&"GU\TKZS??-;N]M
M7M7'V1/V:\V5BBLSFU7?$E],&C]- []VN0LO+<=BU_.>M[L=ELQSAG\0(SHO
MIG(W;-$:MYW^0_(N@D&^&V&7?O;R.*?Y4[)-;=<#J_?DKCE$CDS]GWW0BK6<
M:FD70A@P*5468*/J\%?&#7&W,Q/*[,;3*Y?S'O49E+)F1 W4?5$BO;M?7M?+
M*,@'.M@PJKWE2 F1/QIB)2;2:W[*XS$?]W3V'IZ*M>*' S+OHEOXX$W:KZ)!
MX.Y7G5[%3CY.Z#'>,EWHOJU!S]+]&,\!O80*Q%G+7_WTAWV>FGV,B_*/G^-_
MWN ND\4OT[FY(-#B[RUZ.C\$?UDC-;GU;G<F>Q7WZT-C.\PIK_>5M]^#STS2
M6[GVECZ]W$[S1JOBKXK>W5LG>!'/(M7-/\XROS&V96F,#H>B&/#$3>D^T^1"
M>YV#A/9!1FP_U_>9 >_J I/0B=%(EV9E6 -U'SNJO3M]2(O4L7/EJ[#7SO&-
M#?"W:9X%?*>]G(GPP";+&_8CW&1&XC1W[G%'N!MC,=H&W9(V*.PQG$"R(NC8
M*I'\/E.9+)D9H9T>]\J>>F(9E?-P@GDI>=+883]$R=96(J+VAK%%\ -2_!Q4
MC@B!5S<Z5IZPO7ONTL^O5("OQ!FX<CPO.5<Y0455F)>3E$,IR*R?IU:YP-FR
M81RBKY824=&1$07/=*6^8>;K)]BU3*HXRMM%4N>W9.R"840O8)"$L2O@U:;5
MIE6)5K>8_=WY->%XAR[LX$Y7XB<XUA2R:\&V>8P:,TAZI6I;XVOU!_,;!)*-
MNO.W":PG:,<J[D"T*]^1%Y#U:,4I$2HTR,G3;X%A$P*ZY=A);PB?J@+>?WW"
M;IQ7J6<=G@[-:7!,EE<B'JS'*O5^,+=<#W]'4F%<0[T5$6J!Y2\:WS=\BK\7
MEF7NF#H;W243QHX;RBG-N,A5(2_)[N/YP+)8DXTVG- :?!S^H#G:C)86$1$1
M:1\!81>1)AM9_*2?W7EBLND_N'$P/_8L&'I8E9+8L4RH&@+EC32. 9KRT;V0
MB:N$$_(&8CJ=W=#2\(?T(:5QE!KO5KB_PUI^1D#9%QP>S^4MP\#.:2;V*1LR
M6S]#K.YM!7.NET>\09\X>( T>?/SW60\OQ9P'?:6<7#@_4(1!7NFM$S7&<W)
MW;(Q^PVO%A*.?2\&J'5ZE:Z#*?\!)7%E'/*B,_5;:@YI^B_=.]K$,4ZLC#-U
M6G3OXLX!]]*YB\ZH2(E>,(5ICN\;%+)GOLSO%+/P4HOZT%BF/7=?/ K:EWD_
MV8-V31TS^SF#PTB,['JU1'<&1A0P)4_ MCB4EB?!U_)^A2*."5SYL(ZQ,+]F
MKEA\GJ*,%=_O,X?D(;E1JB@P.-I/K"7**N0I=PBB%-U*] .I+B(*#G=(Y\J1
MY<PC($9,;\^KQ_/\OK<L'HM9N_E\ .RQ=DP"U]>*L,^&9YDI*!+W=<'92<\R
M3UL> +,>?=]=YM5,KU@1YLLZDJ52AJ/+X4?*\WOMHVO?5&6/OE&Y9\'!#9>A
MB\JX:938FT/.'+,8D@A )5!ICLUF5I2.#626S&&6Q-2*S9S+899YBR#YXVZ@
M*-H0^F6+ZC:LA9;&35!NDB&';G%'\!CAOCEYX"YJ$5WOHQPJI-,JP#X4]XS;
M<9G$GR[V,":HV^=0G"!PSN*-U?9.?5&$<N.=[.(TA3?YQRKWCJQGJLF$9%:I
MDEZY"9*L\_I&82^M[*X?G^Z_6ZBJQP'M:)%880;>1 :?\7-)ZSRX*RU'6.W8
M%)&P)K>:A_ZZ8MM$;#T4KY"R;33HP]BJ^Z"Q<U^#Q /'NP9=(9218R_@^[JV
M6.]/.^4\Z5*?]TO*<7OR=15;.9M&E@GX5 GOK^J![L>&OO;8V:=;.JP,%<[E
MS.?#3:VUZRZF>0 MU78OE>S:J[-A-=<=CSV+CX#SC3H?G78S*^CQ<\RNEP]7
MPF.>V#XG+*,A7J\CP5=5K)/0PD544;!W%"KK'DO+J>H9*C_DCIASFYIA-K+#
M%1^9B7O:O#I\PT%S27?:@XFUK>BKW*$-@YH42_I'<KG5RA^#0D_]>TP89P$-
M 1,/&R ,OBS'L-"\4T92_\)<SI^Q-N31EW#&70VZ &UT?W^T2,KQ6F9+*HKU
MA!OD-Z?#TQU236:2MV%*"[7;9:+M].5+I#PC1@J"0;;%9O6&WTR)9'F(Z)'H
M;P^$4\U^$(J>>4O9?]LZAUM=*_4I\S,S).)6?&Y533Q:BT11?_^@861D29FU
M&R6/D,&X<U^1W0B6#:31&?"ED /0QP.$\*66T$6?B84NRA$I/M7418^V0N#N
MR^R2)LZ@EFWC#L34 !P]>^8/\%5@0%0$$-ZC!4S'+ '<\C6;K [N<-C3LX2_
MFYT<1=F5=.:3 O7<MI'MC'C,>/^N+L/MY_EX'PA1_79H,LA6A"S:[7#NQ2,,
M<WDRSSM3J#J(DPM]V__Z[/-4DY]80CCH"<M)+AP)3X*A8_#,>!J0 -EUV]7<
M,=4,@5?.AC]:GHW^N$:Q,FM26DPS8F<?<4H_Q8GV6(KO! ,7,RID@1M7F[CM
MR/\^Q<!B<H.(V(NA1(+3/0&HYF2]&&(Q-_.=J,71Q[6L7=">2!JH3@-HN\R%
M%J8)68T&(]1D\\^F!?%_<$.3=7=@F6_0#0_NF0Y3HTV2J/D&[HX:)[5X= ZX
MS15>JG63+\*;">*)'6AG+*RS!LAFIMFF057W"X85VSSHL_>I5K_;'FLW\IA$
M<WLKK&+6>T-QF: ,OVVYEFI2A.2QZFJ8;PF/L_E>>FH"?63B(?]ZA4-%6Q]P
M<)R+'[XN_5;09Y0QG!&A(5UPD23)X:'&FQIHB,:,1%5A_;OEB"HWH94/1P*-
M+)TRAUSK1R!-XPTL(GYM9O4NP_8[R $YW+(+3.2M-P.IF)X'3MGBANZ0;W@K
MK>V+-Z3<BO'9I'#JE4&?8.GDF'?G4<HMQ:JAK,.O(9XAM35&,E'8JRQUM*=2
M'5B ^0[D)(OJY")U/=9<Z[P%ETZR/ E>F_]<9Y=R5T#MP*G=^-'J=C8?G^D=
MEOV1)M"L&Z>^_:1X6]-&"MOKEL:2<AX[I.ZWH9QIZ-_'$PJSM4-PM,B>X&5^
M+*2SI'#=\WX%-Y%F5T-5845._S289 1/B6C]T#)6"B; #S'\HO-,["7''5=I
MNSP/W-V%J"DA.QP-+M+E(G$:=;UW@Q&LTG>94R;87C=JS]!&3M7$59I-Q#NU
M4:!$CI5\XW-U?0F)+D%_\V):RY1:*$8C*.*L@(>F8>^9_R'-,@W]X=G)6)ZI
M ^\YX'42Y&3HS4.)KM<*).%W7)3?+)\#XD=>F:!^_GPZW9MW]B+W!:7$.NV"
M[ZP#Q\=ZU9HSN_F5>U[.3=]9S@&=3^CRO<YBBM8)]HH]]9_D#G^6Z\QR&#E0
M4I#CX6UG>>UFO8F/F)N4*FQL@X6.%E.8V6=.1*[ 6E,ZTSD1O23=,\:NTLQ0
M+M(3_9H[\SFN\Y*'X8>!)0#*1@C3)TN+)V'A MO-;8#1L$[G<5P9J))X=,&+
M8>7>SN,[>1Y;.97%7K-@EO(R 7YW"-=#*Z64D&D>.-]TI:4EK/6KP@X&J:]
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MPCK#JYJVIQA;$ZIXTLJ$:FO5#-!T66YRJV:FOFW++J1G6 DWB<UXZ";JL7-
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M:Y9#*Z&UK.IUER'&X=/L%2%_6_8ECWE_L78UROR;9ELT)07@Z\BU_.=PX4]
M&C%8^L4YHU%L,%,7DG6QSCK]>&GFL3OC:(?BF"25E- XLR0KV*#=>D8;J!E
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MQ?+/@*]1V2W^7RGE=M,LQY*ND3[302V*8SJV-XCM944M9ZOJPZG>9[':RJN
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M71Q23_FT%Q!B2<.7E3IM$(/ZV;!JJ:M.VHU 6O7 \J A',]ADPB&'H$\LAG
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MROI9L9@2J@%)WA[1^@/U EC\B=*A>12"%FU!M2.4Y DFTPP?9<^\#$0O4DY
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MMWG@7-4JO8YKE: ^#RY] 'H;A68H-+G2-,3^S09TJW>D'X HEX<;SY%XX@\
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MS:5B\[.N8*-9C!M3/\/!;"18H/+,%M,?!5HZS:F)_9W/'P"FU3+'+!7;9%H
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M%(N44.U0O$6D+JCHPI>NC+91U[ X*K$HH>?$.IU:@O:?*Q%QG;>,NK(Z>+\
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MLN]V!)2U<CST!5-5R"/_(7=9L:8GX43\=V4ZC7J 7>,R2#;G[-R@LF6)^C0
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M)PKSE9D(\2A!W])OHLH#A64:<:3?R[BH-9^/5\H,P^U!E1GE\7P3P;^BOT_
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MH;@I/YFP 6N^I/V<:K"##C.%\#WM'7LB=+:R85'_.<8G9Y!D?]/C+H'^^4T
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M-CW0I89^ 7[OQGC ?Q\?!?A/+SYT?Q ([*07"AC<^:5O_[.P[X(K]H/5>I6
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MH3@!X"'_C,D#@"("X ( E["\9*!LR(X)  !<RA+@! !K[$80 ?:,U9CHC9V
M>F!.X4L+3$):NFWS%Y]^:_22RB@/:IJ/:<9C98=#5G?OFXH]=;\0 8FZQM\9
M HF*ZIT\MI[ES]>:VH:B+,WB.B6\?/+N[E[F/>]/[\?WAO!^CL(".\EF#M>D
MCU^Q'XFK7O6KGFV]C7*FL7^O^JW\Q59*X\GARHH(OLK1E+OQP3WY1=H-X P
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MLDAK;6]H/'Q./_@0VD_K()G?;KH14[%T[N21<[1B=WV"AZ:G?3DQ,=7;JV:
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M#C8*?^Y@.*>>\>M4Y$BZ&AY?8$,OF>4CL.VEZ%5(&&_>KNO[9B)8V[2DR]&
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MOLX=5__*^J^_1K'/3VQVX(];K3S71+&1&>C[4:'O&_];>]<9U 33K8,%1%]
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MWF2 ?U$KC+VWTN][")OHJ<. 9\2):F($6X7.U<78;]&&BKU<+9H;5?E%V;B
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M(V/2?%2UNOC= /RP_93!SJ(I[N'^[MI[77_+F!-2L>>WW3,L3%Q1*T]_,8C
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M-Y TX5ZMRP*8?AC=X!3G/MOX9]?L$4LBKN>Q<">%4U_C/1^-IACM.S82+3T
MH%LX&L>H]="+E1L)C2=SCM/-A+O%]WD84)/0SDN^5J4V$[U-<H=7F58%$!IT
M*9RY/K,>I8.Q,17[D.B4R3GVSL?PKIA+\HT8[H5*N_$GM%]45&YDV_/>B/F]
MS_'N13&-CN%(*I2]G%^9N\B%ME1'942?K]^;\5KI@P'VY[1?N$15%!457\>_
MLS:J4I5X\M'"FU0"[$@$N#0[==^7RS'>#__#JO'2['9G3B)@UB=ZA%NI==>'
M[-NN];[JZ/])[4V5B/X'4$L#!!0    ( $PP;U2E#C<\EP<! +5A 0 4
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M>G#!^AQN,@!M2VMN6! F^%O;X;Y"A#\'T0 8 :P 3@ O0 A_@I$!* )4 1H
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M$*=LIS5G>>=8YRD709=0EW[7XZY(USMN-&Y0MSIW(G<[]PKWSU S:#%TW\/
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M*,4N<%]J%D\Q+KUFU<25+DOKS'+Q*O TM@Q39G%6B)T2S%%JB?W_V&;\1E^
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M^3(&9=3B"'YHCXY[(UDJK3?L/;8VSF?&CS$BS%Y9P;*F.A-\\W$-)C.&B6>
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M=W=W=W?=Q36X2W GN+N[2] @"9($<K_OOM^MNO7>^[=K:JJFZTQWG^G3(PY
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M#Y'I?I-483P:R\O/:?/:ZF%*T]T>ER=8XHDPX'!E&CV095D[ZXH]W:_^B?,
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M)!5N5#;0ZC"8'?']6D\XL69YO8YXDPR[3%LJ/\SID.B%$3*D-D;XZUR44,_
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MR6'9ZM%4$HB7B$'8FTTM V.'BID 09>K,;H@="G<,A\PN0V5/M9D5OJZ>H.
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M[*RV IN:[R*ZPHXZ5)*<+@+321NU =R123F:F4\Q;VJYJ[B:J[88'4B/;6X
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MK5Y_^CVC##/NV@^D"@<^G_T4:4Y7?MJ0<O>CX@4[*A%BYF3#[1:%H[Y:\P]
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M%"4T^L]:$-9404U>2 ]\-G=-R M@EQ<EB(C.()F&SI5YM2<2*HJT/+CKFC*
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MUJ!%CKBXMQXR!98$O!7V9+2S0*-EP0;L!G=6=R,\09J;!)*;Q&9$[65(W#]
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MV[YZ/"EKO-\PX'><U-6Q9W0=U:VX([JL%Y(OD3&K2P-T.(*?QUCF :\OMF3
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M-WN_[[R?IJ8%F'6<9Z96^:@L<\2E:ZC$_TRS%,?"4_ICD[L? J0I[]#L/5,
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M"=!/T.>_Y#>L2LQ^J=^I2^K:9=JEI0T<W/AU>6T,72GFTY86&2I*0+XQ8J9
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M=:"Q&5%=-\DB?5D)4S8IZ-_G]^Y^7"SKM,4[S_D)D'H6N2\8['G-S2 ),/E
M+-S<XZA168]4-=5L_R$08Z+K7_DZL.(((AQG.BZK-VB#3;C02^B#V"*7U8E1
M@)T!;"F46;%,!C^-?W[,8</9)\=/:_BZ7UA0+3AEU U2 F(1Y0T?(4-'@9S9
M]GRU]=*6 G_:39\Y!V$UF_!T+==LMKCM<9].MI@EE&GDP&'I>[&F0P./?(TH
MP4?P+LQ>V-R.@]^"1NKOH]5][YX]\P%WP[?0T(&(^*C#^+  T5XR\BF!7M.I
M8AE8VS<K/_^P&H1^6#-3Q+\(+M',F9[YB^?4I1+1T5;A*FM ?H<.,5C,8$0J
MS& D9+;=W]7Z+23.;=)(>1@)03HH#&$]VM4]Q!R'^B38]:@<*,X<#-9Q;KEB
M+GHAGP#1U=MJ=T^PTKX>*VFQ]]/KU:GZK)>@H" "Y[N_8,?I47AX0"7.7],V
M([L<%98'D1EHX;.VB:'4CIY== ZSE5[V1XLJDL?%W;73[$,A']O#MP#8&;3M
M.!R9N*"8F(24),O$R,Y,3>J\,H]Y?K0"R0NZDHQQ*HE\X"T<NLOCP[-=524*
MB_^SRU9-O[W'Y-/9F.//AH5Y13A!;*$20JFV>/B6T&6OAVP.?1^HZWVE4T;S
M,]MFG85,LMIHP6\0^PF*B*=% _9SYPM1- "$OW= 00*AC@V GGYWI"&G?PXM
M0X2>*N43+WN4?;ML8O1 9/VGR&[?FIL;(,L8>Y ?7<_F$SCM!=CNH#;[J<;J
M\K\Y74W$#.UX-?OB93KS];KOX+2@[:\*"'=EV2+)F47[872OZ()OO; @2A^S
M( 18#&EA?^ S23>E:3N#S6Y%L*Y/)G#DNZZ?E \?26@U5&_L'Z6($5@:2H*1
M1A%$F0;%/BFZP"C3.N'KK]+/,N7K*I=0VX-HHN+Q2[5SFVP8,E."WI?LVZ(@
M;R"3NB"6NB*S8 9KL#;;T6._<KO2)T#SXN]S;D7;;P]=+K'ZRR5_,-4%"$(F
MZKSM&[)Q&FRLYN5,9M2N@@;@9K*Q!K1VP! (>=&*6"+$WZA29E'5)-1QP'?N
MBY/XMCZC\-*.B6#YL&JU53-F.BQY@Q4R6S3W2D<QD[0<ABV 0N[[?HJK^1F
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M,C][M D&=#( 5D+B?XK.HO_3-(:<+:X[+9^]"P XRM(: ]:3:M6@J !(5($
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M,FD*\SFU4$&;,(?+]&J\> K.-(O@:=J<OCW#N8P[,=*65=OIY,N7R@TO^K(
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M>ATU47F$]B2-,!$5MC*-K_0<S<B&8*0!W% AU=6ARN4H!0W,=RR,9(S9I*+
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M<5'X0FYF1:4FYJU+B\?[0ZPVJL92\SB:W(0AHL#0KG_&Y^C;V=[3:Q+-V%]
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MAB&)@L'8(H0;K&E?CS 2%VRLJH]%D,8[5\?<)41CX+2%X+(QPR1X(8JQ,1Y
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M\D:7\-?5P6&N&E+_.N6.1;HB)Z/@4@Y.C"I@-K(S(L+E;.&*M[LE'3\VN>B
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ME9_9E_/$:2F.2^4EI;,KIE:W[??5\O:)?4]11#@#SL*RMOY&A6'U2IY\^9P
MBUA*FBG_B62IGL1UF(O# 0FGX&MD!/5QHPO*A*$M<WO;]/KVD)JZA4FW[7#&
M^C2Z&>O%O#.&I9C:[U+X FL!*4)]YY0OY/= #Z8TVY7!O=3S(!86?)<3H6'0
M[^I40BKC_+Y.%I\.X=!'FR466W%%*/^TGP:QL.4_2V!\L<FJZ^)B6CV:/,'C
MYJ\MG.F5F\$.@UTCZ9D7L"%1J&LYW\X5\(4*UM_,Z,J&'U6HU6;'%G><7U=U
M1GGC&\L?H;1LT=<PCAUA=_2M+BTXMV2X&FV0.5F>U0('/+.Y\UW V@:UM9,(
M23+3<V<4[ZP/VZ!.5<QB_EIZEUZI&VBHB:VLIIY.A] >WR<F2]^RQ\N1OUKF
M.[#=<1P.5WM KC7AO[I1Q *NRNI;81XX\QL>>-SRV1KM)E36-]/+#DGL2C%&
M4]51@-/?S&/0![ Z2LY)DN>A [2*WAJ',[D'9Z4>#_[Q)=LIRRPUKIHVI1U4
M\?0.7FUW!+4>J8:#.F;J_2NE-#?B:?T/EX&,$X<3=S,%WZ22:?6N.GB\)@\%
MZ"A</XW>_JS)KOM*4AY(8=$U7TG(N;B>T.SHI41HC)N^)$+;LWUXLRW>7 #,
M*X'A!8%,N6U>0Y67;#BV-$8:#2EXC5.QQL%Z\B';>B>7OAC;1Q@F_9<"\ 3I
M'N_\'G?T IA#CDN-<MR17D1V.>L>M*WD_<(%"N%1A-X,:=*L5D?EBUY'E?QV
M'DD*%:J'GU'.UH_O[]A/;M^5VPG41^Y?X3[C)8UU"BEX\*0NI]<Z[K@^3_^&
MQYOD(Y8NZ-KNES/33?M=[,C^2C;/%(Z[HH.O6%&_=GW^\W=Z6?+-JMP#P!K]
M@/LD9IUXPW:L\]6R7&CD $N1;J(ZE>DBN],PQP57FKMEF>P^7 #(A#DG9PF-
M A87<*+AXB3-3EIU#3F]YIR$RX/P(XJME,:/&D<XQ_T@0<F=W"72*18IS;+T
M5"P$KFQ(- *>$>;VCSQ35P^KSU$>8^7=H+WD*REK%#W=1M=/GMZ3;*']9ZM*
M[P3X5SP?+VUI<74[N-H,V%=&>+-)$O9S0@LZK;$,HMGVPH6GX/8H%*?"%2#L
MUALTNRY5Z-N] 8<EO865?\Z;S+!F"#8-DRQ/.=$YCQV^68G&LDB.P5O$F^R_
ME,C+M76LVL#WJM^P^<?+O?WDT95"2,9Q&N'6K<G58OQY^/#3TW!$YHMQ=-P4
MLF6EJNH"32Y^XL>0J9$JH ?)4T95?!4,%JAQ=KYB@['6*!U+*31+6I/0E,#O
M<:A$?XRRQ>%SMC6*!(>9P=OC<Z3:R$;4;/:DIPC+6 9\U9()2_JG*W\'7?:O
M'""Q;,6<!!]Y<EQNNR[WQP#__9%X=T'9@ZS&-Q%**"J@'I>Y+J3,)>[?VYV"
MM>H09K.<4T\ 7]OZII/KFPQ;+H<XL,B,J8UG7"_JNU:HZEGZZ5<VM4GJ*] 8
M=3%ECP@'UX) /+H<Y?U_.PGZ?RC<X!F2VHW$]:5:JOP[,A("P?8.W5[WWCJ3
M^#SE $]:!76(BS1S$]<T>A.M/_-AS$B+<"E+ICUR"%R<< ,D*<UF1I[O3O^"
MUHCR/7S9L72O>ID=0GU9P&=*0T:WWB%[J(NWP 71Y4D[Y )3"E,_^"/W)?G[
M<9QB4/5]GGM!;/_^?6'GJ)AC^Q:1PN][X'WPX,[C9V%J&+#HM642A3@<8M+&
MK\MB!G_!JU\<KJ*^OHBDOSM."H1.-A*PY%?>>C86S92TL;Z-I?P$T3;I>F)6
MF?((4;F91#I5=O>NG'^S;,'?+I:&#B]"'3]L9\72@I8,P+&*M%K:_W,!@-);
M3<%U.]RJ;?KM^ZNQDVF+^0$N0]UK1*DRLY-+F%+$F^E1+8;8^L>F@]1+#9QZ
MRGQ]I6@_. %@$";UE8IUH V[H;Y *I%\(16;=;"WNN(M#[,<7\=D?V?MM-&J
MWC0EW[(>\BI#(HU-F;$\_16P*0P#5\>//Z:&<"M9J\A#'.!MI(Z @WS9^CYR
MEW#3(3>FHJYP))+KOQJ-_=.8OFR'F+L0#=$"PLJGS"T&MS'!O.8AJI06J"<)
M3/@=K<&S<O.F9]!RR>#:]LKCY,N6] _H)W7-@.S<HKZPP'+!^C>-CZMH&.ZR
M<F%D3P],JHAEI_.<<,UNQ$70DK7JH&Y9E=,QBZ\&V#LO+Z2<+]SQM15"7@MP
M[*.JG\&LMS_<%$?I?/1.J'NJ5[-]X@QH&#)UID^*;" !,Z 3P\64?,8]<R'<
M3/:M:](4T*)TN+Y'WK)<K;4]EH,9T#OY9\T!5;4>D,4[E%HBQ!Z6L+]*BPE+
M,N64&M0=8X[-K$U6?#G"58+/ZJYFWZRX>I8G@XNC-$:_+IP0')S&G( #XT:-
M++T#*C3,\:"F2W'S)%4M=#"7\UCQ.8\\2_Q9?[Z(I-CN-Z]UR2=GVN0(<P[)
M)ORET]63A,/L,ER#F!)@._#YFK-#NP%YS$TNI^6_.N7,/MC,D\A<IODV\?&T
M]U;/_C[H #G$1HB:KLU+<1^0$:Q.P@I5!A B-AST1<64),JO96QX3 =2++-G
M;<4]BUH;NZN6\R6FYX83GJFL+KMSG,9U1D LC]4K: >$Q9B0D/'RY7MX$!SJ
M-L^*LOO ^RJ.QE^<L=A0"GCJRK#XA!(OFFKZ^2:V-K?I8D,C1B',T7F"1M5X
M!F&VQ'38*;Q6QF&1@FFRBK5O(W,^:VE8#:T-FB6DXNG?N\9QL*]YL'_PVSR-
M&VV:6JH[$STCT_-PN=([I*0DS\?P^VSUY$DS49["0P2HY5+L"$DP+<=U;!J/
M$+YKIK@JU!W8G$OSWEM+)VF[/6Q][H+0"L3$6YDJ?O-(AA&M,)V?J"F.%LR5
MU55BM4U@^ 7]1,?BYI$Y<B^DZK8/'%<\>K'C-\2?;TH?58O_FDJ8;7LSO<F:
M,X;$;O,;)B+_")OQ";B*\.,G?88[?(Q%,F^+$RU-:QE=1=EOO+/I+O$'PSI.
MWI[JAOBZ%39W)^O=O:Q7O^>E'TPDE+(1X['X>%.]8D8V"5,KGE8;;-S8Q0-/
M"4U.@X3$I0<B1U'3<:*VM>TI>=+[N%6\N&Y@.*-A&@5/!T?4E.J+0_#46,TJ
M6'[$J<3I!J.)ILU@.L7HB-%8+F#KDY&1_["275Q7N;N[+8Z.F>K#ZXLS^I1M
MLVU$DGG)211/.L815SSMIUBG>A?%-2;^>6!>9%@TGE%D7,I'M4JHBL("VHZF
M^GXVO7+ZFE'_GWN27"4Z$X5K.#E-U3)*K "F0+X-,]$)ZREO4GL"M&3M+_:0
MF%1E:5-Y[Q-?T'-G0?6'?2E%Y5-GQ*/-6\VYBX5D/ZMND^+&*??_,23#&.K]
M.^OS>Q[1C5.H3\*D5*0GQNIOESX3>)1I;2*HQGH<7@C*ZG14 ,RJ;'O$;:>2
M!ES<GAH=;(>B',?_#X3'SQ&PCKNC8_!;%AO0?VPX\><EK6JEXW^>B%]6SEA-
M<W0,-(F?KZVIK:M;;W=,_!5?.B\_+8"/8<K#:XXWY%@,)J8.%?)T"GQ,V1P2
MW1;LX^Z HK2CD:F[W.$?(B;=[&?E/VZ6G;/,'Y3:<M3BQ%G 0+9X$JS5PD<:
MG;&4V?(K%T9]OL<KK63.WM[H(&S@;+N(E0T,<I<<.[IPY8YT<S9?N>++VT1?
ML1M&+0'--F?%EEAX%@AP\9-R/9:6+/QM4NXX&_404,6PT56+;HHY5/],/<W2
MY#SN\<[@>"S^UH#5'+FX,7'P9__(9,9_QX:1479RV;A&/W)'/5^<(6\$.28*
MKY**&@,7-$PQF3"?B=9MX08\G%/DO?2]*6PFBI[>=#ZCO+UYJ_C[=P;=OK=L
M95*KJ@O*RQGG[WUC^><;_6HFSP[9<I 92RL11]%CE.L.R MO@BT_YD)1J#=D
M,2$2L=GH:;!$_4(1>^WS\\:%(&D"N_[6!:GYV."B+-G&UF2_'._Y(ELM@EVM
M.HB[ER)Y/BU'B^Q10Y-,K5/Z2M%<(6N7\3G@CUE8"N$.*+ Q:A.!O<NX6D_%
M6)!MQ=F39JW^T5]XC57K(8!]GL%]JVG!PI6$^0'>AL8YR4AJ,AUR%?]^S?S2
MN%GT=65.^57J/PT>ZX'VRP/HCPAM)C74AIHPS=44C:A;KJ0>.\RG'>EL+%AO
M01JQEZF!V.4YIDWVT*U-MYK?(S@ 4A@@XT[P*ZJ_Y^T?,=W4V/; ;B;DWQ:)
M7!'2[%7/=9G-9_%=^)0EI2,W>.E<K>QZ*SZ%+>MU-_C'34YSV6Z\Y4N5R#[-
MS5R(EN^^[)_J4J4+.3Y-0EJ8C!NW\;2)+$T<85.L/6J?Z$"]6TIBX_4L.KH,
M5%D6W4V-WA=^\<X3YY_JG@LJK^E*47LJIT9T5KMM"<B9!)Y3/>)_![SOC!9/
M.+AZ^L%29%_I,6U:*_W.UN>O!WHKVYLXV]0NN@9&1]3D+*5<$BS[X&EG5AX\
M><S0[I=0_^;ZI0R:2\D5X8ZKQ;Q]$WIY?:G>"EZZXB(MSU@*YSM8Z$5]($O2
MZ$J=.P@F*LK;BQ:R4+9,UYK!+R*BG%>+14%'ID<-@]^PA2&YL<#$3L=N^+S;
M%,4RQ G]P5")\8MAE"?* G*X1WM\D#=VB%Z606K*11]!$B@,G'&LB,OR9\(C
MAI1[;%VW4]'K@5*,LTK$W&<'!X,"[GZ6J:B-7CW&?FFC<YQ*V[C4QW05P'$N
M5X9AU9KY8$R]Q'WOK?O:S*U5RZJ2@;UFY.G 8D<]V/H,"L,:^ZW4F2>FHT7_
MA?0+^G>8F]/(R-W7T%\^CMB'HLOQND;HO6();,O,H^L= 5HI?A,G>.DL+0&+
M)CJL:#=+9[_0L3P\&#?#9@G,?$G,77XH5O/F!W RF/G/O(M?]0;],<GX4\FE
M%Z/L',!^ZDBWOS@OA'OB;"_-7ULF1"F:;ULEQ>MVVF.I@ .CY9":WL^-VSM1
M:<$546;ZGS6U"%-I'I,,_ VU?.4J&Y-#IWR&C]&--=[V8;?+MCXU(;_VF'M#
MP8Z#V8A+7=<S1JI@>JJ)=2QOD<FUF9C6X= GG,P]]VW2=3V^]C6[C*ZZ,UK^
MW=>C?+ND<FZ/#FD97%./ IY.-K.\+)NF1WO&L39WQFGENKVX:,YY!$/H=W]N
M+",[%P5WWS+\CBV/"Y:?6<Z)KA:.XIS2-09=\LJ=YK\SC%B,C2Y_--*PD%&Q
MCM/_VN&-];(N)H&+0^# <::V_D%]-KHVR6(9']M!VJP^[E4LR]81G*/'\'A_
MUI,6/WS)VMR^B0A/;31UMC!2&)%LOJUS^Q U?;#= F3^73G!?$U@Z',$^"/X
MDN@W.UA1F#.&(1SJPIPK6V<K=^'W1D^56?F6T\#=A_D02:AB(;"JS/U9&MY0
M:-G#Q;:<:)0-*1Y!C771$0?B(UD"QQ:3HZ;+]) T;@CL#I\P]IT1B9EIF_JN
M,L5GY&QKPT_Z%^ 0457:WV*#_T^ O3\K'!47D0]QZ'_74S>B'IB7E=/'YDN+
M6=O09G?S\TCX"\!X]#QY"M*)WB(KI *)YV<53.9G6.&)I'F*?PCTB(_BF6CQ
M%%;;X!V CM2\@&B5#RLKU((I"/@[M\N5X*7FH5B\2[A@K<8U[I8,Y$E_%81+
M7VKY@3T1/=#&#%MTS]JAV:$#^4[]T]FR=-ZX9BO=,=W4XGE/8HUV:CQ4.(<0
MB<2ZE4X]A_HWC1[UD\S5=^\U_)\G*,MW"!)A@=+67?O*QX*;H.6^%:9$@'_B
M4HWJ@'1G8QD>ZM:/S0*]ND/0OESC,>7A!RH]:3>U3CRT@I<G"I7*ED90_%=Y
MOZ#A%A/70OLKJAN+2%;7SSV@G"LA1XVP.+$JC%8@#LKJ&C[?$=22B7 \F0 R
M+QLM'$L+_-UV?7)^6&,CLC.CWN.X1;QHW82.-F8\#!TQI#<<+3 XLPJN8DNO
M=ISB+C$B78AC38N/I:I1Y#5\TP?^LY"\$2:Q,U!K%J;O6S8W#C?+Q YK+ 2;
M+H^_>=I(1W7SO/7"1L]7,J:6[=??Y^.4DO*;W_.:9\,%M41&+MFTL;;;=/59
M2\TZ&-O88\]7ZKY8KN%/>1Q^LQE0<VIC"0QL323>\2G3F,S(JD50ZRF3'WDE
M\PND S4U-R:PWL!+\6LGLBQP\ZW\T@+>"Q_9[<;0:ICUNI1]CFFXW[11U1<
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M8BYX;6S<O7N/W#B6)_K_?@K=[HO9:B#9)4J41/8\%EE^-(RMM@W;U;T#XR+
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MLPM:=]+6.\* ]^5U(SB72; CMY&@'9W86NM,BQTT<M\$6\F;J)%75C [L]L
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MB-U-$Y]Y-15(WJVTL5,7P2GK]/@OW^BJK:_YWF0RF18X;:%<3&7$)40 (\8
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MC!G^J-%R84T'4/UG4\=W)7Z2*ZGRJMQ5_^U?\&I=5@N9*)PPI&T;QB% H9"
M*9:!6%(J$T(1A5:VS9A"SHU>FW0AWI/2>VZL^T2Z;;=>:GJFVJ9=SIGM:U&'
M#76*WCRKR_[L,J/MI!FT@^=BZFQ:=T'GEED[&.H!6;;#QQK8BTRIG-=%,A_,
MR4_;. ^E*LR2%(,(1V9;FT! H\BT')-$9B+#<>P4C7ETE+EQ=R-D(#LI'7N+
M'072CGJOAF=D[FR1V0HX0@?"LQ#X[>YU=*1I^W>=4_:@0]?9BX=]]5VWV%Z7
MA_:%52+$,80$<,8Q0#(F (=0@@PAAD429E18M6N_.-+<OO[&<EL/:8-S&DV[
MS]\+1B-3P-&&-+N,R)NV(<T(S' 1':_L<'JT21GBHM+[+''YAF%,8<R-0G[3
M%D?^*)OTMX_K9<Z?FO_NBN0S!3DD4032!";:9(@9P 0+D,J8$Y8HPE*GS@>V
M \^-1YH4@V?2!VWBY@\_K\OR3V[<8HV_'=6,@>K(S',,RIN@D3?XVOXY2N\
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M_WM3\;KZ1DT7G/Y-;MTBA\Z;I8]YO-D8VQDTP42X>Z>'P>G77^THP[0>[&$
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M_FQ/]I)R#-OP?9(5S5=2O*&%J3I0ZLWDYGY3=S![+57.\VHAF222Q#$@(L(
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M+L#K(I,(XY1E@&2Z<1M$#"".)(@Q$22/8[7ZMJJ&L)0_-]>PGS4+\2+6.Q$
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M7 "612P6:9[ B-FE(=VBSMR<U4%AO8E=''C/6(?W[%+*P:CJBQN'TC#$G&R
M? >5%=BU)4%M2A,7MAW2[X+C\>N2U1U,<IDJY0):QYE4-ZDT<:*5"_C.\["<
M/'6D<V;?!=_IA Z3NKNOVK4<]O6QD%'"(SVF) 504@@0#@F0* ZS""59G%F5
MO]VBS-P<<VN+_JR7]8GCEOQ0'KIK@J7WO66L#'WO1"/@V_-VP#<M( [^J,SQ
M<X[C E>W;O<6A:9UN@Z@.W.Y+IXYIHV6\NRB_"6ZS(H<IPEE:J@PR2& E!-
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M#!K5?N?#%]I_S!_66^48WJDG%GIAP,6/_R->%S'#*.)Y!'A"5&"2QC% *$E
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M&#AL_(5,0(.;QA)JT.WA2.O^A2Q7>GY1BS+=]K.::Q9Q3!.940BP8!C !,6
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MPC#*4TF2&#=OS(<U_Y._+ZT%;_BVB)IZ^,_XJDP377D8_#]1<'44/^U?I@:
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M5_9%F]U/[29/]D6_",WYK0+6=QO=9IQM=V3U511/T2*D:8A0 C4_8 P@"W.
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MFCQZ&68_3M;ABWOT)PUF6A;99C76&E"-0=-OL+7!2VAC!Y^O0,=0B[<*>^Q
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MAH=,ZQX0#UX[;KI_+#9,"%YJHM-JC:'+4$KUN2.4";743]420*T%8@8H#P6
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M8'?-4.Q0PZE)C-V#>X'GV(.0D:>=.UJ*_]FIN?G#B_JCR<H3A&$ID009QA+
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MM_,A-HB;.15/.'KV,D<0!EV]@X/BGO;#1B#FU!'9R)_4,XT YM15C7F$\P/
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MCKLB=25,W!#I@G'GO9 N773MG>LB_UG][7_]2_L3]8?^)O[7O_Q?4$L#!!0
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M>4WR"]\QE+]J1G"%1%G'UWJ$H+Y3#8=&U YJ:!%-MWMH1R64-LQ#4D8!_IS
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M\"MB7<KY=#R;3R_+A[/%?9[SKVZ\$LG?TVR>XNEX*;&!S,)DS11*@UL0,5/
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MOXTL&S D3PV%""$9QC6'Z#(#000%KU3I!9.\$HE+'2M5T[Z@B1R[H*AKX;>
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M358+=8:6R4%4U\ZNC?R$E.+L'4JZ5!HC2[^Y>>E*]O,L7_<K>S>9?K[3KVS
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MU%H#&%S<W/TZ&:'69L6*SW]^F,S38U=\R^WTM++PF29'DO? \?] >.? F4"
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M6EL5+,T8B[[,<_)-3/1 XS+CGDJ(SF00B7BPWG!(2N,2LBZ;Q*NPOPEUC7J
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M/^9#-O&]I=(1HC9:EDQ*WBL'$J6I19D!7+0%A!8A9EG0ZS83-WK:-_>7YS/
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M+[@(U0U]/U\NWX;%XGNY*D593I2U6CEBS= K4+G(>@_?@BXI:F<%\XU:(>Q
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M.Q^5& (<_2K$1#(ELK(,$JDW*.UJ3*QM'9&*T?@<A7?=^2W-2N%/$;8[B?!
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M$OW7!2.+(&[[2#5AY'-N2./"@.CQ:T=>HD[&-%2#FELJ_3MGY,Y.(QXK&$Q
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M"0KA%N$ ?A*(#X'X*6[E5@1B$A IL9AHD2&^(3#N@DX)OX5@# S)#!^',;1
M0 7P;Q"+H3M8 B&'Q@,:#)!,]<>\_Y@(DBG1#@RI9$#4-><?4S4 !V5" F.@
MUIN :5S?3K@[,"F]R>(T[!!AAPCWQ)#_ST $@B(:0\SI\)W'6![@ ,2A62RT
MTSB"QRS663M\#U@:@DZ(XX6 R@,&4,$F*($PU BBD86Q.41DT2GO# TH%)IR
M0%Y+I P$ !<X!*\93AI[ BP'*&)\+*>@(4B?2B4P#(3UC]9NL#*_$/MR:LR*
MM;OPWX7_/0%3?K7PGU5[?J)+KEX3W:6 ^;1W[+E')S*+\BR3U$]1'D44+DTH
MM1$6Q 0M!"'5,0#!A8C42YO*@1;78D-@$)I%Z&L(@H!QF4(_S2T$3)N1200/
M2 @_2[0/P1H2B'X;D:W;8(#C/D%U>&QW4@82IOI2V2<'IJNION@K>TEU32&V
MJ*'U(_UL7P 3&]S:EHT'BJ8#3<>*8"SMZEV4 2&=CZQ)MM\3?@ ,>-7G).'0
M\?#P6?CQ""H=/T_K@ZCD.U[YGX5*-L7=)F*"MXIF-8D$ P!L3,[R.!+F=3H5
MX%1NWD7G-3T"J):-9#,EG@I0 'QG1*5A42!%8J-'UP;G_&N1PPG"L(')+%5:
MP#EJTS3#%6/=GDJ=.IEGA31YEF%27!(81@%ST[XD6-^&E&%- ,%8HWJ>@D$/
MF] MYJ'PK4>T(' TZ$_"C\G)'L'4H_)K8.IK,#W 5'\S8W>8^EX]ZFT?=UT&
MUHT)X J^;DX=-X99@.81#35Z8LEC@TE8 O+J0I:&5"S"*1 "X%+<HXRJB<Y@
MUPVKP=Y@IH%#B]-+H@N%,$/%;S.'DE0D ,?29-Q! '!H## EL3Z)(9%F@,K0
M0A*="&N1-%86>2&9IPFPX67L?7>L=H? .P3^&!X%6\5J6R/,4O-JC48F$D4D
M4'0$F"+7%.)F=84-J*R]7%^;,U@+'0.62EL![/%4W6_!)F0;SZ2)+F]&CV\0
MH-ZT<&H>'\3.!-ACH%(/\!ZIZB[]WP'EQ_ HW"J@;%H,6L4RO;F:E1Y-RUK
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M8UE^1@1)*]$*3*ADP-RU$S"C*@0%94P\(Z"N-P;1N!Y.&!WHE-%\M1L.B'!
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M?P!02P$"% ,4    " !,,&]4%$CF:E6Y @")R14 $0              @ $
M    <W1T:RTR,#(Q,3(S,2YH=&U02P$"% ,4    " !,,&]4P0ORRT -   8
M@@  $0              @ &$N0( <W1T:RTR,#(Q,3(S,2YX<V102P$"% ,4
M    " !,,&]48B:.L%\8  "]Y0  %0              @ 'SQ@( <W1T:RTR
M,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ 3#!O5%%O(7EC.   ]'4" !4
M             ( !A=\" '-T=&LM,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( $PP;U0W3M)S\N@  #]J 0 4              "  1L8 P!S='1K+3(P
M,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( $PP;U0([2\^CHD  ,^Z   5
M          "  3\!! !S='1K+3(P,C$Q,C,Q7V<Q,"YJ<&=02P$"% ,4
M" !,,&]4ZHP JA^8  !9#@$ %               @ $ BP0 <W1T:RTR,#(Q
M,3(S,5]G,BYJ<&=02P$"% ,4    " !,,&]4LIU=0'DI 0#I?@$ %
M        @ %1(P4 <W1T:RTR,#(Q,3(S,5]G,RYJ<&=02P$"% ,4    " !,
M,&]4EJ,<I'"3 0!J% ( %               @ '\3 8 <W1T:RTR,#(Q,3(S
M,5]G-"YJ<&=02P$"% ,4    " !,,&]4I.+PA>=U  !4PP  %
M    @ &>X < <W1T:RTR,#(Q,3(S,5]G-2YJ<&=02P$"% ,4    " !,,&]4
M]:<SS_G[   P:P$ %               @ &W5@@ <W1T:RTR,#(Q,3(S,5]G
M-BYJ<&=02P$"% ,4    " !,,&]4>P2YW)'' 0"D 0( %
M@ 'B4@D <W1T:RTR,#(Q,3(S,5]G-RYJ<&=02P$"% ,4    " !,,&]4-?R=
MR)+9  #6,@$ %               @ &E&@L <W1T:RTR,#(Q,3(S,5]G."YJ
M<&=02P$"% ,4    " !,,&]4I0XW/)<' 0"U80$ %               @ %I
M] L <W1T:RTR,#(Q,3(S,5]G.2YJ<&=02P$"% ,4    " !,,&]4;L=2\BBN
M  "E= < %0              @ $R_ P <W1T:RTR,#(Q,3(S,5]L86(N>&UL
M4$L! A0#%     @ 3#!O5()U@Z#N:   G]\$ !4              ( !C:H-
M '-T=&LM,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( $PP;U3PU*L!.@D
M )1"   >              "  :X3#@!S=6(M8V5R='AS96-T:6]N,S R>&%R
M;C(P,BYH=&U02P$"% ,4    " !,,&]4AUZ<GAT)  "70@  '@
M    @ $D'0X <W5B+6-E<G1X<V5C=&EO;C,P,GAC96\R,#(N:'1M4$L! A0#
M%     @ 3#!O5.Y"V,FD!@  9"(  !X              ( !?28. '-U8BUC
M97)T>'-E8W1I;VXY,#9O9G1H97-A+FAT;5!+ 0(4 Q0    ( $PP;U2R-60W
M* ,  $X(   1              "  5TM#@!Y93(P,C%C;VYS96YT+FAT;5!+
4!08     %  4 $(%  "T, X    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
